Clustering O 0 0.0004130146116949618
of O 0 6.3540392147842795e-06
missense O 0 0.01638912968337536
mutations O 0 0.00030915075330995023
in O 0 9.744167073222343e-07
the O 0 7.316931441891938e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.5594170690746978e-05
in O 0 1.8906234799942467e-07
a O 0 1.811968331821845e-06
sporadic B-Disease 0 0.3579718768596649
T I-Disease 1 0.9779564142227173
- I-Disease 0 0.00955007690936327
cell I-Disease 0 0.004398966208100319
leukaemia I-Disease 0 0.0894378274679184
. O 0 3.6078174616704928e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.018787700682878494
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4597490860523976e-07
is O 0 1.786191106134538e-08
a O 0 1.2435450003067672e-07
recessive B-Disease 0 0.0005432291654869914
multi I-Disease 0 0.005911281798034906
- I-Disease 1 0.999904990196228
system I-Disease 0 0.35375842452049255
disorder I-Disease 1 0.9592861533164978
caused O 0 5.974001396680251e-06
by O 0 7.429910198197831e-08
mutations O 0 1.647562953621673e-06
in O 0 8.64952376389283e-09
the O 0 1.9083591595858707e-08
ATM O 0 1.548545583318628e-06
gene O 0 3.0311696264107013e-07
at O 0 1.9561058195449732e-07
11q22 O 0 3.9703018046566285e-06
- O 0 1.5745610653539188e-05
q23 O 0 9.35132811719086e-06
( O 0 8.982889454500764e-08
ref O 0 1.3235590813565068e-05
. O 0 4.2419305401608653e-08
3 O 0 2.506886858100188e-07
) O 0 1.3795514064440795e-07
. O 0 7.358532911894144e-07

The O 0 6.0949832914047875e-06
risk O 0 3.4162694646511227e-06
of O 0 1.9729053235550964e-07
cancer B-Disease 0 5.3336229029810056e-05
, O 0 4.629582051052239e-08
especially O 0 4.7363332811301007e-08
lymphoid B-Disease 0 5.009735104977153e-06
neoplasias I-Disease 0 5.708417666028254e-05
, O 0 9.148939028591485e-08
is O 0 2.1460024868247274e-08
substantially O 0 1.2103030258003855e-06
elevated O 0 1.6255633454420604e-05
in O 0 7.255615628309897e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.372942733723903e-05
and O 0 5.553421829063154e-07
has O 0 9.535269782645628e-07
long O 0 4.794518417838844e-07
been O 0 2.4261018438664905e-07
associated O 0 2.865191675027745e-07
with O 0 1.4986105725256493e-06
chromosomal O 1 1.0
instability O 1 0.9999991655349731
. O 0 1.351263199467212e-05

By O 0 1.1148165867780335e-05
analysing O 0 6.471026426879689e-05
tumour B-Disease 1 0.9999990463256836
DNA O 0 3.467642454779707e-05
from O 0 1.0540411210513412e-07
patients O 0 1.7913434646743553e-07
with O 0 3.174587703824727e-08
sporadic B-Disease 0 0.001833943766541779
T I-Disease 1 0.8738865852355957
- I-Disease 0 0.0010418776655569673
cell I-Disease 0 0.0008404066902585328
prolymphocytic I-Disease 0 0.0015618563629686832
leukaemia I-Disease 1 0.6715118885040283
( O 0 1.474726900596579e-06
T B-Disease 0 0.008759801276028156
- I-Disease 0 6.900894368300214e-05
PLL I-Disease 0 6.946596840862185e-05
) O 0 4.038385981175452e-08
, O 0 6.27828189436741e-09
a O 0 4.2880220263441515e-08
rare O 0 4.896794507658342e-07
clonal B-Disease 0 8.954712939157616e-06
malignancy I-Disease 0 7.828208617866039e-05
with O 0 2.2397788512762418e-08
similarities O 0 2.143536192988904e-07
to O 0 1.712829522659831e-08
a O 0 5.590559908341675e-07
mature B-Disease 0 3.3380456443410367e-06
T I-Disease 0 0.00020353698346298188
- I-Disease 0 1.9472887288429774e-05
cell I-Disease 0 4.790798629983328e-05
leukaemia I-Disease 0 0.000126253959024325
seen O 0 7.405969881801866e-07
in O 0 7.372835142405165e-08
A B-Disease 1 0.9999488592147827
- I-Disease 1 0.9999721050262451
T I-Disease 1 1.0
, O 0 1.1666548971334123e-07
we O 0 9.302657311138773e-09
demonstrate O 0 6.651227124621073e-09
a O 0 7.272551449943876e-09
high O 0 5.0470539747493603e-08
frequency O 0 9.603471085029014e-08
of O 0 4.809293407959103e-09
ATM O 0 6.167674655443989e-06
mutations O 0 3.377228949830169e-06
in O 0 3.5668324471771484e-07
T B-Disease 0 0.009172356687486172
- I-Disease 0 0.00011823400564026088
PLL I-Disease 0 0.0003203593660145998
. O 0 4.035401616420131e-06

In O 0 7.205971542134648e-06
marked O 0 8.142192200466525e-06
contrast O 0 8.82714800809481e-07
to O 0 3.334817222366837e-08
the O 0 4.294258459935918e-08
ATM O 0 9.322141522716265e-06
mutation O 0 1.987021050808835e-06
pattern O 0 5.9736821640399285e-06
in O 0 8.19921638139931e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 7.496657872252399e-08
the O 0 4.170273015802195e-09
most O 0 1.7752808112447838e-09
frequent O 0 2.721341907374608e-08
nucleotide O 0 1.6944403569141286e-07
changes O 0 1.862289700227393e-08
in O 0 2.7765191035200587e-08
this O 0 1.2221074996432435e-07
leukaemia B-Disease 0 0.03952883929014206
were O 0 5.877151124877855e-06
missense O 0 0.0003134804719593376
mutations O 0 7.127545541152358e-05
. O 0 1.695115656730195e-06

These O 0 1.4866208175590145e-06
clustered O 0 1.183293352369219e-05
in O 0 6.068732716357772e-08
the O 0 2.9167125603635213e-08
region O 0 2.0323082594586594e-07
corresponding O 0 3.84468172853758e-08
to O 0 1.2288857043074586e-08
the O 0 1.621306289223412e-08
kinase O 0 8.283699344246997e-07
domain O 0 4.1832684871678794e-08
, O 0 3.166611151073084e-08
which O 0 3.951652161049424e-08
is O 0 4.677473963710099e-09
highly O 0 4.713404333500648e-09
conserved O 0 1.2471217836207416e-08
in O 0 4.997298130859917e-09
ATM O 0 1.246965666723554e-06
- O 0 1.2630126775547978e-06
related O 0 5.589745200040852e-08
proteins O 0 1.6592734297660172e-08
in O 0 1.8962259318300312e-08
mouse O 0 1.245251769432798e-05
, O 0 3.910757584435487e-08
yeast O 0 1.5477645547434804e-06
and O 0 2.3081906874722335e-07
Drosophila O 0 3.639242777353502e-06
. O 0 1.6417188817285933e-06

The O 0 5.5969258028198965e-06
resulting O 0 7.32409853299032e-06
amino O 0 2.53017765317054e-06
- O 0 7.373942480626283e-06
acid O 0 7.181741921158391e-07
substitutions O 0 2.888712913318159e-07
are O 0 1.3823639122279019e-08
predicted O 0 2.2712634972776868e-07
to O 0 7.629073373038864e-09
interfere O 0 5.961816640365214e-08
with O 0 2.1739923639074732e-08
ATP O 0 1.4360547311298433e-06
binding O 0 7.264790156114032e-07
or O 0 2.404720760296186e-07
substrate O 0 5.5667373999312986e-06
recognition O 0 1.6265430531348102e-06
. O 0 1.1369409094186267e-06

Two O 0 3.64039851774578e-06
of O 0 1.757111647293641e-07
seventeen O 0 3.932444997190032e-06
mutated O 0 4.760668161907233e-05
T B-Disease 0 0.004208060447126627
- I-Disease 0 4.129379158257507e-05
PLL I-Disease 0 3.094322164542973e-05
samples O 0 4.115916851787915e-07
had O 0 5.072517410553701e-07
a O 0 9.072651607766602e-08
previously O 0 5.516973942576442e-06
reported O 0 6.277990178205073e-05
A B-Disease 1 0.9999816417694092
- I-Disease 1 0.9999915361404419
T I-Disease 1 1.0
allele O 0 3.8456764741567895e-05
. O 0 2.3860168312239693e-06

In O 0 6.741399829479633e-06
contrast O 0 6.1563446251966525e-06
, O 0 1.0465110023005764e-07
no O 0 1.8246896615892183e-07
mutations O 0 9.497347491560504e-06
were O 0 1.4550071227859007e-06
detected O 0 5.753744289904716e-07
in O 0 4.1281156271111286e-09
the O 0 1.3453542280217334e-08
p53 O 0 2.5118475832641707e-07
gene O 0 9.277464130263979e-08
, O 0 1.6466403351955705e-08
suggesting O 0 8.337913470768399e-08
that O 0 8.297803333334741e-09
this O 0 1.3587360569999873e-07
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.004546948708593845
is O 0 1.970511789295415e-07
not O 0 3.208616661254382e-08
frequently O 0 1.3372218177210016e-07
altered O 0 2.7808998765976867e-06
in O 0 1.8226965892154112e-07
this O 0 6.367673108798044e-07
leukaemia B-Disease 0 0.02841888554394245
. O 0 6.45174350211164e-06

Occasional O 0 0.0007185657159425318
missense O 0 0.020251424983143806
mutations O 0 8.953920041676611e-05
in O 0 1.5727560764844384e-07
ATM O 0 1.8924894902738743e-05
were O 0 4.010104476037668e-06
also O 0 7.222554359032074e-07
found O 0 3.768270460113854e-07
in O 0 9.289713602811389e-07
tumour B-Disease 1 1.0
DNA O 0 9.029697139339987e-06
from O 0 4.415076304553622e-08
patients O 0 5.862260721301027e-08
with O 0 1.6522623269565884e-08
B B-Disease 0 3.1979875529941637e-06
- I-Disease 0 1.5293084288714454e-05
cell I-Disease 0 5.583517122431658e-05
non I-Disease 0 3.6753349377249833e-06
- I-Disease 1 0.7812944054603577
Hodgkins I-Disease 1 0.999889612197876
lymphomas I-Disease 0 0.3105919361114502
( O 0 2.944100856439036e-07
B B-Disease 0 1.7758728745320695e-06
- I-Disease 0 5.440072527562734e-06
NHL I-Disease 0 2.0046384179295273e-06
) O 0 2.1410800243870654e-08
and O 0 2.0551249590994303e-08
a O 0 2.0859349092461343e-07
B B-Disease 0 3.622642907430418e-06
- I-Disease 0 1.2935935046698432e-05
NHL I-Disease 0 7.313391506613698e-06
cell O 0 2.54651386057958e-05
line O 0 8.558333502151072e-05
. O 0 1.740949983286555e-06

The O 0 5.442846600089979e-07
evidence O 0 4.735231229346937e-08
of O 0 5.874189579202493e-09
a O 0 4.516036966606407e-08
significant O 0 5.9149591891127784e-08
proportion O 0 6.317613099326991e-08
of O 0 6.926109019644855e-09
loss O 0 6.481527066171111e-07
- O 0 2.9712571176787606e-06
of O 0 2.4274942944657596e-08
- O 0 8.2836104411399e-06
function O 0 1.294241940286156e-07
mutations O 0 4.62705742165781e-07
and O 0 3.801383030577199e-08
a O 0 9.400118017310888e-08
complete O 0 2.8670831397903385e-07
absence O 0 6.819369247068607e-08
of O 0 2.817746480587857e-09
the O 0 1.3211153948589072e-08
normal O 0 4.486699722860976e-08
copy O 0 2.1145361017715913e-07
of O 0 3.1860021287855034e-09
ATM O 0 6.353217827381741e-07
in O 0 2.568751789056023e-08
the O 0 3.739907938893339e-08
majority O 0 5.997515017952537e-08
of O 0 3.538220383347834e-08
mutated O 0 0.018333526328206062
tumours B-Disease 1 1.0
establishes O 0 5.044550562161021e-06
somatic O 0 1.4699402299811481e-06
inactivation O 0 6.168910203996347e-06
of O 0 2.9177125160373407e-09
this O 0 5.36159472375175e-09
gene O 0 1.070239719069832e-07
in O 0 2.3238364121880295e-08
the O 0 3.26399707262226e-08
pathogenesis O 0 4.600577767632785e-07
of O 0 2.7427169868587953e-08
sporadic B-Disease 0 0.0016652365447953343
T I-Disease 1 0.6603208780288696
- I-Disease 0 0.00010654837387846783
PLL I-Disease 0 2.5847799406619743e-05
and O 0 8.764414616280192e-08
suggests O 0 3.003106385790488e-08
that O 0 4.111786466864942e-09
ATM O 0 4.070564898484008e-07
acts O 0 3.414744469409925e-07
as O 0 1.1203016470062721e-07
a O 0 5.440596396510955e-06
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.01507361140102148
. O 0 5.998635515425121e-06

As O 0 3.010051159435534e-06
constitutional O 0 9.87028897725395e-07
DNA O 0 3.860057404381223e-06
was O 0 6.870055585750379e-06
not O 0 7.175140037674055e-09
available O 0 7.142533231530024e-09
, O 0 9.691293989533278e-09
a O 0 1.2113845571093407e-07
putative O 0 8.223238546634093e-05
hereditary O 0 0.262045681476593
predisposition O 0 0.00022490453557111323
to O 0 1.336569425802736e-06
T B-Disease 0 0.07415928691625595
- I-Disease 0 4.2402843973832205e-05
PLL I-Disease 0 2.0049534214194864e-05
will O 0 4.869031400289714e-08
require O 0 1.0235753578058393e-08
further O 0 1.5710163836502034e-08
investigation O 0 1.4473191356501047e-07
. O 0 8.223361191994627e-08
. O 0 3.421110363888147e-07

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.00030945183243602514
kinase O 0 0.00025099358754232526
is O 0 2.3255397252341936e-07
involved O 0 6.185135248415463e-08
in O 0 2.1189022092471532e-08
the O 0 2.673928811702808e-08
modulation O 0 2.723632519519015e-07
of O 0 9.6966195073378e-09
the O 0 1.958551081315818e-07
Ca2 O 0 5.1519047701731324e-05
+ O 0 1.3740561371378135e-05
homeostasis O 0 0.00011013335461029783
in O 0 2.1075816221127752e-06
skeletal O 0 0.07887626439332962
muscle O 0 0.00021698116324841976
cells O 0 1.105348019336816e-05
. O 0 1.1881292039106484e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9971721768379211
DM B-Disease 1 1.0
) O 0 9.946281352313235e-06
, O 0 5.080859111217251e-08
the O 0 1.3707275314800427e-08
most O 0 8.338422219367203e-08
prevalent O 0 3.326500882394612e-05
muscular B-Disease 1 0.9883389472961426
disorder I-Disease 0 0.07586690038442612
in O 0 2.9112916877238604e-07
adults O 0 4.502972842601594e-06
, O 0 6.755558246140936e-08
is O 0 6.155512721761625e-08
caused O 0 8.869179737303057e-07
by O 0 1.508617231138487e-08
( O 0 9.610928941583552e-08
CTG O 0 4.012751560367178e-06
) O 0 1.8369389565009442e-08
n O 0 5.309128141561814e-07
- O 0 1.0939257890640874e-06
repeat O 0 3.9935159179549373e-07
expansion O 0 3.571968321125496e-08
in O 0 4.5163881523535565e-09
a O 0 2.0608519335496567e-08
gene O 0 8.252145988763004e-08
encoding O 0 8.763378644971453e-08
a O 0 3.020573444700858e-07
protein O 0 3.7982269986969186e-06
kinase O 0 2.4086593839456327e-05
( O 0 4.6119023977553297e-07
DM B-Disease 1 0.9999821186065674
protein O 0 7.123479917936493e-06
kinase O 0 2.5437664589844644e-05
; O 0 4.1254662619394367e-07
DMPK O 0 3.148491305182688e-05
) O 0 1.8280402969139686e-08
and O 0 4.564347122482104e-09
involves O 0 8.694563291555824e-09
changes O 0 1.7287872466908993e-08
in O 0 3.194285369545469e-08
cytoarchitecture O 0 6.022215984557988e-06
and O 0 5.025383416068507e-07
ion O 0 2.1958179786452092e-05
homeostasis O 0 0.00023672373208682984
. O 0 2.756063622655347e-06

To O 0 8.886806881491793e-07
obtain O 0 3.4776039115058666e-07
clues O 0 1.1830999255835195e-06
to O 0 3.9040351396124606e-08
the O 0 2.9363722120478997e-08
normal O 0 1.1907990682402669e-07
biological O 0 3.874525589253608e-08
role O 0 2.3688881967132147e-08
of O 0 9.336306838747532e-09
DMPK O 0 7.95383039076114e-06
in O 0 2.1661156424102046e-08
cellular O 0 4.391409333948104e-07
ion O 0 9.127671205533261e-07
homeostasis O 0 6.209821094671497e-06
, O 0 7.650992728258643e-08
we O 0 1.9868600986683305e-08
have O 0 6.6562013678606036e-09
compared O 0 2.2963378754070618e-08
the O 0 1.0012096929301606e-08
resting O 0 8.658232104608032e-07
[ O 0 1.324896032883771e-07
Ca2 O 0 1.4886991266394034e-06
+ O 0 1.910575292640715e-06
] O 0 9.548546131554758e-07
i O 0 1.554412136783867e-07
, O 0 2.396828957529351e-09
the O 0 3.3677538535670237e-09
amplitude O 0 4.536731168514052e-08
and O 0 1.1360870466603501e-08
shape O 0 1.318793465543422e-07
of O 0 1.5597930058675047e-08
depolarization O 0 1.8950926232719212e-06
- O 0 1.5150733815971762e-05
induced O 0 3.141301931464113e-05
Ca2 O 0 9.316577234130818e-06
+ O 0 4.210218776279362e-06
transients O 0 2.3455024347640574e-05
, O 0 2.734860338193812e-08
and O 0 1.2687026540447732e-08
the O 0 2.7015225612103677e-09
content O 0 1.9356034997031202e-08
of O 0 1.7008873198776087e-09
ATP O 0 3.243709727485111e-07
- O 0 2.7825392407976324e-06
driven O 0 1.0095562856804463e-06
ion O 0 4.939673772241804e-07
pumps O 0 7.040591185614176e-07
in O 0 2.7607034880361425e-08
cultured O 0 3.414699449422187e-06
skeletal O 0 6.071297320886515e-05
muscle O 0 2.93494986181031e-06
cells O 0 4.6690527000237125e-08
of O 0 1.9668791040317046e-09
wild O 0 9.791202160158718e-08
- O 0 6.269827736105071e-06
type O 0 5.597212293650955e-07
and O 0 1.650589069868147e-07
DMPK O 0 1.6769969079177827e-05
[ O 0 5.467750838761276e-07
- O 0 7.789963092363905e-06
/ O 0 9.25254153116839e-06
- O 0 5.748333569499664e-05
] O 0 8.618009815108962e-06
knockout O 0 0.00014629645738750696
mice O 0 0.00021381943952292204
. O 0 1.560553982926649e-06

In O 0 1.2211621651658788e-05
vitro O 0 9.93418216239661e-05
- O 0 7.698941772105172e-05
differentiated O 0 2.049384784186259e-05
DMPK O 0 0.00011017506039934233
[ O 0 2.1596385977318278e-06
- O 0 1.6733849406591617e-05
/ O 0 1.6419928215327673e-05
- O 0 1.3066107385384385e-05
] O 0 7.285680680979567e-07
myotubes O 0 1.169859615401947e-06
exhibit O 0 2.038313908769851e-07
a O 0 1.1184420145582408e-07
higher O 0 1.5784780771355145e-07
resting O 0 1.4187936585585703e-06
[ O 0 2.766301747669786e-07
Ca2 O 0 2.7543187570699956e-06
+ O 0 2.374281393713318e-06
] O 0 8.406480560552154e-07
i O 0 1.4379429558175616e-07
than O 0 5.787156975856078e-09
do O 0 6.3738916367128695e-09
wild O 0 3.4563370832074725e-08
- O 0 3.7246138617774704e-06
type O 0 5.072314479548368e-07
myotubes O 0 4.630881448974833e-06
because O 0 6.852706402327158e-09
of O 0 1.170831320784771e-09
an O 0 7.1399455237042275e-09
altered O 0 4.119547156733461e-06
open O 0 3.4059596032420814e-07
probability O 0 1.719795683641223e-08
of O 0 7.755054376445969e-09
voltage O 0 4.015246668132022e-05
- O 0 7.100588391040219e-06
dependent O 0 3.7425095911203243e-07
l O 0 1.563032469675818e-06
- O 0 9.674376997281797e-07
type O 0 5.587079385804827e-07
Ca2 O 0 6.435212981159566e-06
+ O 0 1.0909940328929224e-06
and O 0 1.3738298321186448e-07
Na O 0 5.820657406729879e-06
+ O 0 4.4448120206652675e-06
channels O 0 3.859453954646597e-06
. O 0 1.480030164202617e-06

The O 0 3.964607458328828e-06
mutant O 0 2.307352224306669e-05
myotubes O 0 1.6007998056011274e-05
exhibit O 0 7.521277893829392e-07
smaller O 0 1.3528917008898134e-07
and O 0 6.980819478030753e-08
slower O 0 2.845638846338261e-06
Ca2 O 0 1.4838213246548548e-05
+ O 0 3.156793127345736e-06
responses O 0 1.5020387422737258e-07
upon O 0 2.0924753485473957e-08
triggering O 0 4.1748515400286124e-07
by O 0 1.3601020754094861e-08
acetylcholine O 0 7.2465400080545805e-06
or O 0 4.3238878788542934e-07
high O 0 7.540783713011479e-07
external O 0 1.270872303393844e-06
K O 0 6.302108886302449e-06
+ O 0 4.248515779181616e-06
. O 0 1.1033660030079773e-06

In O 0 2.0692275484179845e-06
addition O 0 2.6083037596436043e-07
, O 0 7.360372933362669e-08
we O 0 1.7504206084595353e-08
observed O 0 2.5308862561246315e-08
that O 0 2.9408715462864166e-09
these O 0 9.41619315852904e-09
Ca2 O 0 1.8574442947283387e-05
+ O 0 1.8980690583703108e-05
transients O 0 0.00035765720531344414
partially O 0 2.4145308998413384e-05
result O 0 3.867393516543416e-08
from O 0 2.7756703602221933e-09
an O 0 1.7534205198899144e-09
influx O 0 9.938237788276183e-09
of O 0 2.577948743365255e-09
extracellular O 0 1.901193513731414e-07
Ca2 O 0 3.3319167869194644e-06
+ O 0 5.231655109128042e-07
through O 0 1.6963005222692118e-08
the O 0 3.093097333817241e-08
l O 0 3.631012987170834e-06
- O 0 1.51174469920079e-06
type O 0 5.09926678660122e-07
Ca2 O 0 1.3085011232760735e-05
+ O 0 7.896338502177969e-06
channel O 0 2.7299014618620276e-05
. O 0 2.107826730934903e-06

Neither O 0 3.693436156027019e-05
the O 0 2.962469807243906e-07
content O 0 6.241176606636145e-07
nor O 0 9.614448970296507e-08
the O 0 8.901105630343409e-09
activity O 0 8.846912891158354e-08
of O 0 1.3809198229353115e-08
Na O 0 4.107225777261192e-06
+ O 0 2.4140504137903918e-06
/ O 0 3.070677394134691e-06
K O 0 2.099104449371225e-06
+ O 0 1.7330697801298811e-06
ATPase O 0 9.42202859732788e-06
and O 0 5.223364496487193e-07
sarcoplasmic O 0 5.433634214568883e-05
reticulum O 0 7.19730815035291e-05
Ca2 O 0 4.679749326896854e-05
+ O 0 5.79673223910504e-06
- O 0 6.003111138852546e-06
ATPase O 0 4.85700093122432e-06
are O 0 3.9003953844485295e-08
affected O 0 8.944149243461652e-08
by O 0 5.000847735914249e-08
DMPK O 0 0.00017802923684939742
absence O 0 6.464781563408906e-06
. O 0 1.5944228834996466e-06

In O 0 2.156641812689486e-06
conclusion O 0 3.811806266185158e-07
, O 0 5.413696513301147e-08
our O 0 1.232557078623131e-08
data O 0 3.987486962842013e-08
suggest O 0 3.6165626937645357e-08
that O 0 1.2120833225992556e-08
DMPK O 0 2.0703997506643645e-05
is O 0 1.1040649283700077e-08
involved O 0 4.818383025906314e-09
in O 0 7.326460327305995e-09
modulating O 0 2.781632417736546e-07
the O 0 2.1760998336617376e-08
initial O 0 3.567841844187569e-08
events O 0 1.8671126866820487e-08
of O 0 1.3811516375028532e-08
excitation O 0 1.530260647086834e-06
- O 0 4.8507041356060654e-05
contraction O 0 2.74949379672762e-05
coupling O 0 6.272829978115624e-06
in O 0 3.504825656364119e-07
skeletal O 0 0.0004889218835160136
muscle O 0 3.265710984123871e-05
. O 0 2.096296753961724e-07
. O 0 8.575333367843996e-07

Constitutional O 0 0.0001177931044367142
RB1 O 0 0.012906321324408054
- O 0 0.000996468123048544
gene O 0 4.353405529400334e-05
mutations O 0 2.992223744513467e-05
in O 0 2.9546151836257195e-07
patients O 0 8.691481525602285e-07
with O 0 1.380127798711328e-07
isolated O 0 0.00011070635082433
unilateral B-Disease 0 0.0003200345381628722
retinoblastoma I-Disease 0 0.005723887123167515
. O 0 8.032489859033376e-06

In O 0 5.38423182661063e-06
most O 0 3.874581580021186e-07
patients O 0 6.85793281718361e-07
with O 0 3.442553264676462e-08
isolated O 0 1.1500595064717345e-05
unilateral B-Disease 0 5.5598095059394836e-05
retinoblastoma I-Disease 0 0.0008319569169543684
, O 0 8.557874480175087e-07
tumor B-Disease 0 1.0601958820188884e-05
development O 0 1.1919586206943222e-08
is O 0 1.0320540866359806e-08
initiated O 0 5.270294423098676e-08
by O 0 5.0974167109529844e-09
somatic O 0 3.7675229691558343e-07
inactivation O 0 5.319798674463527e-06
of O 0 5.251427293018196e-09
both O 0 3.681546800748947e-08
alleles O 0 1.7543186459079152e-07
of O 0 1.5706779876722976e-08
the O 0 8.279087069240632e-07
RB1 O 0 0.0008105599554255605
gene O 0 1.075692580343457e-05
. O 0 2.264190243295161e-06

However O 0 1.1006273780367337e-05
, O 0 5.1922690147421235e-08
some O 0 2.4973279000306547e-09
of O 0 4.217081350788021e-09
these O 0 2.6432603661419307e-08
patients O 0 2.531575091779814e-07
can O 0 2.0141786194471933e-07
transmit O 0 5.985783354844898e-05
retinoblastoma B-Disease 0 0.00020478302030824125
predisposition O 0 0.00010610177560010925
to O 0 1.3429819034627144e-07
their O 0 5.413107260210381e-07
offspring O 0 3.393508814042434e-05
. O 0 8.334739618476306e-07

To O 0 6.954916216272977e-07
determine O 0 2.5466388819950225e-07
the O 0 6.884859971023616e-08
frequency O 0 4.675665877584834e-06
and O 0 9.048181937032496e-08
nature O 0 5.1567777603622744e-08
of O 0 6.504938809825944e-09
constitutional O 0 7.137659281397646e-07
RB1 O 0 0.00030013383366167545
- O 0 1.8756916688289493e-05
gene O 0 5.5138712014013436e-06
mutations O 0 4.15846716350643e-06
in O 0 1.2046922392983106e-07
patients O 0 2.194343409200883e-07
with O 0 1.4719426566500715e-08
isolated O 0 1.0633135389070958e-05
unilateral B-Disease 0 2.439301897538826e-05
retinoblastoma I-Disease 0 6.309602758847177e-05
, O 0 1.2585707054313389e-07
we O 0 1.0897752922289783e-08
analyzed O 0 4.8310852207578137e-08
DNA O 0 1.8798020562371676e-07
from O 0 1.4383086721636573e-08
peripheral O 0 5.690807938663056e-06
blood O 0 4.061904292029794e-06
and O 0 4.18675682567482e-07
from O 0 3.152377701098885e-07
tumor B-Disease 0 0.0002652601106092334
tissue O 0 5.754849553341046e-05
. O 0 1.7869224393507466e-06

The O 0 1.4010264521857607e-06
analysis O 0 4.516859348768776e-07
of O 0 1.3508314111732034e-07
tumors B-Disease 1 1.0
from O 0 2.7098178634332726e-07
54 O 0 2.2727138002665015e-06
( O 0 6.700916088675513e-08
71 O 0 9.439390282750537e-07
% O 0 2.8495492188085336e-08
) O 0 2.8746756086661662e-09
of O 0 3.4175338115005616e-09
76 O 0 9.930981832440011e-07
informative O 0 3.532897380864597e-06
patients O 0 8.294779945572373e-06
showed O 0 2.7468786356621422e-05
loss O 0 3.213348236386082e-07
of O 0 2.7998865448353172e-08
constitutional O 0 5.954815605946351e-06
heterozygosity O 0 0.005405596923083067
( O 0 4.398653800308239e-06
LOH O 1 0.999812662601471
) O 0 3.327057243041054e-07
at O 0 3.4735666076812777e-07
intragenic O 0 4.790077218785882e-05
loci O 0 1.1491692930576392e-05
. O 0 1.6590382756476174e-06

Three O 0 5.064159267931245e-06
of O 0 3.5173320611647796e-07
13 O 0 2.9196794457675423e-06
uninformative O 0 0.000820784131065011
patients O 0 1.4868468497297727e-05
had O 0 2.8115423447161447e-06
constitutional O 0 2.4510698040103307e-06
deletions O 0 0.00011029330926248804
. O 0 2.326700723642716e-06

For O 0 2.4561709324188996e-06
39 O 0 9.801449778024107e-06
randomly O 0 2.692691850825213e-06
selected O 0 4.745701517094858e-06
tumors B-Disease 1 0.9999998807907104
, O 0 3.2027779184318206e-07
SSCP O 0 4.164536585449241e-05
, O 0 1.0454875365439875e-07
hetero O 0 2.7888540898857173e-06
- O 0 8.563744700040843e-07
duplex O 0 1.0593762453936506e-05
analysis O 0 5.654502288621188e-08
, O 0 5.936895419722532e-09
sequencing O 0 3.371733825474621e-08
, O 0 8.736704693035335e-09
and O 0 1.2970859941674462e-08
Southern O 0 7.228866394370925e-08
blot O 0 8.483219062327407e-06
analysis O 0 7.337230556458962e-08
were O 0 4.110416540470396e-08
used O 0 2.245784713750254e-08
to O 0 6.651280415326255e-08
identify O 0 5.870501809113193e-06
mutations O 0 1.7161317373393103e-05
. O 0 6.702033488181769e-07

Mutations O 0 0.037589848041534424
were O 0 5.547954970097635e-06
detected O 0 1.783782636266551e-06
in O 0 6.378442662935413e-08
21 O 0 1.3869852182324394e-06
( O 0 6.87564707391175e-08
91 O 0 5.821912623105163e-07
% O 0 9.919474308617282e-08
) O 0 1.1782471887045176e-08
of O 0 1.630635750871079e-07
23 O 0 0.010057485662400723
tumors B-Disease 1 1.0
with O 0 2.5041246772161685e-05
LOH O 1 0.9999990463256836
. O 0 7.116113010852132e-06

In O 0 3.93330037695705e-06
6 O 0 4.9669292820908595e-06
( O 0 3.373558286057232e-07
38 O 0 1.7362443713864195e-06
% O 0 7.762101006392186e-08
) O 0 5.901703570287964e-09
of O 0 1.492261958446761e-08
16 O 0 0.0019751216750591993
tumors B-Disease 1 1.0
without O 0 1.1219840416742954e-06
LOH O 1 0.9963871240615845
, O 0 3.389872915704473e-08
one O 0 2.429931100778049e-08
mutation O 0 4.392921653106896e-07
was O 0 1.1714706715793e-06
detected O 0 3.6082263932257774e-07
, O 0 1.4882457044507191e-08
and O 0 3.160480943620314e-08
in O 0 3.26262785677045e-08
9 O 0 8.448514563497156e-07
( O 0 1.4506985834827901e-08
56 O 0 4.268926829809061e-07
% O 0 1.4904300016382876e-08
) O 0 2.5078197296579674e-09
of O 0 3.853878993709259e-09
the O 0 5.219483227847377e-06
tumors B-Disease 1 1.0
without O 0 2.3601107841386693e-06
LOH O 1 0.999572217464447
, O 0 7.381770927850084e-08
both O 0 4.886745585963581e-08
mutations O 0 2.9536333840951556e-06
were O 0 1.705843430954701e-07
found O 0 3.857154240449745e-07
. O 0 1.0142083510800148e-06

Thus O 0 2.670767753443215e-05
, O 0 1.0714938269984486e-07
a O 0 4.276505549682952e-08
total O 0 2.3339241650432996e-08
of O 0 1.09977520423854e-08
45 O 0 6.531608391924237e-07
mutations O 0 3.578553560146247e-06
were O 0 4.87867112042295e-07
identified O 0 3.6919122976541985e-06
in O 0 3.833815299003618e-06
tumors B-Disease 1 1.0
of O 0 1.9836117814975296e-07
36 O 0 1.016126225295011e-05
patients O 0 3.5039875001530163e-06
. O 0 8.578613233112264e-07

Thirty O 0 0.00016820340533740819
- O 0 5.606860577245243e-05
nine O 0 4.832245963370951e-07
of O 0 9.04741881413429e-09
the O 0 3.5491158456579797e-08
mutations O 0 8.81492496773717e-07
- O 0 4.2908322939183563e-07
including O 0 1.740004940131712e-08
34 O 0 3.3670269772301253e-07
small O 0 4.8279254372118885e-08
mutations O 0 1.208617845804838e-06
, O 0 5.317597917553485e-09
2 O 0 1.891688761190835e-08
large O 0 1.2961115736231932e-08
structural O 0 2.4240141556219896e-06
alterations O 0 1.3825592759530991e-05
, O 0 3.8716446937314686e-08
and O 0 8.913120552733744e-08
hypermethylation O 0 2.3903279725345783e-05
in O 0 1.7603569801849517e-07
3 O 0 2.294233490829356e-05
tumors O 1 1.0
- O 0 0.025701798498630524
were O 0 9.213711564370897e-06
not O 0 1.1731001592352186e-07
detected O 0 3.5574936418925063e-07
in O 0 1.0322509957916282e-08
the O 0 3.906418655219568e-08
corresponding O 0 3.58923358589891e-07
peripheral O 0 2.580765612947289e-05
blood O 0 1.103871181840077e-05
DNA O 0 1.0688351721910294e-05
. O 0 9.961402156477561e-07

In O 0 4.5064098230795935e-06
6 O 0 1.0375654710514937e-05
( O 0 3.551398606305156e-07
17 O 0 9.466507435718086e-07
% O 0 3.3741077487547955e-08
) O 0 1.7445502820123693e-09
of O 0 1.076187361448433e-09
the O 0 5.550435844270396e-08
36 O 0 1.7860329535324126e-06
patients O 0 3.696731809554876e-08
, O 0 4.464851599550457e-09
a O 0 7.328056739197564e-08
mutation O 0 3.149065378238447e-06
was O 0 4.162482582614757e-06
detected O 0 2.0698303160315845e-07
in O 0 3.967147055305986e-09
constitutional O 0 5.4707875563053676e-08
DNA O 0 9.700717100713518e-07
, O 0 1.9981893473186574e-08
and O 0 2.043773150717243e-08
1 O 0 1.0546379769493797e-08
of O 0 1.96033211885549e-09
these O 0 3.451468444382044e-08
mutations O 0 1.5438268974321545e-06
is O 0 2.0490308116904998e-08
known O 0 8.307197418844225e-08
to O 0 3.203302512133632e-08
be O 0 2.9061064665825143e-08
associated O 0 7.142672586724075e-08
with O 0 9.34548509690103e-08
reduced O 0 6.746094641130185e-06
expressivity O 0 0.00044333122787065804
. O 0 2.564821443229448e-06

The O 0 1.3181978602005984e-06
presence O 0 2.996795558374288e-07
of O 0 1.4658378511001047e-08
a O 0 8.552019181706783e-08
constitutional O 0 8.15948908439168e-07
mutation O 0 1.1199977052456234e-05
was O 0 0.00019748833437915891
not O 0 4.057456237660517e-08
associated O 0 1.8249606270615004e-08
with O 0 7.019550718467826e-09
an O 0 2.3186741415770484e-08
early O 0 1.4936550769562018e-06
age O 0 2.7438295546744484e-07
at O 0 1.7262608764667675e-07
treatment O 0 1.394432160850556e-06
. O 0 7.337293368436804e-07

In O 0 2.7293369839753723e-06
1 O 0 1.6761885035521118e-06
patient O 0 4.851556695939507e-06
, O 0 9.436693204634139e-08
somatic O 0 5.6789949667290784e-06
mosaicism O 0 0.00234332331456244
was O 0 9.041288285516202e-05
demonstrated O 0 3.0298488695734704e-07
by O 0 2.9248281574467683e-09
molecular O 0 4.1518937621276564e-08
analysis O 0 1.3664100073640384e-08
of O 0 6.436589039537921e-09
DNA O 0 1.0676448027879815e-06
and O 0 1.50963700207285e-07
RNA O 0 5.151764526090119e-07
from O 0 7.646237065728201e-08
peripheral O 0 2.9163984436308965e-05
blood O 0 2.431159737170674e-05
. O 0 1.2671436024902505e-06

In O 0 5.756220616603969e-06
2 O 0 5.067782240075758e-06
patients O 0 8.413916248173336e-07
without O 0 3.468852227683783e-08
a O 0 2.1495340263300022e-07
detectable O 0 4.7679004637757316e-05
mutation O 0 2.0467007288971217e-06
in O 0 3.5821614119413425e-08
peripheral O 0 9.59886601776816e-05
blood O 0 6.217760528670624e-05
, O 0 3.265532484419964e-07
mosaicism O 0 8.004783740034327e-05
was O 0 1.8079919755109586e-05
suggested O 0 2.9087220809742576e-07
because O 0 8.09518674316223e-09
1 O 0 1.5637011685498692e-08
of O 0 2.7940381119861968e-09
the O 0 2.3819737293706567e-07
patients O 0 1.0663753528206144e-05
showed O 0 0.02022973634302616
multifocal O 1 0.9999942779541016
tumors B-Disease 1 1.0
and O 0 2.9804264158883598e-06
the O 0 3.118023172987705e-08
other O 0 1.5171529810231732e-08
later O 0 4.126359556266834e-07
developed O 0 6.777272005820123e-07
bilateral B-Disease 0 2.0967536329408176e-06
retinoblastoma I-Disease 0 0.00020568512263707817
. O 0 3.4864710869442206e-06

In O 0 3.047472773687332e-06
conclusion O 0 5.805257501378946e-07
, O 0 8.332015255518854e-08
our O 0 3.934774994718282e-08
results O 0 7.770307774990215e-08
emphasize O 0 1.2587580044964852e-07
that O 0 9.886396590275126e-09
the O 0 9.380233478850641e-09
manifestation O 0 3.7670201891160104e-07
and O 0 6.658464712927525e-08
transmissibility O 0 1.8049436221190263e-06
of O 0 7.280295477585241e-09
retinoblastoma B-Disease 0 1.9723945570149226e-06
depend O 0 4.2359797447488745e-08
on O 0 3.7716861811532e-07
the O 0 1.9282632379713505e-08
nature O 0 1.2101706303724313e-08
of O 0 1.138027450053869e-09
the O 0 1.3385942132515538e-08
first O 0 3.3295714274572674e-07
mutation O 0 2.96295610269226e-07
, O 0 4.176107903930415e-09
its O 0 2.3014889993788756e-09
time O 0 1.1400920207904619e-08
in O 0 4.451985446962681e-09
development O 0 3.0527600447527448e-09
, O 0 1.8067359164319896e-08
and O 0 1.9942561380048573e-08
the O 0 4.8055430745819194e-09
number O 0 1.167023899739661e-08
and O 0 1.4639992329534834e-08
types O 0 7.790293743425991e-09
of O 0 3.3080436168120286e-09
cells O 0 8.408792240288676e-08
that O 0 1.3142792631981592e-08
are O 0 1.3295281320324648e-08
affected O 0 8.975524679044611e-08
. O 0 6.815429287598818e-08
. O 0 3.8784597222729644e-07

Hereditary B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9997180104255676
of I-Disease 0 2.554651530317642e-07
the I-Disease 0 2.416359734525031e-07
fifth I-Disease 0 1.1457529581093695e-05
component I-Disease 0 2.196370161300365e-07
of I-Disease 0 5.545279790908353e-09
complement I-Disease 0 1.685185253563759e-07
in O 0 2.2313473380108917e-07
man O 0 5.04875133628957e-05
. O 0 1.0094425988427247e-06

I O 0 0.0033720533829182386
. O 0 3.4055232390528545e-05

Clinical O 0 0.0005286390660330653
, O 0 3.193674956492032e-06
immunochemical O 0 8.705224172445014e-05
, O 0 5.211114739722689e-07
and O 0 2.39600836948739e-07
family O 0 9.464629329158925e-07
studies O 0 3.9557212971885747e-07
. O 0 7.725102477706969e-07

The O 0 2.523996045056265e-06
first O 0 5.967687002339517e-07
recognized O 0 3.3424532830395037e-07
human O 0 4.914450641990697e-07
kindred O 0 0.00040098323370330036
with O 0 6.730845780111849e-05
hereditary B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.6846883296966553
of I-Disease 0 2.023795708794296e-08
the I-Disease 0 1.3698735301659326e-07
fifth I-Disease 0 1.0538925380387809e-05
component I-Disease 0 4.0104731624523993e-07
of I-Disease 0 1.6347954101547657e-08
complement I-Disease 0 7.76497245169594e-07
( O 0 3.2373432645727007e-07
C5 O 0 0.00023351206618826836
) O 0 4.460810743012189e-08
is O 0 7.819713232493086e-08
described O 0 4.9881055019795895e-06
. O 0 1.5375308066722937e-06

The O 0 3.624436430982314e-06
proband O 0 2.4963683245005086e-05
, O 0 1.0901000990770626e-07
a O 0 1.4099222767072206e-07
20 O 0 1.4844557938431535e-07
- O 0 1.8714929410634795e-06
year O 0 1.4262903391681903e-07
- O 0 5.129446435603313e-06
old O 0 8.55161215440603e-06
black O 0 1.5391933629871346e-05
female O 0 9.953559128916822e-06
with O 0 1.9710167180164717e-05
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999927282333374
erythematosus I-Disease 1 0.9999998807907104
since O 0 1.6615287677268498e-05
age O 0 1.231008582180948e-06
11 O 0 2.102677854054491e-07
, O 0 8.163397779981096e-08
lacked O 0 2.6994641757482896e-06
serum O 0 2.4138425942510366e-05
hemolytic O 0 0.00010879581532208249
complement O 0 2.226452124887146e-07
activity O 0 2.405239172276197e-07
, O 0 2.1577283959572924e-08
even O 0 4.5674408255536036e-08
during O 0 3.500923924093513e-07
remission O 0 1.0418091733299661e-05
. O 0 7.642518085049232e-07

C5 O 1 0.7355525493621826
was O 0 0.0002504817384760827
undetectable O 0 1.9895596778951585e-05
in O 0 1.381194323357704e-07
her O 0 3.089488700425136e-06
serum O 0 7.308329713850981e-06
by O 0 1.9688807029183408e-08
both O 0 5.837200944824872e-08
immunodiffusion O 0 6.195949390530586e-05
and O 0 5.309853804646991e-06
hemolytic O 0 0.009871136397123337
assays O 0 8.425330452155322e-05
. O 0 3.1277791094908025e-06

Other O 0 1.0392243439127924e-06
complement O 0 8.727778890715854e-07
components O 0 7.1051829308999e-07
were O 0 2.9652991884177027e-07
normal O 0 4.114276066502498e-07
during O 0 2.6028223487628566e-07
remission O 0 1.2694042652583448e-06
of O 0 4.3895504120428086e-08
lupus O 0 0.0021236955653876066
, O 0 2.0008575063457101e-07
but O 0 3.8850856753924745e-08
C1 O 0 9.751847755978815e-06
, O 0 6.156992071737477e-08
C4 O 0 2.234816383861471e-05
, O 0 2.074262539508709e-07
C2 O 0 1.3270398994791321e-05
, O 0 5.5729564962803124e-08
and O 0 9.795385835786874e-08
C3 O 0 4.649953552871011e-05
levels O 0 6.646353085670853e-07
fell O 0 3.73472721548751e-05
during O 0 1.11831980120769e-06
exacerbations O 0 0.0007947444100864232
. O 0 3.8015248264855472e-06

A O 0 3.7361023714765906e-05
younger O 0 7.099836693669204e-06
half O 0 9.257972237719514e-07
- O 0 1.5645668099750765e-05
sister O 0 2.3392836737912148e-05
, O 0 1.5087447025052825e-07
who O 0 1.0214649819317856e-06
had O 0 3.3558175346115604e-05
no O 0 6.385886308635236e-07
underlying O 0 0.00040603880188427866
disease O 0 0.00018859432020690292
, O 0 2.187494345662344e-07
was O 0 0.0002728355466388166
also O 0 4.989566946278501e-07
found O 0 1.118915733400172e-07
to O 0 7.201686003099894e-08
lack O 0 6.234062084331526e-07
immunochemically O 0 9.175777086056769e-05
detectable O 0 3.62330065399874e-05
C5 O 0 0.00023926899302750826
. O 0 2.4921678232203703e-06

By O 0 1.4333199032989796e-05
hemolytic O 0 0.02715618908405304
assay O 0 8.867833821568638e-05
, O 0 1.1643267043837113e-06
she O 0 2.016121015913086e-06
exhibited O 0 5.011972348256677e-07
1 O 0 8.715537802572726e-08
- O 0 2.802507651722408e-06
2 O 0 4.191802815967094e-07
% O 0 7.635144072537514e-09
of O 0 9.699980818567155e-10
the O 0 1.689887163536241e-08
normal O 0 3.5550345955925877e-07
serum O 0 4.36398659076076e-06
C5 O 0 2.6972978957928717e-05
level O 0 5.340297093425761e-08
and O 0 3.146844562706974e-08
normal O 0 6.337793223565313e-08
concentrations O 0 1.5443085032984527e-07
of O 0 1.866036436481977e-09
other O 0 4.0660150801841155e-09
complement O 0 1.584711952773432e-07
components O 0 9.562406830809778e-07
. O 0 7.741002150396525e-07

C5 O 0 0.02209380827844143
levels O 0 9.05758952285396e-06
of O 0 4.4552326272651044e-08
other O 0 1.967472940123116e-08
family O 0 2.121158928503064e-07
members O 0 2.5173914508513917e-08
were O 0 5.3265640787003576e-08
either O 0 8.755104197177843e-09
normal O 0 5.961258864317642e-08
or O 0 1.9834335063251274e-08
approximately O 0 7.699944681860416e-09
half O 0 5.961464211168277e-08
- O 0 2.069158654194325e-06
normal O 0 1.3601504633697914e-07
, O 0 1.2839516116969207e-08
consistent O 0 1.1726035609171959e-07
with O 0 1.322896281408248e-07
autosomal O 0 0.0003005255130119622
codominant O 0 4.9941521865548566e-05
inheritance O 0 1.2418910273481742e-06
of O 0 1.1498690888345209e-08
the O 0 1.1696784696368923e-07
gene O 0 3.986889714724384e-05
determining O 0 0.0005749955307692289
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 6.4301884776796214e-06

Normal O 0 0.002183521632105112
hemolytic O 1 0.9507102370262146
titers O 0 0.012276693247258663
were O 0 2.6627212719176896e-05
restored O 0 5.285764927975833e-06
to O 0 1.0278269257923967e-07
both O 0 1.7910716678670724e-06
homozygous O 1 0.9929798245429993
C5 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
( O 0 1.9891631382051855e-05
C5D B-Disease 1 1.0
) O 0 8.004844858078286e-07
sera O 0 2.7151440917805303e-06
by O 0 3.36080430152208e-09
addition O 0 6.422363529878794e-09
of O 0 6.8325816116043825e-09
highly O 0 2.5812349235820875e-07
purified O 0 1.0154180927202106e-06
human O 0 4.323553639551392e-07
C5 O 0 0.000214210624108091
. O 0 1.5460075246664928e-06

In O 0 2.9870652724639513e-06
specific O 0 8.159800586327037e-07
C5 O 0 0.00021524474141187966
titrations O 0 0.00010515806934563443
, O 0 2.848686051493132e-07
however O 0 9.103212050831644e-08
, O 0 3.057341757539689e-08
it O 0 7.150864433924653e-08
was O 0 1.4048092452867422e-05
noted O 0 1.9466835965431528e-07
that O 0 6.950485520462735e-09
when O 0 8.669773343683573e-09
limited O 0 4.168253298075797e-09
amounts O 0 3.858859010108517e-09
of O 0 7.0851249311942865e-09
C5 O 0 6.271732127061114e-05
were O 0 2.0261003896848706e-07
assayed O 0 4.6622272975582746e-07
in O 0 1.116551029411994e-08
the O 0 5.127439806074108e-09
presence O 0 1.0927976745733758e-08
of O 0 4.346632831442321e-09
low O 0 6.361147484312824e-07
dilutions O 0 7.345810900005745e-06
of O 0 3.3726855974691716e-08
either O 0 6.467258231168671e-07
C5D B-Disease 1 0.9999998807907104
serum O 0 9.505185516900383e-06
, O 0 1.0161427255184208e-08
curving O 0 3.0865032840665663e-07
rather O 0 1.4449463847654442e-08
than O 0 4.75181272108216e-09
linear O 0 3.9133389861945034e-08
dose O 0 2.510070657990582e-07
- O 0 3.910840007392835e-07
response O 0 4.582974000300055e-08
plots O 0 6.353139383463713e-07
were O 0 2.8864130854344694e-06
consistently O 0 3.882451892422978e-06
obtained O 0 5.799956070973167e-08
, O 0 1.0298871089275963e-08
suggesting O 0 5.5033883228361447e-08
some O 0 9.358057440067569e-09
inhibitory O 0 9.874072475213325e-07
effect O 0 1.0372016276960494e-06
. O 0 4.859577416027605e-07

Further O 0 4.2228371057717595e-06
studies O 0 4.843027454626281e-07
suggested O 0 2.1794191695789777e-07
that O 0 1.7119901940532145e-08
low O 0 1.5739653917989926e-06
dilutions O 0 0.00011816683399956673
of O 0 5.135218543728115e-07
C5D B-Disease 1 1.0
serum O 0 1.938720561156515e-05
contain O 0 8.527505457323059e-08
a O 0 5.186894114217466e-08
factor O 0 1.4896804145791975e-07
( O 0 3.1902725794452635e-08
or O 0 2.6433964350758288e-08
factors O 0 2.5433470440816563e-08
) O 0 6.651277750790996e-09
interfering O 0 2.6357140470167906e-08
at O 0 2.1179040743390942e-08
some O 0 1.854911779730628e-09
step O 0 2.058671455529293e-08
in O 0 8.855687738673623e-09
the O 0 9.662394262477392e-08
hemolytic O 0 4.5019467506790534e-05
assay O 0 1.1796389571827604e-06
of O 0 3.727402742015329e-08
C5 O 0 0.00018716299382504076
, O 0 3.126383774088026e-08
rather O 0 6.62292087838523e-09
than O 0 3.958938066261908e-09
a O 0 3.361152067782314e-08
true O 0 4.727952784833178e-07
C5 O 0 7.1275258960668e-05
inhibitor O 0 4.430046828929335e-06
or O 0 2.707456872030889e-07
inactivator O 0 6.63070532027632e-05
. O 0 1.9679719116538763e-06

Of O 0 1.1763944485210232e-06
clinical O 0 6.2591452660853975e-06
interest O 0 3.3112746677943505e-07
are O 0 4.980742929205917e-08
( O 0 3.353960309482318e-08
a O 0 8.618567903795338e-08
) O 0 2.716964608850958e-08
the O 0 1.709180885711703e-08
documentation O 0 3.264004249103891e-07
of O 0 1.4512471580019337e-07
membranous O 1 0.956407368183136
glomerulonephritis B-Disease 1 1.0
, O 0 0.002527946839109063
vasculitis B-Disease 1 1.0
, O 0 1.7237174688489176e-05
and O 0 0.07942156493663788
arthritis B-Disease 1 1.0
in O 0 4.229239038977539e-07
an O 0 1.9080576407759509e-07
individual O 0 1.1273248645693457e-07
lacking O 0 2.388074790360406e-06
C5 O 0 0.03694240376353264
( O 0 4.850363310993089e-08
and O 0 9.926890420786094e-09
its O 0 6.761898596607807e-09
biologic O 0 6.353793082780612e-07
functions O 0 1.0699270802660976e-08
) O 0 1.553457096292732e-08
, O 0 6.7103260725787095e-09
and O 0 5.0739831891633e-08
( O 0 1.3767382789353633e-08
b O 0 4.059802094502629e-08
) O 0 2.407201549203819e-09
a O 0 2.1960220308869793e-08
remarkable O 0 1.780659175665278e-07
propensity O 0 7.1617755565966945e-06
to O 0 1.8811483641911764e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9999998807907104
in O 0 6.382580153285744e-08
the O 0 7.995722484110956e-08
proband O 0 1.550463457533624e-05
, O 0 3.5479313709174676e-08
even O 0 1.1687145473615601e-08
during O 0 1.9745442614294006e-08
periods O 0 2.8156419418223777e-08
of O 0 3.0484077484516092e-09
low O 0 1.1886053243870265e-06
- O 0 3.3948151667573256e-06
dose O 0 3.4090240319528675e-07
or O 0 1.0486465029657666e-08
alternate O 0 8.325216072080366e-08
- O 0 1.1769110642489977e-05
day O 0 1.610944991625729e-06
corticosteroid O 0 7.743295282125473e-05
therapy O 0 5.259822864900343e-05
. O 0 2.8122717594669666e-06

Other O 0 2.164725628972519e-06
observations O 0 3.803700792559539e-06
indicate O 0 2.1103853669046657e-06
that O 0 5.532773883487607e-08
the O 0 1.9527023198406823e-07
C5D B-Disease 1 1.0
state O 0 6.072229297160447e-08
is O 0 1.1877374639368554e-08
compatible O 0 5.342936049146374e-08
with O 0 3.502439227531795e-08
normal O 0 4.445352601578634e-07
coagulation O 0 8.760200671531493e-07
function O 0 2.456315151277977e-08
and O 0 2.118550668228636e-08
the O 0 1.1213658446251884e-08
capacity O 0 1.6731135588088364e-08
to O 0 4.417306520565489e-09
mount O 0 2.2837446067569545e-06
a O 0 3.0287678782769945e-06
neutrophilic O 0 0.011984688229858875
leukocytosis O 0 0.01373391505330801
during O 0 1.2041943591611926e-05
pyogenic B-Disease 0 0.09501395374536514
infection I-Disease 0 0.0004464121884666383
. O 0 5.378824994295428e-07
. O 0 1.1871416063513607e-06

Susceptibility O 1 0.8123936653137207
to O 0 0.00020073527412023395
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.14453843235969543
twins O 0 0.25746089220046997
: O 0 4.662591734927446e-08
the O 0 3.8731791107693425e-09
role O 0 1.569249441502052e-08
of O 0 8.890246760984155e-09
genes O 0 3.212199430890905e-07
, O 0 1.5328326696817385e-07
HLA O 0 3.638050111476332e-05
, O 0 5.2739949296665145e-08
and O 0 3.137758497473442e-08
the O 0 5.765323507489484e-08
environment O 0 1.640114874135179e-06
. O 0 7.812443527654978e-07

OBJECTIVE O 0 1.5558012819383293e-05
To O 0 1.6558973925384635e-07
determine O 0 6.460773249727936e-08
the O 0 1.3940087306707483e-08
relative O 0 2.6902432637143647e-07
effects O 0 1.1719165513568441e-06
of O 0 1.1530096877265805e-08
genetic O 0 2.6711973077908624e-06
and O 0 1.8433802040362934e-07
environmental O 0 6.697376875308692e-08
factors O 0 1.5561113286821637e-08
in O 0 1.7254691897505836e-07
susceptibility O 0 0.03787091001868248
to O 0 0.018670935183763504
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0015259940410032868
AS B-Disease 1 0.9975402355194092
) O 0 7.244566972985922e-07
. O 0 8.962743436313758e-07

METHODS O 0 6.34687312413007e-05
Twins O 0 0.000917221768759191
with O 0 1.4583397387468722e-06
AS B-Disease 1 0.9999552965164185
were O 0 8.810951840132475e-06
identified O 0 7.746533583485871e-07
from O 0 4.993543800679845e-09
the O 0 3.452627339584069e-08
Royal O 0 4.439910298970062e-06
National O 0 2.572569712810946e-07
Hospital O 0 7.992205610207748e-06
for O 0 9.306348829341005e-07
Rheumatic B-Disease 1 0.998327910900116
Diseases I-Disease 0 0.00028258422389626503
database O 0 5.424375558504835e-06
. O 0 4.268110387783963e-06

Clinical O 0 0.00026666821213439107
and O 0 2.5452650334045757e-06
radiographic O 0 0.00023390466230921447
examinations O 0 1.4131561329122633e-05
were O 0 2.1441549051814945e-06
performed O 0 6.708505111419072e-07
to O 0 1.631773827170946e-08
establish O 0 4.971138878318015e-07
diagnoses O 0 0.013998136855661869
, O 0 7.381981390608416e-07
and O 0 1.138418519985862e-05
disease O 0 0.00041983556002378464
severity O 0 8.383983367821202e-05
was O 0 9.389539627591148e-06
assessed O 0 1.3845956914337876e-07
using O 0 3.144324622894601e-08
a O 0 1.2318758990659262e-07
combination O 0 2.890719201786851e-07
of O 0 1.674965410813911e-08
validated O 0 6.202679401212663e-07
scoring O 0 6.895596129652404e-07
systems O 0 5.285815859679133e-06
. O 0 8.670875217831053e-07

HLA O 0 0.0027487273328006268
typing O 0 5.384476753533818e-05
for O 0 4.6946013299020706e-07
HLA O 0 6.720379315083846e-05
- O 0 5.441442226583604e-06
B27 O 0 4.805889602721436e-06
, O 0 8.183789645954676e-08
HLA O 0 6.477735951193608e-06
- O 0 9.235389484274492e-07
B60 O 0 7.994103157216159e-07
, O 0 2.1107378955775857e-08
and O 0 9.00414320881282e-08
HLA O 0 9.526118083158508e-05
- O 0 0.0016970564611256123
DR1 O 1 0.6563624739646912
was O 0 1.1839198123198003e-05
performed O 0 2.920749579971016e-07
by O 0 5.525641721959573e-09
polymerase O 0 4.410287601785967e-07
chain O 0 1.0692577916415757e-06
reaction O 0 2.4545213861415505e-08
with O 0 4.648727625067295e-09
sequence O 0 9.2960625863725e-08
- O 0 2.3744370025724493e-07
specific O 0 1.2633034174314162e-08
primers O 0 2.2019164589437423e-06
, O 0 2.9882222918331536e-08
and O 0 9.937483014255122e-08
zygosity O 0 8.58009843796026e-06
was O 0 2.0314744233473903e-06
assessed O 0 2.5317632434962434e-07
using O 0 1.8998974837813876e-07
microsatellite O 0 0.0001164261411759071
markers O 0 0.00031952204881235957
. O 0 3.379813051651581e-06

Genetic O 0 0.0007333868416026235
and O 0 1.4831867929387954e-06
environmental O 0 3.701113371334941e-07
variance O 0 2.6370773298367567e-07
components O 0 1.1431707207520958e-06
were O 0 1.254067456102348e-06
assessed O 0 1.605842072649466e-07
with O 0 1.4269959436319368e-08
the O 0 8.831806752596094e-08
program O 0 7.891348019484212e-08
Mx O 0 9.283735948883987e-07
, O 0 5.694925864219158e-09
using O 0 3.5297997857952623e-09
data O 0 3.670748682793601e-08
from O 0 4.249645968457116e-09
this O 0 2.7101363375692245e-09
and O 0 4.689929511414448e-08
previous O 0 1.3716329760882218e-07
studies O 0 1.0458740540286726e-08
of O 0 4.1955003915461475e-09
twins O 0 1.699154745438136e-05
with O 0 4.1131426087304135e-07
AS B-Disease 1 0.9999316930770874
. O 0 4.450640062714228e-06

RESULTS O 0 4.898318002233282e-05
Six O 0 8.128088211378781e-07
of O 0 9.541084722286541e-08
8 O 0 9.241431143891532e-06
monozygotic O 0 0.0004707150801550597
( O 0 2.1726093564211624e-06
MZ O 1 0.992611825466156
) O 0 4.572069087771524e-07
twin O 0 0.00020695537386927754
pairs O 0 1.806811269489117e-05
were O 0 6.794989167246968e-05
disease O 0 3.7470879306056304e-06
concordant O 0 8.658721526444424e-06
, O 0 1.3603074933143944e-07
compared O 0 8.696076747582993e-08
with O 0 1.1396984689326928e-08
4 O 0 2.398122944669012e-07
of O 0 7.564247006541791e-09
15 O 0 1.27954677964226e-07
B27 O 0 3.4493541534175165e-06
- O 0 3.427950287004933e-05
positive O 0 8.041510568546073e-07
dizygotic O 0 1.0548316822678316e-05
( O 0 1.1296052093712206e-07
DZ O 0 0.00013465389201883227
) O 0 6.225602078302472e-08
twin O 0 1.1036227078875527e-05
pairs O 0 1.7640336409385782e-06
( O 0 8.026388798043627e-08
27 O 0 2.134667283826275e-06
% O 0 3.143749083278635e-08
) O 0 3.947838500550915e-09
and O 0 1.785353198613393e-08
4 O 0 7.227350096172813e-08
of O 0 1.608176880552037e-08
32 O 0 4.243980583851226e-06
DZ O 0 0.13812406361103058
twin O 0 0.0015063945902511477
pairs O 0 2.8748472686856985e-06
overall O 0 4.825614723813487e-06
( O 0 3.3935606325030676e-08
12 O 0 9.054741667569033e-08
. O 0 3.375504320501932e-08
5 O 0 2.109637478042714e-07
% O 0 5.966013816305349e-08
) O 0 4.285438492956928e-08
. O 0 3.023628494247532e-07

Nonsignificant O 0 0.002445966936647892
increases O 0 3.744188143173233e-05
in O 0 1.2203641119867825e-07
similarity O 0 4.0140011492439953e-07
with O 0 2.8453943201611764e-08
regard O 0 6.814961039935952e-08
to O 0 1.11237021371835e-07
age O 0 1.0053997812065063e-06
at O 0 1.3692299489775905e-06
disease O 0 2.006613794947043e-05
onset O 0 7.191773875092622e-06
and O 0 1.7739419888584962e-07
all O 0 1.5876859826846612e-09
of O 0 3.6783796009132175e-09
the O 0 6.269740424613701e-07
disease O 0 5.634136323351413e-05
severity O 0 2.3134358343668282e-05
scores O 0 3.7348581827245653e-06
assessed O 0 1.4131976513453992e-06
were O 0 1.5148850707191741e-06
noted O 0 1.6054913203333854e-06
in O 0 1.6419787698396249e-06
disease O 0 0.0002765436365734786
- O 0 0.00027641604538075626
concordant O 0 0.10473211854696274
MZ O 1 0.9993454813957214
twins O 0 0.0002355963079025969
compared O 0 1.9205645003239624e-06
with O 0 5.695710001418774e-07
concordant O 0 0.044798824936151505
DZ O 1 0.9959926009178162
twins O 0 0.003412877907976508
. O 0 9.530237548460718e-06

HLA O 0 0.009474003687500954
- O 0 0.0003945211065001786
B27 O 0 3.400885543669574e-05
and O 0 3.6893851529384847e-07
B60 O 0 4.930787781631807e-06
were O 0 2.9618823305099795e-07
associated O 0 4.2579888059890436e-08
with O 0 1.69025771157294e-08
the O 0 1.0110651373906876e-06
disease O 0 6.430066605389584e-06
in O 0 9.413287216375466e-08
probands O 0 3.4445351047907025e-05
, O 0 4.791505503476401e-08
and O 0 1.0665040406365733e-08
the O 0 1.1403855637581728e-08
rate O 0 9.07557421214733e-07
of O 0 1.983577213593435e-08
disease O 0 2.932045845227549e-06
concordance O 0 3.952277438656893e-06
was O 0 7.83538052928634e-06
significantly O 0 2.010397565754829e-06
increased O 0 2.7997617735309177e-07
among O 0 3.304488416233653e-08
DZ O 0 0.02296001836657524
twin O 0 0.00030608195811510086
pairs O 0 1.068784740709816e-06
in O 0 7.855531691802753e-08
which O 0 1.4860124508686567e-07
the O 0 6.221222292879247e-08
co O 0 8.881724170350935e-06
- O 0 0.00023158085241448134
twin O 0 0.008028189651668072
was O 0 9.066958227776922e-06
positive O 0 1.4266802850215754e-08
for O 0 4.185796598221714e-09
both O 0 4.315047519298787e-08
B27 O 0 8.558906301914249e-06
and O 0 1.482225229665346e-06
DR1 O 0 0.00390355265699327
. O 0 2.919865892181406e-06

Additive O 0 0.0001854231086326763
genetic O 0 6.432408554246649e-05
effects O 0 2.3815791792003438e-05
were O 0 6.811374078097288e-07
estimated O 0 6.683772824089829e-08
to O 0 6.434710986269465e-09
contribute O 0 1.7963245113605808e-08
97 O 0 2.927353079940076e-07
% O 0 2.7938051871956304e-08
of O 0 2.1683344009204575e-09
the O 0 2.4323840719375767e-08
population O 0 6.51432756626491e-08
variance O 0 5.028835516895924e-07
. O 0 8.094423833426845e-07

CONCLUSION O 0 3.406068935873918e-05
Susceptibility O 0 0.00043392524821683764
to O 0 2.017494352912763e-06
AS B-Disease 1 0.9973756074905396
is O 0 1.434454617310621e-07
largely O 0 7.713707361745037e-08
genetically O 0 3.5097227168989775e-07
determined O 0 2.06908157451835e-06
, O 0 3.8740228802680576e-08
and O 0 2.4761753536495235e-08
the O 0 2.022892608977145e-08
environmental O 0 1.6048133488766325e-07
trigger O 0 2.492899739081622e-06
for O 0 2.8860272394126696e-08
the O 0 1.0688091833799263e-06
disease O 0 2.300951564393472e-05
is O 0 1.3729443537613406e-07
probably O 0 6.453690843954973e-07
ubiquitous O 0 7.161864232330117e-06
. O 0 1.9015974430658389e-06

HLA O 0 0.0073016854003071785
- O 0 0.00013181781105231494
B27 O 0 8.09785160527099e-06
accounts O 0 1.6729052276787115e-07
for O 0 5.644197997867195e-09
a O 0 4.503194972471647e-08
minority O 0 1.300911804946736e-07
of O 0 3.105912638190489e-09
the O 0 3.91224190821049e-08
overall O 0 2.634477277752012e-05
genetic O 0 2.7970820156042464e-05
susceptibility O 0 3.726572685991414e-05
to O 0 6.067314757274289e-07
AS B-Disease 1 0.9996961355209351
. O 0 4.8266870180668775e-06

Cell O 0 0.0028832529205828905
cycle O 0 0.000144415651448071
- O 0 1.5829184121685103e-05
dependent O 0 7.756897275612573e-07
colocalization O 0 7.260423899424495e-06
of O 0 5.2678018391816295e-08
BARD1 O 0 0.00015287076530512422
and O 0 6.12130236277153e-07
BRCA1 O 0 1.2806694940081798e-05
proteins O 0 7.920752409518172e-08
in O 0 2.722011593903062e-08
discrete O 0 4.498628243254643e-07
nuclear O 0 1.0147597322429647e-06
domains O 0 1.7733849517753697e-06
. O 0 9.89851173471834e-07

Germ O 0 0.029242493212223053
- O 1 0.6547694802284241
line O 0 0.0009738081716932356
mutations O 0 2.695142939046491e-06
of O 0 7.066743190620173e-09
the O 0 7.033048632365535e-08
BRCA1 O 0 5.5296542996075004e-05
gene O 0 1.1332170970490552e-06
predispose O 0 1.9770350263570435e-06
women O 0 1.1634960372930436e-07
to O 0 1.954553674465842e-08
early O 0 1.0435485364723718e-06
- O 0 0.01277993805706501
onset O 0 0.38250043988227844
breast B-Disease 1 0.9999910593032837
and I-Disease 1 0.9999167919158936
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.803529935453298e-08
compromising O 0 1.5203385146378423e-06
the O 0 8.034859177996623e-08
genes O 0 6.227739390851639e-07
presumptive O 0 1.4776122952753212e-05
function O 0 5.181317419555853e-08
as O 0 3.7714048772841124e-08
a O 0 1.6263288671325427e-06
tumor B-Disease 0 0.00014487592852674425
suppressor O 0 0.0005222584004513919
. O 0 4.563292804959929e-06

Although O 0 2.7218120521865785e-06
the O 0 1.2516856884303706e-07
biochemical O 0 1.6428496110165725e-06
properties O 0 5.508785534402705e-07
of O 0 3.824634120519477e-08
BRCA1 O 0 4.36124209954869e-05
polypeptides O 0 3.846967047138605e-06
are O 0 8.195223699658527e-08
not O 0 5.4875396671150156e-08
understood O 0 7.11246457285597e-08
, O 0 1.2212495903440868e-08
their O 0 6.0852585193060804e-09
expression O 0 1.7671744956260227e-07
pattern O 0 2.6873995011555962e-06
and O 0 1.3482831207056734e-07
subcellular O 0 5.337325546861393e-06
localization O 0 9.782659162738128e-07
suggest O 0 4.843402123810847e-08
a O 0 1.2419089756576795e-08
role O 0 5.68378411003323e-08
in O 0 7.78355442321299e-08
cell O 0 1.7749600374372676e-05
- O 0 4.733767855213955e-05
cycle O 0 1.6189866073546e-05
regulation O 0 1.670007122811512e-06
. O 0 6.658939923909202e-07

When O 0 2.0317289454396814e-05
resting O 0 1.8690705474000424e-05
cells O 0 1.4305326203611912e-06
are O 0 2.625748862783439e-08
induced O 0 1.4197128166415496e-06
to O 0 5.094192090382421e-08
proliferate O 0 1.5938483102218015e-06
, O 0 1.4146222859778845e-08
the O 0 1.4828874128625102e-08
steady O 0 2.0637451143556973e-06
- O 0 6.463336603701464e-07
state O 0 5.392063684439563e-09
levels O 0 7.122507472701045e-09
of O 0 1.882516587059513e-09
BRCA1 O 0 9.245364367416187e-07
increase O 0 4.519354490639671e-08
in O 0 1.6572428762628988e-08
late O 0 4.870341285823088e-07
G1 O 0 8.832133971736766e-06
and O 0 3.324776187696443e-08
reach O 0 4.446997792229013e-08
a O 0 3.026567441111183e-08
maximum O 0 1.0513886650187487e-07
during O 0 2.1211954503996822e-07
S O 0 2.5718100005178712e-05
phase O 0 2.410923798379372e-06
. O 0 1.4102733985055238e-06

Moreover O 0 2.724252590269316e-05
, O 0 3.597914428610238e-07
in O 0 8.333350365319347e-08
S O 0 3.528945308062248e-05
phase O 0 8.818288392831164e-07
cells O 0 5.135189553584496e-07
, O 0 6.276069797195305e-08
BRCA1 O 0 8.82520544109866e-06
polypeptides O 0 1.0425537766423076e-06
are O 0 2.2154331702495256e-08
hyperphosphorylated O 0 2.2788995011069346e-06
and O 0 7.796480616661938e-08
accumulate O 0 1.3864612924407993e-07
into O 0 2.486824790537412e-08
discrete O 0 7.713765057815181e-07
subnuclear O 0 1.8143931811209768e-05
foci O 0 2.4916518668760546e-05
termed O 0 1.0494114576431457e-05
" O 0 2.9478981105057755e-06
BRCA1 O 0 5.1084658480249345e-05
nuclear O 0 3.3488897770439507e-06
dots O 0 0.00043797475518658757
. O 0 2.7228297767578624e-06

" O 0 0.00042119284626096487
BRCA1 O 0 0.002926743123680353
associates O 0 0.00016280391719192266
in O 0 2.940206513812882e-07
vivo O 0 7.961115443322342e-06
with O 0 6.145740627516716e-08
a O 0 1.4841884876659606e-06
structurally O 0 0.002088353969156742
related O 0 1.7034079746736097e-06
protein O 0 8.429493391304277e-06
termed O 0 4.306412301957607e-05
BARD1 O 0 0.0019876512233167887
. O 0 6.163717443996575e-06

Here O 0 9.15772579901386e-06
we O 0 2.0259592758975487e-07
show O 0 3.5216854143982346e-07
that O 0 6.38831432198117e-09
the O 0 1.2731121046272165e-08
steady O 0 3.974480023316573e-06
- O 0 2.5775771064218134e-06
state O 0 9.51331458054483e-09
levels O 0 1.3063965909054787e-08
of O 0 2.571020063513174e-09
BARD1 O 0 1.1587921108002774e-05
, O 0 7.528953460678167e-09
unlike O 0 7.393900158803035e-09
those O 0 1.8503780729872688e-09
of O 0 5.932174751421826e-09
BRCA1 O 0 1.6698237232048996e-05
, O 0 4.3323161946773325e-08
remain O 0 4.7847837691961104e-08
relatively O 0 3.974358975256109e-08
constant O 0 1.927129602563582e-07
during O 0 2.1412724038327724e-07
cell O 0 1.5323183106374927e-05
cycle O 0 1.3331945410754997e-05
progression O 0 3.7624315154971555e-05
. O 0 2.1036096313764574e-06

However O 0 2.448267514409963e-05
, O 0 6.230192752809671e-07
immunostaining O 0 2.830665289366152e-05
revealed O 0 9.874856914393604e-06
that O 0 1.8111184374447475e-07
BARD1 O 0 5.4166703193914145e-05
resides O 0 9.497895803178835e-07
within O 0 5.3218517592767967e-08
BRCA1 O 0 5.590604359895224e-06
nuclear O 0 3.546230686879426e-07
dots O 0 5.138151755090803e-05
during O 0 3.1013090051601466e-07
S O 0 1.0645290785760153e-05
phase O 0 3.330812603508093e-08
of O 0 9.402011391657084e-10
the O 0 8.68379057550328e-09
cell O 0 2.0466811747610336e-06
cycle O 0 2.120773615388316e-06
, O 0 1.9122358807521778e-08
but O 0 3.525668423876027e-09
not O 0 3.152670347006392e-09
during O 0 1.456951626011005e-08
the O 0 5.170210926053187e-08
G1 O 0 3.174183439114131e-05
phase O 0 1.1749973509722622e-06
. O 0 6.41119186184369e-07

Nevertheless O 0 0.0004000438202638179
, O 0 1.3264653944133897e-06
BARD1 O 0 2.3733015041216277e-05
polypeptides O 0 5.186233465792611e-06
are O 0 2.094056483770146e-08
found O 0 3.052785046975259e-08
exclusively O 0 1.7380513028797395e-08
in O 0 1.7318731337923055e-08
the O 0 9.905006592703103e-09
nuclear O 0 2.7237721411665916e-08
fractions O 0 2.6058419422270163e-08
of O 0 1.2480682043403135e-09
both O 0 1.1983276593241499e-08
G1 O 0 1.1668128536257427e-05
- O 0 6.0337538343446795e-06
and O 0 3.0529076866514515e-07
S O 0 3.061921233893372e-05
- O 0 5.869001597602619e-06
phase O 0 2.4751468572503654e-06
cells O 0 3.1243564535543555e-06
. O 0 6.331485451482877e-07

Therefore O 0 1.1438837645982858e-05
, O 0 3.257057699102006e-07
progression O 0 3.087002824031515e-06
to O 0 4.4976069091262616e-08
S O 0 6.281698006205261e-05
phase O 0 7.842908189559239e-07
is O 0 3.531592795980032e-08
accompanied O 0 1.1141793976321424e-07
by O 0 2.6915858430953676e-09
the O 0 1.015594364162098e-08
aggregation O 0 1.462162231291586e-07
of O 0 1.30325332747816e-08
nuclear O 0 3.19964584605259e-07
BARD1 O 0 9.817213140195236e-06
polypeptides O 0 6.739162472513271e-07
into O 0 1.43176066558226e-07
BRCA1 O 0 3.5838053008774295e-05
nuclear O 0 3.5009213661396643e-06
dots O 0 0.00037879188312217593
. O 0 3.95100369132706e-06

This O 0 1.6514391063537914e-06
cell O 0 1.6772641174611636e-05
cycle O 0 1.4631648809881881e-05
- O 0 4.274905222700909e-06
dependent O 0 4.924067980027758e-07
colocalization O 0 1.8030029877991183e-06
of O 0 1.6818900050452612e-08
BARD1 O 0 9.084084740607068e-05
and O 0 9.666713367550983e-07
BRCA1 O 0 2.4221646526711993e-05
indicates O 0 1.0290333563034437e-07
a O 0 1.87852915445319e-08
role O 0 3.9575205335040664e-08
for O 0 3.058898911945107e-08
BARD1 O 0 3.4934892028104514e-05
in O 0 3.324541921756463e-07
BRCA1 O 0 0.00022212282055988908
- O 0 0.00026832392904907465
mediated O 0 0.0006766955484636128
tumor B-Disease 0 0.0006960189784877002
suppression O 0 1.9329736460349523e-05
. O 0 2.5548029043420684e-06

Ethnic O 0 7.906441896921024e-05
differences O 0 3.6039884435012937e-05
in O 0 7.527376624238968e-07
the O 0 7.414832907670643e-07
HFE O 0 0.0020492607727646828
codon O 0 5.5501463066320866e-05
282 O 0 2.3565871742903255e-05
( O 0 1.7705173149806797e-06
Cys O 0 0.010647340677678585
/ O 0 0.0001585615100339055
Tyr O 0 0.000379322562366724
) O 0 1.1323032822474488e-06
polymorphism O 0 4.067789268447086e-05
. O 0 3.5360121728444938e-06

Recent O 0 1.8819788238033652e-05
studies O 0 1.2551694226203836e-06
have O 0 1.1520642146933824e-06
shown O 0 1.012456323223887e-05
that O 0 0.0003430080250836909
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0012155637377873063
HH B-Disease 1 0.9153240323066711
) O 0 1.6225537535774492e-07
is O 0 4.0993768379848916e-08
likely O 0 2.3638878587917134e-07
to O 0 4.528284947014072e-08
be O 0 4.3871816046703316e-07
caused O 0 5.455458449432626e-07
by O 0 6.499655036407148e-09
homozygosity O 0 1.7547966990605346e-06
for O 0 4.079469650974943e-09
a O 0 1.8601124907036137e-07
Cys282Tyr O 0 2.241044057882391e-05
mutation O 0 5.929586563979683e-07
in O 0 1.947602257246217e-08
the O 0 4.964855904177057e-08
HFE O 0 6.827269680798054e-05
gene O 0 1.2174631365269306e-06
located O 0 1.0028629731095862e-06
4 O 0 1.9264712136646267e-06
. O 0 1.6014756738513825e-06

5 O 0 9.883423626888543e-05
Mb O 0 0.0004072876472491771
telomeric O 0 0.0003081182949244976
to O 0 2.954506726382533e-06
HLA O 0 0.0005041379481554031
- O 0 3.6393026675796136e-05
A O 0 7.874740731494967e-06
. O 0 3.8064513319113757e-06

Population O 0 7.959817594382912e-06
studies O 0 1.3926963049470942e-07
of O 0 9.045503901461416e-09
this O 0 1.3802246456862122e-08
polymorphism O 0 5.0187059059680905e-06
are O 0 8.514970950557199e-09
facilitated O 0 1.1602793392739841e-07
by O 0 1.0540568418093699e-08
the O 0 1.1653222387053574e-08
fact O 0 2.1654670945281396e-08
that O 0 7.3974266712184544e-09
the O 0 4.8832610843874136e-08
Cys282Tyr O 0 4.9337926611769944e-05
mutation O 0 1.1736545957319322e-06
creates O 0 2.2621952666668221e-07
a O 0 8.453577748923635e-08
Rsal O 0 4.656979854189558e-06
restriction O 0 3.032057236396213e-07
site O 0 1.3860530998499598e-06
. O 0 5.983832807032741e-07

We O 0 8.120402526401449e-06
have O 0 1.3709595236832683e-07
studied O 0 1.1198145699609086e-07
the O 0 3.384865721045571e-08
codon O 0 4.622532742359908e-06
282 O 0 2.826875288519659e-06
( O 0 5.52880635495967e-07
Cys O 0 0.00144085637293756
/ O 0 7.436039595631883e-05
Tyr O 0 8.949420589488e-05
) O 0 1.948934880147135e-07
polymorphism O 0 1.5721592490081093e-06
in O 0 1.4638986911563734e-08
different O 0 3.134881154664981e-08
ethnic O 0 4.460032698716532e-07
groups O 0 3.1640516340303293e-07
. O 0 6.809100909777044e-07

In O 0 2.30588557315059e-06
agreement O 0 3.2806562444420706e-07
with O 0 2.9819080538118214e-08
previous O 0 2.2477031791368063e-07
observations O 0 2.6164582322962815e-07
the O 0 5.427582294714739e-08
Tyr O 0 2.969337765534874e-05
allele O 0 2.23852475755848e-06
appeared O 0 8.570120371587109e-06
to O 0 2.2405137301007017e-08
be O 0 2.1973711739065038e-08
rare O 0 3.85116223355908e-08
or O 0 1.8880415098010417e-07
absent O 0 4.865429445999325e-07
in O 0 1.9049920751967875e-07
Asiatic O 0 2.2500073555420386e-06
( O 0 2.049300285023037e-08
Indian O 0 8.863698219840899e-09
, O 0 6.920668038645772e-09
Chinese O 0 1.0146978368652526e-08
) O 0 2.573695390140074e-08
populations O 0 5.266425660011009e-07
. O 0 3.2574831720921793e-07

The O 0 2.248962573503377e-06
highest O 0 1.6217259144468699e-06
allele O 0 2.8338797619653633e-06
frequency O 0 1.7941864598469692e-06
( O 0 3.9487737524268596e-08
7 O 0 1.0502061797978968e-07
. O 0 1.3669965603924084e-08
5 O 0 1.5215162818549288e-07
% O 0 5.1421430669051915e-08
) O 0 1.4528112934897308e-08
was O 0 3.674136451081722e-06
found O 0 1.53465236962802e-07
in O 0 1.1536580046822564e-07
Swedes O 0 0.0001222869468620047
. O 0 1.419628915755311e-06

Saamis O 0 0.0015514076221734285
( O 0 4.365127097116783e-06
2 O 0 2.0167574348306516e-06
% O 0 3.04105498116769e-07
) O 0 2.7359506660218358e-08
and O 0 1.169139736134639e-07
Mordvinians O 0 1.4028491932549514e-05
( O 0 1.6243149048023042e-08
1 O 0 1.3584894098528366e-08
. O 0 7.68254615479691e-09
8 O 0 1.2441903152193845e-07
% O 0 2.7531470436770178e-08
) O 0 6.782410633121572e-09
had O 0 1.2960615549673093e-06
significantly O 0 1.6924117289818241e-06
lower O 0 5.103985927235044e-07
frequencies O 0 7.063309936938822e-08
of O 0 6.809267816265674e-09
the O 0 2.392149553998024e-07
Tyr O 0 0.00011394057219149545
allele O 0 1.1465737770777196e-05
. O 0 1.1441208016549353e-06

Comparisons O 0 1.267389870918123e-05
with O 0 8.56977351304522e-07
allele O 0 4.514040483627468e-06
frequencies O 0 1.0542969448579242e-06
based O 0 8.212561652953809e-08
on O 0 4.4952659550290264e-07
prevalence O 0 1.8822425772668794e-05
estimates O 0 9.499173074800638e-07
of O 0 5.8041504047423587e-08
HH B-Disease 1 0.9660009145736694
showed O 0 7.897384057287127e-05
some O 0 5.197011709867638e-09
disagreements O 0 4.25198351194922e-07
with O 0 2.055117143129337e-08
the O 0 7.036966565010516e-08
RFLP O 0 1.5488614735659212e-05
data O 0 3.9886364788799256e-07
, O 0 2.9786791699848436e-08
particularly O 0 3.2499325897106246e-08
in O 0 6.105153005364627e-08
Finns O 0 4.290478682378307e-05
. O 0 1.0042929261544487e-06

The O 0 4.478599748836132e-06
newly O 0 5.600689746643184e-06
described O 0 7.943300261104014e-06
HFE O 0 0.00011663783516269177
marker O 0 6.118662895460147e-06
provides O 0 4.2000259270480456e-08
a O 0 1.9808247486707842e-08
new O 0 1.933942783693965e-08
approach O 0 4.96756520362851e-08
to O 0 3.971144302283847e-09
the O 0 4.050781043929419e-09
screening O 0 2.7016065828888713e-08
of O 0 9.31261734393729e-09
HH B-Disease 0 0.0015194142470136285
as O 0 1.0656952298404576e-07
well O 0 2.600896209514758e-08
as O 0 9.35864630235983e-09
studies O 0 2.5990798402375503e-09
of O 0 5.257508317590975e-10
the O 0 6.4494805052106585e-09
relationship O 0 4.420562049745058e-08
between O 0 1.1064116023362658e-07
the O 0 1.688483166617516e-07
HFE O 0 0.0017057331278920174
Tyr O 0 0.00010962078522425145
allele O 0 3.169408046233002e-06
and O 0 1.767599115964913e-07
different O 0 9.638922620069934e-07
disorders O 0 0.006246626842767
including O 0 5.177700131753227e-06
cancer B-Disease 0 0.004918193444609642

Autosomal B-Disease 1 0.9999936819076538
dominant I-Disease 1 0.989321231842041
neurohypophyseal I-Disease 1 0.9998651742935181
diabetes I-Disease 1 0.9999988079071045
insipidus I-Disease 1 0.9965204000473022
associated O 0 2.6112007617484778e-05
with O 0 1.991257789768497e-07
a O 0 1.5067100775922881e-06
missense O 0 0.0003377676475793123
mutation O 0 2.179469902330311e-06
encoding O 0 9.362145760860585e-07
Gly23 O 0 6.622015644097701e-05
- O 0 0.00018029424245469272
- O 0 0.0001520251971669495
> O 0 5.8977170738216955e-06
Val O 0 8.395063923671842e-05
in O 0 5.214142220211215e-07
neurophysin O 0 7.923915109131485e-05
II O 0 0.00016065852832980454
. O 0 3.032299673577654e-06

Autosomal B-Disease 1 0.9999887943267822
dominant I-Disease 1 0.9933367967605591
neurohypophyseal I-Disease 1 0.9998965263366699
diabetes I-Disease 1 0.9999996423721313
insipidus I-Disease 1 0.999953031539917
( O 0 5.18829510838259e-05
ADNDI B-Disease 0 0.0345262736082077
) O 0 4.5866730147281487e-07
is O 0 2.0486504581640474e-07
an O 0 1.3443940588331316e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0009595978772267699
by O 0 1.3836520338372793e-06
progressive O 0 0.03645728528499603
degeneration O 0 0.08330145478248596
of O 0 3.107295043491831e-08
the O 0 9.696475444798125e-08
magnocellular O 0 3.1629246223019436e-05
neurons O 0 1.1806362181232544e-06
of O 0 6.890518822189051e-09
the O 0 5.3795336185658016e-08
hypothalamus O 0 2.4866835701686796e-06
leading O 0 5.318331091075379e-07
to O 0 4.978444678727101e-08
decreased O 0 4.352788891992532e-06
ability O 0 5.904825428615368e-08
to O 0 2.199962700899505e-08
produce O 0 6.36608206150413e-08
the O 0 8.64589893012635e-08
hormone O 0 2.048223905148916e-06
arginine O 0 2.898887714763987e-06
vasopressin O 0 9.810409210331272e-06
( O 0 2.701790151604655e-07
AVP O 0 1.627260098757688e-05
) O 0 5.289811610964534e-07
. O 0 1.3381982171267737e-06

Affected O 0 0.0001475632598157972
individuals O 0 5.588411227108736e-07
are O 0 2.612261340573241e-08
not O 0 3.918193769436584e-08
symptomatic O 0 3.0735427571926266e-06
at O 0 9.580653568264097e-07
birth O 0 1.4590100363420788e-05
, O 0 1.3826729627908207e-07
but O 0 1.0558238727753633e-07
usually O 0 7.172575919867086e-07
develop O 0 1.6366336694773054e-06
diabetes B-Disease 0 0.0003037354617845267
insipidus I-Disease 0 6.639182538492605e-05
at O 0 3.7937385855002503e-07
1 O 0 4.1834761077552685e-07
- O 0 7.463774818461388e-05
6 O 0 6.968926300032763e-06
yr O 0 0.00013099458010401577
of O 0 3.931661751721549e-08
age O 0 9.930507758326712e-07
. O 0 5.283298492031463e-07

The O 0 5.056871486885939e-06
genetic O 0 9.419459274795372e-06
locus O 0 7.012151854723925e-06
of O 0 1.1146916278903518e-07
the O 0 4.5081119424139615e-06
disease O 0 4.85101445519831e-05
is O 0 2.1145980966252864e-08
the O 0 4.248918727967066e-08
AVP O 0 5.01137510582339e-05
- O 0 0.004295653663575649
neurophysin O 0 0.00015523098409175873
II O 0 6.834500527475029e-05
( O 0 8.54843165143393e-08
NPII O 0 3.103257995462627e-06
) O 0 1.2221770262499376e-08
gene O 0 8.332905565566762e-08
, O 0 1.885708833526678e-08
and O 0 1.655453871762802e-07
mutations O 0 1.262224031961523e-06
that O 0 3.173806817358127e-08
cause O 0 4.439878864559432e-07
ADNDI B-Disease 0 0.0001207191453431733
have O 0 9.257239526050398e-07
been O 0 2.946348161003698e-07
found O 0 6.710904898454828e-08
in O 0 2.3604947330113646e-08
both O 0 1.2644123081884118e-08
the O 0 2.4980534973906288e-08
signal O 0 2.9077309591230005e-06
peptide O 0 1.6484504428149194e-08
of O 0 1.0024570062938665e-09
the O 0 1.3407994714498273e-08
prepro O 0 3.5542755085771205e-06
- O 0 3.3942324080271646e-06
AVP O 0 1.1837255442515016e-05
- O 0 1.4166590517561417e-05
NPII O 0 8.55776306707412e-06
precursor O 0 4.971968223799195e-07
and O 0 6.69028992206222e-08
within O 0 1.943889600397597e-07
NPII O 0 4.209728285786696e-05
itself O 0 2.6878274184127804e-06
. O 0 1.2785370699930354e-06

An O 0 3.4669087654037867e-06
affected O 0 4.117928710911656e-06
girl O 0 8.04255178081803e-05
who O 0 8.443585102213547e-07
presented O 0 1.0419977058973018e-07
at O 0 9.711763482300739e-08
9 O 0 3.254179432587989e-07
months O 0 9.295565917000204e-08
of O 0 7.090789289065924e-09
age O 0 2.0094302044526557e-07
and O 0 1.376392191332343e-07
her O 0 1.0444665576869738e-06
similarly O 0 2.196300101786619e-06
affected O 0 2.430015229037963e-07
younger O 0 6.413772553059971e-07
brother O 0 2.8356450911815045e-06
and O 0 2.671548600119422e-07
father O 0 9.056587941813632e-07
were O 0 2.7115086709272873e-07
all O 0 1.747847644395506e-09
found O 0 1.8327323658695605e-08
to O 0 7.389332257190517e-09
have O 0 1.366621216192243e-08
a O 0 1.0565571528786677e-07
novel O 0 4.92111939820461e-06
missense O 0 9.197029430652037e-05
mutation O 0 2.1632893094647443e-06
( O 0 1.7534915741634904e-08
G1758 O 0 8.671776186019997e-07
- O 0 8.398712452617474e-06
- O 0 9.537097503198311e-05
> O 0 2.2151136818138184e-06
T O 0 4.987615284335334e-06
) O 0 9.590563010419828e-09
encoding O 0 2.9296087333818832e-08
the O 0 1.5436450340189367e-08
amino O 0 1.2532409243704024e-07
acid O 0 7.572565863256386e-08
substitution O 0 7.433241222543074e-08
Gly23 O 0 4.5307701839192305e-06
- O 0 1.0407783520349767e-05
- O 0 2.4646398742333986e-05
> O 0 2.9356356208154466e-06
Val O 0 3.1919469620333984e-05
within O 0 5.111039058647293e-07
NPII O 0 5.968569530523382e-05
. O 0 1.5287042742784251e-06

The O 0 1.017068643704988e-05
mutation O 0 8.400717342738062e-05
was O 0 7.94122570368927e-06
confirmed O 0 2.8402712359820725e-07
by O 0 1.4340217013852907e-08
restriction O 0 1.8858190742321312e-07
endonuclease O 0 1.717028862913139e-05
analysis O 0 1.0441150379847386e-06
. O 0 1.4781512618355919e-06

A O 0 4.539730434771627e-05
T1 O 0 0.0016903846990317106
- O 0 2.8726366508635692e-05
weighted O 0 3.370581680428586e-06
magnetic O 0 1.0377963235441712e-06
resonance O 0 1.311440541940101e-06
imaging O 0 1.6118292478495277e-05
of O 0 4.118939500585839e-08
the O 0 5.763574790762505e-07
fathers O 0 5.584794416790828e-05
pituitary O 0 5.054783105151728e-05
gland O 0 1.844774669734761e-05
demonstrates O 0 8.235618338403583e-07
an O 0 8.022945507946133e-08
attenuated O 0 0.00017657486023381352
posterior O 0 0.0007136269123293459
pituitary O 0 0.00048616499407216907
bright O 0 0.00011869624722748995
spot O 0 5.542039070860483e-05
. O 0 3.0662090466648806e-06

This O 0 8.343085937667638e-06
mutation O 0 0.00012639439955819398
may O 0 3.899514013028238e-06
be O 0 1.0117217286165214e-08
valuable O 0 5.838979966199531e-09
for O 0 3.2413141060061434e-09
developing O 0 2.655160358244757e-08
models O 0 2.63695142166398e-07
of O 0 5.5872504844955984e-08
dominantly B-Disease 0 0.025178370997309685
inherited I-Disease 1 0.8699912428855896
neurodegeneration I-Disease 1 1.0
, O 0 2.2582935343962163e-07
as O 0 1.0914061654432317e-08
the O 0 1.0011104834006801e-08
early O 0 1.0271469363942742e-07
age O 0 1.8224458386839615e-08
of O 0 3.1531632860293257e-09
onset O 0 2.933164751084405e-06
of O 0 1.1426853063767339e-07
symptoms O 0 1.241677728103241e-05
suggests O 0 4.2326686156002324e-08
that O 0 4.919559426497244e-09
this O 0 1.7280193276292266e-08
mutation O 0 3.863895017275354e-06
may O 0 5.693320304089866e-07
be O 0 2.0864694860733835e-08
particularly O 0 4.740300596495217e-08
deleterious O 0 1.3785100918539683e-06
to O 0 4.814976861666764e-08
the O 0 2.2004752509019454e-07
magnocellular O 0 3.354774526087567e-05
neuron O 0 1.1976434507232625e-05
. O 0 1.752365648144405e-07
. O 0 7.262310077749135e-07

Frequent O 0 0.0012187922839075327
inactivation O 0 0.0010931058786809444
of O 0 3.1834092624194454e-06
PTEN O 0 0.005340063478797674
/ O 0 0.0006454730173572898
MMAC1 O 0 0.0006583964568562806
in O 0 1.2251771295268554e-05
primary O 0 0.2831031382083893
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 8.723121027287561e-06

Sporadic B-Disease 1 0.9999971389770508
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 8.655765668663662e-06
the O 0 7.778745469977366e-08
most O 0 2.7112699640952087e-08
common O 0 7.755373871987103e-07
male B-Disease 0 0.00016702072753105313
cancer I-Disease 0 1.2721414350380655e-05
in O 0 2.032061630075077e-08
the O 0 1.262759052877982e-08
Western O 0 1.9261833017480967e-07
world O 0 3.2362632396143454e-07
, O 0 5.862551333279953e-08
yet O 0 2.2399241572657047e-08
many O 0 4.560167521372449e-10
of O 0 3.23477800101557e-10
the O 0 5.15939202472282e-09
major O 0 1.6077567721595187e-08
genetic O 0 8.293202569120695e-08
events O 0 1.989583076067447e-08
involved O 0 1.6735189234395875e-08
in O 0 9.156511993069216e-09
the O 0 4.242675188947942e-08
progression O 0 1.8554381995272706e-06
of O 0 5.647924350427047e-09
this O 0 3.624836253379726e-08
often O 0 7.46660725781112e-06
fatal O 0 0.05549046769738197
cancer B-Disease 0 0.0020500284153968096
remain O 0 1.126330175793555e-06
to O 0 9.819797952559384e-08
be O 0 5.191239438318007e-07
elucidated O 0 9.04103071661666e-05
. O 0 1.9005711919817259e-06

Numerous O 0 2.1884048692299984e-05
cytogenetic O 0 0.0005115201929584146
and O 0 2.5202293727488723e-06
allelotype O 0 3.34213582391385e-05
studies O 0 3.687330831780855e-07
have O 0 4.0684378177502367e-07
reported O 0 3.451927568676183e-06
frequent O 0 1.8061110722555895e-06
loss O 0 2.418663825665135e-06
of O 0 9.565574998759985e-08
heterozygosity O 0 0.00013508445408660918
on O 0 4.400395482662134e-05
chromosomal O 1 0.9714113473892212
arm O 0 0.0016176414210349321
10q O 0 1.127232735598227e-05
in O 0 1.68630242569634e-06
sporadic B-Disease 1 0.9995958209037781
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3387648323259782e-05

Deletion O 0 0.0005121079739183187
mapping O 0 3.809594636550173e-05
studies O 0 2.5970748538384214e-06
have O 0 5.945617544966808e-07
unambiguously O 0 3.3575397537788376e-05
identified O 0 1.5869502476562047e-06
a O 0 1.517162218078738e-07
region O 0 2.922457724707783e-07
of O 0 2.667072962481143e-08
chromosome O 0 5.4706215451005846e-05
10q23 O 0 1.7980080428969814e-06
to O 0 5.6685728111460776e-08
be O 0 2.6743624204073058e-08
the O 0 1.3126157938359029e-08
minimal O 0 2.940767274139944e-07
area O 0 5.22628965882177e-07
of O 0 8.384368754832394e-08
loss O 0 1.3399833733274136e-05
. O 0 2.592274540802464e-06

A O 0 2.3936081561259925e-05
new O 0 6.556961579917697e-06
tumor B-Disease 0 8.245311619248241e-05
suppressor O 0 0.00013215545914135873
gene O 0 6.726604169671191e-06
, O 0 4.2911801756417844e-07
PTEN O 0 0.00038029038114473224
/ O 0 5.311127461027354e-05
MMAC1 O 0 0.00015185147640295327
, O 0 4.492582945658796e-07
was O 0 3.9768347050994635e-06
isolated O 0 2.3047598460834706e-06
recently O 0 7.041100616334006e-06
at O 0 6.534923358003653e-08
this O 0 1.9610053580976228e-09
region O 0 2.7494211352063758e-08
of O 0 6.961882181855117e-09
chromosome O 0 5.0582308176672086e-05
10q23 O 0 1.4509193988487823e-06
and O 0 1.4276430704285303e-07
found O 0 7.06635532310429e-08
to O 0 8.239623205952284e-09
be O 0 1.5457635171856055e-08
inactivated O 0 3.207965448837058e-07
by O 0 6.793791307302399e-09
mutation O 0 2.236737657312915e-07
in O 0 1.7361602999699244e-07
three O 0 0.01978854276239872
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.00030364657868631184
lines O 0 7.841320621082559e-05
. O 0 9.131729257205734e-07

We O 0 4.328926661401056e-05
screened O 0 0.00015150208491832018
80 O 0 3.769147224375047e-05
prostate B-Disease 1 0.9920226335525513
tumors I-Disease 1 1.0
by O 0 7.103191279611565e-08
microsatellite O 0 2.8685220968327485e-05
analysis O 0 1.1519593812181483e-07
and O 0 1.3838470636073907e-07
found O 0 3.7584831602544e-07
chromosome O 0 4.25383223046083e-05
10q23 O 0 2.069318497888162e-06
to O 0 3.6101599931726014e-08
be O 0 1.9604753376256667e-08
deleted O 0 1.374090743411216e-06
in O 0 2.6377867357041396e-07
23 O 0 1.9015974430658389e-06
cases O 0 3.129847812033404e-07
. O 0 6.51410402952024e-07

We O 0 8.759810043557081e-06
then O 0 1.702240695067303e-07
proceeded O 0 3.1784355769559625e-07
with O 0 5.83273518373062e-09
sequence O 0 7.624102238423802e-08
analysis O 0 1.7944616459431018e-08
of O 0 4.317943336218377e-09
the O 0 6.081142345237822e-08
entire O 0 1.082848598343844e-06
PTEN O 0 0.00031775771640241146
/ O 0 1.0825413482962176e-05
MMAC1 O 0 9.192366633214988e-06
coding O 0 6.63035643810872e-06
region O 0 1.3773524187854491e-06
and O 0 3.0223023372855096e-07
tested O 0 1.9791619365605584e-07
for O 0 6.269044394713319e-09
homozygous O 0 2.0901672996842535e-06
deletion O 0 2.9384852950897766e-07
with O 0 5.467144070792074e-09
new O 0 5.643781264552672e-08
intragenic O 0 1.4814147107244935e-05
markers O 0 5.66285689274082e-06
in O 0 3.936997217124372e-08
these O 0 1.3707065704693377e-08
23 O 0 3.581577630029642e-07
cases O 0 1.7192316903447136e-08
with O 0 8.68099618855922e-08
10q23 O 0 4.1704417526489124e-05
loss O 0 2.7144578780280426e-06
of O 0 2.3813424832042074e-07
heterozygosity O 0 0.00042114450479857624
. O 0 5.402609986049356e-06

The O 0 8.04168735157873e-07
identification O 0 1.853035485055443e-07
of O 0 7.743421903683156e-09
the O 0 2.438739166166215e-08
second O 0 9.278035690840625e-07
mutational O 0 6.243297684704885e-05
event O 0 9.924382311510271e-07
in O 0 5.7971579536797435e-08
10 O 0 1.1641864006151081e-07
( O 0 4.6128789676913584e-08
43 O 0 2.026518814091105e-06
% O 0 3.6452064477998647e-07
) O 0 6.653436912529287e-07
tumors B-Disease 1 0.9999998807907104
establishes O 0 5.948744001216255e-05
PTEN O 0 0.0038899066857993603
/ O 0 2.583143941592425e-05
MMAC1 O 0 1.8621374692884274e-05
as O 0 2.7651459788557986e-08
a O 0 3.2655478321430564e-08
main O 0 4.985377017874271e-07
inactivation O 0 4.185566012893105e-06
target O 0 1.6082421439023165e-07
of O 0 1.4827291394681197e-08
10q O 0 3.951550297642825e-06
loss O 0 9.261000855076418e-07
in O 0 1.6004694316507084e-06
sporadic B-Disease 1 0.9999841451644897
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0272963208990404e-06
. O 0 1.6683947023921064e-06

Risk O 0 0.0005407558055594563
reversals O 0 6.915163976373151e-05
in O 0 5.760728072345955e-07
predictive O 0 1.0986474990204442e-05
testing O 0 4.509199698077282e-06
for O 0 6.025185939506628e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 0.999998927116394
. O 0 4.21915410697693e-06

The O 0 1.2351101759122685e-06
first O 0 2.409670116776397e-07
predictive O 0 2.164508941859822e-06
testing O 0 6.799639891141851e-07
for O 0 1.8346162278248812e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 5.339533117876272e-07
HD B-Disease 0 0.011235265992581844
) O 0 5.463747925205098e-07
was O 0 3.687250455186586e-06
based O 0 2.6768629979301295e-08
on O 0 9.86317800766301e-08
analysis O 0 1.4126539049641451e-08
of O 0 3.6542400216887927e-09
linked O 0 6.958027825021418e-07
polymorphic O 0 9.432065439796133e-07
DNA O 0 2.8267032803341863e-07
markers O 0 1.621379510652332e-06
to O 0 1.3698729262046072e-08
estimate O 0 4.5147277205614955e-07
the O 0 6.3296479169139275e-09
likelihood O 0 6.057699408756889e-08
of O 0 8.194610323641882e-09
inheriting O 0 2.9200396056694444e-07
the O 0 4.41452030486289e-08
mutation O 0 4.040628880375152e-07
for O 0 4.615132098706454e-08
HD B-Disease 0 0.00019617180805653334
. O 0 2.138269564966322e-06

Limits O 0 1.1582274964894168e-05
to O 0 1.5862042346270755e-07
accuracy O 0 5.170951453692396e-07
included O 0 4.22372501418522e-08
recombination O 0 2.1315395315468777e-07
between O 0 2.0455125593343837e-08
the O 0 1.6975207017821958e-08
DNA O 0 1.7916645447257906e-06
markers O 0 2.1488451238838024e-05
and O 0 2.7187562068320403e-07
the O 0 1.5555821164525696e-07
mutation O 0 5.883318863197928e-06
, O 0 5.9143726360844084e-08
pedigree O 0 1.5304621001632768e-06
structure O 0 1.3232242679350747e-07
, O 0 9.520176647015433e-09
and O 0 1.4338658260726334e-08
whether O 0 9.316738491804699e-09
DNA O 0 3.124214629224298e-07
samples O 0 6.973912292096429e-08
were O 0 7.676764113284662e-08
available O 0 9.860634975211724e-09
from O 0 1.0756789237120756e-08
family O 0 1.3413013277840946e-07
members O 0 6.890522286084888e-08
. O 0 3.4480444810469635e-07

With O 0 1.387538304697955e-06
direct O 0 6.571652306774922e-07
tests O 0 1.455841101005717e-07
for O 0 5.630005794898807e-09
the O 0 2.6368905281515254e-08
HD B-Disease 0 0.0005380450747907162
mutation O 0 9.737802884046687e-07
, O 0 1.6255578216828326e-08
we O 0 7.97860977286291e-09
have O 0 1.2337848964705245e-08
assessed O 0 4.919524343449666e-08
the O 0 1.1402681465710884e-08
accuracy O 0 4.51989444627543e-06
of O 0 2.0131585287685994e-08
results O 0 2.2507103381030902e-07
obtained O 0 1.6209321884730343e-08
by O 0 1.8112757960153658e-09
linkage O 0 2.897045021654776e-07
approaches O 0 9.665988898177602e-08
when O 0 1.4856675889518556e-08
requested O 0 2.050191838520732e-08
to O 0 1.798456850110597e-08
do O 0 1.633583046611875e-08
so O 0 4.783102358629776e-09
by O 0 1.5568020206302435e-09
the O 0 7.683455649498683e-09
test O 0 1.1372571151468946e-07
individuals O 0 4.477159620819293e-08
. O 0 3.0020160579624644e-07

For O 0 6.104897352088301e-07
six O 0 2.7054335305365385e-07
such O 0 9.786604415751299e-09
individuals O 0 1.3230268436359438e-08
, O 0 1.1749214046119505e-08
there O 0 1.5435450251288785e-08
was O 0 1.156668076873757e-06
significant O 0 2.2684295331032445e-08
disparity O 0 3.685246383611229e-07
between O 0 3.941670811968834e-08
the O 0 7.72813919525106e-08
tests O 0 9.588935654392117e-07
. O 0 5.965474088043266e-07

Three O 0 2.2617648937739432e-05
went O 0 3.991070570918964e-06
from O 0 1.7294800258582654e-08
a O 0 7.097936816080619e-08
decreased O 0 1.8412911231280304e-05
risk O 0 8.359203462759979e-08
to O 0 2.963761902563533e-09
an O 0 1.5368149419714427e-08
increased O 0 2.2452338725997834e-06
risk O 0 2.220319714751895e-07
, O 0 1.6854190931780977e-08
while O 0 4.790114083164099e-09
in O 0 3.505632006906012e-09
another O 0 3.2560819818172604e-08
three O 0 3.957867633630485e-08
the O 0 2.076239695725235e-07
risk O 0 1.2605808024090948e-06
was O 0 1.2042184607707895e-05
decreased O 0 6.106747150624869e-06
. O 0 7.668180046493944e-07

Knowledge O 0 2.8937333809153643e-06
of O 0 6.18917113115458e-08
the O 0 3.9847272148563206e-08
potential O 0 3.953401161993497e-08
reasons O 0 1.1121492171639602e-08
for O 0 1.6795874691055701e-09
these O 0 1.9207522239383934e-09
changes O 0 1.2101797786101542e-08
in O 0 7.619870956432351e-08
results O 0 4.545271110600879e-07
and O 0 9.746818108169464e-08
impact O 0 2.103756457927375e-08
of O 0 2.7013165038169973e-09
these O 0 9.229647268682584e-09
risk O 0 5.176644890525495e-08
reversals O 0 3.968178816649015e-07
on O 0 9.63787442742614e-07
both O 0 9.44620168752408e-08
patients O 0 6.684307862769856e-08
and O 0 1.1256688026151096e-08
the O 0 1.7940475771638376e-08
counseling O 0 8.112083804689973e-08
team O 0 1.0562001051539482e-08
can O 0 5.743479025710485e-09
assist O 0 7.671242308049386e-09
in O 0 4.21507140302424e-09
the O 0 3.0618860780151635e-09
development O 0 1.0900305102978791e-09
of O 0 7.999589324292344e-10
strategies O 0 2.4811960486204043e-08
for O 0 2.161455237015275e-09
the O 0 1.6131444624534197e-08
prevention O 0 4.226477301472187e-07
and O 0 1.3973301804526272e-07
, O 0 9.875352979804575e-09
where O 0 1.530289139850538e-08
necessary O 0 1.191467635663912e-08
, O 0 1.078328892845093e-08
management O 0 4.796742558710321e-09
of O 0 7.544648239488083e-10
a O 0 4.5874518406208153e-08
risk O 0 1.3692230993456178e-07
reversal O 0 2.6318917889511795e-07
in O 0 1.2391714321324798e-08
any O 0 9.183989568839479e-09
predictive O 0 4.922640641780163e-07
testing O 0 1.4356396604853217e-07
program O 0 1.5396175001569645e-07
. O 0 7.425900605539937e-08
. O 0 4.870666430178971e-07

A O 0 2.6557521778158844e-05
novel O 0 7.775296580803115e-06
common O 0 3.5705900245375233e-06
missense O 0 0.0005198734579607844
mutation O 0 1.0565310731180944e-05
G301C O 0 2.5268475383199984e-06
in O 0 4.455088387089745e-08
the O 0 5.5866429704565235e-08
N O 0 2.2502226784126833e-05
- O 0 1.8060600268654525e-05
acetylgalactosamine O 0 3.5816014133160934e-05
- O 0 1.3533483979699668e-05
6 O 0 1.545109853395843e-06
- O 0 1.030136536428472e-05
sulfate O 0 1.8834511138265952e-05
sulfatase O 0 2.8996566470596008e-05
gene O 0 1.6372910067730118e-06
in O 0 5.164292815607041e-07
mucopolysaccharidosis B-Disease 0 0.0001854653819464147
IVA I-Disease 0 0.1356629729270935
. O 0 2.0074847270734608e-05

Mucopolysaccharidosis B-Disease 0 0.46199530363082886
IVA I-Disease 1 0.9999023675918579
( O 0 0.01454492099583149
MPS B-Disease 1 0.9999988079071045
IVA I-Disease 1 1.0
) O 0 1.982554067581077e-06
is O 0 2.0136909029133676e-07
an O 0 1.1086123095083167e-06
autosomal B-Disease 1 0.9999825954437256
recessive I-Disease 1 0.9999908208847046
lysosomal I-Disease 1 0.9999223947525024
storage I-Disease 1 0.9999908208847046
disorder I-Disease 1 0.9999951124191284
caused O 0 3.3805627026595175e-05
by O 0 2.330686186269304e-07
a O 0 6.19452548562549e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999983310699463
in O 0 1.098165398616402e-06
N O 0 5.701753616449423e-05
- O 0 3.297830335213803e-05
acetylgalactosamine O 0 7.129489677026868e-05
- O 0 5.372341547627002e-05
6 O 0 3.6615087992686313e-06
- O 0 6.517890142276883e-05
sulfate O 0 5.9202891861787066e-05
sulfatase O 0 8.224329212680459e-05
( O 0 4.0456106376041134e-07
GALNS O 0 1.670878191362135e-05
) O 0 3.5091133554487897e-07
. O 0 5.830802365380805e-07

In O 0 5.316415808920283e-06
previous O 0 2.4691116777830757e-06
studies O 0 1.8618764840994118e-07
, O 0 5.7887167059789135e-08
we O 0 1.969229757037283e-08
have O 0 1.4820166427398362e-08
found O 0 1.7705271915247067e-08
two O 0 3.811249627005964e-08
common O 0 4.210180293284793e-07
mutations O 0 2.2339395400194917e-06
in O 0 5.906560218704726e-08
Caucasians O 0 3.911133717338089e-06
and O 0 6.926341598045838e-07
Japanese O 0 4.3221521650593786e-07
, O 0 4.35726832392902e-08
respectively O 0 4.130323816298187e-07
. O 0 4.265902759925666e-07

To O 0 1.8081689177051885e-06
characterize O 0 7.673727850487921e-06
the O 0 2.398788296886778e-07
mutational O 0 0.0003451969241723418
spectrum O 0 1.329313363385154e-05
in O 0 1.2432219698155222e-08
various O 0 8.208078661198215e-09
ethnic O 0 8.263486250825736e-08
groups O 0 2.7136810132333267e-08
, O 0 3.5300573131280544e-08
mutations O 0 2.407550141469983e-07
in O 0 6.199731394929131e-09
the O 0 2.1249041637361188e-08
GALNS O 0 1.9922501451219432e-05
gene O 0 3.2564736329732114e-07
in O 0 1.5640343065115303e-07
Colombian O 0 5.9179252275498584e-05
MPS B-Disease 1 0.9999334812164307
IVA I-Disease 1 1.0
patients O 0 7.21003016224131e-05
were O 0 1.9034389424632536e-06
investigated O 0 1.0433315082991612e-06
, O 0 3.545016369344012e-08
and O 0 5.066063479830518e-08
genetic O 0 3.0098274805823166e-07
backgrounds O 0 1.4732577824361215e-07
were O 0 6.192205859179012e-08
extensively O 0 9.243974830042134e-08
analyzed O 0 1.8820406921804533e-07
to O 0 1.1096171093072371e-08
identify O 0 1.356927015194742e-07
racial O 0 2.782136334644747e-07
origin O 0 1.2960669870665242e-08
, O 0 7.813701685677188e-09
based O 0 8.278185248400405e-09
on O 0 7.357944298291841e-08
mitochondrial O 0 2.3919792511151172e-06
DNA O 0 7.025398190307897e-06
( O 0 9.950551316251222e-08
mtDNA O 0 1.0255569122818997e-06
) O 0 1.2101662605346064e-07
lineages O 0 2.2073470518080285e-06
. O 0 9.809331231735996e-07

Three O 0 1.2830067134927958e-05
novel O 0 1.9403463738854043e-05
missense O 0 0.003062997478991747
mutations O 0 0.0006204163655638695
never O 0 2.0912697436870076e-05
identified O 0 2.1218845631665317e-06
previously O 0 7.117267841749708e-07
in O 0 2.7390468559929104e-08
other O 0 8.4064470939893e-09
populations O 0 1.234108850667326e-07
and O 0 1.3126063436175173e-07
found O 0 7.407341229281883e-08
in O 0 2.6920595530555147e-08
16 O 0 1.5413981202527793e-07
out O 0 3.0018295404943274e-08
of O 0 2.1569343644500805e-08
19 O 0 3.083089723077137e-06
Colombian O 0 1.8486491171643138e-05
MPS B-Disease 1 0.9974119067192078
IVA I-Disease 1 0.999998927116394
unrelated O 0 1.0015163752541412e-05
alleles O 0 1.023618210638233e-06
account O 0 1.7041230648828787e-07
for O 0 4.716230250778608e-08
84 O 0 1.7405018297722563e-06
. O 0 7.809128987901204e-07

2 O 0 9.4601433374919e-05
% O 0 1.511619302618783e-06
of O 0 9.496780251083692e-09
the O 0 4.153533339490423e-08
alleles O 0 3.4283053196304536e-07
in O 0 4.5366618905973155e-08
this O 0 7.814643510073438e-08
study O 0 3.6027728356202715e-07
. O 0 1.1777077588703833e-06

The O 0 3.895191184710711e-06
G301C O 0 3.5220233257859945e-05
and O 0 1.1028798780898796e-06
S162F O 0 2.712814421101939e-05
mutations O 0 5.515858447324717e-06
account O 0 2.742835647495667e-07
for O 0 5.996680130238019e-08
68 O 0 1.0832622137968428e-05
. O 0 1.9080844140262343e-06

4 O 0 0.00022525712847709656
% O 0 5.1037309276580345e-06
and O 0 3.87632979936825e-07
10 O 0 7.636922418896575e-07
. O 0 1.0349665444664424e-06

5 O 0 5.5767744925105944e-05
% O 0 4.7408073555743613e-07
of O 0 2.876991977984744e-08
mutations O 0 6.89802982378751e-06
, O 0 9.448471871564834e-08
respectively O 0 8.353878229172551e-07
, O 0 2.589926317853042e-08
whereas O 0 3.055540176433169e-08
the O 0 1.501343405152511e-08
remaining O 0 5.048204911872745e-07
F69V O 0 4.973269460606389e-05
is O 0 2.6759032323298015e-08
limited O 0 9.143718671111856e-09
to O 0 8.084385605400257e-09
a O 0 9.653478372229074e-08
single O 0 3.3927178719750373e-06
allele O 0 7.514060598623473e-06
. O 0 1.2083228284609504e-06

The O 0 4.022890607302543e-06
skewed O 0 2.9479202567017637e-05
prevalence O 0 6.0202688473509625e-05
of O 0 9.069641748737922e-08
G301C O 0 2.5749875476321904e-06
in O 0 5.895676480349721e-08
only O 0 2.1236076008790405e-08
Colombian O 0 2.3535276341135614e-06
patients O 0 4.0331602235710307e-07
and O 0 3.4623941047584594e-08
haplotype O 0 3.0531568881997373e-06
analysis O 0 3.880479226836542e-08
by O 0 5.992515816899413e-09
restriction O 0 1.3048605751464493e-07
fragment O 0 4.175786216364941e-06
length O 0 4.6931695578678045e-06
polymorphisms O 0 1.3702025171369314e-05
in O 0 1.4350149513120414e-08
the O 0 1.6205550679160297e-08
GALNS O 0 8.956268175097648e-06
gene O 0 2.182674450068589e-07
suggest O 0 6.572574307028844e-08
that O 0 7.313391670038527e-09
G301C O 0 7.00108671480848e-07
originated O 0 4.955593979616424e-08
from O 0 3.911740265039043e-09
a O 0 4.123144492496067e-08
common O 0 2.0059532346294873e-07
ancestor O 0 1.6456220919280895e-06
. O 0 1.0352044910177938e-06

Investigation O 0 8.523619726474863e-06
of O 0 9.145362156459669e-08
the O 0 6.785570860756707e-08
genetic O 0 1.8302227999811294e-06
background O 0 1.3773524187854491e-06
by O 0 1.710955466194264e-08
means O 0 1.2132860049973715e-08
of O 0 3.5903542361381824e-09
mtDNA O 0 4.4812946953243227e-07
lineages O 0 3.6379552170728857e-07
indicate O 0 2.46032243467198e-07
that O 0 1.4604237819071386e-08
all O 0 5.337198683008637e-09
our O 0 6.696826915231213e-08
patients O 0 1.432838416803861e-07
are O 0 9.66851043671113e-09
probably O 0 5.703723005012762e-08
of O 0 7.463868634260962e-09
native O 0 1.995769167706385e-07
American O 0 1.1629151686065597e-06
descent O 0 0.0001670782221481204

Low O 0 0.0002090554335154593
frequency O 0 3.217615812900476e-05
of O 0 1.049437742040027e-06
BRCA1 O 0 0.0014457637444138527
germline O 0 0.0002788214769680053
mutations O 0 1.574373345647473e-05
in O 0 2.9080646868351323e-07
45 O 0 8.269403224403504e-06
German O 1 0.7843308448791504
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1091622582171112e-05
. O 0 2.1695991563319694e-06

In O 0 2.400422999926377e-06
this O 0 6.282836295667948e-08
study O 0 6.67364545847704e-08
we O 0 2.5322576036046485e-08
investigated O 0 4.548566892026429e-07
45 O 0 8.292188340419671e-07
German O 0 0.13554270565509796
breast B-Disease 1 0.9999986886978149
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 7.738906333543127e-07
for O 0 7.047873396004434e-08
germline O 0 3.777510210056789e-05
mutations O 0 2.371247092014528e-06
in O 0 4.460521552118735e-08
the O 0 2.1943935735180276e-07
BRCA1 O 0 0.00013258375111036003
gene O 0 7.140020443330286e-06
. O 0 2.262882162540336e-06

We O 0 1.1340494893374853e-05
identified O 0 2.9491241093637655e-06
four O 0 4.09070764817443e-07
germline O 0 3.212305819033645e-05
mutations O 0 8.62920205690898e-06
in O 0 1.6628273158403317e-07
three O 0 1.4279999959398992e-05
breast B-Disease 1 0.999873161315918
cancer I-Disease 0 0.017938323318958282
families O 0 2.258709344005183e-07
and O 0 4.8756110260228525e-08
in O 0 7.159462711570086e-08
one O 0 6.431279325624928e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.036838168351096e-06
. O 0 2.8289058207064954e-08
among O 0 5.652267098810171e-09
these O 0 1.8444900051761692e-09
were O 0 1.4892712840719469e-07
one O 0 1.0829523944266839e-07
frameshift O 0 0.000747665879316628
mutation O 0 9.949836794476141e-07
, O 0 1.1489526663410743e-08
one O 0 5.142310044448095e-08
nonsense O 0 2.188868347730022e-05
mutation O 0 2.3326063001150033e-06
, O 0 1.0661074689721772e-08
one O 0 1.0692191132477546e-08
novel O 0 1.446615414124608e-07
splice O 0 7.770219963276759e-05
site O 0 1.6823312762426212e-05
mutation O 0 2.183785227316548e-06
, O 0 2.7893271692391863e-08
and O 0 7.824278469570345e-08
one O 0 4.3310978981025983e-07
missense O 0 0.0002113083319272846
mutation O 0 1.966889431059826e-05
. O 0 1.5827212109797983e-06

The O 0 7.569195531687001e-06
missense O 0 0.0018665085081011057
mutation O 0 0.0002502559218555689
was O 0 6.485143239842728e-05
also O 0 8.632433718958055e-07
found O 0 1.105780782495458e-07
in O 0 1.0268511374533773e-07
2 O 0 4.205030563753098e-06
. O 0 1.1131029395983205e-06

8 O 0 0.00041915569454431534
% O 0 1.6350018086086493e-06
of O 0 6.487616222017323e-09
the O 0 1.1369388985826845e-08
general O 0 2.13510151780838e-08
population O 0 2.2105750119294498e-08
, O 0 8.310458099458629e-09
suggesting O 0 1.3611015958758799e-07
that O 0 1.6520985468559957e-08
it O 0 3.7776899830532784e-08
is O 0 7.756344189147057e-08
not O 0 7.162787483139255e-07
disease O 0 1.4774051123822574e-05
associated O 0 1.1005894293703022e-06
. O 0 1.5822730574654997e-06

The O 0 2.8640436084970133e-06
average O 0 5.232865078141913e-06
age O 0 3.980253779900522e-07
of O 0 5.272556791169336e-08
disease O 0 4.2004932765848935e-05
onset O 0 3.872335219057277e-05
in O 0 2.2882501582444092e-07
those O 0 1.32257582663442e-07
families O 0 5.199815973355726e-07
harbouring O 0 2.7006255550077185e-05
causative O 0 2.5125735191977583e-05
mutations O 0 3.1554707675240934e-05
was O 0 5.083445557829691e-06
between O 0 7.335103191508097e-07
32 O 0 7.184487003542017e-06
. O 0 1.9994261037936667e-06

3 O 0 9.323906124336645e-05
and O 0 6.326624315988738e-06
37 O 0 2.0374276573420502e-05
. O 0 2.401558731435216e-06

4 O 0 0.00010133400792255998
years O 0 1.1485296909086173e-06
, O 0 3.09024343891906e-08
whereas O 0 3.955905469865684e-08
the O 0 1.3053282010844214e-08
family O 0 1.9935683326366416e-07
harbouring O 0 2.741700427577598e-06
the O 0 7.614829655722133e-08
missense O 0 3.7483037885976955e-05
mutation O 0 2.943218305517803e-06
had O 0 1.8584169083624147e-06
an O 0 3.4451677066726916e-08
average O 0 2.419217480564839e-06
age O 0 8.819669972126576e-08
of O 0 9.697433078770246e-09
onset O 0 4.052455551573075e-06
of O 0 4.102583872622745e-08
51 O 0 6.6192874328407925e-06
. O 0 1.0739322533481754e-06

2 O 0 0.00019137325580231845
years O 0 8.166687621269375e-06
. O 0 4.278914730093675e-06

These O 0 1.089775196305709e-06
findings O 0 1.0989448355758213e-06
show O 0 2.9373745746852364e-06
that O 0 1.736084129788651e-07
BRCA1 O 0 9.796123777050525e-05
is O 0 1.766556039228817e-07
implicated O 0 2.6377765038887446e-07
in O 0 1.8589112471545377e-08
a O 0 3.610353260796728e-08
small O 0 2.7991870155119614e-08
fraction O 0 1.0310943565627895e-07
of O 0 4.754036524445837e-07
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.558462241126108e-07
suggesting O 0 1.8512692179228907e-07
the O 0 1.1560485901895845e-08
involvement O 0 7.025473536259597e-08
of O 0 7.209311370104388e-09
another O 0 4.825991481993697e-07
susceptibility O 0 0.00012898744898848236
gene O 0 7.902590368757956e-06
( O 0 1.2246877076904639e-06
s O 0 8.634438563603908e-05
) O 0 4.924898803437827e-06

Paternal O 0 0.3216286599636078
transmission O 1 0.9220494627952576
of O 0 0.00041914431494660676
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0004638617974705994

We O 0 1.0779055628518108e-05
report O 0 3.4966961948157405e-07
a O 0 1.2260333903668652e-07
rare O 0 2.4078141791505914e-07
case O 0 6.861315000605828e-07
of O 0 1.0979957778545213e-06
paternally O 1 0.9999024868011475
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.012342480942606926
DM B-Disease 1 1.0
) O 0 8.506178346578963e-06
. O 0 3.929756985598942e-06

The O 0 3.1233792014973005e-06
proband O 0 6.871745426906273e-05
is O 0 1.9315029931021854e-07
a O 0 2.765107183222426e-07
23 O 0 2.986643494296004e-06
year O 0 1.25141127682582e-07
old O 0 6.48986388114281e-05
, O 0 2.617361315060407e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.15615342557430267
who O 0 0.004861872643232346
suffers O 1 0.9939715266227722
severe O 1 0.7549634575843811
muscular B-Disease 1 0.9994359612464905
weakness I-Disease 0 0.20714041590690613
. O 0 6.93271294949227e-06

He O 0 6.729832239216194e-05
presented O 0 4.848707249038853e-06
with O 0 3.1344141007139115e-06
respiratory O 1 0.7952244281768799
and O 0 1.5652263755328022e-05
feeding O 0 6.438109267037362e-05
difficulties O 0 5.025986411055783e-06
at O 0 3.748421022464754e-07
birth O 0 1.3640396900882479e-05
. O 0 7.973682727424602e-07

His O 0 4.2533374653430656e-05
two O 0 1.8568702216725796e-05
sibs O 1 0.5793188214302063
suffer O 0 0.00033447524765506387
from O 0 7.333445637414115e-07
childhood O 0 0.0001872920838650316
onset O 1 0.9861828088760376
DM B-Disease 1 1.0
. O 0 2.627086541906465e-05

Their O 0 8.163347956724465e-06
late O 0 2.1409003238659352e-05
father O 0 4.382691713544773e-06
had O 0 1.2157389619460446e-06
the O 0 1.338652921845096e-08
adult O 0 1.3366506834699976e-07
type O 0 1.9266352069280401e-07
of O 0 9.736803008308925e-08
DM B-Disease 1 1.0
, O 0 1.4961314320771635e-07
with O 0 3.4250987823725154e-08
onset O 0 9.423143637832254e-06
around O 0 1.836407079736091e-07
30 O 0 2.9196328910074953e-07
years O 0 1.0466965960631569e-07
. O 0 4.5201906573311135e-07

Only O 0 3.1140878036239883e-06
six O 0 1.9348898661064595e-07
other O 0 9.225160191306259e-09
cases O 0 1.4830203731719394e-08
of O 0 1.7115526773636702e-08
paternal O 0 0.003811699105426669
transmission O 0 0.4974614679813385
of O 0 3.260921221226454e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0008422666578553617
been O 0 8.837349014356732e-06
reported O 0 1.3180218957131729e-05
recently O 0 6.121435490058502e-06
. O 0 1.0822591320902575e-06

We O 0 3.992890015069861e-06
review O 0 2.2052967096897191e-07
the O 0 2.4183810509725845e-08
sex O 0 1.4148010052394966e-07
related O 0 1.2847617369970976e-07
effects O 0 2.898705133702606e-06
on O 0 2.297072933288291e-05
transmission O 0 0.20992691814899445
of O 0 3.258052674937062e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.0451825043419376e-05

Decreased O 0 0.0009443234303034842
fertility O 0 1.7981290511670522e-05
of O 0 8.317502420140954e-08
males O 0 3.954797307414992e-07
with O 0 5.6590121033650576e-08
adult O 0 3.179715349688195e-05
onset O 1 0.8011451363563538
DM B-Disease 1 1.0
and O 0 1.9024635548703372e-05
contraction O 0 1.4774445844523143e-05
of O 0 3.5578233692490357e-09
the O 0 1.6798061608369608e-08
repeat O 0 4.830209263673169e-07
upon O 0 4.420477495159503e-08
male O 0 6.751243404323759e-07
transmission O 0 1.8861530861613574e-06
contribute O 0 7.35230143433796e-09
to O 0 4.009640619528909e-09
the O 0 1.703219076887308e-08
almost O 0 9.7945637378416e-08
absent O 0 1.560251803311985e-07
occurrence O 0 1.3279547772526712e-07
of O 0 2.3099252288716343e-08
paternal O 0 9.111100371228531e-05
transmission O 0 0.014160837046802044
of O 0 2.9321769034140743e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.3040065065724775e-05

Also O 0 4.4873573642689735e-05
the O 0 1.2598221132975596e-07
fathers O 0 1.9992496902432322e-07
of O 0 6.685389131177999e-09
the O 0 8.204122536881187e-08
reported O 0 4.151169923716225e-05
congenitally O 0 0.00018004463345278054
affected O 0 7.213543540274259e-07
children O 0 1.317491523877834e-06
showed O 0 1.5968507796060294e-05
, O 0 1.4967687533840035e-08
on O 0 3.837129156636365e-07
average O 0 8.99901522188884e-07
, O 0 2.43734401550455e-08
shorter O 0 1.480360538153036e-06
CTG O 0 4.968066150468076e-06
repeat O 0 2.2606882339459844e-06
lengths O 0 0.0001459378399886191
and O 0 1.6859553397807758e-07
hence O 0 1.0015194362722468e-07
less O 0 6.728758705776272e-08
severe O 0 2.435225178487599e-05
clinical O 0 2.2180387531989254e-05
symptoms O 0 8.8050241174642e-05
than O 0 2.715436231426338e-08
the O 0 6.294315824106889e-08
mothers O 0 9.816236570259207e-07
of O 0 9.87921566775185e-09
children O 0 3.836693849734729e-06
with O 0 4.123995313420892e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 2.4108909201459028e-05

We O 0 9.84299276751699e-06
conclude O 0 1.286576662096195e-06
that O 0 9.839183690019127e-08
paternal O 0 6.924249464645982e-05
transmission O 0 0.05860104784369469
of O 0 2.3718423108221032e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 9.329452041129116e-06
rare O 0 4.4548679056788387e-07
and O 0 3.1186240789793374e-07
preferentially O 0 7.221176474558888e-07
occurs O 0 6.97460436072106e-08
with O 0 7.721534522886486e-09
onset O 0 2.1633036340062972e-06
of O 0 1.0263185146186515e-07
DM B-Disease 1 1.0
past O 0 7.439690307364799e-06
30 O 0 2.767644957657467e-07
years O 0 2.4449754221222975e-08
in O 0 8.728343381392278e-09
the O 0 4.688104837669016e-08
father O 0 1.1288874475212651e-06
. O 0 1.1433088076273634e-07
. O 0 4.5735518483525084e-07

The O 0 9.178263098874595e-06
RB1 O 0 0.001117339706979692
gene O 0 1.7190983271575533e-05
mutation O 0 8.01972328190459e-06
in O 0 8.817853114351237e-08
a O 0 5.244893372946535e-07
child O 0 3.2596217351965606e-05
with O 0 1.088491717382567e-05
ectopic B-Disease 1 0.9999998807907104
intracranial I-Disease 1 0.9999973773956299
retinoblastoma I-Disease 1 0.9318028092384338
. O 0 2.1465470126713626e-05

The O 0 3.244741674279794e-05
RB1 O 0 0.005423943046480417
gene O 0 7.021924102446064e-05
mutation O 0 6.367186870193109e-05
was O 0 5.681752554664854e-06
investigated O 0 8.108454494504258e-07
in O 0 6.137693020491497e-08
a O 0 9.800269253901206e-07
child O 0 2.288021642016247e-05
with O 0 2.6555305794317974e-06
ectopic B-Disease 1 0.9999994039535522
intracranial I-Disease 1 0.9957911968231201
retinoblastoma I-Disease 0 3.661062510218471e-05
using O 0 2.1831657193160936e-07
DNA O 0 1.4387196642928757e-06
obtained O 0 6.721819545418839e-08
from O 0 7.997426720862677e-09
both O 0 1.4506183809714912e-08
the O 0 1.1367929886318962e-07
pineal B-Disease 0 6.873624806758016e-05
and I-Disease 0 1.0573394320090301e-05
retinal I-Disease 1 0.9729304313659668
tumours I-Disease 1 1.0
of O 0 1.7736815038915665e-07
the O 0 1.2695106761384523e-06
patient O 0 5.090915146865882e-05
. O 0 2.3582840640301583e-06

A O 0 7.087657286319882e-05
nonsense O 0 0.0002715789305511862
mutation O 0 2.5933946744771674e-05
in O 0 2.0550157842080807e-07
exon O 0 2.0346760720713064e-05
17 O 0 1.3494962331606075e-05
( O 0 1.1474071470729541e-07
codon O 0 9.156337910098955e-07
556 O 0 5.626100687550206e-07
) O 0 9.7952517208455e-09
of O 0 3.800728620717564e-09
the O 0 9.327854399998614e-08
RB1 O 0 7.904504309408367e-05
gene O 0 2.88383830593375e-07
was O 0 6.4800342443049885e-06
found O 0 4.409648113323783e-08
to O 0 1.700544238758539e-08
be O 0 3.131635750719397e-08
present O 0 2.545569799394798e-08
homozygously O 0 4.698301381722558e-06
in O 0 3.456989716710268e-08
both O 0 2.7898220622546432e-08
the O 0 1.0634636993245294e-07
retinal B-Disease 0 0.000360847421688959
and I-Disease 0 2.737465138125117e-06
the I-Disease 0 3.5820021366816945e-06
pineal I-Disease 1 0.6001800298690796
tumours I-Disease 1 1.0
. O 0 7.8655239121872e-06

The O 0 1.7457049352742615e-06
same O 0 7.703891355959058e-07
mutation O 0 6.521272553072777e-06
was O 0 1.5320757711378974e-06
present O 0 3.29067653126458e-08
heterozygously O 0 1.97621488950972e-06
in O 0 1.9902396175552894e-08
the O 0 2.4243018259539895e-08
DNA O 0 4.857575959249516e-07
from O 0 4.444061563191326e-09
the O 0 4.150735755104051e-09
constitutional O 0 3.887242527866874e-08
cells O 0 2.504909524247978e-08
of O 0 1.3801870757390589e-09
the O 0 5.1724601490832356e-08
patient O 0 8.804213393887039e-07
, O 0 4.968133637817118e-08
proving O 0 1.5534503461367422e-07
it O 0 2.2574015545728798e-08
to O 0 1.0353663704165683e-08
be O 0 2.258206954763864e-08
of O 0 3.391017600051782e-08
germline O 0 7.5947705227008555e-06
origin O 0 6.534998533425096e-07
. O 0 1.16862747745472e-06

The O 0 2.018874283749028e-06
initial O 0 3.0716907986061415e-06
mutation O 0 6.832232429587748e-06
was O 0 5.96340260017314e-06
shown O 0 1.833049338983983e-07
to O 0 1.9753541025124832e-08
have O 0 2.780340651042934e-07
occurred O 0 1.260946191905532e-06
in O 0 3.7264999974695456e-08
the O 0 3.7477670389307605e-07
paternally O 0 6.761597614968196e-05
derived O 0 3.338036094646668e-06
RB1 O 0 0.00031329516787081957
allele O 0 1.3324674000614323e-05
. O 0 1.677000682320795e-06

The O 0 9.491941455053166e-06
mutation O 0 1.925836295413319e-05
is O 0 4.905123418552648e-08
in O 0 7.459542317178602e-09
an O 0 1.3408301136053069e-08
area O 0 2.2234452501379565e-07
of O 0 2.799895648664119e-09
the O 0 2.7566571247916727e-08
gene O 0 1.2505093138770462e-07
that O 0 1.0826339824632214e-08
encodes O 0 6.261279139607723e-08
the O 0 1.7015759468108627e-08
protein O 0 1.2039778596317774e-07
- O 0 1.0258365819026949e-06
binding O 0 1.8008807955993689e-07
region O 0 1.6639789635064517e-07
known O 0 7.480304020646145e-08
as O 0 2.4073541382563235e-08
the O 0 3.8226652065986855e-08
pocket O 0 0.07119988650083542
region O 0 2.450822194077773e-06
and O 0 9.494173127677641e-07
has O 0 6.802026177865628e-07
been O 0 1.371118969473173e-07
detected O 0 2.8547017905111716e-07
in O 0 5.4924060854943946e-09
other O 0 2.6035251732281495e-09
cases O 0 1.3139885624013914e-08
of O 0 1.721285691758112e-08
retinoblastoma B-Disease 0 3.8067297282395884e-05
. O 0 2.2593363269152178e-07
. O 0 7.32287901428208e-07

Low O 0 0.00022856985742691904
levels O 0 9.103590628001257e-07
of O 0 2.9193508055413986e-08
beta O 0 1.4489363309166947e-07
hexosaminidase O 0 6.946299322407867e-07
A O 0 9.258337030360053e-08
in O 0 6.581718992038077e-08
healthy O 0 5.181495339456887e-07
individuals O 0 1.4529665470774944e-08
with O 0 1.9117204885787942e-07
apparent O 0 0.18369291722774506
deficiency O 0 0.007260731887072325
of O 0 2.066389903632171e-08
this O 0 7.898711373854894e-08
enzyme O 0 1.4634794069934287e-06
. O 0 1.2901656418762286e-06

Appreciable O 0 0.00034469147794879973
beta O 0 3.572118657757528e-05
hexosaminidase O 0 7.818592712283134e-05
A O 0 4.2481187847442925e-06
( O 0 2.5108369072768255e-07
hex O 0 5.770566076535033e-06
A O 0 4.30921204497281e-07
) O 0 2.075656801991954e-08
activity O 0 5.652280776757834e-08
has O 0 4.980230272622066e-08
been O 0 7.552976910574216e-08
detected O 0 2.3020703565634903e-07
in O 0 4.7972850580890736e-08
cultured O 0 3.281836325186305e-05
skin O 0 0.03595537692308426
fibroblasts O 0 7.388570338662248e-06
and O 0 1.1066855222452432e-05
melanoma B-Disease 0 0.4540749490261078
tissue O 0 1.3965568541607354e-05
from O 0 5.499296307220902e-08
healthy O 0 1.817496126932383e-07
individuals O 0 6.63974297765435e-09
previously O 0 3.1375014941659174e-07
reported O 0 8.707096640137024e-06
as O 0 1.4839209825368016e-06
having O 0 0.00013480649795383215
deficiency B-Disease 0 2.744257653830573e-05
of I-Disease 0 1.5196196523348249e-09
hex I-Disease 0 9.028027307067532e-06
A I-Disease 0 3.311394607408147e-07
activity O 0 7.552890934903189e-08
indistinguishable O 0 6.441995736850004e-08
from O 0 3.228905365304513e-09
that O 0 2.67509570051061e-09
of O 0 2.0749364892935773e-08
patients O 0 2.3788868475094205e-06
with O 0 0.0008482548873871565
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.22308294475078583
( O 0 6.647297254858131e-07
TSD B-Disease 0 7.400796312140301e-05
) O 0 2.8562757847794273e-07
. O 0 7.402298365377646e-07

Identification O 0 6.48027125862427e-05
and O 0 3.7369920846686e-06
quantitation O 0 7.383469346677884e-05
of O 0 8.573839949121975e-08
hex O 0 6.482644675998017e-05
A O 0 1.6587376876486815e-06
, O 0 6.946167729893205e-08
amounting O 0 1.1599219362778967e-07
to O 0 3.084531385866285e-08
3 O 0 1.1961227528445306e-06
. O 0 1.4572942745871842e-06

5 O 0 0.0002652560651767999
% O 0 1.5320407328545116e-05
- O 0 3.9742528315400705e-05
6 O 0 7.681211172894109e-06
. O 0 1.3104491927151685e-06

9 O 0 0.00012112988042645156
% O 0 7.860894584155176e-07
of O 0 1.346925504464025e-08
total O 0 3.1052980631329774e-08
beta O 0 7.016581804464295e-08
hexosaminidase O 0 1.1876161352120107e-06
activity O 0 2.491511281732528e-07
, O 0 2.4013420585333733e-08
has O 0 1.059145944282136e-07
been O 0 5.3948642886325615e-08
obtained O 0 3.5572419676555e-08
by O 0 2.501233353768839e-08
cellulose O 0 1.475442240916891e-05
acetate O 0 7.463233487214893e-06
gel O 0 4.131048990529962e-05
electrophoresis O 0 1.2248628081579227e-05
, O 0 1.8033728110822267e-07
DEAE O 0 9.270826012652833e-06
- O 0 2.1641394596372265e-06
cellulose O 0 3.153579655190697e-06
ion O 0 8.547646075385273e-07
- O 0 1.5299659708034596e-06
exchange O 0 3.151445753246662e-07
chromatography O 0 1.340730023002834e-06
, O 0 7.586299233253158e-08
radial O 0 3.2352895686926786e-06
immunodiffusion O 0 5.66317521588644e-06
, O 0 6.136206565088287e-08
and O 0 2.703741301957052e-07
radioimmunoassay O 0 5.222342588240281e-05
. O 0 1.5305014358091285e-06

Previous O 0 4.9985741497948766e-05
family O 0 1.7822420659285854e-06
studies O 0 6.238867911179113e-08
suggested O 0 1.282048316397777e-07
that O 0 5.6533671077829695e-09
these O 0 4.142289622421913e-09
individuals O 0 8.136517237744556e-09
may O 0 1.1143387723677733e-07
be O 0 5.9570970378786114e-09
compound O 0 1.8876976071169338e-07
heterozygotes O 0 4.4985509362049925e-07
for O 0 2.316374203559235e-09
the O 0 1.2408364113980497e-08
common O 0 6.983562883533523e-08
mutant O 0 4.133588845434133e-06
TSD B-Disease 0 1.6249605323537253e-05
gene O 0 7.236184274006519e-07
and O 0 1.0587883991775016e-07
a O 0 2.2214931050257292e-07
rare O 0 3.5867972769665357e-07
( O 0 9.925000199473288e-08
allelic O 0 3.311778073111782e-06
) O 0 1.4731088526787062e-07
mutant O 0 1.1113709661003668e-05
gene O 0 1.1524968613230158e-05
. O 0 2.1596529222733807e-06

Thus O 0 7.391290637315251e-06
, O 0 9.344771711994326e-08
the O 0 1.7409778507726514e-08
postulated O 0 9.133923413173761e-07
rate O 0 3.9613954072592605e-07
mutant O 0 8.695394626556663e-07
gene O 0 1.5919128770747193e-07
appears O 0 4.807328650713316e-07
to O 0 9.158624969529683e-09
code O 0 2.0798854194481464e-08
for O 0 3.9502339177488466e-09
the O 0 2.0598459826715043e-08
expression O 0 3.710039209181559e-08
of O 0 4.619136628747356e-09
low O 0 5.260623083813698e-07
amounts O 0 1.3872424098337888e-08
of O 0 8.369266168983813e-09
hex O 0 1.864294426923152e-05
A O 0 1.1296240245428635e-06
. O 0 1.2068660453223856e-06

Heterozygotes O 0 0.0008617459097877145
for O 0 5.175677983970672e-07
the O 0 7.551219738388681e-08
rare O 0 2.4495085426679e-07
mutant O 0 2.386078267591074e-05
may O 0 2.121645593433641e-06
be O 0 1.0180438714257889e-08
indistinguishable O 0 1.001282612378418e-07
from O 0 1.510042224595054e-08
heterozygotes O 0 4.999698717256251e-07
for O 0 8.911637650044213e-09
the O 0 4.4630489526298334e-08
common O 0 7.118299549802032e-07
TSD B-Disease 0 8.095968223642558e-05
mutant O 0 2.7231308195041493e-05
. O 0 2.3946222427184694e-06

However O 0 7.70361384638818e-06
, O 0 9.793984645511955e-08
direct O 0 9.053947280790453e-08
visualization O 0 3.6546014143823413e-06
and O 0 1.0510934771446045e-06
quantitation O 0 4.542315946309827e-05
of O 0 3.573399354195317e-08
hex O 0 9.694405162008479e-05
A O 0 5.96496192883933e-07
by O 0 3.955096250507495e-09
the O 0 4.4886832029078505e-09
methods O 0 8.114575678064284e-08
described O 0 2.1119374196132412e-06
may O 0 4.445038825906522e-07
prevent O 0 7.085005648832521e-08
false O 0 1.3596381620573084e-07
- O 0 7.926850230433047e-06
positive O 0 3.6890261867483787e-07
prenatal O 0 1.064029765984742e-05
diagnosis O 0 9.837146535573993e-06
of O 0 3.054107011735141e-08
TSD B-Disease 0 0.00011168747732881457
in O 0 8.018903372430941e-07
fetuses O 0 5.277045056573115e-05
having O 0 1.6344766606835037e-07
the O 0 4.146140852867575e-08
incomplete O 0 1.2741878663291573e-06
hex B-Disease 0 0.03663291782140732
A I-Disease 0 0.0022214697673916817
deficiency I-Disease 0 9.229078568750992e-05
of O 0 1.755836920303011e-09
the O 0 2.631735362967902e-08
type O 0 1.2514773288785364e-06
described O 0 1.237357309946674e-06
in O 0 6.688478748628768e-08
the O 0 1.5426201116497396e-07
four O 0 2.3593368041474605e-06
healthy O 0 1.1658928997348994e-05
individuals O 0 1.2017195558655658e-06

The O 0 1.0714212294260506e-05
tumor B-Disease 0 0.0002814265026245266
suppressor O 0 0.00019849550153594464
gene O 0 1.598557355464436e-05
Smad4 O 0 0.00015476720000151545
/ O 0 4.0915798308560625e-05
Dpc4 O 0 2.4936678528320044e-05
is O 0 3.61818415228754e-08
required O 0 8.97997409765594e-09
for O 0 7.009984148709236e-09
gastrulation O 0 1.846295162977185e-06
and O 0 7.85284782978124e-07
later O 0 2.14222109207185e-06
for O 0 2.2973763336153752e-08
anterior O 0 3.932204890588764e-06
development O 0 1.6187572171588727e-08
of O 0 6.853163814213303e-09
the O 0 1.6504111499671126e-07
mouse O 0 0.0001172793417936191
embryo O 0 2.1019628547946922e-05
. O 0 2.0250602119631367e-06

Mutations O 0 0.0034165852703154087
in O 0 1.2168966350145638e-06
the O 0 5.486827490130963e-07
SMAD4 O 0 0.0009240192594006658
/ O 0 0.00015194823208730668
DPC4 O 0 0.00025828403886407614
tumor B-Disease 0 4.2832263716263697e-05
suppressor O 0 4.005299706477672e-05
gene O 0 1.049912270900677e-06
, O 0 2.1489432455723545e-08
a O 0 3.87875509488822e-08
key O 0 5.376383569455356e-07
signal O 0 6.764326826669276e-06
transducer O 0 2.142981429642532e-06
in O 0 2.2850743519597927e-08
most O 0 3.243752288994983e-08
TGFbeta O 0 1.7667964129941538e-05
- O 0 7.184062269516289e-06
related O 0 8.364913384184547e-08
pathways O 0 4.594943447955302e-07
, O 0 1.2471193855390084e-08
are O 0 1.06144626421667e-09
involved O 0 2.7263851176684284e-09
in O 0 1.2851987030160217e-08
50 O 0 2.227858004744121e-07
% O 0 4.936217479212246e-08
of O 0 2.2850096570437017e-07
pancreatic B-Disease 1 0.9965097308158875
cancers I-Disease 1 0.8831089735031128
. O 0 4.2045530790346675e-06

Homozygous O 0 0.012472779490053654
Smad4 O 0 0.0015368352178484201
mutant O 0 0.001273627975024283
mice O 0 0.2712445855140686
die O 0 0.00025028554955497384
before O 0 3.5912572116103547e-07
day O 0 4.6955369725765195e-07
7 O 0 1.5174473446677439e-06
. O 0 7.624158797625569e-07

5 O 0 0.00011419346992624924
of O 0 3.5701680189959006e-06
embryogenesis O 0 0.00022321258438751101
. O 0 1.9089919078396633e-05

Mutant O 0 0.00020302044868003577
embryos O 0 2.3203445380204357e-05
have O 0 1.2343059552222257e-06
reduced O 0 8.335717325280712e-07
size O 0 4.7031377903294924e-07
, O 0 1.0109660308899038e-07
fail O 0 2.5264498049182293e-07
to O 0 1.4738894549282122e-08
gastrulate O 0 1.7397385818185285e-05
or O 0 1.2620142797459266e-07
express O 0 4.5164590289914486e-08
a O 0 3.219491873096558e-08
mesodermal O 0 1.5506765294048819e-06
marker O 0 1.3127671081747394e-05
, O 0 9.726668537268779e-08
and O 0 2.118421775776369e-07
show O 0 4.231185812386684e-06
abnormal O 0 1.0027415555668995e-05
visceral O 0 1.9198252630303614e-05
endoderm O 0 6.0492446209536865e-05
development O 0 1.1063636975450208e-06
. O 0 1.274381133953284e-06

Growth B-Disease 1 0.9999997615814209
retardation I-Disease 1 1.0
of O 0 2.6488987714401446e-07
the O 0 2.759819608399994e-07
Smad4 O 0 0.001137329381890595
- O 0 0.0038102963007986546
deficient O 0 6.193704030010849e-05
embryos O 0 8.212449529310106e-07
results O 0 1.3849864899384556e-07
from O 0 9.501563980052197e-09
reduced O 0 1.2406334803927166e-07
cell O 0 7.259311587404227e-07
proliferation O 0 9.03407553209945e-08
rather O 0 1.5388710750130485e-08
than O 0 1.0723193888395599e-08
increased O 0 2.2903351748482237e-07
apoptosis O 0 6.42650456939009e-06
. O 0 7.008167699495971e-07

Aggregation O 0 7.860727055231109e-05
of O 0 7.543905553575314e-07
mutant O 0 2.468219645379577e-05
Smad4 O 0 8.716937009012327e-05
ES O 0 6.04831257078331e-06
cells O 0 9.894132517729304e-07
with O 0 4.770204142801049e-08
wild O 0 2.5107847250183113e-06
- O 0 7.389963866444305e-05
type O 0 5.998790129524423e-06
tetraploid O 0 4.557593638310209e-05
morulae O 0 0.00011909852037206292
rescues O 0 6.737556395819411e-05
the O 0 9.480601761424623e-07
gastrulation B-Disease 0 0.0001648946199566126
defect I-Disease 0 0.0002452305634506047
. O 0 4.793269908986986e-06

These O 0 2.5329588879685616e-06
results O 0 1.349831222796638e-06
indicate O 0 3.619913684360654e-07
that O 0 2.5527024050120417e-08
Smad4 O 0 5.2041908929822966e-05
is O 0 8.151169339498665e-08
initially O 0 3.958211891585961e-07
required O 0 3.659575753545141e-09
for O 0 1.0426906005278624e-09
the O 0 3.3118821018973676e-09
differentiation O 0 2.135806020930886e-08
of O 0 2.183873970551531e-09
the O 0 3.257522962485382e-08
visceral O 0 1.924218395288335e-06
endoderm O 0 4.702474598161643e-06
and O 0 1.3449673019749753e-07
that O 0 6.268530139408313e-09
the O 0 2.3124510306615775e-08
gastrulation B-Disease 0 2.589348923720536e-06
defect I-Disease 0 2.850544206012273e-06
in O 0 1.7491256443236125e-08
the O 0 9.807088474644843e-08
epiblast O 0 4.5554075768450275e-05
is O 0 4.331828762360601e-08
secondary O 0 3.0511550619394257e-08
and O 0 1.1205816718984352e-07
non O 0 2.374896723722486e-07
- O 0 2.5373921744176187e-05
cell O 0 2.3793181753717363e-05
autonomous O 0 2.39362225329387e-06
. O 0 1.793108822312206e-06

Rescued O 0 0.002187796402722597
embryos O 0 0.00023136103118304163
show O 0 0.00045608801883645356
severe O 0 0.00036957254633307457
anterior O 0 0.0006770128384232521
truncations O 0 0.0006820837152190506
, O 0 2.205371174568427e-06
indicating O 0 1.9295455331302946e-06
a O 0 1.5061957014950167e-07
second O 0 9.941500138666015e-07
important O 0 1.035524466175275e-08
role O 0 4.513444906706354e-08
for O 0 4.381161033961689e-08
Smad4 O 0 4.113218165002763e-05
in O 0 4.903650392407144e-07
anterior O 0 8.29627679195255e-05
patterning O 0 0.00048429914750158787
during O 0 3.0251303542172536e-06
embryogenesis O 0 4.3182557419640943e-05
. O 0 3.6782873849006137e-06

Prevalence O 0 0.003690592013299465
of O 0 2.063544343400281e-06
p16 O 0 7.466009992640465e-05
and O 0 1.4971049040468642e-06
CDK4 O 0 0.0006349842296913266
germline O 0 0.00012671855802182108
mutations O 0 8.701883416506462e-06
in O 0 2.2204129379588267e-07
48 O 0 6.41331062070094e-05
melanoma B-Disease 1 0.9849456548690796
- O 1 0.7098079919815063
prone O 0 0.03980724886059761
families O 0 1.073756038749707e-06
in O 0 2.4514528718100337e-07
France O 0 2.649458656378556e-05
. O 0 1.561582735121192e-06

The O 0 2.2816853743279353e-05
French O 0 0.0003099525929428637
Familial B-Disease 0 0.3750098943710327
Melanoma I-Disease 1 0.9995957016944885
Study O 0 3.846592790068826e-06
Group O 0 4.115141564398073e-06
. O 0 1.178892148345767e-06

Germline O 0 0.10457294434309006
mutations O 0 0.0007661613635718822
in O 0 5.259745421426487e-07
the O 0 1.3931133935329854e-07
p16 O 0 2.5530978291499196e-06
and O 0 1.7699235854706785e-07
CDK4 O 0 3.679128349176608e-05
genes O 0 9.021950404530799e-07
have O 0 5.04355114117061e-07
been O 0 8.333452115039108e-07
reported O 0 2.7745639386012044e-07
in O 0 2.8882451985623447e-09
a O 0 1.6965271854019193e-08
subset O 0 1.122446917634079e-07
of O 0 1.0032440656004837e-07
melanoma B-Disease 0 0.028375888243317604
pedigrees O 0 1.324719596595969e-05
, O 0 6.037628708099874e-08
but O 0 1.4441225992811724e-08
their O 0 2.6470496905517393e-08
prevalence O 0 1.187047928397078e-05
is O 0 4.214976812022542e-08
not O 0 9.035106884880406e-09
well O 0 5.564152161241509e-08
known O 0 8.018169523893448e-07
. O 0 6.204560349942767e-07

We O 0 4.921795607515378e-06
searched O 0 1.9739659364859108e-06
for O 0 2.6492163129887558e-08
such O 0 2.521904107766204e-08
germline O 0 1.1890091627719812e-05
mutations O 0 1.9641379367385525e-06
in O 0 8.901618997469996e-08
48 O 0 4.6729469431738835e-06
French O 0 0.0008483332931064069
melanoma B-Disease 1 0.9893317222595215
- O 0 0.13987459242343903
prone O 0 0.00037946179509162903
families O 0 1.3298328838118323e-07
selected O 0 1.9468481937678916e-08
according O 0 5.449487083808435e-09
to O 0 5.938310732034324e-09
two O 0 2.34781438734899e-08
major O 0 3.403010850888677e-08
criteria O 0 1.9786799754228923e-08
families O 0 9.593123628803824e-09
with O 0 4.832805711174615e-09
at O 0 6.915485073477612e-08
least O 0 1.3947667021341204e-08
three O 0 1.989154085890732e-08
affected O 0 2.331926296506026e-08
members O 0 2.3623130118721747e-09
( O 0 8.06047406598509e-09
n O 0 1.8733303477347363e-06
= O 0 3.825272870017216e-06
20 O 0 4.0028570680306075e-08
) O 0 3.43282113846044e-09
or O 0 1.190999654454572e-08
families O 0 1.2137859606298207e-08
with O 0 3.4415403860066363e-09
two O 0 1.420687709696722e-07
affected O 0 8.27564718974827e-08
members O 0 5.707703198964964e-09
, O 0 2.305583945982903e-09
one O 0 1.769381863248043e-09
of O 0 4.769344363886319e-10
them O 0 3.4951899152702026e-09
affected O 0 7.598025320021407e-09
before O 0 3.647408819418274e-09
the O 0 5.598523422634116e-09
age O 0 7.833832249559691e-09
of O 0 7.194156936840557e-10
50 O 0 1.8828588466135443e-08
( O 0 6.068730407093881e-09
n O 0 7.68379436522082e-07
= O 0 6.355118330247933e-06
28 O 0 1.2180136081951787e-06
) O 0 7.401406598717131e-09
, O 0 5.835038230372902e-09
and O 0 1.83974755429972e-08
one O 0 8.889975866566147e-09
additional O 0 3.7673501651624974e-08
minor O 0 3.773247669869306e-07
criterion O 0 4.285113845980959e-06
. O 0 1.4015985243531759e-06

Sixteen O 0 8.672429248690605e-05
different O 0 4.668047040468082e-06
p16 O 0 0.00012191972200525925
germline O 0 0.00026293733390048146
mutations O 0 0.00011495080252643675
were O 0 6.476583962466975e-07
found O 0 1.0217637225196086e-07
in O 0 1.169939451983737e-07
21 O 0 3.7643803807441145e-06
families O 0 5.084116594389343e-08
, O 0 1.0194584731948453e-08
while O 0 1.6396795032846967e-08
one O 0 5.735731534173283e-08
germline O 0 5.881293873244431e-06
mutation O 0 7.013811114120472e-07
, O 0 2.416970090735049e-08
Arg24His O 0 2.4257694803964114e-06
, O 0 1.0884774326314073e-07
was O 0 2.400280891379225e-06
detected O 0 2.1454789589370193e-07
in O 0 1.5738805814180523e-08
the O 0 1.397219620002943e-07
CDK4 O 0 0.00015239353524520993
gene O 0 5.935736226092558e-06
. O 0 1.4000314649820211e-06

The O 0 1.4623661854784586e-06
frequency O 0 2.0603035864041885e-06
of O 0 5.6549339433331625e-08
p16 O 0 3.397137106730952e-06
gene O 0 1.1389702194719575e-06
mutation O 0 5.959082614026556e-07
in O 0 1.0338311540181166e-08
our O 0 1.158461238048858e-08
sample O 0 5.0743022228516566e-08
( O 0 1.9284765784277624e-08
44 O 0 2.2910757024874329e-07
% O 0 1.955072015391579e-08
) O 0 2.389366038357821e-09
is O 0 3.739278664482981e-09
among O 0 2.9509685806061725e-09
the O 0 7.2328081301975544e-09
highest O 0 9.952506729860033e-08
rates O 0 3.5278839050079114e-07
yet O 0 2.0881135043282484e-08
reported O 0 3.433475228575844e-07
and O 0 1.5120569685223018e-08
the O 0 3.0160048680727414e-08
CDK4 O 0 0.00013815062993671745
mutation O 0 5.692185709449404e-07
is O 0 4.13625755868452e-09
the O 0 7.326347972735903e-09
second O 0 3.0100109142949805e-06
mutation O 0 3.826509782811627e-06
detected O 0 3.6656803104051505e-07
in O 0 8.902565795665396e-09
this O 0 1.7676253349918625e-08
gene O 0 1.2587260016516666e-06
worldwide O 0 8.901498063096369e-07
. O 0 8.890756930668431e-07

In O 0 6.770303116354626e-06
summary O 0 7.246450422826456e-06
, O 0 1.613055928828544e-07
our O 0 8.429008602206522e-08
results O 0 1.5720137014341162e-07
show O 0 8.971466058937949e-07
frequent O 0 1.5476847181616904e-07
involvement O 0 7.753622810469096e-08
of O 0 4.4774135510294855e-09
the O 0 4.3303913344061584e-08
p16 O 0 1.1168490345880855e-06
gene O 0 3.850803125260427e-07
in O 0 1.1990861992217106e-07
familial B-Disease 0 0.0012097464641556144
melanoma I-Disease 1 0.9728956818580627
and O 0 3.026965941899107e-06
confirm O 0 7.544812774540333e-07
the O 0 1.6127660984466274e-08
role O 0 1.983206487921052e-08
of O 0 4.512590301430919e-09
the O 0 3.873491039030341e-08
CDK4 O 0 1.075878299161559e-05
gene O 0 1.5869410674440587e-07
as O 0 5.07749753353437e-08
a O 0 9.493159041085164e-07
melanoma B-Disease 0 0.07304202020168304
- O 0 3.308761370135471e-05
predisposing O 0 3.0662638891953975e-05
gene O 0 5.52801247977186e-06
. O 0 5.410320227383636e-07
. O 0 1.3451997347146971e-06

Progression O 0 0.0005427284049801528
of O 0 1.3209451026341412e-06
somatic O 0 6.49799476377666e-05
CTG O 0 0.0002497234963811934
repeat O 0 2.6988956960849464e-05
length O 0 5.973271981929429e-06
heterogeneity O 0 1.0744427527242806e-05
in O 0 1.8229155784865725e-07
the O 0 4.795199401996797e-07
blood O 0 2.04557891265722e-05
cells O 0 1.2172657989140134e-05
of O 0 6.664977718173759e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0008645998896099627
. O 0 5.108011009724578e-06

The O 0 4.560347861115588e-06
genetic O 0 1.1467498552519828e-05
basis O 0 3.1190927529678447e-06
of O 0 2.393400609435048e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.4670865535736084
DM B-Disease 1 1.0
) O 0 3.0883336421538843e-06
is O 0 1.9449034383001162e-08
the O 0 5.185436968702106e-09
expansion O 0 2.4115086816323128e-08
of O 0 4.150054966345351e-09
an O 0 3.9780221783303205e-08
unstable O 0 0.00011605216423049569
CTG O 0 7.428931712638587e-05
repeat O 0 1.1433583040343365e-06
in O 0 3.666249526190768e-08
the O 0 4.12005540795235e-08
34 O 0 4.6338402626133757e-07
UTR O 0 1.676097326708259e-06
of O 0 1.8668206536176513e-08
the O 0 4.463926188691403e-07
DM B-Disease 1 0.9999992847442627
protein O 0 1.4533679859596305e-06
kinase O 0 2.3313141355174594e-06
gene O 0 6.017992291162955e-07
on O 0 1.968076958291931e-06
chromosome O 0 0.0010411557741463184
19 O 0 8.15456314740004e-06
. O 0 1.4376731769516482e-06

One O 0 3.7131937915546587e-06
of O 0 3.8061497065200456e-08
the O 0 3.3469948590436616e-08
principal O 0 8.482715685431685e-08
features O 0 1.6922359691307065e-07
of O 0 1.9851631449796514e-08
the O 0 5.982861694064923e-06
DM B-Disease 1 1.0
mutation O 0 1.0147510693059303e-05
is O 0 1.5395228203374245e-08
an O 0 8.023707032123184e-09
extraordinarily O 0 1.684110202404554e-06
high O 0 4.2199485505989287e-07
level O 0 1.971172558512535e-08
of O 0 4.320488855569238e-09
somatic O 0 1.7237421161553357e-06
mosaicism O 0 6.243285315576941e-05
, O 0 7.616282005074027e-08
due O 0 2.9663194567319806e-08
to O 0 1.1993360971018774e-08
an O 0 2.8432404874934036e-08
extremely O 0 2.5164823114209867e-07
high O 0 2.3204928822906368e-07
degree O 0 1.8159258985406268e-08
of O 0 3.983706697852085e-09
somatic O 0 1.291644252887636e-06
instability O 0 2.7457087981019868e-06
both O 0 3.895473810189287e-08
within O 0 2.233150020458652e-08
and O 0 4.139645071177256e-08
between O 0 5.737602393196539e-08
different O 0 8.503710802187925e-08
tissues O 0 1.1111187632195652e-05
. O 0 1.1259049870204763e-06

This O 0 3.7726103983004577e-06
instability O 0 2.097241122100968e-05
appears O 0 3.2941418339760276e-06
to O 0 3.349019195297842e-08
be O 0 2.0466988104317352e-08
biased O 0 1.6441617844975553e-07
towards O 0 1.57722848115327e-08
further O 0 5.118050427910248e-09
expansion O 0 1.4901431200087245e-08
and O 0 8.679519325482943e-09
continuous O 0 1.4612729160035087e-07
throughout O 0 5.648896816978777e-08
the O 0 7.93921817177079e-09
life O 0 6.235772342932933e-09
of O 0 6.546132524931636e-10
an O 0 2.567315471324605e-09
individual O 0 3.4831644235566728e-09
, O 0 3.849573992908972e-09
features O 0 1.1910421449101705e-07
that O 0 6.134275309932491e-08
could O 0 5.184980409467244e-07
be O 0 3.786765390145774e-08
associated O 0 2.3649379343737564e-08
with O 0 1.1194681626136571e-08
the O 0 4.780396238857065e-07
progressive O 0 6.6972306740353815e-06
nature O 0 5.139407477372515e-08
of O 0 1.7110338035308814e-08
the O 0 1.8940156678581843e-06
disease O 0 5.8210163842886686e-05
. O 0 9.689834996606805e-07

Although O 0 6.258405846892856e-06
increasing O 0 5.120177206663357e-07
measured O 0 1.5424789125972893e-06
allele O 0 8.317024935422523e-07
size O 0 2.2920045239516185e-07
between O 0 1.152446657215478e-06
patients O 0 1.8952661093862844e-06
clearly O 0 2.5441943307669135e-07
correlates O 0 1.708611279127581e-07
with O 0 9.552042712357434e-09
an O 0 3.8605172392180975e-08
increased O 0 3.1607089567842195e-06
severity O 0 8.78581777215004e-05
of O 0 1.7043052480403276e-07
symptoms O 0 5.9556634369073436e-05
and O 0 4.6356969818361904e-08
an O 0 1.245681069406146e-08
earlier O 0 9.923246580001432e-07
age O 0 6.679528752329134e-08
of O 0 3.8622531839394014e-09
onset O 0 1.955417246790603e-06
, O 0 1.1154823731374108e-08
this O 0 1.5677379394674062e-09
correlation O 0 8.498440706716792e-08
is O 0 1.3638896234624553e-08
not O 0 3.975016316104529e-09
precise O 0 2.573197832589358e-07
and O 0 4.372979560685053e-07
measured O 0 4.634831384464633e-06
allele O 0 4.13510889529789e-07
length O 0 1.1248156397414277e-06
cannot O 0 1.3461105652368133e-07
be O 0 3.1892002372302386e-09
used O 0 3.75157283016847e-09
as O 0 5.0085673386490726e-09
an O 0 5.779523970517175e-09
accurate O 0 1.3932279898654087e-06
predictor O 0 1.5784007700858638e-05
of O 0 1.52951873388929e-08
age O 0 1.2323494047450367e-07
of O 0 3.7291449928034126e-08
onset O 0 7.487964467145503e-05
. O 0 2.261924237245694e-06

In O 0 5.549473826249596e-06
order O 0 2.0632066366488289e-07
to O 0 1.4387779856406269e-08
further O 0 6.116913908726929e-08
characterize O 0 8.955045700531628e-07
the O 0 1.5823032128992054e-07
dynamics O 0 4.444197202246869e-06
of O 0 5.369190034798521e-07
DM B-Disease 1 1.0
CTG O 0 0.00020329278777353466
repeat O 0 3.093329951298074e-06
somatic O 0 4.007906227343483e-06
instability O 0 5.600188160315156e-06
, O 0 5.369190247961342e-08
we O 0 2.006388832853645e-08
have O 0 1.4694096606149287e-08
studied O 0 5.239284206481898e-08
repeat O 0 5.68106315768091e-07
length O 0 6.176452984618663e-07
changes O 0 1.622064260686784e-08
over O 0 1.6826440685235866e-08
time O 0 6.591267265321221e-08
in O 0 4.3689527728929534e-07
111 O 0 0.002928347559645772
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.199987289321143e-06
with O 0 3.0503056080988245e-08
varying O 0 1.0001181180996355e-06
clinical O 0 8.046436050790362e-06
severity O 0 8.760669152252376e-05
and O 0 5.642220344270754e-07
CTG O 0 1.1823244676634204e-05
repeat O 0 2.8135920615568466e-07
size O 0 7.30035054630207e-08
over O 0 5.141084002957541e-08
time O 0 3.699948436519662e-08
intervals O 0 9.47765741443618e-08
of O 0 2.264382015226829e-09
1 O 0 1.2816887817734823e-07
- O 0 7.712434126005974e-06
7 O 0 1.859888584476721e-06
years O 0 2.173441373543028e-07
. O 0 4.351554707682226e-07

We O 0 2.4213702999986708e-05
have O 0 1.533471731818281e-07
found O 0 3.0661013283861394e-08
a O 0 2.5557131522191412e-08
direct O 0 4.620971694180298e-08
progression O 0 2.342296056667692e-06
of O 0 4.031757594447072e-09
the O 0 1.5288771137988988e-08
size O 0 1.7960989850962505e-07
heterogeneity O 0 9.792739774638903e-07
over O 0 7.830907833294987e-08
time O 0 1.7794512530144857e-08
related O 0 4.8756731985122315e-09
to O 0 4.1416572393870865e-09
initial O 0 8.034706411308434e-08
CTG O 0 2.4503826807631413e-06
repeat O 0 2.2934125354368007e-07
size O 0 1.41330389169525e-07
and O 0 5.047881757036521e-08
the O 0 1.1853905412806398e-08
time O 0 3.3497343565613846e-08
interval O 0 4.4193228632138926e-07
and O 0 3.7317278156479006e-08
always O 0 2.707890089936882e-08
biased O 0 1.0954212115166229e-07
towards O 0 2.3898641288155886e-08
further O 0 3.198845632823577e-08
expansion O 0 3.522313249959552e-07
. O 0 6.106679393269587e-07

Attempts O 0 2.4982400645967573e-05
to O 0 3.6356141208671033e-07
mathematically O 0 2.0283848698454676e-06
model O 0 3.266766270826338e-07
the O 0 6.65282797740474e-08
dynamics O 0 7.949605787871405e-06
have O 0 1.2784772707163938e-06
proved O 0 3.657007255242206e-06
only O 0 5.8112952672217943e-08
partially O 0 2.313820459676208e-06
successful O 0 9.986677440565472e-08
suggesting O 0 7.162672233107514e-08
that O 0 2.2205595140434298e-09
individual O 0 1.2804316495973467e-09
specific O 0 2.3659068038028863e-09
genetic O 0 1.729698482222375e-07
and O 0 2.5917699986166554e-07
/ O 0 1.1379474017303437e-05
or O 0 6.623744752687344e-08
environmental O 0 8.497484316194459e-08
factors O 0 1.611991073957597e-08
also O 0 1.684831829606992e-07
play O 0 3.6565776184716015e-08
a O 0 3.622423960791821e-08
role O 0 1.0243726933367725e-07
in O 0 1.1876699801405266e-07
somatic O 0 5.28299324287218e-06
mosaicism O 0 6.920717714820057e-05
. O 0 4.6852130708430195e-07
. O 0 1.25600638511969e-06

Aspartylglucosaminuria B-Disease 1 0.9999550580978394
among O 0 2.4019251213758253e-05
Palestinian O 0 0.00018138937593903393
Arabs O 0 0.00014344371447805315
. O 0 6.152517926238943e-06

Aspartylglucosaminuria B-Disease 1 0.9999998807907104
( O 0 0.05583600699901581
AGU B-Disease 1 0.9999998807907104
) O 0 3.981927420682041e-06
is O 0 2.4504430484739714e-07
a O 0 5.147800834492955e-07
rare O 0 5.6455423873558175e-06
disorder B-Disease 0 0.008860750123858452
of I-Disease 0 6.843513489229736e-08
glycoprotein I-Disease 0 0.00010728897905210033
metabolism I-Disease 0 0.012975637800991535
caused O 0 1.373250506730983e-05
by O 0 1.0940618722088402e-07
the O 0 7.836935765226372e-06
deficiency B-Disease 0 0.0005308105028234422
of I-Disease 0 5.464652286235605e-09
the I-Disease 0 1.7050075484803529e-07
lysosomal I-Disease 0 0.0006917125429026783
enzyme I-Disease 0 1.0946586371574085e-05
aspartylglucosaminidase I-Disease 0 0.00018170806288253516
( O 0 4.441166083779535e-07
AGA O 0 1.3887662134948187e-05
) O 0 3.892918982728588e-07
. O 0 6.541901029777364e-07

AGU B-Disease 1 0.9999998807907104
is O 0 6.782895798096433e-05
inherited O 0 0.00016279831470455974
as O 0 4.7252524382201955e-07
an O 0 1.0165420007979264e-06
autosomal O 1 0.9998338222503662
recessive O 1 0.9992840886116028
trait O 0 0.002687775995582342
and O 0 4.875731519859983e-06
occurs O 0 1.0277701534278094e-07
with O 0 7.642006139008117e-09
a O 0 2.5100132461375324e-07
high O 0 2.2840822566649877e-06
frequency O 0 7.30048577679554e-06
in O 0 1.527924524680202e-07
Finland O 0 0.00018368137534707785
because O 0 2.7520497880573203e-08
of O 0 2.0756321106318865e-09
a O 0 1.123432156191484e-07
founder O 0 2.9668824481632328e-06
effect O 0 1.0780593129311455e-06
. O 0 4.0761392483545933e-07

While O 0 8.170084583980497e-06
very O 0 5.130142994858033e-07
few O 0 3.4178231089754263e-07
patients O 0 5.390507453739701e-07
with O 0 4.758527154535841e-07
AGU B-Disease 1 1.0
have O 0 2.814858453348279e-05
been O 0 4.449094831215916e-06
reported O 0 1.0618923624861054e-06
from O 0 1.4438554352125266e-08
non O 0 5.134322478284048e-08
- O 0 3.1561489777232055e-06
Finnish O 0 1.002261706162244e-05
origin O 0 6.935047025535823e-08
, O 0 1.0157438623537018e-07
we O 0 3.152371732539905e-07
diagnosed O 0 3.918528454960324e-05
the O 0 4.4737197413269314e-07
disorder O 0 0.00019834036356769502
in O 0 8.651061733644383e-08
8 O 0 2.700035793168354e-06
patients O 0 2.147855866496684e-07
originating O 0 3.585606833667043e-08
from O 0 1.0791909588192539e-08
3 O 0 5.2277048467885834e-08
unrelated O 0 1.1657028409217673e-07
families O 0 7.534070789461111e-08
, O 0 7.376264488101469e-09
all O 0 1.2070624499926907e-09
Palestinian O 0 2.24473706111894e-06
Arabs O 0 8.534352673450485e-07
from O 0 1.0939279704302862e-08
the O 0 8.746542157211934e-09
region O 0 8.108912652460276e-08
of O 0 2.378980923367635e-08
Jerusalem O 0 7.535039185313508e-05
. O 0 2.7942053293372737e-06

The O 0 8.331455319421366e-06
clinical O 0 4.627450471161865e-05
diagnosis O 0 0.05456113815307617
of O 0 9.063932338904124e-06
AGU B-Disease 1 1.0
is O 0 6.809414117014967e-06
often O 0 9.261884770239703e-07
difficult O 0 3.243827109145059e-07
, O 0 2.0903810238337428e-08
in O 0 4.8583048695149955e-09
particular O 0 7.167589188838974e-09
early O 0 7.200917195859802e-08
in O 0 1.5379937323700688e-08
the O 0 3.903424783402443e-08
course O 0 3.1646493425796507e-07
of O 0 9.535514600145234e-09
the O 0 1.0796520655276254e-06
disease O 0 1.9851227989420295e-05
, O 0 3.891203803618737e-08
and O 0 3.020869598913123e-08
most O 0 1.5767342986805488e-09
of O 0 1.0470291300634926e-09
the O 0 7.138027768860411e-08
patients O 0 2.9637726584041957e-07
are O 0 9.779461862535754e-08
diagnosed O 0 0.00022443819034378976
after O 0 2.112867178993838e-07
the O 0 9.217757934720794e-08
age O 0 8.239532434117791e-08
of O 0 2.9987432537126324e-09
5 O 0 2.35694571415479e-07
years O 0 3.3829431345111516e-07
. O 0 6.856938057353545e-07

However O 0 1.68127899087267e-05
, O 0 2.2878225536260288e-07
since O 0 1.5074948578330805e-07
these O 0 2.9833529424649896e-08
patients O 0 1.212666376204652e-07
excrete O 0 1.043551023371947e-07
early O 0 2.8324961931502912e-08
large O 0 6.059500012867147e-09
amounts O 0 7.528422329983187e-09
of O 0 2.6632438476781317e-09
aspartylglucosamine O 0 2.4741061679378618e-06
in O 0 4.154777144549371e-08
urine O 0 2.731024437707674e-07
, O 0 9.682887380790817e-09
biochemical O 0 1.9729505140730907e-07
screening O 0 1.2997659837310493e-07
is O 0 3.3703514645822e-08
easy O 0 1.3983940050366073e-07
by O 0 3.665235936978206e-08
urine O 0 1.909996171889361e-06
chromatography O 0 3.826170086540515e-06
. O 0 3.018456879999576e-07
. O 0 8.11697248082055e-07

Detection O 0 4.627724410966039e-05
of O 0 7.538598651990469e-07
heterozygous O 0 1.2218447409395594e-05
carriers O 0 1.038518007590028e-06
of O 0 5.38933093707783e-08
the O 0 3.0026772947167046e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 8.991629556476255e-07
ATM O 0 4.12719555242802e-06
) O 0 3.7883403081195866e-08
gene O 0 2.1551623774485051e-07
by O 0 3.125549241644876e-08
G2 O 0 3.017126800841652e-05
phase O 0 1.2930615866935113e-06
chromosomal O 0 0.0003956981236115098
radiosensitivity O 0 4.098785211681388e-05
of O 0 2.1962297580557788e-07
peripheral O 0 0.0015056560514494777
blood O 0 0.0004058843769598752
lymphocytes O 0 9.232634329237044e-05
. O 0 2.2036495010979706e-06

In O 0 0.0045302631333470345
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.005361287388950586
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.101784487735131e-07
patients O 0 3.7967532762195333e-07
, O 0 4.65589096165786e-08
mutations O 0 3.508089321258012e-07
in O 0 7.128637680153815e-09
a O 0 7.92252095038748e-08
single O 0 8.005463314475492e-07
gene O 0 3.26493790225868e-07
, O 0 2.7997050011663305e-08
ATM O 0 6.12686847034638e-07
, O 0 1.801429938552701e-08
result O 0 4.3379056791081894e-08
in O 0 5.007065624340612e-07
an O 0 0.03724067658185959
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.2636379551622667e-06
embraces O 0 5.90169520364725e-07
a O 0 1.0211869749809921e-07
variety O 0 1.794167303614813e-08
of O 0 6.4400027532940385e-09
clinical O 0 3.4692561712290626e-07
features O 0 3.5775467495113844e-06
and O 0 2.8829631446569692e-06
manifests O 0 1.9766278001043247e-06
extreme O 0 3.11202143166156e-06
radiosensitivity O 0 8.779337804298848e-06
and O 0 4.0670098400141796e-08
a O 0 4.2758692586630787e-08
strong O 0 1.3526143050057726e-07
pre O 0 2.3917511953186477e-06
- O 0 5.42124907951802e-05
disposition O 0 6.592583304154687e-06
to O 0 3.0763590075366665e-07
malignancy B-Disease 0 0.0005367461126297712
. O 0 1.5829643871256849e-06

Heterozygotes O 0 0.00043006279156543314
for O 0 1.511737508508304e-07
the O 0 3.665438441657898e-08
ATM O 0 2.5050060230569215e-06
gene O 0 7.620400879204681e-07
have O 0 1.8916676935987198e-07
no O 0 3.493592259928846e-08
clinical O 0 1.3320250502601994e-07
expression O 0 1.3205516324887867e-07
of O 0 4.870600989193008e-08
A B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999955892562866
T I-Disease 1 1.0
but O 0 2.0349104943306884e-06
may O 0 2.1469784314831486e-06
be O 0 2.0737601857945265e-07
cancer B-Disease 0 7.2603547778271604e-06
prone O 0 1.7617840057937428e-06
with O 0 1.8135756008064163e-08
a O 0 3.4003286941697297e-07
moderate O 0 1.2200585842947476e-05
increase O 0 2.3726533981971443e-07
in O 0 2.496281581443327e-08
in O 0 1.1635648178298652e-07
vitro O 0 3.3651755074970424e-05
radiosensitivity O 0 5.864788545295596e-05
. O 0 1.0715015150708496e-06

We O 0 4.268546763341874e-05
performed O 0 5.134066213940969e-06
a O 0 7.697568094044982e-07
blind O 0 1.2885283467767294e-05
chromosomal O 0 0.00013167182623874396
analysis O 0 3.4284397543160594e-07
on O 0 1.2298374940655776e-06
G2 O 0 0.00025336959515698254
- O 0 2.1874826416024007e-05
phase O 0 8.910186579669244e-07
lymphocytes O 0 7.691403993703716e-07
from O 0 1.473768662663133e-08
7 O 0 1.7612352110063512e-07
unrelated O 0 1.2612167665793095e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.952782885287888e-06
, O 0 2.3648071945103766e-08
13 O 0 6.132088259391821e-08
obligate O 0 2.3482515132400295e-07
A B-Disease 1 0.9999902248382568
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 2.543798109400086e-05
( O 0 4.237119455297034e-08
parents O 0 1.0725485388718425e-08
of O 0 1.22086696308088e-09
the O 0 8.416975560976425e-08
patients O 0 3.8080131048445764e-07
) O 0 1.0362475322267528e-08
, O 0 7.957288161719589e-09
and O 0 1.8244112709453475e-07
14 O 0 1.327243239757081e-07
normal O 0 2.3067945775778753e-08
controls O 0 1.0682165907383023e-07
following O 0 1.9452929933549967e-08
X O 0 3.851835208479315e-05
- O 0 3.837901658698684e-06
irradiation O 0 2.082629180222284e-07
with O 0 9.71661506810051e-09
1 O 0 1.138386735988206e-07
Gy O 0 9.340331416751724e-06
in O 0 1.1590424620067097e-08
order O 0 8.181272548313245e-09
to O 0 3.910546997332176e-09
evaluate O 0 2.847234981118163e-08
this O 0 4.217258542382751e-09
cytogenetic O 0 9.841376140684588e-07
method O 0 4.5474045862192725e-08
as O 0 9.320630489639825e-09
a O 0 1.0915581327708423e-08
tool O 0 8.075389246187115e-08
for O 0 3.431773532014404e-09
detection O 0 1.2362539791865856e-07
of O 0 1.9075004686897046e-08
ATM O 0 9.589662113285158e-06
carriers O 0 2.2783301574236248e-06
. O 0 7.677473377043498e-07

Both O 0 9.888059867080301e-05
A B-Disease 1 0.999951958656311
- I-Disease 1 0.9999939203262329
T I-Disease 1 1.0
homozygotes O 0 0.00015740504022687674
and O 0 1.091615331461071e-06
heterozygotes O 0 1.2661503205890767e-05
showed O 0 4.0517061279388145e-06
significantly O 0 5.310196797836397e-07
increased O 0 2.1303831942987017e-07
levels O 0 3.095983558409898e-08
of O 0 1.1028104651700232e-08
radiation O 0 4.8438127123517916e-05
- O 0 7.735148392384872e-05
induced O 0 0.0014448493020609021
chromatid O 0 0.010508757084608078
damage O 0 2.2041576812625863e-05
relative O 0 1.697302991487959e-07
to O 0 1.5606321568384374e-08
that O 0 9.909522979967278e-09
of O 0 1.849444153378954e-08
normal O 0 7.920788220872055e-07
controls O 0 4.6052809921093285e-05
. O 0 3.39284747497004e-06

These O 0 3.070531192861381e-06
results O 0 1.66248310051742e-06
show O 0 7.988738275344076e-07
that O 0 7.1812187307784825e-09
the O 0 1.0583963039323407e-08
G2 O 0 2.2387945136870258e-05
- O 0 2.7435285119281616e-06
phase O 0 4.772215334014618e-07
chromosomal O 0 4.8069534386741e-05
radiosensitivity O 0 1.1346272003720514e-05
assay O 0 3.6695873859571293e-06
can O 0 5.3939999133945093e-08
be O 0 6.664586216231783e-09
used O 0 1.0061699029506599e-08
for O 0 2.2418207290542114e-09
the O 0 5.882812015300942e-09
detection O 0 1.6681370595961198e-07
of O 0 5.1146276547342495e-08
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
heterozygotes O 0 0.00013400727766565979
. O 0 1.5834142459425493e-06

In O 0 3.4772731396515155e-06
combination O 0 2.1363107407523785e-06
with O 0 6.976014788051543e-08
molecular O 0 1.1854853028125945e-06
genetic O 0 2.2300187083601486e-06
analyses O 0 7.604697316310194e-07
, O 0 2.947561306143598e-08
this O 0 1.1691493106980033e-08
test O 0 1.3182038571812882e-07
may O 0 7.485034529963741e-07
be O 0 3.854930596958184e-09
of O 0 6.543498520805713e-10
value O 0 4.38256275714366e-09
in O 0 5.187187568367335e-09
studies O 0 4.497355821087012e-09
of O 0 2.8084212733148206e-09
familial B-Disease 0 2.5531855953886406e-06
and I-Disease 0 9.887435226119123e-07
sporadic I-Disease 0 0.00474706944078207
cancers I-Disease 0 0.0016786555061116815
aimed O 0 6.692631586702191e-07
at O 0 2.2526323562033213e-07
determination O 0 9.149444935019346e-08
of O 0 1.3927881070685544e-09
the O 0 5.2553148499612234e-09
potential O 0 1.2517425318492315e-08
involvement O 0 2.172127189226103e-08
of O 0 3.938677384240918e-09
ATM O 0 1.3257673344924115e-05
mutations O 0 5.68906079934095e-06
in O 0 1.4686411020647938e-07
tumor B-Disease 0 0.00013185979332774878
risk O 0 8.786523153503367e-07
or O 0 3.0717909993427384e-08
development O 0 3.095906819794436e-08
. O 0 7.487027176011907e-08
. O 0 6.167994683892175e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
: O 0 2.9357504445215454e-06
identification O 0 4.377999403004651e-07
and O 0 5.219107279685886e-08
detection O 0 2.0990594862269063e-07
of O 0 1.3370810236779107e-08
founder O 0 4.323477241996443e-06
- O 0 2.3719372620689683e-05
effect O 0 1.2605662504938664e-06
mutations O 0 3.3443694746893016e-07
in O 0 3.1446227843900942e-09
the O 0 8.710979493287141e-09
ATM O 0 7.905235293037549e-07
gene O 0 3.7661939700228686e-07
in O 0 5.03135808571642e-08
ethnic O 0 9.34781780870253e-07
populations O 0 2.7547234822122846e-06
. O 0 8.998363227874506e-07

To O 0 8.417680419370299e-07
facilitate O 0 2.627726018999965e-07
the O 0 4.1386268634369117e-08
evaluation O 0 6.602263624699845e-08
of O 0 1.3840049106761398e-08
ATM O 0 9.508449693385046e-06
heterozygotes O 0 2.5723122689669253e-06
for O 0 2.3000726656619008e-08
susceptibility O 0 1.0529874998610467e-05
to O 0 7.976605331805331e-08
other O 0 1.3771366980108724e-07
diseases O 0 5.886153303436004e-06
, O 0 5.548475012773224e-09
such O 0 2.4042006163682572e-09
as O 0 1.2391687960189302e-06
breast B-Disease 1 0.7061861157417297
cancer I-Disease 0 2.4973280233098194e-05
, O 0 3.309704865728236e-08
we O 0 1.1786360332166623e-08
have O 0 9.285462176933379e-09
attempted O 0 7.971310651555541e-07
to O 0 6.792352902351695e-09
define O 0 1.0062566246915594e-07
the O 0 1.5425472454921874e-08
most O 0 9.995039462751265e-09
common O 0 5.420195492433777e-08
mutations O 0 7.100042012098129e-07
and O 0 1.8504001886299193e-08
their O 0 1.2574760788197636e-08
frequencies O 0 3.013305104104802e-06
in O 0 8.267257726402022e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 4.5684242650168017e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.953022632505963e-07
homozygotes O 0 1.2285597676964244e-06
from O 0 1.8869105389285323e-08
10 O 0 1.9866403633272967e-08
ethnic O 0 1.3740026361119817e-07
populations O 0 1.6726083913454204e-06
. O 0 7.690619554523437e-07

Both O 0 8.319878361362498e-06
genomic O 0 4.528665522229858e-05
mutations O 0 0.00011210456432309002
and O 0 2.8822267950090463e-07
their O 0 5.828445637234836e-08
effects O 0 1.858842324509169e-06
on O 0 5.125814936945972e-07
cDNA O 0 5.79673223910504e-06
were O 0 2.6097620775544783e-06
characterized O 0 1.6131978554767556e-05
. O 0 2.203197709604865e-06

Protein O 0 0.00018906028708443046
- O 0 8.040304237511009e-05
truncation O 0 2.4105645934469067e-05
testing O 0 7.660220262550865e-07
of O 0 9.852006321864337e-09
the O 0 1.123564619120998e-08
entire O 0 5.8732737784339406e-08
ATM O 0 5.092225023872743e-07
cDNA O 0 9.333832053926017e-07
detected O 0 1.0007897799368948e-06
92 O 0 2.1325277543837728e-07
( O 0 1.7156249754179953e-08
66 O 0 6.101934104663087e-07
% O 0 4.6808317222257756e-08
) O 0 1.88220177221865e-08
truncating O 0 1.9557305677153636e-06
mutations O 0 1.642816755520471e-06
in O 0 2.7840599159389967e-08
140 O 0 2.6964593757838884e-07
mutant O 0 7.679482223466039e-06
alleles O 0 4.220325081405463e-06
screened O 0 1.327556401520269e-05
. O 0 2.0699696960946312e-06

The O 0 2.762484200502513e-06
haplotyping O 0 2.780351678666193e-05
of O 0 1.4403407533336576e-07
patients O 0 9.949429795597098e-07
with O 0 5.308733364017826e-08
identical O 0 0.00033173811971209943
mutations O 0 0.0001765194465406239
indicates O 0 1.1896632940988638e-06
that O 0 3.605618204005623e-08
almost O 0 3.16183736970288e-08
all O 0 5.900811506087678e-10
of O 0 5.741723763108553e-10
these O 0 3.438528795030038e-09
represent O 0 1.3391969311271623e-08
common O 0 1.0426040830679995e-07
ancestry O 0 1.5972476603565156e-06
and O 0 1.7958420528429997e-07
that O 0 2.3787359637594818e-08
very O 0 4.359072036663747e-08
few O 0 1.1710735492442836e-07
spontaneously O 0 5.033806473875302e-07
recurring O 0 4.6417894736805465e-06
ATM O 0 8.694845746504143e-05
mutations O 0 2.852038960554637e-05
exist O 0 9.970030987460632e-07
. O 0 8.109660711852484e-07

Assays O 0 0.000298725557513535
requiring O 0 5.222097115620272e-06
minimal O 0 1.6230101209657732e-06
amounts O 0 6.83473473372942e-08
of O 0 9.194699224224223e-09
genomic O 0 6.457643735302554e-07
DNA O 0 2.2157960302138235e-06
were O 0 2.4713676793908235e-07
designed O 0 6.269058303587371e-07
to O 0 6.691729392827028e-09
allow O 0 1.4336197118325344e-08
rapid O 0 1.0649149118080459e-07
screening O 0 7.192777218278934e-08
for O 0 9.237414388962861e-09
common O 0 1.2485227784964081e-07
ethnic O 0 2.9782613637507893e-06
mutations O 0 4.406106017995626e-05
. O 0 1.4351950312629924e-06

These O 0 1.9489066289679613e-06
rapid O 0 3.793452378886286e-06
assays O 0 8.304998118546791e-06
detected O 0 2.9150719456083607e-06
mutations O 0 1.2303302128202631e-06
in O 0 4.7404181913179855e-08
76 O 0 1.372392262055655e-06
% O 0 2.2255429499296042e-08
of O 0 5.481323395173376e-09
Costa O 0 1.6526364561286755e-06
Rican O 0 1.1904580787813757e-05
patients O 0 7.635480301360076e-07
( O 0 1.497362767111099e-08
3 O 0 3.579074459025833e-08
) O 0 4.612278559079641e-09
, O 0 5.346021847429938e-09
50 O 0 1.2032978169429498e-08
% O 0 3.7219591852988287e-09
of O 0 1.8458625739015133e-09
Norwegian O 0 0.007978380657732487
patients O 0 6.955600042601873e-07
( O 0 6.319345935423826e-09
1 O 0 1.958688855552282e-08
) O 0 5.959733595517491e-09
, O 0 6.796007312459551e-09
25 O 0 2.724224046346535e-08
% O 0 6.157741427870178e-09
of O 0 4.957860344489973e-09
Polish O 0 9.013673843583092e-05
patients O 0 2.814786341787112e-07
( O 0 5.918341816624206e-09
4 O 0 6.915735895063335e-08
) O 0 5.367723598936891e-09
, O 0 6.499059956865949e-09
and O 0 4.415926824208327e-08
14 O 0 1.0827107388422519e-07
% O 0 4.8708215238946195e-09
of O 0 2.138311749888544e-09
Italian O 0 2.7048115953220986e-05
patients O 0 8.540393992007012e-07
( O 0 1.2357513234917405e-08
1 O 0 4.107031159605867e-08
) O 0 1.1161463753239786e-08
, O 0 1.0666485472654585e-08
as O 0 1.4646471591106547e-08
well O 0 2.6282892306994654e-08
as O 0 1.8079012065186362e-08
in O 0 3.0755547442140596e-08
patients O 0 6.161620547118218e-08
of O 0 6.185274958880882e-09
Amish O 0 3.57579265255481e-05
/ O 0 6.667329671472544e-06
Mennonite O 0 7.358417406067019e-06
and O 0 1.1867737157444935e-06
Irish O 0 3.0699045510118594e-06
English O 0 5.470494670589687e-07
backgrounds O 0 1.3193802033129032e-06
. O 0 1.1590244639592129e-06

Additional O 0 1.8767956134979613e-05
mutations O 0 0.00029565056320279837
were O 0 1.2004687732769526e-06
observed O 0 3.8805873714409245e-07
in O 0 3.404166548648391e-08
Japanese O 0 2.2918973741070658e-07
, O 0 1.6995294060961896e-08
Utah O 0 2.2056899240396888e-07
Mormon O 0 3.665502106287022e-07
, O 0 2.3474740373785608e-08
and O 0 3.3417705935789854e-08
African O 0 6.988000222918345e-08
American O 0 4.26031647293712e-07
patients O 0 1.3318577885002014e-06
. O 0 3.2275772809953196e-07

These O 0 1.8458304111845791e-06
assays O 0 3.7221464026515605e-06
should O 0 3.607262399896172e-08
facilitate O 0 2.5277648418864374e-08
screening O 0 7.330530138460745e-08
for O 0 7.992215245167245e-08
A B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 1.4742523489985615e-05
in O 0 3.183270180784348e-08
the O 0 2.6537021469152933e-08
populations O 0 9.30734600501637e-08
studied O 0 1.3182867064642778e-07
. O 0 6.495406523754355e-08
. O 0 5.697698384210526e-07

The O 0 1.453845834475942e-05
von B-Disease 1 0.7043195366859436
Hippel I-Disease 1 0.9940434098243713
- I-Disease 1 0.7560274004936218
Lindau I-Disease 1 0.8049843311309814
tumor I-Disease 0 0.0003226824919693172
suppressor O 0 0.00014098657993599772
gene O 0 4.25590451413882e-06
is O 0 7.939417656643855e-08
required O 0 2.242535934726675e-08
for O 0 1.533313032098249e-08
cell O 0 5.1085130507999565e-06
cycle O 0 4.465737674763659e-06
exit O 0 1.7041993487509899e-06
upon O 0 2.5106621137638285e-07
serum O 0 8.070774129009806e-06
withdrawal O 0 1.0710912647482473e-05
. O 0 1.253078721674683e-06

The O 0 8.866194548318163e-06
inactivation O 0 3.839388591586612e-05
of O 0 1.2183767239548615e-07
the O 0 5.124397262079583e-07
von B-Disease 1 0.9993188381195068
Hippel I-Disease 1 0.9999898672103882
- I-Disease 1 0.9997435212135315
Lindau I-Disease 1 0.9969694018363953
( I-Disease 0 2.4504058728780365e-06
VHL I-Disease 0 0.0003283096302766353
) I-Disease 0 1.0887416692639817e-06
tumor I-Disease 0 7.195249054348096e-05
suppressor O 0 0.0004015987797174603
gene O 0 1.30065573102911e-05
predisposes O 0 3.788159301620908e-05
affected O 0 7.936084784887498e-07
individuals O 0 1.3705942158992457e-08
to O 0 1.9493043623697304e-08
the O 0 5.839361278958677e-07
human O 0 0.0004314998514018953
VHL B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999988079071045
and O 0 9.195769621328509e-07
is O 0 1.2503900848059857e-07
associated O 0 4.3279348460600886e-07
with O 0 1.0356113762099994e-06
sporadic B-Disease 1 0.9999765157699585
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.0004775250854436308
RCC B-Disease 1 0.8934482336044312
) O 0 1.2836597989007714e-06
and O 0 1.2174944458820391e-05
brain B-Disease 0 0.000575703161302954
hemangioblastomas I-Disease 0 0.0004123880644328892
. O 0 5.2044324547750875e-06

VHL O 0 0.028616392984986305
- O 0 0.0033758312929421663
negative O 0 4.350799281382933e-05
786 O 0 5.601131488219835e-05
- O 0 0.00021863903384655714
0 O 0 3.2691771139070624e-06
RCC B-Disease 0 0.00011479515524115413
cells O 0 5.745683893110254e-07
are O 0 1.2721872444387827e-08
tumorigenic O 0 4.638908649212681e-06
in O 0 2.5531730329930724e-07
nude O 0 0.452663779258728
mice O 0 0.03166135773062706
which O 0 7.34286516035354e-07
is O 0 2.763453466059218e-08
suppressed O 0 8.718696875575915e-08
by O 0 2.688338218703734e-09
the O 0 1.7065943325178523e-08
reintroduction O 0 2.7029007014789386e-06
of O 0 1.3457267300509557e-07
VHL B-Disease 0 0.00024786326684989035
. O 0 2.7810244773718296e-06

Remarkably O 0 0.0033098857384175062
, O 0 4.2499078745095176e-07
this O 0 2.10187529603445e-08
occurs O 0 6.201307201081363e-08
without O 0 6.853752232416355e-09
affecting O 0 1.560906071063073e-08
the O 0 1.369713586996113e-08
growth O 0 3.787964999446558e-07
rate O 0 5.208685252000578e-07
and O 0 3.385653712939529e-08
cell O 0 1.883381514744542e-06
cycle O 0 5.865034040652972e-07
profile O 0 2.3109306823698716e-07
of O 0 4.724123758848009e-09
these O 0 7.460836393136105e-09
cells O 0 7.135319179951694e-08
in O 0 1.9925261440789654e-08
culture O 0 5.602627197731636e-07
. O 0 7.455496984221099e-07

The O 0 1.8801297301251907e-06
786 O 0 2.465211036906112e-05
- O 0 5.854725168319419e-05
0 O 0 1.0184535312873777e-06
cell O 0 7.171938705141656e-06
line O 0 1.2717023309960496e-05
, O 0 1.0286542284632105e-08
like O 0 8.146051833080037e-09
many O 0 1.177831432386256e-08
cancer B-Disease 0 1.4092261153564323e-06
cells O 0 1.3555288091993134e-07
, O 0 1.6159438231966305e-08
fails O 0 7.7919018792727e-08
to O 0 4.801410824484265e-09
exit O 0 1.9569100118133065e-07
the O 0 5.8458915930259536e-08
cell O 0 3.6410965549293905e-06
cycle O 0 1.7954822624233202e-06
upon O 0 8.145511998236543e-08
serum O 0 4.3130416997883e-06
withdrawal O 0 4.571141289488878e-06
. O 0 1.620255716261454e-06

Here O 0 1.2362801498966292e-05
, O 0 1.336101291826708e-07
it O 0 2.89309838308327e-08
is O 0 2.0178521964453466e-08
shown O 0 3.996784414539434e-08
that O 0 4.843399459275588e-09
reintroduction O 0 3.2920738135544525e-07
of O 0 5.133516722821696e-09
the O 0 3.0690035401903515e-08
wild O 0 5.673342684531235e-07
- O 0 2.679040153452661e-05
type O 0 1.2805199958165758e-06
VHL B-Disease 0 1.903603333630599e-05
gene O 0 7.092394866958784e-07
restores O 0 3.994211510871537e-06
the O 0 4.084344951138519e-08
ability O 0 9.389778199420107e-08
of O 0 3.306455553797605e-08
VHL O 0 0.00033959056599996984
- O 0 0.07987154275178909
negative O 0 0.00011321105557726696
RCC B-Disease 0 0.11240795999765396
cancer I-Disease 0 1.768724905559793e-05
cells O 0 9.541739842688912e-08
to O 0 7.570800875100758e-09
exit O 0 1.6559860682718863e-07
the O 0 3.943272020023869e-08
cell O 0 1.8726711914496263e-06
cycle O 0 6.395595164576662e-07
and O 0 2.5861547570116272e-08
enter O 0 9.226764063896553e-08
G0 O 0 9.467136806051712e-06
/ O 0 2.0558991309371777e-06
quiescence O 0 5.736120328947436e-06
in O 0 1.4454995778123703e-07
low O 0 1.1376306247257162e-05
serum O 0 5.6527842389186844e-05
. O 0 1.5453971400347655e-06

Both O 0 4.001515844720416e-05
VHL O 0 0.0022808369249105453
- O 0 0.0008633979596197605
positive O 0 2.0206714452797314e-06
and O 0 4.4758192530025553e-07
VHL O 0 0.00045930739725008607
- O 0 0.0009474344551563263
negative O 0 1.5539806554443203e-05
RCC B-Disease 0 0.00019873297424055636
cells O 0 6.157263214845443e-07
exit O 0 6.408617991837673e-07
the O 0 5.77581324989751e-08
cell O 0 3.7255588267726125e-06
cycle O 0 1.8428297607897548e-06
by O 0 2.9661386236057297e-08
contact O 0 5.894680725759827e-07
inhibition O 0 5.133332251716638e-06
. O 0 1.1893218925251858e-06

The O 0 1.625236291147303e-05
cyclin O 0 0.00019909636466763914
- O 0 1.9573986719478853e-05
dependent O 0 3.373301979081589e-06
kinase O 0 3.0714025342604145e-05
inhibitor O 0 3.821958216576604e-06
, O 0 7.816596792054042e-08
p27 O 0 3.2257387374556856e-06
, O 0 2.7089543053193665e-08
accumulates O 0 2.686300319965085e-07
upon O 0 1.2462918697053738e-08
serum O 0 5.433537353383144e-07
withdrawal O 0 1.046200054588553e-06
, O 0 4.066715320050207e-08
only O 0 2.037132684762355e-09
in O 0 2.2353221496018705e-09
the O 0 4.335992898063523e-09
presence O 0 1.889636891405644e-08
of O 0 1.1724610615715392e-08
VHL B-Disease 0 2.953159128082916e-05
, O 0 5.51917729296747e-08
as O 0 2.5934161484997276e-08
a O 0 1.1393380816571153e-07
result O 0 4.117439189599281e-08
of O 0 1.4894319111391496e-09
the O 0 1.373433544671343e-08
stabilization O 0 1.8674016644126823e-07
of O 0 8.215159219560064e-09
the O 0 1.209858311312928e-07
protein O 0 1.7189256595884217e-06
. O 0 1.0152494951398694e-06

We O 0 7.287047083082143e-06
propose O 0 2.7378096092434134e-06
that O 0 4.730329550284296e-08
the O 0 3.92553971551024e-08
loss O 0 3.31148925170055e-07
of O 0 1.0753383961059626e-08
wild O 0 1.408179514328367e-06
- O 0 0.000296239391900599
type O 0 5.031251930631697e-06
VHL B-Disease 0 4.431464913068339e-05
gene O 0 1.5854919865887496e-06
results O 0 2.4726949732212233e-07
in O 0 1.3628650208374893e-08
a O 0 3.944152382473476e-08
specific O 0 8.132456486009687e-08
cellular O 0 1.3876223420083988e-05
defect O 0 1.7656595446169376e-05
in O 0 2.0677941847679904e-07
serum O 0 2.1593896235572174e-05
- O 0 1.1092299246229231e-05
dependent O 0 3.3934642829080985e-07
growth O 0 1.4777916135244595e-07
control O 0 1.170566719110866e-07
, O 0 4.1111064774668193e-08
which O 0 1.0002595729474706e-07
may O 0 2.58441730238701e-07
initiate O 0 1.3919330967837595e-06
tumor B-Disease 0 6.607224349863827e-05
formation O 0 2.6014477043645456e-06
. O 0 1.5254363461281173e-06

This O 0 2.8237550395715516e-06
is O 0 7.486140702894772e-07
corrected O 0 8.338727639056742e-06
by O 0 1.3105694307569138e-08
the O 0 2.268489929235784e-08
reintroduction O 0 1.2611615147761768e-06
of O 0 1.5143600151645842e-08
wild O 0 9.741778512761812e-07
- O 0 0.0011826981790363789
type O 0 1.3797272913507186e-05
VHL B-Disease 0 0.00022006519429851323
, O 0 5.817815917907865e-07
implicating O 0 1.3735688298766036e-05
VHL B-Disease 0 4.05658247473184e-05
as O 0 1.0686976281704119e-07
the O 0 3.807442539027761e-08
first O 0 4.6139084020069276e-07
tumor B-Disease 0 1.3329338798939716e-05
suppressor O 0 1.6093656086013652e-05
involved O 0 3.185736474620171e-08
in O 0 1.5197826996882213e-08
the O 0 8.105306648076294e-09
regulation O 0 7.795142664690502e-08
of O 0 2.8659872253200547e-09
cell O 0 9.243953513760061e-07
cycle O 0 1.4050701793166809e-06
exit O 0 9.796756330615608e-07
, O 0 1.253917503163393e-07
which O 0 8.97732306270882e-08
is O 0 2.2634159435597212e-08
consistent O 0 3.155680161626151e-08
with O 0 5.774234868027861e-09
its O 0 3.448862528898644e-08
gatekeeper O 0 3.983105216320837e-06
function O 0 5.445936679393526e-08
in O 0 2.943482257933283e-08
the O 0 2.753788521658862e-07
kidney O 0 2.03496510948753e-05
. O 0 2.8741268920384755e-07
. O 0 8.599812417742214e-07

Piebaldism B-Disease 1 1.0
with O 1 0.5192229747772217
deafness B-Disease 1 1.0
: O 0 8.538570455129957e-07
molecular O 0 5.200882924327743e-07
evidence O 0 1.1423126977661013e-07
for O 0 5.0054662636966896e-08
an O 0 1.0707742603699444e-06
expanded O 0 0.04684565216302872
syndrome O 1 0.9999953508377075
. O 0 5.386337761592586e-06

In O 0 1.764725084285601e-06
a O 0 6.024033041285293e-07
South O 0 5.588304929915466e-07
African O 0 3.4650307156880444e-07
girl O 0 1.580150637892075e-05
of O 0 5.90371058706296e-08
Xhosa O 0 0.0004377762961667031
stock O 0 1.0328653843316715e-06
with O 0 1.5878978842920333e-07
severe O 0 0.00028328722692094743
piebaldism B-Disease 0 0.005472720135003328
and O 0 2.915502955147531e-05
profound O 0 0.0019779682625085115
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.585393849585671e-05
identified O 0 2.559949052738375e-06
a O 0 8.566173193003124e-08
novel O 0 5.272999601402262e-07
missense O 0 3.7910219816694735e-06
substitution O 0 1.0050788290527635e-07
at O 0 4.807241182902544e-08
a O 0 4.358357230671572e-08
highly O 0 5.6906827694547246e-08
conserved O 0 2.4370680762331176e-07
residue O 0 4.04527099817642e-07
in O 0 9.163745318119254e-09
the O 0 1.1998417370762127e-08
intracellular O 0 5.194943923925166e-07
kinase O 0 1.50494508943666e-06
domain O 0 6.571157484813739e-08
of O 0 9.776007559025857e-09
the O 0 3.893430999823977e-08
KIT O 0 2.5738292606547475e-05
proto O 0 0.00016762730956543237
- O 0 2.661456892383285e-05
oncogene O 0 1.868395156634506e-05
, O 0 2.624059618483443e-07
R796G O 0 1.109311415348202e-05
. O 0 1.3306249684319482e-06

Though O 0 4.349857408669777e-05
auditory B-Disease 0 0.000184209828148596
anomalies I-Disease 0 0.013586629182100296
have O 0 4.183422788628377e-06
been O 0 5.782944754173514e-07
observed O 0 5.553807795877219e-07
in O 0 1.0887224277666974e-07
mice O 0 3.574800575734116e-05
with O 0 1.3534865672681917e-07
dominant O 0 2.919425787695218e-05
white O 0 5.14697894686833e-05
spotting O 0 0.00014087717863731086
( O 0 4.949321805725049e-07
W O 0 0.05993208289146423
) O 0 2.4445277801987686e-08
due O 0 3.4121491410132876e-08
to O 0 5.947608627820955e-08
KIT O 0 0.020888300612568855
mutations O 0 0.005360785871744156
, O 0 2.1331661628209986e-05
deafness B-Disease 1 1.0
is O 0 1.4568510096069076e-06
not O 0 4.671003139833374e-08
typical O 0 2.4179664137591317e-07
in O 0 8.286940555990441e-08
human O 0 2.8238176241757174e-07
piebaldism B-Disease 0 6.282860704232007e-05
. O 0 1.507776460130117e-06

Thus O 0 2.060413680737838e-05
, O 0 1.8873356566473376e-07
the O 0 5.847196504760177e-08
occurrence O 0 1.7373673699694336e-06
of O 0 1.4630244322688668e-06
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 8.783848898019642e-05
this O 0 8.332189054272021e-07
patient O 0 7.676004315726459e-06
extends O 0 7.154629315664351e-07
considerably O 0 7.033779070297896e-07
the O 0 1.724943565761805e-08
phenotypic O 0 7.240643640216149e-07
range O 0 1.1723731319079889e-07
of O 0 7.674256785605849e-09
piebaldism B-Disease 0 2.70406326308148e-06
due O 0 4.338401993209118e-08
to O 0 2.5857305629983784e-08
KIT O 0 1.112545851356117e-05
gene O 0 1.134274498326704e-06
mutation O 0 7.696335160289891e-07
in O 0 2.6138563313793384e-08
humans O 0 5.484704246327965e-08
and O 0 1.845151160750902e-07
tightens O 0 0.002616875572130084
the O 0 6.808024011206726e-08
clinical O 0 1.8398095846805518e-07
similarity O 0 2.42274921902208e-07
between O 0 2.483223227045528e-07
piebaldism B-Disease 0 9.601428610039875e-05
and O 0 5.696156080148285e-08
the O 0 4.3637533586604604e-09
various O 0 7.508675459177994e-09
forms O 0 2.1510085446152516e-07
of O 0 4.797056590177817e-06
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999948740005493
. O 0 3.7150780940464756e-07
. O 0 1.3932558431406505e-06

Cycloheximide O 0 0.0006645210669375956
facilitates O 0 1.4076347724767402e-05
the O 0 1.5411804099585424e-07
identification O 0 1.286258708432797e-07
of O 0 1.392733040006533e-08
aberrant O 0 6.1819905567972455e-06
transcripts O 0 9.179646440315992e-06
resulting O 0 8.291824542538961e-07
from O 0 1.0063023303530372e-08
a O 0 3.64593617518949e-08
novel O 0 3.712209775130759e-07
splice O 0 0.00012210158456582576
- O 0 4.012096542282961e-05
site O 0 3.6601263673219364e-06
mutation O 0 6.398279879249458e-07
in O 0 2.2927274301309808e-08
COL17A1 O 0 1.9556018742150627e-05
in O 0 4.104180462149998e-08
a O 0 7.216673907350923e-07
patient O 0 4.335335688665509e-06
with O 0 1.4167994777380954e-06
generalized O 0 0.0006123619969002903
atrophic B-Disease 1 0.9997301697731018
benign I-Disease 1 0.9994255304336548
epidermolysis I-Disease 1 0.999388575553894
bullosa I-Disease 1 0.9603906273841858
. O 0 0.00011981225543422624

Patients O 0 0.003254880663007498
with O 0 1.1505970178404823e-05
generalized O 0 0.0009333925554528832
atrophic B-Disease 1 0.999704897403717
benign I-Disease 1 0.9997592568397522
epidermolysis I-Disease 1 0.9993610978126526
bullosa I-Disease 1 0.9802154302597046
often O 0 0.00017555798694957048
show O 0 3.706244024215266e-05
decreased O 0 1.560952478030231e-05
expression O 0 3.231303935535834e-07
of O 0 2.230578566297936e-08
type O 0 3.4290910662093665e-06
XVII O 0 0.0004858823958784342
collagen O 0 9.17066790862009e-06
, O 0 7.23314244055473e-08
a O 0 1.5144878773298842e-07
transmembrane O 0 1.316709017373796e-06
hemidesmosomal O 0 3.394238774490077e-06
protein O 0 1.9427461950272118e-07
encoded O 0 2.4451205149489397e-07
by O 0 1.2988316200335248e-07
COL17A1 O 0 0.00010616632789606228
. O 0 2.1201449271757156e-06

This O 0 2.3794905246177223e-06
report O 0 3.64012407771952e-07
documents O 0 5.27981249831555e-08
a O 0 5.6337363218972314e-08
novel O 0 4.1147390561491193e-07
splice O 0 0.0001057780027622357
- O 0 8.849131700117141e-05
site O 0 4.637236543203471e-06
mutation O 0 6.209112370925141e-07
in O 0 2.05257855157015e-08
COL17A1 O 0 3.793987343669869e-05
in O 0 5.315826001606183e-08
a O 0 5.655677455251862e-07
patient O 0 2.8492613637354225e-06
with O 0 4.253699046330439e-07
generalized O 0 0.00020695517014246434
atrophic B-Disease 1 0.9984569549560547
benign I-Disease 1 0.9839419722557068
epidermolysis I-Disease 1 0.9037969708442688
bullosa I-Disease 0 0.17578522861003876
, O 0 1.3920723631599685e-06
and O 0 5.132569924626296e-08
applies O 0 2.5167528505676273e-08
a O 0 1.2576871988301264e-08
new O 0 2.2138111788194692e-08
methodology O 0 7.051652062273206e-08
to O 0 1.4209879495297173e-08
define O 0 4.613063708802656e-07
and O 0 2.4208668492065044e-07
characterize O 0 6.743804306097445e-07
the O 0 4.1346581269863236e-08
resulting O 0 3.332385745125066e-07
mRNA O 0 7.592291240143823e-07
splice O 0 5.636328933178447e-05
variants O 0 8.392523341171909e-06
. O 0 3.4993256576854037e-06

Mutational O 0 0.0019892833661288023
analysis O 0 4.222365987516241e-06
of O 0 3.4798929959833913e-07
COL17A1 O 0 0.00018338230438530445
identified O 0 3.913700766133843e-06
a O 0 1.0410594768472947e-06
maternally O 0 5.923705975874327e-05
inherited O 0 6.636454781983048e-05
G O 0 0.0005746982642449439
- O 0 7.129664481908549e-06
to O 0 2.330802004735233e-07
- O 0 0.00016207314911298454
T O 0 3.201830622856505e-05
transversion O 0 1.070546545633988e-06
at O 0 2.4227949424471262e-08
the O 0 7.812762881087565e-09
- O 0 1.5370587789220735e-06
1 O 0 7.427883730315443e-08
position O 0 7.35648484351259e-08
of O 0 3.221113331619563e-08
exon O 0 1.0577942703093868e-05
32 O 0 7.690107850066852e-06
. O 0 1.5167209994615405e-06

This O 0 1.9144492853229167e-06
acceptor O 0 6.1302098401938565e-06
splice O 0 0.00023817196779418737
- O 0 0.00032041402300819755
site O 0 5.995072569930926e-06
mutation O 0 1.602557290425466e-06
led O 0 1.0102643699383407e-07
to O 0 8.375127258375414e-09
the O 0 8.768523684921092e-09
formation O 0 5.85553330267885e-08
of O 0 4.85251661075381e-09
aberrant O 0 9.791851880436298e-07
transcripts O 0 1.0220029480478843e-06
present O 0 7.189115081018826e-08
at O 0 1.3067359816432145e-07
extremely O 0 2.053838272786379e-07
low O 0 3.996897703473223e-06
levels O 0 8.555924182473973e-07
. O 0 5.097438702250656e-07

Based O 0 5.531778242584551e-06
on O 0 9.419947559763386e-07
our O 0 5.019999349542559e-08
recent O 0 4.8814452924261786e-08
finding O 0 7.35760750103509e-08
that O 0 4.946726406274138e-08
cycloheximide O 0 1.513643564976519e-05
stabilized O 0 3.543185812304728e-05
mutant O 0 3.7860322663618717e-06
COL17A1 O 0 6.442618541768752e-06
transcripts O 0 6.128054792498006e-07
in O 0 5.6420052629846396e-08
keratinocytes O 0 2.880561169149587e-06
homozygous O 0 1.961494717761525e-06
for O 0 2.005325150378212e-08
a O 0 8.655961778458732e-07
frameshift O 0 0.08120221644639969
mutation O 0 7.269500201800838e-06
, O 0 2.3632020784702945e-08
the O 0 1.308676100819639e-08
effects O 0 3.022524310836161e-07
of O 0 6.321841272693973e-09
the O 0 5.2074931033985195e-08
splice O 0 0.00017917176592163742
- O 0 0.0002448775339871645
site O 0 3.3777894259401364e-06
mutation O 0 2.337245774697294e-07
on O 0 1.9027401876314798e-08
splicing O 0 1.8027624548722088e-07
of O 0 1.358517920380109e-08
COL17A1 O 0 9.54087772697676e-06
transcripts O 0 7.527520438088686e-07
were O 0 7.523760103822497e-08
determined O 0 2.1744941847146038e-08
using O 0 3.611317112017787e-08
reverse O 0 1.0076555554405786e-06
transcriptase O 0 2.873257699320675e-06
polymerase O 0 9.874996749204001e-07
chain O 0 1.925773176481016e-06
reaction O 0 4.0655052657712076e-08
of O 0 3.3840765745196677e-09
total O 0 1.570004037887429e-08
RNA O 0 1.6272366565317498e-07
from O 0 1.141338756838195e-08
keratinocytes O 0 5.901796384932823e-07
incubated O 0 8.202774779419997e-07
for O 0 1.3052608771602081e-08
2 O 0 4.7658301127739833e-07
. O 0 5.522578021555091e-07

5 O 0 0.0001399806933477521
h O 0 0.00014577442198060453
in O 0 1.2381063640987122e-07
the O 0 5.283328263772091e-08
presence O 0 9.64201447573032e-08
or O 0 4.0470684581350724e-08
absence O 0 6.195478619019923e-08
of O 0 9.057226080244618e-09
10 O 0 1.549038870507502e-07
microg O 0 6.637176738877315e-06
cycloheximide O 0 1.0901913810812403e-05
per O 0 9.654138466430595e-07
ml O 0 1.7197837223648094e-05
. O 0 1.2370352351354086e-06

Using O 0 2.215654603787698e-06
this O 0 1.0179568477042267e-07
approach O 0 2.544148287597636e-07
, O 0 1.3649800401083212e-08
an O 0 1.7422600251393305e-08
abnormally O 0 8.687397894391324e-06
spliced O 0 0.1150900274515152
transcript O 0 0.1854684054851532
was O 0 0.03246185556054115
identified O 0 1.0345096370656393e-06
that O 0 3.735379117131288e-09
contains O 0 2.8173274824183636e-09
an O 0 2.9181133065492304e-09
extra O 0 2.9082743324693183e-08
264 O 0 5.4687738781922235e-08
bases O 0 5.8210130049474174e-08
upstream O 0 1.0099946479158461e-07
from O 0 5.24913401633853e-09
exon O 0 3.67778909549088e-07
32 O 0 4.887892828264739e-07
, O 0 9.736075057276139e-09
resulting O 0 6.010145625623409e-08
in O 0 1.645936897887168e-08
a O 0 3.412924343138002e-07
premature O 0 4.106908818357624e-06
termination O 0 1.4405044339582673e-06
codon O 0 4.242398063070141e-06
27 O 0 5.33560023541213e-06
bp O 0 6.016373390593799e-06
downstream O 0 5.039291295361181e-07
from O 0 1.4228892730727694e-08
the O 0 5.896395904869678e-08
cryptic O 0 1.3931766261521261e-05
splice O 0 0.0002676340809557587
site O 0 1.767229514371138e-05
. O 0 1.8463567812432302e-06

Three O 0 4.67803920400911e-06
other O 0 5.0101846227335045e-08
splice O 0 3.2944859412964433e-05
variants O 0 5.289204182190588e-06
, O 0 1.1593922266683876e-07
including O 0 1.7487854719888674e-08
one O 0 4.7254872015400906e-08
derived O 0 1.0726323829146622e-08
from O 0 1.934318261120893e-09
the O 0 1.9795021177770877e-09
skipping O 0 4.189217150951663e-08
of O 0 6.080942416275548e-09
exon O 0 2.34891513173352e-06
32 O 0 1.4400579857465345e-06
, O 0 5.96012306175453e-08
were O 0 4.6766109562668134e-07
also O 0 8.38221637877723e-07
identified O 0 3.4651270652830135e-06
. O 0 7.431426070070302e-07

These O 0 2.3973848328751046e-06
results O 0 1.3020653568673879e-06
indicate O 0 1.6293284943458275e-07
the O 0 8.820641994589096e-09
usefulness O 0 5.869040364814282e-08
of O 0 1.0481146617280501e-08
cycloheximide O 0 2.6338921088608913e-05
treatment O 0 3.302705806618178e-07
in O 0 1.1107817776689899e-08
evaluating O 0 3.241872192916162e-08
the O 0 3.8462147244899825e-08
abnormal O 0 5.057610792391642e-07
processing O 0 1.860933274144827e-08
of O 0 2.6712767553505046e-09
mRNA O 0 6.421251441679487e-08
due O 0 1.9303092457789717e-08
to O 0 1.0723685051061693e-08
splice O 0 4.302697197999805e-05
- O 0 5.469682582770474e-05
site O 0 9.89820091490401e-06
mutations O 0 2.4983546609291807e-06
, O 0 1.4451448926422472e-08
because O 0 2.1013823570115164e-08
( O 0 3.4240080992731237e-08
i O 0 1.1600381100151935e-07
) O 0 8.585061550547834e-09
aberrant O 0 2.0726965033190936e-07
splicing O 0 7.659124889869418e-07
often O 0 1.538478500151541e-07
generates O 0 1.699306437785708e-07
a O 0 1.0268883698927311e-07
premature O 0 1.624721335247159e-06
termination O 0 1.214714529851335e-06
codon O 0 3.4150382361985976e-06
, O 0 5.1021462610378876e-08
( O 0 2.7534147406527154e-08
ii O 0 1.279296839129529e-06
) O 0 1.041794561729148e-08
transcripts O 0 1.1833014212925264e-07
with O 0 7.05980767179426e-08
premature O 0 2.8302631562837632e-06
termination O 0 9.121354196395259e-07
codons O 0 7.051315265016456e-07
can O 0 3.787400970622912e-08
occur O 0 2.7376160005587735e-08
at O 0 3.699595652051357e-08
low O 0 1.9350663933437318e-06
or O 0 1.2021466488931765e-07
undetectable O 0 1.978174168471014e-06
levels O 0 3.8577276484375034e-08
due O 0 1.3631406226011222e-08
to O 0 5.9402704977173926e-09
nonsense O 0 4.395741939333675e-07
- O 0 3.0895427016730537e-07
mediated O 0 7.021359920145187e-07
mRNA O 0 1.6975570815702667e-07
decay O 0 1.206349935500839e-07
, O 0 5.055924567898273e-09
and O 0 2.962610423651313e-08
( O 0 1.8583262928473232e-08
iii O 0 2.2954177438805345e-06
) O 0 1.5592812374620735e-08
the O 0 1.122024784194764e-08
levels O 0 9.55178780515098e-09
of O 0 9.4238783443501e-10
these O 0 1.5095780181439977e-09
transcripts O 0 1.1607740191266203e-07
can O 0 2.1818435058662544e-08
be O 0 7.527518164351932e-09
increased O 0 3.3142342203973385e-08
by O 0 1.7546692987480128e-08
cycloheximide O 0 1.8159391402150504e-05
. O 0 9.492335379945871e-07

A O 0 4.574762351694517e-05
deletion O 0 0.0005825778935104609
mutation O 0 5.1005314162466675e-05
in O 0 3.155195997806004e-07
COL17A1 O 0 7.77789973653853e-05
in O 0 1.6560601068249525e-07
five O 0 2.026629744023012e-07
Austrian O 0 5.058650640421547e-05
families O 0 3.4707124996202765e-07
with O 0 3.626478815021983e-07
generalized O 0 0.0004325968329794705
atrophic B-Disease 1 0.9996757507324219
benign I-Disease 1 0.9992509484291077
epidermolysis I-Disease 1 0.9977589845657349
bullosa I-Disease 0 0.29574212431907654
represents O 0 1.139319829235319e-05
propagation O 0 3.5340667636774015e-06
of O 0 6.83615581920094e-08
an O 0 1.0666285987781521e-07
ancestral O 0 3.531601760187186e-05
allele O 0 0.00020719663007184863
. O 0 3.524780368024949e-06

Patients O 0 0.0069890497252345085
with O 0 1.8099242879543453e-05
generalized O 0 0.00204578903503716
atrophic B-Disease 1 0.9997962117195129
benign I-Disease 1 0.999872088432312
epidermolysis I-Disease 1 0.9997802376747131
bullosa I-Disease 1 0.9734092354774475
, O 0 4.646532488550292e-06
a O 0 3.603243499128439e-07
usually O 0 2.718657867717411e-07
nonlethal O 0 1.4096602853896911e-06
form O 0 4.2254373511241283e-07
of O 0 5.099621489534911e-07
junctional B-Disease 1 0.990122377872467
epidermolysis I-Disease 1 0.9973880648612976
bullosa I-Disease 0 0.45279762148857117
, O 0 1.1670849744405132e-06
have O 0 1.4159307681893551e-07
generalized O 0 2.8306033073022263e-06
blistering B-Disease 0 0.06281749904155731
, O 0 8.865678864822257e-06
nail B-Disease 1 0.9999979734420776
dystrophy I-Disease 1 0.9997928738594055
, O 0 3.25478913509869e-06
patchy B-Disease 0 0.20946982502937317
alopecia I-Disease 1 0.9999816417694092
, O 0 4.437581537786173e-06
and O 0 1.531002635601908e-05
dental B-Disease 1 0.809474766254425
abnormalities I-Disease 1 0.9999747276306152
. O 0 9.711412531032693e-06

Skin B-Disease 1 0.9999972581863403
fragility I-Disease 1 0.6367425322532654
in O 0 9.935718026099494e-07
most O 0 5.120416091131119e-08
cases O 0 4.8548429276706884e-08
is O 0 4.8709726030438105e-08
due O 0 1.0154979435128553e-07
to O 0 1.3361064077344054e-07
mutations O 0 2.434432190057123e-06
in O 0 1.0416355777920216e-08
the O 0 1.8810638380273303e-08
gene O 0 5.487853513841401e-07
encoding O 0 2.493258762115147e-06
type O 0 4.3986459786538035e-05
XVII O 0 0.0040969946421682835
collagen O 0 0.00018392025958746672
( O 0 7.94335335285723e-07
COL17A1 O 0 5.525115557247773e-05
) O 0 3.2505099056834297e-07
. O 0 6.275267878663726e-07

Recently O 0 0.00033688099938444793
, O 0 1.1912084119103383e-06
we O 0 1.5552024024145794e-07
reported O 0 7.340827892221569e-07
five O 0 5.747131481825818e-08
Austrian O 0 3.493189433356747e-05
families O 0 1.201307782139338e-07
with O 0 1.4469699749497522e-07
generalized O 0 0.00010404828935861588
atrophic B-Disease 1 0.9856957793235779
benign I-Disease 1 0.9861125349998474
epidermolysis I-Disease 1 0.9426071643829346
bullosa I-Disease 0 0.22532154619693756
who O 0 4.7446326789213344e-05
share O 0 5.291557840791938e-07
the O 0 9.813001611291838e-08
same O 0 6.235643468244234e-07
COL17A1 O 0 0.0005312389112077653
mutation O 0 1.8662865841179155e-05
. O 0 1.130022837969591e-06

Affected O 0 6.755937647540122e-05
individuals O 0 2.557591471941123e-07
in O 0 5.134391045658049e-08
three O 0 1.1128052790354559e-07
families O 0 1.6479057762808225e-07
are O 0 6.201907876146606e-09
homozygous O 0 8.093073233794712e-07
for O 0 1.5652767970664172e-08
4003delTC O 0 2.8508486593636917e-06
, O 0 4.456422431076135e-08
whereas O 0 3.41996155839297e-08
those O 0 3.088179489907361e-09
in O 0 1.0493428348468115e-08
two O 0 7.639415144922168e-08
others O 0 4.0063676465251774e-07
are O 0 2.2079159833765516e-08
compound O 0 4.473549779504538e-06
heterozygotes O 0 4.921598156215623e-05
. O 0 2.2494045879284386e-06

To O 0 2.7749870241677854e-06
determine O 0 3.75287413589831e-07
if O 0 3.4117196179295206e-08
the O 0 1.4431065231690354e-08
occurrence O 0 2.920772033121466e-07
of O 0 1.4319171626198113e-08
4003delTC O 0 3.1331767331721494e-06
in O 0 1.4920940927254378e-08
these O 0 5.254092272366506e-09
unrelated O 0 3.821349707777699e-07
families O 0 2.1180157716571557e-07
signifies O 0 1.4987733720772667e-07
propagation O 0 5.863200058797702e-08
of O 0 1.846901409585655e-09
an O 0 9.194103256504604e-09
ancestral O 0 8.5949830008758e-07
allele O 0 1.1257718597335042e-06
or O 0 2.1575802477968864e-08
a O 0 1.8184947236932203e-07
mutational O 0 5.229802991379984e-05
hot O 0 2.8803007808164693e-05
spot O 0 7.691288919886574e-05
, O 0 1.636654047842967e-07
haplotypes O 0 5.2268901526986156e-06
were O 0 1.706204443507886e-06
determined O 0 3.96020936932473e-07
for O 0 3.566556117107211e-08
polymorphisms O 0 0.0005664217751473188
both O 0 5.99135248080529e-08
within O 0 3.914847113151154e-08
and O 0 5.657964834426821e-07
flanking O 0 0.0003870277723763138
COL17A1 O 0 0.0010293330997228622
. O 0 2.6769350824906724e-06

Five O 0 7.102590461727232e-05
intragenic O 0 0.0007196838851086795
polymorphisms O 0 0.037483036518096924
were O 0 9.260143087885808e-06
chosen O 0 2.939410137514642e-07
based O 0 6.563191590203132e-08
on O 0 3.9483791169914184e-07
their O 0 3.4080323985108407e-07
informativeness O 0 0.00017530022887513041
. O 0 1.4082548887017765e-06

One O 0 2.06765548682597e-06
of O 0 3.145746063637489e-08
these O 0 6.475389557891731e-09
, O 0 1.5905813555150417e-08
not O 0 1.0874663836091258e-08
previously O 0 8.293279734061798e-07
reported O 0 3.786685965678771e-06
, O 0 1.3070346582821912e-08
was O 0 7.193161195573339e-07
2988 O 0 2.636428746427555e-07
A O 0 1.2841626073623047e-07
or O 0 1.1107780295560588e-07
C O 0 4.7021200089147897e-07
that O 0 2.663584020012877e-09
introduces O 0 4.834615552340438e-08
a O 0 1.257898318840489e-08
new O 0 1.78719297139196e-08
restriction O 0 2.0879422635289302e-08
site O 0 1.1167451674509721e-07
for O 0 2.4233033357745626e-08
Eco0109 O 0 4.2123269849980716e-06
I O 0 1.7584218312549638e-06
. O 0 6.508540195682144e-07

All O 0 1.050578362082888e-06
the O 0 2.0840320757997688e-07
4003delTC O 0 6.037898401700659e-06
alleles O 0 2.990320126627921e-06
showed O 0 8.83815846464131e-06
the O 0 1.1896783114195841e-08
same O 0 4.10480680557157e-08
haplotype O 0 4.23798610427184e-06
for O 0 1.4328050745859855e-08
these O 0 1.1296910074065636e-08
five O 0 1.0461118193916263e-07
polymorphic O 0 3.0318538847495802e-05
markers O 0 0.0002894880308303982
. O 0 2.945065716630779e-06

Fourteen O 0 0.00018539288430474699
microsatellite O 0 0.001815246301703155
polymorphisms O 0 0.16701973974704742
were O 0 9.424796189705376e-06
selected O 0 4.393059782614728e-08
based O 0 5.612874787175315e-08
on O 0 1.6668408306941274e-06
their O 0 3.7092084426149086e-07
high O 0 4.5038104872219265e-06
heterozygosity O 0 1.6065027011791244e-05
and O 0 1.2005587279872998e-07
their O 0 1.0834789065938821e-08
location O 0 2.0603553707587707e-07
within O 0 2.8654094208491188e-08
10q23 O 0 1.381206402584212e-06
- O 0 5.318459443515167e-06
q25 O 0 7.260991878865752e-06
near O 0 5.021832294005435e-06
COL17A1 O 0 8.434583287453279e-05
. O 0 1.4214834891390637e-06

Three O 0 1.3000505532545503e-05
families O 0 3.349273129060748e-06
shared O 0 1.4186964563123183e-06
microsatellite O 0 0.0003610010608099401
polymorphisms O 0 0.008092359639704227
covering O 0 4.941284714732319e-06
at O 0 7.178126111284655e-07
most O 0 2.103266893982436e-08
19 O 0 5.356614565243945e-07
cM O 0 4.950991751684342e-06
, O 0 5.1372417431139183e-08
whereas O 0 3.857322994349488e-08
the O 0 3.5341059856364154e-08
others O 0 1.5287524490759097e-07
shared O 0 2.352413375206197e-08
smaller O 0 3.720839458765113e-08
regions O 0 5.2205905376467854e-08
consistent O 0 8.020558794896715e-08
with O 0 1.666488991247661e-08
cross O 0 1.0170608220505528e-05
- O 0 5.809416506963316e-06
over O 0 7.351659547794043e-08
events O 0 5.0273481377871576e-08
during O 0 3.020235794792825e-08
passage O 0 2.7586770201537547e-08
of O 0 3.261307224278198e-09
this O 0 7.937612345187972e-09
mutation O 0 1.1230315521970624e-07
through O 0 1.1077097461509311e-08
several O 0 9.502056741439446e-08
generations O 0 7.39668166716001e-07
. O 0 4.966461801814148e-07

These O 0 1.6528161950191134e-06
results O 0 1.0944235100396327e-06
indicate O 0 3.8275720726232976e-07
that O 0 1.5728904401157706e-08
4003delTC O 0 8.790254469204228e-06
occurs O 0 8.982340915508757e-08
on O 0 5.4434234897371425e-08
a O 0 9.413897572585483e-08
single O 0 6.008805257806671e-07
ancestral O 0 3.580635848265956e-06
allele O 0 4.996117695554858e-06
. O 0 1.3462043568779336e-07
. O 0 8.567134841541701e-07

The O 0 1.3818355000694282e-05
haptoglobin O 0 0.00021267311240080744
- O 0 4.4478412746684626e-05
gene O 0 1.0620568900776561e-05
deletion O 0 1.7013355318340473e-05
responsible O 0 9.295403629039356e-07
for O 0 2.0488438678967213e-07
anhaptoglobinemia B-Disease 0 0.00022919007460586727
. O 0 3.2719435694161803e-06

We O 0 1.6704576410120353e-05
have O 0 1.459707306139535e-07
found O 0 3.186313790592976e-08
an O 0 1.2818764716371334e-08
allelic O 0 5.650153525493806e-06
deletion O 0 1.0668718459783122e-05
of O 0 5.5201880400090886e-08
the O 0 2.5070994524867274e-07
haptoglobin O 0 5.1617153076222166e-05
( O 0 9.62068611443101e-08
Hp O 0 6.408331501006614e-07
) O 0 1.2452558095787936e-08
gene O 0 6.093833349041233e-08
from O 0 9.476297968546987e-09
an O 0 1.357463652595925e-08
individual O 0 2.9598483664017294e-08
with O 0 9.716969628925654e-08
anhaptoglobinemia B-Disease 0 0.00011061550321755931
. O 0 1.542399445497722e-06

The O 0 5.445808255899465e-06
Hp O 0 2.556068830017466e-05
gene O 0 2.9907221232861048e-06
cluster O 0 6.300044788076775e-07
consists O 0 4.590086177813646e-08
of O 0 1.115422865183291e-08
coding O 0 1.0261673196509946e-05
regions O 0 3.682253009174019e-07
of O 0 1.3844854152011976e-08
the O 0 4.568538614080353e-08
alpha O 0 1.6345437359177595e-07
chain O 0 1.3695890856979531e-06
and O 0 2.7496414034544614e-08
beta O 0 2.9473588014639063e-08
chain O 0 1.109039970970116e-07
of O 0 1.3396100895235463e-09
the O 0 1.3215993632798018e-08
haptoglobin O 0 2.4081684841803508e-06
gene O 0 4.343660293670837e-07
( O 0 5.357374988079755e-08
Hp O 0 7.427685204675072e-07
) O 0 6.888245529523829e-09
and O 0 8.259764427975824e-09
of O 0 1.0929345206633911e-09
the O 0 1.479621403177589e-08
alpha O 0 5.836655603275176e-08
chain O 0 5.782591188108199e-07
and O 0 1.2837507945562265e-08
beta O 0 2.4422860178674455e-08
chain O 0 1.477639557379007e-07
of O 0 1.666933258093195e-09
the O 0 1.6397983415572526e-08
haptoglobin O 0 7.062836630211677e-06
- O 0 3.368014176885481e-06
related O 0 2.922053567999683e-07
gene O 0 1.3629751265398227e-06
( O 0 1.4754019161955512e-07
Hpr O 0 6.770993877580622e-06
) O 0 2.6607064995687324e-08
, O 0 6.748575920312305e-09
in O 0 2.0278452694810767e-08
tandem O 0 6.874925475131022e-06
from O 0 4.1652036486539146e-08
the O 0 1.2460606058084522e-07
5 O 0 9.197138410854677e-07
side O 0 5.4404617912950926e-06
. O 0 1.2329870742178173e-06

Southern O 0 6.510269304271787e-05
blot O 0 0.00019127439009025693
and O 0 1.032332647810108e-06
PCR O 0 1.2984496606804896e-05
analyses O 0 1.1450212014096905e-06
have O 0 2.92910129928714e-07
indicated O 0 3.858507966469915e-07
that O 0 3.170749662828598e-09
the O 0 5.089449750528274e-09
individual O 0 3.811574611489732e-09
with O 0 2.3406157012573203e-08
anhaptoglobinemia B-Disease 0 7.947086123749614e-05
was O 0 2.4205966838053428e-05
homozygous O 0 8.422803148278035e-07
for O 0 1.1963949830828824e-09
the O 0 6.632642435278058e-09
gene O 0 1.468197154963491e-07
deletion O 0 7.680080216232454e-07
and O 0 7.685994063422186e-08
that O 0 3.467844678084475e-09
the O 0 7.181931049871082e-09
gene O 0 1.3842695523180737e-07
deletion O 0 2.3891179807833396e-06
was O 0 7.105967142706504e-06
included O 0 2.039726965108457e-08
at O 0 7.739615881519057e-08
least O 0 2.555011313631894e-08
from O 0 4.8098347527059104e-09
the O 0 7.535390089685734e-09
promoter O 0 1.1523301282068132e-06
region O 0 9.369615838750178e-08
of O 0 7.250280376069895e-09
Hp O 0 5.021407218919194e-07
to O 0 2.026739309712866e-08
Hpr O 0 2.727552100623143e-06
alpha O 0 7.24324777934271e-08
but O 0 9.363305686349577e-09
not O 0 4.12061895715965e-09
to O 0 2.1033391917057997e-08
Hpr O 0 1.6925223462749273e-05
beta O 0 6.654857998000807e-07
( O 0 1.1614240236212936e-07
Hpdel O 0 6.727232630510116e-06
) O 0 2.628788706715568e-07
. O 0 8.146698178279621e-07

In O 0 1.5750210877740756e-06
addition O 0 1.7324059342627152e-07
, O 0 9.359685293475195e-08
we O 0 2.6271713693404308e-08
found O 0 2.5753454480081928e-08
seven O 0 1.196722010377016e-08
individuals O 0 1.1147543999001641e-09
with O 0 2.5326716279749917e-09
hypohaptoglobinemia B-Disease 0 4.92200706503354e-06
in O 0 3.50622251232835e-08
three O 0 2.3759569955927873e-07
families O 0 8.520596139760528e-08
, O 0 8.709833743125728e-09
and O 0 2.9371788556886713e-08
the O 0 1.3250168962031239e-08
genotypes O 0 4.79358106986183e-07
of O 0 5.420688786728078e-09
six O 0 6.051325129874385e-08
of O 0 3.262912606771806e-09
the O 0 5.3203095262688294e-08
seven O 0 6.083990911065484e-07
individuals O 0 8.900019388136116e-09
were O 0 3.567576456475763e-08
found O 0 1.4231851253043715e-08
to O 0 1.8359932241196475e-08
be O 0 7.745315855345325e-08
Hp2 O 0 5.3673749789595604e-05
/ O 0 1.4536073649651371e-05
Hpdel O 0 3.6912177165504545e-05
. O 0 1.3094010000713752e-06

The O 0 9.794199286261573e-06
phenotypes O 0 0.00029686876223422587
and O 0 2.176354428229388e-06
genotypes O 0 4.668218389269896e-05
in O 0 1.0286585450103303e-07
one O 0 4.6602000480788774e-08
of O 0 3.1692499735669344e-09
these O 0 6.5843033247858784e-09
three O 0 1.712534611897354e-07
families O 0 4.4274938204580394e-07
showed O 0 3.699222133946023e-06
the O 0 1.8429751946769102e-08
father O 0 5.092754236102337e-07
to O 0 1.8580534444367913e-08
be O 0 4.0950709490061854e-08
hypohaptoglobinemic B-Disease 0 4.075955530424835e-06
( O 0 2.7064958274536366e-08
Hp2 O 0 6.708588102810609e-07
) O 0 7.929743972567849e-09
and O 0 2.77570357809509e-08
Hp2 O 0 6.379467322403798e-06
/ O 0 2.126985918948776e-06
Hpdel O 0 3.5139667033945443e-06
, O 0 2.7468422203469345e-08
the O 0 1.0608458111960317e-08
mother O 0 9.327754355581419e-07
to O 0 9.549383506168851e-09
be O 0 1.0771016079047513e-08
Hp2 O 0 7.442461651407939e-07
- O 0 3.1849259585214895e-07
1 O 0 2.957021294491824e-08
and O 0 2.6888370641131587e-08
Hp1 O 0 2.8233512239239644e-06
/ O 0 9.858284784058924e-07
Hp2 O 0 2.2838796667201677e-06
, O 0 1.5262898500623123e-08
one O 0 4.063472225368514e-09
of O 0 8.437912035752504e-10
the O 0 8.553239005948399e-09
two O 0 8.466567891218801e-08
children O 0 1.2778163238635898e-07
to O 0 1.3194433101659797e-08
be O 0 3.630960065947875e-08
hypohaptoglobinemic B-Disease 0 9.178787877317518e-06
( O 0 2.7764288645926172e-08
Hp2 O 0 1.2693594726442825e-06
) O 0 1.0444426656874839e-08
and O 0 2.3248826863664362e-08
Hp2 O 0 7.090479357430013e-06
/ O 0 1.9326819256093586e-06
Hpdel O 0 4.750764219352277e-06
, O 0 2.546837407635394e-08
and O 0 6.478366731954566e-09
the O 0 4.218658311572199e-09
other O 0 2.5938844405715145e-09
child O 0 1.3612211091640347e-07
to O 0 4.86231899188283e-09
be O 0 1.1327872861954802e-08
Hp1 O 0 1.111708115786314e-06
and O 0 7.464683449143195e-08
Hp1 O 0 7.1328813646687195e-06
/ O 0 2.8144504540250637e-06
Hpdel O 0 4.086861736141145e-06
, O 0 1.577017805232117e-08
showing O 0 7.443001948104211e-08
an O 0 3.473001219944649e-09
anomalous O 0 1.075559794116998e-06
inheritance O 0 1.1276414397798362e-06
of O 0 3.5772863782312925e-08
Hp O 0 1.4207341337169055e-05
phenotypes O 0 4.904103207081789e-06
in O 0 4.026103539445103e-08
the O 0 1.0231737235244509e-07
child O 0 2.72032002612832e-06
with O 0 1.5884326387549663e-07
Hp1 O 0 0.00017205727635882795
. O 0 1.4812981135037262e-06

The O 0 4.891515345661901e-06
Hp2 O 0 0.00011805511167040095
/ O 0 5.0610819016583264e-05
Hpdel O 0 4.3352178181521595e-05
individuals O 0 1.2294992757233558e-07
had O 0 6.112336450314615e-07
an O 0 2.3447848107593927e-08
extremely O 0 3.4436834539519623e-07
low O 0 2.4463151930831373e-06
level O 0 3.362460176958848e-08
of O 0 1.0469157984971389e-08
Hp O 0 4.518976766121341e-06
( O 0 2.801622756010147e-08
mean O 0 4.440149226070389e-08
+ O 0 3.3298539392490056e-07
/ O 0 8.139918463712092e-07
- O 0 1.8167767166232807e-06
SD O 0 4.464758967515081e-05
= O 0 2.017711722146487e-06
0 O 0 1.1423616541605952e-07
. O 0 1.8088325504095337e-08
049 O 0 2.7385513021727093e-06
+ O 0 6.576486271114845e-07
/ O 0 6.830641723354347e-07
- O 0 6.819544182690152e-07
0 O 0 1.1253064968741455e-07
. O 0 2.0081614593436825e-08
043 O 0 2.2337264908856014e-06
mg O 0 2.221439217464649e-06
/ O 0 6.623023978136189e-07
ml O 0 1.585676386639534e-06
; O 0 4.814260989860486e-08
n O 0 5.91676439398725e-07
= O 0 7.568168030047673e-07
6 O 0 1.3034042467552354e-07
) O 0 1.0068974987120782e-08
, O 0 9.390330291125792e-09
compared O 0 4.426011912528338e-08
with O 0 3.7934286822860486e-09
the O 0 5.390061019738823e-08
level O 0 5.65630351445634e-08
( O 0 4.730299707489394e-09
1 O 0 8.8516696195029e-09
. O 0 5.856245266500082e-09
64 O 0 8.168241549810773e-08
+ O 0 2.927548621300957e-07
/ O 0 2.981879845265212e-07
- O 0 2.38727722035037e-07
1 O 0 3.1671611111505626e-08
. O 0 1.385790504571105e-08
07 O 0 2.5983183604694204e-07
mg O 0 1.477982095821062e-06
/ O 0 8.817750085654552e-07
ml O 0 7.382079729723046e-07
) O 0 1.1410339340045539e-08
obtained O 0 7.872146490228715e-09
from O 0 7.191279571827636e-09
52 O 0 2.9686438551834726e-07
healthy O 0 1.4238806045341335e-07
volunteers O 0 1.1387221832137584e-07
having O 0 9.574061721195903e-08
phenotype O 0 7.235898920043837e-06
Hp2 O 0 2.397787284280639e-06
, O 0 1.2093445356242682e-08
whereas O 0 1.4206412046746664e-08
the O 0 1.5787874119155276e-08
serum O 0 2.2903032004251145e-06
Hp O 0 4.994294613425154e-07
level O 0 1.4506431611494008e-08
of O 0 1.3472510884682265e-09
an O 0 4.0283141267138944e-09
individual O 0 7.143976965551246e-09
with O 0 4.7737451325247093e-08
Hp1 O 0 0.00010228483006358147
/ O 0 1.2456568583729677e-05
Hpdel O 0 2.6403506126371212e-05
was O 0 5.595410129899392e-06
0 O 0 9.096040685108164e-07
. O 0 7.243758659569721e-07

50 O 0 4.8961141146719456e-05
mg O 0 9.75372240645811e-05
/ O 0 3.7342288123909384e-05
ml O 0 1.518207682238426e-05
, O 0 1.1244096498330691e-07
which O 0 5.7883521975554686e-08
was O 0 7.477121926058317e-07
approximately O 0 8.319609001716799e-09
half O 0 2.4355175654022787e-08
the O 0 3.279727822658174e-09
level O 0 1.0760051516456315e-08
of O 0 1.879334687870937e-09
Hp O 0 8.640142823423957e-07
in O 0 2.9964237313606645e-08
control O 0 2.5434499093535123e-06
sera O 0 5.175078968022717e-06
from O 0 6.383186423875031e-09
the O 0 2.622600447921286e-08
Hp1 O 0 7.22027471056208e-05
phenotype O 0 1.3237106031738222e-05
( O 0 1.0721435295124593e-08
1 O 0 1.2798000881275584e-08
. O 0 5.04106711929353e-09
26 O 0 9.731381567235076e-08
+ O 0 8.836794052058394e-08
/ O 0 2.0255825461390486e-07
- O 0 4.50402836804642e-07
0 O 0 3.684005278614677e-08
. O 0 6.4533192123406025e-09
33 O 0 8.424428443731813e-08
mg O 0 5.943718406342668e-07
/ O 0 4.084380975655222e-07
ml O 0 1.0928913525276585e-06
; O 0 2.9403681267581305e-08
n O 0 8.440196097581065e-07
= O 0 9.313861255577649e-07
9 O 0 1.734879333525896e-07
) O 0 6.32863361715863e-09
, O 0 3.1768998542958116e-09
showing O 0 1.0633014113636818e-07
a O 0 4.2679495493302966e-08
gene O 0 7.25741529095103e-07
- O 0 2.0188714188407175e-05
dosage O 0 8.724286090000533e-06
effect O 0 1.8725426116361632e-06
. O 0 8.938877726905048e-07

The O 0 3.2471343729412183e-06
other O 0 3.693257610848377e-07
allele O 0 1.2523162695288192e-05
( O 0 2.1186197329825518e-07
Hp2 O 0 8.287655873573385e-06
) O 0 1.791691417452057e-08
of O 0 3.6240805911802454e-09
individuals O 0 4.754342253221466e-09
with O 0 1.2609587152212498e-08
Hp2 O 0 6.72116075293161e-05
/ O 0 1.4453537005465478e-05
Hpdel O 0 2.9086768336128443e-05
was O 0 4.439355507201981e-06
found O 0 3.993188002482384e-08
to O 0 4.038085776869593e-08
have O 0 1.3664809728197724e-07
, O 0 6.019458709261016e-09
in O 0 4.629438610237457e-09
all O 0 4.143221765673388e-09
exons O 0 2.24051518671331e-06
, O 0 1.6264222324480215e-07
no O 0 6.968129184770078e-08
mutation O 0 1.9216531654819846e-07
, O 0 5.515838452652133e-09
by O 0 4.55686599565297e-09
DNA O 0 5.784522159046901e-07
sequencing O 0 1.3637201163874124e-06
. O 0 7.827844683561125e-07

On O 0 9.20847560337279e-06
the O 0 7.241880695119107e-08
basis O 0 3.125692416006132e-08
of O 0 6.392251172826491e-09
the O 0 3.713834217933254e-08
present O 0 5.321405538438739e-08
study O 0 1.2583829978041194e-08
, O 0 4.091250893623055e-09
the O 0 4.99832752964835e-09
mechanism O 0 5.13021127801494e-08
of O 0 1.069306865275621e-08
anhaptoglobinemia B-Disease 0 4.9274218326900154e-05
and O 0 6.890350334742834e-08
the O 0 7.984668926042104e-09
mechanism O 0 6.539736574495691e-08
of O 0 7.312666028269632e-09
anomalous O 0 1.1049202157664695e-06
inheritance O 0 9.471428938923054e-07
of O 0 2.7193287621685158e-08
Hp O 0 3.117680535069667e-05
phenotypes O 0 4.583889676723629e-05
were O 0 2.5810923034441657e-06
well O 0 5.09610174503905e-07
explained O 0 3.6419023672351614e-06
. O 0 7.68764948588796e-07

However O 0 1.1391602129151579e-05
, O 0 2.0619575025193626e-07
the O 0 4.707638723289165e-08
mechanism O 0 3.305579525658686e-07
of O 0 1.2851599251462176e-07
hypohaptoglobinemia B-Disease 0 0.0002928243193309754
remains O 0 2.5407091015949845e-05
unknown O 0 2.6369056286057457e-05

ATM O 0 0.004358997102826834
mutations O 0 0.008648931980133057
and O 0 5.507984496944118e-06
phenotypes O 0 0.00178901432082057
in O 0 0.0001520795631222427
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 8.724903455004096e-05
in O 0 2.3945278826431604e-07
the O 0 4.0288890090778295e-07
British O 0 1.7416608898201957e-05
Isles O 0 1.1566005014174152e-05
: O 0 1.423269235800717e-08
expression O 0 1.5897260396968704e-08
of O 0 2.296218548636375e-09
mutant O 0 5.19097682172287e-07
ATM O 0 9.166997756437922e-07
and O 0 3.209338572673914e-08
the O 0 3.253809310876932e-08
risk O 0 1.7200852653331822e-07
of O 0 1.1437428071303657e-07
leukemia B-Disease 1 0.9105688333511353
, O 0 0.00017682973702903837
lymphoma B-Disease 1 1.0
, O 0 2.6900970624410547e-06
and O 0 5.347235128283501e-05
breast B-Disease 1 0.9975852966308594
cancer I-Disease 0 0.004672004375606775
. O 0 2.5585236471670214e-06

We O 0 5.434726062958362e-06
report O 0 2.431127938962163e-07
the O 0 2.04560617333982e-08
spectrum O 0 2.832869938629301e-07
of O 0 1.1158824975154857e-08
59 O 0 1.195558184008405e-06
ATM O 0 1.5083609469002113e-05
mutations O 0 1.9843773770844564e-05
observed O 0 2.479068371030735e-06
in O 0 1.0532396117923781e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00018901431758422405
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.058306780687417e-07
patients O 0 1.5385386120669864e-07
in O 0 1.80085280021558e-08
the O 0 1.9136138007525005e-07
British O 0 9.809959919948597e-06
Isles O 0 4.26703663833905e-05
. O 0 2.3242303086590255e-06

Of O 0 2.498168669262668e-06
51 O 0 1.2738093573716469e-05
ATM O 0 5.290377157507464e-05
mutations O 0 2.5986235414166003e-05
identified O 0 1.3700372392122517e-06
in O 0 9.6340542654616e-08
families O 0 2.0679479462160089e-07
native O 0 5.0190223532808886e-08
to O 0 3.163146544693518e-08
the O 0 9.518981158862516e-08
British O 0 4.406177595228655e-06
Isles O 0 2.9058348900434794e-06
, O 0 3.6255343616176106e-08
11 O 0 8.77284449529725e-08
were O 0 2.621845851535909e-07
founder O 0 1.7234232245755265e-06
mutations O 0 5.464435730573314e-07
, O 0 8.304183118923447e-09
and O 0 4.390697583289693e-08
2 O 0 2.7312738737350628e-08
of O 0 1.9563357600560494e-09
these O 0 6.679067965364993e-09
11 O 0 4.770286210487029e-08
conferred O 0 4.132892073016592e-08
a O 0 1.1415721701268922e-07
milder O 0 0.0006830719066783786
clinical O 0 1.2115133358747698e-05
phenotype O 0 3.334275243105367e-05
with O 0 3.4653734104495015e-08
respect O 0 4.6584940349703174e-08
to O 0 1.337821373681436e-07
both O 0 6.646278052357957e-06
cerebellar B-Disease 1 0.9887511134147644
degeneration I-Disease 1 0.9925410747528076
and O 0 3.1015745207696455e-06
cellular O 0 2.022523040068336e-05
features O 0 4.0529819671064615e-05
. O 0 6.846934866189258e-06

We O 0 2.9360217013163492e-05
report O 0 8.716150432519498e-07
, O 0 1.6268977276467922e-08
in O 0 1.404079519318202e-08
two O 0 8.464620009362989e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 2.598883384052897e-07
, O 0 4.3944319294553225e-09
an O 0 5.680876213887132e-09
ATM O 0 4.9067134568758775e-06
mutation O 0 1.1286958851997042e-06
( O 0 1.3059930914494089e-08
7271T O 0 2.078480463296728e-07
- O 0 1.6241249340964714e-06
- O 0 1.0486591236258391e-05
> O 0 1.573644226482429e-06
G O 0 2.9048125725239515e-05
) O 0 1.643863178912852e-08
that O 0 1.6555620874214583e-08
may O 0 6.041188953531673e-07
be O 0 8.787728766890268e-09
associated O 0 7.441906202387827e-09
with O 0 1.6680719028272506e-09
an O 0 1.1094479113182842e-08
increased O 0 5.38018412044039e-07
risk O 0 1.5067948311298096e-07
of O 0 7.467203744226936e-08
breast B-Disease 1 0.8630293607711792
cancer I-Disease 0 5.61709821340628e-05
in O 0 5.261826885316623e-08
both O 0 2.3477723232190328e-07
homozygotes O 0 1.871858512458857e-05
and O 0 4.803859496860241e-07
heterozygotes O 0 5.7737643146538176e-06
( O 0 3.104753432126017e-08
relative O 0 1.5075249848450767e-07
risk O 0 1.0388602333932795e-07
12 O 0 2.8791054873522626e-08
. O 0 5.308436801243488e-09
7 O 0 1.3184526892473514e-07
; O 0 2.733210635597061e-07
P O 0 4.301781882531941e-05
= O 0 2.468466391292168e-06
. O 0 3.558245964541129e-08
0025 O 0 1.0707027513490175e-06
) O 0 8.691810826633173e-09
, O 0 3.766220224576955e-09
although O 0 5.935434366222125e-09
there O 0 2.4039301660394585e-09
is O 0 3.0550435514697938e-09
a O 0 3.478883670027244e-08
less O 0 3.378429482836509e-07
severe O 0 0.0019285116577520967
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.0006134183495305479
in O 0 2.0780811738063676e-08
terms O 0 1.465653198806649e-08
of O 0 3.787803404264878e-09
the O 0 2.8355071179930746e-08
degree O 0 2.89728234292852e-07
of O 0 3.5124514852213906e-07
cerebellar B-Disease 1 0.9743547439575195
degeneration I-Disease 1 0.9969692826271057
. O 0 6.895832939335378e-06

This O 0 6.294685135799227e-06
mutation O 0 2.9117631129338406e-05
( O 0 3.0515511184603383e-07
7271T O 0 3.470080855549895e-06
- O 0 2.0781088096555322e-05
- O 0 5.279763718135655e-05
> O 0 5.517294539458817e-06
G O 0 9.159168257610872e-05
) O 0 1.4796102121295007e-08
also O 0 3.4045495311829654e-08
allows O 0 8.841140264337355e-09
expression O 0 9.61336432681037e-09
of O 0 8.156433306538702e-10
full O 0 2.179081803888039e-08
- O 0 7.298330615412851e-07
length O 0 1.9736148715310264e-07
ATM O 0 1.5341562686899124e-07
protein O 0 2.5262657743496675e-08
at O 0 6.5952381334000165e-09
a O 0 1.1926841736453753e-08
level O 0 2.143633892615071e-08
comparable O 0 6.130532881343242e-08
with O 0 1.586460740554685e-08
that O 0 4.7416119031140624e-08
in O 0 1.1361264284914796e-07
unaffected O 0 1.0665940862963907e-05
individuals O 0 1.4136841741674289e-07
. O 0 3.0194070177458343e-07

In O 0 3.0252112992457114e-06
addition O 0 2.7571260829972744e-07
, O 0 7.021280623575876e-08
we O 0 2.1132033012349893e-08
have O 0 1.788833259297462e-08
studied O 0 1.0064984934388121e-07
18 O 0 2.6265486212651012e-06
A B-Disease 1 0.999993085861206
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 2.6415125375933712e-06
, O 0 9.356272201443971e-09
in O 0 9.459720118343284e-09
15 O 0 7.65624861287506e-08
families O 0 2.6598439006875196e-08
, O 0 1.3249562336170584e-08
who O 0 9.919897365762154e-07
developed O 0 0.0001749824295984581
leukemia B-Disease 1 0.8787385821342468
, O 0 0.00017654235125519335
lymphoma B-Disease 1 1.0
, O 0 7.215875257315929e-07
preleukemic O 0 0.00012341576803009957
T O 0 0.0003244336985517293
- O 0 5.696292191714747e-06
cell O 0 5.637596132146427e-06
proliferation O 0 1.0773388794405037e-06
, O 0 2.0348528551039635e-07
or O 0 9.100645547732711e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 9.9186775059934e-07
mostly O 0 1.2774982849350636e-07
in O 0 1.553176218749286e-07
childhood O 0 9.476132618146949e-06
. O 0 2.9112798074493185e-06

A O 0 1.8422902940073982e-05
wide O 0 2.8512292828963837e-06
variety O 0 9.635855491296752e-08
of O 0 2.6540007524999965e-08
ATM O 0 3.2866188121261075e-05
mutation O 0 3.9527185435872525e-06
types O 0 4.928249452973432e-08
, O 0 1.2218041689493475e-08
including O 0 4.433971412254323e-08
missense O 0 0.002760878764092922
mutations O 0 8.617540515842848e-06
and O 0 1.1004324562691181e-07
in O 0 8.329250533734012e-08
- O 0 3.1291543564293534e-05
frame O 0 0.03598703816533089
deletions O 0 3.993701102444902e-05
, O 0 3.453102124240104e-07
were O 0 4.733949197088805e-07
seen O 0 2.3211703137349105e-07
in O 0 2.3355941181080198e-08
these O 0 9.360719843698462e-08
patients O 0 1.0563198884483427e-06
. O 0 5.033782031205192e-07

We O 0 1.3938079064246267e-05
also O 0 6.193316721692099e-07
show O 0 1.1720931070158258e-06
that O 0 2.9499910070285296e-08
25 O 0 1.593875680327983e-07
% O 0 5.295210048217314e-09
of O 0 9.63430224487638e-10
all O 0 3.50366171630867e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.950318376970245e-07
carried O 0 1.0125040006414565e-07
in O 0 7.491195219699875e-09
- O 0 1.4337134643938043e-06
frame O 0 4.058149716001935e-05
deletions O 0 1.616689405636862e-05
or O 0 7.261499490596179e-07
missense O 0 0.00024845596635714173
mutations O 0 7.76194610807579e-06
, O 0 1.4233886957981667e-08
many O 0 1.7346063474477091e-09
of O 0 1.1656624110401026e-08
which O 0 5.078721187601332e-06
were O 0 1.1294192518107593e-05
also O 0 2.4715427571209148e-06
associated O 0 1.1706112701403981e-07
with O 0 1.8400248436023503e-08
expression O 0 1.0951892903676708e-07
of O 0 1.0940990335939205e-08
mutant O 0 4.897106919088401e-06
ATM O 0 8.879370398062747e-06
protein O 0 2.9485843242582632e-06
. O 0 1.5439507023984334e-06

The O 0 6.430078428820707e-06
DMPK O 0 0.00016374675033148378
gene O 0 2.8943022698513232e-05
of O 0 1.5815789993212093e-06
severely O 1 0.9913669228553772
affected O 0 0.13761606812477112
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.032165806740522385
is O 0 7.767053489260434e-07
hypermethylated O 0 7.649968028999865e-05
proximal O 0 3.324398130644113e-05
to O 0 2.1461215737872408e-07
the O 0 5.940941960602686e-08
largely O 0 2.703746702081844e-07
expanded O 0 1.0391570413048612e-06
CTG O 0 4.706329127657227e-05
repeat O 0 1.6499074263265356e-05
. O 0 1.676693614172109e-06

Using O 0 7.060876669129357e-06
methylation O 0 4.576350693241693e-05
- O 0 3.316061702207662e-05
sensitive O 0 1.1398254855521373e-06
restriction O 0 2.2349658479470236e-07
enzymes O 0 1.6902683341868396e-07
, O 0 1.9079951840694775e-08
we O 0 8.846352095304155e-09
characterized O 0 3.408889881484356e-08
the O 0 4.068862136108464e-09
methylation O 0 1.3781788084088475e-06
pattern O 0 2.296308593940921e-05
on O 0 3.582268618629314e-06
the O 0 2.343584668551557e-07
5 O 0 3.6571952932717977e-07
side O 0 2.558215896897309e-07
of O 0 3.840524342990648e-09
the O 0 6.421336706807779e-08
CTG O 0 7.655425179109443e-06
repeat O 0 2.5528760261295247e-07
in O 0 7.086651709897751e-09
the O 0 2.5319195628981106e-08
DMPK O 0 2.6253189844283042e-06
gene O 0 5.871761743492243e-08
of O 0 4.718297308414776e-09
normal O 0 2.2523659026774112e-07
individuals O 0 5.087877674725405e-09
and O 0 1.0036953490555334e-08
of O 0 3.130602621581602e-08
patients O 0 1.659753479543724e-06
affected O 0 6.829769176874834e-07
with O 0 3.360704431543127e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.35070683882077e-06
showing O 0 7.535040253969782e-07
expansions O 0 3.716279479704099e-07
of O 0 1.89422681984297e-08
the O 0 9.345182405695596e-08
repetitive O 0 2.4260829377453774e-05
sequence O 0 2.934194299086812e-06
. O 0 1.2379191502986941e-06

The O 0 4.4881735448143445e-06
gene O 0 6.172329449327663e-06
segment O 0 1.2553869964904152e-05
analyzed O 0 1.6051453712861985e-06
corresponds O 0 4.0583856275588914e-07
to O 0 2.2842160163349945e-08
the O 0 7.190514139665538e-08
genomic O 0 4.151540451857727e-06
SacI O 0 8.189643995137885e-05
- O 0 1.5897321645752527e-05
HindIII O 0 6.907416718604509e-06
fragment O 0 1.1629928167167236e-06
carrying O 0 1.6566367833092954e-07
exons O 0 1.003895522444509e-05
11 O 0 1.8400972976451158e-06
- O 0 1.6095467799459584e-05
15 O 0 1.4042127531865845e-06
. O 0 7.964790142978018e-07

There O 0 3.6143123907095287e-06
is O 0 1.0660387772531976e-07
constitutive O 0 1.1905043493243284e-06
methylation O 0 5.1996103138662875e-06
in O 0 1.5034531486435299e-07
intron O 0 0.00017627404304221272
12 O 0 1.5701094753239886e-06
at O 0 3.276290883036381e-08
restriction O 0 2.6292216404044666e-08
sites O 0 1.4065212994296417e-08
of O 0 5.704481775836712e-09
SacII O 0 9.667649464972783e-06
and O 0 8.363765147123559e-08
HhaI O 0 1.463293870074267e-06
, O 0 6.091343873748656e-09
localized O 0 9.442779003165924e-08
1 O 0 2.0385874321959818e-08
, O 0 7.001618840263291e-09
159 O 0 9.277570711674343e-08
- O 0 6.707487614221463e-07
1 O 0 4.705592004938808e-08
, O 0 1.1769714092224604e-08
232 O 0 1.1442294578500878e-07
bp O 0 1.0385239193055895e-06
upstream O 0 2.8944450392032195e-08
of O 0 1.8179557859099305e-09
the O 0 1.4342542264955682e-08
CTG O 0 7.979236215760466e-06
repeat O 0 5.918039960306487e-07
, O 0 1.4513101831425956e-08
whereas O 0 7.46452322175628e-09
most O 0 1.5285323007319107e-09
, O 0 4.73703520853519e-09
if O 0 2.0955297497238234e-09
not O 0 7.689553882528344e-09
all O 0 9.609912865471415e-10
, O 0 1.4580099350069986e-09
of O 0 2.677661981032031e-10
the O 0 1.8370641674536614e-09
other O 0 8.546547913823588e-10
sites O 0 7.0784254013744885e-09
of O 0 1.9127601724733267e-09
SacII O 0 1.9451429125183495e-06
, O 0 1.1880048056411852e-08
HhaI O 0 5.954804578323092e-07
, O 0 4.870245540189444e-09
and O 0 2.0539298262178818e-08
HpaII O 0 1.11542271952203e-06
in O 0 6.729193202659189e-09
this O 0 3.0260929317904584e-09
region O 0 7.197731122232653e-08
are O 0 7.651821398724223e-09
unmethylated O 0 9.233328341906599e-07
, O 0 2.3559607598144794e-08
in O 0 1.604328936366528e-08
normal O 0 1.3865418679870345e-07
individuals O 0 9.013435331439723e-09
and O 0 1.5977176914816482e-08
most O 0 3.4908460566640542e-09
of O 0 7.348712749433162e-09
the O 0 3.2391622539762466e-07
patients O 0 2.8907295472890837e-06
. O 0 6.618932388846588e-07

In O 0 1.0136020591744455e-06
a O 0 1.9953371577230428e-07
number O 0 5.4800821658318455e-08
of O 0 2.5236749578994022e-08
young O 0 7.130937547117355e-07
and O 0 1.0926454478976666e-06
severely O 0 0.1333564668893814
affected O 0 3.823259703494841e-06
patients O 0 4.75299401614393e-07
, O 0 3.857433128473531e-08
however O 0 2.5040401752107755e-08
, O 0 4.4016794653600755e-09
complete O 0 1.0601054256653697e-08
methylation O 0 1.744689939187083e-07
of O 0 2.884627869903511e-09
these O 0 2.3950512684223213e-09
restriction O 0 2.2127727206111558e-08
sites O 0 5.215743570374798e-08
was O 0 2.48322362494946e-06
found O 0 3.700668216310987e-08
in O 0 8.644740923102745e-09
the O 0 8.337801915558885e-08
mutated O 0 1.4010763152327854e-05
allele O 0 1.3759182365902234e-05
. O 0 1.041366431309143e-06

In O 0 3.774129027078743e-06
most O 0 7.407312807572453e-08
of O 0 1.612243316628792e-08
these O 0 6.001668850785791e-08
patients O 0 3.258213041590352e-07
, O 0 1.2997903198197491e-08
the O 0 1.544846917056475e-08
onset O 0 2.755051582425949e-06
of O 0 4.3745139066686534e-08
the O 0 2.7596570362220518e-05
disease O 0 0.48627912998199463
was O 1 0.5970230102539062
congenital O 1 0.9999972581863403
. O 0 7.73028386902297e-06

Preliminary O 0 5.013181362301111e-05
in O 0 3.1177607979770983e-06
vivo O 0 7.917359471321106e-05
footprinting O 0 0.0001675250387052074
data O 0 4.0600619399810967e-07
gave O 0 1.0206612444108032e-07
evidence O 0 6.579106148763003e-09
for O 0 1.5510136508467554e-09
protein O 0 5.037993844325683e-08
- O 0 4.5344472709984984e-07
DNA O 0 4.980112180419383e-07
contact O 0 8.642419402349333e-08
in O 0 1.9566277487115258e-08
normal O 0 7.883149066856276e-08
genes O 0 5.499799726749188e-08
at O 0 1.9179561050464145e-08
an O 0 8.360252934380696e-09
Sp1 O 0 2.4600317374279257e-06
consensus O 0 3.372106505139527e-08
binding O 0 4.679126774931319e-08
site O 0 3.4655428748919803e-07
upstream O 0 5.3104852071328423e-08
of O 0 1.326057819106552e-09
the O 0 1.3730615755491726e-08
CTG O 0 8.038789019337855e-06
repeat O 0 3.425004706514301e-07
and O 0 1.9855985300409884e-08
for O 0 1.0181288034871727e-09
a O 0 1.2162563400863746e-08
significant O 0 1.2329850029857425e-08
reduction O 0 3.118290337056351e-08
of O 0 1.1583743964038717e-09
this O 0 1.1108999276032705e-09
interaction O 0 1.1012214251593377e-08
in O 0 1.8150462466337558e-08
cells O 0 7.408782209950004e-08
with O 0 8.08262878848609e-09
a O 0 3.2751762546467944e-07
hypermethylated O 0 4.2706073145382106e-05
DMPK O 0 3.5387216485105455e-05
gene O 0 1.649105001888529e-06
. O 0 2.1170525599245593e-07
. O 0 8.757895102462498e-07

The O 0 3.6783883842872456e-05
hemochromatosis B-Disease 1 0.9999984502792358
gene O 0 1.2734935808111914e-05
product O 0 5.629492534353631e-07
complexes O 0 3.345262769016699e-07
with O 0 3.493145683819421e-08
the O 0 9.014109281224592e-08
transferrin O 0 5.374156899051741e-06
receptor O 0 9.169463623948104e-07
and O 0 3.997482735940139e-07
lowers O 0 2.9418904887279496e-05
its O 0 3.5759356364906125e-08
affinity O 0 8.255641148480208e-08
for O 0 8.885229441091269e-09
ligand O 0 5.039868256062618e-07
binding O 0 9.891292620523018e-07
. O 0 9.600116754882038e-07

We O 0 2.197062349296175e-05
recently O 0 5.429991688288283e-06
reported O 0 6.693863952023094e-07
the O 0 2.169096546822402e-08
positional O 0 1.8485465034245863e-06
cloning O 0 2.8070203939023486e-07
of O 0 7.040293237281503e-09
a O 0 6.838595112412804e-08
candidate O 0 1.2414907359925564e-06
gene O 0 8.961308594734874e-06
for O 0 0.00012347531446721405
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.029457561671733856
HFE O 0 0.28836721181869507
. O 0 1.0702570762077812e-05

The O 0 1.1338731837895466e-06
gene O 0 2.5594413273211103e-06
product O 0 4.5605901277667726e-07
, O 0 4.139700493510645e-08
a O 0 4.457153579551232e-08
member O 0 1.7150197706428116e-08
of O 0 2.8736175661236985e-09
the O 0 1.8332288576061728e-08
major O 0 4.0008877988384484e-08
histocompatibility O 0 5.392034267970303e-07
complex O 0 7.769210697006201e-08
class O 0 1.6242552192125004e-07
I O 0 1.4922341051715193e-06
- O 0 1.076733951776987e-06
like O 0 6.047829259614446e-08
family O 0 2.534379461849312e-07
, O 0 4.7279932857691165e-08
was O 0 1.6608619262115099e-06
found O 0 3.132364767566287e-08
to O 0 5.1849227133971e-09
have O 0 3.546104920815196e-08
a O 0 1.0922666149326687e-07
mutation O 0 6.731768849022046e-07
, O 0 2.4672932141811543e-08
Cys O 0 1.5166549928835593e-05
- O 0 2.6956258807331324e-06
282 O 0 1.6308237036355422e-06
- O 0 1.691005854809191e-05
- O 0 3.40421793225687e-05
> O 0 2.027150912908837e-06
Tyr O 0 5.266247626423137e-06
( O 0 2.2984719905139173e-08
C282Y O 0 3.531465608830331e-07
) O 0 4.860353008950824e-09
, O 0 2.8558759801455835e-09
in O 0 8.353079117284778e-09
85 O 0 8.816221708229932e-08
% O 0 1.5258153851505085e-08
of O 0 1.1486328332921403e-08
patient O 0 5.2261775635997765e-06
chromosomes O 0 7.064897363306955e-05
. O 0 3.3035198612196837e-06

This O 0 3.741492491826648e-06
mutation O 0 1.1811252988991328e-05
eliminates O 0 2.491374061719398e-06
the O 0 9.442130277648175e-08
ability O 0 2.0210806894738198e-07
of O 0 3.85677125791517e-08
HFE O 0 0.00010876718442887068
to O 0 6.396717822099163e-08
associate O 0 1.2445866559573915e-07
with O 0 4.275885601146001e-08
beta2 O 0 7.401128095807508e-05
- O 0 0.00012042321759508923
microglobulin O 0 8.815777255222201e-05
( O 0 1.156683140379755e-07
beta2m O 0 2.9056077437417116e-06
) O 0 2.5230589173474982e-08
and O 0 3.1807150691065544e-08
prevents O 0 2.876487599223765e-07
cell O 0 6.897154889884405e-06
- O 0 4.8513658839510754e-05
surface O 0 2.536755710025318e-05
expression O 0 5.268784661893733e-06
. O 0 1.7161312371172244e-06

A O 0 4.0323109715245664e-05
second O 0 1.3066581232124008e-05
mutation O 0 4.787724265042925e-06
that O 0 6.727398726980027e-08
has O 0 1.330776768782016e-07
no O 0 1.7179663913680088e-08
effect O 0 5.06684578738259e-08
on O 0 6.348596457428357e-07
beta2m O 0 1.9052251445828006e-05
association O 0 2.4553127531135033e-08
, O 0 8.246115790200292e-09
H63D O 0 3.608601900850772e-06
, O 0 2.4070466508874233e-08
was O 0 1.104172270061099e-06
found O 0 3.685059368763177e-08
in O 0 1.242387615008056e-08
eight O 0 6.108064809495772e-08
out O 0 3.07622336492841e-08
of O 0 6.402598895505207e-09
nine O 0 1.1227590448470437e-06
patients O 0 1.9480002322325163e-07
heterozygous O 0 1.5359921690105693e-07
for O 0 5.45640332916264e-09
the O 0 6.227241300393871e-08
C282Y O 0 1.162579792435281e-05
mutant O 0 1.3022692655795254e-05
. O 0 9.14848271804658e-07

In O 0 2.683877710296656e-06
this O 0 6.053564760577501e-08
report O 0 1.7333709934064245e-07
, O 0 2.2860159987203588e-08
we O 0 1.639670088593448e-08
demonstrate O 0 2.5741764275721835e-08
in O 0 1.6746204423156996e-08
cultured O 0 1.7289327161051915e-06
293 O 0 9.166927839032724e-07
cells O 0 5.618604745905031e-07
overexpressing O 0 4.285505838197423e-06
wild O 0 2.3229949874803424e-07
- O 0 4.1612997847551014e-06
type O 0 7.425107355629734e-07
or O 0 8.151496189157115e-08
mutant O 0 3.5427526654530084e-06
HFE O 0 3.2277363061439246e-05
proteins O 0 5.229280830576499e-08
that O 0 5.299018557280988e-09
both O 0 2.8957358733094907e-09
the O 0 1.4713952722900103e-08
wild O 0 2.2283298051206657e-07
- O 0 1.0823998309206218e-05
type O 0 7.932679295663547e-07
and O 0 2.569369996763271e-07
H63D O 0 6.342794222291559e-05
HFE O 0 3.257173375459388e-05
proteins O 0 1.9849024113227642e-07
form O 0 5.13358813236664e-08
stable O 0 6.761462145732366e-07
complexes O 0 2.0214199025758717e-07
with O 0 2.741367488567903e-08
the O 0 2.893121404667909e-07
transferrin O 0 8.239951421273872e-05
receptor O 0 9.857976692728698e-06
( O 0 5.971359655632114e-07
TfR O 0 0.0002548280172049999
) O 0 4.27154901672111e-07
. O 0 7.753650947961432e-07

The O 0 6.918611688888632e-06
C282Y O 0 7.214239303721115e-05
mutation O 0 1.4859084330964833e-05
nearly O 0 7.567251145701448e-07
completely O 0 9.675134151621023e-07
prevents O 0 8.797039896535352e-08
the O 0 1.6407025071885073e-08
association O 0 1.5112552986806804e-08
of O 0 1.8029278070486043e-09
the O 0 4.6120344876499075e-08
mutant O 0 1.4837575690762606e-05
HFE O 0 5.273126589599997e-05
protein O 0 3.8969380966591416e-07
with O 0 6.396216889470452e-08
the O 0 8.6613124494761e-07
TfR O 0 0.004094971809536219
. O 0 2.419646762064076e-06

Studies O 0 6.261861926759593e-06
on O 0 6.126809921624954e-07
cell O 0 3.947388449887512e-06
- O 0 2.493715328455437e-06
associated O 0 1.901193513731414e-07
transferrin O 0 1.050889068210381e-06
at O 0 6.41078869989542e-08
37 O 0 1.7754619818788342e-07
degrees O 0 3.9021298903207935e-07
C O 0 1.9344245174579555e-06
suggest O 0 2.7515511646925006e-08
that O 0 2.4590138814062357e-09
the O 0 9.479082407892747e-09
overexpressed O 0 3.4788022276188713e-06
wild O 0 4.1735776790119417e-07
- O 0 9.6411877166247e-06
type O 0 8.353607654498774e-07
HFE O 0 1.646458804316353e-05
protein O 0 2.3866215315138106e-07
decreases O 0 2.9992230565767386e-07
the O 0 7.434258986194209e-09
affinity O 0 5.495542154676514e-08
of O 0 8.364749781719638e-09
the O 0 1.1684932843536444e-07
TfR O 0 0.00011450695456005633
for O 0 1.7174544097997568e-07
transferrin O 0 4.2939169361488894e-05
. O 0 2.162672444683267e-06

The O 0 5.781648724223487e-06
overexpressed O 0 0.00011424858530517668
H63D O 0 5.654569395119324e-05
protein O 0 1.3852945812686812e-06
does O 0 5.125653146365039e-08
not O 0 4.402048947582671e-09
have O 0 9.693919444941912e-09
this O 0 3.2771578784007716e-09
effect O 0 1.0481869594514137e-07
, O 0 6.9997767582208326e-09
providing O 0 1.6953616288617468e-09
the O 0 2.0459094418612267e-09
first O 0 1.039922370438262e-08
direct O 0 4.725664748406189e-09
evidence O 0 5.702849747990513e-09
for O 0 1.5675705178352928e-09
a O 0 3.721676833379206e-08
functional O 0 1.2057104470386548e-07
consequence O 0 6.02579106612211e-08
of O 0 5.1226600739084915e-09
the O 0 1.2890474465621082e-07
H63D O 0 0.0003007207124028355
mutation O 0 1.0058332918561064e-05
. O 0 1.2329777518971241e-06

Addition O 0 9.467805284657516e-06
of O 0 2.5293476824117533e-07
soluble O 0 1.43798445151333e-06
wild O 0 1.1101051313744392e-06
- O 0 8.8761757069733e-05
type O 0 6.370518349285703e-06
HFE O 0 0.0018928131321445107
/ O 0 5.171973680262454e-05
beta2m O 0 1.2124796739954036e-05
heterodimers O 0 4.859836280957097e-06
to O 0 7.432192461465092e-08
cultured O 0 2.3492400487157283e-06
cells O 0 6.040457378730935e-07
also O 0 2.6139565534322173e-07
decreased O 0 6.916243364685215e-07
the O 0 1.426030049600513e-08
apparent O 0 5.014434236727539e-07
affinity O 0 5.150349480231853e-08
of O 0 4.806202991147757e-09
the O 0 2.9328122153060576e-08
TfR O 0 1.828323547670152e-05
for O 0 1.934679749737711e-09
its O 0 4.551914400963142e-09
ligand O 0 2.520764397218045e-08
under O 0 2.02564933715621e-08
steady O 0 1.1944891866733087e-06
- O 0 2.7055932605435373e-06
state O 0 1.9207163859391585e-08
conditions O 0 4.1888540636136895e-07
, O 0 7.375659638597654e-09
both O 0 3.464922349039057e-09
in O 0 2.8618153180559602e-08
293 O 0 4.852306574321119e-07
cells O 0 2.0996280625240615e-07
and O 0 7.878684726847496e-08
in O 0 3.1731988769934105e-07
HeLa O 0 0.0004618708335328847
cells O 0 6.312497134786099e-06
. O 0 1.2074589221811038e-06

Furthermore O 0 1.5396453818539158e-05
, O 0 2.1046218989795307e-07
at O 0 4.38186305018462e-08
4 O 0 2.0592474925251736e-07
degrees O 0 1.7692987057671417e-06
C O 0 2.15448162634857e-05
, O 0 3.9845676980121425e-08
the O 0 3.424922567774047e-08
added O 0 9.138733503277763e-07
soluble O 0 1.839179759599574e-07
complex O 0 5.3560469837066194e-08
of O 0 3.139769688687011e-08
HFE O 0 0.001641932874917984
/ O 0 2.606732232379727e-05
beta2m O 0 6.917318387422711e-06
inhibited O 0 3.643979482603754e-07
binding O 0 4.5498509848584945e-08
of O 0 6.500324722935602e-09
transferrin O 0 1.7613707541386248e-06
to O 0 5.63248967466734e-08
HeLa O 0 0.00014222828031051904
cell O 0 2.1128294974914752e-05
TfR O 0 8.053417695919052e-05
in O 0 4.5077666044335274e-08
a O 0 2.0160082669917756e-07
concentration O 0 1.0292713341186754e-05
- O 0 3.4821746339730453e-06
dependent O 0 1.0675520343284006e-06
manner O 0 4.325956069806125e-06
. O 0 1.1878687473654281e-06

Scatchard O 0 0.0007565132109448314
plots O 0 2.2535426978720352e-05
of O 0 2.5171905804199923e-07
these O 0 2.4552472055461294e-08
data O 0 1.756538665631524e-07
indicate O 0 2.550836484260799e-07
that O 0 1.8079115093883047e-08
the O 0 4.4218435135690015e-08
added O 0 1.1307710110486369e-06
heterodimer O 0 1.9961814814450918e-06
substantially O 0 1.8876430658565369e-06
reduced O 0 1.0338671074805461e-07
the O 0 1.016716577595389e-08
affinity O 0 1.7473558955316548e-07
of O 0 3.8528671808535364e-08
TfR O 0 0.00014767910761293024
for O 0 1.6541454783691734e-07
transferrin O 0 4.831605474464595e-05
. O 0 1.257871531379351e-06

These O 0 2.631274583109189e-06
results O 0 5.076935849501751e-07
establish O 0 1.255413195622168e-07
a O 0 9.992469074404653e-08
molecular O 0 3.907425139004772e-07
link O 0 8.887341209629085e-06
between O 0 5.360213890526211e-06
HFE O 0 0.051396727561950684
and O 0 2.8705466093015275e-07
a O 0 9.035557724246246e-08
key O 0 3.8324995443872467e-07
protein O 0 1.5314110157760297e-07
involved O 0 1.6617342168956384e-08
in O 0 2.336405025005206e-08
iron O 0 7.309567445190623e-05
transport O 0 7.516129585383169e-08
, O 0 8.634030379539581e-09
the O 0 1.3355237804546505e-08
TfR O 0 3.762962660402991e-05
, O 0 5.8129803193196494e-08
and O 0 2.5055499008885818e-08
raise O 0 2.7754600395724083e-08
the O 0 3.018334027160563e-09
possibility O 0 7.462616302689185e-09
that O 0 1.1811408739959006e-08
alterations O 0 2.1631508388963994e-06
in O 0 1.7281676534253165e-08
this O 0 4.045337842484287e-09
regulatory O 0 6.933817076060222e-08
mechanism O 0 4.7313716322605615e-07
may O 0 1.078867740034184e-06
play O 0 1.1425496992956141e-08
a O 0 2.3884286548536693e-08
role O 0 3.2115679005073616e-08
in O 0 3.518139735092518e-08
the O 0 2.2770086616219487e-07
pathogenesis O 0 4.085914042661898e-05
of O 0 3.182084401487373e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.132271220034454e-05
. O 0 2.4193100216507446e-06

Genomic O 0 9.867075277725235e-05
organization O 0 2.611913487271522e-06
of O 0 1.1278850564622189e-07
the O 0 4.388449497128022e-07
UBE3A O 0 0.0005553036462515593
/ O 0 3.2269359508063644e-05
E6 O 0 3.8580590626224875e-05
- O 0 7.592242036480457e-05
AP O 0 2.4872406356735155e-05
gene O 0 1.7691080529402825e-06
and O 0 1.970729783806746e-07
related O 0 8.083908937805973e-07
pseudogenes O 0 4.075967081007548e-05
. O 0 5.695792424376123e-06

The O 0 7.63706339057535e-06
UBE3A O 0 0.00028679039678536355
gene O 0 6.3334155129268765e-06
encodes O 0 4.398024429974612e-06
the O 0 3.064242548589391e-07
E6 O 0 3.7169400457059965e-05
- O 0 4.6564451622543857e-05
AP O 0 6.17435443928116e-06
ubiquitin O 0 8.657166858938581e-07
- O 0 5.830218583469104e-07
protein O 0 8.836845211135369e-08
ligase O 0 1.4485799226804374e-07
and O 0 1.1121984755391168e-07
has O 0 2.50946300184296e-07
recently O 0 1.7788663626561174e-06
been O 0 4.818789989258221e-07
shown O 0 3.159233230576319e-08
to O 0 4.574770784415705e-09
be O 0 6.409896258219305e-08
mutated O 0 0.00011686785001074895
in O 0 0.2212115377187729
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 3.884262696374208e-05
who O 0 9.86979898698337e-07
lack O 0 1.617469251868897e-07
15q11 O 0 5.238487574388273e-06
- O 0 9.34041145228548e-06
q13 O 0 6.913651759532513e-06
deletions O 0 7.763530447846279e-06
or O 0 8.572856131650042e-07
chromosome O 0 0.0004320686566643417
15 O 0 2.428317884550779e-06
paternal O 0 5.1946815801784396e-05
uniparental B-Disease 0 0.003445534035563469
disomy I-Disease 0 0.00046495083370245993
. O 0 6.489737643278204e-06

Previous O 0 4.9355101509718224e-05
UBE3A O 0 0.0003067933430429548
cDNA O 0 1.784694177331403e-05
analysis O 0 1.8036944311461411e-06
has O 0 6.440153015319083e-07
shown O 0 2.2855347481254285e-07
a O 0 1.1736652538729686e-07
coding O 0 1.7564108929946087e-05
region O 0 5.231889304013748e-07
of O 0 2.8154380160572146e-08
approximately O 0 1.1825253665165292e-07
2 O 0 6.656920845671266e-07
. O 0 9.746127034304664e-07

6 O 0 0.00020417102496139705
kb O 0 0.000532601319719106
and O 0 1.4956864333726116e-06
a O 0 6.590009320461832e-07
3 O 0 9.385502380609978e-06
- O 0 0.005765612702816725
untranslated O 0 0.0032170515041798353
region O 0 1.1871973583765794e-05
( O 0 1.843017969349603e-07
UTR O 0 8.939439794630744e-06
) O 0 1.5417148446772444e-08
of O 0 6.309951228189448e-09
< O 0 7.127354706426559e-07
50 O 0 1.1534358179687842e-07
bp O 0 1.8733213664745563e-06
, O 0 8.389020145216364e-09
whereas O 0 6.778530625695112e-09
Northern O 0 1.804975902075512e-08
analysis O 0 2.855501435305996e-08
has O 0 3.3560144885314e-08
indicated O 0 4.103554473999793e-08
mRNA O 0 1.787554282373094e-08
sizes O 0 5.4233389334967796e-08
of O 0 6.124126095130578e-09
5 O 0 2.6114972229152045e-07
- O 0 6.368933554767864e-06
8 O 0 1.336759396508569e-06
kb O 0 9.453930397285149e-05
. O 0 1.689386522230052e-06

We O 0 6.973580184421735e-06
have O 0 1.866468579692082e-07
analyzed O 0 2.147767901305997e-07
additional O 0 3.941588033740118e-08
cDNA O 0 4.4278530708652397e-07
clones O 0 2.804429868774605e-06
and O 0 5.702200311930028e-08
provide O 0 5.0172781485002815e-09
evidence O 0 3.186731545312682e-09
for O 0 1.2669222337891028e-09
an O 0 5.149806359128206e-09
additional O 0 8.179436150612673e-08
0 O 0 8.886391924534109e-07
. O 0 6.125740696916182e-07

5 O 0 5.2014776883879676e-05
kb O 0 3.3833333873189986e-05
of O 0 2.05788495577508e-07
5 O 0 1.13394037271064e-06
- O 0 1.4237833966035396e-05
UTR O 0 3.826091779046692e-05
and O 0 3.1797696919966256e-07
> O 0 5.45520379091613e-07
2 O 0 1.6290006499275478e-07
kb O 0 5.968784989818232e-06
of O 0 6.951124476017867e-08
3 O 0 2.8900101369799813e-06
- O 0 0.00012329156743362546
UTR O 0 0.0004542459500953555
. O 0 2.9137186174921226e-06

We O 0 3.723425470525399e-05
have O 0 2.056352883528234e-07
established O 0 5.757477694601221e-08
the O 0 9.655684252152241e-09
genomic O 0 2.42008667328264e-07
organization O 0 4.831075983702249e-08
of O 0 1.3523829167638723e-08
UBE3A O 0 2.208125442848541e-05
and O 0 6.496186699678219e-08
the O 0 7.848938388121951e-09
sequence O 0 8.449999455706347e-08
of O 0 2.7433184612846162e-08
intron O 0 7.147555152187124e-05
- O 0 4.303444075048901e-05
exon O 0 2.3038785002427176e-05
borders O 0 1.5137965419853572e-05
. O 0 3.366206328792032e-06

We O 0 5.589078500634059e-05
have O 0 4.6803856434962654e-07
also O 0 1.4284070459780196e-07
mapped O 0 4.035563506477047e-06
two O 0 7.035155391577064e-08
highly O 0 8.98828815820707e-08
homologous O 0 5.48976913705701e-07
processed O 0 9.5280609002657e-07
pseudogenes O 0 2.379259058216121e-06
, O 0 6.736001267881875e-08
UBE3AP1 O 0 8.77132060850272e-06
and O 0 1.854209443763466e-07
UBE3AP2 O 0 7.6159344644111115e-06
, O 0 7.029706594607887e-09
to O 0 5.851399365042198e-09
chromosomes O 0 6.917410360074427e-07
2 O 0 2.6882480597123504e-07
and O 0 5.324024527908477e-07
21 O 0 7.501978984691959e-07
, O 0 4.403445430511965e-08
respectively O 0 3.793792586748168e-07
, O 0 1.960939144396434e-08
and O 0 8.320676414541595e-08
determined O 0 1.6446337269826472e-07
their O 0 2.2344877947944042e-08
genomic O 0 1.2813359262509039e-06
organization O 0 2.687017683911108e-07
. O 0 4.1022792629519245e-07

These O 0 2.7749101718654856e-06
results O 0 8.704338370080222e-07
will O 0 5.022297600021375e-08
form O 0 6.894002257951115e-09
the O 0 7.305263505230641e-09
basis O 0 1.589535081336635e-08
for O 0 3.669346826384867e-09
studies O 0 1.3366602935604988e-08
of O 0 7.892683839827441e-09
mutation O 0 7.083512514327595e-07
and O 0 9.045938753615701e-08
imprinting O 0 8.949813491199166e-06
of O 0 3.151073428853124e-07
UBE3A O 0 0.0003245827683713287
. O 0 2.4201174255722435e-06

Mutation O 0 0.0059502567164599895
spectrum O 0 0.00015529640950262547
and O 0 5.358752332540462e-06
genotype O 0 0.01280707586556673
- O 0 0.3653284013271332
phenotype O 0 0.0035300476010888815
analyses O 0 3.2947953059192514e-06
in O 0 1.2799656587958452e-06
Cowden B-Disease 1 0.9836375713348389
disease I-Disease 0 0.001318282331340015
and O 0 5.318530384101905e-06
Bannayan B-Disease 1 0.9786836504936218
- I-Disease 1 0.9999940395355225
Zonana I-Disease 1 0.9999957084655762
syndrome I-Disease 1 0.9999951124191284
, O 0 4.236525512624212e-07
two O 0 5.422560661827447e-06
hamartoma B-Disease 1 0.9962769150733948
syndromes I-Disease 1 0.9743212461471558
with O 0 6.340383151837159e-06
germline O 0 0.11554301530122757
PTEN O 0 0.04962340369820595
mutation O 0 0.0005009935121051967
. O 0 6.617267899855506e-06

The O 0 0.00012152321869507432
tumour B-Disease 1 0.9999967813491821
suppressor O 0 0.016154227778315544
gene O 0 0.00017871840100269765
PTEN O 0 0.0011962970020249486
, O 0 5.403555292105011e-07
which O 0 8.989865563080457e-08
maps O 0 3.0151588816806907e-06
to O 0 4.0980484072861145e-07
10q23 O 0 9.573927673045546e-05
. O 0 1.923816626003827e-06

3 O 0 4.3163330701645464e-05
and O 0 3.866796589591104e-07
encodes O 0 1.4875765828037402e-06
a O 0 2.617329073473229e-07
403 O 0 6.746557232872874e-07
amino O 0 6.566158390342025e-07
acid O 0 6.136663159850286e-07
dual O 0 1.1886302218044875e-06
specificity O 0 5.520689228433184e-06
phosphatase O 0 0.014486415311694145
( O 0 3.6923557900081505e-07
protein O 0 1.0047259593193303e-06
tyrosine O 0 6.461114935518708e-06
phosphatase O 0 0.0002338049962418154
; O 0 5.675138936567237e-07
PTPase O 0 1.5040461221360601e-05
) O 0 3.283992811020653e-08
, O 0 2.392860842803657e-08
was O 0 3.6937017284799367e-06
shown O 0 1.9039985943436477e-07
recently O 0 3.2873521149667795e-07
to O 0 1.0372818159964936e-08
play O 0 4.392523322849229e-08
a O 0 5.405184211326741e-08
broad O 0 3.887513742029114e-07
role O 0 1.6849378425831674e-07
in O 0 2.7997242568744696e-07
human O 0 1.7394480664734147e-06
malignancy B-Disease 0 0.000641796737909317
. O 0 1.3640348015542259e-06

Somatic O 0 0.006263752933591604
PTEN O 0 0.024290479719638824
deletions O 0 0.0014279764145612717
and O 0 2.833149665093515e-05
mutations O 0 0.00010122555249836296
were O 0 7.264401915563212e-07
observed O 0 1.2079241287210607e-06
in O 0 1.7332388324575732e-07
sporadic B-Disease 0 0.4725228548049927
breast I-Disease 1 0.9994015693664551
, I-Disease 0 1.0688605470932089e-05
brain I-Disease 0 0.0034965567756444216
, I-Disease 0 2.1654295778716914e-06
prostate I-Disease 1 0.6894688010215759
and I-Disease 0 0.00018322606047149748
kidney I-Disease 0 0.07111112773418427
cancer I-Disease 0 0.0026538947131484747
cell O 0 0.00017945368017535657
lines O 0 0.001924381242133677
and O 0 2.2670286625725566e-07
in O 0 2.7879709207923042e-08
several O 0 2.6222960514132865e-07
primary O 0 4.1949566366383806e-05
tumours B-Disease 1 0.9999998807907104
such O 0 1.3052265046553657e-07
as O 0 3.515647040330805e-05
endometrial B-Disease 1 0.9998849630355835
carcinomas I-Disease 1 1.0
, O 1 0.9020283818244934
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9892348647117615
thyroid B-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
. O 0 3.35855147568509e-05

In O 0 3.2940663459157804e-06
addition O 0 3.279167515302106e-07
, O 0 2.867643615900306e-07
PTEN O 0 0.00023837413755245507
was O 0 1.3583680811279919e-05
identified O 0 4.157592741194094e-07
as O 0 1.0905405467553919e-08
the O 0 1.9052640354288997e-08
susceptibility O 0 5.368603979150066e-06
gene O 0 4.38504855537758e-07
for O 0 8.226577108416677e-08
two O 0 0.00011809598072431982
hamartoma B-Disease 1 0.9999940395355225
syndromes I-Disease 1 0.9999982118606567
Cowden B-Disease 1 0.9999476671218872
disease I-Disease 0 0.3556346893310547
( O 0 2.4501298412360484e-07
CD B-Disease 0 4.6559474867535755e-05
; O 0 2.5318938696727855e-06
MIM O 0 0.0001362624898320064
158350 O 0 4.412922862684354e-06
) O 0 2.930038967008386e-08
and O 0 1.5647624707071373e-07
Bannayan B-Disease 0 0.00012616369349416345
- I-Disease 0 0.00195589242503047
Zonana I-Disease 0 0.0009373869397677481
( I-Disease 0 4.0036940163190593e-07
BZS I-Disease 0 1.3329618923307862e-05
) I-Disease 0 9.027960601315499e-08
or I-Disease 0 2.1080568046727421e-07
Ruvalcaba I-Disease 0 0.00011276780423941091
- I-Disease 0 0.00010480269702384248
Riley I-Disease 0 0.000439416675362736
- I-Disease 1 0.999100923538208
Smith I-Disease 1 0.9991249442100525
syndrome I-Disease 1 0.9999938011169434
( O 0 1.2167317890998675e-06
MIM O 0 0.000247071438934654
153480 O 0 2.4528830181225203e-05
) O 0 4.050857285164966e-07
. O 0 8.244568334703217e-07

Constitutive O 0 0.00016212076297961175
DNA O 0 2.3347636670223437e-05
from O 0 5.143182875144703e-07
37 O 0 1.6776629081505234e-06
CD B-Disease 0 8.618452739028726e-06
families O 0 2.583320792837185e-07
and O 0 5.651116552485291e-08
seven O 0 2.3286911243758368e-07
BZS B-Disease 0 2.1348758309613913e-05
families O 0 3.332497158226033e-07
was O 0 1.1580015097933938e-06
screened O 0 2.278708279845887e-06
for O 0 3.2945584393928584e-07
germline O 0 0.00028138034394942224
PTEN O 0 0.0020327228121459484
mutations O 0 0.0001592521439306438
. O 0 3.9073424886737484e-06

PTEN O 1 0.870098888874054
mutations O 0 0.060500677675008774
were O 0 6.252661023609107e-06
identified O 0 4.838554445996124e-07
in O 0 2.7363004306835137e-08
30 O 0 4.8100389449245995e-08
of O 0 3.4387321878881494e-09
37 O 0 8.748729669605382e-07
( O 0 4.462222946699512e-08
81 O 0 7.731337632321811e-07
% O 0 3.751195620793624e-08
) O 0 7.638697674394734e-09
CD B-Disease 0 2.080125341308303e-06
families O 0 4.061823588585867e-08
, O 0 3.6038425577089583e-09
including O 0 7.522781508839671e-09
missense O 0 9.420249625691213e-06
and O 0 2.337221474135731e-07
nonsense O 0 3.1316799322667066e-06
point O 0 3.874425146932481e-06
mutations O 0 2.8835736429755343e-06
, O 0 1.8627657638603523e-08
deletions O 0 4.588703461649857e-07
, O 0 1.8725978989664327e-08
insertions O 0 4.918468903269968e-07
, O 0 1.388044346128936e-08
a O 0 9.610708673335466e-08
deletion O 0 3.305153950350359e-05
/ O 0 4.18221861764323e-06
insertion O 0 3.969381396018434e-06
and O 0 9.871982911136001e-07
splice O 0 0.000552136218175292
site O 0 0.00010382370237493888
mutations O 0 7.895834278315306e-05
. O 0 3.1423276141140377e-06

These O 0 2.538830813136883e-06
mutations O 0 2.6294523195247166e-05
were O 0 3.064190252644039e-07
scattered O 0 2.0944642642461986e-07
over O 0 4.0545707236105955e-08
the O 0 6.018979092914378e-08
entire O 0 1.0449353027297548e-07
length O 0 1.4848411638013204e-06
of O 0 1.732084697891878e-08
PTEN O 0 9.288568253396079e-05
, O 0 4.98725469810779e-08
with O 0 6.4213225847709055e-09
the O 0 2.497824880265398e-08
exception O 0 3.387520308706371e-08
of O 0 4.304080203354488e-09
the O 0 3.220855404606482e-08
first O 0 1.0886212749028346e-06
, O 0 1.389594501688407e-07
fourth O 0 1.3764275536232162e-05
and O 0 6.446506972679344e-07
last O 0 1.847690214162867e-06
exons O 0 6.908643990755081e-05
. O 0 2.3135642095439835e-06

A O 0 2.9503164114430547e-05
hot O 0 4.478297705645673e-05
spot O 0 2.814364415826276e-05
for O 0 2.6302933520128136e-07
PTEN O 0 0.0005611491505987942
mutation O 0 6.519885573652573e-06
in O 0 7.772309373876851e-08
CD B-Disease 0 0.00014984840527176857
was O 0 6.540928734466434e-05
identified O 0 4.764984566918429e-07
in O 0 1.6059148677527446e-08
exon O 0 1.9270005395810585e-06
5 O 0 5.433267915577744e-07
that O 0 5.30336663473463e-09
contains O 0 6.282894204900913e-09
the O 0 1.3219271011166711e-08
PTPase O 0 3.5164875953341834e-06
core O 0 6.38314020307007e-07
motif O 0 6.547336965923023e-07
, O 0 4.597689340357647e-09
with O 0 3.12671621927052e-09
13 O 0 2.3306368390763055e-08
of O 0 2.5160891148345854e-09
30 O 0 9.527046529456129e-08
( O 0 1.346172950889013e-08
43 O 0 2.553730666932097e-07
% O 0 2.48532607827201e-08
) O 0 8.588058264535903e-09
CD B-Disease 0 1.290008640353335e-05
mutations O 0 3.406158612051513e-06
identified O 0 1.2826902207052626e-07
in O 0 1.4016552363216306e-08
this O 0 3.056263153666805e-08
exon O 0 1.6021987903513946e-05
. O 0 3.037367378055933e-06

Seven O 0 7.794837983965408e-06
of O 0 6.136873764717166e-08
30 O 0 2.7158071702615416e-07
( O 0 2.7911685407389086e-08
23 O 0 3.981047314027819e-07
% O 0 3.269230930413869e-08
) O 0 4.622838556400666e-09
were O 0 1.0779734793686657e-07
within O 0 4.95949636913906e-09
the O 0 9.178491744421535e-09
core O 0 9.513787517789751e-07
motif O 0 1.790895794329117e-06
, O 0 1.6393698842875892e-08
the O 0 1.3251306718586875e-08
majority O 0 5.774788647272544e-08
( O 0 6.608724678613953e-09
five O 0 7.887687836216628e-09
of O 0 6.015304254702869e-09
seven O 0 9.224740438185108e-08
) O 0 2.9843076898572463e-09
of O 0 1.5616854476263597e-09
which O 0 2.1329873334252625e-07
were O 0 1.093459559342591e-06
missense O 0 6.336271326290444e-05
mutations O 0 1.8644135479917168e-06
, O 0 1.1380801190341572e-08
possibly O 0 4.9800686241496805e-08
pointing O 0 1.5204574310700991e-06
to O 0 2.1558937746135598e-08
the O 0 1.4553629412716873e-08
functional O 0 5.012517334535005e-08
significance O 0 2.9037238391538267e-08
of O 0 7.844088933950388e-09
this O 0 2.953075828315832e-08
region O 0 1.2531038464658195e-06
. O 0 9.372276394969958e-07

Germline O 1 0.8233362436294556
PTEN O 1 0.8430644869804382
mutations O 0 0.06197534129023552
were O 0 7.384484433714533e-06
identified O 0 1.3883259271096904e-06
in O 0 2.5343545928535605e-08
four O 0 3.8793395162883826e-08
of O 0 1.4307842022276418e-08
seven O 0 1.0786444590848987e-06
( O 0 1.3584640612407384e-07
57 O 0 3.761753532671719e-06
% O 0 1.1536327093608634e-07
) O 0 6.002699137752643e-08
BZS B-Disease 0 1.3865191249351483e-05
families O 0 3.012348770425888e-07
studied O 0 7.583636261188076e-07
. O 0 8.72740486101975e-07

Interestingly O 0 0.000662446313071996
, O 0 2.441167225697427e-06
none O 0 3.1839874736760976e-07
of O 0 8.672899731720918e-09
these O 0 3.3993455161862585e-08
mutations O 0 1.0495155038370285e-05
was O 0 1.1109174010925926e-05
observed O 0 4.246322475864872e-07
in O 0 3.208543120081231e-08
the O 0 9.275606061009967e-08
PTPase O 0 2.967022555822041e-05
core O 0 5.198578946874477e-06
motif O 0 1.2520009477157146e-05
. O 0 1.3216229035606375e-06

It O 0 7.944286153360736e-06
is O 0 1.91960907613975e-07
also O 0 1.5832239341762033e-07
worthy O 0 4.9853529304755284e-08
of O 0 9.946790946457895e-09
note O 0 3.188146990851237e-07
that O 0 8.33749691508956e-09
a O 0 1.3494486950094142e-07
single O 0 2.899528908528737e-06
nonsense O 0 2.920910446846392e-06
point O 0 7.070938181641395e-07
mutation O 0 5.566337790696707e-07
, O 0 1.4418409577388047e-08
R233X O 0 4.720415347492235e-07
, O 0 2.7699705640316097e-08
was O 0 8.653171903461043e-07
observed O 0 3.988544605704192e-08
in O 0 3.701343898043774e-09
the O 0 2.1364295221815155e-08
germline O 0 8.872968919604318e-07
DNA O 0 1.4095699896188307e-07
from O 0 4.4423922318515e-09
two O 0 9.856385041473459e-09
unrelated O 0 3.225555929020629e-07
CD B-Disease 0 7.935908070066944e-05
families O 0 3.551100462573231e-07
and O 0 6.789039730392687e-08
one O 0 1.1705242286552675e-07
BZS B-Disease 0 3.810005000559613e-05
family O 0 1.68692963598005e-06
. O 0 7.767550300741277e-07

Genotype O 1 0.6928699016571045
- O 0 0.2249847799539566
phenotype O 0 0.0008437639917246997
studies O 0 7.805763289070455e-07
were O 0 1.4205010074874735e-06
not O 0 5.567389749217e-08
performed O 0 1.5048259456307278e-06
on O 0 6.010455990690389e-07
this O 0 1.2619715938910758e-08
small O 0 3.095145473253069e-08
group O 0 1.3112237695622753e-07
of O 0 1.689307005392493e-08
BZS B-Disease 0 5.4494303185492754e-05
families O 0 6.386117661349999e-07
. O 0 5.783307983620034e-07

However O 0 1.468286518502282e-05
, O 0 1.0178573575103655e-06
genotype O 0 0.00029097116203047335
- O 0 0.0008203848847188056
phenotype O 0 7.151837780838832e-05
analysis O 0 1.7109496752709674e-07
inthe O 0 1.054491713148309e-05
group O 0 2.9913761068200984e-07
of O 0 8.671923623637667e-09
CD B-Disease 0 5.1848721341229975e-05
families O 0 4.3832505980390124e-07
revealed O 0 9.599219765732414e-07
two O 0 1.0863323574028527e-08
possible O 0 2.45744917748425e-08
associations O 0 3.992538299968373e-09
worthy O 0 1.3213423244451405e-08
of O 0 2.0149322210727405e-09
follow O 0 5.9266586305284363e-08
- O 0 5.320549462339841e-06
up O 0 4.360494472166465e-07
in O 0 6.730786594744131e-08
independent O 0 3.171928142364777e-07
analyses O 0 1.0806636510096723e-06
. O 0 5.800320650450885e-07

The O 0 1.8161357502322062e-06
first O 0 1.7266623899558908e-06
was O 0 3.3348223951179534e-06
an O 0 3.47293003244431e-08
association O 0 4.095594263731073e-08
noted O 0 6.887827908030886e-08
in O 0 2.0707418002530176e-08
the O 0 3.986201946304391e-08
group O 0 1.6046739403918764e-07
of O 0 3.5140272913736226e-09
CD B-Disease 0 2.4993005354190245e-05
families O 0 4.440907730440813e-07
with O 0 2.3862580746936146e-06
breast B-Disease 1 0.9998759031295776
disease I-Disease 0 0.0020708602387458086
. O 0 1.563873297527607e-06

A O 0 2.290233169333078e-05
correlation O 0 3.1122657674131915e-05
was O 0 1.788517511158716e-05
observed O 0 3.750981534267339e-07
between O 0 2.2782113973107698e-08
the O 0 1.9894804026421298e-08
presence O 0 3.6602554587261693e-07
/ O 0 7.494651072192937e-06
absence O 0 6.066522217906822e-08
of O 0 7.2700827580263194e-09
a O 0 1.454782363907725e-06
PTEN O 0 0.0019745484460145235
mutation O 0 2.9268774142110487e-06
and O 0 2.0019927049474973e-08
the O 0 1.0155924989874165e-08
type O 0 2.2062054938487563e-07
of O 0 1.4894560251832445e-07
breast O 0 0.021166160702705383
involvement O 0 6.8041167651244905e-06
( O 0 2.87311024749215e-07
unaffected O 0 7.649760846106801e-06
versus O 0 5.9225309087196365e-05
benign O 0 0.02200171910226345
versus O 0 0.008571615442633629
malignant O 1 0.6165682077407837
) O 0 9.748265483722207e-07
. O 0 2.0963236693205545e-06

Specifically O 0 6.978409146540798e-06
and O 0 2.682626529804111e-07
more O 0 8.939523787887538e-09
directly O 0 1.4861636365992581e-08
, O 0 7.117075817575369e-09
an O 0 1.038705210731905e-08
association O 0 7.926661993451489e-08
was O 0 0.00022042469936423004
also O 0 1.3347861340662348e-06
observed O 0 1.9243563542659103e-07
between O 0 1.0253672577675843e-08
the O 0 8.077619462198982e-09
presence O 0 1.3389262143448377e-08
of O 0 7.249755018534643e-09
a O 0 1.5593280977554969e-06
PTEN O 0 0.16251209378242493
mutation O 0 0.0001156925136456266
and O 0 0.00011088564497185871
malignant B-Disease 1 0.9999977350234985
breast I-Disease 1 0.9999951124191284
disease I-Disease 0 0.03896697238087654
. O 0 1.9090709884039825e-06

Secondly O 0 0.0009851487120613456
, O 0 1.7192140830957214e-06
there O 0 9.394722866318261e-08
appeared O 0 3.755974830710329e-06
to O 0 3.2026857610389925e-08
be O 0 2.6333470515282897e-08
an O 0 1.3512535090853817e-08
interdependent O 0 6.656015102635138e-06
association O 0 2.9234852760851027e-08
between O 0 1.2612129296485364e-07
mutations O 0 3.2243547138932627e-06
upstream O 0 2.2186264914125786e-07
and O 0 1.3958951328163494e-08
within O 0 5.038394590428652e-09
the O 0 1.3704817725113116e-08
PTPase O 0 5.060494913777802e-06
core O 0 9.24005803426553e-07
motif O 0 1.776804651854036e-06
, O 0 9.070987516679452e-09
the O 0 6.2821632340615e-09
core O 0 2.3834871853978257e-07
motif O 0 2.2409547284496512e-07
containing O 0 2.0585222415547832e-08
the O 0 9.436761594372456e-09
majority O 0 1.5153512222809695e-08
of O 0 1.3171400858880133e-08
missense O 0 9.366110316477716e-05
mutations O 0 6.629067229368957e-06
, O 0 4.845167111966475e-08
and O 0 3.9764518788842906e-08
the O 0 9.775654064014816e-09
involvement O 0 3.7528341323422865e-08
of O 0 2.159633805121075e-09
all O 0 2.1694928076243514e-09
major O 0 6.093856086408778e-08
organ O 0 1.1402568816265557e-05
systems O 0 2.8003355510008987e-06
( O 0 4.186198054867418e-08
central O 0 7.71703341229113e-08
nervous O 0 1.5413671690112096e-06
system O 0 4.384538385693304e-07
, O 0 4.365916197457409e-07
thyroid O 0 0.0010214541107416153
, O 0 4.905900254925655e-07
breast O 0 0.10759284347295761
, O 0 1.227997290698113e-05
skin O 1 0.9973307847976685
and O 0 0.008958950638771057
gastrointestinal O 1 0.9981702566146851
tract O 0 0.20593324303627014
) O 0 1.75044931438606e-06
. O 0 2.1089247184136184e-06

However O 0 7.420147994707804e-06
, O 0 5.805268443737077e-08
these O 0 2.6576820744139695e-09
observations O 0 2.982681479579696e-08
would O 0 2.2661330589812678e-08
need O 0 9.529878219893817e-09
to O 0 2.707187896078267e-08
be O 0 5.3372421149333604e-08
confirmed O 0 2.633757105741097e-07
by O 0 1.2539594917981844e-09
studying O 0 1.947519701062106e-09
a O 0 3.685486582583053e-09
larger O 0 1.0891310964211698e-08
number O 0 5.2009085926840726e-09
of O 0 7.216148567579239e-09
CD B-Disease 0 1.9213090126868337e-05
families O 0 7.373756147899257e-07
. O 0 3.121581642062665e-07

Molecular O 0 0.011176892556250095
defects O 1 0.9997885823249817
leading O 0 5.092665105621563e-06
to O 0 6.542630615058442e-08
human O 0 1.5401961661609676e-07
complement B-Disease 0 2.7658645194605924e-05
component I-Disease 1 0.7990139126777649
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.198239160288722e-08
an O 0 3.782174573530028e-08
African O 0 1.437831969042236e-07
- O 0 9.2138161562616e-06
American O 0 1.2762284313794225e-06
family O 0 2.667859689609031e-06
. O 0 1.3393013205131865e-06

Complement B-Disease 0 0.010010087862610817
component I-Disease 1 0.9947052597999573
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.194737463578349e-06
C6D B-Disease 0 0.0040415311232209206
) O 0 1.430574798177986e-06
was O 0 0.008005981333553791
diagnosed O 0 0.002394996117800474
in O 0 4.0475779172766124e-08
a O 0 5.160034675100178e-07
16 O 0 1.4038753306522267e-06
- O 0 9.839867743721697e-06
year O 0 2.281221185285176e-07
- O 0 2.5888205072988058e-06
old O 0 4.006499693787191e-06
African O 0 6.225317150665433e-08
- O 0 1.1415953622417874e-06
American O 0 2.679803685623483e-07
male O 0 3.2262064451060724e-06
with O 0 1.7097250747610815e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999996423721313
. O 0 8.663858352520037e-06

The O 0 1.1429992810008116e-05
patients O 0 1.8738321159617044e-05
father O 0 2.5383515094290487e-06
and O 0 2.752034902187006e-07
two O 0 4.129662158902647e-07
brothers O 0 0.001542462850920856
also O 0 2.1503985863091657e-06
had O 0 1.0253915206703823e-05
C6D B-Disease 0 3.0261486244853586e-05
, O 0 2.8523933437440974e-08
but O 0 9.920284149700365e-09
gave O 0 5.274618786188512e-08
no O 0 1.2108909430708081e-08
history O 0 2.0698927016837843e-08
of O 0 1.2797602266800823e-07
meningitis B-Disease 1 0.9999927282333374
or O 0 5.185183340472577e-07
other O 0 2.4400100073762587e-07
neisserial B-Disease 0 0.0044175186194479465
infection I-Disease 0 0.0002392295718891546
. O 0 1.8237534504805808e-06

By O 0 1.2200248420413118e-06
using O 0 4.831692876905436e-07
exon O 0 7.235981229314348e-06
- O 0 4.338586222729646e-06
specific O 0 1.03058113154475e-07
polymerase O 0 5.218517344474094e-06
chain O 0 1.9705692466231994e-05
reaction O 0 2.768017282051005e-07
( O 0 3.248228352958904e-08
PCR O 0 9.331873798146262e-07
) O 0 2.3063591925165383e-08
/ O 0 3.057254787108832e-07
single O 0 2.340279223744801e-07
- O 0 9.367992788611446e-06
strand O 0 2.5296534658991732e-05
conformation O 0 1.0991020644723903e-06
polymorphism O 0 4.3474562971823616e-07
as O 0 6.250859829748379e-09
a O 0 1.1535662203243646e-08
screening O 0 5.1599560180193293e-08
step O 0 6.047944367537639e-08
and O 0 9.162801184459113e-09
nucleotide O 0 8.049708100088537e-08
sequencing O 0 3.367036072177143e-08
of O 0 2.5661648361818834e-09
target O 0 1.9565479192351631e-07
exons O 0 1.762071406119503e-06
, O 0 1.4885897314798058e-07
we O 0 1.6671725333594622e-08
determined O 0 3.563421202557038e-08
that O 0 8.464626333193337e-09
the O 0 6.477986147501724e-08
proband O 0 1.1360608368704561e-05
was O 0 1.0364343552282662e-06
a O 0 4.271182518778005e-08
compound O 0 4.057809235291643e-07
heterozygote O 0 1.5329818552345387e-06
for O 0 2.3059193665631028e-08
two O 0 5.413540975496289e-07
C6 O 0 0.0013186560245230794
gene O 0 2.1524854673771188e-05
mutations O 0 2.1154504793230444e-05
. O 0 1.0446876785863424e-06

The O 0 1.6940459772740724e-06
first O 0 3.6397182157088537e-07
, O 0 7.823174286158974e-08
1195delC O 0 6.558091740771488e-07
located O 0 4.136377640406863e-08
in O 0 1.2674377103394363e-08
exon O 0 2.278369265695801e-06
7 O 0 3.533520612108987e-06
, O 0 4.6533699560313835e-08
is O 0 6.749283798512806e-09
a O 0 4.839671419176739e-08
novel O 0 2.1573412141151493e-06
mutation O 0 1.6480846625199774e-06
, O 0 3.1540313472078196e-08
while O 0 1.2048710473777646e-08
the O 0 6.223984883035882e-09
second O 0 3.0934754136069387e-07
, O 0 2.010905753024872e-08
1936delG O 0 1.4022091932019976e-07
in O 0 7.015361180862101e-09
exon O 0 5.339971380635689e-07
12 O 0 4.4002885601912567e-07
, O 0 3.049456154258223e-08
has O 0 2.5755645083336276e-07
been O 0 1.8291551384663762e-07
described O 0 3.762449409805413e-07
before O 0 1.3955862243619777e-08
to O 0 2.308344093648884e-08
cause O 0 2.808648389418522e-07
C6D B-Disease 0 1.0197918527410366e-05
in O 0 8.15152301214539e-09
an O 0 7.250723133012116e-09
unrelated O 0 3.2262263971460925e-07
African O 0 1.7646549110850174e-07
- O 0 7.498111244785832e-06
American O 0 3.74984381323884e-07
individual O 0 1.3936397635916364e-07
. O 0 4.0481310747964017e-07

Both O 0 3.8631216739304364e-05
mutations O 0 0.00021833341452293098
result O 0 9.27470921396889e-07
in O 0 4.878992854173703e-07
premature O 0 4.986414569430053e-05
termination O 0 2.827023490681313e-05
codons O 0 7.008571992628276e-05
and O 0 7.5951470535073895e-06
C6 O 0 0.008040026761591434
null O 0 0.00019138255447614938
alleles O 0 9.612020221538842e-05
. O 0 7.958989954204299e-06

Allele O 0 0.0002915423538070172
- O 0 1.4666911738459021e-05
specific O 0 2.0788391452697397e-07
PCR O 0 1.068787241820246e-05
indicated O 0 6.617707981604326e-07
that O 0 7.740069918327208e-09
the O 0 1.5265285924215277e-08
probands O 0 2.0140101696597412e-05
two O 0 6.719985776726389e-07
brothers O 0 0.0008839992224238813
also O 0 2.004263706112397e-06
inherited O 0 1.8091416222887347e-06
the O 0 4.352724758405202e-08
1195delC O 0 2.6880684345087502e-06
mutation O 0 2.606021496376343e-07
from O 0 4.482215931744804e-09
their O 0 2.807689014616699e-08
heterozygous O 0 1.9194733340555103e-06
mother O 0 1.6958886135398643e-06
and O 0 3.004940296591485e-08
the O 0 2.3787904979144514e-08
1936delG O 0 2.573045776443905e-06
mutation O 0 3.1486339935327123e-07
from O 0 1.0687379869978031e-08
their O 0 3.573106255316816e-08
homozygous O 0 2.065581975330133e-05
father O 0 2.667653461685404e-06
. O 0 1.9231583792134188e-07
. O 0 4.545570106984087e-07

PAX6 O 0 0.11549822241067886
mutations O 0 0.009171386249363422
reviewed O 0 0.00025971332797780633
. O 0 2.3656346456846222e-05

Mutations O 0 0.054494742304086685
in O 0 2.823633622028865e-06
PAX6 O 0 9.229264105670154e-05
are O 0 8.427015529832715e-08
responsible O 0 9.147246515794905e-08
for O 0 1.3130764919822013e-08
human O 0 4.1788666749198455e-07
aniridia B-Disease 1 1.0
and O 0 0.0001109573568101041
have O 0 2.2141800855024485e-06
also O 0 1.8067036080537946e-06
been O 0 2.4018831368266547e-07
found O 0 5.836655603275176e-08
in O 0 1.2115197023376822e-07
patients O 0 4.5883706434324267e-07
with O 0 1.3829290992362075e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.2895031431980897e-05
with O 0 0.03351040557026863
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999972581863403
, O 0 1.314161181653617e-06
with O 0 2.6772363526106346e-06
autosomal B-Disease 1 0.9765715599060059
dominant I-Disease 0 0.07134445011615753
keratitis I-Disease 1 0.9609447717666626
, O 0 1.6396112414440722e-06
and O 0 5.919869181525428e-07
with O 0 4.022000211989507e-06
isolated B-Disease 1 0.9715486764907837
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 1.855153459473513e-05

No O 0 2.1031819414929487e-05
locus O 0 1.7631016817176715e-05
other O 0 9.961413383052786e-08
than O 0 7.00663136399271e-08
chromosome O 0 9.212917211698368e-05
11p13 O 0 1.2700490515271667e-05
has O 0 8.01051157850452e-07
been O 0 3.705308984081057e-07
implicated O 0 7.58728958771826e-07
in O 0 4.353401834578108e-07
aniridia B-Disease 1 0.9999997615814209
, O 0 5.596443770627957e-07
and O 0 4.999293423679774e-07
PAX6 O 0 2.1408164684544317e-05
is O 0 1.890167453666436e-07
clearly O 0 8.965242415115426e-08
the O 0 5.209248143955847e-09
major O 0 2.0260358724044636e-08
, O 0 2.5337891784715794e-08
if O 0 5.2904951530763356e-09
not O 0 4.3398897808799575e-09
only O 0 3.582829366521878e-09
, O 0 1.4561320149653056e-08
gene O 0 5.195830681259395e-07
responsible O 0 1.0178370075664134e-06
. O 0 1.2991356470593018e-06

Twenty O 0 0.00010786703205667436
- O 0 7.303115853574127e-05
eight O 0 1.1277684279775713e-06
percent O 0 3.3903523899425636e-07
of O 0 2.0425805047352696e-08
identified O 0 2.308411467311089e-06
PAX6 O 0 9.029020293382928e-05
mutations O 0 5.394336312747328e-06
are O 0 4.0051407523833404e-08
C O 0 5.392340426624287e-06
- O 0 4.298599742469378e-05
T O 0 2.528006189095322e-05
changes O 0 2.3058490228322626e-08
at O 0 2.5907265666091917e-08
CpG O 0 7.972138860168343e-07
dinucleotides O 0 7.865573934395798e-07
, O 0 1.4006556803281e-08
20 O 0 2.3821639771881564e-08
% O 0 5.123734769796329e-09
are O 0 7.036276006289199e-10
splicing O 0 2.8488301495599444e-07
errors O 0 2.857642812159611e-06
, O 0 1.605075716781812e-08
and O 0 1.05368895830793e-08
more O 0 6.313607969765656e-10
than O 0 4.7330432906278475e-09
30 O 0 5.035255767893432e-08
% O 0 9.755704688529931e-09
are O 0 1.6946407610518577e-09
deletion O 0 9.676214176579379e-07
or O 0 1.0460061616868188e-07
insertion O 0 2.4396058506681584e-06
events O 0 1.0001333521358902e-06
. O 0 1.1812601314886706e-06

There O 0 4.63541482531582e-06
is O 0 1.2691123174590757e-07
a O 0 1.7497704618563148e-07
noticeably O 0 0.00011305550287943333
elevated O 0 4.6130691771395504e-05
level O 0 1.501266808645596e-07
of O 0 1.1979118141880463e-08
mutation O 0 6.685621087854088e-07
in O 0 1.1601970051344779e-08
the O 0 2.49597693624537e-08
paired O 0 1.2448329016478965e-06
domain O 0 1.5556118171389244e-07
compared O 0 4.822537107429525e-07
with O 0 1.8388284672710142e-08
the O 0 9.797011557566293e-08
rest O 0 4.890970117799043e-08
of O 0 4.0111856058899775e-09
the O 0 4.963445121575205e-08
gene O 0 2.1040730189270107e-06
. O 0 1.0487424333405215e-06

Increased O 0 0.00012471234367694706
mutation O 0 2.5204160920111462e-05
in O 0 1.1791919263259842e-07
the O 0 4.6429175171169845e-08
homeodomain O 0 5.109974608785706e-06
is O 0 9.100330089495401e-08
accounted O 0 7.453230921328213e-08
for O 0 1.8747519092698894e-09
by O 0 6.023927134890528e-09
the O 0 1.2178446695543244e-07
hypermutable O 0 4.836727021029219e-05
CpG O 0 1.4437390746024903e-05
dinucleotide O 0 3.426286184549099e-06
in O 0 4.6333450853808245e-08
codon O 0 2.6297541353415e-06
240 O 0 1.1567641422516317e-06
. O 0 4.8852501777219e-07

Very O 0 1.0280529750161804e-05
nearly O 0 1.3257989621706656e-06
all O 0 3.7563790300509936e-08
mutations O 0 2.3742315988783957e-06
appear O 0 4.706678282673238e-07
to O 0 1.4480633581115399e-07
cause O 0 9.892085472529288e-06
loss O 0 1.4556760561390547e-06
of O 0 1.018490625170898e-08
function O 0 1.9292858866037932e-08
of O 0 2.689481970463703e-09
the O 0 2.772016038932179e-08
mutant O 0 8.065372639975976e-06
allele O 0 1.348282239632681e-06
, O 0 9.23371512584481e-09
and O 0 4.321304647447732e-09
more O 0 8.432940457048232e-10
than O 0 2.2082560224845338e-09
80 O 0 1.2874436627896557e-08
% O 0 3.414549532010369e-09
of O 0 2.6911803896467745e-09
exonic O 0 5.175271326152142e-06
substitutions O 0 6.620750241381756e-07
result O 0 1.2811121052891394e-07
in O 0 1.0346720102916152e-07
nonsense O 0 1.0160777492274065e-05
codons O 0 1.3213923921284731e-05
. O 0 1.9033319631489576e-06

In O 0 1.0542879635977442e-06
a O 0 2.2177465552886133e-07
gene O 0 2.43400222643686e-07
with O 0 1.770547441992676e-08
such O 0 1.4593517505545606e-08
extraordinarily O 0 5.003632850275608e-06
high O 0 8.264327675533423e-07
sequence O 0 1.4075737908569863e-07
conservation O 0 1.4629692124401572e-08
throughout O 0 6.360023174778462e-09
evolution O 0 1.756387035811713e-08
, O 0 6.769809157702866e-09
there O 0 8.55193338367144e-09
are O 0 1.194462040388089e-08
presumed O 0 1.4600204849557485e-05
undiscovered O 0 2.155560468963813e-05
missense O 0 0.0001677974796621129
mutations O 0 7.234877557493746e-06
, O 0 1.2947871219637364e-08
these O 0 2.316462577311995e-09
are O 0 2.5580966234173275e-09
hypothesized O 0 2.784156265533966e-07
to O 0 3.607365428592857e-08
exist O 0 3.470003662187082e-08
in O 0 1.581922504101385e-08
as O 0 1.7201951152401307e-07
- O 0 1.728113966237288e-05
yet O 0 5.411022243606567e-07
unidentified O 0 6.934372777323006e-06
phenotypes O 0 1.891937426989898e-05
. O 0 1.9933554540330078e-07
. O 0 1.022790797833295e-06

Genetic O 0 0.0010703083826228976
heterogeneity O 0 0.0006994244758971035
and O 0 7.0039582169556525e-06
penetrance O 0 4.4342592445900664e-05
analysis O 0 1.335132111535131e-07
of O 0 1.0666933114578114e-08
the O 0 1.3670988607827894e-07
BRCA1 O 0 0.00017713656416162848
and O 0 3.976007974415552e-06
BRCA2 O 0 0.00016032611893024296
genes O 0 4.622599135473138e-06
in O 0 5.64643642064766e-06
breast B-Disease 1 0.9998611211776733
cancer I-Disease 0 0.014424547553062439
families O 0 3.5544180718716234e-06
. O 0 1.3969945484859636e-06

The O 0 0.012028445489704609
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0029221863951534033
Consortium O 0 5.667828372679651e-05
. O 0 3.71298165191547e-06

The O 0 1.5750330248920363e-06
contribution O 0 2.1210861689269223e-07
of O 0 8.407909746210862e-08
BRCA1 O 0 0.00010478580952621996
and O 0 3.0804033031017752e-06
BRCA2 O 0 0.008404755033552647
to O 0 0.00022087153047323227
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.10965842008590698
assessed O 0 1.5391020724564441e-06
by O 0 2.897991713268766e-08
linkage O 0 1.7482307157479227e-05
and O 0 1.0115135182786616e-06
mutation O 0 4.6321258651005337e-07
analysis O 0 1.21695720167736e-08
in O 0 8.163301146169033e-09
237 O 0 1.728084271235275e-07
families O 0 4.8052701373535456e-08
, O 0 5.801767954949355e-09
each O 0 1.2719317821208165e-09
with O 0 6.426603693654442e-09
at O 0 7.481031616407563e-08
least O 0 5.026990823608912e-09
four O 0 7.676073110474135e-09
cases O 0 1.7620308767618553e-08
of O 0 1.3455805003559362e-07
breast B-Disease 1 0.9951996803283691
cancer I-Disease 0 0.00048128922935575247
, O 0 2.0917688914323662e-08
collected O 0 2.7151926929036563e-08
by O 0 3.0962080899143984e-08
the O 0 0.00022698273824062198
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.00012832398351747543
Consortium O 0 6.879509328427957e-06
. O 0 1.953788114406052e-06

Families O 0 0.00022641602845396847
were O 0 3.0508547297358746e-06
included O 0 1.7928131512690015e-07
without O 0 2.6131484531788374e-08
regard O 0 2.0780099418971076e-08
to O 0 8.414852814553342e-09
the O 0 2.5284544236114925e-08
occurrence O 0 8.362694075003674e-07
of O 0 4.846978072237107e-07
ovarian B-Disease 1 0.8311125636100769
or I-Disease 0 2.2656872715742793e-06
other I-Disease 0 6.121337037257035e-07
cancers I-Disease 0 0.2591962218284607
. O 0 3.462193944869796e-06

Overall O 0 0.17454327642917633
, O 0 6.43210150883533e-05
disease O 0 0.0002127477346220985
was O 0 7.505337180191418e-06
linked O 0 2.2977021671977127e-06
to O 0 5.981806339150353e-08
BRCA1 O 0 8.192617315216921e-06
in O 0 2.349588434924499e-08
an O 0 7.396382173396887e-09
estimated O 0 1.7760800119503983e-07
52 O 0 8.311982355735381e-07
% O 0 5.7976969891626595e-09
of O 0 7.886329922435209e-10
families O 0 1.4271130055476533e-08
, O 0 3.5065015335788985e-09
to O 0 9.698450043060802e-09
BRCA2 O 0 3.7383003927971004e-06
in O 0 5.8792362978010715e-08
32 O 0 3.77815894125888e-07
% O 0 5.040720729709847e-09
of O 0 1.191812537548742e-09
families O 0 5.581519957331693e-08
, O 0 1.1070064864782125e-08
and O 0 1.0356211888051803e-08
to O 0 7.956392877872531e-09
neither O 0 1.2331989651670483e-08
gene O 0 2.1305776698454792e-08
in O 0 1.2890457590231108e-08
16 O 0 1.8256348255363264e-07
% O 0 1.566133711605744e-08
( O 0 5.044366258033506e-09
95 O 0 7.172077687300771e-08
% O 0 5.699655503121903e-08
confidence O 0 2.0667434341703483e-07
interval O 0 7.468811986655055e-07
[ O 0 1.8324114137158176e-07
CI O 0 6.917344762769062e-06
] O 0 3.6607858078241406e-07
6 O 0 9.513281895578984e-08
% O 0 3.345047971947679e-08
- O 0 3.4241954836033983e-06
28 O 0 3.2851439755177125e-06
% O 0 2.841148116772274e-08
) O 0 4.716083967792883e-09
, O 0 8.586666488952233e-09
suggesting O 0 1.7538069130296208e-07
other O 0 3.45989192851448e-08
predisposition O 0 5.026738654123619e-05
genes O 0 4.781135430675931e-06
. O 0 1.6430313962700893e-06

The O 0 4.494186669035116e-06
majority O 0 1.1001592383763636e-06
( O 0 1.1102230246251565e-07
81 O 0 6.175257567520021e-07
% O 0 6.966866550328632e-08
) O 0 4.315926283027238e-09
of O 0 5.02447949912721e-09
the O 0 1.0209702850261237e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.6127864910231438e-06
were O 0 2.95971972263942e-07
due O 0 4.153034538489919e-08
to O 0 6.785349881965885e-08
BRCA1 O 0 2.0907591533614323e-05
, O 0 4.44289405265863e-08
with O 0 1.1231788832333223e-08
most O 0 3.180405983016499e-08
others O 0 2.2207476035873697e-07
( O 0 3.3015275846537406e-08
14 O 0 5.230792226029735e-07
% O 0 3.19832729189784e-08
) O 0 6.248725981095049e-09
due O 0 3.6497002753321794e-08
to O 0 4.576575634018809e-07
BRCA2 O 0 0.0004287390038371086
. O 0 2.0133638827246614e-06

Conversely O 0 0.0003114012652076781
, O 0 6.71262625928648e-07
the O 0 6.200455260341187e-08
majority O 0 5.713446071808903e-08
of O 0 5.1413757695684126e-09
families O 0 1.3632775619498716e-07
with O 0 5.5315496183538926e-08
male B-Disease 0 1.0312224731023889e-05
and I-Disease 0 1.8563480352895567e-06
female I-Disease 0 0.0003555155417416245
breast I-Disease 1 0.9679733514785767
cancer I-Disease 0 0.00011145458847749978
were O 0 5.406843683886109e-07
due O 0 6.67443487145647e-08
to O 0 5.119503043715667e-07
BRCA2 O 0 0.0025483949575573206
( O 0 2.2148677203404077e-07
76 O 0 1.7030312164934003e-06
% O 0 1.6918293965773046e-07
) O 0 8.02747592842934e-08
. O 0 4.46290442823738e-07

The O 0 1.7523885844639153e-06
largest O 0 9.059576200343145e-07
proportion O 0 3.4131261372749577e-07
( O 0 9.224388719530907e-08
67 O 0 2.0926563593093306e-06
% O 0 5.092783439408777e-08
) O 0 2.8770508198050493e-09
of O 0 3.5699641021125217e-09
families O 0 1.631116361977547e-07
due O 0 2.5456280638991302e-08
to O 0 1.1670016064613264e-08
other O 0 1.0783534953873186e-08
genes O 0 3.23748849950789e-07
was O 0 6.438791024265811e-05
found O 0 8.653900351873745e-08
in O 0 3.8289915238465255e-08
families O 0 3.5170664602901525e-08
with O 0 5.867336394516087e-09
four O 0 9.796432465236649e-08
or O 0 3.908080614678511e-08
five O 0 2.4189255043438607e-08
cases O 0 1.9830325825864747e-08
of O 0 4.122366092929042e-08
female O 0 0.0033745975233614445
breast B-Disease 1 0.9857062697410583
cancer I-Disease 0 0.0001584516285220161
only O 0 1.9944030782426125e-07
. O 0 6.227757580745674e-07

These O 0 1.8466527080818196e-06
estimates O 0 8.829498256091028e-06
were O 0 8.964675544120837e-07
not O 0 2.4179660940149006e-08
substantially O 0 1.852732907536847e-06
affected O 0 6.749427683416798e-08
either O 0 1.0110310810773626e-08
by O 0 2.9379951804742177e-09
changing O 0 6.25017051447685e-08
the O 0 2.9021402170315014e-08
assumed O 0 5.056757572674542e-07
penetrance O 0 9.003591117107135e-07
model O 0 1.1153594670076927e-07
for O 0 2.009080901643756e-08
BRCA1 O 0 9.62476224231068e-06
or O 0 6.07379249117912e-08
by O 0 5.5618145644587e-09
including O 0 1.6574988492834564e-08
or O 0 3.951479641273181e-07
excluding O 0 3.7650734157068655e-06
BRCA1 O 0 0.00045361401862464845
mutation O 0 5.551511549128918e-06
data O 0 1.1329599374221289e-06
. O 0 1.1999617299807142e-06

Among O 0 9.373954526381567e-06
those O 0 3.120617577678786e-07
families O 0 3.5128971376252593e-07
with O 0 8.73573981152731e-07
disease O 0 5.595627590082586e-05
due O 0 1.6419053849858756e-07
to O 0 1.3913317786773405e-07
BRCA1 O 0 5.7452645705780014e-05
that O 0 1.018496277538361e-06
were O 0 2.7664582376019098e-05
tested O 0 1.4952528317735414e-06
by O 0 4.8885424597244764e-09
one O 0 3.2237177371996495e-09
of O 0 9.191222782867214e-10
the O 0 6.820940701146583e-09
standard O 0 1.1231215069074096e-07
screening O 0 2.6197657376769712e-08
methods O 0 2.8753406766668377e-08
, O 0 2.9170911020059975e-08
mutations O 0 4.6658391283926903e-07
were O 0 7.544309710283414e-08
detected O 0 1.5100458483630064e-07
in O 0 4.27590762797081e-09
the O 0 1.1221960249940821e-08
coding O 0 9.602973705113982e-07
sequence O 0 1.3637716733683192e-07
or O 0 1.3727945891162108e-08
splice O 0 1.689061036813655e-06
sites O 0 5.537028258117971e-08
in O 0 4.059025560110285e-09
an O 0 7.278268654431486e-09
estimated O 0 1.039429093907529e-07
63 O 0 3.138090960419504e-07
% O 0 1.2919107561515375e-08
( O 0 5.6242850376975184e-09
95 O 0 4.234961892279898e-08
% O 0 3.562863781780834e-08
CI O 0 1.1546806490514427e-05
51 O 0 2.1487646790774306e-06
% O 0 1.1539782462932635e-07
- O 0 6.9320185502874665e-06
77 O 0 1.0870350024561048e-06
% O 0 8.948192231628127e-08
) O 0 8.14409801819238e-08
. O 0 5.937027367508563e-07

The O 0 5.184380370337749e-06
estimated O 0 2.2502370029542362e-06
sensitivity O 0 3.56172381543729e-06
was O 0 7.482488854293479e-06
identical O 0 2.740644333698583e-07
for O 0 5.013776949169824e-09
direct O 0 2.3299879359228726e-08
sequencing O 0 1.9219335456455156e-07
and O 0 5.154044302457805e-08
other O 0 1.0242706238727806e-08
techniques O 0 1.383287894896057e-06
. O 0 1.280649371437903e-06

The O 0 4.272822479833849e-06
penetrance O 0 0.00011766231909859926
of O 0 6.413724236153939e-07
BRCA2 O 0 0.0009987619705498219
was O 0 1.0923392437689472e-05
estimated O 0 1.1221429474517208e-07
by O 0 5.98748872704391e-09
maximizing O 0 1.4199888198618282e-07
the O 0 4.4367293838831756e-08
LOD O 0 0.00022975016327109188
score O 0 1.1994787882940727e-06
in O 0 1.4350223409564933e-07
BRCA2 O 0 0.0001482942170696333
- O 0 0.0003606935206335038
mutation O 0 4.898433417110937e-06
families O 0 6.675682584500464e-08
, O 0 4.937730668785889e-09
over O 0 1.611185673766613e-08
all O 0 1.3881476412791471e-08
possible O 0 2.290494478529581e-07
penetrance O 0 1.6832635083119385e-05
functions O 0 6.431970973608259e-07
. O 0 1.0838198249984998e-06

The O 0 2.090454245262663e-06
estimated O 0 9.53906237555202e-07
cumulative O 0 8.521129757355084e-07
risk O 0 4.64053584892099e-07
of O 0 1.1629224871967381e-07
breast B-Disease 1 0.6429291367530823
cancer I-Disease 0 0.00016377423889935017
reached O 0 1.8446531839799718e-06
28 O 0 1.3817624449075083e-06
% O 0 2.2289540879683045e-08
( O 0 5.476787912073178e-09
95 O 0 2.8801599327721306e-08
% O 0 2.3036861307446088e-08
CI O 0 3.8663797568005975e-06
9 O 0 4.5401159809443925e-07
% O 0 2.123802111952955e-08
- O 0 6.132427756710968e-07
44 O 0 2.784198613881017e-07
% O 0 6.449295764099361e-09
) O 0 9.545044754588616e-10
by O 0 1.2397405324549027e-09
age O 0 2.275926824779617e-08
50 O 0 4.637498385307026e-09
years O 0 2.801829657173016e-09
and O 0 1.4319363472736768e-08
84 O 0 7.821353875669956e-08
% O 0 8.87364492996312e-09
( O 0 3.3753484451892746e-09
95 O 0 3.1749330275943066e-08
% O 0 1.6691643622834818e-08
CI O 0 2.249825001854333e-06
43 O 0 4.629347927220806e-07
% O 0 3.219295052758753e-08
- O 0 3.806680410889385e-07
95 O 0 2.2544375610777934e-07
% O 0 1.4698272821078717e-08
) O 0 2.2263950683054645e-09
by O 0 3.532311776410779e-09
age O 0 8.402667361906424e-08
70 O 0 7.535479085163388e-08
years O 0 1.0439531905603872e-07
. O 0 3.8471543462037516e-07

The O 0 4.0584360249340534e-05
corresponding O 0 0.15658971667289734
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0003695552877616137
were O 0 2.1835894585819915e-06
0 O 0 2.1688872493541567e-06
. O 0 1.5430968005603063e-06

4 O 0 6.363035208778456e-05
% O 0 1.269375161427888e-06
( O 0 6.896280524415488e-08
95 O 0 1.9534734008175292e-07
% O 0 7.519628297814052e-08
CI O 0 9.609729204385076e-06
0 O 0 2.50594268891291e-07
% O 0 3.632788647678353e-08
- O 0 3.402194010959647e-07
1 O 0 1.7369403337852418e-07
% O 0 1.9038727927522814e-08
) O 0 1.5107878281739318e-09
by O 0 1.6651950929258419e-09
age O 0 3.626973210657525e-08
50 O 0 7.996023398959551e-09
years O 0 5.675569791918633e-09
and O 0 4.577182011189507e-08
27 O 0 2.8208515345795604e-07
% O 0 4.820212229361687e-09
( O 0 1.609249955514258e-09
95 O 0 2.024699163882815e-08
% O 0 1.4890463084782368e-08
CI O 0 2.479352133377688e-06
0 O 0 1.1108372888202211e-07
% O 0 1.8483403252389508e-08
- O 0 9.153291102848016e-07
47 O 0 2.73247019322298e-06
% O 0 2.190892800513211e-08
) O 0 1.2519519865250572e-09
by O 0 3.0043023624415355e-09
age O 0 1.0058306543214712e-07
70 O 0 5.4495313150937363e-08
years O 0 1.0806908790073066e-07
. O 0 3.651281303973519e-07

The O 0 3.799788828473538e-06
lifetime O 0 3.9949427446117625e-06
risk O 0 1.7914338741320535e-06
of O 0 3.6306073525338434e-07
breast B-Disease 1 0.9998929500579834
cancer I-Disease 0 0.064129538834095
appears O 0 1.6488895653310465e-06
similar O 0 2.754402395055422e-08
to O 0 1.1493780149862687e-08
the O 0 5.387594015360264e-08
risk O 0 7.396921830604697e-08
in O 0 1.6854288631407144e-08
BRCA1 O 0 1.0450280569784809e-05
carriers O 0 1.1011799472271377e-07
, O 0 1.686274408996269e-08
but O 0 1.7683268183077416e-08
there O 0 2.3807784188534242e-08
was O 0 6.980619673413457e-07
some O 0 1.0657491555932097e-09
suggestion O 0 1.4634073508545953e-08
of O 0 2.1272306138797603e-09
a O 0 1.7926029727277637e-07
lower O 0 4.2597862375259865e-06
risk O 0 2.6656417162485013e-07
in O 0 3.5591419589309226e-08
BRCA2 O 0 8.504401193931699e-06
carriers O 0 1.4188896102496074e-07
< O 0 2.549579107835598e-07
50 O 0 3.5678080934076206e-08
years O 0 1.5738837788603632e-08
of O 0 9.578935866727534e-09
age O 0 3.4624244449332764e-07
. O 0 3.913123407528474e-07

Eye B-Disease 1 0.9998306035995483
movement I-Disease 0 0.00680964021012187
abnormalities I-Disease 1 0.9652917385101318
correlate O 0 3.240486330469139e-05
with O 0 2.3557777240057476e-06
genotype O 0 0.015527383424341679
in O 0 1.893561966426205e-05
autosomal O 1 0.9997372031211853
dominant O 1 0.8882631659507751
cerebellar B-Disease 1 0.9998878240585327
ataxia I-Disease 1 0.9999994039535522
type I-Disease 0 0.1572968065738678
I I-Disease 0 0.004018361680209637
. O 0 5.632711236103205e-06

We O 0 2.3482105461880565e-05
compared O 0 1.0298212146153674e-05
horizontal O 0 0.0018580191535875201
eye O 0 0.10719232261180878
movements O 0 4.148807056481019e-05
( O 0 1.7663724349858967e-07
visually O 0 6.607661475754867e-07
guided O 0 8.963307891463046e-07
saccades O 0 9.350314940093085e-05
, O 0 1.3550015864893794e-07
antisaccades O 0 3.2121122330863727e-06
, O 0 4.618407700718308e-08
and O 0 8.044152366437629e-08
smooth O 0 3.0547209917131113e-06
pursuit O 0 8.447430445812643e-06
) O 0 3.3554449885286886e-08
in O 0 1.475385769111881e-08
control O 0 7.3360411079193e-07
subjects O 0 1.5792127783242904e-07
( O 0 2.356095407662906e-08
n O 0 5.223691005085129e-06
= O 0 1.1203074791410472e-05
14 O 0 3.5853676649821864e-07
) O 0 9.606783812898811e-09
and O 0 7.675959068365046e-08
patients O 0 7.299876614297318e-08
with O 0 7.195724904818235e-09
three O 0 3.040280205368617e-08
forms O 0 7.482957897764209e-08
of O 0 3.825138037427678e-07
autosomal O 0 0.13801561295986176
dominant O 0 0.0002504855510778725
cerebellar B-Disease 0 0.001097089028917253
ataxias I-Disease 0 0.00037780535058118403
type I-Disease 0 1.904028067656327e-05
I I-Disease 0 2.0742752894875593e-05
spinocerebellar B-Disease 0 0.0015360483666881919
ataxias I-Disease 0 5.2352523198351264e-05
1 I-Disease 0 7.390123641926039e-07
and I-Disease 0 2.2289971468580916e-07
2 I-Disease 0 2.6151235488214297e-07
( O 0 4.245823959081463e-08
SCA1 B-Disease 0 4.703789272753056e-06
, O 0 3.972941442498268e-08
n O 0 1.4984847211962915e-06
= O 0 1.6386264860557276e-06
11 O 0 1.0048354681657656e-07
; O 0 2.3241067736989862e-08
SCA2 B-Disease 0 2.1867006125830812e-06
, O 0 1.8316631766879254e-08
n O 0 9.709779078548308e-07
= O 0 1.3731568060393329e-06
10 O 0 3.079217236745535e-08
) O 0 1.5564110000809706e-08
and O 0 3.028141577487986e-07
SCA3 B-Disease 1 0.9999997615814209
/ O 0 6.827328616054729e-05
Machado B-Disease 0 1.159949715656694e-05
- I-Disease 0 0.00012623131624422967
Joseph I-Disease 0 0.001392660429701209
disease I-Disease 0 0.00015346358122769743
( O 0 5.297465008879954e-07
MJD B-Disease 1 0.9999969005584717
) O 0 1.9151420360685734e-07
( O 0 7.449889949384669e-08
n O 0 3.2343054954253603e-06
= O 0 6.80783568896004e-06
16 O 0 5.244173166829569e-07
) O 0 1.8319344974315754e-07
. O 0 6.229836344573414e-07

In O 0 7.391762665065471e-06
SCA1 B-Disease 0 0.00010641181143000722
, O 0 2.9870659545849776e-07
saccade O 0 1.1691151485138107e-05
amplitude O 0 1.4039422921996447e-06
was O 0 2.6409154543216573e-06
significantly O 0 1.457587586628506e-06
increased O 0 4.1637548520156997e-07
, O 0 4.1237740333599504e-08
resulting O 0 2.1121095983289706e-07
in O 0 2.2807881805420038e-07
hypermetria B-Disease 0 0.00012071775563526899
. O 0 1.7541005945531651e-06

The O 0 5.424401479103835e-06
smooth O 0 2.5655659555923194e-05
pursuit O 0 2.6314492060919292e-05
gain O 0 9.983753989217803e-05
was O 0 4.990138768334873e-05
decreased O 0 2.973659684357699e-05
. O 0 1.2422534609868308e-06

In O 0 1.0824649507412687e-05
SCA2 B-Disease 0 0.00016752870578784496
, O 0 6.459085284404864e-07
saccade O 0 3.519753227010369e-05
velocity O 0 1.081632035493385e-05
was O 0 1.611337393114809e-05
markedly O 0 0.0003326892328914255
decreased O 0 7.804357301210985e-05
. O 0 2.287504685227759e-06

The O 0 2.1083574210933875e-06
percentage O 0 4.171554792264942e-06
of O 0 3.345086696526778e-08
errors O 0 2.6639672796591185e-06
in O 0 2.9471911489054037e-07
antisaccades O 0 0.00023236179549712688
was O 0 3.635445318650454e-05
greatly O 0 2.6450138079781027e-07
increased O 0 6.221079615897906e-07
and O 0 1.8326525719203346e-07
was O 0 1.9349631656950805e-06
significantly O 0 3.036348346086015e-07
correlated O 0 1.9012658469819144e-07
with O 0 9.472073259075842e-08
age O 0 1.3429413456833572e-06
at O 0 2.6557636374491267e-06
disease O 0 6.755048525519669e-05
onset O 0 0.00010617190127959475
. O 0 3.1816184673516545e-06

In O 0 2.1946752895019017e-06
addition O 0 1.0266885652754354e-07
, O 0 1.1095430352270341e-08
a O 0 2.0578784898361846e-08
correlation O 0 4.793516836798517e-07
between O 0 2.954130593479931e-07
smooth O 0 1.3922018297307659e-05
pursuit O 0 2.0696890715043992e-05
gain O 0 7.336376438615844e-05
and O 0 1.8792356115682196e-07
the O 0 4.588105451119873e-09
number O 0 7.717853911515249e-09
of O 0 7.082814335035437e-09
trinucleotide O 0 6.105728243710473e-05
repeats O 0 3.4342690923949704e-05
was O 0 1.1571488357731141e-05
found O 0 4.184801127848914e-07
. O 0 6.995507533247292e-07

In O 0 8.158512355294079e-05
SCA3 B-Disease 1 0.9999843835830688
, O 0 3.4881506962847197e-06
gaze B-Disease 0 0.00011179680586792529
- I-Disease 0 0.00014863793330732733
evoked I-Disease 0 0.00011778434418374673
nystagmus I-Disease 0 0.02713465690612793
was O 0 4.273471131455153e-05
often O 0 1.9277747753676522e-07
present O 0 1.9537225171006867e-08
as O 0 4.5175703178301774e-08
was O 0 3.5976406707050046e-06
saccade O 0 3.90822560802917e-06
hypometria O 0 5.576413514063461e-06
and O 0 1.429262823648969e-07
smooth O 0 2.481727278791368e-06
pursuit O 0 1.1383706805645488e-05
gain O 0 8.545106538804248e-06
was O 0 1.5845540474401787e-05
markedly O 0 0.00013352259702514857
decreased O 0 3.53373761754483e-05
. O 0 1.1390179679438006e-06

Three O 0 8.574518687964883e-06
major O 0 6.613423693124787e-07
criteria O 0 2.4672516474311124e-07
, O 0 5.2509989245663746e-08
saccade O 0 2.312139486093656e-06
amplitude O 0 2.0539029321753333e-07
, O 0 1.5379555406980217e-08
saccade O 0 1.328250277765619e-06
velocity O 0 7.344349910454184e-07
, O 0 2.4508956641966506e-08
and O 0 9.844886683652021e-09
presence O 0 1.5172252787465368e-08
of O 0 6.1266023365647015e-09
gaze B-Disease 0 3.514734999043867e-05
- I-Disease 0 2.7214016881771386e-05
evoked I-Disease 0 2.1500238290173e-05
nystagmus I-Disease 0 3.161853601341136e-05
, O 0 1.2159246942644586e-08
permitted O 0 8.947984575513601e-09
the O 0 4.342390003131413e-09
correct O 0 2.1043348397142836e-07
assignment O 0 2.689955280743561e-08
of O 0 2.6735194058602474e-09
90 O 0 3.3376299057863434e-08
% O 0 3.723024111224049e-09
of O 0 4.1969711039868685e-10
the O 0 1.6194457330698242e-08
SCA1 B-Disease 0 1.1758923392335419e-05
, O 0 1.1689308188067571e-08
90 O 0 8.328245648669963e-09
% O 0 1.521458403708209e-09
of O 0 2.4341081927836683e-10
the O 0 9.134933698362602e-09
SCA2 B-Disease 0 1.9715882444870658e-05
, O 0 2.042884617026175e-08
and O 0 2.6634584315843313e-08
93 O 0 6.198965252224298e-08
% O 0 4.998251146304256e-09
of O 0 5.987599860368675e-10
the O 0 7.780436561688475e-08
patients O 0 1.536582630023986e-07
with O 0 6.533215923809621e-08
SCA3 B-Disease 1 1.0
to O 0 6.96832813673609e-08
their O 0 2.7601348762118505e-08
genetically O 0 6.144545636743715e-07
confirmed O 0 4.857084149989532e-06
patient O 0 1.0099307701239013e-06
group O 0 3.9150197039816703e-07
and O 0 8.025669728795037e-08
, O 0 1.6480290909726136e-08
therefore O 0 2.469364623891579e-08
, O 0 1.5492847893483486e-08
may O 0 9.683648016789448e-08
help O 0 2.6780426765071752e-08
orient O 0 1.3857768408342963e-06
diagnoses O 0 2.334594501007814e-05
of O 0 1.5452240376134796e-08
SCA1 B-Disease 0 3.1656491046305746e-05
, O 0 4.888470073183271e-08
SCA2 B-Disease 0 1.0353128345741425e-05
, O 0 3.9509362892431454e-08
and O 0 1.779459068984579e-07
SCA3 B-Disease 1 0.9999939203262329
at O 0 1.69805090877162e-07
early O 0 9.895248354041541e-08
clinical O 0 1.4703073247801512e-07
stages O 0 2.5348677468173264e-07
of O 0 7.603825125102048e-09
the O 0 7.517003837165248e-07
diseases O 0 6.231021689018235e-05
. O 0 1.1154104839761203e-07
. O 0 5.923697585785703e-07

Genetic O 0 0.0002235992142232135
basis O 0 4.484844339458505e-06
and O 0 7.438885063493217e-07
molecular O 0 4.795514996658312e-06
mechanism O 0 1.7684702470432967e-05
for O 0 2.275843871757388e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.00028452309197746217

Ventricular B-Disease 1 0.9995884299278259
fibrillation I-Disease 1 0.9999117851257324
causes O 0 0.00011723684292519465
more O 0 1.0869276678704409e-07
than O 0 1.7146078334917547e-08
300 O 0 3.358941214059996e-08
, O 0 1.2048411157650207e-08
000 O 0 7.832610293689868e-08
sudden O 0 5.879252285012626e-07
deaths O 0 4.806590823136503e-06
each O 0 4.143642229337274e-08
year O 0 5.4363265888923706e-08
in O 0 2.666945775331442e-08
the O 0 3.591103165945242e-07
USA O 0 1.9530205463524908e-05
alone O 0 1.5351369029303896e-06
. O 0 5.11298424044071e-07

In O 0 1.2082998637197306e-06
approximately O 0 2.789317363749433e-07
5 O 0 1.7451193912165763e-07
- O 0 8.209597581299022e-06
12 O 0 7.962975132613792e-07
% O 0 1.510984404262672e-08
of O 0 9.908743825448596e-10
these O 0 3.2040161634938613e-09
cases O 0 1.5694439525759663e-08
, O 0 1.566077045822567e-08
there O 0 5.819811299545563e-09
are O 0 6.293352949882092e-09
no O 0 9.781905419004033e-08
demonstrable O 0 0.0015863683074712753
cardiac O 0 0.0026090899482369423
or O 0 5.59656086807081e-07
non O 0 5.828912321703683e-07
- O 0 0.0047494894824922085
cardiac O 0 0.04009620472788811
causes O 0 1.182066966975981e-06
to O 0 2.4397392550667973e-08
account O 0 5.83739065973532e-08
for O 0 2.559907397170491e-09
the O 0 2.708334356782416e-08
episode O 0 0.00010399215534562245
, O 0 2.537308034789021e-07
which O 0 1.3256986619580857e-07
is O 0 3.0702622666467505e-08
therefore O 0 4.908576656248442e-08
classified O 0 8.231920105572499e-07
as O 0 4.5903114369139075e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.0013979291543364525
IVF B-Disease 1 1.0
) O 0 3.3768230878195027e-06
. O 0 1.7104385960919899e-06

A O 0 1.4938182175683323e-05
distinct O 0 6.4708142417657655e-06
group O 0 2.1605387701129075e-06
of O 0 2.158984671041253e-07
IVF B-Disease 1 1.0
patients O 0 0.001620531897060573
has O 0 2.276390659972094e-06
been O 0 3.897027340826753e-07
found O 0 8.195395651000581e-08
to O 0 6.121147588800113e-09
present O 0 9.493629882229015e-09
with O 0 1.0261811844713975e-08
a O 0 4.521682228642021e-07
characteristic O 0 1.623944081075024e-05
electrocardiographic O 0 0.00015720674127805978
pattern O 0 0.00011234898556722328
. O 0 1.1766592251660768e-06

Because O 0 5.664660875481786e-06
of O 0 2.141472066341521e-08
the O 0 7.68527286254539e-09
small O 0 1.2301567764438914e-08
size O 0 4.7760490673454115e-08
of O 0 6.521473139287082e-09
most O 0 2.7234552391064426e-08
pedigrees O 0 1.9176691239408683e-06
and O 0 4.4323311243488206e-08
the O 0 1.116551029411994e-08
high O 0 9.332247259408177e-07
incidence O 0 1.916477776831016e-05
of O 0 2.1405490713277686e-08
sudden B-Disease 0 1.6193358533200808e-05
death I-Disease 0 1.998182779061608e-05
, O 0 2.3078333910575566e-08
however O 0 1.0798354210805883e-08
, O 0 2.5018476179639038e-09
molecular O 0 4.0855837823983165e-08
genetic O 0 1.5010735410214693e-07
studies O 0 8.022604802704336e-09
of O 0 1.4289896377306377e-08
IVF B-Disease 1 1.0
have O 0 4.60973978988477e-06
not O 0 4.644520501528859e-08
yet O 0 6.579799105566053e-08
been O 0 2.4905966711230576e-07
done O 0 4.046474941787892e-07
. O 0 5.489790169121989e-07

Because O 0 0.00036507868207991123
IVF B-Disease 1 0.9999998807907104
causes O 0 0.002941062906756997
cardiac O 1 0.9395793080329895
rhythm O 1 0.7702162861824036
disturbance O 0 0.00019643477571662515
, O 0 2.145714290691103e-07
we O 0 2.664759257697824e-08
investigated O 0 1.7124676787716453e-07
whether O 0 1.8988282945997526e-08
malfunction O 0 9.177808351523709e-06
of O 0 4.283474908106655e-09
ion O 0 6.999965194154356e-07
channels O 0 3.064679958697525e-06
could O 0 1.9968231299571926e-06
cause O 0 8.510499469593924e-07
the O 0 2.3112346525522298e-07
disorder O 0 4.2663006752263755e-05
by O 0 5.382322143532292e-09
studying O 0 1.9771860593209567e-08
mutations O 0 3.40645016194685e-07
in O 0 1.71114464819766e-08
the O 0 1.487455989490627e-07
cardiac O 0 9.40681784413755e-05
sodium O 0 4.989718036085833e-06
channel O 0 1.6746493201935664e-05
gene O 0 6.113483323133551e-06
SCN5A O 0 0.0001168150338344276
. O 0 2.3246202545124106e-06

We O 0 2.622322972456459e-05
have O 0 2.2807054733675614e-07
now O 0 4.4547824984420004e-08
identified O 0 9.37757249630522e-08
a O 0 1.9265598893980496e-07
missense O 0 0.00015507533680647612
mutation O 0 1.8713590179686435e-06
, O 0 1.9604492251801275e-08
a O 0 4.92051910327973e-08
splice O 0 0.0001955937477760017
- O 0 8.69228460942395e-05
donor O 0 7.855888384256104e-07
mutation O 0 1.1802162589447107e-06
, O 0 1.7367325355621688e-08
and O 0 3.784606406043167e-08
a O 0 4.0496405517842504e-07
frameshift O 0 0.010029351338744164
mutation O 0 2.593090357549954e-06
in O 0 1.8319006755973533e-08
the O 0 4.688614296810556e-08
coding O 0 1.2542272997961845e-05
region O 0 4.884238933300367e-07
of O 0 1.5098033046001547e-08
SCN5A O 0 3.9499202102888376e-05
in O 0 2.3969406015567074e-07
three O 0 2.614245886434219e-06
IVF B-Disease 1 0.9999998807907104
families O 0 3.379742111064843e-06
. O 0 5.93296931583609e-07

We O 0 3.07475529552903e-05
show O 0 2.8526599180622725e-06
that O 0 2.7416447778705333e-08
sodium O 0 2.1159826246730518e-07
channels O 0 1.171788568399279e-07
with O 0 8.927289130156169e-09
the O 0 1.2818574646189518e-07
missense O 0 8.836086635710672e-05
mutation O 0 2.157242533940007e-06
recover O 0 2.9531756240430695e-07
from O 0 1.0778600234573332e-08
inactivation O 0 1.4597479776057298e-06
more O 0 2.081630645633936e-09
rapidly O 0 2.890335082383899e-08
than O 0 2.307995128347784e-09
normal O 0 7.822663405931962e-09
and O 0 1.0729331201275727e-08
that O 0 3.553788152643733e-09
the O 0 5.284265114369191e-08
frameshift O 0 0.0006447265623137355
mutation O 0 1.9928852452721912e-06
causes O 0 4.535736408683988e-08
the O 0 7.535504664701875e-09
sodium O 0 4.7062337671377463e-07
channel O 0 4.171761702309595e-06
to O 0 2.3420044570343634e-08
be O 0 3.971857864826234e-08
non O 0 1.009769263760063e-07
- O 0 3.4626959859451745e-06
functional O 0 1.5563477973046247e-06
. O 0 1.0274717396896449e-06

Our O 0 2.711402703425847e-05
results O 0 2.607963324408047e-06
indicate O 0 6.216293400029826e-07
that O 0 5.11934175051465e-08
mutations O 0 1.724422759252775e-06
in O 0 3.440892371031623e-08
cardiac O 0 3.7937952583888546e-05
ion O 0 6.103440227889223e-06
- O 0 6.603350630030036e-05
channel O 0 1.416695613443153e-05
genes O 0 1.340298751983937e-07
contribute O 0 1.2377777025562864e-08
to O 0 4.9486201803006225e-09
the O 0 2.3389912229276888e-08
risk O 0 1.057359497735888e-07
of O 0 1.296648122206534e-08
developing O 0 5.083840051156585e-07
IVF B-Disease 1 0.9999995231628418
. O 0 6.025354082339618e-07
. O 0 4.1771215819608187e-07

Molecular O 0 5.40568471478764e-05
heterogeneity O 0 6.841190770501271e-05
in O 0 7.978611620274023e-07
mucopolysaccharidosis B-Disease 0 7.230140909086913e-05
IVA I-Disease 0 0.08470432460308075
in O 0 2.6866255211643875e-06
Australia O 0 5.33221566456632e-07
and O 0 3.59823019380201e-07
Northern O 0 8.720782034288277e-07
Ireland O 0 7.050501267258369e-07
: O 0 2.2736490024044542e-08
nine O 0 1.1355534468293627e-07
novel O 0 4.736929497539677e-07
mutations O 0 5.98653230099444e-07
including O 0 9.458709371301666e-09
T312S O 0 1.5380442164314445e-06
, O 0 6.259581297740624e-09
a O 0 1.960714790527618e-08
common O 0 7.932515444508681e-08
allele O 0 4.983570534022874e-07
that O 0 4.225215377573477e-08
confers O 0 1.0072481018141843e-06
a O 0 2.85897863250284e-06
mild O 0 0.05734047293663025
phenotype O 0 0.018192509189248085
. O 0 2.373151801293716e-06

Mucopolysaccharidosis B-Disease 1 0.5840263962745667
IVA I-Disease 1 0.9998366832733154
( O 0 0.0464070625603199
MPS B-Disease 1 0.9999985694885254
IVA I-Disease 1 1.0
) O 0 4.475179594010115e-06
is O 0 1.8395832057649386e-07
an O 0 1.3787191619485384e-06
autosomal B-Disease 1 0.9999974966049194
recessive I-Disease 1 0.9999990463256836
lysosomal I-Disease 1 0.9999850988388062
storage I-Disease 1 0.9999979734420776
disorder I-Disease 1 0.999995231628418
caused O 0 3.136342638754286e-05
by O 0 9.969016190325419e-08
a O 0 0.00010565258708084002
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999992847442627
in O 0 5.772177473772899e-07
N O 0 4.200377225060947e-05
- O 0 2.404454971838277e-05
acetylgalactosamine O 0 6.706600834149867e-05
- O 0 3.927672150894068e-05
6 O 0 5.0072508201992605e-06
- O 0 0.00011300785990897566
sulfate O 0 0.00012194518785690889
sulfatase O 0 0.00013221989502198994
( O 0 7.354730655606545e-07
GALNS O 0 3.303007906652056e-05
) O 0 4.921186018691515e-07
. O 0 8.296475471070153e-07

Previous O 0 2.0671428501373157e-05
studies O 0 2.4183654545595346e-07
of O 0 4.149613630488602e-08
patients O 0 1.6820094117520057e-07
from O 0 7.618051078850385e-09
a O 0 1.375898790456631e-07
British O 0 5.624975528917275e-06
- O 0 5.9095727920066565e-05
Irish O 0 2.569965772636351e-06
population O 0 2.6410683418021108e-08
showed O 0 3.4689719541347586e-07
that O 0 1.8237592547265535e-09
the O 0 1.1141852773732808e-08
I113F O 0 3.928082151105627e-06
mutation O 0 7.029761945887003e-07
is O 0 6.694039988985878e-09
the O 0 3.5173799428633856e-09
most O 0 6.5672458582355375e-09
common O 0 4.408336096162202e-08
single O 0 1.8681083702176693e-06
mutation O 0 8.669338967592921e-06
among O 0 8.80808443071146e-07
MPS B-Disease 1 0.9999891519546509
IVA I-Disease 1 1.0
patients O 0 0.00020704042981378734
and O 0 4.0795421796246956e-07
produces O 0 3.4822667771550186e-07
a O 0 5.245143483989523e-07
severe O 0 0.0016524090897291899
clinical O 0 0.0001476061879657209
phenotype O 0 0.003183591179549694
. O 0 3.649600103017292e-06

We O 0 7.362123596976744e-06
studied O 0 1.2148951782364747e-06
mutations O 0 1.5781844240336795e-06
in O 0 2.0212111095929686e-08
the O 0 3.4073426746772384e-08
GALNS O 0 2.0539338947855867e-05
gene O 0 3.6257529245631304e-07
from O 0 3.7429622068430035e-08
23 O 0 4.103762307750003e-07
additional O 0 5.376978720050829e-07
MPS B-Disease 1 0.9999856948852539
IVA I-Disease 1 1.0
patients O 0 0.00011405232362449169
( O 0 3.8553075398795045e-08
15 O 0 3.067505360832001e-08
from O 0 4.995734936841245e-09
Australia O 0 1.4009335913556242e-08
, O 0 8.130327522337666e-09
8 O 0 2.687524514044526e-08
from O 0 5.768532762573386e-09
Northern O 0 3.5644075069285464e-07
Ireland O 0 4.5584158669953467e-07
) O 0 6.7459247077295e-09
, O 0 1.4647190127448084e-09
with O 0 2.1568016261852563e-09
various O 0 3.39618964062538e-08
clinical O 0 8.139320016198326e-06
phenotypes O 0 0.0010579711524769664
( O 0 4.281312726561737e-07
severe O 0 2.1626396119245328e-05
, O 0 9.253535893094522e-08
16 O 0 1.431528602324761e-07
cases O 0 3.008191740150323e-08
; O 0 5.108787703989037e-08
intermediate O 0 3.1984978221544225e-08
, O 0 1.215929312792241e-08
4 O 0 9.954500512776576e-08
cases O 0 6.759334780781501e-08
; O 0 7.486027016057051e-07
mild O 0 2.743367622315418e-05
, O 0 1.3114788544044131e-07
3 O 0 6.165507215882826e-07
cases O 0 1.581316695364876e-07
) O 0 1.5194081015579286e-07
. O 0 6.373468863785092e-07

We O 0 9.078085895453114e-06
found O 0 2.191060417544577e-07
two O 0 4.195021929831455e-08
common O 0 2.1441086062168324e-07
mutations O 0 1.5345777910624747e-06
that O 0 1.3586604730164709e-08
together O 0 4.038170331455149e-08
accounted O 0 1.3278204846756125e-07
for O 0 9.561229141752392e-09
32 O 0 8.195057716875453e-07
% O 0 7.719355821222962e-09
of O 0 8.61711313415725e-10
the O 0 1.7993695422546807e-08
44 O 0 2.533441829655203e-07
unrelated O 0 1.66477093443973e-07
alleles O 0 2.521390172205429e-07
in O 0 9.60008321726491e-08
these O 0 3.3648893804638647e-07
patients O 0 3.068879777856637e-06
. O 0 9.276788546230819e-07

One O 0 4.709848326456267e-06
is O 0 1.1582296366441369e-07
the O 0 6.194876078779998e-08
T312S O 0 1.4816421753494069e-05
mutation O 0 1.7595709778106539e-06
, O 0 1.6958217941009934e-08
a O 0 5.9560775866884796e-08
novel O 0 3.1595484415447572e-06
mutation O 0 1.4039611642147065e-06
found O 0 6.582622802397964e-08
exclusively O 0 9.310311099852697e-08
in O 0 2.3260699322236178e-07
milder O 0 0.0013210506876930594
patients O 0 2.3565378796774894e-05
. O 0 1.3849603419657797e-06

The O 0 1.7722353504723287e-06
other O 0 6.392460960569224e-08
is O 0 2.444499713760706e-08
the O 0 3.9600497103720045e-08
previously O 0 1.3071065723124775e-06
described O 0 2.8827048481616657e-06
I113F O 0 2.778010866677505e-06
that O 0 4.591837310385927e-08
produces O 0 2.9298138315425604e-07
a O 0 1.8264599930262193e-06
severe O 0 0.007743224035948515
phenotype O 0 0.002435482107102871
. O 0 2.84891370938567e-06

The O 0 8.648561561130919e-06
I113F O 0 3.4585700632305816e-05
and O 0 6.456535288634768e-07
T312S O 0 1.0172694601351395e-05
mutations O 0 2.747055077634286e-06
accounted O 0 1.5661807140077144e-07
for O 0 7.250971822969632e-09
8 O 0 4.987311967852293e-07
( O 0 2.053103287380509e-08
18 O 0 2.6137820441363147e-07
% O 0 1.4565570971569741e-08
) O 0 3.054204444907782e-09
and O 0 4.380826723604514e-08
6 O 0 6.978196438467421e-07
( O 0 2.068815163625004e-08
14 O 0 2.5640437684160133e-07
% O 0 1.411016548047428e-08
) O 0 1.433206220369243e-09
of O 0 1.6304103622744037e-09
44 O 0 2.433660881706601e-07
unrelated O 0 4.890503646493016e-07
alleles O 0 8.681018925926764e-07
, O 0 3.2740678079790086e-07
respectively O 0 1.1735426141967764e-06
. O 0 8.297251383737603e-07

The O 0 2.0058107566001127e-06
relatively O 0 6.162926524666545e-07
high O 0 6.717166911585082e-07
residual O 0 3.3407750379410572e-06
GALNS O 0 4.231059210724197e-05
activity O 0 6.201909741321288e-07
seen O 0 1.514028724614036e-07
when O 0 6.139434738372529e-09
the O 0 6.368739313700189e-09
T312S O 0 4.573817875552777e-07
mutant O 0 3.6380242818268016e-07
cDNA O 0 4.407087885738292e-07
is O 0 2.988911873558209e-08
overexpressed O 0 9.703039722808171e-07
in O 0 1.8201703255726898e-08
mutant O 0 2.459149982314557e-06
cells O 0 9.254947741510477e-08
provides O 0 5.122972268623016e-09
an O 0 1.4964881556167597e-09
explanation O 0 1.2747375599531097e-08
for O 0 3.5543643583935136e-09
the O 0 2.662255553786963e-07
mild O 0 0.09154501557350159
phenotype O 0 0.0022565145045518875
in O 0 2.813747528307431e-07
patients O 0 2.455844878568314e-07
with O 0 2.9538025358988307e-08
this O 0 2.2954519351969793e-07
mutation O 0 1.0443378414493054e-05
. O 0 1.1598472156038042e-06

The O 0 9.490715342508338e-07
distribution O 0 2.0317212090503745e-07
and O 0 3.413978433286502e-08
relative O 0 6.278057185227226e-08
frequencies O 0 7.526602274765537e-08
of O 0 1.889470135907345e-09
the O 0 1.4349793353574114e-08
I113F O 0 1.446779720026825e-06
and O 0 8.48600123504184e-08
T312S O 0 1.9541905658115866e-06
mutations O 0 4.1065970890485914e-07
in O 0 9.823409641285252e-09
Australia O 0 2.604450699550398e-08
corresponded O 0 7.333593288194606e-08
to O 0 9.506603504405575e-09
those O 0 4.932920294464793e-09
observed O 0 2.948061528229573e-08
in O 0 5.2261968086497745e-09
Northern O 0 5.426302891464729e-07
Ireland O 0 7.65413744829857e-07
and O 0 1.3270306453705416e-07
are O 0 2.003622823210094e-09
unique O 0 2.9260389666774245e-09
to O 0 3.614023302844771e-09
these O 0 2.1785739878765753e-09
two O 0 9.631588859804197e-09
populations O 0 2.6206954828467133e-08
, O 0 9.862854533082555e-09
suggesting O 0 3.087809830049082e-08
that O 0 4.135996878318338e-09
both O 0 2.210123817292242e-08
mutations O 0 8.882705628820986e-07
were O 0 2.0884806417598156e-07
probably O 0 9.400261546943511e-08
introduced O 0 6.282381548317062e-08
to O 0 2.3887887223850157e-08
Australia O 0 2.5379003787406873e-08
by O 0 5.528635771412382e-09
Irish O 0 1.0667628913552107e-07
migrants O 0 2.1073025990858696e-08
during O 0 1.5252595630954602e-08
the O 0 1.5995624380593654e-08
19th O 0 1.4032302715349942e-06
century O 0 2.3386355678667314e-06
. O 0 5.934791715844767e-07

Haplotype O 0 0.0011001916136592627
analysis O 0 3.282767011114629e-06
using O 0 1.530016902506759e-06
6 O 0 1.691737111286784e-06
RFLPs O 0 5.727964435209287e-06
provides O 0 2.5292308691859944e-08
additional O 0 1.0626197699536988e-08
data O 0 3.1637195974099086e-08
that O 0 6.462397728057567e-09
the O 0 2.926709896655666e-08
I113F O 0 8.557004548492841e-06
mutation O 0 8.314946740028972e-07
originated O 0 5.7145253862245227e-08
from O 0 7.540133850625352e-09
a O 0 5.887225995593326e-08
common O 0 3.763407789847406e-07
ancestor O 0 4.387296030472498e-06
. O 0 1.994478452616022e-06

The O 0 1.7202507933689049e-06
other O 0 1.509434071067517e-07
9 O 0 1.1092076874774648e-06
novel O 0 1.1861095572385238e-06
mutations O 0 3.5814691727864556e-06
identified O 0 3.3567545187906944e-07
in O 0 1.806832550244053e-08
these O 0 2.614449634563698e-08
23 O 0 3.010051159435534e-06
patients O 0 1.3496983797267603e-07
were O 0 1.0267786620943298e-07
each O 0 6.874805169587717e-09
limited O 0 8.290147235356926e-09
to O 0 8.243678628616635e-09
a O 0 1.2958771833382343e-07
single O 0 3.620787992986152e-06
family O 0 1.762755459822074e-06
. O 0 7.010815465946507e-07

These O 0 1.2445824495443958e-06
data O 0 2.840520494373777e-07
provide O 0 1.5375567485875763e-08
further O 0 1.6043779638152955e-08
evidence O 0 1.3672885934568058e-08
for O 0 4.531833575072142e-09
extensive O 0 2.8231204396433895e-07
allelic O 0 8.123772204271518e-06
heterogeneity O 0 2.4860595658537932e-05
in O 0 1.125620383390924e-05
MPS B-Disease 1 0.9999754428863525
IVA I-Disease 1 0.9999998807907104
in O 0 4.224629719828954e-06
British O 0 0.00011491902114357799
- O 0 0.113284170627594
Irish O 0 5.4786298278486356e-05
patients O 0 3.176032521423622e-07
and O 0 1.589150144809537e-08
provide O 0 2.4655983921206825e-09
evidence O 0 5.9804805552232665e-09
for O 0 3.54012907877177e-09
their O 0 3.05570928560428e-08
transmission O 0 5.0981957429030444e-06
to O 0 1.1962176138524683e-08
Australia O 0 1.7651995420919775e-08
by O 0 6.5463856557812505e-09
British O 0 1.7580714484211057e-06
- O 0 1.2079185580660123e-05
Irish O 0 5.058753913544933e-07
migrants O 0 1.3800712395095616e-07
. O 0 4.7074859566009764e-08
. O 0 3.439784279635205e-07

Identification O 0 2.0702438632724807e-05
of O 0 7.119318183868018e-07
constitutional O 0 8.847941899148282e-06
WT1 O 0 0.015060427598655224
mutations O 0 0.000304106913972646
, O 0 2.1236648706235428e-07
in O 0 3.428141894801229e-07
patients O 0 1.9493695617711637e-06
with O 0 4.794421784026781e-07
isolated O 0 0.0806511789560318
diffuse B-Disease 1 0.9997609257698059
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.088601493393071e-06
and O 0 3.76972941751319e-08
analysis O 0 3.3284180744885816e-08
of O 0 5.249587076150419e-08
genotype O 0 0.02834152989089489
/ O 0 0.002488217782229185
phenotype O 0 4.0897346480051056e-05
correlations O 0 2.128270352841355e-06
by O 0 8.173818066836702e-09
use O 0 1.708242258757764e-08
of O 0 1.0318316867596877e-08
a O 0 3.7553911624854663e-07
computerized O 0 4.05571554438211e-05
mutation O 0 1.03649144875817e-05
database O 0 2.159694076908636e-06
. O 0 1.3500718978320947e-06

Constitutional O 0 4.850394543609582e-05
mutations O 0 7.782500324537978e-05
of O 0 6.056093582174071e-08
the O 0 9.616815077606589e-08
WT1 O 0 3.644012031145394e-05
gene O 0 6.092660100875946e-07
, O 0 2.355583283986107e-08
encoding O 0 2.067951925255329e-07
a O 0 3.3653398077149177e-06
zinc O 0 0.0806519165635109
- O 0 0.00013274920638650656
finger O 0 3.126914452877827e-05
transcription O 0 6.075977694308676e-07
factor O 0 1.527901218878469e-07
involved O 0 4.760260807756822e-08
in O 0 2.9980617455294123e-07
renal O 0 0.044215280562639236
and O 0 1.5183317145783803e-06
gonadal O 0 1.8652048311196268e-05
development O 0 6.50712479455251e-08
, O 0 2.334169124651453e-08
are O 0 3.83172205076221e-09
found O 0 1.8639173759993355e-08
in O 0 1.5972636546734975e-08
most O 0 3.768535705717113e-08
patients O 0 1.35970694259413e-07
with O 0 4.1478975276731944e-07
Denys B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.6114898901141714e-06
DDS B-Disease 1 1.0
) O 0 7.876518566263258e-07
, O 0 3.79980718889783e-07
or O 0 8.991476533992682e-06
diffuse B-Disease 1 0.9998143315315247
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.1244195270119235e-05
DMS B-Disease 0 0.01046760380268097
) O 0 9.818187152177416e-08
associated O 0 1.0371377356932499e-07
with O 0 5.167983658793673e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.9056884411838837e-05
/ O 0 0.00021486374316737056
or O 0 8.427813554590102e-06
Wilms B-Disease 1 0.9013845324516296
tumor I-Disease 0 0.16063730418682098
( O 0 5.273082479106961e-06
WT B-Disease 1 0.9999328851699829
) O 0 8.683460919201025e-07
. O 0 9.089043260246399e-07

Most O 0 2.3291551769943908e-05
mutations O 0 0.0016709704650565982
in O 0 1.0958210623357445e-05
DDS B-Disease 1 1.0
patients O 0 0.1069270446896553
lie O 0 1.4745026419404894e-05
in O 0 7.69310730674988e-08
exon O 0 6.459377345890971e-06
8 O 0 1.6570965044593322e-06
or O 0 8.293107356394103e-08
exon O 0 2.843162064891658e-06
9 O 0 2.3404695639328565e-06
, O 0 4.1768583258772196e-08
encoding O 0 9.270482905776589e-07
zinc O 0 0.006275204475969076
finger O 0 0.0014890804886817932
2 O 0 2.864791895262897e-06
or O 0 7.804870278960152e-07
zinc O 0 0.0014976541278883815
finger O 0 0.0005046362639404833
3 O 0 8.753294196139905e-07
, O 0 5.976605876867325e-08
respectively O 0 1.3884870497804513e-07
, O 0 4.80429651616987e-09
with O 0 5.411949111078229e-09
a O 0 4.863360345552792e-07
hot O 0 0.002639681100845337
spot O 0 0.016369370743632317
( O 0 1.8879244123581884e-07
R394W O 0 8.579276027376181e-07
) O 0 1.2148860584204613e-08
in O 0 2.9897329056893795e-08
exon O 0 7.015335540927481e-06
9 O 0 8.298229658976197e-06
. O 0 1.1352516366969212e-06

We O 0 5.48628077012836e-06
analyzed O 0 9.989561249312828e-07
a O 0 1.31107384504503e-07
series O 0 1.4932392389255256e-07
of O 0 3.3149802902698866e-08
24 O 0 9.39220808504615e-06
patients O 0 1.8651020639026683e-07
, O 0 1.6434807292853293e-08
10 O 0 1.9454970967558438e-08
with O 0 8.471720747138534e-08
isolated B-Disease 0 0.031025612726807594
DMS I-Disease 1 0.5277239680290222
( O 0 1.8082086228332628e-07
IDMS B-Disease 0 1.9058375983149745e-05
) O 0 2.6634076277787244e-08
, O 0 1.6108876010889617e-08
10 O 0 3.4440901686139114e-08
with O 0 1.8064919515836664e-07
DDS B-Disease 1 1.0
, O 0 1.2459577192203142e-06
and O 0 1.8752467667582096e-07
4 O 0 2.5560552785464097e-07
with O 0 2.573850679254974e-07
urogenital B-Disease 1 0.8608623147010803
abnormalities I-Disease 1 0.9999674558639526
and O 0 1.535806222818792e-05
/ O 0 0.0009573113056831062
or O 0 2.8758218832081184e-05
WT B-Disease 1 0.9999969005584717
. O 0 5.792543106508674e-06

We O 0 2.8246249712537974e-05
report O 0 8.349819836439565e-06
WT1 O 0 0.0008187242201529443
heterozygous O 0 0.00019255548249930143
mutations O 0 2.4138609660440125e-05
in O 0 2.1958423701562424e-07
16 O 0 4.5943347686261404e-06
patients O 0 8.688613775120757e-07
, O 0 3.499420841990286e-08
4 O 0 1.581542790063395e-07
of O 0 2.828560496936916e-08
whom O 0 1.9044703094550641e-06
presented O 0 5.39396296517225e-07
with O 0 1.1222258535781293e-06
IDMS B-Disease 0 0.008052840828895569
. O 0 3.7239817629597383e-06

One O 0 2.3212831365526654e-05
male O 0 2.1551844838541e-05
and O 0 4.014992498468928e-07
two O 0 1.0188771284447284e-06
female O 0 0.0001249202759936452
IDMS B-Disease 0 0.06650559604167938
patients O 0 9.675572073319927e-06
with O 0 1.5703595863669761e-06
WT1 O 0 0.08775493502616882
mutations O 0 0.0007505442481487989
underwent O 0 0.0003337897651363164
normal O 0 1.6277226677630097e-05
puberty O 0 0.00018237929907627404
. O 0 6.412661605281755e-06

Two O 0 8.36307808640413e-05
mutations O 0 0.0005326091195456684
associated O 0 1.3518150581148802e-06
with O 0 2.593117471860751e-07
IDMS B-Disease 0 0.01174999214708805
are O 0 2.909889040836333e-08
different O 0 8.59828563903875e-09
from O 0 3.352636568365597e-08
those O 0 3.620710842255903e-08
described O 0 1.288119256059872e-05
in O 0 5.955519554845523e-06
DDS B-Disease 1 1.0
patients O 0 0.0002290611737407744
. O 0 1.7751990526448935e-06

No O 0 0.00010437801392981783
WT1 O 0 0.004409629851579666
mutations O 0 0.002068140311166644
were O 0 9.702034731162712e-06
detected O 0 2.5598856154829264e-06
in O 0 3.196375431002707e-08
the O 0 4.5470400777958275e-08
six O 0 7.237509294100164e-07
other O 0 3.991406458681013e-07
IDMS B-Disease 0 0.02649855986237526
patients O 0 2.7872004011442186e-06
, O 0 6.437966959538244e-08
suggesting O 0 6.951945579203311e-07
genetic O 0 1.192416561934806e-06
heterogeneity O 0 2.609941475384403e-06
of O 0 9.758964836237283e-08
this O 0 1.740515017445432e-06
disease O 0 0.0002718247415032238
. O 0 2.5930828542186646e-06

We O 0 1.4335631931317039e-05
analyzed O 0 1.3757896340393927e-05
genotype O 0 0.0006919209263287485
/ O 0 0.0011393543099984527
phenotype O 0 0.00012608022370841354
correlations O 0 1.8814189388649538e-05
, O 0 2.7166285576640803e-07
on O 0 6.841464141871256e-07
the O 0 4.73275711954102e-08
basis O 0 3.7071178127234816e-08
of O 0 5.431980643066936e-09
the O 0 5.011895609641215e-08
constitution O 0 4.361534067243156e-08
of O 0 3.9819445518674e-09
a O 0 2.4011481514207844e-07
WT1 O 0 4.1683899326017126e-05
mutation O 0 2.575220889866614e-07
database O 0 1.8777409849235482e-08
of O 0 3.741062126749739e-09
84 O 0 2.1682760120711464e-07
germ O 0 8.184636499208864e-06
- O 0 0.00011656956485239789
line O 0 0.014419184997677803
mutations O 0 1.7189519212479354e-06
, O 0 3.002532222851073e-09
to O 0 1.7194012880139553e-09
compare O 0 1.3417435162921265e-08
the O 0 4.424423050153337e-09
distribution O 0 3.655489777543153e-08
and O 0 2.692686251748455e-08
type O 0 3.0457709243592035e-08
of O 0 1.3776470630944004e-08
mutations O 0 2.4036667127802502e-06
, O 0 8.243835836196922e-09
according O 0 2.907635021642818e-09
to O 0 7.152430647749952e-09
the O 0 6.37833252881137e-08
different O 0 6.462338433266268e-07
symptoms O 0 4.469449777388945e-05
. O 0 6.993212764427881e-07

This O 0 3.4148556551372167e-06
demonstrated O 0 5.624702225759393e-06
( O 0 1.3947193622243503e-07
1 O 0 1.7590984668913734e-07
) O 0 1.4888617450026231e-08
the O 0 2.1922220483361343e-08
association O 0 2.2419543554974553e-08
between O 0 6.170841260200177e-08
mutations O 0 1.108705305341573e-06
in O 0 2.6647848372363114e-08
exons O 0 1.4194220057106577e-05
8 O 0 3.224317879357841e-06
and O 0 7.171133233896398e-07
9 O 0 3.01427371596219e-06
and O 0 7.623860369676549e-07
DMS B-Disease 0 0.018696174025535583
; O 0 9.516912058415983e-08
( O 0 1.365019031140946e-08
2 O 0 6.722191159269642e-08
) O 0 1.2514226988002974e-08
among O 0 2.3662735770813015e-08
patients O 0 7.44058894497357e-08
with O 0 7.308375415959745e-08
DMS B-Disease 0 0.005241356790065765
, O 0 1.4478182208677026e-08
a O 0 1.2311942576559431e-08
higher O 0 1.8437768645185315e-08
frequency O 0 6.62628423242495e-08
of O 0 3.927050240548624e-09
exon O 0 3.1632903301215265e-06
8 O 0 1.7068309716705699e-06
mutations O 0 9.297123710894084e-07
among O 0 1.5367826122769657e-08
46 O 0 4.5022332528787956e-07
, O 0 5.693625482194875e-08
XY O 0 0.00037678045919165015
patients O 0 3.27552925227792e-07
with O 0 5.069417241543306e-08
female O 0 2.5711944545037113e-05
phenotype O 0 1.8086921045323834e-05
than O 0 1.4244804447116621e-08
among O 0 1.8215422059597586e-08
46 O 0 3.597886859552091e-07
, O 0 7.963972592506252e-08
XY O 0 0.00020485350978560746
patients O 0 1.79582656301136e-07
with O 0 1.241984826094722e-08
sexual O 0 2.996509635977418e-07
ambiguity O 0 5.752164042860386e-07
or O 0 6.952687954253634e-07
male O 0 2.334189230168704e-05
phenotype O 0 0.00021658926561940461
; O 0 2.092735229553e-07
and O 0 2.2181821179856342e-07
( O 0 2.9996488848382796e-08
3 O 0 1.0215960344339692e-07
) O 0 6.8007923736956855e-09
statistically O 0 8.896900283161813e-08
significant O 0 9.547616919292068e-09
evidence O 0 1.926304094013176e-08
that O 0 3.229313350061602e-08
mutations O 0 7.064144256219151e-07
in O 0 1.4371021705983367e-08
exons O 0 6.600635515496833e-06
8 O 0 1.6196872820728458e-06
and O 0 4.1438133280280454e-07
9 O 0 3.9612896785001794e-07
preferentially O 0 3.3377324371031136e-07
affect O 0 9.055484895270638e-08
amino O 0 8.342129120819664e-08
acids O 0 2.0467535222223887e-08
with O 0 1.9366808157172954e-09
different O 0 4.489479454861112e-09
functions O 0 3.05681702172933e-08
. O 0 7.233363419345551e-08
. O 0 4.816014893549436e-07

The O 0 7.338584509852808e-06
185delAG O 0 0.00025774503592401743
BRCA1 O 0 0.0007333676912821829
mutation O 0 1.6279820556519553e-05
originated O 0 3.4727122510957997e-07
before O 0 1.540027838586866e-08
the O 0 4.031634581735943e-09
dispersion O 0 2.829724508046638e-07
of O 0 7.340853258597235e-09
Jews O 0 2.8355026415738394e-07
in O 0 1.8021722780758864e-08
the O 0 3.16224131324816e-08
diaspora O 0 3.4741302101792826e-07
and O 0 3.0401008643821115e-07
is O 0 2.3306990115656845e-08
not O 0 1.0786230575376976e-08
limited O 0 3.275566129445906e-08
to O 0 9.505301079570927e-08
Ashkenazim O 0 2.1172969354665838e-05
. O 0 8.370162163373607e-07

The O 0 6.826761364209233e-06
185delAG O 0 8.394510950893164e-05
mutation O 0 2.313614277227316e-05
in O 0 2.3738326149214117e-07
BRCA1 O 0 5.480762411025353e-05
is O 0 1.4918556701104535e-07
detected O 0 1.0948265298793558e-06
in O 0 4.940568842926041e-08
Ashkenazi O 0 1.4178485798765905e-05
Jews O 0 1.661392730056832e-07
both O 0 1.5620674531646728e-08
in O 0 2.9010922730776656e-07
familial B-Disease 0 0.33628299832344055
breast I-Disease 1 0.9999990463256836
and I-Disease 1 0.9999886751174927
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5721396948720212e-06
in O 0 4.866969760541906e-08
the O 0 3.4627436917844534e-08
general O 0 9.891115837490361e-08
population O 0 3.1403871503243863e-07
. O 0 3.9302003074226377e-07

All O 0 4.7030266614456195e-06
tested O 0 1.15597194962902e-05
Ashkenazi O 0 3.083811316173524e-05
mutation O 0 4.6678960643475875e-06
carriers O 0 2.6206711822851503e-07
share O 0 5.9140678132507674e-08
the O 0 9.504065978660492e-09
same O 0 3.7165126087757017e-08
allelic O 0 3.301129481769749e-06
pattern O 0 3.428738273214549e-05
at O 0 2.0793923738438025e-07
the O 0 2.3057593523390096e-07
BRCA1 O 0 0.0001293469686061144
locus O 0 7.415199797833338e-05
. O 0 4.9318268793285824e-06

Our O 0 1.1471589459688403e-05
previous O 0 7.819607503734005e-07
study O 0 1.6282162107472686e-07
showed O 0 3.620145662353025e-06
that O 0 9.14106923488589e-09
this O 0 1.4418574778574111e-08
Ashkenazi O 0 7.073553570080549e-05
mutation O 0 3.849642780551221e-06
also O 0 4.790738330484601e-07
occurs O 0 2.8126310169795943e-08
in O 0 5.802431868318081e-09
Iraqi O 0 2.026921634978862e-07
Jews O 0 4.33158930945865e-08
with O 0 3.5218910010570426e-09
a O 0 5.720370310768885e-08
similar O 0 3.810890234490216e-07
allelic O 0 5.7123219448840246e-05
pattern O 0 0.0005740454071201384
. O 0 4.379738129500765e-06

We O 0 1.2635037819563877e-05
extended O 0 1.2212447018100647e-06
our O 0 6.932918239499486e-08
analysis O 0 2.106824403824703e-08
to O 0 3.4376566038218925e-09
other O 0 4.418132082406601e-09
non O 0 4.230223282775114e-08
- O 0 2.061467284875107e-06
Ashkenazi O 0 3.1258614399121143e-06
subsets O 0 3.6841322526015574e-07
354 O 0 3.4910584645331255e-07
of O 0 6.516859940575159e-09
Moroccan O 0 4.51822234026622e-06
origin O 0 3.8171712901657884e-08
, O 0 2.489368355895749e-08
200 O 0 3.1493904373292025e-08
Yemenites O 0 1.3286556850289344e-06
and O 0 3.7466051594492455e-08
150 O 0 5.455500939888225e-08
Iranian O 0 2.9361518727455405e-07
Jews O 0 8.609151223026856e-07
. O 0 5.398692337621469e-07

Heteroduplex O 0 0.0005665874923579395
analysis O 0 3.743523393495707e-06
complemented O 0 3.797857743847999e-06
by O 0 4.525944774513846e-08
direct O 0 1.144699837141161e-07
DNA O 0 6.595133754672133e-07
sequencing O 0 3.726990769337135e-07
of O 0 3.5423934008349534e-08
abnormally O 0 3.941636350646149e-06
migrating O 0 1.3958690203708102e-07
bands O 0 1.4506537127090269e-06
were O 0 2.805527117288875e-07
employed O 0 1.1909846762137022e-06
. O 0 5.496170274454926e-07

Four O 0 5.0682119763223454e-06
of O 0 7.95580490375869e-08
Moroccan O 0 7.724322131252848e-06
origin O 0 1.003481315819954e-07
( O 0 1.3750849348070915e-08
1 O 0 1.2631828916198629e-08
. O 0 6.599164326104301e-09
1 O 0 1.050488691589635e-07
% O 0 4.461823266410647e-08
) O 0 6.916629935460605e-09
and O 0 6.374623495730702e-08
none O 0 2.2910226604722084e-08
of O 0 1.2559007167567415e-09
the O 0 3.628986888770669e-08
Yemenites O 0 6.110894901212305e-06
or O 0 1.2428786533291714e-07
Iranians O 0 3.691056917887181e-07
was O 0 6.054165737623407e-07
a O 0 6.22851175080541e-08
carrier O 0 2.2178862479904637e-07
of O 0 4.476627957217261e-09
the O 0 6.427635668160292e-08
185delAG O 0 1.4129324881650973e-05
mutation O 0 5.837418029841501e-06
. O 0 5.297627012623707e-07

BRCA1 O 0 0.00870934221893549
allelic O 0 0.0007265954627655447
patterns O 0 0.0011953002540394664
were O 0 6.45128193355049e-06
determined O 0 3.121093641311745e-07
for O 0 1.033945551398574e-08
four O 0 6.828376086787102e-08
of O 0 6.180238987241182e-09
these O 0 1.7991430567576572e-08
individuals O 0 3.7124583407432965e-09
and O 0 8.800391526619933e-09
for O 0 2.318151004487845e-09
12 O 0 1.6705657301940846e-08
additional O 0 1.7915514405331123e-08
non O 0 7.93872132476281e-08
- O 0 7.573556558782002e-06
Ashkenazi O 0 1.0424174433865119e-05
185delAG O 0 2.4895521164580714e-06
mutation O 0 4.507053290581098e-07
carriers O 0 6.585838718820014e-08
who O 0 3.498654166378401e-07
had O 0 0.0020745894871652126
breast B-Disease 1 0.9999839067459106
/ I-Disease 1 0.9999939203262329
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.2473672541091219e-05

Six O 0 4.848516618949361e-05
non O 0 9.100014722207561e-06
- O 0 0.00036018030368722975
Ashkenazi O 0 0.0003261906385887414
individuals O 0 7.751936692557138e-08
shared O 0 3.504784729102539e-08
the O 0 1.9447810473138816e-08
common O 0 1.7225673332177394e-07
Ashkenazi O 0 3.373497384018265e-05
haplotype O 0 3.925189594156109e-05
, O 0 1.5208243553388456e-07
four O 0 1.165318295193174e-07
had O 0 9.174020760838175e-07
a O 0 4.3263213456157246e-08
closely O 0 2.2738318250503653e-07
related O 0 4.6280547394417226e-08
pattern O 0 5.122007496538572e-05
, O 0 1.2269551064036932e-07
and O 0 4.662395980403744e-08
the O 0 2.5409324422298596e-08
rest O 0 1.378204785851267e-07
( O 0 2.042907887300771e-08
n O 0 2.2243752937356476e-06
= O 0 6.682926596113248e-06
6 O 0 4.249064886607812e-07
) O 0 1.701394225506192e-08
displayed O 0 1.2207621580273553e-07
a O 0 1.3346839011774136e-07
distinct O 0 2.6768484531203285e-06
BRCA1 O 0 0.00021153330453671515
allelic O 0 0.00011924954014830291
pattern O 0 0.000272579985903576
. O 0 4.5571132432087325e-06

We O 0 4.357552825240418e-06
conclude O 0 6.332596740321605e-07
that O 0 2.808867272108273e-08
the O 0 4.738908288004495e-08
185delAG O 0 7.139599620131776e-05
BRCA1 O 0 0.0008792735752649605
mutation O 0 6.448065050790319e-06
occurs O 0 4.8729702939454e-08
in O 0 5.39574607216764e-09
some O 0 2.9987319294377812e-09
non O 0 4.2869586991400865e-08
- O 0 4.780761173606152e-06
Ashkenazi O 0 8.338441148225684e-06
populations O 0 8.625194425349036e-08
at O 0 2.919651542754309e-08
rates O 0 1.0401886640920566e-07
comparable O 0 2.9196236539519305e-08
with O 0 7.131235157942228e-09
that O 0 1.7176452260514452e-08
of O 0 5.492712418231349e-08
Ashkenazim O 0 0.000120540164061822
. O 0 9.500024589215172e-07

The O 0 2.1230139282124583e-06
majority O 0 4.845924763685616e-07
of O 0 3.3573588353874584e-08
Jewish O 0 9.453921165913926e-07
185delAG O 0 1.5401770724565722e-05
mutation O 0 2.7424507607065607e-06
carriers O 0 1.424957929430093e-07
have O 0 1.321992648684045e-08
a O 0 2.2904721674876782e-08
common O 0 7.23431554661147e-08
allelic O 0 4.326042926550144e-06
pattern O 0 0.00015038932906463742
, O 0 8.951180063831998e-08
supporting O 0 2.170586554939291e-08
the O 0 1.3435795587213306e-08
founder O 0 3.042043772438774e-07
effect O 0 1.95060234631228e-08
notion O 0 2.3433539553252558e-08
, O 0 1.4111781077019714e-08
but O 0 5.678709946721483e-09
dating O 0 1.332465870973465e-07
the O 0 3.245435920007367e-08
mutations O 0 4.123455994431424e-07
origin O 0 3.9313969857346365e-09
to O 0 3.4977643004197034e-09
an O 0 9.812698209543669e-09
earlier O 0 6.178344165164162e-07
date O 0 5.161058425073861e-07
than O 0 3.0519348825919224e-08
currently O 0 9.78319292244123e-08
estimated O 0 3.687074467961793e-07
. O 0 4.1759585656109266e-07

However O 0 1.620228613319341e-05
, O 0 1.322409275417158e-07
the O 0 1.0764382274430773e-08
different O 0 1.4628325217813654e-08
allelic O 0 4.2747501538542565e-06
pattern O 0 7.707499753450975e-05
at O 0 2.510844012704183e-07
the O 0 6.771710303610234e-08
BRCA1 O 0 3.906570054823533e-05
locus O 0 3.4485647120163776e-06
even O 0 7.497287413116283e-08
in O 0 7.62268825837964e-09
some O 0 3.184045915816114e-09
Jewish O 0 2.2431397894706606e-07
mutation O 0 4.483671318666893e-07
carriers O 0 2.548771504962133e-08
, O 0 1.2488903244900484e-08
might O 0 2.893821360316906e-08
suggest O 0 1.715566178006611e-08
that O 0 2.9996702899381944e-09
the O 0 2.6511221662417483e-08
mutation O 0 1.6878856285984511e-06
arose O 0 1.823094635255984e-07
independently O 0 1.7773727734038403e-07
. O 0 6.8634619765362e-08
. O 0 4.707176515239553e-07

Crystal O 0 0.0014426164561882615
structure O 0 5.80407822781126e-06
of O 0 1.2119056691517471e-07
the O 0 3.5878003927791724e-06
hemochromatosis B-Disease 1 1.0
protein O 0 8.137695112964138e-05
HFE O 0 0.0027680445928126574
and O 0 6.038043807166105e-07
characterization O 0 5.235268645265023e-07
of O 0 5.554128712503825e-09
its O 0 1.3811568777555294e-08
interaction O 0 4.9548752656392026e-08
with O 0 3.7031110622365304e-08
transferrin O 0 9.29100588109577e-06
receptor O 0 5.1691740736714564e-06
. O 0 1.3434741958917584e-06

HFE O 0 0.05455496907234192
is O 0 3.905781341018155e-06
an O 0 1.7140672525783884e-07
MHC O 0 1.619388240214903e-05
- O 0 1.8284352336195298e-05
related O 0 1.934364064481997e-07
protein O 0 1.9903977488411329e-07
that O 0 1.2677350724743519e-08
is O 0 1.0540608386122585e-08
mutated O 0 2.820945610437775e-07
in O 0 1.033874994504913e-07
the O 0 1.156204916696879e-06
iron B-Disease 1 0.999622106552124
- I-Disease 1 0.9999946355819702
overload I-Disease 1 0.9999910593032837
disease I-Disease 1 0.9998569488525391
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00010923679656116292

HFE O 0 0.006990347057580948
binds O 0 0.00010293304512742907
to O 0 2.2886765691509936e-06
transferrin O 0 5.192838580114767e-05
receptor O 0 1.1126010576845147e-05
( O 0 7.442831133630534e-07
TfR O 0 0.0006591162527911365
) O 0 1.3863304104688723e-07
and O 0 7.333313334356717e-08
reduces O 0 2.8268192409086623e-07
its O 0 8.786839700292148e-09
affinity O 0 3.430401207538125e-08
for O 0 8.714702737222524e-09
iron O 0 0.00010786939674289897
- O 0 8.27343319542706e-06
loaded O 0 1.6864197505128686e-06
transferrin O 0 3.415510491322493e-06
, O 0 7.128544154966221e-08
implicating O 0 5.816423708893126e-06
HFE O 0 0.00034224611590616405
in O 0 1.1560009625100065e-06
iron O 0 0.007715433835983276
metabolism O 0 3.168467083014548e-05
. O 0 1.285139546780556e-06

The O 0 2.001276152441278e-05
2 O 0 2.5899473257595673e-05
. O 0 6.1003620430710725e-06

6 O 0 7.427373202517629e-05
A O 0 5.063579465058865e-06
crystal O 0 6.996124284341931e-05
structure O 0 1.3845219655195251e-06
of O 0 9.244467946700752e-08
HFE O 0 0.0042757089249789715
reveals O 0 4.881911081611179e-06
the O 0 1.8501003395954285e-08
locations O 0 5.80043717945955e-07
of O 0 7.418114478241478e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.009618587791919708
and O 0 9.321911420556717e-07
a O 0 9.923331845129724e-07
patch O 0 0.4781801700592041
of O 0 1.0923187687694735e-07
histidines O 0 2.4539733203710057e-05
that O 0 1.1641341757240298e-07
could O 0 1.601675734264063e-07
be O 0 1.0015421381126544e-08
involved O 0 1.3933175502245376e-08
in O 0 6.962708454238964e-08
pH O 0 0.0001446629175916314
- O 0 7.601668585266452e-06
dependent O 0 6.573056339220784e-07
interactions O 0 6.932785368007899e-07
. O 0 7.066744842632033e-07

We O 0 2.415546441625338e-05
also O 0 8.582991881667112e-07
demonstrate O 0 5.125751272316847e-07
that O 0 8.239626225758911e-08
soluble O 0 4.582940164254978e-06
TfR O 0 0.009881217032670975
and O 0 7.915736546237895e-07
HFE O 0 0.00011113408982055262
bind O 0 1.064520461113716e-06
tightly O 0 5.438349944597576e-06
at O 0 1.3438915402730345e-07
the O 0 9.571191839086168e-09
basic O 0 7.674407243030146e-08
pH O 0 2.23925076170417e-06
of O 0 3.2969573737773317e-09
the O 0 1.8110071664523275e-08
cell O 0 2.423420255581732e-06
surface O 0 8.331995559274219e-06
, O 0 1.3237391272014065e-07
but O 0 2.202212989743657e-08
not O 0 4.92028195964167e-09
at O 0 1.9158136410624138e-08
the O 0 4.024461119911393e-08
acidic O 0 1.003966372081777e-05
pH O 0 1.5066042578837369e-05
of O 0 7.06856582155524e-08
intracellular O 0 1.1271102266618982e-05
vesicles O 0 4.3056978029198945e-05
. O 0 3.1330243928096024e-06

TfR O 1 0.9126351475715637
HFE O 0 0.021927250549197197
stoichiometry O 0 0.00042113466770388186
( O 0 8.703983439772855e-06
2 O 0 4.86295675727888e-06
1 O 0 8.409864449276938e-07
) O 0 1.0902539315793547e-07
differs O 0 6.565707622030459e-07
from O 0 1.6049646944793494e-07
TfR O 0 0.0002176174457417801
transferrin O 0 7.416540029225871e-06
stoichiometry O 0 1.3640374163514934e-06
( O 0 4.688561006105374e-08
2 O 0 1.2861015363796469e-07
2 O 0 3.341388605804241e-07
) O 0 1.7080370895428132e-08
, O 0 9.828000635536682e-09
implying O 0 4.25638901901948e-08
a O 0 7.269362001238733e-09
different O 0 2.178482505499346e-09
mode O 0 3.812776583345112e-08
of O 0 2.769789508860754e-09
binding O 0 3.1679704193265934e-08
for O 0 1.8310203131477465e-08
HFE O 0 9.212899749400094e-05
and O 0 2.684292610410921e-07
transferrin O 0 9.876954436549568e-07
to O 0 7.080345909571406e-08
TfR O 0 5.388226782088168e-05
, O 0 2.8870678292491903e-08
consistent O 0 5.976264105811424e-08
with O 0 6.918556394452935e-09
our O 0 2.293055523239218e-08
demonstration O 0 1.4913976542629825e-07
that O 0 2.769463414153961e-08
HFE O 0 1.881189200503286e-05
, O 0 6.011085673662819e-08
transferrin O 0 2.3552856873720884e-06
, O 0 4.989053081771999e-08
and O 0 1.715828830128885e-07
TfR O 0 8.354564488399774e-05
form O 0 5.424083937555224e-08
a O 0 1.6324000284839713e-07
ternary O 0 2.5960223410947947e-06
complex O 0 4.261667527316604e-06
. O 0 3.1774582112120697e-06

Identification O 0 8.02875183580909e-06
of O 0 2.1233043412394181e-07
three O 0 4.067274232966156e-07
novel O 0 5.666697688866407e-06
mutations O 0 5.249805326457135e-06
and O 0 3.7423198762098764e-08
a O 0 7.595174622565537e-08
high O 0 7.33709043743147e-07
frequency O 0 4.793078005604912e-07
of O 0 4.143221765673388e-09
the O 0 7.722304218304998e-08
Arg778Leu O 0 4.888626062893309e-05
mutation O 0 1.169485926766356e-06
in O 0 4.8574641198229074e-08
Korean O 0 1.4338816072267946e-06
patients O 0 5.93792265135562e-07
with O 0 4.5489835542866786e-07
Wilson B-Disease 0 0.010966437868773937
disease I-Disease 0 0.000330821902025491
. O 0 1.4024743677509832e-06

Four O 0 4.152868132223375e-05
mutations O 0 0.000152132663060911
- O 0 3.543983257259242e-05
- O 0 4.196501322439872e-05
R778L O 0 4.709763288701652e-06
, O 0 4.783205298508619e-08
A874V O 0 6.226890150173858e-07
, O 0 1.5091870864125667e-08
L1083F O 0 2.377262546815473e-07
, O 0 5.8817235526476e-09
and O 0 1.0457942956065835e-08
2304delC O 0 6.939108629921975e-07
- O 0 5.718069132853998e-06
- O 0 5.138798314874293e-06
in O 0 3.219282973532245e-08
the O 0 3.729849495925919e-08
copper O 0 3.588121899156249e-06
- O 0 5.695395088878286e-07
transporting O 0 7.979344474051686e-08
enzyme O 0 6.642088834496462e-08
, O 0 1.825566364743736e-08
P O 0 3.7828854146937374e-06
- O 0 8.897509360394906e-07
type O 0 5.58898136659991e-07
ATPase O 0 5.654174401570344e-06
( O 0 8.927667494162961e-08
ATP7B O 0 5.1183542382204905e-06
) O 0 1.81140809019098e-08
, O 0 8.391084271863747e-09
were O 0 8.400520101758957e-08
identified O 0 3.8954817682679277e-07
in O 0 8.028333553511402e-08
Korean O 0 2.7321575544192456e-06
Patients O 0 1.4712753682033508e-06
with O 0 4.4403276433513383e-07
Wilson B-Disease 0 0.004879859276115894
disease I-Disease 0 0.00011286397784715518
. O 0 1.1308723060210468e-06

Arg778Leu O 0 0.001166598405689001
, O 0 4.2736760974548815e-07
the O 0 3.296003114883206e-08
most O 0 1.9342380142006732e-08
frequently O 0 1.804124508453242e-06
reported O 0 2.1062191990495194e-06
mutation O 0 9.285059121566519e-08
of O 0 1.2308978281083682e-09
this O 0 2.4498194584055e-09
enzyme O 0 4.1272123496582935e-08
, O 0 5.143948555996758e-08
was O 0 2.9687151254620403e-05
found O 0 9.365756881152265e-08
in O 0 1.70445719760437e-08
six O 0 4.458029323473056e-08
of O 0 4.15802592357295e-09
eight O 0 2.7213113185098337e-07
unrelated O 0 3.08247831526387e-06
patients O 0 2.8327835366326326e-07
studied O 0 6.34783390296434e-08
, O 0 4.725196234289797e-09
an O 0 4.8206718616938815e-09
allele O 0 1.4583062579731632e-07
frequency O 0 2.2791921594489395e-07
of O 0 4.0202337459049886e-08
37 O 0 4.130715751671232e-06
. O 0 9.92170384961355e-07

5 O 0 0.0001058441775967367
% O 0 3.938942427339498e-06
, O 0 6.902610749648375e-08
which O 0 2.670473264743123e-08
is O 0 1.3344466864850801e-08
considerably O 0 8.831147511045856e-07
higher O 0 2.5841760020739457e-07
than O 0 1.1979917502458193e-08
those O 0 2.5976127915328107e-09
in O 0 4.187417967926876e-09
other O 0 6.7698735506382945e-09
Asian O 0 7.292821635473956e-08
populations O 0 6.527860136884556e-07
. O 0 5.213764211475791e-07

The O 0 3.1218783078656998e-06
novel O 0 2.56437624557293e-06
single O 0 1.1632702126007644e-06
nucleotide O 0 2.3532898012490477e-06
deletion O 0 3.4718984807113884e-06
, O 0 1.2076506550329213e-07
2304delC O 0 3.3232754503842443e-06
, O 0 1.1570615754408209e-07
was O 0 3.7726465507148532e-06
found O 0 1.0802024519307452e-07
in O 0 7.11483920667888e-08
one O 0 6.793495117562998e-07
patient O 0 8.257432455138769e-06
. O 0 1.4968935602155398e-06

Since O 0 1.0670272786228452e-05
a O 0 1.1059270264013321e-06
mutation O 0 3.3488229291833704e-06
at O 0 2.0918253085255856e-07
cDNA O 0 7.9075889516389e-06
nucleotide O 0 3.1580086215399206e-05
2302 O 0 8.756492752581835e-05
( O 0 1.4557272720594483e-07
2302insC O 0 3.260804305682541e-06
) O 0 4.770340567006315e-08
had O 0 4.166282906226115e-06
been O 0 1.127336076933716e-06
previously O 0 1.4778439663132303e-06
described O 0 1.9689348391693784e-06
, O 0 2.9018634606359228e-08
this O 0 1.5420846821712075e-09
region O 0 1.2799172388611169e-08
of O 0 1.6034746863624605e-09
the O 0 3.1929268118346954e-08
ATP7B O 0 3.838868724415079e-05
gene O 0 9.509051892564457e-07
may O 0 7.479532655452203e-07
be O 0 3.454089636534263e-08
susceptible O 0 5.766950721408648e-07
to O 0 6.006936814628716e-08
gene O 0 7.56692270442727e-06
rearrangements O 0 0.014592201448976994
causing O 0 0.00027268833946436644
Wilson B-Disease 0 0.01023503765463829
disease I-Disease 0 0.00023123578284867108
. O 0 1.042349026647571e-06

Disruption O 0 0.00027459627017378807
of O 0 3.382762372439174e-07
splicing O 0 7.4916215453413315e-06
regulated O 0 6.18216347447742e-07
by O 0 3.6099258693411684e-08
a O 0 1.8264586287841666e-07
CUG O 0 0.00011155953689012676
- O 0 4.087812612851849e-06
binding O 0 4.903804438072257e-07
protein O 0 2.425098728053854e-06
in O 0 4.962677394360071e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.395391493337229e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9948701858520508
DM B-Disease 1 1.0
) O 0 3.2996671507135034e-05
is O 0 5.812203767163737e-07
caused O 0 6.206714715517592e-07
by O 0 1.0392879445930703e-08
a O 0 1.7083978320897586e-07
CTG O 0 8.152293048624415e-06
expansion O 0 9.004315160154874e-08
in O 0 3.688329286433145e-08
the O 0 9.935227751611819e-08
3 O 0 8.42763256514445e-07
untranslated O 0 5.425363724498311e-06
region O 0 3.2690880402697076e-07
of O 0 2.0610837481171984e-08
the O 0 1.6172592722796253e-06
DM B-Disease 1 1.0
gene O 0 2.8627806386793964e-05
. O 0 3.096314003414591e-06

One O 0 4.543252998701064e-06
model O 0 3.802685114351334e-06
of O 0 5.329287091626611e-07
DM B-Disease 1 1.0
pathogenesis O 0 8.495349902659655e-05
suggests O 0 1.1815236575785093e-06
that O 0 3.696435513234064e-08
RNAs O 0 6.669044978480088e-07
from O 0 6.669672369952195e-09
the O 0 3.1166298430918005e-09
expanded O 0 4.3693692219903824e-08
allele O 0 1.0701600672291534e-07
create O 0 1.1738171323827373e-08
a O 0 4.0082891672454934e-08
gain O 0 8.920610525819939e-07
- O 0 2.680915713426657e-06
of O 0 1.6709417849369856e-08
- O 0 7.184788955783006e-06
function O 0 1.3181684721530473e-07
mutation O 0 1.7616366676520556e-07
by O 0 2.9941424894985857e-09
the O 0 6.38111696815713e-09
inappropriate O 0 2.435892554331076e-07
binding O 0 4.353737637075028e-08
of O 0 3.823355854137844e-09
proteins O 0 1.607900834699194e-08
to O 0 1.811681116237196e-08
the O 0 1.9516448901413241e-07
CUG O 0 0.00029637329862453043
repeats O 0 1.717294071568176e-05
. O 0 1.0204680620518047e-06

Data O 0 1.653404069656972e-05
presented O 0 3.430268634474487e-06
here O 0 1.0703315211912923e-07
indicate O 0 2.5404776238246995e-07
that O 0 7.126421230907454e-09
the O 0 3.227521716553383e-08
conserved O 0 6.245880399546877e-07
heterogeneous O 0 1.2187618949610624e-06
nuclear O 0 1.0906226179940859e-06
ribonucleoprotein O 0 1.535223304927058e-06
, O 0 2.179771918520146e-08
CUG O 0 1.9667752440000186e-06
- O 0 5.8377185041536e-07
binding O 0 1.2581807595779537e-07
protein O 0 2.358847979166967e-07
( O 0 2.3872994248108625e-08
CUG O 0 1.0627438314259052e-05
- O 0 0.00012961750326212496
BP O 0 0.0001874330046121031
) O 0 2.5145745041754708e-08
, O 0 1.1449384551553976e-08
may O 0 5.992380636143935e-08
mediate O 0 3.833515165752033e-06
the O 0 1.6544090897241404e-07
trans O 0 1.4873828149575274e-05
- O 0 0.0007823032792657614
dominant O 0 2.1082851162645966e-06
effect O 0 6.833457177890523e-08
of O 0 5.328064656140441e-09
the O 0 6.367988447664175e-08
RNA O 0 4.232230821799021e-06
. O 0 5.294253355714318e-07

CUG O 0 0.009046778082847595
- O 1 0.615071713924408
BP O 0 0.007524477783590555
was O 0 5.076043635199312e-06
found O 0 6.110430206263118e-08
to O 0 6.17284090509429e-09
bind O 0 6.405898744787919e-08
to O 0 1.2610597011075697e-08
the O 0 3.845591223239353e-08
human O 0 4.560933462016692e-07
cardiac O 0 0.0058097983710467815
troponin O 0 0.001107927761040628
T O 0 0.000241192989051342
( O 0 9.326058147962613e-08
cTNT O 0 6.639776870542846e-07
) O 0 2.1643769443357996e-08
pre O 0 3.3593579473745194e-07
- O 0 2.8952847515029134e-06
messenger O 0 1.0011601716541918e-06
RNA O 0 2.6101801609001996e-07
and O 0 1.0899499081062913e-08
regulate O 0 7.00361155736573e-08
its O 0 4.058354363678518e-08
alternative O 0 2.671462198122754e-07
splicing O 0 8.38424421090167e-06
. O 0 1.3665543292518123e-06

Splicing O 0 0.00020397352636791766
of O 0 2.899860874094884e-06
cTNT O 0 0.00017866285634227097
was O 0 7.539537909906358e-05
disrupted O 0 0.00024239985214080662
in O 0 8.33983995107701e-06
DM B-Disease 1 1.0
striated O 1 0.7941508889198303
muscle O 0 0.00044919014908373356
and O 0 2.875524955925357e-07
in O 0 7.622967501674793e-08
normal O 0 9.217175716003112e-07
cells O 0 5.130930844643444e-07
expressing O 0 7.092523901519598e-08
transcripts O 0 3.663852510271681e-07
that O 0 4.8809329911136956e-08
contain O 0 5.112452754474361e-07
CUG O 0 0.00026862186496146023
repeats O 0 4.989163426216692e-05
. O 0 2.4171281438611913e-06

Altered O 0 0.0008276531007140875
expression O 0 4.8265906116284896e-06
of O 0 7.209836638821798e-08
genes O 0 9.69129473560315e-07
regulated O 0 4.0002552736950747e-07
posttranscriptionally O 0 5.628694907500176e-06
by O 0 7.015645309138563e-08
CUG O 0 0.00032305464264936745
- O 0 0.009336710907518864
BP O 0 0.00017037559882737696
therefore O 0 1.5387631435714866e-07
may O 0 7.237682808636237e-08
contribute O 0 2.558141964925653e-08
to O 0 1.4306101547845174e-07
DM B-Disease 1 1.0
pathogenesis O 0 8.712316048331559e-05
. O 0 4.820757339984993e-07
. O 0 1.1915357163161389e-06

Identification O 0 1.54694225784624e-05
of O 0 1.5818505971765262e-07
a O 0 3.103770893631008e-07
novel O 0 9.104605851462111e-06
nonsense O 0 9.952585241990164e-05
mutation O 0 3.9093811210477725e-06
and O 0 5.472551123375524e-08
a O 0 1.3429729506242438e-07
missense O 0 3.789637730733375e-06
substitution O 0 7.79741711198767e-08
in O 0 2.4095546891089725e-08
the O 0 4.2145988032871173e-08
vasopressin O 0 2.745051688179956e-06
- O 0 4.780393646797165e-05
neurophysin O 0 2.4179664251278155e-05
II O 0 6.125300842541037e-06
gene O 0 1.4220948685306212e-07
in O 0 1.7810132035833703e-08
two O 0 9.733052053206848e-08
Spanish O 0 1.6202017150135362e-06
kindreds O 0 1.566321043355856e-05
with O 0 8.692915116625954e-07
familial B-Disease 0 0.07977467030286789
neurohypophyseal I-Disease 1 0.9952834248542786
diabetes I-Disease 1 0.9997602105140686
insipidus I-Disease 0 0.45551571249961853
. O 0 1.794644231267739e-05

Familial B-Disease 1 0.9998903274536133
neurohypophyseal I-Disease 1 0.9999872446060181
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.999996542930603
( O 0 0.03160199522972107
FNDI B-Disease 1 1.0
) O 0 1.441051381334546e-06
is O 0 1.036030639056662e-07
an O 0 3.288619154773187e-07
autosomal B-Disease 1 0.9997676014900208
dominant I-Disease 1 0.9994667172431946
disease I-Disease 1 0.9508271813392639
caused O 0 0.0021926420740783215
by O 0 1.1641107448667753e-05
deficiency O 1 0.5858244299888611
in O 0 1.2271529215013288e-07
the O 0 5.540693450711842e-07
antidiuretic O 0 0.00021612677664961666
hormone O 0 6.382711035257671e-06
arginine O 0 6.115349151514238e-06
vasopressin O 0 4.758100658364128e-06
( O 0 7.691757986094672e-08
AVP O 0 1.7454219687351724e-06
) O 0 9.801119915664458e-09
encoded O 0 1.1437117919399498e-08
by O 0 6.600725299676924e-09
the O 0 2.441955437859633e-08
AVP O 0 4.357126454124227e-05
- O 0 0.000540015462320298
neurophysin O 0 9.777422383194789e-05
II O 0 2.5805293262237683e-05
( O 0 8.992197564339222e-08
AVP O 0 6.5076228565885685e-06
- O 0 3.595117959775962e-05
NPII O 0 1.4600554095522966e-05
) O 0 4.128936836877983e-08
gene O 0 3.7259601981531887e-07
on O 0 2.2972506030782824e-06
chromosome O 0 0.00038303720066323876
20p13 O 0 4.305299444240518e-05
. O 0 2.3254208372236462e-06

In O 0 1.8443065528117586e-06
this O 0 2.1958292961699044e-08
study O 0 1.8824135139539067e-08
, O 0 1.6047513540229374e-08
we O 0 6.32889918250612e-09
analyzed O 0 6.62872423617955e-08
two O 0 4.086144755888199e-08
families O 0 3.9141230701034146e-08
with O 0 1.9881301938085016e-08
FNDI B-Disease 1 0.9998481273651123
using O 0 2.5420133553666346e-08
direct O 0 1.4489315525167967e-08
automated O 0 1.7807764152166783e-07
fluorescent O 0 8.612378223915584e-07
, O 0 1.9360612668606336e-08
solid O 0 6.397559815241038e-08
phase O 0 8.510362903280111e-08
, O 0 1.892977152806452e-08
single O 0 1.378415248609599e-07
- O 0 3.6932190141669707e-06
stranded O 0 4.796763732883846e-07
DNA O 0 1.1509414576948984e-07
sequencing O 0 7.125064627189204e-08
of O 0 1.0359037183604869e-08
PCR O 0 4.00167709813104e-06
- O 0 1.9602755401137983e-06
amplified O 0 5.79034531256184e-06
AVP O 0 3.102741175098345e-05
- O 0 3.478004873613827e-05
NPII O 0 4.091099981451407e-05
DNA O 0 1.1339013326505665e-05
. O 0 1.592977469044854e-06

In O 0 4.597034603648353e-06
one O 0 1.0981302267509818e-07
of O 0 6.572483890465719e-09
the O 0 5.7799674380021315e-08
families O 0 2.4704442580514296e-07
, O 0 6.576448896566944e-08
affected O 0 5.8043163164711586e-08
individuals O 0 3.31628791094829e-09
presented O 0 2.666050491484384e-08
a O 0 4.6170338663387156e-08
novel O 0 1.634906766412314e-06
nonsense O 0 3.4812446756404825e-06
mutation O 0 1.3065802306755359e-07
in O 0 7.7303177192789e-09
exon O 0 8.473270440845226e-07
3 O 0 2.062193544816182e-07
of O 0 5.1495803177203925e-09
the O 0 3.9319541400573144e-08
gene O 0 2.717779068461823e-07
, O 0 1.3969018830550795e-08
consisting O 0 5.909340572429755e-09
in O 0 1.1261714227828179e-08
a O 0 1.205561090955598e-07
G O 0 5.6342007155762985e-05
to O 0 6.743714209278551e-08
T O 0 9.295526069763582e-06
transition O 0 4.138303211220773e-08
at O 0 2.752254424365219e-08
nucleotide O 0 4.051738073940214e-07
2101 O 0 1.4387663895831793e-06
, O 0 9.026992486838026e-09
which O 0 6.347129044570465e-09
produces O 0 9.834489667071011e-09
a O 0 1.330114063335941e-08
stop O 0 1.7482359737641673e-07
signal O 0 1.2980841574972146e-06
in O 0 6.426029841577474e-08
codon O 0 7.441805337293772e-06
82 O 0 2.8652755190705648e-06
( O 0 1.8791030242937268e-07
Glu O 0 0.0001474240270908922
) O 0 7.67915082633408e-08
of O 0 5.762509402984506e-08
NPII O 0 0.00033714284654706717
. O 0 2.540979266996146e-06

The O 0 1.2061344023095444e-05
premature O 0 5.446198338177055e-05
termination O 0 8.843242540024221e-06
eliminates O 0 3.836635187326465e-06
part O 0 8.591749178776809e-08
of O 0 1.821552508829427e-08
the O 0 1.310960016098761e-07
C O 0 6.076585850678384e-05
- O 0 1.1120324415969662e-05
terminal O 0 3.194474516021728e-07
domain O 0 1.8115461131174015e-08
of O 0 2.9508504528763524e-09
NPII O 0 1.0012814527726732e-05
, O 0 4.252337593158018e-09
including O 0 8.400079520853865e-10
a O 0 8.552309083142973e-09
cysteine O 0 3.270128701160502e-08
residue O 0 5.846494133265878e-08
in O 0 5.470617736591521e-09
position O 0 3.4687204220062995e-07
85 O 0 8.349275759655939e-08
, O 0 2.1397816851731477e-08
which O 0 7.800556289794258e-08
could O 0 5.6982532470328806e-08
be O 0 1.1130341093235074e-08
involved O 0 4.133410502760171e-09
in O 0 1.2749418409896407e-08
the O 0 6.026215970678095e-08
correct O 0 3.518956418702146e-06
folding O 0 1.2310883903410286e-06
of O 0 1.761667967059566e-08
the O 0 2.642500191996078e-07
prohormone O 0 0.00014458017540164292
. O 0 1.9886629161192104e-06

In O 0 2.846433972081286e-06
the O 0 1.45821161368076e-07
second O 0 1.8675918909139e-06
family O 0 3.1078317874744243e-07
, O 0 1.0529556782046257e-08
a O 0 1.3454876324203724e-08
G279A O 0 2.1028201047101902e-07
substitution O 0 3.2983678011078155e-08
at O 0 3.05124814303781e-08
position O 0 2.1846445008577575e-07
- O 0 1.3285682598507265e-06
1 O 0 3.2384917858507833e-08
of O 0 2.394950904260895e-09
the O 0 2.991718162093093e-08
signal O 0 3.537327529556933e-06
peptide O 0 1.24451787542057e-07
was O 0 3.1198527494780137e-07
observed O 0 5.558169391406409e-08
in O 0 7.784441535818587e-09
all O 0 1.1797021137738284e-08
affected O 0 1.301585683677331e-07
individuals O 0 4.200562742084912e-08
. O 0 3.752434167836327e-07

This O 0 7.323162662942195e-06
missense O 0 0.002950262511149049
mutation O 0 0.0001009142433758825
, O 0 3.006425117746403e-07
which O 0 2.615367975522531e-07
replaces O 0 2.0545705410768278e-05
Ala O 0 0.000126603088574484
with O 0 4.220761411488638e-07
Thr O 0 0.00037051725666970015
, O 0 4.9932129542185066e-08
is O 0 1.2829234563582759e-08
frequent O 0 2.1916245884767704e-07
among O 0 5.01509930472821e-07
FNDI B-Disease 1 1.0
patients O 0 5.906418664380908e-06
and O 0 5.534366778192634e-07
is O 0 9.929468802738484e-08
thought O 0 5.924816903757346e-08
to O 0 6.5658181114258696e-09
reduce O 0 7.961268977396685e-08
the O 0 1.1020872214828614e-08
efficiency O 0 9.354901209235322e-08
of O 0 5.723423512904446e-09
cleavage O 0 4.996499228582252e-06
by O 0 4.7345448450641925e-08
signal O 0 6.761617896700045e-06
peptidases O 0 1.2497605894168373e-05
. O 0 1.563126375003776e-07
. O 0 3.8859792539369664e-07

Genetic O 0 0.0006203991943039
heterogeneity O 0 0.00011063395504606888
of O 0 1.8673176782613155e-06
Saethre B-Disease 1 0.8995633125305176
- I-Disease 1 0.999995231628418
Chotzen I-Disease 1 0.9999946355819702
syndrome I-Disease 1 0.9999992847442627
, O 0 1.4106943524438975e-07
due O 0 6.906547866947221e-08
to O 0 5.653984658238187e-08
TWIST O 0 0.0002977097174152732
and O 0 9.046505510923453e-06
FGFR O 0 0.020809022709727287
mutations O 0 6.465760088758543e-05
. O 0 1.7636484699323773e-06

Thirty O 0 0.00011549190094228834
- O 0 7.300804281840101e-05
two O 0 3.472891023648117e-07
unrelated O 0 3.036287125723902e-06
patients O 0 9.19110561881098e-07
with O 0 1.5808605979827917e-08
features O 0 1.1117695066786837e-06
of O 0 2.0235417252933985e-07
Saethre B-Disease 1 0.9914903044700623
- I-Disease 1 0.9999898672103882
Chotzen I-Disease 1 0.99997878074646
syndrome I-Disease 1 0.9999160766601562
, O 0 4.511224105385736e-08
a O 0 3.215101571640844e-07
common O 0 1.581573815201409e-05
autosomal B-Disease 1 0.885037362575531
dominant I-Disease 0 0.048911962658166885
condition I-Disease 0 0.00046815647510811687
of O 0 5.387644819165871e-07
craniosynostosis B-Disease 1 0.9753080606460571
and O 0 0.002146907150745392
limb B-Disease 1 0.9705909490585327
anomalies I-Disease 0 0.1211286336183548
, O 0 2.9603688744828105e-07
were O 0 6.662471605523024e-07
screened O 0 9.389865454068058e-07
for O 0 1.7159687004664193e-08
mutations O 0 1.1303267228868208e-06
in O 0 2.4778097795774556e-08
TWIST O 0 4.739793803310022e-05
, O 0 2.190402454971263e-07
FGFR2 O 0 1.8002498109126464e-05
, O 0 5.239343892071702e-08
and O 0 2.3898670065136685e-07
FGFR3 O 0 8.868189615895972e-05
. O 0 1.1404832775951945e-06

Nine O 0 0.00016177671204786748
novel O 0 8.258085472334642e-06
and O 0 9.68160406955576e-07
three O 0 4.331994318818033e-07
recurrent O 0 0.002854361664503813
TWIST O 1 0.8764991760253906
mutations O 0 0.015011834912002087
were O 0 2.6771829197969055e-06
found O 0 1.437420706906778e-07
in O 0 1.260682580550565e-07
12 O 0 1.5387910252684378e-06
families O 0 4.965131097378617e-07
. O 0 6.58376563933416e-07

Seven O 0 2.929926813521888e-05
families O 0 1.4531156011798885e-06
were O 0 3.755376951630751e-07
found O 0 3.134420367700841e-08
to O 0 1.5327751512472787e-08
have O 0 4.330300384935981e-08
the O 0 1.9598957123889704e-08
FGFR3 O 0 4.212190106045455e-05
P250R O 0 3.1009624308353523e-06
mutation O 0 3.169935212099517e-07
, O 0 1.1068270744374331e-08
and O 0 2.612171812188535e-08
one O 0 1.967656793055994e-08
individual O 0 1.3456621594798435e-08
was O 0 3.5311995816300623e-06
found O 0 5.07851467546061e-08
to O 0 3.0202009781987726e-08
have O 0 2.270619781086225e-08
an O 0 2.505898955007524e-08
FGFR2 O 0 2.9307653676369227e-05
VV269 O 0 2.8039644348609727e-06
- O 0 4.8479951146873645e-06
270 O 0 1.3989597391628195e-06
deletion O 0 1.1638011528702918e-05
. O 0 1.5378858506664983e-06

To O 0 1.8349206811762997e-06
date O 0 9.154967415270221e-07
, O 0 1.9332901501911692e-08
our O 0 6.432342658513335e-09
detection O 0 7.27175049064499e-08
rate O 0 1.6022349313971063e-07
for O 0 3.388313629670847e-09
TWIST O 0 2.4780500098131597e-05
or O 0 6.278015121097269e-07
FGFR O 0 0.0001269126369152218
mutations O 0 3.193943257429055e-06
is O 0 5.0299956200206e-08
68 O 0 7.591444273202796e-07
% O 0 2.4797435216328267e-08
in O 0 1.0466802535802344e-08
our O 0 2.948807491520711e-07
Saethre B-Disease 0 0.07022429257631302
- I-Disease 1 0.9986692667007446
Chotzen I-Disease 1 0.9999010562896729
syndrome I-Disease 1 0.9999828338623047
patients O 0 5.225616632742458e-07
, O 0 3.98490795916473e-09
including O 0 7.244392197236493e-09
our O 0 3.80197775484703e-08
five O 0 1.5076932413649047e-07
patients O 0 2.051653495982464e-07
elsewhere O 0 1.5858276469771226e-07
reported O 0 3.872498268719937e-07
with O 0 1.0711280395980793e-07
TWIST O 0 0.005557954777032137
mutations O 0 0.00011538480612216517
. O 0 1.905273279589892e-06

More O 0 8.381784937228076e-07
than O 0 5.954532866780937e-08
35 O 0 1.0486589729907791e-07
different O 0 1.9898751091318445e-08
TWIST O 0 0.00023546066950075328
mutations O 0 2.6676339984987862e-05
are O 0 3.699193129591549e-08
now O 0 4.667423070259247e-08
known O 0 3.5903422457295164e-08
in O 0 2.353337791305421e-08
the O 0 6.20845526100311e-08
literature O 0 2.0832926850289368e-07
. O 0 4.6349981630555703e-07

The O 0 1.970401854123338e-06
most O 0 8.911591464766389e-08
common O 0 4.6908958495350817e-08
phenotypic O 0 1.021859702632355e-06
features O 0 6.178660441946704e-06
, O 0 2.759077517566766e-07
present O 0 1.673132743462702e-08
in O 0 2.2585687986520497e-08
more O 0 5.589421814278239e-09
than O 0 3.6047362872437816e-09
a O 0 4.3002010841064475e-08
third O 0 1.4832008901066729e-06
of O 0 2.3136863092076965e-08
our O 0 1.0717594989273493e-07
patients O 0 5.408443470855673e-08
with O 0 1.7781484729084696e-08
TWIST O 0 0.0037768215406686068
mutations O 0 1.142932796938112e-05
, O 0 9.413391843793306e-09
are O 0 4.97768271046084e-09
coronal B-Disease 0 1.5109335436136462e-05
synostosis I-Disease 0 8.897407496988308e-06
, O 0 5.695710925124331e-08
brachycephaly B-Disease 0 2.8556839879456675e-06
, O 0 5.9250087502960014e-08
low B-Disease 0 2.876016696973238e-05
frontal I-Disease 1 0.9999502897262573
hairline I-Disease 1 0.9999997615814209
, O 0 1.2611732017830946e-05
facial B-Disease 1 0.8172993659973145
asymmetry I-Disease 0 0.010303981602191925
, O 0 3.1391914490086492e-06
ptosis B-Disease 0 0.00802216399461031
, O 0 4.1854076471281587e-07
hypertelorism B-Disease 0 4.122863174416125e-05
, O 0 1.652597063639405e-07
broad B-Disease 0 5.792736828880152e-06
great I-Disease 0 9.167310963675845e-06
toes I-Disease 0 0.14821487665176392
, O 0 7.402892521213289e-08
and O 0 2.399278002940264e-07
clinodactyly B-Disease 0 4.605206413543783e-05
. O 0 1.3076763707431382e-06

Significant O 0 1.091422927856911e-05
intra O 0 2.6879588403971866e-05
- O 0 5.2811177738476545e-05
and O 0 5.23246853845194e-07
interfamilial O 0 2.6954232453135774e-05
phenotypic O 0 1.358949884888716e-05
variability O 0 5.0847964303102344e-05
is O 0 3.138782034284304e-08
present O 0 1.7822095799147064e-08
for O 0 1.156467632767999e-08
either O 0 5.551896720135119e-07
TWIST O 0 0.03880922123789787
mutations O 0 0.00010948977433145046
or O 0 9.254785027223988e-07
FGFR O 0 0.0014622373273596168
mutations O 0 2.230821701232344e-05
. O 0 8.653312306705629e-07

The O 0 2.0656314063671743e-06
overlap O 0 1.8342014982408728e-06
in O 0 7.383291489304611e-08
clinical O 0 2.5567891270839027e-07
features O 0 1.9497711036819965e-06
and O 0 1.1115554343632539e-06
the O 0 3.819734928356411e-08
presence O 0 8.67864500264659e-08
, O 0 1.214510803038138e-08
in O 0 4.180323642799522e-09
the O 0 4.930644337264312e-09
same O 0 1.9183767463459844e-08
genes O 0 3.5343692417200145e-08
, O 0 4.425148691922232e-09
of O 0 2.1410135886412718e-09
mutations O 0 1.0443494602441206e-07
for O 0 1.2006011740339773e-09
more O 0 1.7650774175592687e-09
than O 0 9.623361663102514e-09
one O 0 4.163757694186643e-08
craniosynostotic B-Disease 0 3.4681383112911135e-05
condition I-Disease 0 1.1044019174732966e-06
- O 0 3.7140685549275076e-07
such O 0 2.961416667446315e-09
as O 0 4.493962535434548e-08
Saethre B-Disease 0 4.044116394652519e-06
- I-Disease 0 2.3336831418419024e-06
Chotzen I-Disease 0 2.3847928787290584e-06
, I-Disease 0 8.701397824495416e-09
Crouzon I-Disease 0 3.7808769093317096e-07
, I-Disease 0 1.1300832269967032e-08
and I-Disease 0 1.8718466776590503e-07
Pfeiffer I-Disease 0 0.1266615092754364
syndromes I-Disease 0 0.02187458425760269
- O 0 8.592339327151421e-06
support O 0 5.401989611186764e-08
the O 0 1.636077406885761e-08
hypothesis O 0 1.0795351101933193e-07
that O 0 1.2588199815866119e-08
TWIST O 0 1.613145650480874e-05
and O 0 4.352500866389164e-07
FGFRs O 0 7.595226634293795e-06
are O 0 2.207295901612838e-09
components O 0 7.956377778839396e-09
of O 0 7.723107153800868e-10
the O 0 4.83610662627143e-09
same O 0 9.206298834385507e-09
molecular O 0 5.393218316385173e-08
pathway O 0 5.0733635958977175e-08
involved O 0 3.745816989919604e-09
in O 0 4.625034577543374e-09
the O 0 1.4436103867865313e-08
modulation O 0 6.245815029615187e-07
of O 0 1.8228807618925202e-07
craniofacial O 1 0.9709304571151733
and O 0 0.0008154542301781476
limb O 0 0.005188459996134043
development O 0 2.0079124141147986e-08
in O 0 4.387867846844529e-08
humans O 0 5.854305129560089e-08
. O 0 6.262533247536339e-08
. O 0 3.7808263186889235e-07

Mutation O 0 0.0008742876816540956
analysis O 0 1.4349213415698614e-05
of O 0 3.005633743669023e-06
UBE3A O 1 0.85284024477005
in O 1 0.5047730803489685
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.027245623990893364
. O 0 1.2088475159544032e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.7501683235168457
AS B-Disease 1 0.9999706745147705
) O 0 9.71457666310016e-07
is O 0 1.1014697776090543e-07
caused O 0 9.187074283545371e-07
by O 0 5.890359489058028e-08
chromosome O 0 0.00026638974668458104
15q11 O 0 1.1187434211024083e-05
- O 0 2.0402409063535742e-05
q13 O 0 5.869040251127444e-06
deletions O 0 2.3159839201980503e-06
of O 0 2.207941385279355e-08
maternal O 0 6.718167696817545e-06
origin O 0 9.540647738504049e-08
, O 0 2.2778898767228384e-08
by O 0 2.550060074213434e-08
paternal O 0 9.576055890647694e-05
uniparental B-Disease 0 0.03759515658020973
disomy I-Disease 0 0.04006253927946091
( O 0 2.631495362948044e-06
UPD B-Disease 1 0.9999988079071045
) O 0 1.1869814642295751e-07
15 O 0 1.5448151202690497e-07
, O 0 1.5354553184465658e-08
by O 0 2.3253173608850375e-08
imprinting O 0 0.29074856638908386
defects O 1 0.999842643737793
, O 0 1.204228112783312e-07
and O 0 8.119870642531168e-08
by O 0 3.5343962423439734e-08
mutations O 0 2.126458412021748e-06
in O 0 4.254830798799958e-08
the O 0 3.930072693947295e-07
UBE3A O 0 0.000198073495994322
gene O 0 9.840665370575152e-06
. O 0 2.256804691569414e-06

UBE3A O 0 0.0035873758606612682
encodes O 0 8.340412023244426e-05
a O 0 4.3887694118893705e-06
ubiquitin O 0 1.9481432900647633e-05
- O 0 1.1925783837796189e-05
protein O 0 9.886058478514315e-07
ligase O 0 8.954199870458979e-07
and O 0 2.36729007951908e-07
shows O 0 7.328318588406546e-06
brain O 0 4.0904287743614987e-05
- O 0 1.0205331818724517e-05
specific O 0 4.14503460888227e-07
imprinting O 0 0.00016499590128660202
. O 0 3.833789833151968e-06

Here O 0 2.0180686988169327e-05
we O 0 7.855483659113816e-07
describe O 0 2.3933505417517154e-06
UBE3A O 0 0.00013359288277570158
coding O 0 0.00013466543168760836
- O 0 0.003029954619705677
region O 0 2.3331054762820713e-05
mutations O 0 2.2866408471600153e-05
detected O 0 4.19699489384584e-07
by O 0 9.21464327063859e-09
SSCP O 0 4.6908785407140385e-06
analysis O 0 4.99208958615327e-08
in O 0 6.56871392834546e-08
13 O 0 3.340016746733454e-06
AS B-Disease 1 0.9919622540473938
individuals O 0 4.484287075001703e-08
or O 0 7.298122284282726e-08
families O 0 4.828054329664155e-07
. O 0 7.425305739161558e-07

Two O 0 1.2502756362664513e-05
identical O 0 3.163778092130087e-05
de O 0 5.262075501377694e-05
novo O 0 2.698309072002303e-05
5 O 0 1.2277655514481012e-06
- O 0 1.3337349628272932e-05
bp O 0 5.622257049253676e-06
duplications O 0 8.572438900955603e-07
in O 0 5.197937014145282e-08
exon O 0 5.1161191549908835e-06
16 O 0 5.825827884109458e-06
were O 0 2.4569721972511616e-06
found O 0 1.512933067715494e-06
. O 0 8.32338059808535e-07

Among O 0 3.473902097539394e-06
the O 0 6.843513489229736e-08
other O 0 9.230229025547487e-09
11 O 0 9.978032977642215e-08
unique O 0 9.127396083385975e-08
mutations O 0 3.0265503028203966e-06
, O 0 3.3234510254942506e-08
8 O 0 1.4306155549093091e-07
were O 0 4.28158202225859e-08
small O 0 1.9354779112745746e-08
deletions O 0 1.0597890423014178e-06
or O 0 5.244653067393301e-08
insertions O 0 2.7566788958210964e-06
predicted O 0 5.452980076370295e-06
to O 0 3.901824285890143e-08
cause O 0 4.884630584456318e-07
frameshifts O 0 1.1608117347350344e-05
, O 0 5.583415330079333e-08
1 O 0 6.219774206783768e-08
was O 0 8.768508905632189e-07
a O 0 6.190705903463822e-08
mutation O 0 1.52600804881331e-07
to O 0 4.447868739987371e-09
a O 0 2.8185221268017813e-08
stop O 0 1.0132477967772502e-07
codon O 0 1.734498766836623e-07
, O 0 5.583721485180604e-09
1 O 0 1.6821434911662436e-08
was O 0 2.4520605279576557e-07
a O 0 1.3347093386073539e-07
missense O 0 2.0069219317520037e-05
mutation O 0 3.493306337531976e-07
, O 0 1.2418971628846975e-08
and O 0 5.9229972038110645e-08
1 O 0 3.357314994900662e-07
was O 0 5.616316411760636e-05
predicted O 0 2.356024651817279e-06
to O 0 3.571961570969506e-08
cause O 0 1.0909341341402978e-07
insertion O 0 1.563888218925058e-07
of O 0 1.130557514272823e-08
an O 0 1.760304968456694e-07
isoleucine O 0 0.030241256579756737
in O 0 7.90383509752246e-08
the O 0 3.783718227623467e-08
hect O 0 8.73239116572222e-07
domain O 0 2.2394157639382684e-08
of O 0 3.1577194192777824e-09
the O 0 3.000673132191878e-08
UBE3A O 0 9.834145203058142e-06
protein O 0 1.2458218634492368e-07
, O 0 9.289819580260428e-09
which O 0 3.921825530994738e-09
functions O 0 4.447962442810649e-09
in O 0 8.485010027925455e-09
E2 O 0 1.1391005045879865e-06
binding O 0 1.3427859357761918e-07
and O 0 4.679162302068107e-08
ubiquitin O 0 1.3453999372359249e-06
transfer O 0 5.891775458621851e-07
. O 0 1.2589192692757933e-06

Eight O 0 9.449438948649913e-06
of O 0 5.385713919281443e-08
the O 0 2.7582190753605573e-08
cases O 0 1.1195945859299172e-07
were O 0 1.2173829873063369e-06
familial O 0 2.9971557523822412e-05
, O 0 5.240528366812214e-07
and O 0 3.2689635531824024e-07
five O 0 2.712023388085072e-07
were O 0 9.387160844198661e-07
sporadic O 0 8.326378156198189e-05
. O 0 1.9600549876486184e-06

In O 0 3.696975682032644e-06
two O 0 8.274619176518172e-07
familial O 0 0.0001543901744298637
cases O 0 1.4298641417553881e-06
and O 0 4.571153624510771e-07
one O 0 1.0771595526648525e-07
sporadic O 0 2.223430601588916e-05
case O 0 5.820746196150139e-07
, O 0 1.2384701619794214e-07
mosaicism O 0 1.1070318578276783e-05
for O 0 6.85550674006663e-08
UBE3A O 0 0.00031636509811505675
mutations O 0 1.8450278730597347e-05
was O 0 6.366899015119998e-06
detected O 0 8.024106250559271e-07
in O 0 2.928172904148596e-08
the O 0 4.501348982444142e-08
mother O 0 2.6784571218740894e-06
of O 0 1.0177371834174664e-08
three O 0 1.3809615211357595e-06
AS B-Disease 1 0.9999996423721313
sons O 0 0.0037556577008217573
, O 0 3.609698850937093e-08
in O 0 7.894340292580182e-09
the O 0 4.65597977949983e-08
maternal O 0 4.3652144086081535e-06
grandfather O 0 1.272500981031044e-06
of O 0 2.269908483398808e-09
two O 0 1.5285600341030658e-07
AS B-Disease 1 0.9999548196792603
first O 0 2.658381163200829e-06
cousins O 0 5.090574995847419e-05
, O 0 1.3166683743293106e-07
and O 0 5.2784528747906734e-08
in O 0 2.8577190391843033e-08
the O 0 1.2581460850924486e-07
mother O 0 3.372388391653658e-06
of O 0 3.0867604028372853e-09
an O 0 1.1681355971404628e-07
AS B-Disease 1 0.9999914169311523
daughter O 0 0.0809672400355339
. O 0 1.9106155377812684e-06

The O 0 8.83455982148007e-07
frequencies O 0 6.037531647962169e-07
with O 0 2.9378231403143218e-08
which O 0 7.79863711386497e-08
we O 0 3.142795534927245e-08
detected O 0 4.444801504632778e-07
mutations O 0 4.051038615671132e-07
were O 0 9.965879144147038e-08
5 O 0 1.4251604341097845e-07
( O 0 2.020054878926203e-08
14 O 0 1.5828464938749676e-07
% O 0 1.4418711558050745e-08
) O 0 7.903888654681168e-10
of O 0 5.80524017745887e-10
35 O 0 2.6624629612115314e-08
in O 0 4.0576479953813305e-09
sporadic O 0 3.335814881211263e-06
cases O 0 1.205425377293068e-07
and O 0 1.5318916268824978e-07
8 O 0 3.907552184045926e-07
( O 0 1.3047979585678604e-08
80 O 0 2.0561168767585514e-08
% O 0 9.243900755961931e-09
) O 0 1.0442449127623377e-09
of O 0 1.2352817657657056e-09
10 O 0 2.30091075081873e-08
in O 0 3.88423337938093e-08
familial O 0 1.8359782188781537e-05
cases O 0 5.857024234501296e-07
. O 0 1.5701932909450989e-07
. O 0 9.39093069973751e-07

The O 0 5.787307964055799e-05
hemochromatosis B-Disease 1 0.9999990463256836
845 O 0 0.0014701677719131112
G O 0 0.026733998209238052
- O 0 8.550756319891661e-05
- O 0 4.284247916075401e-05
> O 0 5.263252660370199e-07
A O 0 5.6161304939905676e-08
and O 0 2.9036684168204374e-08
187 O 0 2.0328374716882536e-07
C O 0 9.442199484510638e-07
- O 0 2.970098421428702e-06
- O 0 2.2917036403669044e-05
> O 0 6.620133717660792e-06
G O 0 8.35115642985329e-05
mutations O 0 1.9183478343620664e-06
: O 0 3.033786555306506e-08
prevalence O 0 2.358790197831695e-06
in O 0 4.1418648066837704e-08
non O 0 5.43003523034713e-07
- O 0 9.566554217599332e-05
Caucasian O 0 0.00011189928773092106
populations O 0 4.723162419395521e-06
. O 0 1.048360445565777e-06

Hemochromatosis B-Disease 1 0.9997243285179138
, O 0 9.184426016872749e-05
the O 0 9.620400669518858e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 2.6696793611336034e-06
iron I-Disease 1 0.9940720200538635
metabolism I-Disease 0 9.242941450793296e-05
, O 0 4.264954611699068e-08
leads O 0 4.223390703828045e-07
, O 0 7.032270588069878e-08
if O 0 3.014359961639457e-08
untreated O 0 1.7335078155156225e-06
, O 0 2.3521712577689868e-08
to O 0 8.878456014826952e-08
progressive O 0 4.291035293135792e-05
iron B-Disease 1 0.5476646423339844
overload I-Disease 0 0.0006787532474845648
and O 0 1.3204462447902188e-06
premature B-Disease 0 1.5750627426314168e-05
death I-Disease 0 1.6787587810540572e-05
. O 0 9.585269253875595e-07

The O 0 6.458573625423014e-05
hemochromatosis B-Disease 1 0.9999995231628418
gene O 0 3.4674802009249106e-05
, O 0 3.4526146919233724e-07
HFE O 0 0.00023526072618551552
, O 0 4.2257153154423577e-07
recently O 0 2.9865950637031347e-06
has O 0 6.68849111207237e-07
been O 0 3.837100166492746e-07
identified O 0 8.635085464447911e-07
, O 0 2.7170576899493426e-08
and O 0 1.6256880286391606e-08
characterization O 0 6.686182985049527e-08
of O 0 3.2495719448633054e-09
this O 0 5.168315109216337e-09
gene O 0 2.3188847819710645e-07
has O 0 4.761105628858786e-06
shown O 0 3.5729908631765284e-07
that O 0 5.867940799930693e-09
it O 0 3.0359557090520184e-09
contains O 0 4.646564910615325e-09
two O 0 7.00417288612698e-08
mutations O 0 1.8184894088335568e-06
that O 0 1.722730935682648e-08
result O 0 4.726875246774398e-08
in O 0 4.546242138303569e-08
amino O 0 1.874992818784449e-07
acid O 0 1.3454123859446554e-07
substitutions O 0 9.795012090307864e-08
- O 0 3.2474054023623466e-07
cDNA O 0 9.12488644644327e-07
nucleotides O 0 7.265289241331629e-07
845 O 0 1.0516229167478741e-06
G O 0 1.6875163055374287e-05
- O 0 5.38409312866861e-06
- O 0 5.0761982492986135e-06
> O 0 2.087767683178754e-07
A O 0 9.489613717050815e-08
( O 0 2.4014337185462864e-08
C282Y O 0 2.1031711128216557e-07
) O 0 5.855418816480551e-09
and O 0 1.0130078109682472e-08
187 O 0 1.027509455298059e-07
C O 0 9.318570164396078e-07
- O 0 1.0353553079767153e-05
- O 0 8.68037313921377e-05
> O 0 7.831586117390543e-06
G O 0 0.00010790334636112675
( O 0 2.3988067709979077e-07
H63D O 0 1.7192884115502238e-05
) O 0 3.182839805049298e-07
. O 0 6.882593766022183e-07

Although O 0 0.009856016375124454
hemochromatosis B-Disease 1 1.0
is O 0 3.6184235341352178e-06
common O 0 2.486007133484236e-07
in O 0 1.9120760441637685e-07
Caucasians O 0 1.2837374015362002e-05
, O 0 5.654502288621188e-08
affecting O 0 1.750915714637813e-07
> O 0 6.870769766464946e-07
= O 0 1.083513893718191e-06
1 O 0 1.5084454219049803e-07
/ O 0 2.4985499749163864e-06
300 O 0 2.2984632863654042e-08
individuals O 0 1.1211834793911635e-09
of O 0 5.972817240795791e-10
northern O 0 9.476627127469328e-08
European O 0 3.586824348644768e-08
origin O 0 2.4460948822024875e-08
, O 0 1.9628100034196905e-08
it O 0 3.097802903084812e-08
has O 0 2.9031349413344287e-07
not O 0 2.7847503858424716e-08
been O 0 6.646980210689435e-08
recognized O 0 1.3821371602773525e-08
in O 0 1.4558904304351472e-08
other O 0 3.5867966374780735e-08
populations O 0 9.050846188074502e-07
. O 0 6.297534014265693e-07

The O 0 1.7109508689827635e-06
present O 0 2.4279788135572744e-07
study O 0 4.50581545408113e-08
used O 0 2.853851732709245e-08
PCR O 0 1.266725575987948e-06
and O 0 4.045162071975028e-08
restriction O 0 1.408068044383981e-07
- O 0 7.135182045203692e-07
enzyme O 0 1.162469018822776e-07
digestion O 0 1.1709574465612604e-07
to O 0 6.592106860381364e-09
analyze O 0 2.4834024614506234e-08
the O 0 1.2190945142265264e-08
frequency O 0 1.2668957083405985e-07
of O 0 3.3230185270127777e-09
the O 0 1.9642294901700552e-08
845 O 0 1.2653539442908368e-06
G O 0 2.9168822948122397e-05
- O 0 3.5789528283203254e-06
- O 0 1.6943043874562136e-06
> O 0 8.505721638130126e-08
A O 0 2.9166848491968267e-08
and O 0 7.243977417914493e-09
187 O 0 6.948022956976274e-08
C O 0 4.62047836435886e-07
- O 0 9.097966540139169e-07
- O 0 5.768772098235786e-06
> O 0 1.5468954188690986e-06
G O 0 2.265229522890877e-05
mutations O 0 3.665732890567597e-07
in O 0 1.6722713880312767e-08
HLA O 0 5.7902734624804e-06
- O 0 7.077266559463169e-07
typed O 0 6.368170488713076e-07
samples O 0 4.129212527459458e-08
from O 0 1.0024135299602221e-08
non O 0 8.1223490155935e-08
- O 0 1.071745191438822e-05
Caucasian O 0 1.5867726688156836e-05
populations O 0 1.2989605124857917e-07
, O 0 8.540637530529693e-09
comprising O 0 8.816050112159246e-09
Australian O 0 1.8209551200243368e-08
Aboriginal O 0 9.570812409265272e-08
, O 0 8.630424375155599e-09
Chinese O 0 3.839755180479187e-09
, O 0 7.919481070928214e-09
and O 0 7.236771182306256e-08
Pacific O 0 7.853671490920533e-07
Islanders O 0 8.911588338378351e-06
. O 0 1.024125026560796e-06

Results O 0 0.0003351992345415056
showed O 0 2.5349610950797796e-05
that O 0 2.6531454366818252e-08
the O 0 2.218168937417886e-08
845 O 0 2.435365786368493e-06
G O 0 0.00021701138757634908
- O 0 1.044714190356899e-05
- O 0 1.1983196600340307e-05
> O 0 3.925030966911436e-07
A O 0 3.5796654174191644e-07
mutation O 0 3.5256443879916333e-06
was O 0 2.60653359873686e-06
present O 0 8.026048270437514e-09
in O 0 1.086396661520439e-08
these O 0 4.061611935668452e-09
populations O 0 3.0790410221470665e-08
( O 0 6.559584431187204e-09
allele O 0 4.1132945938215926e-08
frequency O 0 1.0203653744156327e-07
0 O 0 2.3500366097550796e-08
. O 0 6.032205401851343e-09
32 O 0 1.7166668442314403e-07
% O 0 2.3994878972644074e-08
) O 0 3.447150787039277e-09
, O 0 4.791329555331458e-09
and O 0 3.9627927606034064e-08
, O 0 1.9468595624516638e-08
furthermore O 0 3.60375516095246e-08
, O 0 1.438445806911659e-08
it O 0 3.52292062189008e-08
was O 0 2.324149500054773e-05
always O 0 2.646949042173219e-07
seen O 0 7.826069747807196e-08
in O 0 5.758638899067137e-09
conjunction O 0 3.407992821280459e-08
with O 0 5.9472455404829816e-08
HLA O 0 0.00014889526937622577
haplotypes O 0 5.323620371200377e-06
common O 0 6.594825663341908e-08
in O 0 7.487641084935603e-08
Caucasians O 0 2.7920398224523524e-06
, O 0 2.300919632602927e-08
suggesting O 0 4.995051483547286e-08
that O 0 7.325048567707881e-09
845 O 0 6.376386636475218e-07
G O 0 4.0914121200330555e-05
- O 0 8.096862984530162e-06
- O 0 1.0187732186750509e-05
> O 0 2.773137737221987e-07
A O 0 1.461267515878717e-06
may O 0 2.334393002456636e-06
have O 0 3.1607640949005145e-08
been O 0 3.745575938296497e-08
introduced O 0 3.098896073083779e-08
into O 0 6.41778408194682e-09
these O 0 5.121741697422522e-09
populations O 0 5.0740801782467315e-08
by O 0 2.2054159387607797e-08
Caucasian O 0 1.2254481589479838e-05
admixture O 0 1.172044449049281e-05
. O 0 1.2661856771956082e-06

187 O 0 0.00016003806376829743
C O 0 6.63819519104436e-05
- O 0 5.518144098459743e-05
- O 0 4.0316339436685666e-05
> O 0 5.689560111932224e-06
G O 0 0.00031087000388652086
was O 0 1.0818515647770255e-06
present O 0 1.6587007323209946e-08
at O 0 1.867002197286638e-08
an O 0 9.224438102251042e-09
allele O 0 3.133497443741362e-07
frequency O 0 3.63624849342159e-07
of O 0 4.156006028210868e-08
2 O 0 3.384777073733858e-06
. O 0 2.0052925719937775e-06

68 O 0 0.028310302644968033
% O 0 3.8185080484254286e-06
in O 0 2.1226719937317284e-08
the O 0 1.5684923582170995e-08
two O 0 1.526319550748667e-07
populations O 0 5.659060207108269e-07
analyzed O 0 1.5792654721735744e-06
( O 0 4.0864492234504723e-08
Australian O 0 1.3347323601919925e-07
Aboriginal O 0 5.899168513678887e-07
and O 0 1.6709169869955076e-07
Chinese O 0 4.496294536693313e-08
) O 0 9.210710771867525e-08
. O 0 3.4552368788354215e-07

In O 0 1.6724535498724435e-06
the O 0 2.1240740011307935e-07
Australian O 0 1.9321295496865787e-07
Aboriginal O 0 1.6772919764207472e-07
samples O 0 3.358005784548368e-08
, O 0 6.610792357975015e-09
187 O 0 5.265139790822104e-08
C O 0 3.4453159969416447e-07
- O 0 1.1291200507912436e-06
- O 0 1.5398187315440737e-05
> O 0 2.1963419385429006e-06
G O 0 0.00014388165436685085
was O 0 4.451123459148221e-06
found O 0 1.9818868324250616e-08
to O 0 9.05976538234654e-09
be O 0 1.9465177913957632e-08
associated O 0 7.03919482702986e-08
with O 0 7.390308098820242e-08
HLA O 0 0.00041506168781779706
haplotypes O 0 8.464858183288015e-06
common O 0 4.9319446304707526e-08
in O 0 5.098119260082967e-08
Caucasians O 0 2.3047664399200585e-06
, O 0 4.629687921919867e-08
suggesting O 0 3.2000482974581246e-07
that O 0 3.361613920560558e-08
it O 0 4.1238447323621585e-08
was O 0 8.432302820438053e-07
introduced O 0 7.457325779114399e-08
by O 0 1.0173139664004793e-08
recent O 0 1.9980488730197976e-07
admixture O 0 8.6795880633872e-06
. O 0 2.5141894184343982e-06

In O 0 3.1558961381961126e-06
the O 0 1.6095769694857154e-07
Chinese O 0 2.1905334435246004e-08
samples O 0 3.3242688601831105e-08
analyzed O 0 3.9262133100237406e-08
, O 0 4.847771073457352e-09
187 O 0 2.87066637127964e-08
C O 0 1.9245949545165786e-07
- O 0 8.705932259545079e-07
- O 0 5.189227067603497e-06
> O 0 9.120309982790786e-07
G O 0 5.9874677390325814e-05
was O 0 2.8346908038656693e-06
present O 0 1.3066284054730204e-08
in O 0 3.735089038059414e-08
association O 0 6.604175428748249e-09
with O 0 1.8607622109811928e-09
a O 0 3.616790422711347e-08
wide O 0 1.7177262634504586e-07
variety O 0 2.182834002439904e-08
of O 0 2.194263437615973e-08
HLA O 0 4.178761810180731e-05
haplotypes O 0 4.3785480556834955e-06
, O 0 2.3953907302143307e-08
showing O 0 2.957062008590583e-07
this O 0 5.415377479778272e-09
mutation O 0 1.1041390735044843e-07
to O 0 1.0749221068806492e-08
be O 0 2.171514168480826e-08
widespread O 0 6.541171160279191e-08
and O 0 3.776192158966296e-07
likely O 0 3.428766603974509e-07
to O 0 1.6083548715073448e-08
predate O 0 3.954525880089932e-07
the O 0 9.47904599257754e-09
more O 0 3.627926181692942e-09
genetically O 0 8.849360000340312e-08
restricted O 0 2.7012664105541262e-08
845 O 0 1.174208819065825e-06
G O 0 3.24265674862545e-05
- O 0 1.1410356819396839e-05
- O 0 1.2543685443233699e-05
> O 0 9.130736202678236e-07
A O 0 1.0059848136734217e-06
mutation O 0 9.57175507210195e-06
. O 0 1.2399891602399293e-06

Genotype O 1 0.9207344651222229
- O 0 0.38365769386291504
phenotype O 0 0.015930751338601112
correlations O 0 0.0024984371848404408
in O 0 7.523421663790941e-05
attenuated B-Disease 1 0.9997593760490417
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999990463256836
coli I-Disease 1 0.9999997615814209
. O 0 8.489308675052598e-05

Germ O 0 0.016938114538788795
- O 1 0.519048810005188
line O 0 0.0006800929550081491
mutations O 0 5.1030497161264066e-06
of O 0 1.9156747299575727e-08
the O 0 2.821634552674368e-07
tumor B-Disease 0 0.00013119970390107483
suppressor O 0 0.0003426076436880976
APC O 0 1.1779339729400817e-05
are O 0 7.244394595318226e-08
implicated O 0 9.545518878439907e-06
in O 0 1.433779198123375e-05
attenuated B-Disease 1 0.999974250793457
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.0005352789885364473
AAPC B-Disease 1 1.0
) O 0 5.821052013743611e-07
, O 0 5.65915243555537e-08
a O 0 2.8497024118223635e-07
variant O 0 0.002091263420879841
of O 0 0.00010334110265830532
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 8.766419341554865e-05
FAP B-Disease 0 0.00026154419174417853
) O 0 1.8790111653288477e-06
. O 0 2.2076924324210268e-06

AAPC B-Disease 1 0.9999994039535522
is O 0 1.4068147720536217e-05
recognized O 0 4.067045438205241e-07
by O 0 1.3888759475833012e-08
the O 0 1.2360177770176506e-08
occurrence O 0 2.069396174420035e-07
of O 0 2.1717543319255128e-08
< O 0 1.9818241980829043e-06
100 O 0 1.61075632831853e-07
colonic B-Disease 0 1.0862393537536263e-05
adenomas I-Disease 0 3.2745800126576796e-05
and O 0 1.5309758794046502e-07
a O 0 2.1249938697565085e-07
later O 0 5.537352080864366e-06
onset O 0 0.0008619404979981482
of O 0 0.005025029648095369
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.693151882089296e-07
age O 0 1.6018744020129816e-07
> O 0 4.728701412659575e-07
40 O 0 1.546443968436506e-07
years O 0 5.055570539980181e-08
) O 0 6.477875302834946e-08
. O 0 2.3385368308481702e-07

The O 0 2.784628350127605e-06
aim O 0 1.3740121858063503e-06
of O 0 2.1352683177155996e-08
this O 0 1.0032972674878238e-08
study O 0 1.5351480087133496e-08
was O 0 7.974458071657864e-07
to O 0 3.288944583346165e-08
assess O 0 2.7370708721718984e-06
genotype O 0 0.00040970006375573575
- O 0 0.00432924646884203
phenotype O 0 0.00020656068227253854
correlations O 0 4.936117693432607e-05
in O 0 9.042219062393997e-06
AAPC B-Disease 1 0.9999995231628418
families O 0 1.3018905519857071e-05
. O 0 2.418064241282991e-06

By O 0 3.952967290388187e-06
protein O 0 5.52761730432394e-06
- O 0 7.942982847453095e-06
truncation O 0 2.992629015352577e-05
test O 0 1.049021534527128e-06
( O 0 1.1193341009629876e-07
PTT O 0 9.566100516167353e-07
) O 0 1.210124356276765e-08
assay O 0 2.222277259988914e-07
, O 0 8.739838186500037e-09
the O 0 7.703866877761811e-09
entire O 0 5.2552174167885823e-08
coding O 0 1.7309769191342639e-06
region O 0 1.3674299736976536e-07
of O 0 4.506354844835414e-09
the O 0 3.5946932541719434e-08
APC B-Disease 0 8.687561035003455e-07
gene O 0 2.079186174341885e-07
was O 0 5.214999873714987e-06
screened O 0 7.783759770063625e-07
in O 0 2.5557424621069913e-08
affected O 0 5.712149686587509e-08
individuals O 0 5.592909246843192e-09
from O 0 2.0110897835934338e-08
11 O 0 4.141602857998805e-06
AAPC B-Disease 1 0.9999988079071045
kindreds O 0 0.00016541678633075207
, O 0 4.549251997332249e-08
and O 0 1.964630413908708e-08
their O 0 2.8275140451228253e-08
phenotypic O 0 3.777196752707823e-06
differences O 0 4.531245394900907e-06
were O 0 3.489394885036745e-06
examined O 0 8.822225936455652e-06
. O 0 1.139783080361667e-06

Five O 0 2.2587193598155864e-05
novel O 0 1.402407815476181e-05
germ O 0 0.00035554482019506395
- O 0 0.0028601002413779497
line O 0 0.001200174679979682
APC B-Disease 0 1.7008309441735037e-05
mutations O 0 6.595450940949377e-06
were O 0 3.2894720902731933e-07
identified O 0 4.69576548312034e-07
in O 0 1.2810802729745774e-07
seven O 0 2.3414227143803146e-06
kindreds O 0 0.0002632127143442631
. O 0 2.504516260160017e-06

Mutations O 0 0.4012058675289154
were O 0 2.521065471228212e-05
located O 0 6.058000394659757e-07
in O 0 4.1437690612156075e-08
three O 0 2.257474918110347e-08
different O 0 6.5462613108024925e-09
regions O 0 2.0893207164363048e-08
of O 0 3.4113469826735354e-09
the O 0 3.115549773724524e-08
APC B-Disease 0 1.3876945104129845e-06
gene O 0 1.850933841751612e-07
( O 0 1.7011021924417946e-08
1 O 0 2.1254757953670378e-08
) O 0 4.643189388531255e-09
at O 0 1.3630964801336631e-08
the O 0 1.2970265750311682e-08
5 O 0 6.10656201160964e-08
end O 0 1.2880262545422738e-07
spanning O 0 2.885428216359287e-07
exons O 0 1.5305744227589457e-06
4 O 0 2.088321195969911e-07
and O 0 1.5051402613153186e-07
5 O 0 5.7571259759470195e-08
, O 0 1.0820476958883773e-08
( O 0 4.464757896727178e-09
2 O 0 1.0998507882220565e-08
) O 0 2.4681343635535313e-09
within O 0 2.0654904453465406e-09
exon O 0 3.3296632295787276e-07
9 O 0 9.255685426978744e-07
, O 0 3.249635227575709e-08
and O 0 1.1445917635910519e-07
( O 0 1.864635557069505e-08
3 O 0 6.744524938540053e-08
) O 0 6.1041842691622605e-09
at O 0 1.606604094206432e-08
the O 0 1.9809004214721426e-08
3 O 0 5.952953756604984e-07
distal O 0 7.981489034136757e-06
end O 0 1.0099029168486595e-06
of O 0 1.4576409412825342e-08
the O 0 8.56713739949555e-08
gene O 0 3.943780029658228e-06
. O 0 1.0229605322820134e-06

Variability O 0 0.001964939059689641
in O 0 3.0930920047467225e-07
the O 0 6.432320986959894e-08
number O 0 3.5125384556522476e-07
of O 0 2.8645175916608423e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.6917657852172852
most O 0 8.571746690222426e-08
apparent O 0 1.748917497934599e-06
in O 0 4.9369706545121517e-08
individuals O 0 5.863711738385291e-09
with O 0 2.265264598122485e-08
mutations O 0 4.499435817706399e-06
in O 0 1.0227464741774384e-07
region O 0 1.008108256428386e-06
1 O 0 5.953873483122152e-07
, O 0 1.4233363287985412e-07
and O 0 1.1121258012281032e-06
upper O 0 0.0013157216599211097
- O 0 0.30922427773475647
gastrointestinal O 0 0.01237427070736885
manifestations O 0 4.7929179345373996e-06
were O 0 1.2717865729428013e-06
more O 0 1.921002201754618e-08
severe O 0 7.844248102628626e-06
in O 0 5.8483561105049375e-08
them O 0 1.5732946678781445e-07
. O 0 8.16638646483625e-07

In O 0 3.5893403946829494e-06
individuals O 0 1.2147592087785597e-07
with O 0 6.889904113904777e-08
mutations O 0 7.620431460964028e-06
in O 0 5.871302377613574e-08
either O 0 1.6108914735468716e-07
region O 0 7.330355629164842e-07
2 O 0 1.7887876992972451e-06
or O 0 2.839626631612191e-07
region O 0 2.6431402488924505e-07
3 O 0 5.720598892366979e-07
, O 0 2.194447645820219e-08
the O 0 1.3554870115228823e-08
average O 0 1.4782878565711144e-07
number O 0 2.6547435361123917e-09
of O 0 2.967381673713021e-09
adenomas B-Disease 0 3.7756194615212735e-06
tended O 0 9.219847925123759e-07
to O 0 2.0391901500715903e-08
be O 0 1.3514855901064493e-08
lower O 0 1.1364819130221804e-07
than O 0 2.6656525875523585e-09
those O 0 1.4792341795910602e-09
in O 0 3.964416350754618e-09
individuals O 0 8.786751326539388e-10
with O 0 2.8609408175839235e-09
mutations O 0 2.854938543350727e-07
in O 0 1.0794029670080363e-08
region O 0 1.2371715740755462e-07
1 O 0 1.2379989300370653e-07
, O 0 4.748997284309553e-08
although O 0 3.631278389093495e-08
age O 0 9.106372544920305e-08
at O 0 1.4693051753056352e-07
diagnosis O 0 2.866550858016126e-05
was O 0 3.6866490518150385e-06
similar O 0 7.174676852628181e-07
. O 0 1.6126526816151454e-06

In O 0 1.6408566807513125e-05
all O 0 3.085689968429506e-06
AAPC B-Disease 1 0.9999756813049316
kindreds O 0 0.000581713393330574
, O 0 2.4005368004509364e-07
a O 0 1.904781328221361e-07
predominance O 0 1.4496355106530245e-05
of O 0 4.382615372833243e-07
right O 0 0.030320296064019203
- O 1 0.9999779462814331
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0006581803900189698
rectal B-Disease 1 0.9996135830879211
polyp I-Disease 0 0.013737126253545284
sparing O 0 9.689551916380879e-06
was O 0 9.269835572922602e-06
observed O 0 6.9592424551956356e-06
. O 0 1.6911095599425607e-06

No O 0 0.000204262716579251
desmoid B-Disease 1 0.8739253878593445
tumors I-Disease 1 1.0
were O 0 1.5127430742722936e-05
found O 0 2.1094324154091737e-07
in O 0 5.454606366583903e-08
these O 0 1.2970963325642515e-07
kindreds O 0 0.00019467294623609632
. O 0 1.8563301864560344e-06

Our O 0 5.6291887631232385e-06
data O 0 6.430462349271693e-07
suggest O 0 1.8716019667408546e-07
that O 0 2.046097691277282e-08
, O 0 5.197857433358877e-08
in O 0 1.3095944950691774e-06
AAPC B-Disease 1 1.0
families O 0 4.499659098655684e-06
, O 0 1.1828676704794816e-08
the O 0 2.9435369697239366e-09
location O 0 9.394615574365162e-08
of O 0 4.661548924644876e-09
the O 0 2.707152191305795e-07
APC B-Disease 0 4.225358134135604e-05
mutation O 0 1.605680154170841e-05
may O 0 1.2051626754328026e-06
partially O 0 2.2939777863939526e-06
predict O 0 5.64036383821076e-07
specific O 0 9.538155865129738e-08
phenotypic O 0 6.308940101007465e-06
expression O 0 3.388019877093029e-06
. O 0 2.3485008568968624e-06

This O 0 3.1946772196533857e-06
should O 0 2.596574688595865e-07
help O 0 2.9259286549176977e-08
in O 0 1.372663582799305e-08
the O 0 9.344590878868075e-09
design O 0 3.5110312524011533e-07
of O 0 1.4563403816225673e-08
tailored O 0 2.8007472792523913e-05
clinical O 0 1.8186627812610823e-06
- O 0 4.925956091028638e-05
management O 0 1.1063630722674134e-07
protocols O 0 8.40479970065644e-08
in O 0 1.1650667097740097e-08
this O 0 5.802188507431083e-09
subset O 0 1.2573363505907764e-07
of O 0 7.303358984245278e-08
FAP B-Disease 0 3.493815893307328e-05
patients O 0 1.2695845725829713e-06
. O 0 1.7054790646398033e-07
. O 0 7.401670245599234e-07

Wilms B-Disease 1 0.5730159282684326
' I-Disease 0 0.00141141377389431
tumor I-Disease 0 0.00026326291845180094
1 O 0 1.373598252030206e-06
and O 0 7.258736900439544e-07
Dax O 1 0.9436638355255127
- O 0 3.077061046496965e-05
1 O 0 1.0740924238916705e-07
modulate O 0 6.602414828194014e-07
the O 0 6.573188926495277e-08
orphan O 0 3.5656355521496153e-06
nuclear O 0 3.764089910873736e-07
receptor O 0 5.521640673578077e-07
SF O 0 0.00018026934412773699
- O 0 2.4528749236196745e-06
1 O 0 3.659494041130529e-08
in O 0 1.0024039376332894e-08
sex O 0 2.2363323637364374e-07
- O 0 5.437041181721725e-07
specific O 0 6.031850574572672e-08
gene O 0 1.17644151487184e-06
expression O 0 1.7631690525377053e-06
. O 0 1.212900542668649e-06

Products O 0 1.2131620678701438e-05
of O 0 2.6708076461545716e-07
steroidogenic O 0 2.4846167434589006e-05
factor O 0 5.772948270532652e-07
1 O 0 5.109099561195762e-07
( O 0 2.3314177610700426e-07
SF O 0 0.012127062305808067
- O 0 5.170340955373831e-05
1 O 0 6.380809054462588e-07
) O 0 5.0112358707110616e-08
and O 0 6.345533734020137e-07
Wilms B-Disease 0 0.0005906023434363306
tumor I-Disease 0 3.4386997867841274e-05
1 O 0 4.40000349044567e-07
( O 0 9.904671571803192e-08
WT1 O 0 1.7879410734167323e-05
) O 0 6.19649469513206e-08
genes O 0 7.675139102047979e-08
are O 0 2.467913207127026e-09
essential O 0 4.12417300310608e-09
for O 0 4.3122971860043435e-09
mammalian O 0 2.806407621847029e-07
gonadogenesis O 0 4.143882506468799e-06
prior O 0 3.4722479114179805e-08
to O 0 2.1696759944234145e-08
sexual O 0 7.180344141488604e-07
differentiation O 0 5.561812940868549e-06
. O 0 1.7299190631092642e-06

In O 0 5.0071939767804e-06
males O 0 4.941879069519928e-06
, O 0 2.4956611355264613e-07
SF O 0 0.0060385228134691715
- O 0 5.395959669840522e-05
1 O 0 1.2937459814565955e-07
participates O 0 4.272917664138731e-08
in O 0 8.837869991396019e-09
sexual O 0 3.976580487119463e-08
development O 0 3.379819535354045e-09
by O 0 4.083423821299448e-09
regulating O 0 1.4768041012303001e-07
expression O 0 7.100617693822642e-08
of O 0 5.575027106630159e-09
the O 0 1.1865876103911432e-07
polypeptide O 0 2.0364330339361914e-05
hormone O 0 4.711007477453677e-06
Mullerian O 0 5.650051753036678e-05
inhibiting O 0 1.2790340406354517e-05
substance O 0 3.804361085713026e-06
( O 0 8.558445756534638e-07
MIS O 0 0.0005963494768366218
) O 0 6.512588015539222e-07
. O 0 1.4079244010645198e-06

Here O 0 1.7699499949230812e-05
, O 0 5.440604695650109e-07
we O 0 1.356525984874679e-07
show O 0 4.757066278671118e-07
that O 0 9.118938493202222e-08
WT1 O 0 0.00012164054351160303
- O 0 0.0001114399274229072
KTS O 0 0.00013691774802282453
isoforms O 0 1.434004730072047e-06
associate O 0 1.617765406081162e-07
and O 0 8.135342000059609e-08
synergize O 0 5.548452463699505e-06
with O 0 5.022618552175118e-07
SF O 0 0.4499345123767853
- O 0 4.694978997576982e-05
1 O 0 3.011599289948208e-07
to O 0 4.7654662438390005e-08
promote O 0 1.2888019682577578e-06
MIS O 0 0.004311349708586931
expression O 0 4.5052925088384654e-06
. O 0 1.3963684750706307e-06

In O 0 8.540071576135233e-06
contrast O 0 1.077321849152213e-05
, O 0 1.1419851944083348e-06
WT1 O 0 0.001115686260163784
missense O 0 0.021082960069179535
mutations O 0 0.0001300427393289283
, O 0 1.0469761946296785e-07
associated O 0 2.437016917156143e-07
with O 0 2.690990186238196e-07
male B-Disease 0 0.0008335133315995336
pseudohermaphroditism I-Disease 1 0.9999998807907104
in O 0 1.6931518985074945e-05
Denys B-Disease 1 0.9999939203262329
- I-Disease 1 0.9999971389770508
Drash I-Disease 1 0.999991774559021
syndrome I-Disease 1 0.9999978542327881
, O 0 1.9388944849652034e-07
fail O 0 2.4509620288881706e-07
to O 0 3.0119235105985354e-08
synergize O 0 1.9042641724809073e-05
with O 0 1.5982303693817812e-06
SF O 1 0.986741840839386
- O 0 0.001436932710930705
1 O 0 2.8678782655333634e-06
. O 0 1.3967654695079545e-06

Additionally O 0 2.7966845664195716e-05
, O 0 3.0085533353485516e-07
the O 0 5.009056991411853e-08
X O 0 0.009515131823718548
- O 0 0.008068704977631569
linked O 0 4.897935286862776e-05
, O 0 5.2965052788067624e-08
candidate O 0 1.8009255597917218e-07
dosage O 0 7.024748924777668e-07
- O 0 1.355266817881784e-06
sensitive O 0 4.006402036793588e-07
sex O 0 3.226940350486984e-07
- O 0 9.763524531081202e-07
reversal O 0 1.006576894724276e-06
gene O 0 2.514992445412645e-07
, O 0 7.078360653167692e-08
Dax O 0 0.29937028884887695
- O 0 1.4109317817201372e-05
1 O 0 1.5260067698363855e-07
, O 0 2.5200671771585803e-08
antagonizes O 0 1.4844716815787251e-06
synergy O 0 5.678197680936137e-07
between O 0 1.241142371100068e-07
SF O 0 0.015840061008930206
- O 0 2.3684788175160065e-05
1 O 0 3.56610087237641e-07
and O 0 2.963673750855378e-07
WT1 O 0 1.6934362065512687e-05
, O 0 4.786262763900595e-08
most O 0 5.215829990135035e-09
likely O 0 2.658139841571483e-08
through O 0 1.8102811472076041e-09
a O 0 7.015989567094039e-09
direct O 0 9.16325504363158e-09
interaction O 0 2.2491370543775702e-08
with O 0 8.565896081336177e-08
SF O 1 0.9042431712150574
- O 0 0.00030708216945640743
1 O 0 1.9830340534099378e-06
. O 0 1.0314479368389584e-06

We O 0 5.985475581837818e-06
propose O 0 3.009663487318903e-06
that O 0 1.0677338480036269e-07
WT1 O 0 2.5515897505101748e-05
and O 0 3.2878895126486896e-06
Dax O 1 0.9974933862686157
- O 0 3.725649003172293e-05
1 O 0 3.078580732562841e-07
functionally O 0 5.67128665807104e-07
oppose O 0 4.753637483645434e-08
each O 0 6.821044618021688e-09
other O 0 3.5597649272745002e-09
in O 0 2.9309109805808475e-08
testis O 0 2.776615019683959e-06
development O 0 2.881165350743231e-08
by O 0 2.620640415784692e-08
modulating O 0 1.000283100438537e-05
SF O 0 0.06912551075220108
- O 0 3.557799573172815e-05
1 O 0 6.684696245429222e-07
- O 0 1.0570349331828766e-05
mediated O 0 3.813793227891438e-05
transactivation O 0 8.017977233976126e-05
. O 0 6.888641905788973e-07
. O 0 1.0822808462762623e-06

A O 0 2.024684363277629e-05
mouse O 0 7.81328635639511e-05
model O 0 1.2540157513285521e-05
for O 0 7.405189990095096e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
imprinting O 0 0.00396144250407815
- O 0 0.06337544322013855
centre O 0 0.00021802305127494037
mutations O 0 0.00011275984434178099
. O 0 3.9533592826046515e-06

Imprinting O 0 0.0007769797230139375
in O 0 2.2092024209996453e-06
the O 0 3.599276965360332e-07
15q11 O 0 1.6844003766891547e-05
- O 0 4.696931500802748e-05
q13 O 0 5.0438675316399895e-06
region O 0 1.0786398263462615e-07
involves O 0 1.8053237127446664e-08
an O 0 1.0321761223508474e-08
imprinting O 0 2.7448411856312305e-05
centre O 0 1.5445586541318335e-05
( O 0 1.2083003753105004e-07
IC O 0 1.1618465123319766e-06
) O 0 7.959322090300702e-09
, O 0 3.588519481567687e-09
mapping O 0 1.714919335427112e-07
in O 0 1.4658852798277167e-08
part O 0 1.4426827732449965e-08
to O 0 1.8943282498185e-08
the O 0 4.4255898501432966e-08
promoter O 0 6.876695806568023e-06
and O 0 1.5311073298107658e-07
first O 0 9.622558394539737e-08
exon O 0 1.5229099972202675e-06
of O 0 1.0869504762922588e-07
SNRPN O 0 0.00036163139156997204
. O 0 1.3925637176726013e-06

Deletion O 0 0.0008079014951363206
of O 0 7.467786531378806e-07
this O 0 1.7384499528816377e-07
IC O 0 9.710940503282472e-06
abolishes O 0 1.6450210750917904e-05
local O 0 2.639835088302789e-07
paternally O 0 5.111046903039096e-06
derived O 0 1.198602461727205e-07
gene O 0 3.4363316103735997e-07
expression O 0 2.3956357608767576e-07
and O 0 1.3029406886744255e-07
results O 0 1.256117911907495e-06
in O 0 9.619428601581603e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.904924809234217e-05
PWS B-Disease 1 0.9999994039535522
) O 0 3.052563215533155e-06
. O 0 3.645870719992672e-06

We O 0 1.1038364391424693e-05
have O 0 1.4002581849581475e-07
created O 0 1.2876751043222612e-07
two O 0 7.711809502097822e-08
deletion O 0 3.331545303808525e-05
mutations O 0 1.223649724124698e-05
in O 0 2.9429247661028057e-07
mice O 0 0.0018313723849132657
to O 0 1.4529771306115435e-06
understand O 0 5.7215711422031745e-06
PWS B-Disease 1 1.0
and O 0 5.595312018158438e-07
the O 0 1.532409754645414e-08
mechanism O 0 1.2817437777812302e-07
of O 0 2.0254638855021767e-08
this O 0 8.546948038201663e-08
IC O 0 2.4578894226578996e-05
. O 0 2.0477727957768366e-06

Mice O 0 0.17062072455883026
harbouring O 0 0.00025949132395908237
an O 0 8.269034310615098e-07
intragenic O 0 4.249287667335011e-05
deletion O 0 2.552071600803174e-05
in O 0 2.685667652713164e-07
Snrpn O 0 5.3557891078526154e-05
are O 0 7.802729129480213e-08
phenotypically O 0 1.2046883057337254e-05
normal O 0 6.742428126926825e-07
, O 0 2.962112866100597e-08
suggesting O 0 1.390009458646091e-07
that O 0 1.7456860845754818e-08
mutations O 0 7.333970870604389e-07
of O 0 1.0568752095707623e-08
SNRPN O 0 0.0006551548140123487
are O 0 2.735016657595679e-08
not O 0 1.2170245256015733e-08
sufficient O 0 2.540336119238873e-08
to O 0 8.697337250396231e-08
induce O 0 4.7249195631593466e-05
PWS B-Disease 1 0.9999992847442627
. O 0 6.247957571758889e-06

Mice O 0 0.03666841611266136
with O 0 4.6615204496447404e-07
a O 0 1.4024688255176443e-07
larger O 0 2.0998844263431238e-07
deletion O 0 2.5468141302553704e-06
involving O 0 1.378884491032295e-07
both O 0 9.782073817632408e-08
Snrpn O 0 4.271283614798449e-05
and O 0 1.780287277597381e-07
the O 0 3.421534700009943e-07
putative O 0 0.0020558075048029423
PWS O 1 1.0
- O 0 0.10260028392076492
IC O 0 4.773314867634326e-05
lack O 0 1.796421003064097e-07
expression O 0 7.311066241300068e-08
of O 0 7.052483486091887e-09
the O 0 8.996864409027694e-08
imprinted O 0 5.072180283605121e-05
genes O 0 3.2441723760712193e-06
Zfp127 O 0 3.2612944778520614e-05
( O 0 9.375461473837277e-08
mouse O 0 2.578791736596031e-06
homologue O 0 6.474455858551664e-06
of O 0 7.192681295009606e-08
ZNF127 O 0 0.0001361264003207907
) O 0 5.329073715643062e-08
, O 0 3.764469624911726e-08
Ndn O 0 1.5078490832820535e-05
and O 0 9.92051525372517e-08
Ipw O 0 2.9354146136029158e-06
, O 0 1.0302116493221547e-07
and O 0 1.251928125611812e-07
manifest O 0 4.3428607909845596e-07
several O 0 7.336922891454378e-08
phenotypes O 0 3.027245656994637e-05
common O 0 6.996068009357259e-07
to O 0 1.19678034025128e-05
PWS B-Disease 1 1.0
infants O 0 0.10723550617694855
. O 0 3.6554172311298316e-06

These O 0 7.976360052452947e-07
data O 0 4.434720324297814e-07
demonstrate O 0 1.3928080022651557e-07
that O 0 1.5548444309843035e-08
both O 0 1.790266956902542e-08
the O 0 3.969010720084043e-08
position O 0 8.752735425332503e-07
of O 0 8.474044577155837e-09
the O 0 8.667760198477481e-08
IC O 0 2.8892716272821417e-06
and O 0 1.0114887061263289e-07
its O 0 4.86202234029065e-09
role O 0 1.5505383643699133e-08
in O 0 5.6165130324359325e-09
the O 0 3.5548659571560393e-09
coordinate O 0 1.110430574158272e-07
expression O 0 4.919073859355194e-08
of O 0 2.5368633860267664e-09
genes O 0 6.860948786879817e-08
is O 0 7.316921735167625e-09
conserved O 0 2.3630624568227176e-08
between O 0 4.435155531723467e-08
mouse O 0 5.472615157486871e-05
and O 0 2.716859057727561e-07
human O 0 2.3009238958593414e-08
, O 0 2.837671253530516e-08
and O 0 4.099188899431283e-08
indicate O 0 7.433624205077649e-08
that O 0 5.220766929880938e-09
the O 0 1.0550905926720588e-08
mouse O 0 7.014238690317143e-06
is O 0 1.100566304756967e-08
a O 0 1.1289327694896656e-08
suitable O 0 2.3294278506114097e-08
model O 0 1.434808893918671e-07
system O 0 7.58023901425986e-08
in O 0 2.5477215004343634e-08
which O 0 4.572818923520572e-08
to O 0 4.527436203716206e-09
investigate O 0 2.891013473060866e-08
the O 0 8.878452639748957e-09
molecular O 0 6.101311100792373e-08
mechanisms O 0 3.3528539944427393e-08
of O 0 2.621853845141686e-09
imprinting O 0 4.620523213816341e-06
in O 0 8.629670844584325e-08
this O 0 1.6658216139830984e-08
region O 0 7.188347694864206e-08
of O 0 4.902754646707308e-09
the O 0 6.002504449043045e-08
genome O 0 8.104387916318956e-07
. O 0 7.290415027227937e-08
. O 0 4.1019353602678166e-07

Mutations O 0 0.0015799979446455836
of O 0 3.672440413993172e-07
the O 0 1.0214110801598508e-07
ATM O 0 6.770458185201278e-06
gene O 0 3.457383172644768e-06
detected O 0 3.6772419207409257e-06
in O 0 6.962760608075769e-07
Japanese O 0 0.0004864018701482564
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00017176370602101088
: O 0 1.978891361886781e-08
possible O 0 4.007318565868445e-08
preponderance O 0 7.675760116399033e-07
of O 0 6.721419421040764e-09
the O 0 2.666213383406557e-08
two O 0 2.1258856008898874e-07
founder O 0 1.7355592717649415e-05
mutations O 0 3.945103799196659e-06
4612del165 O 0 2.5899416868924163e-06
and O 0 3.531175707394141e-07
7883del5 O 0 1.7760319678927772e-05
. O 0 1.3627827684103977e-06

The O 0 4.539026576821925e-06
ATM O 0 6.0811828006990254e-05
( O 0 2.7351788958185352e-06
A O 1 0.9997469782829285
- O 1 0.9999910593032837
T O 1 1.0
, O 0 1.2742616206651292e-07
mutated O 0 1.3384751582634635e-06
) O 0 3.02642888527771e-08
gene O 0 1.6656206014431518e-07
on O 0 9.506767355560442e-07
human O 0 1.6746577102821902e-06
chromosome O 0 0.0009139266912825406
11q22 O 0 4.2229330574627966e-05
. O 0 1.6783669707365334e-06

3 O 0 0.0001760649320203811
has O 0 3.742138460438582e-06
recently O 0 3.7600461837428156e-06
been O 0 3.7708409195147397e-07
identified O 0 9.704115910835753e-08
as O 0 1.331731080966847e-08
the O 0 9.54606882430653e-09
gene O 0 8.741992729710546e-08
responsible O 0 3.473910581419659e-08
for O 0 5.96717253387169e-09
the O 0 1.9965631281593232e-07
human O 0 5.635496199829504e-05
recessive B-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999885559082031
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.002717342460528016
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.1834904398710933e-06
. O 0 1.3877394167138846e-06

In O 0 2.897643753385637e-06
order O 0 1.765063899483721e-07
to O 0 1.8818354874383658e-08
define O 0 1.7160137133487297e-07
the O 0 1.9491853464614906e-08
types O 0 6.823207598927183e-08
of O 0 1.2761368850533472e-07
disease O 0 6.050801675883122e-05
- O 0 1.6516611140104942e-05
causing O 0 1.1877554015882197e-06
ATM O 0 5.111875907459762e-06
mutations O 0 1.8686821476876503e-06
in O 0 2.7447265793512088e-08
Japanese O 0 1.1114196922790143e-06
A B-Disease 1 0.9999947547912598
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 2.0308953025960363e-06
as O 0 1.3081070449061372e-08
well O 0 1.1040712344367876e-08
as O 0 9.455606964081653e-09
to O 0 4.4632084694740115e-09
look O 0 2.1466000532655016e-08
for O 0 2.3738850885024476e-09
possible O 0 3.22904227800791e-08
mutational O 0 3.190703864675015e-06
hotspots O 0 4.016059392597526e-06
, O 0 3.659417302515067e-08
reverse O 0 1.5368990489150747e-06
- O 0 3.3146470741485246e-06
transcribed O 0 1.0661267424438847e-06
RNA O 0 1.555530246832859e-07
derived O 0 1.0888050461232979e-08
from O 0 5.8738307551209346e-09
ten O 0 4.333861625127611e-08
patients O 0 4.974268463797671e-08
belonging O 0 1.6273384417786474e-08
to O 0 6.951492714790675e-09
eight O 0 5.5313808644541496e-08
unrelated O 0 2.652275838954665e-07
Japanese O 0 1.962329406524077e-06
A B-Disease 1 0.9998738765716553
- I-Disease 1 0.9999529123306274
T I-Disease 1 1.0
families O 0 7.71024929235864e-07
was O 0 3.292836936452659e-07
analyzed O 0 1.22674919111887e-07
for O 0 1.0543725004197313e-08
mutations O 0 2.931242022441438e-07
by O 0 2.3117576741782386e-09
the O 0 1.1326446447412764e-08
restriction O 0 1.0429859287341969e-07
endonuclease O 0 6.199915333127137e-06
fingerprinting O 0 1.3682665667147376e-06
method O 0 9.672376108937897e-07
. O 0 1.270214397663949e-06

As O 0 1.2753092960338108e-05
has O 0 1.673019824011135e-06
been O 0 5.297313805385784e-07
reported O 0 1.0172635711569455e-06
by O 0 9.216400975731176e-09
others O 0 1.1683662393124905e-07
, O 0 4.330366465410407e-08
mutations O 0 1.03913714610826e-06
that O 0 5.904619904129049e-09
lead O 0 1.6470775676680205e-07
to O 0 1.8265033929765195e-08
exon O 0 1.4138420283416053e-06
skipping O 0 2.60010324382165e-06
or O 0 4.891585945188126e-07
premature O 0 8.442788157481118e-07
protein O 0 1.6270318781153037e-07
truncation O 0 7.064487363095395e-06
were O 0 3.7134702779439976e-06
also O 0 7.425496733048931e-07
predominant O 0 1.5047484112074017e-06
in O 0 9.584165638898412e-08
our O 0 1.9607433898727322e-07
mutants O 0 1.5668840205762535e-05
. O 0 9.96994572233234e-07

Six O 0 1.285016151086893e-05
different O 0 6.522489570670587e-07
mutations O 0 2.6081097530550323e-05
were O 0 1.1165700470883166e-06
identified O 0 8.495084102833061e-07
on O 0 1.4876744671710185e-06
12 O 0 2.521659610010829e-07
of O 0 3.1005147338447614e-09
the O 0 7.53088187366302e-08
16 O 0 7.892136295595265e-07
alleles O 0 1.7050917904271046e-06
examined O 0 6.502870746771805e-06
. O 0 2.082271066683461e-06

Four O 0 2.4523356842109933e-05
were O 0 1.186184249490907e-06
deletions O 0 3.849991571769351e-06
involving O 0 4.3326264176357654e-07
a O 0 3.5578771075961413e-06
loss O 0 7.456922503479291e-06
of O 0 1.8363925491371447e-08
a O 0 3.0448825327766826e-07
single O 0 1.7691889979687403e-06
exon O 0 6.052969638403738e-06
exon O 0 1.1683661796269007e-05
7 O 0 2.3174952730187215e-06
, O 0 4.153097776793402e-08
exon O 0 1.702130020930781e-06
16 O 0 7.070102014949953e-07
, O 0 4.107281625920223e-08
exon O 0 2.656523520272458e-06
33 O 0 2.084203970298404e-06
or O 0 8.371010551400104e-08
exon O 0 8.11454992799554e-06
35 O 0 5.213717486185487e-06
. O 0 1.1608741488089436e-06

The O 0 5.67063898415654e-06
others O 0 4.355840701464331e-06
were O 0 1.623724017463246e-07
minute O 0 5.812858034914825e-07
deletions O 0 2.671890115379938e-06
, O 0 4.193342206804118e-08
4649delA O 0 5.490292664944718e-07
in O 0 2.3957104744454227e-08
exon O 0 3.0054357011977118e-06
33 O 0 3.1984695851861034e-06
and O 0 6.030033006254598e-08
7883del5 O 0 9.963767979570548e-07
in O 0 5.495783383935304e-08
exon O 0 1.2888467608718202e-05
55 O 0 4.7966268539312296e-06
. O 0 1.0799641358971712e-06

The O 0 8.70817711984273e-06
mutations O 0 3.590075357351452e-05
4612del165 O 0 9.023516213346738e-06
and O 0 2.1429086416446808e-07
7883del5 O 0 3.546839934642776e-06
were O 0 5.313777933224628e-07
found O 0 2.3783549352174305e-08
in O 0 3.9183265521103294e-09
more O 0 1.4801316838841672e-09
than O 0 1.8572375859449153e-09
two O 0 6.151449571945022e-09
unrelated O 0 1.2090865197933454e-07
families O 0 6.071140745689263e-08
; O 0 2.4997216740985095e-08
44 O 0 1.9198341760784388e-07
% O 0 2.114190955637696e-08
( O 0 4.6766173156242985e-09
7 O 0 4.9420389558463285e-08
of O 0 5.307758677020047e-09
16 O 0 9.143911938735982e-07
) O 0 2.6132815911239504e-09
of O 0 7.505349675085426e-10
the O 0 1.9953137808670363e-08
mutant O 0 1.0910242963291239e-05
alleles O 0 5.13350528308365e-07
had O 0 4.889393039775314e-06
one O 0 7.26620141833223e-09
of O 0 1.413887784629253e-09
the O 0 3.0172362386338136e-08
two O 0 1.3598850046037114e-06
mutations O 0 2.5038476451300085e-05
. O 0 7.986506602719601e-07

The O 0 3.6905148590449244e-06
4612del165 O 0 2.357131234020926e-05
mutations O 0 6.4616019699315075e-06
in O 0 3.288254646349742e-08
three O 0 3.5830087341537364e-08
different O 0 3.955475236239181e-08
families O 0 4.2419713963681716e-07
were O 0 6.638908871536842e-07
all O 0 2.7898365839718053e-09
ascribed O 0 1.6458780294215103e-07
to O 0 4.249167684378108e-09
the O 0 8.449092980811201e-09
same O 0 1.389647650285042e-07
T O 0 2.7291151127428748e-05
- O 0 9.549393098495784e-07
- O 0 7.952918963383127e-07
> O 0 6.014342801563544e-08
A O 0 1.1746525530043073e-08
substitution O 0 2.0776491638230254e-08
at O 0 2.0436678127566665e-08
the O 0 9.80934888872298e-09
splice O 0 3.2124980862136e-06
donor O 0 3.17662340876268e-07
site O 0 5.293849767440406e-07
in O 0 1.463756973407726e-07
intron O 0 0.0002727991377469152
33 O 0 2.6704925403464586e-05
. O 0 2.0399797904246952e-06

Microsatellite O 0 0.0033328733406960964
genotyping O 0 0.0002329725248273462
around O 0 1.4260850775826839e-06
the O 0 9.401337308645452e-08
ATM O 0 4.429653927218169e-06
locus O 0 1.2000946298940107e-05
also O 0 3.5050870792474598e-06
indicated O 0 7.139988156268373e-07
that O 0 4.635658523710617e-09
a O 0 8.96131027161573e-08
common O 0 3.7490073623303033e-07
haplotype O 0 0.00047053658636286855
was O 0 0.003806873457506299
shared O 0 6.56063789961081e-08
by O 0 5.406872727320433e-09
the O 0 1.7771347060602238e-08
mutant O 0 4.580169843393378e-06
alleles O 0 3.2121351978275925e-07
in O 0 4.27803925617809e-08
both O 0 5.740737947235175e-07
mutations O 0 2.447462065902073e-05
. O 0 7.699543402850395e-07

This O 0 1.1266696446909918e-06
suggests O 0 5.488104193318577e-07
that O 0 1.155268236630036e-08
these O 0 4.844424861261132e-09
two O 0 5.3000121624791063e-08
founder O 0 2.9088765586493537e-05
mutations O 0 3.392648068256676e-05
may O 0 1.1804650057456456e-06
be O 0 2.4561652267607315e-08
predominant O 0 3.218448512143368e-07
among O 0 1.884687605979707e-08
Japanese O 0 7.366482179804734e-08
ATM O 0 2.1268317595968256e-06
mutant O 0 9.924828191287816e-06
alleles O 0 7.487385573767824e-06
. O 0 1.2006770475636586e-06

W474C O 0 0.0010490842396393418
amino O 0 4.092493327334523e-05
acid O 0 1.221426464326214e-05
substitution O 0 1.092291199711326e-06
affects O 0 4.861153115598427e-07
early O 0 6.29630818593796e-08
processing O 0 1.840635555083736e-08
of O 0 3.5921898788870976e-09
the O 0 9.312421056506537e-09
alpha O 0 6.603976743235762e-08
- O 0 4.900363492765791e-08
subunit O 0 3.699581085925274e-08
of O 0 4.023767985472659e-09
beta O 0 4.387549878970276e-08
- O 0 5.570092298512463e-07
hexosaminidase O 0 9.071827662410215e-07
A O 0 1.7142733099717589e-07
and O 0 7.537463631024366e-08
is O 0 2.9967321069079844e-08
associated O 0 1.2967066709279607e-07
with O 0 3.972457420786668e-07
subacute O 1 0.8771576881408691
G B-Disease 1 0.8823359608650208
( I-Disease 0 8.771310149313649e-07
M2 I-Disease 0 0.0002358808706048876
) I-Disease 0 7.653860620848718e-07
gangliosidosis I-Disease 0 3.591479253373109e-05
. O 0 2.3424456685461337e-06

Mutations O 0 0.0025484771467745304
in O 0 5.55046710815077e-07
the O 0 1.8449752303695277e-07
HEXA O 0 0.00021321683016140014
gene O 0 9.480167477704526e-07
, O 0 2.1262826166434934e-08
encoding O 0 5.8992643658939414e-08
the O 0 1.977996966218143e-08
alpha O 0 6.734947533004743e-08
- O 0 4.266679809461493e-08
subunit O 0 4.722405222423731e-08
of O 0 5.452200912969829e-09
beta O 0 6.836781807351144e-08
- O 0 1.8024700239038793e-06
hexosaminidase O 0 3.469174316705903e-06
A O 0 4.260962498392473e-07
( O 0 2.860456760345187e-08
Hex O 0 4.5640545067726634e-06
A O 0 4.39171941479799e-07
) O 0 1.502477964265836e-08
, O 0 3.5673435316851965e-09
that O 0 3.6443630335725175e-09
abolish O 0 2.3138767346608802e-07
Hex O 0 2.6412453735247254e-06
A O 0 1.373928029124727e-07
enzyme O 0 1.0982072353726835e-06
activity O 0 4.963283117831452e-06
cause O 0 0.004782910458743572
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.30383527278900146
( O 0 2.0291186331178324e-07
TSD B-Disease 0 4.66942074126564e-05
) O 0 3.149035876504058e-08
, O 0 1.7334429003312835e-08
the O 0 1.748562823422617e-07
fatal O 0 0.00045472232159227133
infantile B-Disease 0 0.002760577015578747
form I-Disease 0 1.3131246134889807e-07
of I-Disease 0 7.512675637144639e-08
G I-Disease 0 0.0809188261628151
( I-Disease 0 1.0805198513708092e-07
M2 I-Disease 0 2.920431325037498e-05
) I-Disease 0 7.741859775478588e-08
gangliosidosis I-Disease 0 2.7369899271434406e-06
, I-Disease 0 4.752621762804665e-08
Type I-Disease 0 2.4192280534407473e-07
1 I-Disease 0 5.461653813654266e-07
. O 0 1.541214260214474e-06

Less O 0 0.000358000019332394
severe O 0 0.11257665604352951
, O 0 3.2266216294374317e-06
subacute O 0 0.13446326553821564
( O 0 3.2368573101848597e-06
juvenile O 0 0.008337970823049545
- O 1 0.6982395648956299
onset O 0 0.1631379872560501
) O 0 6.477331453424995e-07
and O 0 3.0073422294663033e-06
chronic O 0 0.04185132682323456
( O 0 2.412935486972856e-07
adult O 0 7.3836181400110945e-06
- O 0 0.05364494398236275
onset O 0 0.001720282481983304
) O 0 3.379517821144873e-08
variants O 0 2.8117037231822906e-07
are O 0 1.1935921584438347e-08
characterized O 0 3.129525509848463e-07
by O 0 5.8063513996842175e-09
a O 0 1.0499318392476198e-07
broad O 0 9.905046454150579e-07
spectrum O 0 6.252269599826832e-07
of O 0 4.284504750984297e-09
clinical O 0 2.904212124121841e-07
manifestations O 0 5.248256229606341e-07
and O 0 2.244517958160941e-07
are O 0 5.929098101375985e-09
associated O 0 3.673648407698238e-08
with O 0 1.7249929484819404e-08
residual O 0 1.1463059308880474e-05
levels O 0 8.062016121357374e-08
of O 0 6.211508640774355e-09
Hex O 0 1.507138858869439e-05
A O 0 5.058373062638566e-07
enzyme O 0 9.157097906609124e-07
activity O 0 1.1951774467888754e-06
. O 0 7.972648177201336e-07

We O 0 9.699370821181219e-06
identified O 0 1.1484507922432385e-06
a O 0 1.9652418359328294e-07
1422 O 0 2.8151347578386776e-05
G O 0 0.00026996826636604965
- O 0 5.396814231062308e-05
- O 0 7.357449794653803e-05
> O 0 5.388978479459183e-06
C O 0 4.327623173594475e-06
( O 0 4.842792478143565e-08
amino O 0 1.5925522234283562e-07
acid O 0 2.531500058466918e-07
W474C O 0 1.994043685726865e-07
) O 0 2.656232789277624e-09
substitution O 0 8.42575786919042e-09
in O 0 8.520884442475563e-09
the O 0 1.6319106066475797e-08
first O 0 4.65076119837704e-08
position O 0 9.225374242305406e-08
of O 0 5.481030740384085e-09
exon O 0 1.1967514410571312e-06
13 O 0 2.0144342727235198e-07
of O 0 9.951345525394117e-09
HEXA O 0 4.142248508287594e-05
of O 0 8.11082756513315e-09
a O 0 1.0250879967088622e-07
non O 0 1.246742868943329e-07
- O 0 5.41011695531779e-06
Jewish O 0 1.4314591680886224e-06
proband O 0 2.7971487725153565e-05
who O 0 9.584766758052865e-07
manifested O 0 1.0381784250057535e-06
a O 0 3.4780748592311284e-07
subacute O 0 0.00021590966207440943
variant O 0 3.557467425707728e-05
of O 0 1.0529254268476507e-06
G B-Disease 0 0.428710013628006
( I-Disease 0 9.339922257822764e-07
M2 I-Disease 0 0.0002391100861132145
) I-Disease 0 1.0768818583528628e-06
gangliosidosis I-Disease 0 6.115768337622285e-05
. O 0 2.5873989670799347e-06

On O 0 1.2070780030626338e-05
the O 0 3.321639212572336e-07
second O 0 6.601762834179681e-06
maternally O 0 0.00011806118709500879
inherited O 0 7.966533303260803e-05
allele O 0 7.141607056837529e-06
, O 0 8.084759173243583e-08
we O 0 2.5231166489447787e-08
identified O 0 1.5439403000527818e-07
the O 0 5.771309119495527e-08
common O 0 6.846948053862434e-06
infantile O 1 0.9734859466552734
disease O 0 0.0003942432813346386
- O 0 3.13740165438503e-05
causing O 0 2.4452051547996234e-06
4 O 0 7.493297857763537e-07
- O 0 1.5650248315068893e-05
bp O 0 6.590709745069034e-06
insertion O 0 1.2888474429928465e-06
, O 0 6.981285594065412e-08
+ O 0 1.2988531352675636e-06
TATC O 0 1.288623025175184e-05
1278 O 0 1.1260519386269152e-05
, O 0 4.698041067285885e-08
in O 0 3.713040896968778e-08
exon O 0 9.820161722018383e-06
11 O 0 4.072827323398087e-06
. O 0 1.6830922504595947e-06

Pulse O 0 0.002758729038760066
- O 0 0.0001636961824260652
chase O 0 5.785603661934147e-06
analysis O 0 1.1589986570470501e-07
using O 0 8.867760925568291e-08
proband O 0 6.3480911194346845e-06
fibroblasts O 0 1.3482796248354134e-06
revealed O 0 1.7583062117410009e-06
that O 0 8.719641009236057e-09
the O 0 2.0169133918557236e-08
W474C O 0 6.769391234229261e-07
- O 0 2.3140070481986186e-07
containing O 0 4.8953189946132625e-08
alpha O 0 1.0083373069846857e-07
- O 0 4.8086260306945405e-08
subunit O 0 5.3369163310890144e-08
precursor O 0 1.2313920194628736e-07
was O 0 9.305568369200046e-07
normally O 0 2.2530398879894165e-08
synthesized O 0 7.739334506595696e-08
, O 0 8.18445666794787e-09
but O 0 2.5355813004779293e-09
not O 0 2.5248771962083083e-09
phosphorylated O 0 2.7357264897887035e-08
or O 0 1.39137359411734e-08
secreted O 0 1.043437549697046e-07
, O 0 1.3548847377364837e-08
and O 0 2.7136188407439477e-08
the O 0 1.8462507966887642e-08
mature O 0 6.093751636626621e-08
lysosomal O 0 4.1301427700091153e-07
alpha O 0 7.434262272454362e-08
- O 0 2.0507985709627974e-07
subunit O 0 2.477427756275574e-07
was O 0 4.1820590013230685e-06
not O 0 1.6605912378508947e-07
detected O 0 3.9801511775294784e-06
. O 0 1.086317865883757e-06

When O 0 6.594607839360833e-06
the O 0 2.9507319254662434e-07
W474C O 0 2.6776040158438263e-06
- O 0 5.889797876079683e-07
containing O 0 6.206951752574241e-08
alpha O 0 1.2255343051492673e-07
- O 0 1.3771143869689695e-07
subunit O 0 2.3553188555069937e-07
was O 0 1.0932728855550522e-06
transiently O 0 1.1802195558630046e-06
co O 0 1.2259882851139992e-06
- O 0 6.250163096410688e-06
expressed O 0 1.9215152136098368e-08
with O 0 2.689558797897007e-09
the O 0 1.03281418972756e-08
beta O 0 2.7336035657299362e-08
- O 0 7.558309533806096e-08
subunit O 0 2.8230360271663812e-08
to O 0 6.150675080363044e-09
produce O 0 1.7298065202453472e-08
Hex O 0 2.7463713649922283e-06
A O 0 2.324355676819323e-07
( O 0 2.8834357124196686e-08
alphabeta O 0 4.2611739559106354e-07
) O 0 5.594701590894147e-09
in O 0 1.7437727706237638e-08
COS O 0 0.000987924518994987
- O 0 1.3335531548364088e-05
7 O 0 6.508043384201301e-07
cells O 0 5.159394689258079e-08
, O 0 3.2975231434306806e-09
the O 0 3.4800233805754033e-09
mature O 0 1.0641246994680387e-08
alpha O 0 1.2334343324482688e-08
- O 0 3.161071404633731e-08
subunit O 0 2.3358259326755615e-08
was O 0 4.932231831844547e-07
present O 0 6.915799044548976e-09
, O 0 8.821970709504967e-09
but O 0 2.658883779815824e-09
its O 0 6.411054798149962e-09
level O 0 6.877483116340954e-08
was O 0 2.532442067604279e-06
much O 0 1.8462085193959865e-08
lower O 0 1.7742229374562157e-07
than O 0 2.715797364771788e-09
that O 0 1.7969096210990188e-09
from O 0 1.4535866954545895e-09
normal O 0 8.254897210235868e-09
alpha O 0 2.274586030637238e-08
- O 0 3.3159668788584895e-08
subunit O 0 3.6864864938479514e-08
transfections O 0 5.725893288399675e-07
, O 0 7.45365369425599e-09
although O 0 3.31981309109608e-09
higher O 0 3.185461450172511e-09
than O 0 1.2356965450877055e-09
in O 0 3.5575251633446214e-09
those O 0 1.2123236636796264e-08
cells O 0 5.955146065161898e-08
transfected O 0 6.346562599901517e-07
with O 0 5.924056356576557e-09
an O 0 5.657358581601102e-09
alpha O 0 8.273185159168861e-08
- O 0 1.1080483375280892e-07
subunit O 0 2.9272106871758297e-07
associated O 0 4.182507211680786e-07
with O 0 6.761958388779021e-07
infantile O 0 0.29437676072120667
TSD B-Disease 0 0.0031045274809002876
. O 0 6.344097073451849e-06

Furthermore O 0 2.505199699953664e-05
, O 0 1.707231689351829e-07
the O 0 1.5803601982611326e-08
precursor O 0 1.1101806762781052e-07
level O 0 1.655056891536333e-08
of O 0 2.4212181148897116e-09
the O 0 1.5564822319902305e-08
W474C O 0 4.4487455852504354e-07
alpha O 0 2.7891514875477696e-08
- O 0 2.6610312175989748e-08
subunit O 0 2.1617818646291198e-08
was O 0 4.0714888882575906e-07
found O 0 1.1007342592961322e-08
to O 0 8.435132592410355e-09
accumulate O 0 8.895220560134476e-08
in O 0 4.62984450777526e-09
comparison O 0 2.168525803369903e-08
to O 0 3.910069157342377e-09
the O 0 5.818923121125863e-09
normal O 0 4.9977771254816616e-08
alpha O 0 4.9018410663848044e-08
- O 0 9.555818536455263e-08
subunit O 0 1.90367913432965e-07
precursor O 0 7.875452183725429e-07
levels O 0 2.9350320573939825e-07
. O 0 3.3727508252923144e-07

We O 0 1.526747837488074e-05
conclude O 0 1.6232422694884008e-06
that O 0 4.2618808038241696e-08
the O 0 4.73714614201981e-08
1422 O 0 8.998382327263243e-06
G O 0 0.0001070990547304973
- O 0 1.3373100955504924e-05
- O 0 2.0070003301952966e-05
> O 0 1.103780618905148e-06
C O 0 1.5887734434727463e-06
mutation O 0 2.688432800823648e-07
is O 0 8.198659529057295e-09
the O 0 1.9630496339573256e-08
cause O 0 3.871183764658781e-07
of O 0 5.2971621755659726e-08
Hex B-Disease 0 0.4445568919181824
A I-Disease 0 0.25657474994659424
enzyme I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 1.80816385864091e-07
the O 0 4.702639841980272e-07
proband O 0 0.0001706118055153638
. O 0 2.7777775812865e-06

The O 0 2.8339420623524347e-06
resulting O 0 2.962629878311418e-06
W474C O 0 4.110356712772045e-06
substitution O 0 6.250534170249011e-07
clearly O 0 7.76251397383021e-07
interferes O 0 3.389114056062681e-07
with O 0 1.0050823284757371e-08
alpha O 0 5.0425217779093146e-08
- O 0 5.240663369932008e-08
subunit O 0 2.2587713033317414e-08
processing O 0 1.916950331803946e-08
, O 0 7.059562268096897e-09
but O 0 3.179300378519656e-09
because O 0 9.379407250875715e-10
the O 0 9.900659181383276e-10
base O 0 2.3516957270430794e-08
substitution O 0 4.06170741484857e-08
falls O 0 2.2861699108034372e-05
at O 0 2.062778925449038e-08
the O 0 5.9959912590557e-09
first O 0 2.7361437560102786e-08
position O 0 1.4965725370075234e-07
of O 0 5.890165688526849e-09
exon O 0 1.4074237242311938e-06
13 O 0 3.4066871990034997e-07
, O 0 8.97822705070439e-09
aberrant O 0 5.166525056665705e-07
splicing O 0 2.7568103178055026e-06
may O 0 1.6309917327816947e-06
also O 0 6.525681328639621e-08
contribute O 0 1.1689887280397215e-08
to O 0 4.1237029790863744e-08
Hex B-Disease 0 0.024094242602586746
A I-Disease 0 0.0010252265492454171
deficiency I-Disease 0 0.00018791184993460774
in O 0 1.3047058544657375e-08
this O 0 3.659388880805636e-08
proband O 0 1.5111381799215451e-05
. O 0 2.3528514248027932e-07
. O 0 9.088697083825537e-07

Two O 0 9.108749509323388e-06
frequent O 0 5.947054160060361e-05
missense O 0 0.04638924077153206
mutations O 0 0.044638533145189285
in O 0 0.000520689005497843
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.4919965653680265e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.0001782050239853561
an O 0 0.0025636202190071344
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9722877740859985
by O 0 1.1075555448769592e-05
early O 0 0.050110962241888046
childhood O 1 0.999500036239624
deafness B-Disease 1 1.0
and O 1 0.9834325909614563
goiter B-Disease 1 1.0
. O 0 4.4071020965930074e-05

A O 0 3.6040088161826134e-05
century O 0 6.558875611517578e-06
after O 0 2.2488374895601737e-07
its O 0 2.1914610570661353e-08
recognition O 0 5.0241851567989215e-08
as O 0 3.8189307360880775e-07
a O 0 5.868291555088945e-05
syndrome O 1 0.9998725652694702
by O 0 4.025274336072471e-08
Vaughan O 0 1.3979173672851175e-05
Pendred O 0 8.540405360690784e-06
, O 0 2.200546056485564e-08
the O 0 1.4172586304539436e-07
disease O 0 1.921008515637368e-05
gene O 0 1.4014140106155537e-06
( O 0 3.671414674499829e-07
PDS O 0 2.8182050300529227e-05
) O 0 5.680900727611515e-08
was O 0 1.3527269402402453e-06
mapped O 0 1.8610542610986158e-05
to O 0 4.4734636617249635e-07
chromosome O 0 0.00041851893183775246
7q22 O 0 2.5682318664621562e-05
- O 0 4.760750016430393e-05
q31 O 0 4.2798867070814595e-05
. O 0 1.8624338053996325e-06

1 O 0 3.559577453415841e-05
and O 0 1.7222434962604893e-06
, O 0 1.713487165488914e-07
recently O 0 3.439430656726472e-06
, O 0 3.6259908853253364e-08
found O 0 3.156956296379576e-08
to O 0 4.353287064162714e-09
encode O 0 2.1169635999740422e-07
a O 0 4.5567207962449174e-07
putative O 0 3.9249949622899294e-05
sulfate O 0 4.3934473069384694e-05
transporter O 0 0.00022085658565629274
. O 0 2.5793747226998676e-06

We O 0 3.417626066948287e-05
performed O 0 8.59362626215443e-06
mutation O 0 1.285046437260462e-06
analysis O 0 4.178404111598866e-08
of O 0 8.187610589516225e-09
the O 0 5.141652792417517e-08
PDS B-Disease 0 1.5570987670798786e-05
gene O 0 4.4612619376493967e-07
in O 0 1.7105303129483218e-07
patients O 0 3.046299923425977e-07
from O 0 1.4774219181390436e-08
14 O 0 2.814416006913234e-07
Pendred B-Disease 0 6.316086000879295e-06
families O 0 3.6997434449403954e-08
originating O 0 2.2210647543374762e-08
from O 0 7.51271578280921e-09
seven O 0 1.691525319813536e-08
countries O 0 1.4690866301236838e-09
and O 0 2.9216904451345727e-08
identified O 0 5.572227905759064e-07
all O 0 3.424596073386965e-08
mutations O 0 3.064276825170964e-06
. O 0 3.8645919175905874e-07

The O 0 4.674948286265135e-06
mutations O 0 1.1954980436712503e-05
include O 0 2.3640316371142944e-08
three O 0 4.37942304643002e-08
single O 0 4.987236366105208e-07
base O 0 9.61708792601712e-07
deletions O 0 3.815253876382485e-06
, O 0 4.7488708077025876e-08
one O 0 2.8520940276166584e-08
splice O 0 4.013232683064416e-05
site O 0 1.284277459490113e-05
mutation O 0 2.525693616917124e-06
and O 0 1.634147821505394e-07
10 O 0 1.0865156809813925e-06
missense O 0 0.0002645143831614405
mutations O 0 7.720998110016808e-05
. O 0 1.9006165530299768e-06

One O 0 3.404435483389534e-05
missense O 0 0.004719204269349575
mutation O 0 0.0001480989158153534
( O 0 6.618951147174812e-07
L236P O 0 8.64677167555783e-06
) O 0 1.3741023963120824e-07
was O 0 2.2578510652238037e-06
found O 0 5.461102148274222e-08
in O 0 1.1666455357328687e-08
a O 0 9.434084091708428e-08
homozygous O 0 2.7984267489955528e-06
state O 0 3.552500515979773e-09
in O 0 7.672340096576136e-09
two O 0 8.77659331877112e-08
consanguineous O 0 1.584717392688617e-05
families O 0 1.240582463424289e-07
and O 0 3.9371400362142595e-08
in O 0 1.089571632917341e-08
a O 0 1.8150433334085392e-07
heterozygous O 0 3.5107200346828904e-07
state O 0 2.164574297580657e-09
in O 0 5.827364368826693e-09
five O 0 1.0624515489610076e-08
additional O 0 2.3377690894221814e-08
non O 0 2.1093357815971103e-07
- O 0 2.449886051181238e-05
consanguineous O 0 8.561076538171619e-05
families O 0 1.055398456628609e-06
. O 0 4.7653117007939727e-07

Another O 0 6.674420728813857e-05
missense O 0 0.005881601478904486
mutation O 0 0.0001992324978346005
( O 0 7.38507935693633e-07
T416P O 0 7.286372692760779e-06
) O 0 9.105938403308755e-08
was O 0 2.408866748737637e-06
found O 0 1.0646083126175654e-07
in O 0 1.4926349933830352e-08
a O 0 2.8162926923869236e-07
homozygous O 0 2.5246411041734973e-06
state O 0 4.024888866638321e-09
in O 0 1.8756647790496572e-08
one O 0 9.360077513065335e-08
family O 0 1.5338433456690836e-07
and O 0 5.7945158005168196e-08
in O 0 7.339607588363606e-09
a O 0 1.5092311400621838e-07
heterozygous O 0 5.237660616330686e-07
state O 0 5.494323662702527e-09
in O 0 1.7978805999518954e-08
four O 0 2.206622014000459e-07
families O 0 4.711995700290572e-07
. O 0 8.843958312354516e-07

Pendred B-Disease 0 0.06988856941461563
patients O 0 0.00020351541752461344
in O 0 1.6470541197577404e-07
three O 0 7.142726587971993e-08
non O 0 1.4021530603258725e-07
- O 0 1.5700055882916786e-05
consanguineous O 0 5.583847450907342e-05
families O 0 1.9032684122066712e-06
were O 0 9.796056019695243e-07
shown O 0 1.082027480947545e-07
to O 0 4.378585494180243e-09
be O 0 1.2515420699799051e-08
compound O 0 5.777481533186801e-07
heterozygotes O 0 1.3746923741564387e-06
for O 0 2.513342245435979e-08
L236P O 0 5.206314199313056e-06
and O 0 2.831748986409366e-07
T416P O 0 1.8383572751190513e-05
. O 0 1.4455356449616374e-06

In O 0 3.7131655972189037e-06
total O 0 5.437668164631759e-07
, O 0 6.02077037115123e-08
one O 0 2.1224575874612128e-08
or O 0 2.7677049985186386e-08
both O 0 5.5851057112477065e-09
of O 0 3.258049385834738e-09
these O 0 1.7603175805902538e-08
mutations O 0 1.5425730452989228e-06
were O 0 4.803410433851241e-07
found O 0 1.0453101140228682e-07
in O 0 4.068584757987992e-08
nine O 0 1.6624419174604554e-07
of O 0 2.7049256168254487e-09
the O 0 7.697217796476252e-08
14 O 0 6.873352162983792e-07
families O 0 8.741375978615906e-08
analyzed O 0 1.0401614645161317e-06
. O 0 9.352294227937819e-07

The O 0 1.2492463383750874e-06
identification O 0 5.025489144827588e-07
of O 0 2.8941361307488478e-08
two O 0 4.3452266140775464e-07
frequent O 0 2.6849715140997432e-05
PDS B-Disease 0 0.04804663732647896
mutations O 0 1.237587184732547e-05
will O 0 1.1520974396717065e-08
facilitate O 0 2.4107636775738683e-08
the O 0 3.1925981858194064e-08
molecular O 0 1.0182700862060301e-05
diagnosis O 0 0.03899957984685898
of O 0 0.0002011780597968027
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.256772975466447e-05

Insertional O 0 0.01262795552611351
mutation O 0 0.000276000500889495
by O 0 5.093954200674489e-07
transposable O 0 3.7722111301263794e-05
element O 0 1.6402759683842305e-06
, O 0 1.2560910533920833e-07
L1 O 0 0.00015102868201211095
, O 0 6.234680682837279e-08
in O 0 2.817995259363215e-08
the O 0 5.304300429997966e-07
DMD B-Disease 1 0.9999997615814209
gene O 0 4.329645889811218e-06
results O 0 5.930847919444204e-07
in O 0 5.240633527137106e-07
X B-Disease 1 0.9999488592147827
- I-Disease 1 0.9999933242797852
linked I-Disease 1 0.9999624490737915
dilated I-Disease 1 0.9998565912246704
cardiomyopathy I-Disease 1 1.0
. O 0 2.952593240479473e-05

X B-Disease 1 0.999873161315918
- I-Disease 1 0.9999926090240479
linked I-Disease 1 0.9999730587005615
dilated I-Disease 1 0.9999979734420776
cardiomyopathy I-Disease 1 1.0
( O 0 2.893041164497845e-05
XLDCM B-Disease 0 0.004038119688630104
) O 0 1.0796875926644134e-07
is O 0 2.3202977317282603e-08
a O 0 1.947487646702939e-07
clinical O 0 1.4147068213787861e-05
phenotype O 0 7.316387200262398e-05
of O 0 5.0137600737798493e-08
dystrophinopathy B-Disease 0 0.0009355141082778573
which O 0 9.555486712997663e-07
is O 0 4.9224997411556615e-08
characterized O 0 4.3498286572685174e-07
by O 0 2.6405041708699173e-08
preferential O 0 1.7668369309831178e-06
myocardial B-Disease 0 0.059451933950185776
involvement I-Disease 0 6.008999662299175e-07
without O 0 4.642394912934833e-08
any O 0 2.1877609057696645e-08
overt O 0 9.729708381200908e-07
clinical O 0 5.33315824213787e-06
signs O 0 3.440438013058156e-05
of O 0 4.0034019548329525e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 8.218856964958832e-05

To O 0 1.8413961697660852e-06
date O 0 1.4185502550390083e-06
, O 0 5.493320287541792e-08
several O 0 6.75678251127465e-08
mutations O 0 2.9213922516646562e-06
in O 0 1.3016638433782646e-07
the O 0 1.3494230188371148e-05
Duchenne B-Disease 1 0.9999996423721313
muscular I-Disease 1 0.9982737302780151
dystrophy I-Disease 1 0.9307737946510315
gene O 0 2.608015165606048e-05
, O 0 5.5310024436039384e-06
DMD O 1 1.0
, O 0 6.639694447585498e-07
have O 0 2.4113114704960026e-07
been O 0 3.837070892132033e-07
identified O 0 5.797572271148965e-07
in O 0 8.163335962763085e-08
patients O 0 1.0627255875306219e-07
with O 0 3.001686366133072e-08
XLDCM B-Disease 0 0.0010775348637253046
, O 0 6.06843144623781e-08
but O 0 5.173898198762572e-09
a O 0 1.512322356234108e-08
pathogenic O 0 3.365584788639353e-08
correlation O 0 4.84807891609762e-08
of O 0 4.417263888001344e-09
these O 0 2.7313049599797523e-08
cardiospecific O 0 0.00019794097170233727
mutations O 0 1.1965634257649072e-05
in O 0 3.1395487098961894e-07
DMD O 1 0.9999998807907104
with O 0 1.8837681636796333e-07
the O 0 1.0726301979957498e-06
XLDCM B-Disease 0 0.14524854719638824
phenotype O 0 0.00021916728292126209
has O 0 2.5720373741933145e-06
remained O 0 3.298615411040373e-06
to O 0 3.10033883010874e-08
be O 0 1.2513061165009276e-07
elucidated O 0 4.271218131179921e-05
. O 0 1.6221961232076865e-06

We O 0 5.349647835828364e-05
report O 0 6.733291115779139e-07
here O 0 3.335847864605057e-08
the O 0 5.7627920213576544e-09
identification O 0 2.3418213146442213e-08
of O 0 6.0034408555509344e-09
a O 0 5.212133302734401e-08
unique O 0 2.3289067030418664e-07
de O 0 5.2223363127268385e-06
novo O 0 2.501019707779051e-06
L1 O 0 1.7431328842576477e-06
insertion O 0 2.16520760432104e-07
in O 0 1.131407501020476e-08
the O 0 3.0496714487071586e-08
muscle O 0 7.218532118713483e-07
exon O 0 1.3967481891086209e-06
1 O 0 4.022369921585778e-07
in O 0 7.080257091729436e-07
DMD O 1 1.0
in O 0 9.474816806687159e-07
three O 0 1.1388517577870516e-06
XLDCM B-Disease 0 0.07544813305139542
patients O 0 5.691529167961562e-07
from O 0 7.55326201584694e-09
two O 0 2.1131345562253046e-08
unrelated O 0 1.1700883533194428e-06
Japanese O 0 1.1303503697490669e-06
families O 0 4.339610768511193e-07
. O 0 5.289923024065502e-07

The O 0 2.2375088519765995e-06
insertion O 0 9.285611668019556e-06
was O 0 3.871109583997168e-06
a O 0 1.345675570973981e-07
5 O 0 3.4839774798456347e-07
- O 0 1.923801846714923e-06
truncated O 0 7.83734549258952e-07
form O 0 3.2754225998132824e-08
of O 0 6.155017384656958e-09
human O 0 4.025896416237629e-08
L1 O 0 1.5180266927927732e-05
inversely O 0 1.402950601914199e-06
integrated O 0 1.9990284272353165e-07
in O 0 1.9732453893084312e-08
the O 0 8.948926932816903e-08
5 O 0 1.2450727808754891e-06
- O 0 1.476707802794408e-05
untranslated O 0 2.4400744223385118e-05
region O 0 3.2775696467979287e-07
in O 0 2.0472064932164358e-08
the O 0 4.807525755268216e-08
muscle O 0 6.589280587832036e-07
exon O 0 8.183725412891363e-07
1 O 0 4.2228631969010166e-07
, O 0 6.118955298006767e-08
which O 0 6.011200781586012e-08
affected O 0 8.268528084443005e-09
the O 0 3.518232150057088e-09
transcription O 0 4.190927711533732e-07
or O 0 1.4384298197001044e-07
the O 0 3.085154887116914e-08
stability O 0 1.6434860583558475e-07
of O 0 5.256918900187202e-09
the O 0 1.266802627242214e-07
muscle O 0 1.4787208328925772e-06
form O 0 7.56860529804726e-09
of O 0 4.3692831575015134e-09
dystrophin O 0 1.1848568419736694e-06
transcripts O 0 9.407424386154162e-07
but O 0 8.702448184294553e-08
not O 0 5.468833830235553e-09
that O 0 1.8457816386430181e-09
of O 0 3.5401424014480654e-09
the O 0 2.598563924038899e-07
brain O 0 1.7345764717902057e-05
or O 0 1.0329387833962755e-07
Purkinje O 0 4.8033336497610435e-05
cell O 0 1.2536245776573196e-05
form O 0 8.345040924950808e-08
, O 0 1.674622893688138e-07
probably O 0 4.177918242476153e-07
due O 0 2.4079696459011757e-08
to O 0 1.4791305069650207e-08
its O 0 2.4144449994878414e-08
unique O 0 3.586543684264143e-08
site O 0 4.199633565349359e-07
of O 0 2.1500174085531398e-08
integration O 0 9.67425762610219e-07
. O 0 1.3122374866725295e-06

We O 0 7.5948069024889264e-06
speculate O 0 7.871788056945661e-07
that O 0 7.670554857952538e-09
this O 0 2.179720848261013e-09
insertion O 0 5.928490764972594e-08
of O 0 2.1706683117628245e-09
an O 0 1.1846513991997654e-08
L1 O 0 9.684426913736388e-05
sequence O 0 1.8430282580084167e-06
in O 0 1.8700068267207826e-06
DMD O 1 1.0
is O 0 7.094687930475629e-07
responsible O 0 4.342425796721727e-08
for O 0 2.581698188564019e-09
some O 0 2.013967881353551e-09
of O 0 1.5328824876092995e-09
the O 0 1.1677808942067713e-08
population O 0 8.824310171462457e-09
of O 0 3.011467963887071e-09
Japanese O 0 3.908923531525943e-07
patients O 0 1.0816621909270907e-07
with O 0 3.087339095486641e-08
XLDCM B-Disease 0 0.0001559882948640734
. O 0 2.220360073579286e-07
. O 0 4.0144564650290704e-07

Severe O 1 0.5614275932312012
early O 0 3.3891690691234544e-05
- O 0 0.30447813868522644
onset O 1 0.9452641010284424
obesity B-Disease 1 1.0
, O 0 0.003642243565991521
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.00038732215762138367
red O 0 0.011789470911026001
hair O 1 0.9997543692588806
pigmentation O 1 0.980068027973175
caused O 0 3.371831189724617e-05
by O 0 4.0427528347208863e-07
POMC O 0 0.013175811618566513
mutations O 0 2.2028820239938796e-05
in O 0 2.2459610704572697e-07
humans O 0 1.4419764511330868e-06
. O 0 1.2704506389127346e-06

Sequential O 0 0.00013720907736569643
cleavage O 0 0.0003655905311461538
of O 0 1.419562210003278e-07
the O 0 4.6446444912362495e-08
precursor O 0 2.180367175697029e-07
protein O 0 3.601446962875343e-07
pre O 0 2.0103743736399338e-06
- O 0 3.915857450920157e-05
pro O 0 1.6876321751624346e-05
- O 0 0.00037881082971580327
opiomelanocortin O 0 0.0001533373724669218
( O 0 2.8921394346070883e-07
POMC O 0 1.9795783373410814e-05
) O 0 6.659150386667534e-08
generates O 0 1.3563150957907055e-07
the O 0 5.710155903670966e-08
melanocortin O 0 3.1625320843886584e-05
peptides O 0 3.7004747355240397e-06
adrenocorticotrophin O 0 2.854694685083814e-05
( O 0 2.54985394576579e-07
ACTH O 0 9.984836651710793e-06
) O 0 2.3501620205479412e-08
, O 0 1.5312584977777988e-08
melanocyte O 0 7.20751131666475e-06
- O 0 1.0398457561677787e-05
stimulating O 0 1.5252733192028245e-06
hormones O 0 1.0787750852614408e-06
( O 0 3.587795660564552e-08
MSH O 0 3.322391421534121e-06
) O 0 8.653961991456072e-09
alpha O 0 1.8950256475136484e-08
, O 0 2.7200846020036806e-09
beta O 0 5.125875279787806e-09
and O 0 3.2938145544392228e-09
gamma O 0 2.8828145204329303e-08
as O 0 5.1991437821641284e-09
well O 0 2.8122861817081457e-09
as O 0 5.01654140450114e-09
the O 0 6.832633570041935e-09
opioid O 0 1.8973462090343673e-07
- O 0 5.67218478408904e-07
receptor O 0 6.508478236355586e-07
ligand O 0 9.276832315663341e-07
beta O 0 1.7421524489691365e-06
- O 0 3.97982366848737e-05
endorphin O 0 0.000371465808711946
. O 0 2.870140860977699e-06

While O 0 4.41824568042648e-06
a O 0 3.8552198589059117e-07
few O 0 1.6197168406506535e-07
cases O 0 5.495657617871075e-08
of O 0 8.306912491207186e-08
isolated O 1 0.709750771522522
ACTH B-Disease 1 0.9999700784683228
deficiency I-Disease 0 0.45027899742126465
have O 0 1.993826828083911e-07
been O 0 1.5332539078372065e-06
reported O 0 1.4564630873792339e-05
( O 0 1.998955951876269e-07
OMIM O 0 0.00016081133799161762
201400 O 0 2.4621185730211437e-06
) O 0 1.4290741923161931e-08
, O 0 8.591745093156078e-09
an O 0 6.63019079638616e-08
inherited O 0 0.01085414458066225
POMC O 0 0.23103483021259308
defect O 0 0.0002588705683592707
has O 0 1.5859545783314388e-06
not O 0 3.902843914715959e-08
been O 0 3.1262175070878584e-07
described O 0 1.3775020306638908e-06
so O 0 9.47630169889635e-08
far O 0 2.2667649091090425e-07
. O 0 5.319528213476588e-07

Recent O 0 1.0145885426027235e-05
studies O 0 6.67205370064039e-07
in O 0 5.180151063655103e-08
animal O 0 1.5105672446225071e-07
models O 0 5.829996325701359e-07
elucidated O 0 2.03299782697286e-06
a O 0 6.927022866420884e-08
central O 0 2.7675254088421752e-08
role O 0 2.5046086093993836e-08
of O 0 1.072511679467425e-08
alpha O 0 2.2767176233173814e-07
- O 0 7.608145097037777e-06
MSH O 0 1.157418137154309e-05
in O 0 1.51195589381814e-08
the O 0 1.4011501292543471e-08
regulation O 0 5.307355976924555e-08
of O 0 2.064687087965922e-09
food O 0 3.6724294716350414e-08
intake O 0 9.367096254209173e-08
by O 0 2.610685889692377e-09
activation O 0 3.917752877669045e-08
of O 0 3.343943122402493e-09
the O 0 9.290567959396867e-08
brain O 0 6.259002020669868e-06
melanocortin O 0 5.923064236412756e-06
- O 0 3.555262310328544e-06
4 O 0 5.046120463703119e-07
- O 0 2.1585985905403504e-06
receptor O 0 7.641381216672016e-07
( O 0 7.589309802824573e-08
MC4 O 0 1.0457419193699025e-05
- O 0 4.715349405159941e-06
R O 0 1.724360481603071e-05
; O 0 6.645725392218083e-08
refs O 0 8.958778607848217e-07
3 O 0 2.794685087792459e-07
- O 0 7.670896593481302e-06
5 O 0 4.4442251123655296e-07
) O 0 9.574880444063183e-09
and O 0 1.2789411307778664e-08
the O 0 1.2997209530851705e-08
linkage O 0 2.268707703478867e-06
of O 0 2.0308913661892802e-08
human O 0 6.306488558038836e-07
obesity B-Disease 1 0.9999755620956421
to O 0 2.819880648985418e-07
chromosome O 0 6.090195165597834e-05
2 O 0 2.2307112601538392e-07
in O 0 2.1550386364310725e-08
close O 0 1.343564832723132e-07
proximity O 0 1.0567506336656152e-07
to O 0 9.507115095175322e-08
the O 0 1.1143472988806025e-07
POMC O 0 5.8437981351744384e-05
locus O 0 2.2340225314110285e-06
, O 0 6.396840035449713e-08
led O 0 3.286160321636089e-08
to O 0 5.073032216529327e-09
the O 0 6.614853997888304e-09
proposal O 0 3.787162583535064e-08
of O 0 2.802374776678107e-09
an O 0 2.2302979019173108e-08
association O 0 1.6319262385877664e-08
of O 0 1.4866000874746987e-08
POMC O 0 6.54544637654908e-05
with O 0 4.111303155696078e-07
human O 0 2.1467947590281256e-05
obesity B-Disease 1 0.9999995231628418
. O 0 2.192340843976126e-06

The O 0 1.671791778790066e-06
dual O 0 1.763909153851273e-06
role O 0 5.307781520969002e-07
of O 0 5.5884228800096025e-08
alpha O 0 9.227412647305755e-07
- O 0 1.7043803381966427e-05
MSH O 0 1.6514059097971767e-05
in O 0 2.4916388952078705e-08
regulating O 0 1.3006625465550314e-07
food O 0 9.239673204319843e-08
intake O 0 3.7524196727645176e-07
and O 0 8.623073455282793e-08
influencing O 0 5.890573220312945e-07
hair O 0 0.04769597202539444
pigmentation O 0 0.00026914564659819007
predicts O 0 6.069987648515962e-06
that O 0 1.6681871883861277e-08
the O 0 1.291012097226485e-07
phenotype O 0 0.0001155169156845659
associated O 0 8.614804158924017e-08
with O 0 2.919885488950058e-08
a O 0 3.1376052902487572e-06
defect O 0 0.00026526040164753795
in O 0 5.993958893668605e-07
POMC O 0 8.388764399569482e-05
function O 0 1.2130354321016057e-07
would O 0 7.209369101701668e-08
include O 0 1.4456733765655372e-07
obesity B-Disease 1 0.9999982118606567
, O 0 3.058356981000543e-07
alteration O 0 8.17426189314574e-06
in O 0 2.019633029703982e-06
pigmentation O 1 0.9358066320419312
and O 0 0.009960719384253025
ACTH B-Disease 1 0.9996652603149414
deficiency I-Disease 0 0.35827773809432983
. O 0 2.0898862658214057e-06

The O 0 3.222934310542769e-06
observation O 0 4.666560926125385e-06
of O 0 5.211000342342231e-08
these O 0 2.0422736213276949e-07
symptoms O 0 1.681392859609332e-05
in O 0 1.6200667474208785e-08
two O 0 6.848711109341821e-08
probands O 0 1.7059268429875374e-05
prompted O 0 1.1048469161778485e-07
us O 0 6.419363263177047e-09
to O 0 1.9479764468144367e-09
search O 0 2.798909548573647e-08
for O 0 1.5991687973837543e-08
mutations O 0 8.445091452813358e-07
within O 0 2.4292914346801808e-08
their O 0 1.1013962364359031e-07
POMC O 0 0.0002140925935236737
genes O 0 4.9673176363285165e-06
. O 0 1.335966658189136e-06

Patient O 0 0.014618965797126293
1 O 0 3.758290040423162e-05
was O 0 1.0140719496121164e-05
found O 0 8.647317173426927e-08
to O 0 9.264587319535167e-09
be O 0 5.70964120427675e-09
a O 0 3.177701657364196e-08
compound O 0 5.67538279483415e-07
heterozygote O 0 1.2630692935999832e-06
for O 0 7.635609478029437e-09
two O 0 1.1534567079252156e-07
mutations O 0 1.0012346365328995e-06
in O 0 1.6415194536989475e-08
exon O 0 3.1677641345595475e-06
3 O 0 2.254778337373864e-06
( O 0 3.845701357363396e-08
G7013T O 0 6.298873245214054e-07
, O 0 4.307079493059973e-08
C7133delta O 0 5.857281848875573e-06
) O 0 1.4624697897147598e-08
which O 0 1.127699622571754e-08
interfere O 0 1.3927941466818083e-08
with O 0 3.380593138757604e-09
appropriate O 0 1.9036331622146463e-08
synthesis O 0 6.639340455194542e-08
of O 0 1.9335887557758724e-08
ACTH O 0 1.6054105799412355e-05
and O 0 2.1696000374049618e-07
alpha O 0 1.9248664102633484e-06
- O 0 3.57861390511971e-05
MSH O 0 0.00032990481122396886
. O 0 2.5547492441546638e-06

Patient O 0 0.00476218294352293
2 O 0 4.332850221544504e-05
was O 0 1.336387049377663e-05
homozygous O 0 2.3993566173885483e-06
for O 0 8.828703990104714e-09
a O 0 1.6223108900703664e-07
mutation O 0 9.938808034348767e-07
in O 0 5.123014545915794e-08
exon O 0 1.5836507373023778e-05
2 O 0 1.5954534319462255e-05
( O 0 3.7654038465007034e-07
C3804A O 0 7.843485036573838e-06
) O 0 9.983534710045205e-08
which O 0 6.027067342984083e-07
abolishes O 0 0.00016900915943551809
POMC O 0 0.0005533299990929663
translation O 0 7.070715128065785e-06
. O 0 1.342452151220641e-06

These O 0 2.4789856070128735e-06
findings O 0 1.0955409379675984e-06
represent O 0 6.003603658655265e-08
the O 0 1.980938257872822e-08
first O 0 6.150959563910874e-08
examples O 0 3.994711406107854e-08
of O 0 3.114409352633629e-08
a O 0 0.0003936213906854391
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999986886978149
within O 0 1.1116215148376796e-07
the O 0 7.153715841923258e-08
POMC O 0 5.336359754437581e-05
gene O 0 2.5021788019330415e-07
and O 0 3.28513287684018e-08
define O 0 1.2343572564077476e-07
a O 0 2.9435619808282354e-07
new O 0 1.165163757832488e-05
monogenic B-Disease 1 0.8948713541030884
endocrine I-Disease 1 0.9757260680198669
disorder I-Disease 0 0.0034457072615623474
resulting O 0 6.451623448811006e-07
in O 0 7.609312291378956e-08
early O 0 1.1028473636542913e-05
- O 1 0.7686766982078552
onset O 1 0.9829742908477783
obesity B-Disease 1 1.0
, O 0 0.00421909661963582
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 6.843238952569664e-05
red O 0 0.0005546960746869445
hair O 1 0.9401929378509521
pigmentation O 0 0.018120553344488144
. O 0 4.95171036618558e-07
. O 0 7.7768152095814e-07

A O 0 2.2379130314220674e-05
European O 0 4.659809746954124e-06
multicenter O 0 8.4578430687543e-05
study O 0 2.1246726191748166e-06
of O 0 9.928738109010737e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.494791441966299e-08
classification O 0 3.6864096841782157e-07
of O 0 2.0450443116715178e-08
105 O 0 5.6542176025686786e-06
mutations O 0 1.1605902727751527e-05
and O 0 5.00561867511351e-08
a O 0 5.941214098470482e-08
general O 0 2.1508540726244973e-08
system O 0 4.210926718428709e-08
for O 0 2.1145620365814466e-08
genotype O 0 8.235082532337401e-06
- O 0 5.197354767005891e-06
based O 0 2.2198244664650701e-07
prediction O 0 2.1459918571054004e-06
of O 0 1.325136196328458e-07
metabolic O 0 0.07703433185815811
phenotype O 0 0.0007286538602784276
. O 0 2.2426336272474146e-06

Phenylketonuria B-Disease 1 0.9985412359237671
( O 0 0.00011710457329172641
PKU B-Disease 0 0.002123237820342183
) O 0 3.2221939818555256e-06
and O 0 9.181817404169124e-06
mild B-Disease 1 0.9979684948921204
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.018298683688044548
MHP B-Disease 1 1.0
) O 0 1.0404341992398258e-06
are O 0 6.244796395549201e-07
allelic B-Disease 0 0.46290653944015503
disorders I-Disease 1 0.9993403553962708
caused O 0 1.1444883057265542e-05
by O 0 1.7521084316740598e-07
mutations O 0 6.956681318115443e-06
in O 0 3.79731055488719e-08
the O 0 1.1026763502286485e-07
gene O 0 5.725702976633329e-06
encoding O 0 4.036704558529891e-05
phenylalanine O 0 0.18836842477321625
hydroxylase O 1 0.7078542709350586
( O 0 7.79351557866903e-06
PAH O 0 0.00035643926821649075
) O 0 9.920124739437597e-07
. O 0 1.488863858867262e-06

Previous O 0 2.5352199372719042e-05
studies O 0 8.376119353670219e-07
have O 0 1.5449712975623697e-07
suggested O 0 1.7212830982771266e-07
that O 0 1.0630778923825801e-08
the O 0 1.9016662022863784e-08
highly O 0 4.6595070557486906e-07
variable O 0 1.1606711268541403e-05
metabolic O 0 0.05693676695227623
phenotypes O 0 0.0009012448717840016
of O 0 1.775384953361936e-05
PAH B-Disease 1 0.9998189806938171
deficiency I-Disease 0 0.23914334177970886
correlate O 0 4.1258521378040314e-05
with O 0 1.7163838492706418e-05
PAH O 0 0.14730782806873322
genotypes O 0 0.0009096217690967023
. O 0 9.412294275534805e-06

We O 0 2.1483800082933158e-05
identified O 0 3.16003979605739e-06
both O 0 1.1594629256705957e-07
causative O 0 2.621587918838486e-05
mutations O 0 4.206742232781835e-05
in O 0 2.924091404565843e-07
686 O 0 0.0001790909591363743
patients O 0 6.2591452660853975e-06
from O 0 3.4254778569220434e-08
seven O 0 1.0953772999755529e-07
European O 0 1.109253631170759e-07
centers O 0 7.277868689925526e-07
. O 0 6.179711817821953e-07

On O 0 5.823633728141431e-06
the O 0 6.271390873280325e-08
basis O 0 5.780408329769671e-08
of O 0 4.303505551916942e-09
the O 0 3.733707387709728e-08
phenotypic O 0 5.488175247592153e-06
characteristics O 0 4.0003888557293976e-07
of O 0 2.8192317813591217e-08
297 O 0 5.704229351977119e-06
functionally O 0 2.6087367587024346e-05
hemizygous O 0 7.358945003943518e-05
patients O 0 2.806447696457326e-07
, O 0 6.951068165506058e-09
105 O 0 2.6685636811407676e-08
of O 0 1.7500225713007467e-09
the O 0 1.1125103327458419e-07
mutations O 0 4.496347173699178e-06
were O 0 2.4903047801672074e-07
assigned O 0 7.316882744135e-08
to O 0 2.424042833126805e-08
one O 0 1.196413901283222e-08
of O 0 2.082309658035797e-09
four O 0 7.954878356031259e-08
arbitrary O 0 9.52075333771063e-06
phenotype O 0 0.00024582844343967736
categories O 0 1.5042979839563486e-06
. O 0 9.205176070281595e-07

We O 0 4.302927209209884e-06
proposed O 0 9.171807278107735e-07
and O 0 5.108860818836547e-07
tested O 0 2.6733943059298326e-07
a O 0 1.9038727927522814e-08
simple O 0 1.742303190610528e-08
model O 0 6.447588418723171e-08
for O 0 5.471796793443673e-09
correlation O 0 5.300760790305503e-07
between O 0 2.878071256873227e-07
genotype O 0 1.3220983419159893e-05
and O 0 1.9460431133211387e-07
phenotypic O 0 8.590618563175667e-06
outcome O 0 3.909940460289363e-06
. O 0 3.0523331133736065e-06

The O 0 7.704230483795982e-06
observed O 0 1.3396127542364411e-05
phenotype O 0 9.54235511017032e-05
matched O 0 7.430132427543867e-06
the O 0 1.0441522846349471e-07
predicted O 0 6.39648933429271e-05
phenotype O 0 4.309673749958165e-05
in O 0 1.9308400567297213e-07
79 O 0 3.7925444758002413e-06
% O 0 2.2424034185064556e-08
of O 0 8.760528968920767e-10
the O 0 2.71588671552081e-08
cases O 0 1.6099208721698233e-07
, O 0 6.095111615422866e-08
and O 0 7.650832145600361e-08
in O 0 1.117279513351832e-08
only O 0 6.874463664985342e-09
5 O 0 6.996452750485105e-09
of O 0 1.5413260667784812e-09
184 O 0 3.001443360517442e-07
patients O 0 1.5054317259455274e-07
was O 0 1.2720266795440693e-06
the O 0 1.997861431846104e-08
observed O 0 3.6557796079250693e-07
phenotype O 0 6.28546786174411e-07
more O 0 2.3676989258092362e-09
than O 0 2.6854223289518586e-09
one O 0 9.526279320937192e-09
category O 0 9.580126913988352e-08
away O 0 1.1119227139033683e-07
from O 0 9.97420457338194e-09
that O 0 1.7018875198004935e-08
expected O 0 2.406689247891336e-07
. O 0 3.298950446151139e-07

Among O 0 5.4396887207985856e-06
the O 0 1.138682037549188e-07
seven O 0 9.326574001988774e-08
contributing O 0 7.737992291367846e-08
centers O 0 5.409082959317857e-08
, O 0 1.071231903182479e-08
the O 0 8.281659802378272e-09
proportion O 0 3.955754479534335e-08
of O 0 6.022537135663697e-09
patients O 0 4.2059582483489066e-08
for O 0 5.314971573966432e-09
whom O 0 1.8084087116676528e-07
the O 0 3.9634880266703476e-08
observed O 0 7.1933654908207245e-06
phenotype O 0 1.408549360348843e-05
did O 0 2.188329091268315e-07
not O 0 7.862633211175307e-09
match O 0 9.096876851799607e-08
the O 0 1.0663356420081982e-07
predicted O 0 4.600171450874768e-05
phenotype O 0 1.352107574348338e-05
was O 0 1.7025521401592414e-06
4 O 0 1.2057346054916707e-07
% O 0 2.963978040781967e-08
- O 0 2.9579377951449715e-06
23 O 0 2.007582907026517e-06
% O 0 4.778463846832892e-08
( O 0 1.9935752604283152e-08
P O 0 9.762353329278994e-06
< O 0 3.708943552283017e-07
. O 0 8.520283145685426e-09
0001 O 0 4.761078287174314e-07
) O 0 3.904837342361134e-09
, O 0 3.2642446523567514e-09
suggesting O 0 3.676550264231082e-08
that O 0 2.299251455895046e-09
differences O 0 2.310506985736538e-08
in O 0 3.613120469481146e-09
methods O 0 9.311533766265256e-09
used O 0 1.0245578607737116e-08
for O 0 5.561995308767109e-09
mutation O 0 2.7627083909465e-07
detection O 0 6.056371262275206e-07
or O 0 2.5268404897360597e-06
phenotype O 0 0.0013416772708296776
classification O 0 9.683621101430617e-06
may O 0 3.3350768262607744e-06
account O 0 2.452378211614814e-08
for O 0 2.3646480329375663e-09
a O 0 1.957829631749064e-08
considerable O 0 3.5463891379095e-08
proportion O 0 5.1975501236256605e-08
of O 0 3.2513220560304035e-08
genotype O 0 0.0006084750639274716
- O 0 0.1009690910577774
phenotype O 0 0.0012154579162597656
inconsistencies O 0 0.00011311156413285062
. O 0 3.445974243732053e-06

Our O 0 9.460123692406341e-06
data O 0 1.1241239690207294e-06
indicate O 0 3.6291015703682206e-07
that O 0 2.069778304303327e-08
the O 0 2.2633366825175472e-07
PAH O 0 0.002348341280594468
- O 0 0.020811347290873528
mutation O 0 2.7798825612990186e-05
genotype O 0 3.440126192799653e-06
is O 0 9.874147721689042e-09
the O 0 5.855083973216324e-09
main O 0 2.3086288081231032e-07
determinant O 0 9.476009950049047e-07
of O 0 8.635417003688417e-08
metabolic O 1 0.7373858094215393
phenotype O 0 0.0002705658262129873
in O 0 1.995230718421226e-07
most O 0 1.2854213764512679e-06
patients O 0 1.3492929610947613e-05
with O 0 4.346672722022049e-05
PAH B-Disease 1 0.9998171925544739
deficiency I-Disease 0 0.37566080689430237
. O 0 2.7516148293216247e-06

In O 0 1.4081647350394633e-06
the O 0 6.422757792279299e-08
present O 0 2.9028321080204478e-08
study O 0 2.3054971265423774e-08
, O 0 1.2143879679626934e-08
the O 0 1.1080732775781144e-08
classification O 0 3.691722270104947e-07
of O 0 3.4875334620210197e-08
105 O 0 2.5131652364507318e-05
PAH O 0 0.0014426467241719365
mutations O 0 6.976426448090933e-06
may O 0 1.160547142831092e-07
allow O 0 9.02170871341923e-09
the O 0 2.381196395617735e-08
prediction O 0 8.327422165166354e-07
of O 0 4.179095736134286e-09
the O 0 5.902967714632723e-08
biochemical O 0 2.0598969058482908e-05
phenotype O 0 1.4207247659214772e-05
in O 0 2.8796216966497923e-08
> O 0 2.7531609703146387e-07
10 O 0 2.738968518656293e-08
, O 0 7.0690751030610954e-09
000 O 0 3.760759170745587e-08
genotypes O 0 7.058648634483689e-07
, O 0 7.492583620205551e-08
which O 0 6.501083475995983e-07
may O 0 5.584181508311303e-07
be O 0 2.9822135871881983e-09
useful O 0 3.3475613392397463e-09
for O 0 2.6247057860473433e-09
the O 0 2.698423884339718e-08
management O 0 1.0461138089112865e-07
of O 0 3.313311580654954e-08
hyperphenylalaninemia B-Disease 1 0.9999963045120239
in O 0 4.877461833530106e-06
newborns O 0 0.00010390749230282381
. O 0 7.491296969419636e-07

Somatic O 0 0.0005668892408721149
instability O 0 6.921331078046933e-05
of O 0 1.5156770416524523e-07
the O 0 1.14571555798193e-07
CTG O 0 7.454891601810232e-05
repeat O 0 5.628688995784614e-06
in O 0 2.055384413779393e-07
mice O 0 1.4053399354452267e-05
transgenic O 0 1.2119511438868358e-06
for O 0 7.485813569019228e-08
the O 0 1.837602030718699e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.1275843462499324e-05
is O 0 1.4024072925167275e-07
age O 0 5.432791638781964e-08
dependent O 0 3.064896958449026e-08
but O 0 1.9041305421296784e-08
not O 0 3.410137061621299e-09
correlated O 0 8.139656415551144e-08
to O 0 7.840065485709147e-09
the O 0 1.658071191457111e-08
relative O 0 1.7852194389433862e-07
intertissue O 0 2.4130972633429337e-06
transcription O 0 1.1666086265904596e-06
levels O 0 2.3192475850919436e-07
and O 0 1.7979412803015293e-07
proliferative O 0 0.0007809242815710604
capacities O 0 9.92315290204715e-06
. O 0 2.3262991817318834e-06

A O 0 0.00014136066602077335
( O 0 8.052399607549887e-06
CTG O 0 7.09319647285156e-05
) O 0 1.9665598927076644e-07
nexpansion O 0 2.0441648302949034e-06
in O 0 2.3198950316327682e-08
the O 0 9.357203367699185e-08
3 O 0 6.957132427487522e-06
- O 0 0.009862867183983326
untranslated O 0 0.0007442987989634275
region O 0 1.0895334526139777e-05
( O 0 1.1999327398370951e-07
UTR O 0 5.248904017207678e-06
) O 0 1.4670852976905735e-08
of O 0 6.650947792508077e-09
the O 0 6.520095325868169e-07
DM O 1 0.9999998807907104
protein O 0 8.247625373769552e-06
kinase O 0 3.4158470953116193e-05
gene O 0 2.3345489807979902e-06
( O 0 1.4350797528095427e-07
DMPK O 0 3.747142181964591e-05
) O 0 4.113059404176056e-08
is O 0 1.8902532872289157e-08
responsible O 0 1.2868819965206058e-07
for O 0 5.536932121685822e-07
causing O 0 0.2720099687576294
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00024086666235234588
DM B-Disease 1 1.0
) O 0 4.769476618093904e-06
. O 0 3.538231567290495e-06

Major O 0 1.879223964351695e-05
instability O 0 2.5153449314530008e-05
, O 0 9.227291997149223e-08
with O 0 1.3832448964024024e-08
very O 0 1.3192948955520478e-08
large O 0 1.0390698967910339e-08
expansions O 0 3.012231104548846e-07
between O 0 1.7046531297637557e-07
generations O 0 2.4006649823604675e-07
and O 0 4.654586049923637e-08
high O 0 3.822738392500469e-07
levels O 0 1.6788421319802183e-08
of O 0 2.301374868451944e-09
somatic O 0 9.28923554965877e-07
mosaicism O 0 3.27177403960377e-05
, O 0 2.7921643663830764e-08
is O 0 1.69425042884086e-08
observed O 0 1.5515773554852785e-07
in O 0 2.242510959149513e-07
patients O 0 3.0541123123839498e-06
. O 0 7.371260153377079e-07

There O 0 4.0945628825284075e-06
is O 0 7.613203223399978e-08
a O 0 8.129835293857468e-08
good O 0 1.2104133872981038e-07
correlation O 0 4.5609246512867685e-07
between O 0 1.7333015023268672e-07
repeat O 0 6.590817065443844e-06
size O 0 3.822442977252649e-06
( O 0 4.8855994805308e-08
at O 0 5.272687531032716e-08
least O 0 8.080547786448733e-09
in O 0 1.9714548216143157e-08
leucocytes O 0 1.607518788659945e-05
) O 0 1.6979774031256056e-08
, O 0 1.617177147750226e-08
clinical O 0 3.5834739264828386e-07
severity O 0 1.990985037991777e-05
and O 0 8.076311246441037e-07
age O 0 3.066950000629731e-07
of O 0 9.129206546276691e-08
onset O 0 0.000138144037919119
. O 0 2.4297703475895105e-06

The O 0 2.2069991246098652e-05
trinucleotide O 0 0.0012075583217665553
repeat O 0 9.690587467048317e-05
instability O 0 1.4230938177206554e-05
mechanisms O 0 1.900330175885756e-06
involved O 0 2.86422988438062e-07
in O 0 2.0203226540616015e-06
DM B-Disease 1 1.0
and O 0 7.717724656686187e-06
other O 0 1.3571056456385122e-07
human O 0 1.799434539861977e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 0.9999998807907104
are O 0 1.0288626128840406e-07
unknown O 0 3.12788051815005e-06
. O 0 8.80014169979404e-07

We O 0 2.0054983906447887e-05
studied O 0 1.5475297914235853e-06
somatic O 0 7.470532182196621e-06
instability O 0 2.444636038489989e-06
by O 0 2.5117703472687936e-08
measuring O 0 4.309164523874642e-06
the O 0 1.4228082534373243e-07
CTG O 0 5.5113287089625373e-05
repeat O 0 2.8247029604244744e-06
length O 0 4.052973508805735e-06
at O 0 4.815914067535232e-08
several O 0 1.8967396542279857e-08
ages O 0 1.105203111251285e-07
in O 0 6.381239092689839e-09
various O 0 9.187967719981316e-09
tissues O 0 2.453546130709583e-07
of O 0 6.1878115964475455e-09
transgenic O 0 3.545906338331406e-06
mice O 0 1.1690995961544104e-05
carrying O 0 1.0842441611202958e-07
a O 0 1.2447362962575426e-07
( O 0 1.1353292705962303e-07
CTG O 0 4.373536285129376e-06
) O 0 2.196763482231745e-08
55expansion O 0 5.447489002108341e-07
surrounded O 0 2.645258234679204e-07
by O 0 1.29622774736049e-08
45 O 0 8.710818377721807e-08
kb O 0 1.971223127839039e-06
of O 0 9.313878557293265e-09
the O 0 1.273782856969774e-07
human O 0 1.5556460084553692e-06
DM B-Disease 1 1.0
region O 0 1.775717123564391e-06
, O 0 4.8228607774092325e-09
using O 0 1.0569195296739053e-08
small O 0 6.301282695631016e-08
- O 0 6.917028258612845e-06
pool O 0 3.033334905921947e-06
PCR O 0 3.799591650022194e-05
. O 0 1.5750902093714103e-06

These O 0 8.687720765010454e-06
mice O 0 0.00021014681260567158
have O 0 7.040140985736798e-07
been O 0 6.251655122468947e-07
shown O 0 2.909459908551071e-07
to O 0 2.35260646519464e-08
reproduce O 0 2.1929263311903924e-06
the O 0 2.1610276235151105e-08
intergenerational O 0 3.854385340673616e-06
and O 0 2.1058444588106795e-07
somatic O 0 7.929109528959088e-07
instability O 0 5.844620432071679e-07
of O 0 7.004544055888573e-09
the O 0 5.563228455685021e-08
55 O 0 5.094225912216643e-07
CTG O 0 4.8986062211042736e-06
repeat O 0 6.83996404404752e-07
suggesting O 0 1.736706849442271e-07
that O 0 9.75564873328949e-09
surrounding O 0 6.686654785426072e-08
sequences O 0 2.855279035429703e-07
and O 0 4.637987416344913e-08
the O 0 1.5220630089629594e-08
chromatin O 0 2.4059963266154227e-07
environment O 0 1.3634596029987733e-07
are O 0 3.6138234627003385e-09
involved O 0 1.4792038705024879e-08
in O 0 5.3398487409594964e-08
instability O 0 5.838269771629712e-06
mechanisms O 0 3.922751602658536e-06
. O 0 1.4880689604979125e-06

As O 0 7.198979346867418e-06
observed O 0 1.6719209270377178e-06
in O 0 1.771696034325032e-08
some O 0 3.7051581802671762e-09
of O 0 3.990384023211391e-09
the O 0 5.9473705960044754e-08
tissues O 0 2.5134247607638827e-06
of O 0 7.413630100927548e-07
DM B-Disease 1 1.0
patients O 0 1.3320709513209295e-05
, O 0 2.4808835874523538e-08
there O 0 5.505674138817085e-09
is O 0 3.1815450274308432e-09
a O 0 1.4274287529758567e-08
tendency O 0 2.496072966096108e-07
for O 0 5.114507484194064e-09
repeat O 0 9.715531632537022e-07
length O 0 2.125387936757761e-06
and O 0 3.655963709547905e-08
somatic O 0 2.851485589872027e-07
mosaicism O 0 1.8661052081370144e-06
to O 0 1.912925284841549e-08
increase O 0 5.7031140698882155e-08
with O 0 1.3524654285390625e-08
the O 0 1.035076593325357e-07
age O 0 1.2016205630516197e-07
of O 0 4.6687476107365455e-09
the O 0 9.112801535593462e-08
mouse O 0 0.00012831541243940592
. O 0 3.6750579965882935e-06

Furthermore O 0 5.359426359063946e-05
, O 0 4.4485801709015504e-07
we O 0 6.950779862791023e-08
observed O 0 1.363364816597823e-07
no O 0 1.2544147054427413e-08
correlation O 0 1.6227842536409298e-07
between O 0 2.5269743630929042e-08
the O 0 3.4439324281265726e-08
somatic O 0 2.1505607037397567e-06
mutation O 0 4.00102044295636e-06
rate O 0 6.29458918410819e-06
and O 0 4.872803742728138e-07
tissue O 0 2.5571194782969542e-05
proliferation O 0 3.242186494389898e-06
capacity O 0 6.890172699058894e-07
. O 0 3.809244049080007e-07

The O 0 2.9989107588335173e-06
somatic O 0 2.9831006031599827e-05
mutation O 0 1.9903623979189433e-05
rates O 0 7.827807166904677e-07
in O 0 1.8010384295052972e-08
different O 0 3.144720395198419e-08
tissues O 0 2.5119845759036252e-06
were O 0 1.5255498055921635e-06
also O 0 3.1544979606223933e-07
not O 0 5.341088904486924e-09
correlated O 0 4.644086715188678e-08
to O 0 5.121194579515986e-09
the O 0 7.775122767839093e-09
relative O 0 1.4585218366391928e-07
inter O 0 3.932204890588764e-06
- O 0 0.00018345226999372244
tissue O 0 8.456265277345665e-06
difference O 0 5.089219357046204e-08
in O 0 3.304858608998984e-09
transcriptional O 0 2.2468780969120417e-07
levels O 0 2.7584558637272494e-08
of O 0 1.0527422267259112e-09
the O 0 1.496175094928276e-08
three O 0 9.432878300685843e-08
genes O 0 2.163948380484726e-07
( O 0 2.018283318250269e-08
DMAHP O 0 3.129867764073424e-06
, O 0 2.6701421518282586e-08
DMPK O 0 6.9754682954226155e-06
and O 0 1.10314331891459e-07
59 O 0 3.971794342305657e-07
) O 0 6.210655545402233e-09
surrounding O 0 3.011590266055464e-08
the O 0 1.002490392920663e-07
repeat O 0 8.861385140335187e-06
. O 0 2.718437315252231e-07
. O 0 1.03081265478977e-06

A O 0 2.6284847990609705e-05
novel O 0 4.258654735167511e-05
missense O 0 0.0034904591739177704
mutation O 0 3.688375363708474e-05
in O 0 3.122936789168307e-07
patients O 0 5.695123377336131e-07
from O 0 3.2505344194078134e-08
a O 0 4.6229467898228904e-07
retinoblastoma B-Disease 0 0.0003217541961930692
pedigree O 0 0.00010425964137539268
showing O 0 1.9998775314888917e-05
only O 0 1.7931756701727863e-07
mild O 0 1.0655956430127844e-05
expression O 0 1.254498869229792e-07
of O 0 1.0555778473531063e-08
the O 0 3.609279417560174e-07
tumor B-Disease 0 0.0009736541542224586
phenotype O 0 0.00025916911545209587
. O 0 1.9030850353374262e-06

We O 0 6.90772003508755e-06
have O 0 3.676473170344252e-08
used O 0 3.248030466806995e-08
single O 0 4.1133540662485757e-07
strand O 0 1.7110984117607586e-05
conformation O 0 1.6481067177664954e-06
polymorphism O 0 6.144768462945649e-07
analysis O 0 1.1115532494443414e-08
to O 0 4.112743479112169e-09
study O 0 5.87627368986432e-09
the O 0 1.264571469761222e-08
27 O 0 3.6838304140474065e-07
exons O 0 2.2736453786365018e-07
of O 0 8.803178630500952e-09
the O 0 1.069715196422294e-07
RB1 O 0 2.1685978936147876e-05
gene O 0 8.105294568849786e-08
in O 0 1.7386614814540735e-08
individuals O 0 2.2792274734229068e-09
from O 0 1.933359250472222e-09
a O 0 8.730845024729206e-08
family O 0 1.1785054994106758e-06
showing O 0 2.067706736852415e-05
mild O 0 1.5100968084880151e-05
expression O 0 1.049963813670729e-07
of O 0 1.4541531534462138e-08
the O 0 4.237830637521256e-07
retinoblastoma B-Disease 0 0.0010455242590978742
phenotype O 0 0.0011583456071093678
. O 0 2.144956397387432e-06

In O 0 2.5443184767937055e-06
this O 0 1.0362835922705926e-07
family O 0 7.782305146974977e-07
affected O 0 2.712587274800171e-07
individuals O 0 1.2270915838996643e-08
developed O 0 4.817554213332187e-07
unilateral B-Disease 0 0.051728505641222
tumors I-Disease 1 1.0
and O 0 8.703397907083854e-05
, O 0 5.119439094869449e-08
as O 0 1.5429858279958353e-08
a O 0 5.9254492867921726e-08
result O 0 2.7389425838464376e-08
of O 0 4.084311999719148e-09
linkage O 0 3.9417718653567135e-06
analysis O 0 1.5481852244647598e-07
, O 0 7.8406522163732e-08
unaffected O 0 2.2835552044853102e-06
mutation O 0 1.0105310366270714e-06
carriers O 0 1.3993077629947948e-07
were O 0 3.575936204924801e-07
also O 0 5.793852437818714e-07
identified O 0 5.710220420951373e-07
within O 0 2.3253260650335505e-08
the O 0 1.027701514999535e-07
pedigree O 0 2.7078260245616548e-05
. O 0 1.3129058515914949e-06

A O 0 4.299616193748079e-05
single O 0 4.227164936310146e-06
band O 0 2.898414777519065e-06
shift O 0 6.438654622797912e-07
using O 0 1.3527730402529414e-07
SSCP O 0 8.486410661134869e-05
was O 0 3.746930815395899e-06
identified O 0 1.5555362153918395e-07
in O 0 1.7507744587419438e-08
exon O 0 3.5300481613376178e-06
21 O 0 5.179221261641942e-06
which O 0 5.897340926708239e-08
resulted O 0 3.6416412996231884e-08
in O 0 1.3643449925382356e-08
a O 0 5.150172910362016e-07
missense O 0 6.157885945867747e-05
mutation O 0 7.918983442323224e-07
converting O 0 1.5310838819004857e-07
a O 0 3.654193676538853e-07
cys O 0 0.0002496596716810018
- O 0 5.663737829308957e-05
- O 0 3.971706610172987e-05
> O 0 1.1660847576422384e-06
arg O 0 9.061226933226862e-07
at O 0 5.47031788755703e-08
nucleotide O 0 3.998702595708892e-07
position O 0 4.893060463473375e-07
28 O 0 3.344522383486037e-07
in O 0 1.810976257843322e-08
the O 0 1.833495133496399e-07
exon O 0 3.7240151868900284e-05
. O 0 4.014543264929671e-06

The O 0 1.033435546560213e-05
mutation O 0 3.771646152017638e-05
destroyed O 0 2.924843556684209e-06
an O 0 1.5520953411396476e-07
NdeI O 0 3.0231462005758658e-05
restriction O 0 2.285049504280323e-06
enzyme O 0 2.3633294858882437e-06
site O 0 6.09035214438336e-06
. O 0 3.29926024278393e-06

Analysis O 0 4.031051503261551e-06
of O 0 1.303373124983409e-07
all O 0 3.276084825643011e-08
family O 0 1.5981724743596715e-07
members O 0 3.733621767310069e-08
demonstrated O 0 1.1760226215073999e-07
that O 0 6.126509521919843e-09
the O 0 4.277337239955159e-08
missense O 0 0.0001783952466212213
mutation O 0 5.9285061979608145e-06
co O 0 1.8202556475443998e-06
- O 0 5.856600182596594e-06
segregated O 0 5.85789621254662e-07
with O 0 1.791445924936852e-07
patients O 0 2.6423565486766165e-06
with O 0 3.992155598098179e-06
tumors B-Disease 1 1.0
or O 0 5.498503742273897e-05
who O 0 9.420902642887086e-05
, O 0 3.550578497879542e-08
as O 0 8.255936378986917e-09
a O 0 5.300780259176463e-08
result O 0 2.2044192249381922e-08
of O 0 3.517594659996348e-09
linkage O 0 1.4570066468877485e-06
analysis O 0 1.845825181590044e-07
had O 0 6.026109986123629e-05
been O 0 1.4510467281070305e-06
predicted O 0 9.53482356180757e-07
to O 0 6.980164002357014e-09
carry O 0 6.078556680222391e-08
the O 0 7.98270889390551e-08
predisposing O 0 6.076875433791429e-05
mutation O 0 3.711882163770497e-05
. O 0 1.3667041685039294e-06

These O 0 8.382360192626948e-07
observations O 0 5.806220428894449e-07
point O 0 5.142746317687852e-07
to O 0 3.120932490219275e-08
another O 0 9.982925774920659e-08
region O 0 1.8279571634138847e-07
of O 0 6.508636740676366e-09
the O 0 1.4465975084476668e-07
RB1 O 0 4.6824679884593934e-05
gene O 0 3.091770679475303e-07
where O 0 2.2947713773646683e-07
mutations O 0 5.713898190151667e-07
only O 0 6.444844213859824e-09
modify O 0 7.897927645217351e-08
the O 0 1.362433543761199e-08
function O 0 5.0520592154157384e-09
of O 0 1.1207879069274895e-09
the O 0 1.6083978593428583e-08
gene O 0 1.6226202603775164e-07
and O 0 1.666445257342275e-07
raise O 0 5.242763023716179e-08
important O 0 3.511795965138731e-09
questions O 0 1.2744993505009461e-08
for O 0 4.702682243618028e-09
genetic O 0 5.283278028400673e-07
counseling O 0 1.2221249789945432e-07
in O 0 3.980579776907689e-08
families O 0 3.513626722906338e-08
with O 0 1.1778719333221943e-08
these O 0 1.781461733685319e-08
distinctive O 0 4.52637368653086e-06
phenotypes O 0 2.1661528080585413e-05
. O 0 2.022008089852534e-07
. O 0 5.53113807200134e-07

Maternal B-Disease 0 0.017836954444646835
disomy I-Disease 0 0.07306306064128876
and O 0 0.006600868422538042
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 7.099626600393094e-06
with O 0 3.007784528108459e-07
gamete O 0 1.3030420632276218e-05
complementation O 0 7.836955046514049e-05
in O 0 7.037866112113988e-08
a O 0 8.735525369729658e-08
case O 0 1.2847482366851182e-07
of O 0 2.75837699348358e-08
familial O 0 5.749375486630015e-05
translocation O 0 0.0023222730960696936
( O 0 3.400186017188389e-07
3 O 0 3.278416897956049e-07
; O 0 2.8041253585797676e-07
15 O 0 2.2286400280790986e-07
) O 0 1.658216675082258e-08
( O 0 2.2856104564539237e-08
p25 O 0 6.269895607147191e-07
; O 0 4.0045982530045876e-08
q11 O 0 5.252366577224166e-07
. O 0 2.1281124418237596e-08
2 O 0 1.3117190178491e-07
) O 0 1.612323927702164e-07
. O 0 5.656276584886655e-07

Maternal B-Disease 1 0.812448263168335
uniparental I-Disease 1 0.9887069463729858
disomy I-Disease 1 0.8800450563430786
( I-Disease 0 0.00021047024347353727
UPD I-Disease 1 0.9999992847442627
) I-Disease 0 3.3606207239245123e-07
for I-Disease 0 3.4539315407755566e-08
chromosome I-Disease 0 0.003293359652161598
15 I-Disease 0 1.3762572734776768e-06
is O 0 1.806935934212106e-08
responsible O 0 2.0435781067362768e-08
for O 0 1.4947766358019976e-09
an O 0 6.744406810810233e-09
estimated O 0 1.8081155417348782e-07
30 O 0 7.270556778848913e-08
% O 0 3.972659090578645e-09
of O 0 1.3414459543170665e-09
cases O 0 7.759496156722889e-08
of O 0 3.994653070549248e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.667924440582283e-05
PWS B-Disease 1 0.9999992847442627
) O 0 3.466931957518682e-06
. O 0 2.521866690585739e-06

We O 0 3.62757382390555e-05
report O 0 4.653795713238651e-07
on O 0 5.1184336768983485e-08
an O 0 8.429100972762171e-09
unusual O 0 6.184981771184539e-08
case O 0 7.436148052875069e-08
of O 0 7.854928263384409e-09
maternal B-Disease 0 3.1545839647151297e-06
disomy I-Disease 0 2.7598598535405472e-05
15 I-Disease 0 6.007509796290833e-07
in O 0 3.591948996017891e-07
PWS B-Disease 1 0.9999998807907104
that O 0 2.397288199063041e-07
is O 0 2.3600625453923385e-08
most O 0 4.001755815608021e-09
consistent O 0 6.279793751673424e-08
with O 0 1.1499744267950973e-08
adjacent O 0 7.31297575384815e-07
- O 0 1.4385178474185523e-05
1 O 0 1.9839789899833704e-07
segregation O 0 1.8490865727471828e-07
of O 0 4.278534859736283e-09
a O 0 1.3104249774187338e-07
paternal O 0 2.3579834305564873e-05
t O 0 5.4603231546934694e-05
( O 0 1.8527805067947156e-08
3 O 0 4.000826692163173e-08
; O 0 4.562442867950267e-08
15 O 0 4.855259305713844e-08
) O 0 8.80673933778553e-09
( O 0 9.482119978088122e-09
p25 O 0 4.531265744844859e-07
; O 0 3.778828627787334e-08
q11 O 0 3.92487010003606e-07
. O 0 6.2470095762989786e-09
2 O 0 2.138296473219725e-08
) O 0 2.3088053691111554e-09
with O 0 3.651404290039295e-09
simultaneous O 0 5.93339393617498e-07
maternal O 0 2.178676368203014e-05
meiotic O 0 4.8075493396027014e-05
nondisjunction O 0 2.0984376533306204e-05
for O 0 1.8077464858379244e-07
chromosome O 0 0.00023802416399121284
15 O 0 1.7212944385391893e-06
. O 0 1.437312675989233e-06

The O 0 4.293531674193218e-06
patient O 0 2.6071746106026694e-05
( O 0 3.6560584248945815e-07
J O 0 9.812841017264873e-05
. O 0 5.5186720970823444e-08
B O 0 5.141152996657183e-07
. O 0 1.4091689592987677e-08
) O 0 4.82129758339056e-09
, O 0 1.8357506625932274e-09
a O 0 1.7458559042893285e-08
17 O 0 2.799425544708356e-07
- O 0 2.0994548322050832e-06
year O 0 1.100688535871086e-07
- O 0 3.855528575513745e-06
old O 0 1.592798980709631e-05
white O 0 6.332056727842428e-06
male O 0 8.372517754651199e-07
with O 0 4.1650773141554964e-07
PWS B-Disease 1 1.0
, O 0 8.797222221801348e-07
was O 0 5.985755251458613e-06
found O 0 6.051394052519754e-08
to O 0 1.6621305221065086e-08
have O 0 4.200835235224076e-08
47 O 0 1.5156929578097333e-07
chromosomes O 0 2.606943496630265e-07
with O 0 1.0442116504805199e-08
a O 0 4.733172431770072e-07
supernumerary O 0 0.006234847474843264
, O 0 3.7808985098308767e-07
paternal O 0 6.218555063242093e-05
der O 0 0.009457427076995373
( O 0 3.683703297951979e-08
15 O 0 3.0260366656875703e-08
) O 0 2.3131205839632685e-09
consisting O 0 4.479762782949592e-09
of O 0 4.802070296960892e-09
the O 0 2.3413552696638362e-07
short O 0 2.106369356624782e-05
arm O 0 0.0004427165549714118
and O 0 1.1521638043632265e-07
the O 0 3.6173631201563694e-08
proximal O 0 2.334830423933454e-05
long O 0 7.744038157397881e-06
arm O 0 1.6026833691284992e-05
of O 0 1.4604823128649969e-08
chromosome O 0 3.8991151086520404e-05
15 O 0 3.575397613531095e-07
, O 0 3.527176772877283e-08
and O 0 7.374522397185501e-07
distal O 0 0.014936205931007862
chromosome O 1 0.7546761631965637
arm O 0 0.0034556149039417505
3p O 0 0.000761939852964133
. O 0 5.821767899760744e-06

The O 0 1.0008441677200608e-05
t O 0 0.000163560442160815
( O 0 9.942621659320139e-08
3 O 0 1.1572866753795097e-07
; O 0 1.6553606485558703e-07
15 O 0 3.796623104790342e-07
) O 0 1.6749432063534186e-08
was O 0 1.2935647646372672e-06
present O 0 1.918973424608339e-08
in O 0 1.7061518420291577e-08
the O 0 1.5773547801245513e-08
balanced O 0 1.4088107036513975e-07
state O 0 5.466101793416556e-09
in O 0 2.0585300575248766e-08
the O 0 2.688022391339473e-07
patients O 0 7.605683549627429e-07
father O 0 7.498395007132785e-07
and O 0 1.1297765212248123e-07
a O 0 2.7941254643337743e-07
sister O 0 4.7009911213535815e-05
. O 0 2.0616578240151284e-06

Fluorescent O 0 0.00022096189786680043
in O 0 1.693097829047474e-06
situ O 0 4.217649347992847e-06
hybridization O 0 1.5470783409909927e-06
analysis O 0 2.7721091555577004e-07
demonstrated O 0 4.170212548615382e-07
that O 0 2.3981105101711364e-08
the O 0 3.748421022464754e-07
PWS B-Disease 1 0.9999997615814209
critical O 0 1.2480281839089002e-06
region O 0 1.0416852092021145e-06
resided O 0 1.0124998652827344e-06
on O 0 2.1251113935250032e-07
the O 0 2.0059793826021632e-08
derivative O 0 4.2554680135253875e-07
chromosome O 0 3.1936157029122114e-05
3 O 0 4.962726052326616e-07
and O 0 2.4436937451355334e-07
that O 0 2.4568585388351494e-08
there O 0 2.869806969840738e-08
was O 0 8.807514859654475e-06
no O 0 3.2627337276380786e-08
deletion O 0 8.195158898161026e-07
of O 0 1.6907447886183036e-08
the O 0 1.5234154489007778e-06
PWS B-Disease 1 1.0
region O 0 1.6100434550025966e-06
on O 0 1.1051857882193872e-06
the O 0 7.776638710765837e-08
normal O 0 1.878923825415768e-07
pair O 0 5.328189445208409e-07
of O 0 1.8422513292648546e-08
15s O 0 6.754810897291463e-07
present O 0 7.820996472673869e-08
in O 0 4.330928504714393e-07
J O 0 0.0013010280672460794
. O 0 2.0913676053169183e-06

B O 0 0.0027846763841807842
. O 0 5.456491999211721e-05

Methylation O 0 8.914210047805682e-05
analysis O 0 1.5703595863669761e-06
at O 0 2.322080376870872e-07
exon O 0 1.306610556639498e-06
alpha O 0 1.8528959344621398e-07
of O 0 3.898735112528584e-09
the O 0 5.6972289108614405e-09
small O 0 2.98237416984648e-08
nuclear O 0 2.1312672515705344e-07
ribonucleoprotein O 0 2.0565698832797352e-06
- O 0 1.3455936596074025e-06
associated O 0 2.857147478607658e-07
polypeptide O 0 1.2349582902970724e-06
N O 0 2.842397861968493e-06
( O 0 3.9732444889750695e-08
SNRPN O 0 2.144661948477733e-06
) O 0 1.2382240122121857e-08
gene O 0 8.807582929648561e-08
showed O 0 5.97325595208531e-07
a O 0 5.210165454627713e-08
pattern O 0 4.6893052058294415e-05
characteristic O 0 4.054478495163494e-07
of O 0 6.5739635957129394e-09
only O 0 1.8998823847482527e-08
the O 0 7.425900605539937e-08
maternal O 0 9.46639647736447e-06
chromosome O 0 8.280089969048277e-05
15 O 0 5.268711902317591e-07
in O 0 4.709893346444005e-07
J O 0 0.0016656335210427642
. O 0 2.867137254725094e-06

B O 0 0.0027314473409205675
. O 0 5.2912451792508364e-05

Maternal B-Disease 0 0.05855213850736618
disomy I-Disease 0 0.03916969522833824
was O 0 8.082322165137157e-05
confirmed O 0 1.2697904594460852e-06
by O 0 3.6748190268554026e-08
polymerase O 0 1.9524170511431294e-06
chain O 0 4.866027666139416e-06
reaction O 0 9.799664724141621e-08
analysis O 0 2.2997085125098238e-08
of O 0 1.3192369863190834e-08
microsatellite O 0 2.6503985282033682e-05
repeats O 0 5.013940608478151e-06
at O 0 4.722234336895781e-08
the O 0 1.9764545555744917e-08
gamma O 0 6.271743586694356e-07
- O 0 3.4386598599667195e-06
aminobutyric O 0 1.2638593943847809e-05
acid O 0 1.0877121212615748e-06
receptor O 0 1.2395067869874765e-06
beta3 O 0 4.799976068170508e-06
subunit O 0 3.6827871099376353e-06
( O 0 6.484389700744941e-07
GABRB3 O 0 3.776090670726262e-05
) O 0 3.4469067600184644e-07
locus O 0 1.6396239516325295e-05
. O 0 2.7755770588555606e-06

A O 0 8.647235517855734e-05
niece O 0 0.003146063070744276
( O 0 9.625483698982862e-07
B O 0 9.657895816417295e-07
. O 0 3.14510408827573e-08
B O 0 3.545666231730138e-07
. O 0 6.341490443872999e-09
) O 0 2.1639383618321517e-09
with O 0 3.4492027012333892e-09
45 O 0 8.035074472445558e-08
chromosomes O 0 6.621975217058207e-07
and O 0 3.474785614798748e-08
the O 0 7.471075313958409e-09
derivative O 0 1.55038222260373e-07
3 O 0 2.427476317734545e-07
but O 0 1.7977470179175725e-08
without O 0 8.232020398679651e-09
the O 0 4.2385984500015184e-08
der O 0 6.148972897790372e-05
( O 0 1.0870413014174574e-08
15 O 0 2.7245723899227414e-08
) O 0 5.282287496299887e-09
demonstrated O 0 4.726622648831835e-08
a O 0 9.639348519385749e-08
phenotype O 0 4.0029470255831257e-05
consistent O 0 2.2491933293622424e-07
with O 0 6.658032702944183e-08
that O 0 2.2088138962317316e-07
reported O 0 2.61930199485505e-06
for O 0 8.91286155990656e-09
haploinsufficiency O 0 5.601170869340422e-06
of O 0 6.44030038188248e-08
distal O 0 9.774122008820996e-05
3 O 0 1.3345938896236476e-05
p O 0 0.00011693985288729891
. O 0 1.8598815358927823e-06

Uniparental B-Disease 1 0.999998927116394
disomy I-Disease 1 0.9999963045120239
associated O 0 9.388195758219808e-05
with O 0 5.318919420460588e-07
unbalanced O 0 0.00010092954471474513
segregation O 0 1.242926373379305e-05
of O 0 3.5724589508845384e-08
non O 0 2.7818552439384803e-07
- O 0 1.1182344678672962e-05
Robertsonian O 0 2.1661135178874247e-05
translocations O 0 4.358040678198449e-05
has O 0 1.8464588720235042e-06
been O 0 1.0632076055117068e-06
reported O 0 3.404476501600584e-06
previously O 0 4.613789883478603e-07
but O 0 7.554907455187276e-08
has O 0 7.62039292112604e-07
not O 0 1.465060694982867e-08
, O 0 3.3944196342616806e-09
to O 0 1.988713194123193e-09
our O 0 2.793963504998942e-09
knowledge O 0 2.4944430965234687e-09
, O 0 4.757272353828057e-09
been O 0 3.669817516538387e-08
observed O 0 4.267794651013901e-08
in O 0 2.3332109577722804e-09
a O 0 4.5028343720332487e-08
case O 0 5.346009288587084e-07
of O 0 6.844988433840626e-07
PWS B-Disease 1 0.9999997615814209
. O 0 6.862342615931993e-06

Furthermore O 0 0.00011094920773757622
, O 0 6.501741154352203e-07
our O 0 1.3265321285871323e-07
findings O 0 1.4333961928514327e-07
are O 0 1.2537042515248231e-08
best O 0 2.0181704485366936e-07
interpreted O 0 2.622423664888629e-07
as O 0 6.27342444659007e-08
true O 0 3.054282160519506e-07
gamete O 0 8.88798513187794e-06
complementation O 0 3.2267205824609846e-05
resulting O 0 2.1450914573506452e-06
in O 0 9.99264784695697e-07
maternal B-Disease 0 0.03463740646839142
UPD I-Disease 1 1.0
15 I-Disease 0 5.852308095199987e-05
and O 0 2.5635970814619213e-05
PWS B-Disease 1 0.9999960660934448

Schwartz B-Disease 1 0.9736667275428772
- I-Disease 1 0.9999486207962036
Jampel I-Disease 1 0.9975641965866089
syndrome I-Disease 1 0.9999792575836182
type I-Disease 0 4.325374447944341e-06
2 I-Disease 0 3.4452118597982917e-06
and O 0 5.271900590742007e-06
Stuve B-Disease 1 0.9635494947433472
- I-Disease 1 0.9999994039535522
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.999992847442627
: O 0 3.1458302629516766e-08
a O 0 7.650730537989148e-08
case O 0 1.726119336353804e-07
for O 0 3.726222885802599e-08
" O 0 1.5767915328979143e-06
lumping O 0 2.256116204080172e-06
" O 0 1.712756557026296e-06
. O 0 7.967555575305596e-07

Recent O 0 3.571352135622874e-05
studies O 0 2.1286050468916073e-06
demonstrated O 0 1.3723254141950747e-06
the O 0 2.3651274716485204e-08
existence O 0 2.6702542399448248e-08
of O 0 4.1093168867689656e-09
a O 0 1.8719234162745124e-07
genetically O 0 1.6013671029213583e-06
distinct O 0 6.451850822486449e-07
, O 0 1.9617888824541296e-07
usually O 0 3.0971413877978193e-08
lethal O 0 3.6415020332469794e-08
form O 0 4.162699518417412e-09
of O 0 2.430309953282972e-09
the O 0 2.0122300270486448e-07
Schwartz B-Disease 0 0.44584813714027405
- I-Disease 1 0.9998346567153931
Jampel I-Disease 1 0.9999938011169434
syndrome I-Disease 1 0.9999996423721313
( O 0 1.092187062567973e-06
SJS B-Disease 0 0.0002938798279501498
) O 0 2.780647356814825e-08
of O 0 3.681125804178009e-08
myotonia B-Disease 1 0.594435453414917
and O 0 0.00012522282486315817
skeletal B-Disease 1 0.9935075044631958
dysplasia I-Disease 1 0.9999940395355225
, O 0 1.9244771465309896e-06
which O 0 2.3691374906320561e-07
we O 0 4.2162955793401125e-08
called O 0 2.085434744003578e-06
SJS B-Disease 0 0.0003989026590716094
type I-Disease 0 1.0217885346719413e-06
2 I-Disease 0 1.5116148688321118e-06
. O 0 1.1582952765820664e-06

This O 0 9.197818144457415e-05
disorder O 1 0.8685457706451416
is O 0 3.0716859100721194e-07
reminiscent O 0 1.8830003682523966e-05
of O 0 4.8566672461447524e-08
another O 0 2.3528812107542763e-06
rare O 0 2.848459871529485e-06
condition O 0 1.3880074220651295e-05
, O 0 6.426422061167614e-08
the O 0 3.405443180781731e-07
Stuve B-Disease 1 0.8663743138313293
- I-Disease 1 0.999997615814209
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 1.940855099746841e-06
SWS B-Disease 1 0.6027838587760925
) O 0 1.0895595892179699e-07
, O 0 3.128877423819176e-08
which O 0 2.9388599998014797e-08
comprises O 0 2.4852598201619003e-08
campomelia B-Disease 0 7.671796083741356e-06
at O 0 1.903049167140125e-07
birth O 0 3.937207111448515e-06
with O 0 5.316180704539875e-07
skeletal B-Disease 1 0.9806575179100037
dysplasia I-Disease 1 0.999974250793457
, O 0 2.719868689382565e-06
contractures B-Disease 0 0.0005830232985317707
, O 0 1.1546827494157696e-07
and O 0 1.6160092286554573e-07
early B-Disease 0 1.0865686590477708e-06
death I-Disease 0 2.175572262785863e-05
. O 0 9.866664640867384e-07

To O 0 1.5545647329417989e-06
test O 0 2.7693374704540474e-07
for O 0 7.703764737243546e-09
possible O 0 5.6716768170872456e-08
nosologic O 0 1.6217743905144744e-05
identity O 0 1.207735294883605e-06
between O 0 4.460623870272684e-07
these O 0 3.136807436021627e-07
disorders O 0 0.006408856716006994
, O 0 4.554835086878484e-08
we O 0 8.972902421078288e-09
reviewed O 0 3.330818998392715e-08
the O 0 1.8693645742473564e-08
literature O 0 4.990068802612768e-09
and O 0 3.55264284657153e-09
obtained O 0 1.7541362806738903e-09
a O 0 1.1245401054793547e-08
follow O 0 1.6035579974982284e-08
- O 0 1.047266323439544e-06
up O 0 7.846696092883576e-08
of O 0 1.252998482748069e-09
the O 0 4.903343508999569e-09
only O 0 7.553924596948036e-09
two O 0 4.549694665456627e-08
surviving O 0 6.887637027830351e-06
patients O 0 6.133736718538785e-08
, O 0 1.5851805423849896e-09
one O 0 1.4007939252991264e-09
with O 0 1.0191551602645177e-08
SJS B-Disease 0 7.150753390305908e-06
type I-Disease 0 3.052720742857673e-08
2 I-Disease 0 7.125689904796673e-08
at O 0 1.517117311777838e-07
age O 0 1.0078163370508264e-07
10 O 0 1.3926268138675368e-08
years O 0 7.810885271908319e-09
and O 0 4.873358605550493e-09
another O 0 1.2866776977205063e-08
with O 0 9.811746792820486e-08
SWS B-Disease 0 0.2598632872104645
at O 0 4.3428485696495045e-07
age O 0 1.5624898708210821e-07
7 O 0 3.4527531056482985e-07
years O 0 2.3805452542546846e-07
. O 0 3.776905259655905e-07

Patients O 0 0.1886702924966812
reported O 0 0.00011042485857615247
as O 0 2.8979485477975686e-07
having O 0 1.0035930699814344e-06
either O 0 2.7765911454480374e-06
neonatal O 1 0.9999997615814209
SJS B-Disease 1 0.9993829727172852
or O 0 1.2926552699354943e-05
SWS B-Disease 1 0.5588827729225159
presented O 0 2.1793401572267612e-07
a O 0 8.401754314490972e-08
combination O 0 3.4741432841656206e-07
of O 0 1.1207072603269808e-08
a O 0 1.8099009366778773e-06
severe O 0 0.0004892406868748367
, O 0 3.0124007821541454e-07
prenatal O 0 0.017904510721564293
- O 1 0.9949859380722046
onset O 1 0.9999288320541382
neuromuscular B-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9988535642623901
( O 0 1.2276907455088804e-06
with O 0 2.1149278836674057e-05
congenital B-Disease 1 1.0
joint I-Disease 0 0.004510263912379742
contractures I-Disease 1 0.9999500513076782
, O 0 0.00022022365010343492
respiratory O 1 0.9249073266983032
and O 0 3.394458872207906e-06
feeding O 0 1.2161738595750649e-05
difficulties O 0 1.869587663350103e-06
, O 0 3.6038031225871237e-08
tendency O 0 3.5860995240000193e-07
to O 0 3.990918884255734e-08
hyperthermia B-Disease 0 0.006810085382312536
, O 0 1.092487451614943e-07
and O 0 8.138290752413013e-08
frequent O 0 3.6692969729301694e-07
death O 0 1.6468797184643336e-05
in O 0 7.985942147570313e-07
infancy O 0 2.4626613594591618e-05
) O 0 5.2738915456984614e-09
with O 0 2.3125998893647193e-09
a O 0 2.0064582884060655e-07
distinct O 0 1.85473766123323e-06
campomelic B-Disease 0 0.00040861047455109656
- I-Disease 0 0.01223236508667469
metaphyseal I-Disease 0 0.005040961317718029
skeletal I-Disease 1 0.5695159435272217
dysplasia I-Disease 1 0.9996861219406128
. O 0 1.0503787052584812e-05

The O 0 1.6482104001624975e-06
similarity O 0 1.2283604746698984e-06
of O 0 2.795414921763495e-08
the O 0 4.0404895429446697e-08
clinical O 0 1.259842747458606e-06
and O 0 3.6805295167141594e-07
radiographic O 0 8.17302570794709e-05
findings O 0 9.90986450233322e-07
is O 0 5.3163429214464486e-08
so O 0 8.012725594142012e-09
extensive O 0 2.6284345366889283e-08
that O 0 3.169511586520457e-08
these O 0 1.1983989622876834e-07
disorders O 0 0.0013547077542170882
appear O 0 4.4433352286432637e-07
to O 0 3.738923481932943e-08
be O 0 2.4599767556310326e-08
a O 0 7.90397081118499e-08
single O 0 1.8154535155190388e-06
entity O 0 3.5153309454472037e-06
. O 0 1.2905902622151189e-06

The O 0 2.5196934529958526e-06
follow O 0 4.182231521099311e-07
- O 0 7.223302418424282e-06
up O 0 2.48702434646475e-07
observation O 0 2.5977436735047377e-07
of O 0 2.363286455420166e-09
an O 0 1.0026850461031245e-08
identical O 0 4.859076398133766e-06
and O 0 1.9483978519474476e-07
unique O 0 6.312193079338613e-08
pattern O 0 3.686423224280588e-05
of O 0 3.7834016097804124e-07
progressive O 0 0.16235655546188354
bone B-Disease 1 0.9949354529380798
dysplasia I-Disease 1 0.9997146725654602
in O 0 6.575739917025203e-07
the O 0 2.7324080065227463e-07
two O 0 4.107707354705781e-06
patients O 0 3.850648681691382e-06
( O 0 2.2002270227972076e-08
one O 0 1.0319635812550132e-08
with O 0 1.3532310561004124e-07
SJS B-Disease 0 0.0007078976486809552
type I-Disease 0 2.436085253521014e-07
2 I-Disease 0 2.3813377936221514e-07
, O 0 3.3394130127817334e-08
one O 0 2.5227700817254117e-08
with O 0 5.967886522739718e-07
SWS B-Disease 1 0.9427682757377625
) O 0 1.0505687697559551e-07
surviving O 0 5.989999181110761e-07
beyond O 0 2.748095653259952e-07
infancy O 0 9.200401223097288e-07
adds O 0 9.678552004288576e-08
to O 0 4.927767083273693e-09
the O 0 3.926069247484065e-09
evidence O 0 9.649167687086901e-09
in O 0 1.0400889927097978e-08
favor O 0 4.227327465855524e-08
of O 0 2.5531893044217213e-08
identity O 0 2.5472077140875626e-06
. O 0 5.788224939351494e-07

The O 0 6.9810116656299215e-06
hypothesis O 0 1.0030801604443695e-05
that O 0 1.0172828979193582e-06
SWS B-Disease 0 0.06181306019425392
and O 0 3.5314960769028403e-06
SJS B-Disease 0 0.001490348600782454
type I-Disease 0 5.926341941631108e-07
2 I-Disease 0 4.6301167344608984e-07
are O 0 1.0296258956543625e-08
the O 0 1.1955714285249996e-07
same O 0 1.055001666827593e-05
disorder O 0 0.11452142149209976
should O 0 7.724587192114996e-08
be O 0 1.3143445443120072e-08
testable O 0 5.437208017156081e-08
by O 0 1.958422535253135e-09
molecular O 0 9.491803609762428e-08
methods O 0 1.289210871391333e-07
. O 0 1.0727534771604041e-07
. O 0 5.231395334703848e-07

A O 0 2.0338728063507006e-05
mouse O 0 6.934148404980078e-05
model O 0 5.0077956075256225e-06
of O 0 1.8759066051643458e-06
severe O 1 0.9998052716255188
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 4.433739741216414e-05
defects O 1 0.9997840523719788
in O 0 5.806381068396149e-06
hemostasis O 0 0.429656058549881
and O 0 0.000740160932764411
thrombosis B-Disease 0 0.38761118054389954
. O 0 6.3403290369024035e-06

von B-Disease 1 0.9996277093887329
Willebrand I-Disease 1 0.9992790818214417
factor I-Disease 0 0.0003165648377034813
( I-Disease 0 2.0984878574381582e-05
vWf I-Disease 0 0.005294029600918293
) I-Disease 0 0.00019731497741304338
deficiency I-Disease 1 0.996013879776001
causes O 0 0.007193896919488907
severe O 1 0.9999932050704956
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 8.357484148291405e-06
humans O 0 6.940789717191365e-06
. O 0 3.8204748307180125e-06

We O 0 3.97561734644114e-06
generated O 0 6.274484007917636e-07
a O 0 9.216896756925053e-08
mouse O 0 2.545131337683415e-06
model O 0 2.507414933461405e-07
for O 0 1.643289415653726e-08
this O 0 1.7704350341318786e-07
disease O 0 2.0713303001684835e-06
by O 0 6.929306461955775e-09
using O 0 1.4975461226640618e-07
gene O 0 1.4734390560988686e-06
targeting O 0 5.90013041801285e-06
. O 0 2.222415787400678e-06

vWf B-Disease 0 0.009030484594404697
- I-Disease 1 0.8699542880058289
deficient I-Disease 0 0.08201399445533752
mice O 0 0.0008927278686314821
appeared O 0 1.0415112228656653e-05
normal O 0 3.84407371711859e-07
at O 0 1.0212318102276186e-07
birth O 0 3.254575176470098e-06
; O 0 1.634582673659679e-07
they O 0 3.6560891203407664e-08
were O 0 1.5849401791001583e-07
viable O 0 2.3903663759483607e-07
and O 0 2.763188149401685e-07
fertile O 0 7.2687935244175605e-06
. O 0 1.0019223282142775e-06

Neither O 0 0.000849275616928935
vWf O 0 0.0045375097543001175
nor O 0 0.0002348541747778654
vWf O 0 0.001171904499642551
propolypeptide O 0 0.0017407916020601988
( O 0 1.0279685739078559e-05
von B-Disease 1 0.5389118194580078
Willebrand I-Disease 1 0.969921350479126
antigen O 0 0.00045972398947924376
II O 0 0.0001957556960405782
) O 0 1.4149870253277186e-07
were O 0 9.5559464341477e-08
detectable O 0 2.0684825585703948e-07
in O 0 5.998919583305451e-09
plasma O 0 4.551756376258709e-07
, O 0 9.701100367465187e-08
platelets O 0 1.2831212643504841e-06
, O 0 1.794875714722366e-08
or O 0 1.945144489923223e-08
endothelial O 0 5.378337277761602e-07
cells O 0 9.854979055035074e-08
of O 0 6.698421373130259e-09
the O 0 1.5477954207199218e-07
homozygous O 0 6.329471216304228e-05
mutant O 0 5.179347863304429e-05
mice O 0 0.00013264064909890294
. O 0 1.6172284631466027e-06

The O 0 1.1123697731818538e-05
mutant O 0 0.00174265680834651
mice O 1 0.9054346680641174
exhibited O 0 0.02976575680077076
defects O 1 0.9841135144233704
in O 0 3.499508522963879e-07
hemostasis O 0 4.182888733339496e-05
with O 0 8.365136494603576e-08
a O 0 8.523015253558697e-07
highly O 0 2.9125490073056426e-06
prolonged O 0 0.002813079860061407
bleeding O 1 0.8077178597450256
time O 0 3.5526150554687774e-07
and O 0 5.294768357089197e-07
spontaneous O 0 3.3222993351955665e-06
bleeding O 0 0.00015561659529339522
events O 0 5.0200945622691506e-08
in O 0 3.763062750294921e-08
approximately O 0 2.2875601857208494e-08
10 O 0 3.629104483593437e-08
% O 0 3.6032943739883194e-08
of O 0 4.8534914753872727e-08
neonates O 0 0.00023683455947320908
. O 0 2.3032130229694303e-06

As O 0 2.0086956737941364e-06
in O 0 1.0882614986940098e-07
the O 0 1.058931786701578e-07
human O 0 6.422146157092357e-07
disease O 0 7.758778338029515e-06
, O 0 5.5525402054001916e-09
the O 0 5.4128368454087195e-09
factor O 0 3.554583116738286e-08
VIII O 0 0.00011069705215049908
level O 0 1.247746723720411e-07
in O 0 2.267352350315832e-08
these O 0 1.672347771375371e-08
mice O 0 1.1181833542650566e-05
was O 0 2.9282150535436813e-06
reduced O 0 1.1285510481684469e-07
strongly O 0 3.2132771110582325e-08
as O 0 1.6220054632754e-08
a O 0 5.000370961738554e-08
result O 0 3.5248763907702596e-08
of O 0 3.0324776023604727e-09
the O 0 7.39438235086709e-08
lack O 0 4.927299812607089e-08
of O 0 1.0655951676596942e-08
protection O 0 2.601884432351653e-07
provided O 0 7.01374531786314e-08
by O 0 8.763913683651481e-08
vWf O 0 2.0684125047409907e-05
. O 0 1.4954666767152958e-06

Defective O 1 0.9454330205917358
thrombosis B-Disease 1 0.9535788297653198
in O 0 2.8909198590554297e-06
mutant O 0 0.0002333971788175404
mice O 0 0.4843577742576599
was O 0 0.0022523573134094477
also O 0 4.408085715112975e-06
evident O 0 5.352345624487498e-07
in O 0 8.333919332415007e-09
an O 0 5.959517324072294e-09
in O 0 5.600384511694756e-08
vivo O 0 3.4631186736078234e-06
model O 0 9.760302646100172e-07
of O 0 6.630418170061603e-07
vascular B-Disease 1 0.9833855032920837
injury I-Disease 0 0.3810885548591614
. O 0 1.2520416021288838e-05

In O 0 2.622841520860675e-06
this O 0 7.827352987987979e-08
model O 0 2.927964430909924e-07
, O 0 2.2124183374216955e-08
the O 0 4.784273244240467e-08
exteriorized O 0 1.4185749023454264e-05
mesentery O 0 8.300407353090122e-05
was O 0 1.0345024747948628e-05
superfused O 0 4.871613782597706e-06
with O 0 1.116381014298895e-07
ferric O 0 1.5767865988891572e-05
chloride O 0 5.12282713316381e-06
and O 0 3.379312545348512e-07
the O 0 2.730586246002531e-08
accumulation O 0 3.2590801879450737e-07
of O 0 4.359030469913705e-08
fluorescently O 0 0.00013543023669626564
labeled O 0 5.61072702112142e-05
platelets O 0 3.675257175927982e-05
was O 0 4.557956344797276e-06
observed O 0 4.287605008812534e-07
by O 0 3.6354297350271736e-08
intravital O 0 8.696500117366668e-06
microscopy O 0 6.122345894254977e-06
. O 0 1.1242880191275617e-06

We O 0 1.346133831248153e-05
conclude O 0 1.103534373214643e-06
that O 0 3.5198446823869745e-08
these O 0 1.8847234883878627e-08
mice O 0 2.0716186554636806e-05
very O 0 1.2178608699286997e-07
closely O 0 5.567501830228139e-06
mimic O 0 0.0017739791655912995
severe O 0 0.008119868114590645
human O 0 0.0001182272462756373
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.5487346647423692e-05
will O 0 4.980468020221451e-07
be O 0 2.7030496951852e-08
very O 0 3.789169422674377e-09
useful O 0 4.233538408726645e-09
for O 0 1.5093246652497783e-09
investigating O 0 2.124385467539014e-08
the O 0 5.771525923847776e-09
role O 0 2.040820490378792e-08
of O 0 5.3013238243693195e-09
vWf O 0 5.986561291138059e-07
in O 0 5.1032362335945436e-08
normal O 0 3.7053513324281084e-07
physiology O 0 3.209535179848899e-07
and O 0 4.574445995331189e-07
in O 0 8.170405862983898e-07
disease O 0 9.397441317560151e-06
models O 0 5.535222271646489e-07
. O 0 7.322914541418868e-08
. O 0 3.353263764438452e-07

Oral O 0 0.0007969805155880749
contraceptives O 0 0.016867972910404205
and O 0 3.4032298117381288e-06
the O 0 3.9107990801312553e-07
risk O 0 4.927534519083565e-06
of O 0 5.889409749215702e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2993700693186838e-05

Hereditary B-Disease 1 0.9999997615814209
Ovarian I-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.998392641544342
Clinical O 0 9.456653060624376e-05
Study O 0 4.147772870055633e-06
Group O 0 5.817721557832556e-06
. O 0 1.8427084569339058e-06

BACKGROUND O 0 0.00044283122406341136
Women O 0 2.0555113223963417e-05
with O 0 2.678321777693782e-07
mutations O 0 6.694631792925065e-06
in O 0 3.471354048656394e-08
either O 0 4.74300492214752e-08
the O 0 1.5167036337970785e-07
BRCA1 O 0 7.465447561116889e-05
or O 0 2.3288710337965313e-07
the O 0 1.5673089137635543e-07
BRCA2 O 0 1.4525389815389644e-05
gene O 0 3.102838661561691e-07
have O 0 6.564167875922067e-08
a O 0 1.2110737657167192e-07
high O 0 3.7279471598594682e-06
lifetime O 0 8.809395239950391e-07
risk O 0 1.3305652828421444e-06
of O 0 8.216020432882942e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.928484031552216e-06

Oral O 0 0.000511163379997015
contraceptives O 0 0.10597100853919983
protect O 0 0.00026601357967592776
against O 0 0.15254449844360352
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.6567769850771583e-07
general O 0 4.969564315615571e-08
, O 0 9.908657716550806e-08
but O 0 6.40922337424854e-08
it O 0 1.9345442581197858e-08
is O 0 1.0254494142714066e-08
not O 0 8.803413109603753e-09
known O 0 2.7665807422749822e-08
whether O 0 6.7253691504731705e-09
they O 0 3.260102232616191e-08
also O 0 2.2199640170583734e-07
protect O 0 3.693912731250748e-07
against O 0 4.551248196094093e-07
hereditary B-Disease 0 0.0004966342239640653
forms I-Disease 0 1.7829629541665781e-06
of I-Disease 0 6.277218199102208e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 5.9325557231204584e-06

METHODS O 0 1.719637839414645e-05
We O 0 7.873274512348871e-07
enrolled O 0 4.771032422468124e-07
207 O 0 2.324937440789654e-06
women O 0 1.3553831195167731e-06
with O 0 9.03691670828266e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7887092553792172e-06
161 O 0 4.0033043546827685e-07
of O 0 8.69368488309874e-09
their O 0 1.570731029687522e-07
sisters O 0 7.466821989510208e-05
as O 0 5.812093206714053e-08
controls O 0 4.967844802195032e-07
in O 0 1.1974321090235662e-08
a O 0 9.559701652506192e-08
case O 0 9.92492232398945e-07
- O 0 2.597198727016803e-05
control O 0 2.7841347218782175e-06
study O 0 3.1363077823698404e-07
. O 0 6.001188239679323e-07

All O 0 2.729503648879472e-06
the O 0 5.311599693413882e-07
patients O 0 1.365252956020413e-06
carried O 0 2.79421101367916e-07
a O 0 9.679216361746512e-08
pathogenic O 0 4.503903880959115e-07
mutation O 0 5.528738142857037e-07
in O 0 2.5513102741570037e-08
either O 0 3.094835960837372e-07
BRCA1 O 0 0.00011742906644940376
( O 0 1.0068287537023934e-07
179 O 0 2.590532233170961e-07
women O 0 3.033566997601156e-07
) O 0 4.5416836513823e-08
or O 0 6.750959755663644e-07
BRCA2 O 0 0.000483896117657423
( O 0 2.495568196536624e-07
28 O 0 1.7470272268838016e-06
women O 0 3.9172007859633595e-07
) O 0 2.248155368533844e-07
. O 0 5.018567890147096e-07

The O 0 5.23988137501874e-06
control O 0 9.507306458544917e-06
women O 0 2.8831418603658676e-06
were O 0 4.3579501607382554e-07
enrolled O 0 4.796351404934285e-08
regardless O 0 1.281563655197715e-08
of O 0 3.5866309922027995e-09
whether O 0 1.9779065496550174e-08
or O 0 2.2684082523483085e-07
not O 0 5.9096368687505674e-08
they O 0 6.18403817043145e-08
had O 0 3.2996158552123234e-06
either O 0 2.8656998551923607e-07
mutation O 0 4.742353667097632e-06
. O 0 5.252070991446089e-07

Lifetime O 0 6.099605161580257e-05
histories O 0 9.421921276953071e-06
of O 0 1.3665462006429152e-07
oral O 0 7.675598681089468e-07
- O 0 8.19779234007001e-06
contraceptive O 0 2.185898119932972e-05
use O 0 1.9246132865191612e-07
were O 0 3.0485261959256604e-07
obtained O 0 1.790263581824547e-08
by O 0 5.399246827408888e-09
interview O 0 8.780424423093791e-07
or O 0 4.271076647910377e-08
by O 0 4.978327972082752e-09
written O 0 2.0969981306961927e-08
questionnaire O 0 6.614868652832229e-08
and O 0 4.175050349886078e-08
were O 0 2.0777432041541033e-07
compared O 0 1.8112099553491134e-07
between O 0 1.846082255951842e-07
patients O 0 1.9592144440139236e-07
and O 0 1.64786797540728e-07
control O 0 2.1387202195910504e-06
women O 0 4.3348455847080913e-07
, O 0 2.1897273327908806e-08
after O 0 1.565372187428693e-08
adjustment O 0 6.663279350505036e-08
for O 0 4.0876630968966765e-09
year O 0 2.7974042637879393e-08
of O 0 8.459510425495864e-09
birth O 0 5.367283392843092e-06
and O 0 4.758949501137977e-07
parity O 0 1.2195478120702319e-05
. O 0 7.709227816121711e-07

RESULTS O 0 6.58545977785252e-05
The O 0 4.1272289763583103e-07
adjusted O 0 0.00016550450527574867
odds O 0 5.2647748816525564e-05
ratio O 0 7.11069515091367e-05
for O 0 0.00022663264826405793
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 8.354946317012946e-07
with O 0 1.5031400124598804e-08
any O 0 1.1054429371881724e-08
past O 0 5.040406136913589e-08
use O 0 1.7875681379564412e-08
of O 0 1.8574937143966963e-08
oral O 0 1.3210911902206135e-06
contraceptives O 0 0.011538075283169746
was O 0 0.00010338684660382569
0 O 0 1.0007142918766476e-06
. O 0 5.258752366898989e-07

5 O 0 2.1768881197203882e-05
( O 0 7.143781886043143e-07
95 O 0 8.617200251137547e-07
percent O 0 3.3112125947809545e-06
confidence O 0 6.081322680984158e-07
interval O 0 3.2577656838839175e-07
, O 0 9.790058541625513e-09
0 O 0 1.9578969556732773e-08
. O 0 3.4990321751138254e-09
3 O 0 1.762387036308155e-08
to O 0 1.7607071356451343e-08
0 O 0 1.2733177356949454e-07
. O 0 3.284963412397701e-08
8 O 0 3.420398968501104e-07
) O 0 6.999058399514979e-08
. O 0 3.647014636953827e-07

The O 0 8.010137207747903e-06
risk O 0 1.0633460988174193e-05
decreased O 0 5.537367542274296e-06
with O 0 2.144827959682516e-08
increasing O 0 4.3406949146174156e-08
duration O 0 8.041099164302068e-08
of O 0 2.397089637895533e-09
use O 0 3.8691123194212196e-08
( O 0 3.5650803198450376e-08
P O 0 1.586709572620748e-06
for O 0 3.939789383622383e-09
trend O 0 1.0169264186288274e-07
, O 0 4.977397605188116e-09
< O 0 5.8894158883049386e-08
0 O 0 1.6137722269604637e-08
. O 0 2.319659353489101e-09
001 O 0 5.448555029374802e-08
) O 0 1.6622343501637715e-09
; O 0 1.6679446712686286e-09
use O 0 1.5641239414776464e-09
for O 0 4.0659529076947365e-09
six O 0 7.882382391244391e-08
or O 0 3.654854907608751e-08
more O 0 9.806392142763798e-09
years O 0 1.0600169275676308e-07
was O 0 1.1239887953706784e-06
associated O 0 6.745976222077843e-09
with O 0 1.4174952323031675e-09
a O 0 7.757321185408728e-08
60 O 0 2.8339454161141475e-07
percent O 0 1.5423509580614336e-07
reduction O 0 1.374648803675882e-07
in O 0 1.1898580254410263e-07
risk O 0 2.0848799522354966e-06
. O 0 9.919831427396275e-07

Oral O 0 0.00028229557210579515
- O 0 0.00012616693857125938
contraceptive O 0 7.633572386112064e-05
use O 0 8.632878802927735e-07
protected O 0 7.596051727887243e-05
against O 0 0.3472484052181244
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 6.346901670895022e-08
for O 0 7.503406784792332e-09
carriers O 0 3.83130007719501e-08
of O 0 6.395336704656529e-09
the O 0 1.7984248756874877e-07
BRCA1 O 0 0.0031855390407145023
mutation O 0 8.602424713899381e-06
( O 0 5.2931728333760475e-08
odds O 0 1.935782620421378e-06
ratio O 0 1.123465835917159e-06
, O 0 2.3695525541711504e-08
0 O 0 1.543756944499819e-08
. O 0 3.30772809142843e-09
5 O 0 9.930809952152231e-09
; O 0 1.0129053151786138e-08
95 O 0 6.689423059924593e-08
percent O 0 7.728079367552709e-07
confidence O 0 1.736062671398031e-07
interval O 0 7.910290378276841e-08
, O 0 2.036297352958627e-09
0 O 0 4.18266798973832e-09
. O 0 8.976168142105223e-10
3 O 0 7.620245767725464e-09
to O 0 3.825762817655232e-09
0 O 0 4.228819250329252e-08
. O 0 1.9502897075085457e-08
9 O 0 4.3024903106925194e-07
) O 0 2.9825035774422304e-09
and O 0 6.450796341539444e-09
for O 0 5.150366355621827e-09
carriers O 0 1.9318118660294203e-08
of O 0 1.412642447462531e-09
the O 0 1.7216804337749636e-07
BRCA2 O 0 0.0004335232079029083
mutation O 0 3.4049892292387085e-06
( O 0 4.191791092011954e-08
odds O 0 1.0386863777966937e-06
ratio O 0 5.031939167565724e-07
, O 0 1.186897335969661e-08
0 O 0 1.5375741568846024e-08
. O 0 2.6512216866336757e-09
4 O 0 2.3766453693951917e-08
; O 0 1.5177896273144142e-08
95 O 0 9.267136391599706e-08
percent O 0 1.1661159078357741e-06
confidence O 0 1.3607667881387897e-07
interval O 0 1.3676543630936067e-07
, O 0 4.322425972702604e-09
0 O 0 7.853880212849162e-09
. O 0 1.4788561486511753e-09
2 O 0 1.4259130765026384e-08
to O 0 6.516101880293945e-09
1 O 0 6.743469782577449e-08
. O 0 2.3941893800838443e-08
1 O 0 1.2232433732606296e-07
) O 0 1.1355165696613767e-07
. O 0 5.343226803233847e-07

CONCLUSIONS O 0 3.400713831069879e-05
Oral O 0 1.99991773115471e-05
- O 0 3.609594932640903e-05
contraceptive O 0 3.940566966775805e-05
use O 0 1.6433888561095955e-07
may O 0 3.974287494656892e-07
reduce O 0 8.5120674953032e-08
the O 0 4.6660169061851775e-08
risk O 0 8.486776437166554e-07
of O 0 5.379459253163077e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 4.0062872130874894e-07
women O 0 2.724817136368074e-07
with O 0 4.553045584998472e-08
pathogenic O 0 3.040705905732466e-06
mutations O 0 2.9062423436698737e-06
in O 0 3.74187010265814e-08
the O 0 5.09834762851824e-07
BRCA1 O 0 0.0006398225086741149
or O 0 1.4498235941573512e-05
BRCA2 O 0 0.0015108947409316897
gene O 0 0.00011616077244980261

A O 0 3.172436845488846e-05
Japanese O 0 7.645691766811069e-06
family O 0 3.4754696116579e-06
with O 0 1.4691793239762774e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.965138665127597e-07
a O 0 4.1495158598081616e-07
codon O 0 6.856356776552275e-06
291 O 0 1.2362651204966824e-06
deletion O 0 4.524888936430216e-06
: O 0 1.944729177694171e-08
a O 0 6.746738279161946e-08
clinical O 0 6.529728011628322e-07
, O 0 5.2523112969993235e-08
biochemical O 0 2.307964678038843e-06
, O 0 7.298178417158852e-08
pathological O 0 1.8210665757578681e-06
, O 0 1.0238511549687246e-07
and O 0 2.302426196365559e-07
genetic O 0 6.3653142206021585e-06
report O 0 1.4353702226799214e-06
. O 0 1.034862975757278e-06

We O 0 6.229982773220399e-06
report O 0 1.3422302913568274e-07
a O 0 9.984410809238398e-08
Japanese O 0 7.013148888290743e-07
family O 0 9.879988738248358e-07
with O 0 1.8148848539567553e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.004335326608270407
ALD B-Disease 1 1.0
) O 0 1.1638012153980526e-07
with O 0 1.4646583501587429e-08
a O 0 2.6539407826930983e-07
three O 0 3.3648441899458703e-07
base O 0 2.0744935227412498e-06
pair O 0 2.0016235794173554e-05
deletion O 0 3.285017373855226e-05
( O 0 1.075504911796088e-07
delGAG O 0 2.2826930035080295e-06
291 O 0 6.895240289850335e-07
) O 0 2.224074613366156e-08
in O 0 5.518756296396532e-08
the O 0 2.726636466832133e-06
ALD B-Disease 1 1.0
gene O 0 3.291031316621229e-05
. O 0 3.667016017061542e-06

A O 0 1.2896814951091073e-05
variety O 0 6.154926950330264e-07
of O 0 1.4038188567155885e-07
phenotypes O 0 8.298920147353783e-05
were O 0 1.606508362783643e-06
observed O 0 5.095805590826785e-07
within O 0 2.372433094421922e-08
this O 0 3.316226226957042e-08
family O 0 1.3027422482991824e-06
. O 0 1.2265379609743832e-06

While O 0 5.898364179302007e-06
the O 0 2.2997467397090077e-07
proband O 0 2.0948724340996705e-05
( O 0 1.2948110850174999e-07
patient O 0 1.2046776873830822e-06
1 O 0 6.62754814584332e-07
) O 0 7.491412645777018e-08
was O 0 5.39293705514865e-06
classified O 0 1.6920762391237076e-07
as O 0 3.4898900480584416e-07
having O 0 8.539257123629795e-08
a O 0 5.3702251534559764e-08
rare O 0 7.1407377788546e-08
intermediate O 0 2.3242398228262573e-08
type O 0 2.864010717473775e-08
of O 0 1.0470216693647671e-08
adult O 0 4.323197117628297e-06
cerebral O 0 0.00010737269622040913
and O 0 1.601848339305434e-06
cerebello O 0 0.0007830383838154376
- O 0 0.008368629962205887
brain O 0 2.6656682166503742e-05
stem O 0 1.760610501833071e-07
forms O 0 4.009573828511748e-08
, O 0 2.594593517812882e-08
his O 0 2.553854869802308e-07
younger O 0 3.3945530049095396e-06
brother O 0 5.45391094419756e-06
( O 0 4.086869864750042e-08
patient O 0 3.189570350059512e-07
2 O 0 2.803334098189225e-07
) O 0 4.216456517269762e-08
and O 0 4.4398620957508683e-07
nephew O 0 0.00014011649182066321
( O 0 1.0205074829627847e-07
patient O 0 6.686558435831103e-07
3 O 0 5.245598799774598e-07
) O 0 3.737141440751657e-08
had O 0 3.913738055416616e-06
a O 0 3.951226062781643e-06
childhood O 0 0.0037638647481799126
ALD B-Disease 1 1.0
type O 0 6.600681081181392e-05
. O 0 4.519485173659632e-06

Another O 0 7.152492617024109e-05
nephew O 0 0.002810973674058914
( O 0 3.802663513852167e-06
patient O 0 5.590844011749141e-06
4 O 0 9.420459718967322e-07
) O 0 2.648019226114684e-08
of O 0 2.6680906373144353e-08
patient O 0 9.376019079354592e-06
1 O 0 2.7771473014581716e-06
was O 0 0.0005067409365437925
classified O 0 3.2118930448632454e-07
as O 0 7.405900248613762e-08
having O 0 4.739984049706436e-08
an O 0 1.9728540578967113e-08
adolescent O 0 5.327302005753154e-06
form O 0 3.1588541560267913e-07
. O 0 1.1749345958378399e-06

The O 0 3.291258963145083e-06
tau O 0 3.984951490565436e-06
level O 0 2.9106226406838687e-07
in O 0 7.404374713360085e-08
the O 0 3.2532113891647896e-07
cerebrospinal O 0 0.06488534063100815
fluid O 0 0.0014276336878538132
( O 0 2.1072478375572246e-06
CSF O 0 0.07097717374563217
) O 0 3.9789021855085593e-08
in O 0 4.621615445898897e-08
patient O 0 3.651807446658495e-06
1 O 0 2.350163185838028e-06
was O 0 0.00014601620205212384
as O 0 8.425279673929253e-08
high O 0 2.0199631478590163e-07
as O 0 3.6270837000529355e-08
that O 0 4.018897659108234e-09
of O 0 1.730017729073552e-08
patients O 0 1.8220341644337168e-06
with O 0 1.360358055535471e-05
Alzheimers B-Disease 1 0.9999998807907104
disease I-Disease 0 0.009631691500544548
( O 0 2.2474287675322557e-07
AD B-Disease 0 8.874460036167875e-06
) O 0 2.2081631811943225e-07
. O 0 9.761382671058527e-07

His O 0 0.00012234026507940143
brain O 0 0.0003426726325415075
magnetic O 0 9.631161447032355e-06
resonance O 0 1.1232463293708861e-05
image O 0 0.00011406277189962566
( O 0 6.733586701557215e-07
MRI O 0 0.00034976538154296577
) O 0 2.0068976027687313e-06
showed O 0 0.06945919990539551
abnormalities B-Disease 1 0.9383954405784607
in I-Disease 0 5.890505505590227e-08
the I-Disease 0 1.4806427373059705e-07
bilateral I-Disease 0 3.3476605949545046e-06
cerebellar I-Disease 0 0.3213628828525543
hemispheres I-Disease 0 0.0018564561614766717
and O 0 1.4199947145243641e-05
brain O 0 5.965065065538511e-05
stem O 0 8.127832415993907e-07
, O 0 7.490340436788756e-08
but O 0 1.598580290362861e-08
not O 0 3.3495028972652108e-09
in O 0 8.387115890684527e-09
the O 0 3.991212338405603e-07
cerebral O 0 0.0002844436385203153
white O 0 3.907532573066419e-06
matter O 0 1.5669256114847485e-08
, O 0 1.1158228119256819e-08
where O 0 1.4733442021963583e-08
marked O 0 1.9552086882868025e-07
reductions O 0 1.1037200664532065e-07
of O 0 4.0259711120427255e-09
the O 0 1.264357365471369e-07
cerebral O 0 0.00014732622366864234
blood O 0 2.329422613911447e-06
flow O 0 6.565268790836853e-07
and O 0 1.750134259737024e-07
oxygen O 0 4.5944045723445015e-07
metabolism O 0 1.0806585351019748e-06
were O 0 1.370558209146111e-07
clearly O 0 1.2904435209293297e-07
demonstrated O 0 4.3514795322607824e-08
by O 0 6.560084919726705e-09
positron O 0 1.4887190218360047e-06
emission O 0 1.2976100833839155e-06
tomography O 0 8.21537832962349e-05
( O 0 2.9341617846512236e-07
PET O 0 6.201299129315885e-06
) O 0 3.9242115690285573e-07
. O 0 9.377479273098288e-07

In O 0 1.1991290193691384e-05
patients O 0 6.024582489772001e-06
2 O 0 1.1045493693018216e-06
and O 0 2.613228957670799e-07
3 O 0 6.294657168837148e-07
, O 0 1.7174455635426966e-08
the O 0 1.8481005170656317e-08
autopsy O 0 0.0007020078483037651
findings O 0 2.5109450234594988e-06
showed O 0 6.82246100041084e-05
massive O 0 3.2959392228804063e-06
demyelination B-Disease 1 0.9999996423721313
of I-Disease 0 1.5683436060953682e-07
the I-Disease 0 3.189127937730518e-06
cerebral I-Disease 0 0.005348186939954758
white I-Disease 0 1.3261695130495355e-05
matter I-Disease 0 2.0481399687355406e-08
with O 0 3.950647808892427e-09
sparing O 0 2.9225374120755987e-08
of O 0 4.351892624043785e-09
the O 0 6.434541433009144e-08
U O 0 9.392861102242023e-05
- O 0 0.0038065172266215086
fibers O 0 2.2613226974499412e-05
, O 0 5.611565878638203e-09
compatible O 0 2.5236172263021217e-08
with O 0 6.634223836954334e-09
the O 0 2.3402719762088964e-08
findings O 0 2.0020065960579814e-07
of O 0 1.3429716716473195e-07
childhood O 0 0.0002948244218714535
ALD B-Disease 1 1.0
. O 0 7.919474228401668e-06

Oleic O 1 0.9866794943809509
and O 0 7.193067722255364e-05
erucic O 0 0.014699909836053848
acids O 0 3.352276689838618e-05
( O 0 3.086856565914786e-07
Lorenzos O 0 9.45468491408974e-06
Oil O 0 3.4151294130424503e-06
) O 0 1.433641649839501e-08
were O 0 1.4858347441304431e-08
administered O 0 6.752850723046322e-09
to O 0 1.7225632475970087e-08
patients O 0 7.097084164797707e-08
1 O 0 3.026365646974227e-08
and O 0 7.602000806627984e-08
4 O 0 2.1325622867607308e-07
, O 0 1.72585856716978e-08
but O 0 1.2620655631678801e-08
sufficient O 0 2.4938925591300176e-08
effectiveness O 0 1.6940494163009134e-07
was O 0 6.727765594405355e-06
not O 0 2.435220380903047e-08
obtained O 0 1.520746053529365e-07
. O 0 3.452391013070155e-07

The O 0 2.0139666503382614e-06
findings O 0 2.9873220341869455e-07
in O 0 3.173498086539439e-08
this O 0 1.0065058120289905e-08
family O 0 1.0381393167335773e-07
suggest O 0 8.977716703384431e-08
that O 0 2.1402795979952316e-08
delGAG291 O 0 1.968754531844752e-06
is O 0 6.126579243925789e-09
part O 0 2.9985203209292877e-09
of O 0 2.549499278359235e-09
the O 0 4.7930409863283785e-08
cause O 0 3.621491941885324e-07
of O 0 3.8132199620122265e-08
Japanese O 0 1.0268339792673942e-05
ALD B-Disease 1 0.9999998807907104
with O 0 2.337638278504528e-07
phenotypic O 0 2.2672786144539714e-05
variations O 0 5.0570200983202085e-05
. O 0 2.9088348583172774e-06

Moreover O 0 2.605017289170064e-05
, O 0 3.33120993900593e-07
although O 0 2.447364089164239e-08
the O 0 5.848766360116997e-09
scale O 0 2.0719809867841832e-07
of O 0 3.788410474214743e-09
the O 0 1.6896100518692947e-08
study O 0 1.112872727304648e-08
is O 0 1.6218848486460047e-08
limited O 0 1.4262448999602384e-08
, O 0 1.4766695421997156e-08
there O 0 3.826405414741885e-09
is O 0 2.3137161075936774e-09
a O 0 7.389430400905894e-09
possibility O 0 1.2749710620596488e-08
that O 0 1.5370172690154504e-08
PET O 0 5.560077056543378e-07
can O 0 2.6746276304834282e-08
detect O 0 4.2625313767530315e-07
an O 0 2.0109364839981936e-08
insidious B-Disease 0 0.00010927200492005795
lesion I-Disease 0 0.053918369114398956
which O 0 6.103884402364201e-07
is O 0 3.977073603778081e-08
undetectable O 0 2.4638819695610437e-07
by O 0 5.797177404787135e-09
computed O 0 3.792989673456759e-07
tomogram O 0 8.265555152320303e-06
( O 0 5.655063262111071e-08
CT O 0 2.8171758458483964e-05
) O 0 2.5645711332344945e-08
or O 0 1.2010529459871577e-08
MRI O 0 2.2855160750623327e-06
analysis O 0 2.389750264342183e-08
, O 0 3.084613453552265e-08
and O 0 7.659096468159987e-08
that O 0 8.029646281215719e-09
the O 0 9.797456179683195e-09
higher O 0 4.423269217568304e-08
level O 0 9.987911830933172e-09
of O 0 1.5329993940937925e-09
tau O 0 2.7143540748397754e-08
reflects O 0 2.204271964956206e-08
the O 0 3.0647200333078217e-09
process O 0 1.6295624405415765e-08
of O 0 3.001795079171643e-08
neuronal B-Disease 0 0.0010560291120782495
degeneration I-Disease 1 0.9481883645057678
in O 0 5.31212572241202e-05
ALD B-Disease 1 1.0
. O 0 2.810073237924371e-05

Lorenzos O 0 0.003378187073394656
Oil O 0 0.0003909441875293851
should O 0 5.378506671149808e-07
be O 0 1.4246517743288223e-08
given O 0 3.856372110533357e-09
in O 0 5.1483333152191335e-09
the O 0 2.395472975535995e-08
early O 0 8.480998872073542e-07
stage O 0 5.400605914473999e-06
. O 0 1.311115056523704e-07
. O 0 4.6484154836434755e-07

Nonsense O 0 0.0015582963824272156
mutation O 0 0.00011455086496425793
in O 0 2.6436796929374395e-07
exon O 0 5.367682206269819e-06
4 O 0 1.8099527778758784e-06
of O 0 2.119403319511548e-08
human O 0 6.649668904401551e-08
complement O 0 4.1393104766029865e-07
C9 O 0 2.4635681256768294e-05
gene O 0 6.75103080993722e-07
is O 0 3.287163607978982e-08
the O 0 1.1813615863331961e-08
major O 0 9.446525695011587e-08
cause O 0 2.838143018379924e-07
of O 0 2.5347606680270474e-08
Japanese O 0 9.177457286568824e-06
complement B-Disease 0 0.00011151879880344495
C9 I-Disease 1 0.6664390563964844
deficiency I-Disease 0 0.01687597669661045
. O 0 1.7668958207650576e-06

Deficiency B-Disease 1 0.999904990196228
of I-Disease 0 4.4384097463989747e-07
the I-Disease 0 4.811075768884621e-07
ninth I-Disease 0 1.6391533790738322e-05
component I-Disease 0 2.1342509626265382e-07
of I-Disease 0 4.865751801474971e-09
human I-Disease 0 4.544239473602829e-08
complement I-Disease 0 6.107517833697784e-07
( O 0 1.5391154306598764e-07
C9 O 0 1.1611062291194685e-05
) O 0 1.222093093389276e-08
is O 0 2.2543069633229607e-09
the O 0 3.28059779342027e-09
most O 0 3.035169626741663e-08
common O 0 1.081884875020478e-05
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
in O 0 1.5489072779928392e-07
Japan O 0 6.935404144314816e-07
but O 0 5.431320815318941e-08
is O 0 1.086645351477955e-08
rare O 0 1.2443559960217954e-08
in O 0 1.2510407820798264e-08
other O 0 7.255426481833638e-09
countries O 0 1.785080705474229e-08
. O 0 3.0915290949451446e-07

We O 0 7.5101343099959195e-06
studied O 0 3.962415462410718e-07
the O 0 2.5670866321547692e-08
molecular O 0 2.8353727543617424e-07
basis O 0 2.1990696552620648e-07
of O 0 1.2807153098037816e-06
C9 B-Disease 1 0.9998899698257446
deficiency I-Disease 0 0.08141836524009705
in O 0 4.144156307006597e-08
four O 0 2.040895026311773e-07
Japanese O 0 2.1085606931592338e-06
C9 B-Disease 0 0.0021434123627841473
- I-Disease 0 0.13698242604732513
deficient I-Disease 0 0.0078070275485515594
patients O 0 6.295771981967846e-06
who O 0 6.730493169015972e-06
had O 0 0.014352502301335335
suffered O 1 0.8292632102966309
from O 0 2.3616201360709965e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 1.0425068467156962e-05

Direct O 0 2.3327716917265207e-05
sequencing O 0 1.074772808351554e-05
of O 0 4.5144005866859516e-07
amplified O 0 1.0595499588816892e-05
C9 O 0 3.545234358171001e-05
cDNA O 0 4.9383074838260654e-06
and O 0 7.75149146647891e-07
DNA O 0 4.038296992803225e-06
revealed O 0 1.6815954495541519e-06
a O 0 2.3148943739670358e-07
nonsense O 0 1.405056650582992e-06
substitution O 0 4.951715482093277e-07
( O 0 1.1140370759221696e-07
CGA O 0 6.985460004216293e-06
- O 0 4.091919254278764e-05
- O 0 2.680126272025518e-05
> O 0 1.5213596498142579e-06
TGA O 0 5.379587491916027e-06
) O 0 2.864961246018538e-08
at O 0 1.2442230357123663e-08
codon O 0 1.9229767644901585e-07
95 O 0 2.5362792754890506e-08
in O 0 6.04669647685796e-09
exon O 0 7.905130132712657e-07
4 O 0 5.42635973488359e-07
in O 0 2.9158560010955625e-08
the O 0 7.448469574455885e-08
four O 0 3.0768069336772896e-06
C9 B-Disease 0 0.018249867483973503
- I-Disease 0 0.11424798518419266
deficient I-Disease 0 0.0003425044706091285
individuals O 0 1.4978489559780428e-07
. O 0 4.6771458528382936e-07

An O 0 2.512518904040917e-06
allele O 0 1.7648513676249422e-05
- O 0 2.6372588308731792e-06
specific O 0 4.5087642064345346e-08
polymerase O 0 1.2963632798346225e-06
chain O 0 1.9706478724401677e-06
reaction O 0 6.383005768384464e-08
system O 0 1.910085245526716e-08
designed O 0 3.3973822155530797e-07
to O 0 1.4766161626766916e-08
detect O 0 6.267958951866603e-07
exclusively O 0 1.4796073699585577e-08
only O 0 5.417174708810535e-09
one O 0 3.2899591939639095e-09
of O 0 6.595536894415943e-10
the O 0 8.597351275341225e-09
normal O 0 4.240207474026647e-08
and O 0 6.041533850975611e-08
mutant O 0 2.0805816802749177e-06
alleles O 0 1.870131853820567e-07
indicated O 0 3.6305138451098173e-07
that O 0 8.605587353827104e-09
all O 0 1.427232110273735e-09
the O 0 9.934712608128393e-09
four O 0 1.82451742603007e-07
patients O 0 2.170938984136228e-07
were O 0 1.1221451501342017e-07
homozygous O 0 3.5618865013020695e-07
for O 0 1.4008794124720225e-09
the O 0 4.847530821194823e-09
mutation O 0 8.382946248275402e-08
in O 0 5.254342738680862e-09
exon O 0 5.742265898334153e-07
4 O 0 2.4126350126607576e-06
and O 0 6.566847332578618e-07
that O 0 3.600285580773743e-08
the O 0 1.7774940630488345e-08
parents O 0 4.703438349906719e-08
of O 0 7.3106716236281954e-09
patient O 0 8.951296877057757e-07
2 O 0 9.815656767386827e-07
were O 0 1.7932834452949464e-06
heterozygous O 0 1.0906177521974314e-05
. O 0 9.900683153318823e-07

The O 0 3.864868176606251e-06
common O 0 1.5589474742228049e-06
mutation O 0 3.0900189358362695e-06
at O 0 8.936186191021989e-08
codon O 0 3.631608080922888e-07
95 O 0 7.614887920226465e-08
in O 0 1.487822753887258e-08
exon O 0 1.983185484277783e-06
4 O 0 5.018198407924501e-06
might O 0 9.364002835354768e-07
be O 0 2.718955371960874e-08
responsible O 0 2.798263665226841e-08
for O 0 7.0220411707566655e-09
most O 0 9.176989834713822e-08
Japanese O 0 6.430323537642835e-06
C9 B-Disease 0 0.2769947648048401
deficiency I-Disease 0 0.00033497688127681613
. O 0 1.1207548311631399e-07
. O 0 3.3923444675565406e-07

BRCA1 O 0 0.0033145230263471603
required O 0 3.114337459919625e-06
for O 0 1.0382263582187079e-07
transcription O 0 1.5080157027114183e-05
- O 0 0.0011190333170816302
coupled O 0 0.00010226200538454577
repair O 0 9.32582697714679e-05
of O 0 1.0891294977000143e-07
oxidative O 0 6.917142309248447e-05
DNA O 0 0.00012005493772448972
damage O 0 0.00019189091108273715
. O 0 4.0692011680221185e-06

The O 0 9.132123523158953e-05
breast B-Disease 1 0.999911904335022
and I-Disease 1 0.9693940877914429
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.002364899730309844
gene O 0 2.1640486011165194e-05
BRCA1 O 0 0.00012162687198724598
encodes O 0 1.203583633468952e-05
a O 0 2.8298554752836935e-05
zinc O 0 0.47168755531311035
finger O 0 0.0008203212637454271
protein O 0 5.565032097365474e-07
of O 0 3.953227789565972e-08
unknown O 0 1.2499315289460355e-06
function O 0 7.488654318876797e-07
. O 0 1.4223975313143455e-06

Association O 0 9.676900845079217e-06
of O 0 1.1441279923474212e-07
the O 0 9.204142514818159e-08
BRCA1 O 0 6.4369746723969e-06
protein O 0 1.5099507777449617e-07
with O 0 7.907300592080446e-09
the O 0 4.760024552297182e-08
DNA O 0 4.930947397951968e-06
repair O 0 4.509200152824633e-05
protein O 0 5.941938638898137e-07
Rad51 O 0 1.495846936450107e-05
and O 0 6.381862505122626e-08
changes O 0 1.0610158085455623e-08
in O 0 2.7343374231492135e-09
the O 0 6.538997787686185e-09
phosphorylation O 0 7.91101442132458e-08
and O 0 8.081799052206406e-08
cellular O 0 4.0523448774365534e-07
localization O 0 2.6279263920514495e-07
of O 0 3.795157965669205e-09
the O 0 1.500081303618117e-08
protein O 0 8.465598710927225e-08
after O 0 3.1661102184443735e-08
exposure O 0 5.3604008343199894e-08
to O 0 3.454489805321259e-09
DNA O 0 3.1943162071002007e-07
- O 0 1.193630623674835e-06
damaging O 0 4.221208200760884e-07
agents O 0 3.6812167536481866e-08
are O 0 3.949962579241628e-09
consistent O 0 2.8861871115282156e-08
with O 0 4.048031687631237e-09
a O 0 2.6488525151080466e-08
role O 0 5.8705968086769644e-08
for O 0 2.6813598452690712e-08
BRCA1 O 0 1.2797466297342908e-05
in O 0 2.8322918410594866e-07
DNA O 0 1.5503585018450394e-05
repair O 0 0.00019380672893021256
. O 0 1.5283602579074795e-06

Here O 0 9.14333577384241e-06
, O 0 1.2856429520979873e-07
it O 0 1.9678857654525928e-08
is O 0 2.1113539361294897e-08
shown O 0 7.831833670479682e-08
that O 0 1.526246151684063e-08
mouse O 0 4.8124940803973004e-05
embryonic O 0 6.4582254708511755e-06
stem O 0 7.324056696234038e-06
cells O 0 2.3697434698988218e-06
deficient B-Disease 0 5.794886419607792e-06
in I-Disease 0 9.697696157218161e-08
BRCA1 I-Disease 0 2.6198460545856506e-05
are O 0 3.75630762050605e-08
defective O 0 3.798285206357832e-06
in O 0 1.4236796630484605e-07
the O 0 8.20032113324487e-08
ability O 0 5.156325499910963e-08
to O 0 9.294002900617215e-09
carry O 0 2.0144375056929675e-08
out O 0 2.7131841662253464e-08
transcription O 0 5.309290713739756e-07
- O 0 8.10777328297263e-06
coupled O 0 4.341549811215373e-06
repair O 0 7.981025191838853e-06
of O 0 1.1861120086109622e-08
oxidative O 0 2.585092715889914e-06
DNA O 0 1.4014544831297826e-05
damage O 0 5.7563425798434764e-05
, O 0 8.59286330978648e-08
and O 0 1.4643838142092136e-07
are O 0 1.9402497386522555e-08
hypersensitive O 0 3.0105045425443677e-06
to O 0 2.808003216614452e-07
ionizing O 0 2.699258766369894e-05
radiation O 0 1.3857933481631335e-05
and O 0 8.220396807701036e-08
hydrogen O 0 8.450110158264579e-07
peroxide O 0 4.260917557985522e-05
. O 0 1.3373701222008094e-06

These O 0 2.0988964024581946e-06
results O 0 1.3137902215021313e-06
suggest O 0 3.2413254302809946e-07
that O 0 3.226979927717366e-08
BRCA1 O 0 1.3717531146539841e-05
participates O 0 2.0992075633330387e-07
, O 0 3.1569079794735444e-08
directly O 0 4.166522415971485e-08
or O 0 8.851774424556424e-08
indirectly O 0 1.5216456006328372e-07
, O 0 7.878095509283867e-09
in O 0 1.0893825397317869e-08
transcription O 0 1.7790869151212974e-06
- O 0 0.00082908890908584
coupled O 0 2.9719840313191526e-05
repair O 0 3.585343074519187e-05
of O 0 3.974298223852202e-08
oxidative O 0 8.62642173160566e-06
DNA O 0 2.4036524337134324e-05
damage O 0 3.0131011953926645e-05
. O 0 3.0748455515094975e-07
. O 0 1.721000558063679e-06

Truncation O 0 0.005172292236238718
mutations O 0 0.0015414057997986674
in O 0 3.439777458424942e-07
the O 0 1.1953993350743986e-07
transactivation O 0 1.8021049982053228e-05
region O 0 7.525202363467542e-07
of O 0 6.974444488605513e-08
PAX6 O 0 0.0001539848162792623
result O 0 7.932044354674872e-07
in O 0 1.2082946909686143e-07
dominant O 0 1.4376634680957068e-05
- O 0 0.00019985466497018933
negative O 0 8.03803777671419e-06
mutants O 0 4.9276521167485043e-05
. O 0 1.2223761132190702e-06

PAX6 O 0 0.004405319225043058
is O 0 2.141334789484972e-06
a O 0 2.6590683432914375e-07
transcription O 0 7.219626922960742e-07
factor O 0 8.395699069296825e-08
with O 0 8.878588531047171e-09
two O 0 8.47433909711981e-08
DNA O 0 5.2128921197436284e-06
- O 0 5.106700882606674e-06
binding O 0 2.614340530726622e-07
domains O 0 2.2711985536716384e-07
( O 0 2.55917651514892e-08
paired O 0 1.4741109453098034e-06
box O 0 1.2344306014711037e-05
and O 0 9.956652320397552e-07
homeobox O 0 5.2867735576001e-06
) O 0 2.2221367856900542e-08
and O 0 9.672494805101906e-09
a O 0 9.799703093449352e-08
proline O 0 1.015164434647886e-05
- O 0 1.8992841432918794e-05
serine O 0 5.137539119459689e-06
- O 0 2.887220398406498e-05
threonine O 0 2.9699041988351382e-05
( O 0 1.8793217293477937e-07
PST O 0 9.624633094063029e-06
) O 0 5.7547001830471345e-08
- O 0 2.0784814296348486e-06
rich O 0 3.6153943483441253e-07
transactivation O 0 8.204048754123505e-06
domain O 0 1.7453636473874212e-06
. O 0 1.2403440905472962e-06

PAX6 O 0 0.020083915442228317
regulates O 0 0.00045161900925450027
eye O 0 0.0008081629639491439
development O 0 6.940048820069933e-07
in O 0 8.847301558034815e-08
animals O 0 8.12200866562307e-08
ranging O 0 8.815213448087889e-08
from O 0 1.5062884273220334e-08
jellyfish O 0 1.0863722366138973e-07
to O 0 2.0881016027374244e-08
Drosophila O 0 2.3651688252357417e-07
to O 0 4.31685016621941e-08
humans O 0 3.2623049150970473e-07
. O 0 4.473037051866413e-07

Heterozygous O 0 0.30340030789375305
mutations O 0 0.0010738923447206616
in O 0 4.6013371957087656e-07
the O 0 9.165042058612016e-08
human O 0 2.5276548853980785e-07
PAX6 O 0 4.8400212108390406e-05
gene O 0 1.7424648603991955e-06
result O 0 1.358935719508736e-07
in O 0 2.1852377685149804e-08
various O 0 3.416062810401854e-08
phenotypes O 0 1.0352358913223725e-05
, O 0 4.862553382167789e-08
including O 0 2.6466665303814807e-07
aniridia B-Disease 1 1.0
, O 0 5.173245881451294e-05
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999994039535522
, O 0 6.391567694663536e-06
autosomal B-Disease 0 0.015436659567058086
dominant I-Disease 0 0.00020718992163892835
keratitis I-Disease 0 0.2537337839603424
, O 0 1.7976873323277687e-06
and O 0 7.68302743381355e-06
familial B-Disease 0 0.17161379754543304
foveal I-Disease 1 0.9929333925247192
dysplasia I-Disease 1 0.999995231628418
. O 0 3.471980744507164e-05

It O 0 1.1004804036929272e-05
is O 0 2.3920378566799627e-07
believed O 0 1.1222243045949654e-07
that O 0 3.6918816892494988e-09
the O 0 1.9504200921005577e-08
mutated O 0 4.8248048187815584e-06
allele O 0 1.2184550541860517e-06
of O 0 3.7474912062407384e-08
PAX6 O 0 2.373917232034728e-05
produces O 0 1.7461282197928085e-07
an O 0 7.596852036328983e-09
inactive O 0 2.6623595772434783e-07
protein O 0 4.055364115629345e-07
and O 0 1.2801829143427312e-06
aniridia B-Disease 1 0.9999998807907104
is O 0 2.0166460217296844e-06
caused O 0 1.23464155876718e-06
due O 0 7.49597219851239e-08
to O 0 1.5536355135736812e-07
genetic O 0 2.0311168555053882e-05
haploinsufficiency O 0 0.00014617167471442372
. O 0 2.329642711629276e-06

However O 0 1.2521228200057521e-05
, O 0 1.5715281165284978e-07
several O 0 3.26410933837451e-08
truncation O 0 2.2800106307840906e-05
mutations O 0 3.0913968657841906e-05
have O 0 5.134127150085988e-07
been O 0 5.163864784663019e-07
found O 0 7.80058613258916e-08
to O 0 2.0709668646645696e-08
occur O 0 1.1952004719262277e-08
in O 0 5.241280298662332e-09
the O 0 6.904664928697457e-08
C O 0 1.9830606106552295e-05
- O 0 1.1030219866370317e-05
terminal O 0 1.1679868521241588e-06
half O 0 4.4230922924271e-08
of O 0 8.875828072518743e-09
PAX6 O 0 7.378008376690559e-06
in O 0 2.629387836350361e-07
patients O 0 4.854408075516403e-07
with O 0 2.89617759108296e-07
Aniridia B-Disease 1 0.9999998807907104
resulting O 0 1.1647599649222684e-06
in O 0 1.064230215064299e-08
mutant O 0 5.775173121946864e-07
proteins O 0 1.1795716403639744e-08
that O 0 2.288562672703165e-09
retain O 0 1.2550033012814765e-08
the O 0 5.490635945903932e-09
DNA O 0 2.289850300485341e-07
- O 0 2.657293691754603e-07
binding O 0 5.791532586840731e-08
domains O 0 5.873811304013543e-08
but O 0 3.5836784206821903e-08
have O 0 1.181322630827708e-07
lost O 0 6.48268326131074e-07
most O 0 5.177985151760822e-09
of O 0 2.4679509547098633e-09
the O 0 5.512885437042314e-08
transactivation O 0 1.274527585337637e-05
domain O 0 1.85806436547864e-06
. O 0 1.2039517969242297e-06

It O 0 3.931477749574697e-06
is O 0 1.0437460673529131e-07
not O 0 1.105645441867864e-08
clear O 0 3.908520440631946e-08
whether O 0 7.200859908351731e-09
such O 0 8.43588843224552e-09
mutants O 0 2.9582695788121782e-05
really O 0 1.0436639286126592e-06
behave O 0 8.099236481484695e-08
as O 0 2.27572272137877e-08
loss O 0 1.619753788872913e-07
- O 0 9.92113655229332e-07
of O 0 1.6337512676045662e-08
- O 0 6.89324861014029e-06
function O 0 9.166266323745731e-08
mutants O 0 1.360145688522607e-06
as O 0 8.254176719901807e-08
predicted O 0 8.936473818721424e-07
by O 0 4.126693298189821e-08
haploinsufficiency O 0 2.987869447679259e-05
. O 0 1.5082467825777712e-06

Contrary O 0 1.88156063813949e-05
to O 0 1.3844226032233564e-07
this O 0 1.4094028166766748e-08
theory O 0 3.947170057472249e-08
, O 0 2.1896477520044755e-08
our O 0 7.994773731923033e-09
data O 0 9.967856584580659e-08
showed O 0 9.977040917874547e-07
that O 0 2.2299735391584363e-09
these O 0 2.813943966728516e-09
mutants O 0 6.8035444655834e-07
are O 0 3.2830764773450483e-09
dominant O 0 1.8107677135503764e-07
- O 0 3.6655826534115477e-06
negative O 0 1.199605463853004e-07
in O 0 1.0824915186447015e-08
transient O 0 7.720535677435691e-07
transfection O 0 9.727641554491129e-06
assays O 0 2.8646197733905865e-06
when O 0 1.326681342561642e-07
they O 0 2.536506649164494e-08
are O 0 5.469678487912688e-09
coexpressed O 0 6.031725092725537e-07
with O 0 2.6739748193449486e-08
wild O 0 1.0637055538609275e-06
- O 0 0.0001159786042990163
type O 0 1.0615475730446633e-05
PAX6 O 0 0.00017939996905624866
. O 0 2.865595206458238e-06

We O 0 1.2238119779794943e-05
found O 0 1.8317300032322237e-07
that O 0 5.91042281783416e-09
the O 0 1.2720537512223018e-08
dominant O 0 1.91942194760486e-06
- O 0 0.00016373425023630261
negative O 0 1.5530266637142631e-06
effects O 0 9.081946927835816e-07
result O 0 4.317360691175054e-08
from O 0 2.131348875167305e-09
the O 0 4.527332730930311e-09
enhanced O 0 1.4676049886475084e-07
DNA O 0 5.484902771968336e-07
binding O 0 5.7002971232122945e-08
ability O 0 3.544894511264829e-08
of O 0 1.0004137074304253e-08
these O 0 3.4640056156831633e-08
mutants O 0 9.079089977603871e-06
. O 0 7.508240855713666e-07

Kinetic O 0 4.516309127211571e-05
studies O 0 1.1177974101883592e-06
of O 0 4.087665317342726e-08
binding O 0 4.134430184876692e-07
and O 0 6.538046477544412e-07
dissociation O 0 2.059164398815483e-05
revealed O 0 3.3256183087360114e-06
that O 0 3.56009088875453e-09
various O 0 3.6035541217671607e-09
truncation O 0 2.0219688394718105e-06
mutants O 0 4.357669240562245e-06
have O 0 8.701717746362192e-08
3 O 0 6.666825669299214e-08
- O 0 2.2367150904756272e-06
5 O 0 1.9719593069567054e-07
- O 0 1.3371903833103715e-06
fold O 0 7.558206789326505e-07
higher O 0 1.2970562401903862e-08
affinity O 0 7.710085014878132e-09
to O 0 7.890332276438983e-10
various O 0 9.020104663193251e-10
DNA O 0 4.489173832666893e-08
- O 0 6.582597933402212e-08
binding O 0 1.4122848668307597e-08
sites O 0 2.1407899453151913e-08
when O 0 1.8859532602277795e-08
compared O 0 2.2810027644482034e-08
with O 0 2.9775415466559707e-09
the O 0 3.253722624663169e-08
wild O 0 2.3351635718427133e-06
- O 0 0.00011895572970388457
type O 0 7.262820417963667e-06
PAX6 O 0 0.0001712637604214251
. O 0 2.869599029509118e-06

These O 0 1.5373740325230756e-06
results O 0 4.936810569233785e-07
provide O 0 2.3002966642593492e-08
a O 0 2.964905299052134e-08
new O 0 1.1122916987460485e-07
insight O 0 1.5206590830985078e-07
into O 0 8.525614880738885e-09
the O 0 9.592172389716325e-09
role O 0 3.689489957992009e-08
of O 0 1.1912177022566084e-08
mutant O 0 7.395231932605384e-06
PAX6 O 0 3.5667169868247584e-05
in O 0 4.779288360623468e-07
causing O 0 8.757195246289484e-06
aniridia B-Disease 1 0.9999942779541016
. O 0 6.184675953591068e-07
. O 0 1.6921260339586297e-06

Reversal O 0 0.0015286972047761083
of O 0 1.3358722753764596e-05
severe O 1 0.9781613349914551
hypertrophic B-Disease 1 0.9999973773956299
cardiomyopathy I-Disease 1 1.0
and O 0 0.0004074414318893105
excellent O 0 1.006309139484074e-05
neuropsychologic O 0 0.0001271637447644025
outcome O 0 9.93270532489987e-07
in O 0 3.437616555856948e-07
very B-Disease 0 7.06814716977533e-07
- I-Disease 0 0.00401440542191267
long I-Disease 0 8.63550121721346e-06
- I-Disease 0 3.1123960070544854e-05
chain I-Disease 0 9.642521035857499e-06
acyl I-Disease 0 9.791161801331327e-07
- I-Disease 0 1.2630451919903862e-06
coenzyme I-Disease 0 1.8978199705088628e-06
A I-Disease 0 5.743203018937493e-06
dehydrogenase I-Disease 0 0.005598490126430988
deficiency I-Disease 0 0.11793173849582672
. O 0 3.2052637379820226e-06

Very B-Disease 0 2.542854599596467e-05
- I-Disease 0 0.0007354231202043593
long I-Disease 0 1.0257464964524843e-05
- I-Disease 0 5.56196719116997e-05
chain I-Disease 0 9.910178050631657e-06
acyl I-Disease 0 1.0105165983986808e-06
- I-Disease 0 7.128136303435895e-07
coenzyme I-Disease 0 3.236343388834939e-07
A I-Disease 0 2.42968155816925e-07
dehydrogenase I-Disease 0 1.1102099051640835e-05
( I-Disease 0 9.388862167725165e-07
VLCAD I-Disease 0 0.022508298978209496
) I-Disease 0 2.482408945070347e-06
deficiency I-Disease 0 6.176776514621451e-05
is O 0 4.629326255667365e-08
a O 0 2.730706455622567e-06
disorder O 0 0.010914834216237068
of O 0 5.113603762652019e-08
fatty O 0 3.7554266327788355e-06
acid O 0 7.070028118505434e-07
beta O 0 5.6628127964586383e-08
oxidation O 0 1.0563979202515839e-07
that O 0 3.235096102116586e-08
reportedly O 0 1.5689061001467053e-06
has O 0 9.442490522815206e-08
high O 0 2.6904152150564187e-07
rates O 0 4.692828383667802e-07
of O 0 1.759303991377692e-08
morbidity O 0 0.24891448020935059
and O 0 2.931280050688656e-06
mortality O 0 0.00024053001834545285
. O 0 1.2872468460045638e-06

We O 0 5.753575351263862e-06
describe O 0 6.324654009404185e-07
the O 0 2.367293916449853e-08
outcome O 0 4.8196170610026456e-08
of O 0 4.444248080659463e-09
a O 0 1.2980021324437985e-07
5 O 0 3.2953187201201217e-07
- O 0 4.710198936663801e-06
year O 0 5.738642272490324e-08
- O 0 2.0292400222388096e-06
old O 0 9.340500582766254e-06
girl O 0 0.0008158529526554048
with O 0 1.4336835192807484e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.1625120300304843e-06
was O 0 4.134684786549769e-06
first O 0 9.465102834838035e-08
seen O 0 5.597719336947193e-07
at O 0 5.446486994742372e-08
5 O 0 4.1258587657466705e-08
months O 0 2.997864356757418e-08
of O 0 5.409864112237983e-09
age O 0 1.3077607263767277e-07
with O 0 1.3874932847102173e-06
severe O 1 0.9965659976005554
hypertrophic B-Disease 1 0.9999982118606567
cardiomyopathy I-Disease 1 1.0
, O 0 0.037579260766506195
hepatomegaly B-Disease 1 1.0
, O 0 0.003154807025566697
encephalopathy B-Disease 0 0.2662017047405243
, O 0 2.39756019482229e-07
and O 0 1.4188181012286805e-06
hypotonia B-Disease 0 0.046636100858449936
. O 0 3.874702542816522e-06

Biochemical O 0 0.0014321287162601948
studies O 0 0.00024571784888394177
indicated O 1 0.9776180386543274
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 9.123558993451297e-05
by O 0 9.710078074931516e-08
a O 0 1.6065235968198976e-06
stable O 0 5.3082167141838e-05
yet O 0 1.1448312307038577e-06
inactive O 0 4.51989444627543e-06
enzyme O 0 4.8188085202127695e-06
. O 0 1.408140747116704e-06

Molecular O 0 9.334901551483199e-05
genetic O 0 1.6982638044282794e-05
analysis O 0 4.922016501041071e-07
of O 0 5.338341679816949e-08
her O 0 8.135571079037618e-06
VLCAD O 0 0.01096605509519577
gene O 0 5.133293143444462e-06
revealed O 0 4.319240815675585e-06
a O 0 3.0027632647033897e-07
T1372C O 0 1.4381351320480462e-05
( O 0 1.0742092371174294e-07
F458L O 0 4.1802486521191895e-06
) O 0 1.8451706296218617e-07
missense O 0 5.2507919463096187e-05
mutation O 0 3.390576466699713e-06
and O 0 1.3252322617063328e-07
a O 0 2.338184913242003e-06
1668 O 0 0.02027874067425728
ACAG O 0 0.0009480476146563888
1669 O 0 7.22604090697132e-05
splice O 0 0.0002849666925612837
site O 0 7.091667066561058e-05
mutation O 0 4.8007779696490616e-05
. O 0 2.722941417232505e-06

After O 0 1.272717781830579e-05
initial O 0 1.9203064312023344e-06
treatment O 0 7.600158369314158e-07
with O 0 7.346122998797e-08
intravenous O 0 4.155435090069659e-05
glucose O 0 0.0024728854186832905
and O 0 3.985936416484037e-07
carnitine O 0 2.3150919332692865e-06
, O 0 2.121397102428091e-08
the O 0 3.3622548301082134e-08
patient O 0 6.51322181965952e-07
has O 0 1.7887604997213202e-07
thrived O 0 3.0915467164049915e-07
on O 0 1.348743552398446e-07
a O 0 1.5025071320451389e-07
low O 0 3.234206815250218e-06
- O 0 6.66141295369016e-06
fat O 0 3.3318849546049023e-06
diet O 0 1.1169582592174265e-07
supplemented O 0 4.782776485967588e-08
with O 0 6.064125201987736e-09
medium O 0 2.0005445833248814e-07
- O 0 4.4739508666680194e-06
chain O 0 8.066234840953257e-06
triglyceride O 0 2.3783470624039182e-06
oil O 0 3.682895908241335e-07
and O 0 2.860014802763544e-08
carnitine O 0 7.326700028897903e-07
and O 0 3.657079616914416e-08
avoidance O 0 1.2903281003673328e-06
of O 0 1.356060295165662e-07
fasting O 0 3.840889985440299e-05
. O 0 8.51490767672658e-07

Her O 0 0.0035018688067793846
ventricular O 1 0.9290513396263123
hypertrophy O 0 0.029290949925780296
resolved O 0 2.2201400497579016e-05
significantly O 0 4.890596301265759e-06
over O 0 1.9606368084623682e-07
1 O 0 6.440773745453043e-07
year O 0 1.4824412630787265e-07
, O 0 7.675241420201928e-08
and O 0 9.242631335837359e-07
cognitively O 0 1.3665120604855474e-05
, O 0 1.139479408607258e-07
she O 0 1.2119593293391517e-06
is O 0 5.501202604563105e-09
in O 0 6.194128765457663e-09
the O 0 3.376573332047883e-08
superior O 0 6.293126944001415e-07
range O 0 2.6374596018285956e-07
for O 0 3.887183197548438e-08
age O 0 6.639396588070667e-07
. O 0 5.163323066881276e-07

Clinical O 0 0.0001978973887162283
recognition O 0 2.208123441960197e-05
of O 0 6.016440238454379e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.3086550982043264e-07
important O 0 3.2839736263667874e-08
because O 0 5.723404328250581e-08
it O 0 4.1963829744418035e-08
is O 0 9.811406798121425e-09
one O 0 6.097853333386638e-09
of O 0 1.8310124527687321e-09
the O 0 3.681420324141982e-08
few O 0 4.4121472342339985e-07
directly O 0 6.983761977608083e-07
treatable O 0 4.1647825128166005e-05
causes O 0 5.914761800340784e-07
of O 0 3.5885011584468884e-07
cardiomyopathy B-Disease 1 1.0
in O 0 6.015220151311951e-06
children O 0 7.586879746668274e-06
. O 0 2.3732394538455992e-07
. O 0 9.135822551797901e-07

Cloning O 0 1.1323776561766863e-05
of O 0 1.0770630609613363e-07
a O 0 2.814810500240128e-07
novel O 0 1.40953659411025e-06
member O 0 8.095931036677939e-08
of O 0 6.387790740802757e-09
the O 0 8.05027582373441e-08
low O 0 1.1036669093300588e-05
- O 0 1.5289146176655777e-05
density O 0 4.165226528130006e-06
lipoprotein O 0 5.0284506869502366e-05
receptor O 0 3.2143548196472693e-06
family O 0 2.833001417457126e-06
. O 0 1.375430656480603e-06

A O 0 8.194978363462724e-06
gene O 0 4.514944521361031e-06
encoding O 0 1.3419453352980781e-06
a O 0 8.5835563368164e-07
novel O 0 2.958563982247142e-06
transmembrane O 0 2.358281790293404e-06
protein O 0 2.302716893609613e-06
was O 0 7.329835625569103e-06
identified O 0 3.59977804009759e-07
by O 0 6.280389985846568e-09
DNA O 0 1.6427354410097905e-07
sequence O 0 5.1825132629801374e-08
analysis O 0 1.1020850898546541e-08
within O 0 4.313251533716311e-09
the O 0 4.6429082800614196e-08
insulin B-Disease 0 0.0014850934967398643
- I-Disease 1 0.7906063199043274
dependent I-Disease 0 0.3434324562549591
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.2088313269487116e-05
IDDM B-Disease 0 0.00045270624104887247
) O 0 2.244408676688181e-07
locus O 0 7.049311079754261e-06
IDDM4 O 0 8.924399298848584e-05
on O 0 6.079871582187479e-06
chromosome O 0 0.0008179523283615708
11q13 O 0 9.0337052824907e-05
. O 0 3.841413217742229e-06

Based O 0 8.752286703384016e-06
on O 0 5.211194320509094e-07
its O 0 9.562600666868093e-08
chromosomal O 0 0.00034923007478937507
position O 0 3.865738108288497e-06
, O 0 2.660945064292264e-08
this O 0 5.529247282254346e-09
gene O 0 7.087141540296216e-08
is O 0 1.4878766663173337e-08
a O 0 3.483279087390656e-08
candidate O 0 2.095167559446054e-07
for O 0 2.0462382011032787e-08
conferring O 0 1.8181840459874365e-06
susceptibility O 0 0.00020566824241541326
to O 0 5.499754479387775e-06
diabetes B-Disease 0 0.4183705747127533
. O 0 8.627548595541157e-06

The O 0 2.7587641397985863e-06
gene O 0 4.939810423820745e-06
, O 0 8.711299415153917e-08
termed O 0 1.8141466853194288e-06
low O 0 9.868135748547502e-06
- O 0 1.2042771231790539e-05
density O 0 1.9368278572073905e-06
lipoprotein O 0 1.420766693627229e-05
receptor O 0 5.214977818468469e-07
related O 0 8.183399557992743e-08
protein O 0 5.030902912039892e-07
5 O 0 3.508865802359651e-07
( O 0 6.53180833865008e-08
LRP5 O 0 2.6276553398929536e-05
) O 0 1.4213187071732136e-08
, O 0 3.937378423302107e-09
encodes O 0 2.6992578838758163e-08
a O 0 1.2526787607214374e-08
protein O 0 9.040660131631739e-08
of O 0 1.4556294836154393e-08
1615 O 0 1.0165420462726615e-05
amino O 0 1.1565055757500886e-07
acids O 0 2.9393868672400458e-08
that O 0 1.7078211067556026e-09
contains O 0 7.722330330750538e-09
conserved O 0 8.009826046873059e-08
modules O 0 3.1188830007522483e-07
which O 0 1.6327800267390558e-07
are O 0 2.473955040827036e-09
characteristic O 0 3.6034663253303734e-08
of O 0 3.2457685428255445e-09
the O 0 4.2809940481447484e-08
low O 0 7.972580533532891e-06
- O 0 3.785407534451224e-05
density O 0 2.8570475478773005e-05
lipoprotein O 0 0.008946279995143414
( O 0 5.469983648254129e-07
LDL O 0 4.840478504775092e-05
) O 0 1.721333973137007e-07
receptor O 0 1.188126930173894e-06
family O 0 1.6328608580806758e-06
. O 0 1.3735457287111785e-06

These O 0 2.2374276795744663e-06
modules O 0 1.1907916359632509e-06
include O 0 9.556711688674113e-08
a O 0 4.78490278510435e-07
putative O 0 1.5339777746703476e-05
signal O 0 1.5805198927409947e-05
peptide O 0 1.869204737658947e-07
for O 0 1.7283349196262066e-09
protein O 0 2.2079243322536968e-08
export O 0 1.0214574075462224e-08
, O 0 4.8651020989609606e-09
four O 0 1.3049124447661598e-08
epidermal O 0 1.0308981472917367e-06
growth O 0 4.6669873654536786e-07
factor O 0 1.2784757075223752e-07
( O 0 5.330283414650694e-08
EGF O 0 1.5055178437251016e-06
) O 0 2.7714765593600532e-08
repeats O 0 7.382889180007624e-07
with O 0 2.1998745936002706e-08
associated O 0 2.9486727726180106e-07
spacer O 0 2.903746280935593e-05
domains O 0 7.340981937886681e-07
, O 0 4.048589374860967e-08
three O 0 6.387318052247792e-08
LDL O 0 1.3150011909601744e-05
- O 0 6.42300574327237e-06
receptor O 0 8.365797157239285e-07
( O 0 4.84517634902204e-08
LDLR O 0 6.136024239822291e-06
) O 0 2.4691434674650736e-08
repeats O 0 5.819980515298084e-07
, O 0 1.0397577909770916e-08
a O 0 3.140728210837551e-08
single O 0 1.068309870788653e-06
transmembrane O 0 2.9100010578986257e-07
spanning O 0 3.263587018409453e-07
domain O 0 1.2033120810883702e-07
, O 0 3.108089074999043e-08
and O 0 2.2592235637830527e-08
a O 0 7.543604141346805e-08
cytoplasmic O 0 3.3519254429847933e-06
domain O 0 1.3810088148602517e-06
. O 0 7.01613942055701e-07

The O 0 1.7497984572401037e-06
encoded O 0 1.3134882692611427e-06
protein O 0 1.948170847754227e-06
has O 0 1.1439369984600489e-07
a O 0 2.6207652936705017e-08
unique O 0 2.6998344893058857e-08
organization O 0 1.3954186250941802e-08
of O 0 9.684125501507879e-09
EGF O 0 3.963484232372139e-06
and O 0 1.831181606348764e-07
LDLR O 0 5.1880968385376036e-05
repeats O 0 3.6770632050320273e-06
; O 0 4.223982585926933e-08
therefore O 0 1.5510766004922516e-08
, O 0 5.745045772442836e-09
LRP5 O 0 6.539582500408869e-06
likely O 0 6.64377353132295e-08
represents O 0 6.473895641789795e-09
a O 0 9.752783469707538e-09
new O 0 2.3391161008134986e-08
category O 0 8.758782854556557e-08
of O 0 6.150417064532121e-09
the O 0 1.272877057090227e-07
LDLR O 0 0.0002734118315856904
family O 0 2.7306543870508904e-06
. O 0 1.4430619330596528e-06

Both O 0 6.3703364503453486e-06
human O 0 9.895519497149508e-07
and O 0 3.287170500243519e-07
mouse O 0 3.1904557545203716e-05
LRP5 O 0 9.635568130761385e-05
cDNAs O 0 1.2589115613081958e-05
have O 0 4.4222150563655305e-07
been O 0 1.301275460718898e-07
isolated O 0 5.336901267583016e-07
and O 0 5.924014345737305e-08
the O 0 7.166058413332621e-09
encoded O 0 8.804391171679526e-08
mature O 0 2.862361370148392e-08
proteins O 0 6.76736888749474e-09
are O 0 2.051900427346709e-09
95 O 0 3.934564674068497e-08
% O 0 1.945463701247263e-08
identical O 0 1.8274621993441542e-07
, O 0 5.6971991568843805e-08
indicating O 0 3.1406537459588435e-07
a O 0 1.0987860576960884e-07
high O 0 4.400674811222416e-07
degree O 0 2.4838191947651467e-08
of O 0 3.523933811422353e-09
evolutionary O 0 2.624014712182543e-07
conservation O 0 1.3020189726375975e-07
. O 0 8.488137837048271e-08
. O 0 5.614357405647752e-07

The O 0 6.256693268369418e-06
APC B-Disease 0 2.5261335395043716e-05
variants O 0 3.2792718229757156e-06
I1307K O 0 6.68506163492566e-06
and O 0 1.6622642817765154e-07
E1317Q O 0 2.1477608243003488e-06
are O 0 3.213883914554572e-08
associated O 0 2.413555421298952e-06
with O 1 0.7664772868156433
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.3423197490046732e-05
but O 0 1.8316775651783246e-07
not O 0 2.1525449866999224e-08
always O 0 4.0635978137970596e-08
with O 0 4.675564824196954e-09
a O 0 3.9562644360557897e-07
family O 0 1.1447427823441103e-06
history O 0 4.011758392152842e-07
. O 0 6.125682148194755e-07

Classical O 0 0.24888616800308228
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.008484103716909885
FAP B-Disease 0 0.0009158209431916475
) O 0 4.3045994857493497e-07
is O 0 2.7777584676869083e-08
a O 0 3.8682424019498285e-07
high O 0 0.0005164526519365609
- O 1 0.9999407529830933
penetrance O 1 0.9994358420372009
autosomal B-Disease 1 0.9996650218963623
dominant I-Disease 1 0.5426599383354187
disease I-Disease 0 0.0013134123291820288
that O 0 5.5406307097882745e-08
predisposes O 0 2.754886281763902e-06
to O 0 5.0643148341578126e-08
hundreds O 0 5.2904777447793094e-08
or O 0 5.201497188522808e-08
thousands O 0 1.264735942640982e-07
of O 0 1.8287142665940337e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9971965551376343
carcinoma I-Disease 1 1.0
and O 0 2.2989728677202947e-05
that O 0 1.5689599308643665e-07
results O 0 3.8820823533569637e-07
from O 0 2.5113438439916536e-08
truncating O 0 1.302244436374167e-05
mutations O 0 5.495905497809872e-06
in O 0 3.7176331346699953e-08
the O 0 2.4579514956712956e-07
APC B-Disease 0 8.798431736067869e-06
gene O 0 5.668000540026696e-06
. O 0 1.64703817517875e-06

A O 0 3.3053049264708534e-05
variant O 0 0.00012061375309713185
of O 0 1.6495658883286524e-06
FAP B-Disease 0 0.00029923749389126897
is O 0 5.742973371525295e-06
attenuated B-Disease 1 0.9688483476638794
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
, O 0 2.597124421299668e-06
which O 0 2.2042434011382284e-07
results O 0 7.52930162661869e-08
from O 0 1.2085143552553745e-08
germ O 0 1.5910411093500443e-05
- O 0 0.0010294645326212049
line O 0 0.007590756751596928
mutations O 0 6.740248750247702e-07
in O 0 1.2527170412113264e-08
the O 0 3.0856433852477494e-08
5 O 0 3.3724677450663876e-07
and O 0 1.5571212941267731e-07
3 O 0 1.3659207809268992e-07
regions O 0 2.2651002851148405e-08
of O 0 5.231173272335354e-09
the O 0 1.1343811934239056e-07
APC B-Disease 0 8.29860073281452e-06
gene O 0 3.0392739063245244e-06
. O 0 1.3948351806902792e-06

Attenuated B-Disease 1 0.9999197721481323
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 1.0
patients O 0 0.38211169838905334
have O 0 6.121242677181726e-06
" O 0 5.507201876753243e-06
multiple O 0 0.00014345218369271606
" O 1 0.9996234178543091
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.0064463822345715e-06
typically O 0 8.691168318364362e-08
fewer O 0 1.3025326595084152e-08
than O 0 3.311010354778432e-09
100 O 0 1.3514855901064493e-08
) O 0 4.1200687306286454e-09
without O 0 8.867351297681125e-09
the O 0 5.651828516306523e-08
florid O 0 0.0026498790830373764
phenotype O 0 4.690101195592433e-05
of O 0 2.221874062513507e-08
classical O 0 1.3190480103730806e-06
FAP B-Disease 0 3.550481051206589e-05
. O 0 1.4584079508495051e-06

Another O 0 1.7197329725604504e-05
group O 0 3.08622566080885e-06
of O 0 5.400547209433171e-08
patients O 0 5.943378482697881e-07
with O 0 3.493645550634028e-08
multiple O 0 1.3036361451668199e-05
adenomas B-Disease 0 0.010777548886835575
has O 0 8.080724910541903e-06
no O 0 2.572196819983219e-07
mutations O 0 8.990489277493907e-07
in O 0 6.570114674531169e-09
the O 0 5.210205245020916e-08
APC B-Disease 0 6.062023203412537e-07
gene O 0 1.7373496064010396e-07
, O 0 4.219368676672275e-08
and O 0 7.815359026608348e-08
their O 0 8.070770007861938e-08
phenotype O 0 3.480546729406342e-05
probably O 0 5.017519697503303e-07
results O 0 3.62802481390645e-08
from O 0 3.6007645753954876e-09
variation O 0 7.035134217403538e-07
at O 0 1.5905274608485342e-07
a O 0 3.5908701079279126e-07
locus O 0 1.2542477634269744e-05
, O 0 1.7874205582302238e-07
or O 0 1.324668659208328e-07
loci O 0 2.202461359956942e-07
, O 0 1.0969282371320332e-08
elsewhere O 0 2.6508489625598486e-08
in O 0 1.5792151586424552e-08
the O 0 1.0542220252318657e-07
genome O 0 4.1158714338962454e-06
. O 0 6.340652021208371e-07

Recently O 0 0.0005706207593902946
, O 0 7.79905178660556e-07
however O 0 7.404473478800355e-08
, O 0 1.5977084544260833e-08
a O 0 1.2236328927883733e-07
missense O 0 3.285314960521646e-05
variant O 0 1.0028984434029553e-05
of O 0 1.557204427626857e-07
APC B-Disease 0 1.968304241017904e-05
( O 0 7.170258697897225e-08
I1307K O 0 2.814997969835531e-06
) O 0 7.043277605589537e-08
was O 0 2.6758020794659387e-06
described O 0 3.935030576940335e-07
that O 0 1.5314629564500137e-08
confers O 0 1.0816869888685687e-07
an O 0 1.5187278989969855e-08
increased O 0 2.0351762941572815e-06
risk O 0 7.495159024983877e-06
of O 0 0.013152248226106167
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.2360293339952477e-06
including O 0 9.64203294984145e-08
multiple O 0 1.2132188203395344e-05
adenomas B-Disease 0 0.00187738798558712
, O 0 2.263371214894505e-07
in O 0 3.44727823176072e-07
Ashkenazim O 0 0.00015454924141522497
. O 0 1.6015977735150955e-06

We O 0 2.027830487350002e-05
have O 0 1.6734144026031572e-07
studied O 0 4.1848647214237644e-08
a O 0 2.0656411692243637e-08
set O 0 1.9764100045449595e-07
of O 0 1.4214162291636967e-08
164 O 0 7.141784408304375e-06
patients O 0 8.289547395179397e-07
with O 0 1.1124461707368027e-06
multiple O 1 0.9992824196815491
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.013321173377335072
/ I-Disease 1 0.7620065212249756
or I-Disease 0 0.0020232785027474165
carcinoma I-Disease 1 1.0
and O 0 9.771007171366364e-06
analyzed O 0 7.36664605938131e-06
codons O 0 8.710801921552047e-06
1263 O 0 4.511298902798444e-05
- O 0 3.0923638405511156e-05
1377 O 0 1.6502755897818133e-05
( O 0 8.925982086793738e-08
exon O 0 3.276102688687388e-06
15G O 0 7.829599780961871e-06
) O 0 1.9097866399420127e-08
of O 0 3.4627882783411223e-09
the O 0 2.2697451029785043e-08
APC B-Disease 0 6.748397822775587e-07
gene O 0 1.865950594037713e-07
for O 0 1.9388847860568603e-08
germ O 0 2.6599725970299914e-05
- O 0 8.287871605716646e-05
line O 0 5.054407301940955e-05
variants O 0 4.743511453852989e-06
. O 0 2.2338244889397174e-06

Three O 0 3.660911897895858e-05
patients O 0 7.371748779405607e-06
with O 0 5.1184631644218825e-08
the O 0 9.064660844160244e-08
I1307K O 0 1.088448152586352e-05
allele O 0 3.6247681691747857e-06
were O 0 8.163411848727264e-07
detected O 0 9.41261987463804e-07
, O 0 7.392659373550714e-09
each O 0 3.569092577038191e-09
of O 0 1.937756977099525e-08
Ashkenazi O 0 0.00010647169983712956
descent O 0 2.70301679847762e-05
. O 0 9.210031635120686e-07

Four O 0 0.00011103323777206242
patients O 0 3.0469636840280145e-05
had O 0 2.5941094463632908e-06
a O 0 4.904365482616413e-07
germ O 0 0.00017294086865149438
- O 0 0.00016831602260936052
line O 0 6.130448309704661e-05
E1317Q O 0 4.699246801465051e-06
missense O 0 8.056724254856817e-06
variant O 0 1.4055418660063879e-06
of O 0 4.065024583610466e-08
APC O 0 2.8922268029418774e-06
that O 0 1.5061684166539635e-07
was O 0 9.960075840353966e-05
not O 0 2.3967617224229798e-08
present O 0 5.534491531733465e-09
in O 0 2.397374387896889e-08
controls O 0 4.584851558320224e-05
; O 0 3.559974572908686e-07
one O 0 8.507113236078112e-09
of O 0 1.624552714574179e-09
these O 0 5.496084476419583e-09
individuals O 0 3.167358597622183e-09
had O 0 4.745158719288156e-07
an O 0 4.018338106703823e-09
unusually O 0 2.5107556211878546e-07
large O 0 7.650493571986772e-09
number O 0 4.24442125890323e-09
of O 0 7.363992082787263e-09
metaplastic B-Disease 0 4.5398039219435304e-05
polyps I-Disease 0 1.0938466402876657e-05
of I-Disease 0 6.99874824761082e-09
the I-Disease 0 1.0336896139051532e-07
colorectum I-Disease 0 4.240620182827115e-05
. O 0 1.1459355846454855e-06

There O 0 7.044740868877852e-06
is O 0 7.63970646744383e-08
increasing O 0 3.809178394931223e-08
evidence O 0 1.804105131952838e-08
that O 0 1.162764551310147e-08
there O 0 9.564366187930773e-09
exist O 0 2.2464059057369923e-08
germ O 0 5.720135959563777e-06
- O 0 1.982935646083206e-05
line O 0 1.0018756256613415e-05
variants O 0 8.139222273939595e-08
of O 0 3.313379348668377e-09
the O 0 3.009838778211815e-08
APC B-Disease 0 5.720178819501598e-07
gene O 0 1.7541815111599135e-07
that O 0 1.6530725233110388e-08
predispose O 0 1.3829024680944713e-07
to O 0 7.743835794826737e-09
the O 0 6.326123624944557e-09
development O 0 9.531841094201354e-09
of O 0 9.453302851625267e-08
multiple O 1 0.9984965324401855
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9984040856361389
carcinoma I-Disease 1 1.0
, O 0 3.614898332671146e-06
but O 0 7.111827216021993e-08
without O 0 1.3523468567200325e-08
the O 0 4.312093793146232e-08
florid O 0 0.011134443804621696
phenotype O 0 5.8447625633561984e-05
of O 0 1.1334139848884206e-08
classical O 0 2.5329103436888545e-07
FAP B-Disease 0 3.032313998119207e-06
, O 0 2.156411937903613e-08
and O 0 1.4698692929471235e-08
possibly O 0 2.3509601376758837e-08
with O 0 9.877425100057735e-09
importance O 0 3.629970422025508e-07
for O 0 0.06656088680028915
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 7.586720585095463e-06
in O 0 2.1740088840260796e-08
the O 0 2.2081939832219177e-08
general O 0 2.037102575513927e-08
population O 0 4.6193857627940815e-08
. O 0 6.901385773971924e-08
. O 0 5.827061499985575e-07

Genomic O 0 0.00013306060282047838
structure O 0 6.704458428430371e-06
of O 0 2.6995854796041385e-07
the O 0 3.4249369491590187e-06
human O 0 0.019887650385499
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999997615814209
diarrhea I-Disease 1 1.0
( O 0 6.729112647008151e-05
CLD B-Disease 0 0.0293524581938982
) O 0 7.548900384790613e-07
gene O 0 1.0840341019502375e-05
. O 0 2.9268608159327414e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999996423721313
diarrhea I-Disease 1 1.0
( O 0 0.0015781950205564499
CLD B-Disease 1 0.9212451577186584
) O 0 1.9872636585205328e-06
is O 0 2.3225165080020815e-07
caused O 0 1.8525455516282818e-06
by O 0 5.42920766122279e-08
mutations O 0 3.507471546981833e-06
in O 0 2.690432410190624e-08
a O 0 6.748500709363725e-07
gene O 0 1.8255162785862922e-06
which O 0 3.694169947721093e-07
encodes O 0 1.8775763237499632e-06
an O 0 1.0787216524477117e-06
intestinal O 0 0.01486214715987444
anion O 0 4.084780448465608e-05
transporter O 0 0.000646421336568892
. O 0 4.4775192691304255e-06

We O 0 3.3827203878900036e-05
report O 0 8.031256584217772e-07
here O 0 2.150197886408023e-08
the O 0 1.5620139848238068e-08
complete O 0 8.383665317523992e-08
genomic O 0 2.392955025243282e-07
organization O 0 2.3588745179381476e-08
of O 0 2.329622272867482e-09
the O 0 3.238368151414761e-08
human O 0 4.048266077916196e-07
CLD B-Disease 0 9.133420826401561e-05
gene O 0 7.465316116395115e-07
which O 0 1.9475564272397605e-07
spans O 0 1.9118695036013378e-06
approximately O 0 1.2131256710290472e-07
39kb O 0 5.531076567422133e-06
, O 0 6.866682866757401e-08
and O 0 4.888209303999247e-08
comprises O 0 1.29335106180406e-07
21 O 0 1.0150704383704579e-06
exons O 0 3.5039654903812334e-05
. O 0 4.162359346082667e-06

All O 0 4.204581273370422e-06
exon O 0 8.626413909951225e-05
/ O 0 5.340982897905633e-05
intron O 0 0.0001951189333340153
boundaries O 0 4.39307814303902e-06
conform O 0 1.004088971967576e-06
to O 0 6.838764221583915e-08
the O 0 2.446515452447784e-07
GT O 0 0.00012640331988222897
/ O 0 0.0003697867796290666
AG O 0 0.1390366405248642
rule O 0 3.183709623044706e-06
. O 0 1.4490747162199114e-06

An O 0 1.630094402571558e-06
analysis O 0 3.167291140471207e-07
of O 0 2.020247613643278e-08
the O 0 5.428275429153473e-08
putative O 0 7.036724127829075e-06
promoter O 0 6.649048827966908e-06
region O 0 3.167940860748786e-07
sequence O 0 1.560616453843977e-07
shows O 0 3.325664579278964e-07
a O 0 3.154895011903136e-07
putative O 0 2.8027294320054352e-05
TATA O 0 1.5783283743076026e-05
box O 0 2.657149480000953e-06
and O 0 1.768405013535812e-07
predicts O 0 1.3472025557348388e-06
multiple O 0 1.1703144053853975e-07
transcription O 0 7.7227008432601e-07
factor O 0 1.3833484047154343e-07
binding O 0 3.8799097978881036e-07
sites O 0 1.4419256331166252e-06
. O 0 1.4306880302683567e-06

The O 0 1.4006845958647318e-06
genomic O 0 4.214899036014685e-06
structure O 0 1.2087492677892442e-06
was O 0 1.6924536794249434e-06
determined O 0 3.600381859314439e-08
using O 0 1.9400832940164037e-08
DNA O 0 7.770395313855261e-07
from O 0 3.6501648370546036e-09
several O 0 2.2390131970695393e-09
sources O 0 5.040471151573911e-09
including O 0 1.9145232066364315e-09
multiple O 0 2.3389242542748434e-08
large O 0 4.3031629815004635e-08
- O 0 3.937496330763679e-06
insert O 0 1.4400703548744787e-05
libaries O 0 6.997162017796654e-06
and O 0 3.144732474424927e-08
genomic O 0 3.7188107171459706e-07
DNA O 0 8.314733577208244e-07
from O 0 7.44516057693545e-08
Finnish O 0 0.0005848098662681878
CLD B-Disease 0 0.05049445480108261
patients O 0 2.8768770334863802e-06
and O 0 2.0478397289025452e-07
controls O 0 1.5093090951268096e-05
. O 0 1.4352251582749886e-06

Exon O 0 0.00030535069527104497
- O 0 7.504883978981525e-05
specific O 0 4.452136579402577e-07
primers O 0 1.113191137847025e-05
developed O 0 5.897418873246352e-07
in O 0 1.9424232888809456e-08
this O 0 5.662097457559412e-09
study O 0 7.257419554207445e-09
will O 0 4.566001354788796e-09
facilitate O 0 4.349048410290379e-08
mutation O 0 2.629618620630936e-07
screening O 0 7.220997844115118e-08
studies O 0 2.0628339925110595e-08
of O 0 1.4301075879075142e-08
patients O 0 2.2354646489475272e-07
with O 0 8.443554833093003e-08
the O 0 1.1272371011727955e-05
disease O 0 0.0002629160007927567
. O 0 1.6382656440327992e-06

Genomic O 0 7.030392589513212e-05
sequencing O 0 5.150446213519899e-06
of O 0 1.577553945253385e-07
a O 0 7.243440336424101e-07
BAC O 0 0.0001237093674717471
clone O 0 0.0009656749898567796
H O 1 0.9999998807907104
_ O 0 6.055170729268866e-07
RG364P16 O 0 2.0371703612909187e-06
revealed O 0 7.170538083300926e-07
the O 0 6.873126956463693e-09
presence O 0 7.318331274319689e-09
of O 0 1.4263312753115542e-09
another O 0 4.4889766570577194e-08
, O 0 1.206386368579615e-08
highly O 0 8.52811954388244e-09
homologous O 0 8.199226186889064e-08
gene O 0 1.0666001060144481e-07
3 O 0 4.742317472050672e-08
of O 0 4.332115555172322e-09
the O 0 1.5109664275314572e-07
CLD B-Disease 0 0.0002393707982264459
gene O 0 4.2154434254371154e-07
, O 0 1.2570589014160305e-08
with O 0 2.6694686461326e-09
a O 0 2.9280110780405266e-08
similar O 0 5.363867927599131e-08
genomic O 0 2.6824298515748524e-07
structure O 0 3.763903180242778e-07
, O 0 2.6198206271033087e-08
recently O 0 2.2647553521437658e-07
identified O 0 1.5640328854260588e-07
as O 0 7.671743418313781e-08
the O 0 2.5857612854451872e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 4.8129255446838215e-05
( O 0 6.962720817682566e-07
PDS B-Disease 0 3.867500709020533e-05
) O 0 1.1339993477577082e-07
. O 0 8.76304397934291e-08
. O 0 1.0467659876667312e-06

The O 0 9.084199518838432e-06
APCI1307K O 0 0.000700242817401886
allele O 0 0.00012204288941575214
and O 0 7.903586265456397e-06
cancer B-Disease 0 7.208310853457078e-05
risk O 0 3.8154689718794543e-07
in O 0 1.105615865526488e-08
a O 0 1.9704177134372003e-07
community O 0 7.713251193308679e-08
- O 0 3.87702039006399e-06
based O 0 9.126473088372222e-08
study O 0 2.6013921683443186e-08
of O 0 2.2692471901564204e-08
Ashkenazi O 0 3.471324816928245e-05
Jews O 0 2.248482360300841e-06
. O 0 7.600796720907965e-07

Mutations O 0 0.041559163480997086
in O 0 1.895475747915043e-06
APC O 0 2.100423807860352e-05
are O 0 1.4723153185514093e-07
classically O 0 0.0012792885536327958
associated O 0 2.009756281040609e-05
with O 0 0.0002342353982385248
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 8.823549433145672e-05
FAP B-Disease 0 6.202730583027005e-05
) O 0 9.130285860692311e-08
, O 0 3.5891098093543405e-08
a O 0 9.395329243488959e-07
highly O 0 0.0010950675932690501
penetrant O 1 0.9999852180480957
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
disorder I-Disease 1 1.0
characterized O 0 0.0008581340662203729
by O 0 9.655630037741503e-07
multiple O 0 0.0061676944606006145
intestinal O 1 0.9983420372009277
polyps B-Disease 1 0.7531024217605591
and O 0 1.3447752280626446e-06
, O 0 3.866419717724057e-08
without O 0 1.405480798410963e-08
surgical O 0 4.09171707360656e-06
intervention O 0 1.5478381953926146e-07
, O 0 8.247421412477252e-09
the O 0 1.2354615108733924e-08
development O 0 1.407982068712954e-07
of O 0 0.0021942798048257828
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.752187123813201e-06
CRC B-Disease 0 0.0001554537593619898
) O 0 3.205262260053132e-07
. O 0 7.665956900382298e-07

APC B-Disease 0 0.0007486800896003842
is O 0 3.1461624985240633e-06
a O 0 6.757930350431707e-06
tumour O 1 0.9999998807907104
- O 0 0.0012992839328944683
suppressor O 0 0.00034352095099166036
gene O 0 2.6017801246780436e-06
, O 0 1.173848858115889e-07
and O 0 1.9879942669831507e-07
somatic O 0 8.984259693534113e-06
loss O 0 2.0919120288453996e-05
occurs O 0 3.550169822119642e-06
in O 0 7.61898581913556e-06
tumours B-Disease 1 1.0
. O 0 1.937921842909418e-05

The O 0 9.00310988072306e-06
germline O 0 0.0001220772392116487
T O 0 0.00012009603960905224
- O 0 2.223278670498985e-06
to O 0 3.170811879726898e-08
- O 0 1.9189571958122542e-06
A O 0 2.5342802700834e-07
transversion O 0 2.8708802801702404e-06
responsible O 0 3.419857108610813e-08
for O 0 2.5354265353882965e-09
the O 0 1.8104202581525897e-08
APC O 0 9.949818604582106e-07
I1307K O 0 1.058057023328729e-06
allele O 0 2.2006285860243224e-07
converts O 0 3.565964235008323e-08
the O 0 5.25920551552872e-09
wild O 0 5.518566581486084e-08
- O 0 1.0070647249449394e-06
type O 0 5.7398136021902246e-08
sequence O 0 4.46951489152525e-08
to O 0 1.786984960006066e-08
a O 0 1.1568225772862206e-06
homopolymer O 0 0.33294814825057983
tract O 0 0.16013647615909576
( O 0 2.0029921188324806e-07
A8 O 0 0.0003948247467633337
) O 0 8.062399814434684e-08
that O 0 2.6880115910898894e-08
is O 0 6.525868201379126e-08
genetically O 0 4.2515230234130286e-06
unstable O 0 0.0016564816469326615
and O 0 1.2647069524973631e-05
prone O 0 5.0664519221754745e-05
to O 0 1.3606032212010177e-07
somatic O 0 1.6362562746508047e-05
mutation O 0 2.1507559722522274e-05
. O 0 1.4549571005773032e-06

The O 0 1.2907224117952865e-05
I1307K O 0 9.684076212579384e-05
allele O 0 6.412882794393227e-05
was O 0 8.807397534837946e-06
found O 0 2.0465530781166308e-07
in O 0 1.4870090581098339e-07
6 O 0 5.2772129492950626e-06
. O 0 1.2996126770303817e-06

1 O 0 4.77483517897781e-05
% O 0 1.4805594901190489e-06
of O 0 4.518621921079102e-08
unselected O 0 3.3228323445655406e-05
Ashkenazi O 0 0.00033972496748901904
Jews O 0 4.085505679540802e-06
and O 0 2.1077894984955492e-07
higher O 0 6.653093720387915e-08
proportions O 0 3.7447372847054794e-07
of O 0 9.579117943303572e-09
Ashkenazim O 0 1.9918492398574017e-05
with O 0 2.0423163960003876e-07
family O 0 1.0714034033298958e-06
or O 0 7.915270572311783e-08
personal O 0 3.235812187085685e-07
histories O 0 1.0119100579686346e-06
of O 0 9.68704796378006e-08
CRC B-Disease 0 0.000897612189874053
( O 0 1.2271962646082102e-07
ref O 0 9.618162584956735e-05
. O 0 7.116874911616833e-08
2 O 0 3.4843793628169806e-07
) O 0 1.775363642764205e-07
. O 0 7.463429483323125e-07

To O 0 1.8915175132860895e-06
evaluate O 0 6.338016191875795e-07
the O 0 2.698423884339718e-08
role O 0 5.092171662113287e-08
of O 0 1.9699662345828983e-08
I1307K O 0 5.100247562950244e-06
in O 0 7.531642154390283e-07
cancer B-Disease 0 1.380584217258729e-05
, O 0 4.0914095222888136e-08
we O 0 2.5462544073207027e-08
genotyped O 0 2.3453762878489215e-06
5 O 0 1.880490572148119e-07
, O 0 5.059352403691264e-08
081 O 0 7.46363184589427e-06
Ashkenazi O 0 6.1626888054888695e-06
volunteers O 0 1.4243641999200918e-07
in O 0 1.3723756353556382e-08
a O 0 1.716345963131971e-07
community O 0 2.833907615240605e-07
survey O 0 1.8791741922541405e-06
. O 0 8.961538924268098e-07

Risk O 0 0.000237987405853346
of O 0 6.664524221378088e-07
developing O 0 1.7749312974046916e-05
colorectal B-Disease 1 1.0
, I-Disease 0 3.067211582674645e-05
breast I-Disease 0 0.46852725744247437
and I-Disease 0 3.2438133530376945e-06
other I-Disease 0 4.830619673157344e-07
cancers I-Disease 0 0.080153688788414
were O 0 5.37066455308377e-07
compared O 0 2.159765131182212e-07
between O 0 1.1332317484402665e-07
genotyped O 0 1.2444207641237881e-05
I1307K O 0 1.050186710926937e-06
carriers O 0 6.178367328857348e-08
and O 0 1.7612478586670477e-08
non O 0 1.5382694229515437e-08
- O 0 1.3711872952626436e-06
carriers O 0 6.530574125918065e-08
and O 0 9.592172389716325e-09
their O 0 4.3669756699671325e-09
first O 0 5.156659810268138e-08
- O 0 4.54078372058575e-06
degree O 0 2.5150885107905196e-07
relatives O 0 5.86998055496224e-07
. O 0 4.0904501474869903e-07

Sperm O 0 8.248489029938355e-05
DNA O 0 7.092028226907132e-06
analysis O 0 2.977720043872978e-07
in O 0 5.392271518189773e-08
a O 0 2.8571496386575745e-06
Friedreich B-Disease 1 0.9947139620780945
ataxia I-Disease 1 0.9992641806602478
premutation O 0 0.015004533343017101
carrier O 0 2.7498112103785388e-05
suggests O 0 6.733367854394601e-07
both O 0 3.356526789843883e-08
meiotic O 0 4.815299234905979e-06
and O 0 6.96277453471339e-08
mitotic O 0 5.526766813090944e-07
expansion O 0 1.7022243525843805e-07
in O 0 5.320968909927615e-08
the O 0 1.2407885208176594e-07
FRDA B-Disease 0 9.012891678139567e-05
gene O 0 7.466764145647176e-06
. O 0 2.008632463912363e-06

Friedreich B-Disease 1 0.999971866607666
ataxia I-Disease 1 0.9999990463256836
is O 0 0.0010270517086610198
usually O 0 3.081266186200082e-05
caused O 0 3.621437372203218e-06
by O 0 1.0408610862100431e-08
an O 0 5.494973365216538e-09
expansion O 0 8.528074602054403e-08
of O 0 1.499649293634775e-08
a O 0 1.0136175205843756e-06
GAA O 0 5.183082612347789e-05
trinucleotide O 0 1.1236234058742411e-05
repeat O 0 8.677674827595183e-07
in O 0 3.6514059331693716e-08
intron O 0 2.03644267458003e-05
1 O 0 1.6730632523831446e-07
of O 0 1.2728814446916203e-08
the O 0 8.902909343078136e-08
FRDA B-Disease 0 0.00017982503050006926
gene O 0 7.123425348254386e-06
. O 0 1.487762460783415e-06

Occasionally O 0 6.992842827457935e-05
, O 0 3.6455682561609137e-07
a O 0 1.089177317226131e-07
fully O 0 7.685510183819133e-08
expanded O 0 1.3879787275072886e-07
allele O 0 1.5995157127690618e-06
has O 0 3.733821358764544e-07
been O 0 1.695243696531179e-07
found O 0 3.745604715277295e-08
to O 0 8.896760661514236e-09
arise O 0 1.5306335754416978e-08
from O 0 2.0331112349225577e-09
a O 0 1.7405460184249932e-08
premutation O 0 1.4461506907537114e-06
of O 0 7.354840292350673e-09
100 O 0 6.707053046284273e-08
or O 0 5.019788673621406e-08
less O 0 1.5462050839687436e-07
triplet O 0 0.0002700496406760067
repeats O 0 5.116388638271019e-05
. O 0 1.6922824670473346e-06

We O 0 2.0349711121525615e-05
have O 0 2.4911454943321587e-07
examined O 0 2.6398450359010894e-07
the O 0 1.7429380605449296e-08
sperm O 0 1.7054775014457846e-07
DNA O 0 8.336243695339363e-08
of O 0 5.9022555731758075e-09
a O 0 3.3338446314701287e-07
premutation O 0 0.00010727854532888159
carrier O 0 1.0676747479010373e-05
. O 0 1.5856884374443325e-06

This O 0 2.087842176479171e-06
mans O 0 2.165117984986864e-05
leucocyte O 0 2.268636853841599e-05
DNA O 0 8.933900062402245e-06
showed O 0 2.3322791093960404e-06
one O 0 2.5818572169100662e-08
normal O 0 2.045957927521158e-07
allele O 0 5.201130761633976e-07
and O 0 5.59687123313779e-08
one O 0 1.9714548216143157e-08
allele O 0 1.5070175152231968e-07
of O 0 7.892759334993116e-09
approximately O 0 7.432957715991506e-08
100 O 0 1.9524490824096574e-07
repeats O 0 8.898018677427899e-06
. O 0 1.853966637099802e-06

His O 0 1.6277086615446024e-05
sperm O 0 2.170360676245764e-05
showed O 0 5.2266659622546285e-06
an O 0 9.041794868380748e-09
expanded O 0 1.63430669886111e-07
allele O 0 5.641735469907871e-07
in O 0 2.4900426609519855e-08
a O 0 2.155717595542228e-07
tight O 0 1.804474595701322e-05
range O 0 6.327404662442859e-07
centering O 0 5.951613957222435e-07
on O 0 1.7827117915203416e-07
a O 0 3.1508925246725994e-08
size O 0 5.931883606535848e-08
of O 0 1.18567999862762e-08
approximately O 0 1.8189700767834438e-07
320 O 0 1.2748029121212312e-06
trinucleotide O 0 3.5066197597188875e-05
repeats O 0 3.0290419090306386e-05
. O 0 1.3177215123505448e-06

His O 0 0.00015267236449290067
affected O 0 3.007245140906889e-05
son O 0 9.462994785280898e-05
has O 0 9.235442348654033e-07
repeat O 0 1.7863021639641374e-06
sizes O 0 1.0707394721976016e-06
of O 0 5.424259796882325e-08
1040 O 0 7.499827461288078e-06
and O 0 3.9173764321276394e-07
540 O 0 5.5435230024158955e-06
. O 0 1.0789439102154574e-06

These O 0 9.892339676298434e-07
data O 0 6.666685408163175e-07
suggest O 0 2.1030248831266363e-07
that O 0 7.315749783742831e-09
expansion O 0 9.317292892774276e-08
occurs O 0 2.420610023534664e-08
in O 0 4.032926881336607e-09
two O 0 5.181495055239793e-08
stages O 0 1.7264960661123041e-06
, O 0 1.1226841678535493e-08
the O 0 5.243400380550156e-09
first O 0 5.1118288268980905e-08
during O 0 6.967849941474924e-08
meiosis O 0 1.8454556993674487e-07
followed O 0 7.990112038669395e-08
by O 0 2.433064860696277e-09
a O 0 2.993247960603185e-08
second O 0 2.0269564515729144e-07
mitotic O 0 4.759752300742548e-06
expansion O 0 2.934558096967521e-06
. O 0 1.3138127314960002e-06

We O 0 3.057829962926917e-05
also O 0 1.0398667882327572e-06
show O 0 5.718885631722515e-07
that O 0 4.663594399545445e-09
in O 0 3.3869760329707788e-09
all O 0 2.436613133482979e-09
informative O 0 1.499440998031787e-07
carrier O 0 1.0968643664455158e-06
father O 0 1.647592995368541e-07
to O 0 2.2208825001257537e-08
affected O 0 5.921077317339041e-08
child O 0 6.672378844996274e-07
transmissions O 0 1.4110150914348196e-05
, O 0 1.7252562045655395e-08
with O 0 6.831199605983329e-09
the O 0 3.266644199584334e-08
notable O 0 6.03815877298075e-08
exception O 0 1.0583134368857827e-08
of O 0 1.6011396652970689e-09
the O 0 4.027701550057827e-08
premutation O 0 1.1050550710933749e-05
carrier O 0 3.96471364183526e-07
, O 0 4.3134820160162235e-09
the O 0 3.648285673563123e-09
expansion O 0 4.452743596061737e-08
size O 0 2.449088185585424e-07
decreases O 0 1.4509014363284223e-06
. O 0 6.911199790238243e-08
. O 0 5.076539082438103e-07

The O 0 4.8865867938729934e-06
R496H O 0 3.423354064580053e-05
mutation O 0 3.110045781795634e-06
of O 0 3.2151962869875206e-08
arylsulfatase O 0 1.4682179426017683e-05
A O 0 3.230680022170418e-06
does O 0 1.3581249049821054e-06
not O 0 6.433719477172417e-07
cause O 0 5.2909323130734265e-05
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999995231628418
. O 0 1.2244365279912017e-05

Deficiency B-Disease 1 0.9999611377716064
of I-Disease 0 2.3509903712692903e-06
arylsulfatase I-Disease 0 0.0005407560965977609
A I-Disease 0 4.274665116099641e-05
( O 0 2.109741217282135e-06
ARSA O 0 0.0007053214940242469
) O 0 1.8593905792840815e-07
enzyme O 0 2.4796524940029485e-06
activity O 0 6.318321084108902e-06
causes O 0 0.00017729640239849687
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0002109502092935145
MLD B-Disease 1 0.9999991655349731
) O 0 5.506303750735242e-06
. O 0 4.739740234072087e-06

A O 0 1.0187432053498924e-05
number O 0 7.597905096190516e-07
of O 0 1.9148497187870817e-07
ARSA O 0 0.013330657966434956
gene O 0 3.7687485018977895e-05
mutations O 0 1.7976368326344527e-05
responsible O 0 1.2738938721668092e-06
for O 0 9.941860525941593e-07
MLD B-Disease 1 1.0
have O 0 1.814360439311713e-05
been O 0 4.6492673391185235e-06
identified O 0 6.619401119678514e-06
. O 0 1.1878811392307398e-06

Recently O 0 8.764438098296523e-05
, O 0 1.6739585362302023e-07
the O 0 3.890995969868527e-08
R496H O 0 2.980727686008322e-06
mutation O 0 6.017372697897372e-07
of O 0 2.4551814803430716e-08
ARSA O 0 0.0020593665540218353
was O 0 5.331790362106403e-06
proposed O 0 2.8637430204980774e-08
to O 0 2.4096372897020046e-08
be O 0 2.9716654026401557e-08
a O 0 2.4591659553152567e-07
cause O 0 2.6848094876186224e-06
of O 0 3.099736147760268e-07
MLD B-Disease 1 1.0
( O 0 6.74702050673659e-07
Draghia O 0 4.582788824336603e-05
et O 0 4.7662095312261954e-05
al O 0 1.6089850760181434e-05
. O 0 9.968275094252022e-08
, O 0 3.8208135322292947e-08
1997 O 0 1.4338664300339587e-07
) O 0 9.805947343011212e-08
. O 0 3.1985683790480834e-07

We O 0 2.1903364540776238e-05
have O 0 3.841926172754029e-07
investigated O 0 6.818380029471882e-07
the O 0 2.882418570493428e-08
R496H O 0 3.4362994938419433e-06
mutation O 0 8.533230584362173e-07
and O 0 2.3798614634529258e-08
found O 0 2.837173163072748e-08
this O 0 8.003652851584775e-09
mutation O 0 1.6960845528046775e-07
at O 0 1.483507094945935e-08
a O 0 4.507276685217221e-08
relatively O 0 2.918766206505552e-08
high O 0 1.285839061893057e-07
frequency O 0 2.2977846469984797e-07
in O 0 5.968857408333861e-09
an O 0 5.3174864511618125e-09
African O 0 1.701939567055888e-08
American O 0 1.5826286059450467e-08
population O 0 8.86653950260552e-09
( O 0 6.840522814854921e-09
f O 0 6.457447057073296e-07
= O 0 7.735290523669391e-07
0 O 0 5.042704387392405e-08
. O 0 8.731007916651379e-09
09 O 0 1.4658343161499943e-07
, O 0 2.636900475749826e-08
n O 0 2.7530004444997758e-06
= O 0 6.557099368365016e-06
61 O 0 1.0732646842370741e-06
subjects O 0 4.1242779502681515e-07
) O 0 2.3804612681033177e-07
. O 0 7.888975233072415e-07

The O 0 5.970116944808979e-06
ARSA O 0 0.0003486507630441338
enzyme O 0 2.9831307983840816e-06
activity O 0 8.315510626744071e-07
in O 0 3.76831330584082e-08
subjects O 0 2.339828455433235e-07
with O 0 6.711634625844454e-08
and O 0 9.233927471541392e-07
without O 0 2.0536162992357276e-08
the O 0 2.2108405772769402e-08
R496H O 0 2.7859168767463416e-06
mutation O 0 8.611335147179489e-07
was O 0 1.1855033790197922e-06
determined O 0 4.196134852918476e-07
and O 0 1.0940306083284668e-07
found O 0 4.9133355162211956e-08
to O 0 1.2780461133843346e-08
be O 0 3.1192840310723113e-08
normal O 0 4.8193049906331e-07
. O 0 6.047212650628353e-07

It O 0 7.012686637608567e-06
is O 0 9.379879628568233e-08
therefore O 0 5.327071761485058e-08
concluded O 0 7.328502960035621e-08
that O 0 4.083751115047107e-09
the O 0 2.309158730895433e-08
R496H O 0 5.275315743347164e-06
mutation O 0 3.9212972069435637e-07
of O 0 1.454205822426502e-08
ARSA O 0 0.00012063192116329446
does O 0 5.6014101801338256e-08
not O 0 7.825065928557251e-09
negatively O 0 2.41300401881972e-08
influence O 0 1.2726628639825321e-08
the O 0 5.478156595017936e-09
activity O 0 8.369190140911087e-08
of O 0 1.1057424309512953e-08
ARSA O 0 0.004660929087549448
and O 0 6.129656071607315e-07
is O 0 2.980833357923984e-08
not O 0 1.3124505926498387e-08
a O 0 2.605407587452646e-07
cause O 0 6.432593181671109e-06
of O 0 2.2065662506065564e-06
MLD B-Disease 1 0.9999992847442627

Down O 0 0.0009305155253969133
- O 0 5.304714431986213e-05
regulation O 0 1.6817573396110674e-06
of O 0 1.6628732169010618e-07
transmembrane O 0 1.123174479289446e-05
carbonic O 0 4.540756708593108e-05
anhydrases O 0 0.00011004286352545023
in O 0 1.5327597793657333e-05
renal B-Disease 1 0.9999953508377075
cell I-Disease 1 0.9999953508377075
carcinoma I-Disease 1 1.0
cell O 1 0.6627559661865234
lines O 0 0.00017468234000261873
by O 0 5.384686829756902e-08
wild O 0 1.1439777836130816e-06
- O 0 0.00015449547208845615
type O 0 2.6787130991579033e-05
von B-Disease 1 0.9701365828514099
Hippel I-Disease 1 0.992141604423523
- I-Disease 0 0.1782996654510498
Lindau I-Disease 0 0.035652242600917816
transgenes O 0 0.0008601044537499547
. O 0 1.0873069186345674e-05

To O 0 3.04621744362521e-06
discover O 0 4.1537978177075274e-06
genes O 0 2.8918848329340108e-06
involved O 0 2.7211035558138974e-07
in O 0 5.963414650977938e-07
von B-Disease 1 0.9999839067459106
Hippel I-Disease 1 0.9999948740005493
- I-Disease 1 0.9999151229858398
Lindau I-Disease 1 0.9996654987335205
( O 0 1.3138641179466504e-06
VHL B-Disease 0 0.00013274059165269136
) O 0 1.7406166819000646e-07
- O 0 1.6884918295545503e-05
mediated O 0 7.894298323662952e-05
carcinogenesis O 0 0.0022311904467642307
, O 0 3.724460952980735e-07
we O 0 1.9535332285158802e-07
used O 0 2.174483597627841e-05
renal B-Disease 1 0.9998918771743774
cell I-Disease 1 0.9999692440032959
carcinoma I-Disease 1 1.0
cell O 1 0.5767146348953247
lines O 0 0.0036571382079273462
stably O 0 7.34746572561562e-05
transfected O 0 4.5295939344214275e-05
with O 0 1.938763318776182e-07
wild O 0 3.2139384984475328e-06
- O 0 0.00023624142340850085
type O 0 1.0819313501997385e-05
VHL O 0 0.0007174692000262439
- O 0 0.0014623828465119004
expressing O 0 3.779921144086984e-06
transgenes O 0 0.00012082370813004673
. O 0 5.3064213716425e-06

Large O 0 6.912959179317113e-06
- O 0 1.2150331713201012e-05
scale O 0 1.8147921991840121e-06
RNA O 0 1.0010055575548904e-06
differential O 0 8.017779578040063e-07
display O 0 3.9293757936320617e-07
technology O 0 8.073433122035567e-08
applied O 0 2.7467216057175392e-08
to O 0 9.303030346075047e-09
these O 0 5.6879891907613e-09
cell O 0 2.4236535409727367e-06
lines O 0 8.816808986011893e-06
identified O 0 1.356165029164913e-07
several O 0 1.3849502877860687e-08
differentially O 0 2.5692918370623374e-06
expressed O 0 5.846672479492554e-08
genes O 0 1.1006360267629134e-07
, O 0 8.11941802680849e-09
including O 0 4.210956916494979e-09
an O 0 2.670351051392572e-08
alpha O 0 1.5359672715931083e-06
carbonic O 0 7.011389243416488e-06
anhydrase O 0 6.425248102459591e-06
gene O 0 7.405024007312022e-07
, O 0 1.5571822586935014e-07
termed O 0 5.764708021160914e-06
CA12 O 0 0.00026261137099936604
. O 0 2.955614263555617e-06

The O 0 3.209778697055299e-06
deduced O 0 5.304783371684607e-06
protein O 0 1.049612933456956e-06
sequence O 0 7.803396329109091e-07
was O 0 2.5716033178468933e-06
classified O 0 8.07757700727052e-08
as O 0 2.7668024316085393e-08
a O 0 1.2659910453294287e-07
one O 0 3.4353126920905197e-07
- O 0 0.00011840822116937488
pass O 0 4.545350293483352e-06
transmembrane O 0 1.1391919088055147e-06
CA O 0 8.395328450205852e-07
possessing O 0 6.339243441289e-08
an O 0 3.04433029896245e-08
apparently O 0 2.7896735446120147e-06
intact O 0 2.382739552331259e-07
catalytic O 0 1.0591055144004713e-07
domain O 0 8.701734088845114e-08
in O 0 1.3422118527728344e-08
the O 0 4.441352174922031e-08
extracellular O 0 3.6600531529984437e-06
CA O 0 2.9515571441152133e-05
module O 0 2.000013046199456e-05
. O 0 1.0066403319797246e-06

Reintroduced O 0 0.00030039632110856473
wild O 0 2.0691542886197567e-05
- O 0 0.0001415466540493071
type O 0 5.826266715303063e-06
VHL B-Disease 0 9.978614980354905e-05
strongly O 0 2.313624008820625e-06
inhibited O 0 2.238857632619329e-06
the O 0 4.126771813162122e-08
overexpression O 0 8.769044370637857e-07
of O 0 1.1527876431216555e-08
the O 0 4.067956282938212e-08
CA12 O 0 1.576989598106593e-05
gene O 0 2.6516966045164736e-07
in O 0 4.7733713870456995e-08
the O 0 7.810991746737272e-07
parental O 0 0.18639075756072998
renal B-Disease 1 0.9999974966049194
cell I-Disease 1 0.999994158744812
carcinoma I-Disease 1 1.0
cell O 1 0.7498800158500671
lines O 0 0.022701341658830643
. O 0 2.7416976990934927e-06

Similar O 0 2.758005211944692e-05
results O 0 8.716169759281911e-06
were O 0 6.586993777091266e-07
obtained O 0 5.2758160506982676e-08
with O 0 6.479135805648184e-08
CA9 O 0 0.00025603154790587723
, O 0 5.031156291579464e-08
encoding O 0 2.643619154696353e-07
another O 0 3.500110096865683e-06
transmembrane O 0 7.523855856561568e-06
CA O 0 4.694512426794972e-06
with O 0 1.1991759585328055e-08
an O 0 6.91826897991632e-08
intact O 0 2.4403432234976208e-06
catalytic O 0 3.67094207831542e-06
domain O 0 3.3215801522601396e-06
. O 0 1.5441332834598143e-06

Although O 0 5.154932750883745e-06
both O 0 7.708530347372289e-08
domains O 0 1.6653933698762557e-07
of O 0 7.012725511401641e-09
the O 0 7.932076329097981e-08
VHL B-Disease 0 1.9386798157938756e-05
protein O 0 1.7417025333088532e-07
contribute O 0 1.4634129463786394e-08
to O 0 8.70526672969163e-09
regulation O 0 7.86014737741425e-08
of O 0 1.4070526077603063e-08
CA12 O 0 9.145893272943795e-05
expression O 0 1.7577518462985608e-07
, O 0 6.984373079887973e-09
the O 0 5.458381302503312e-09
elongin O 0 7.932528092169377e-07
binding O 0 4.699904820881784e-08
domain O 0 8.034675147428061e-08
alone O 0 2.5347276277898345e-07
could O 0 7.466577045533995e-08
effectively O 0 6.915418566677545e-07
regulate O 0 2.2866236122354167e-06
CA9 O 0 0.00027227451209910214
expression O 0 3.863062374875881e-06
. O 0 7.987115964169789e-07

We O 0 3.869463034789078e-05
mapped O 0 0.00011223912588320673
CA12 O 0 0.0005914490320719779
and O 0 3.002264520546305e-06
CA9 O 0 0.0005558864213526249
loci O 0 5.226536359259626e-06
to O 0 1.6978744099560572e-07
chromosome O 0 7.35988505766727e-05
bands O 0 8.269805221061688e-06
15q22 O 0 8.007816177268978e-06
and O 0 4.497615861964732e-07
17q21 O 0 2.20842248381814e-05
. O 0 1.9249084743933054e-06

2 O 0 0.00022359451395459473
respectively O 0 1.7484240743215196e-05
, O 0 1.157163111997761e-07
regions O 0 5.501970576915483e-07
prone O 0 1.1449707926658448e-05
to O 0 1.9242995108470495e-07
amplification O 0 2.1382133127190173e-05
in O 0 8.836710208015575e-08
some O 0 6.257637608086952e-08
human O 0 2.6586778858472826e-06
cancers B-Disease 0 0.009603133425116539
. O 0 2.3632708234799793e-06

Additional O 0 5.3081780606589746e-06
experiments O 0 2.4112089249683777e-06
are O 0 3.548032978528681e-08
needed O 0 1.141908541058001e-07
to O 0 1.9885359137106207e-08
define O 0 1.7502144089576177e-07
the O 0 3.412565519056443e-08
role O 0 9.802076306186791e-08
of O 0 7.757942199759782e-08
CA O 0 1.5996065485524014e-05
IX O 0 7.870642730267718e-05
and O 0 4.116036507184617e-06
CA O 0 5.721215984522132e-06
XII O 0 4.399496901896782e-06
enzymes O 0 8.849124100152039e-08
in O 0 3.354329924931676e-09
the O 0 6.79639633460738e-09
regulation O 0 8.351792502026001e-08
of O 0 1.5119905327765082e-08
pH O 0 1.3685021258424968e-05
in O 0 1.4488348298868914e-08
the O 0 1.2423544859530011e-08
extracellular O 0 2.3820078354219731e-07
microenvironment O 0 5.47043964616023e-06
and O 0 5.6586777930078824e-08
its O 0 5.483393739069697e-09
potential O 0 1.6719013729016297e-08
impact O 0 4.7783267120848905e-08
on O 0 4.70402210339671e-06
cancer B-Disease 0 1.4529865438817069e-05
cell O 0 7.1135955295176245e-06
growth O 0 1.4572915461030789e-06
. O 0 4.5844254259463924e-07

A O 0 1.362890179734677e-05
gene O 0 5.873743702977663e-06
encoding O 0 2.227419145128806e-06
a O 0 7.813852676008537e-07
transmembrane O 0 3.633923142842832e-06
protein O 0 6.591034207303892e-07
is O 0 4.93894845021714e-08
mutated O 0 3.868835847242735e-06
in O 0 1.3589229865829111e-06
patients O 0 2.7656114980345592e-05
with O 0 0.00423078378662467
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9987566471099854
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999955892562866
( O 0 0.0017117521492764354
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.436180915945442e-06
. O 0 3.5253383430244867e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0008325992967002094
WFS B-Disease 0 0.1664215624332428
; O 0 6.015883991494775e-05
OMIM O 0 0.02787914127111435
222300 O 0 3.5934186598751694e-05
) O 0 1.93465183428998e-07
is O 0 1.26957715451681e-07
an O 0 2.8212382403580705e-06
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9973092079162598
defined O 0 2.6508291739446577e-06
by O 0 2.668060687938123e-07
young O 0 1.6453567468488473e-06
- O 0 5.583005986409262e-05
onset O 0 0.00010588204168016091
non O 0 1.4324656376629719e-06
- O 0 0.0005394146428443491
immune O 0 1.5951096429489553e-05
insulin B-Disease 0 0.00032427257974632084
- I-Disease 0 0.15563605725765228
dependent I-Disease 0 0.012078937143087387
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0037956777960062027
progressive O 0 0.40473902225494385
optic B-Disease 1 0.999994158744812
atrophy I-Disease 0 0.16902361810207367
. O 0 9.092111213249154e-06

Linkage O 0 0.00019601959502324462
to O 0 1.096545361178869e-06
markers O 0 4.947777051711455e-05
on O 0 1.177437570731854e-05
chromosome O 0 0.07828839123249054
4p O 0 0.41217613220214844
was O 0 0.0020053391344845295
confirmed O 0 2.3479744868382113e-06
in O 0 7.02732307900078e-08
five O 0 5.018075057705573e-07
families O 0 6.478487080130435e-07
. O 0 7.705963867010723e-07

On O 0 2.7750716071750503e-06
the O 0 7.377420985221761e-08
basis O 0 5.229280830576499e-08
of O 0 1.7324447654232245e-08
meiotic O 0 0.0005287883104756474
recombinants O 0 0.09786691516637802
and O 0 0.00019122296362183988
disease O 0 0.0004534203326329589
- O 0 4.1120183595921844e-05
associated O 0 1.6414464880654123e-06
haplotypes O 0 1.1294569048914127e-05
, O 0 3.106968904376117e-08
the O 0 5.157948379519439e-08
WFS B-Disease 0 3.87302934541367e-05
gene O 0 8.086314551292162e-07
was O 0 1.6393595387853566e-06
localized O 0 9.036597816702852e-07
to O 0 6.99597464404178e-08
a O 0 1.2454206625989173e-06
BAC O 0 0.00019818269356619567
/ O 0 1.2519210031314287e-05
P1 O 0 8.144226740114391e-06
contig O 0 5.1559404710133094e-06
of O 0 1.7369048421755906e-08
less O 0 3.156396388703797e-08
than O 0 2.04526262592708e-08
250 O 0 1.567876921626521e-07
kb O 0 5.4870746680535376e-05
. O 0 1.489170585955435e-06

Mutations O 0 0.004125477280467749
in O 0 3.1043126114127517e-07
a O 0 3.010045759310742e-07
novel O 0 2.3995510218810523e-06
gene O 0 5.1487663768057246e-06
( O 0 1.859950913285502e-07
WFS1 O 0 1.7403292076778598e-05
) O 0 1.3227140271965254e-08
encoding O 0 7.273123259210479e-08
a O 0 7.80624205276581e-08
putative O 0 2.442003278702032e-06
transmembrane O 0 1.7706140909012902e-07
protein O 0 9.270848266851317e-08
were O 0 2.4465037995469174e-07
found O 0 4.038963652419625e-08
in O 0 1.898303203518026e-08
all O 0 7.753175879088303e-09
affected O 0 1.99451459792499e-08
individuals O 0 2.2130079990745344e-09
in O 0 1.1800441512832549e-08
six O 0 3.0541716000698216e-07
WFS B-Disease 0 3.670206933747977e-05
families O 0 1.3454791769618168e-07
, O 0 8.531194417571442e-09
and O 0 1.5169561606853676e-08
these O 0 7.804333179706191e-09
mutations O 0 1.542406721455336e-06
were O 0 1.5965440525178565e-07
associated O 0 5.8851039597129784e-08
with O 0 7.280132052756016e-08
the O 0 1.2939934094902128e-05
disease O 0 0.006732500623911619
phenotype O 0 0.00027616790612228215
. O 0 1.8048557421934674e-06

WFS1 O 0 0.003973467741161585
appears O 0 5.89429255342111e-05
to O 0 1.6255894763617107e-07
function O 0 8.68553442501252e-08
in O 0 6.63904913267288e-08
survival O 0 4.309653832024196e-06
of O 0 3.322798391991455e-08
islet O 0 4.1737363062566146e-05
beta O 0 2.6419359073770465e-06
- O 0 8.01540954853408e-05
cells O 0 2.259143002447672e-06
and O 0 1.8245017940898833e-07
neurons O 0 1.2448352890714887e-06
. O 0 6.059202206643022e-08
. O 0 4.501829948821978e-07

Stable O 0 0.0001809205859899521
interaction O 0 1.7184207763421e-06
between O 0 1.4629029010393424e-07
the O 0 2.8241077032475914e-08
products O 0 9.624393726426206e-08
of O 0 7.710791116721794e-09
the O 0 2.369094431742269e-07
BRCA1 O 0 0.0002319857303518802
and O 0 9.402711839356925e-06
BRCA2 O 0 0.0007936800247989595
tumor B-Disease 0 4.492387597565539e-05
suppressor O 0 3.556798765202984e-05
genes O 0 5.767456627836509e-07
in O 0 4.9146660074939064e-08
mitotic O 0 1.5143337805056944e-05
and O 0 2.3742586563457735e-06
meiotic O 0 0.0004952719318680465
cells O 0 1.938506102305837e-05
. O 0 2.084208063024562e-06

BRCA1 O 1 0.7868284583091736
and O 0 5.2346731536090374e-05
BRCA2 O 0 0.0005859502707608044
account O 0 3.768475380638847e-07
for O 0 1.6124369395242866e-08
most O 0 1.6929034174495428e-08
cases O 0 1.477041422504044e-08
of O 0 5.990732798721865e-09
familial O 0 1.1402872587495949e-05
, O 0 1.4904023259987298e-07
early O 0 8.246464062722225e-07
onset O 0 8.43632806208916e-05
breast B-Disease 0 0.05642709881067276
and I-Disease 0 1.9147093553328887e-05
/ I-Disease 1 0.8204618692398071
or I-Disease 1 0.9262552857398987
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.4547086379934626e-07
encode O 0 9.464127259661836e-08
products O 0 1.910098461621601e-07
that O 0 4.4603147841826285e-09
each O 0 8.301586973402664e-09
interact O 0 3.7370412542259146e-08
with O 0 7.06312093257111e-08
hRAD51 O 0 3.054537228308618e-05
. O 0 1.5966262481015292e-06

Results O 0 7.255274977069348e-05
presented O 0 2.959980747618829e-06
here O 0 1.6446432482553064e-07
show O 0 9.889160992315738e-07
that O 0 1.294153122444186e-07
BRCA1 O 0 0.00016825279453769326
and O 0 1.8307486243429594e-05
BRCA2 O 0 0.0010636354563757777
coexist O 0 1.156835878646234e-06
in O 0 1.5398429198398844e-08
a O 0 1.0246286308301933e-07
biochemical O 0 2.221244130851119e-06
complex O 0 2.4568967660343333e-07
and O 0 3.7040652500763827e-07
colocalize O 0 1.0785287486214656e-05
in O 0 6.949453990046095e-08
subnuclear O 0 9.44586190598784e-06
foci O 0 3.081443537666928e-06
in O 0 2.1814855699631153e-08
somatic O 0 4.883857513959811e-07
cells O 0 3.770298064864619e-07
and O 0 6.710367728146593e-08
on O 0 1.2593788767389924e-07
the O 0 1.5035329425927557e-08
axial O 0 2.394149021256453e-07
elements O 0 1.0017105722681663e-07
of O 0 2.992340242258251e-08
developing O 0 3.9920956851347e-07
synaptonemal O 0 1.9248376702307723e-05
complexes O 0 3.3106318824138725e-06
. O 0 7.871682896620769e-07

Like O 0 0.00010663813736755401
BRCA1 O 0 0.004966974724084139
and O 0 1.2814783985959366e-05
RAD51 O 0 0.0013913983711972833
, O 0 1.394752757732931e-06
BRCA2 O 0 3.8821552152512595e-05
relocates O 0 9.520744242763612e-06
to O 0 4.073660022640979e-07
PCNA O 0 7.133508916012943e-05
+ O 0 7.100644552338053e-07
replication O 0 3.037370674974227e-07
sites O 0 4.713946211154507e-08
following O 0 2.82639796012063e-08
exposure O 0 9.08304045310615e-08
of O 0 1.1159399626592403e-08
S O 0 2.5794566681724973e-05
phase O 0 3.402291213205899e-07
cells O 0 1.9292203035092825e-07
to O 0 3.927411995618968e-08
hydroxyurea O 0 1.7943002603715286e-05
or O 0 8.026861451071454e-07
UV O 0 6.668185960734263e-05
irradiation O 0 8.797525879344903e-06
. O 0 1.2507006204032223e-06

Thus O 0 2.3727834559394978e-05
, O 0 6.300525683400338e-07
BRCA1 O 0 5.0234233640367165e-05
and O 0 2.0377124201331753e-06
BRCA2 O 0 8.541798160877079e-05
participate O 0 5.66365550014325e-08
, O 0 3.393055436617942e-08
together O 0 5.0310031696199076e-08
, O 0 9.98166527210742e-09
in O 0 5.951577453089385e-09
a O 0 2.7059030571763287e-07
pathway O 0 2.0539491742965765e-06
( O 0 1.2800812498880987e-07
s O 0 2.2829432055004872e-05
) O 0 2.614858374272444e-08
associated O 0 1.4251299695899888e-08
with O 0 2.603962157010642e-09
the O 0 1.0579945808331104e-08
activation O 0 3.9523758488257954e-08
of O 0 3.654943903086405e-09
double O 0 3.5522764392226236e-06
- O 0 8.609124051872641e-05
strand O 0 0.00039011507760733366
break O 0 8.209432962758001e-06
repair O 0 0.0001001669152174145
and O 0 8.245370963777532e-07
/ O 0 4.240856469550636e-06
or O 0 1.869440069413031e-07
homologous O 0 3.178664428560296e-06
recombination O 0 1.8093893231707625e-05
. O 0 2.3254297047969885e-06

Dysfunction O 1 0.5707139372825623
of O 0 7.236405394905887e-07
this O 0 1.1631708929371598e-07
pathway O 0 3.694543693200103e-06
may O 0 2.5475769689364824e-06
be O 0 8.925502115175732e-09
a O 0 3.201354203952178e-08
general O 0 3.4866488363149983e-08
phenomenon O 0 3.81300623075731e-07
in O 0 1.5491430360725644e-08
the O 0 5.417838622179261e-08
majority O 0 1.5929950691884187e-08
of O 0 2.7018423054414598e-09
cases O 0 2.9357449804479074e-08
of O 0 4.104321504883046e-08
hereditary B-Disease 1 0.7470188736915588
breast I-Disease 1 0.6302363276481628
and I-Disease 0 0.0010131052695214748
/ I-Disease 1 0.9033474326133728
or I-Disease 1 0.8913511037826538
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.540249503610539e-07
. O 0 8.503141089022392e-07

A O 0 4.085392356500961e-05
novel O 0 1.5124805031518918e-05
Arg362Ser O 0 0.0002630807866808027
mutation O 0 7.5231596383673605e-06
in O 0 3.119010116847676e-08
the O 0 6.231447002846835e-08
sterol O 0 1.1765754607040435e-05
27 O 0 9.569080248184036e-06
- O 0 1.6586316633038223e-05
hydroxylase O 0 5.585689359577373e-05
gene O 0 3.0768626402277732e-06
( O 0 1.240207581076902e-07
CYP27 O 0 2.616877100081183e-05
) O 0 1.5883804493910247e-08
: O 0 2.543185662062797e-09
its O 0 6.705464627998481e-09
effects O 0 1.8884664143570262e-07
on O 0 2.0191311023154412e-07
pre O 0 1.5917307791823987e-06
- O 0 8.010770784494525e-07
mRNA O 0 1.6170697847428528e-07
splicing O 0 5.265391678221931e-07
and O 0 8.816642349529502e-08
enzyme O 0 6.239998242563161e-07
activity O 0 8.715235821910028e-07
. O 0 6.564987415913492e-07

A O 0 1.979904845939018e-05
novel O 0 5.715392035199329e-06
C O 0 5.675741249433486e-06
to O 0 4.4622403549965384e-08
A O 0 8.542284604118322e-07
mutation O 0 9.575611557011143e-07
in O 0 8.917317551038195e-09
the O 0 4.9388635403602166e-08
sterol O 0 7.89531350164907e-06
27 O 0 4.200428975309478e-06
- O 0 9.896321898850147e-06
hydroxylase O 0 2.9434340831357986e-05
gene O 0 1.5892703686404275e-06
( O 0 1.000971394660155e-07
CYP27 O 0 5.921401680097915e-05
) O 0 7.086519815402426e-08
was O 0 1.0694556067392114e-06
identified O 0 8.194238887426764e-08
by O 0 4.454618451887882e-09
sequencing O 0 1.7671273155883682e-07
amplified O 0 1.4267095593822887e-06
CYP27 O 0 2.491397708581644e-06
gene O 0 1.0617125667522487e-07
products O 0 5.9341694225167885e-08
from O 0 1.0205361888893094e-08
a O 0 1.5671220410240494e-07
patient O 0 5.59829231860931e-06
with O 0 3.424835540499771e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 1.8729783732851502e-06
CTX B-Disease 0 0.0005784772802144289
) O 0 8.577549692745379e-07
. O 0 1.0458340966579271e-06

The O 0 8.019669621717185e-06
mutation O 0 3.8474263419630006e-05
changed O 0 1.6203254062929773e-06
the O 0 5.87252309003361e-08
adrenodoxin O 0 3.4687309380387887e-06
cofactor O 0 1.3422754818748217e-06
binding O 0 3.783617898989178e-07
residue O 0 1.5135883586481214e-06
362Arg O 0 3.2439277219964424e-06
to O 0 7.456870321220777e-08
362Ser O 0 1.3640500583278481e-05
( O 0 1.2540682803319214e-07
CGT O 0 3.2563416425546166e-06
362Arg O 0 9.75130660663126e-07
to O 0 4.2279886258711485e-08
AGT O 0 6.6898769546241965e-06
362Ser O 0 3.080462192883715e-06
) O 0 4.058230373971128e-08
, O 0 1.345441447142548e-08
and O 0 1.3896966777338093e-07
was O 0 1.486489509261446e-05
responsible O 0 4.1829656538538984e-07
for O 0 3.346484618305112e-07
deficiency O 0 1.142220207839273e-05
in O 0 5.619899212661039e-09
the O 0 3.0306804177371305e-08
sterol O 0 4.302368779462995e-06
27 O 0 2.5844913125183666e-06
- O 0 9.092606774174783e-07
hydroxylase O 0 2.092574504786171e-06
activity O 0 9.107709786349005e-08
, O 0 6.948046138433028e-09
as O 0 7.897156706349051e-09
confirmed O 0 9.465571793043637e-08
by O 0 3.240436363682875e-09
expression O 0 1.218624845478189e-08
of O 0 2.403599985711935e-09
mutant O 0 2.9126053391337337e-07
cDNA O 0 3.3728696280377335e-07
into O 0 2.1861221455310442e-07
COS O 0 0.0003492237301543355
- O 0 1.4681647371617146e-05
1 O 0 6.534680210279475e-07
cells O 0 9.431579996999062e-07
. O 0 6.305610895651625e-07

Quantitative O 0 1.5113616427697707e-05
analysis O 0 2.629776645335369e-06
showed O 0 1.5152018931985367e-05
that O 0 8.940069129437234e-09
the O 0 1.2676553140522628e-08
expression O 0 4.1710148224183285e-08
of O 0 7.087584741327646e-09
CYP27 O 0 7.415153504553018e-06
gene O 0 2.174496813722726e-07
mRNA O 0 1.4971634243465815e-07
in O 0 2.596266845955597e-08
the O 0 9.516585208757533e-08
patient O 0 1.8036392930298462e-06
represented O 0 4.844492309530324e-07
52 O 0 4.42364216723945e-06
. O 0 6.779075647500576e-07

5 O 0 0.00019658898236230016
% O 0 1.0550241995588294e-06
of O 0 1.8575113003294064e-08
the O 0 9.575394699368189e-08
normal O 0 1.7282769704252132e-06
level O 0 1.3590616845249315e-06
. O 0 1.2923379699714133e-06

As O 0 2.2202784748515114e-06
the O 0 1.8325494011151022e-07
mutation O 0 3.1113777367863804e-06
occurred O 0 3.840032434254681e-07
at O 0 2.0995475580321e-08
the O 0 1.552601069931825e-08
penultimate O 0 4.478210939851124e-06
nucleotide O 0 2.830655319030484e-07
of O 0 8.707109699912507e-09
exon O 0 2.343332880627713e-06
6 O 0 2.443305447741295e-06
( O 0 2.67809383558415e-08
- O 0 2.317075313840178e-06
2 O 0 1.0246833426208468e-07
position O 0 1.0720600585045759e-07
of O 0 8.90652351870358e-09
exon O 0 1.6691776636434952e-06
6 O 0 1.0516730526433093e-06
- O 0 2.7046669401897816e-06
intron O 0 3.071168248425238e-05
6 O 0 5.676919840880146e-07
splice O 0 6.025778020557482e-06
site O 0 6.237713705559145e-07
) O 0 3.152273331252786e-09
of O 0 5.614411158205712e-10
the O 0 7.128596379857299e-09
gene O 0 1.8033901483249792e-07
, O 0 4.117187657470822e-08
we O 0 2.2238115349182408e-08
hypothesized O 0 7.230838861005395e-08
that O 0 7.006949243049121e-09
the O 0 8.02958908252549e-08
mutation O 0 1.2582154340634588e-05
may O 0 1.8646536545929848e-06
partially O 0 1.4449457239607e-06
affect O 0 2.570741841623203e-08
the O 0 1.07490771839025e-08
normal O 0 4.7091113231090276e-08
splicing O 0 3.241699744194193e-07
efficiency O 0 9.595103733772703e-08
in O 0 7.773876653516254e-09
exon O 0 1.8207973653261433e-06
6 O 0 2.384438175795367e-06
and O 0 2.706114798911585e-07
cause O 0 1.2435735641247447e-07
alternative O 0 2.0156520008640655e-08
splicing O 0 3.8234131238823466e-07
elsewhere O 0 1.602118686605536e-07
, O 0 5.5785687180787136e-09
which O 0 2.748970118204852e-08
resulted O 0 3.103533785520085e-08
in O 0 2.4565586898006586e-08
decreased O 0 4.3654185901687015e-06
transcript O 0 5.286390205583302e-06
in O 0 2.179030644811064e-07
the O 0 6.827125389463617e-07
patient O 0 1.9711351342266425e-05
. O 0 2.3706611500529107e-06

Transfection O 0 0.0010016622254624963
of O 0 1.2091851431250689e-06
constructed O 0 4.957346391165629e-06
minigenes O 0 3.0248589609982446e-05
, O 0 9.67938262874668e-08
with O 0 1.0224070479125658e-07
or O 0 4.870220209340914e-07
without O 0 2.537750276587758e-08
the O 0 3.603260267937003e-08
mutation O 0 3.690518326493475e-07
, O 0 4.023829269783619e-09
into O 0 1.8652759337101088e-08
COS O 0 0.0002701665216591209
- O 0 2.6553229872661177e-06
1 O 0 9.684018209554779e-08
cells O 0 6.321204892856258e-08
confirmed O 0 3.9845144073069605e-08
that O 0 2.811476162989379e-09
the O 0 6.715857647776602e-09
mutant O 0 5.5613304539292585e-06
minigene O 0 2.261445661133621e-05
was O 0 2.915544655479607e-06
responsible O 0 1.6139599878783883e-08
for O 0 1.3840781853957651e-09
a O 0 1.2050158204601757e-08
mRNA O 0 9.024999059192851e-08
species O 0 6.832268972800648e-09
alternatively O 0 1.1912727160279246e-07
spliced O 0 1.3442864656099118e-05
at O 0 1.5329511882100633e-07
an O 0 2.80121668083666e-08
activated O 0 7.3931305450969376e-06
cryptic O 0 2.636539420564077e-06
5 O 0 1.371227540403197e-07
splice O 0 7.561158781754784e-06
site O 0 3.1844049317442114e-06
88 O 0 8.525494763489405e-07
bp O 0 2.772688048935379e-06
upstream O 0 1.4206362664026528e-07
from O 0 4.28212709735476e-09
the O 0 1.0886451740077518e-08
3 O 0 1.6833686800055148e-07
end O 0 1.589317548678082e-07
of O 0 3.937958581445855e-08
exon O 0 9.83279460342601e-06
6 O 0 6.01064402871998e-06
. O 0 1.824673859118775e-06

Our O 0 5.594124104391085e-06
data O 0 6.882351044623647e-07
suggest O 0 2.530978804315964e-07
that O 0 7.218764253025256e-09
the O 0 1.5009254283882e-08
C O 0 1.092741285901866e-06
to O 0 2.957788503010761e-08
A O 0 6.944749202375533e-07
mutation O 0 8.505573987349635e-07
at O 0 3.4142257021585465e-08
the O 0 2.3715465147233772e-08
penultimate O 0 3.942764124076348e-06
nucleotide O 0 3.2159144325305533e-07
of O 0 9.533259515137615e-09
exon O 0 6.413931714632781e-07
6 O 0 1.899738037991483e-07
of O 0 2.384744846040121e-09
the O 0 1.517882353141431e-08
CYP27 O 0 1.1868600267916918e-05
gene O 0 2.131179854814036e-07
not O 0 3.876758114529366e-08
only O 0 4.329127634150609e-08
causes O 0 7.825710213182901e-07
the O 0 9.285471378461807e-07
deficiency B-Disease 0 2.4190781914512627e-05
in I-Disease 0 7.112434641243226e-09
the I-Disease 0 4.164107281212637e-08
sterol I-Disease 0 4.973764589522034e-06
27 I-Disease 0 1.8192473589806468e-06
- I-Disease 0 1.5226514733512886e-06
hydroxylase I-Disease 0 2.889464667532593e-06
activity I-Disease 0 1.3842536361607927e-07
, O 0 2.3426210304933193e-08
but O 0 1.9825332486789193e-08
also O 0 5.840329890816065e-07
partially O 0 4.944594365952071e-06
leads O 0 7.48034665321029e-08
to O 0 3.8924192757860965e-09
alternative O 0 3.684426985728351e-08
pre O 0 3.0072624213062227e-07
- O 0 4.975948399987828e-07
mRNA O 0 6.646980210689435e-08
splicing O 0 1.6732435881294805e-07
of O 0 8.913253246589647e-09
the O 0 5.2974048259102346e-08
gene O 0 2.764363216556376e-06
. O 0 8.185645015146292e-07

To O 0 2.1329619812604506e-06
our O 0 1.634827384577875e-07
knowledge O 0 2.0240776166247088e-08
, O 0 1.8839903859202423e-08
this O 0 4.937645847746808e-09
is O 0 7.745312835538698e-09
the O 0 8.716598109970164e-09
first O 0 3.356405500198889e-07
report O 0 1.891276326659863e-07
regarding O 0 2.290419764960916e-08
effects O 0 2.0859687310803565e-07
on O 0 2.3105558000224846e-07
pre O 0 9.755760856933193e-07
- O 0 3.098471097473521e-07
mRNA O 0 4.798950570261695e-08
splicing O 0 7.67673427048976e-08
of O 0 2.862141412762753e-09
a O 0 3.621153155108914e-08
mutation O 0 1.755485214971486e-07
at O 0 2.339102778137203e-08
the O 0 3.195631848029734e-08
- O 0 1.710227479634341e-05
2 O 0 7.10279834947869e-07
position O 0 1.1403523103581392e-07
of O 0 6.156544163360422e-09
a O 0 1.7087157289097377e-07
5 O 0 2.8378210004120774e-07
splice O 0 6.173855217639357e-05
site O 0 1.894916749733966e-05
. O 0 1.5590247812724556e-06

ATM O 0 0.002890652744099498
germline O 0 0.005215685348957777
mutations O 0 0.001015811343677342
in O 0 2.3800216695235576e-06
classical O 0 0.0069922213442623615
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.04255805164575577
in O 0 2.791222470932553e-07
the O 0 3.805917856425367e-07
Dutch O 0 5.2110746764810756e-05
population O 0 9.80967683972267e-07
. O 0 7.278187581505335e-07

Germline O 1 0.8800756335258484
mutations O 0 0.006218875292688608
in O 0 2.921710802183952e-07
the O 0 5.8073286623994136e-08
ATM O 0 2.8262199975870317e-06
gene O 0 8.992735729407286e-07
are O 0 1.0967107222370487e-08
responsible O 0 6.32648848863937e-08
for O 0 1.2281304861971876e-07
the O 0 0.08786794543266296
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.043675441294908524
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.3346424313785974e-06
. O 0 1.877680119832803e-06

In O 0 1.7718197113936185e-06
our O 0 2.0767269859334192e-07
study O 0 4.307975132178399e-08
, O 0 1.6167730265692626e-08
we O 0 8.093118175622749e-09
have O 0 9.097289144222032e-09
determined O 0 3.276809579233486e-08
the O 0 1.1433606950106423e-08
ATM O 0 1.6660097799103823e-06
mutation O 0 3.887510047206888e-07
spectrum O 0 9.487767727023311e-08
in O 0 6.905557459191414e-09
19 O 0 1.9357517544449365e-07
classical O 0 4.3355402112865704e-07
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 6.270984158618376e-07
, O 0 2.6794668706031644e-09
including O 0 1.261251547646225e-09
some O 0 1.7066846824675963e-09
immigrant O 0 2.713826745548431e-07
populations O 0 4.949718146463056e-08
, O 0 1.0024593599666787e-08
as O 0 1.569551777436118e-08
well O 0 1.500241353369347e-08
as O 0 1.1857048676233717e-08
12 O 0 2.205491611562138e-08
of O 0 2.9006004265141883e-09
Dutch O 0 1.4050326626602327e-06
ethnic O 0 1.8420567471366667e-07
origin O 0 2.5766161115825525e-07
. O 0 4.409156417750637e-07

Both O 0 3.318445578770479e-06
the O 0 2.0409962075973453e-07
protein O 0 6.365644935613091e-07
truncation O 0 1.0764652870420832e-05
test O 0 1.2635150596906897e-06
( O 0 1.6365900989967486e-07
PTT O 0 8.808689244688139e-07
) O 0 1.2285482853258145e-08
and O 0 1.0933105087929107e-08
the O 0 1.1196944704749967e-08
restriction O 0 7.776223753808154e-08
endonuclease O 0 2.4356490939680953e-06
fingerprinting O 0 2.198376705564442e-06
( O 0 5.6989819086084026e-08
REF O 0 7.617895789735485e-06
) O 0 3.734132558719239e-09
method O 0 1.6191153306976958e-08
were O 0 1.2635425150619994e-07
used O 0 4.802201303277798e-08
and O 0 2.1703304753373232e-07
compared O 0 5.3361429053211396e-08
for O 0 9.276907575461735e-10
their O 0 2.4610784521428286e-09
detection O 0 5.21654932583715e-08
efficiency O 0 2.0494528740755413e-08
, O 0 2.8442481703194744e-09
identifying O 0 3.0055076649659895e-08
76 O 0 9.077221818643011e-08
% O 0 7.859034312218682e-09
and O 0 1.7544717678674715e-08
60 O 0 6.296873067412889e-08
% O 0 6.609897074127957e-09
of O 0 1.3814565047454153e-09
the O 0 7.122170586626453e-08
mutations O 0 9.26333996176254e-06
, O 0 1.2915367619825702e-07
respectively O 0 1.3940812095825095e-06
. O 0 5.971028826934344e-07

Most O 0 2.229520214314107e-05
patients O 0 3.158728577545844e-05
were O 0 8.227124794757401e-07
found O 0 8.704722631591721e-08
to O 0 3.7160802435209916e-08
be O 0 1.1227681540049161e-07
compound O 0 1.2869772945123259e-05
heterozygote O 0 0.00010508328705327585
. O 0 3.1708016194897937e-06

Seventeen O 0 0.0007155951461754739
mutations O 0 0.0005901620024815202
were O 0 1.0051553545054048e-06
distinct O 0 1.6411993897236243e-07
, O 0 3.482322341596955e-08
of O 0 1.362540125171563e-08
which O 0 1.1923881402253755e-06
10 O 0 1.9810842388778838e-07
were O 0 7.839468594283971e-07
not O 0 1.6488253606894432e-07
reported O 0 3.4894715099653695e-06
previously O 0 3.1179629331745673e-06
. O 0 1.1064797718063346e-06

Mutations O 0 0.002398489508777857
are O 0 3.2219065815297654e-07
small O 0 1.663713788957466e-07
deletions O 0 7.941982403281145e-06
or O 0 1.3097344435664127e-06
point O 0 3.5211902286391705e-05
mutations O 0 8.873848855728284e-05
frequently O 0 2.57579790741147e-06
affecting O 0 9.818605803957325e-07
splice O 0 9.355612564831972e-05
sites O 0 6.334732461255044e-06
. O 0 2.8695772016362753e-06

Moreover O 0 9.339299867860973e-05
, O 0 1.0667074548109667e-06
a O 0 1.1652421108010458e-06
16 O 0 4.798283043783158e-06
. O 0 2.600309016997926e-06

7 O 0 8.297464228235185e-05
- O 0 3.088717858190648e-05
kb O 0 2.7651160053210333e-05
genomic O 0 1.7836737242760137e-06
deletion O 0 2.164874331356259e-06
of O 0 1.9166762399436266e-08
the O 0 5.572723082991615e-08
3 O 0 5.17840305747086e-07
end O 0 1.9148168917126895e-07
of O 0 3.5093117300988297e-09
the O 0 1.8271130386438017e-08
gene O 0 1.7126049556281941e-07
, O 0 1.866193954924711e-08
most O 0 4.592360713928656e-09
likely O 0 3.4632524403832576e-08
a O 0 2.3651455904882823e-08
result O 0 7.895033071747548e-09
of O 0 1.8790442535276952e-09
recombination O 0 1.1631354368546454e-07
between O 0 1.6209220632390497e-07
two O 0 5.105037530483969e-07
LINE O 0 0.08729566633701324
elements O 0 1.3063588539807824e-06
, O 0 2.5654404112174234e-07
was O 0 1.0157832548429724e-05
identified O 0 2.8773433768947143e-06
. O 0 8.371934541173687e-07

The O 0 1.7250741848329199e-06
most O 0 9.658543120849572e-08
frequently O 0 4.7525495006084384e-07
found O 0 5.542955818782502e-07
mutation O 0 1.5358733662651503e-06
, O 0 2.2167986557519725e-08
identified O 0 9.76665575080915e-08
in O 0 6.194377011325969e-09
three O 0 4.28024300447305e-08
unrelated O 0 5.408566039477591e-07
Turkish O 0 2.618557573441649e-06
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999972581863403
T I-Disease 1 1.0
individuals O 0 4.5563641748458394e-08
, O 0 2.2535342480978215e-08
was O 0 1.4491313322650967e-06
previously O 0 2.452275680298044e-07
described O 0 2.449172029628244e-07
to O 0 1.889669221100121e-08
be O 0 1.2176259112095522e-08
a O 0 6.339787717024592e-08
Turkish O 0 2.8795284379157238e-06
A B-Disease 1 0.9999960660934448
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
founder O 0 4.5599797886097804e-05
mutation O 0 9.771965778782032e-06
. O 0 7.665438488402287e-07

The O 0 2.7215551199333277e-06
presence O 0 3.3889332939907035e-07
of O 0 1.7915274597157804e-08
a O 0 2.1045354969828622e-07
founder O 0 9.979962669603992e-06
mutation O 0 1.7760643231667927e-06
among O 0 1.2887507949699284e-08
relatively O 0 8.682200736132017e-09
small O 0 6.1459375366723634e-09
ethnic O 0 4.674604170418206e-08
population O 0 9.812530343822345e-09
groups O 0 1.5937480224437195e-09
in O 0 1.4478009902063604e-09
Western O 0 4.868975267413589e-08
Europe O 0 3.0582725685235346e-07
could O 0 1.0531488925380472e-07
indicate O 0 2.3852283703718058e-08
a O 0 1.5222457960817337e-08
high O 0 3.414031084503222e-07
carrier O 0 2.357844834932621e-07
frequency O 0 1.629960877380654e-07
in O 0 1.0105954295624997e-08
such O 0 1.3604082305107568e-08
communities O 0 3.3145036582027387e-07
. O 0 4.79998050195718e-07

In O 0 1.2517371942522004e-05
patients O 0 4.897410690318793e-06
of O 0 3.1317970439204146e-08
Dutch O 0 4.242054274072871e-06
ethnic O 0 3.855800798646669e-07
origin O 0 1.4253929236929253e-07
, O 0 8.780142479736242e-08
however O 0 4.256470376162724e-08
, O 0 1.0828611785029807e-08
no O 0 8.516789939960745e-09
significant O 0 1.2737411125840481e-08
founder O 0 2.651327690728067e-07
effect O 0 5.6290854644203137e-08
could O 0 1.4907918455264735e-07
be O 0 4.2647268827522566e-08
identified O 0 1.8781619246510672e-06
. O 0 6.663533440587344e-07

The O 0 9.887709893519059e-06
observed O 0 1.66224199347198e-05
genetic O 0 3.740439979083021e-06
heterogeneity O 0 2.851754288712982e-06
including O 0 4.625645644296128e-08
the O 0 2.955498956680458e-08
relative O 0 4.6945069698267616e-07
high O 0 1.0103700560648576e-06
percentage O 0 7.218553150778462e-07
of O 0 1.0088776036809577e-08
splice O 0 0.00010274389205733314
- O 0 0.00011179307330166921
site O 0 1.855079062806908e-05
mutations O 0 9.615210728952661e-06
had O 0 6.24356198386522e-06
no O 0 8.129664763600886e-08
reflection O 0 1.5640478068235097e-07
on O 0 3.9649935956731497e-07
the O 0 1.1828676633740542e-06
phenotype O 0 0.00027027371106669307
. O 0 1.7509735243947944e-06

All O 0 1.1737793101929128e-05
patients O 0 1.3331995432963595e-05
manifested O 0 6.799057246098528e-06
classical O 0 2.6699340196501e-06
A B-Disease 1 0.9999955892562866
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
and O 0 3.977916378516966e-07
increased O 0 2.181635920806002e-07
cellular O 0 1.1328756954753771e-06
radioresistant O 0 9.33783667278476e-06
DNA O 0 3.147600182273891e-06
synthesis O 0 2.9856669243599754e-06
. O 0 1.0599234201436047e-06

Determination O 0 7.153761544032022e-05
of O 0 1.7269985619350336e-07
the O 0 4.1398742212095385e-08
genomic O 0 7.182296144492284e-07
structure O 0 1.4939870141006395e-07
of O 0 4.5797121650537065e-09
the O 0 6.067239155527204e-08
COL4A4 O 0 4.692776201409288e-05
gene O 0 3.8939884916544543e-07
and O 0 5.450113604865692e-08
of O 0 3.9564337583897213e-08
novel O 0 9.426231554243714e-05
mutations O 0 0.09989260882139206
causing O 0 0.0006553789717145264
autosomal B-Disease 1 0.9999990463256836
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.8835190682439134e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.0279873094987124e-05
a O 0 7.492207259929273e-06
progressive O 0 0.006763668730854988
hematuric B-Disease 1 0.9158586859703064
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.00039745800313539803
by O 0 4.663285722017463e-07
glomerular B-Disease 0 0.46024835109710693
basement I-Disease 1 0.9993276596069336
membrane I-Disease 1 0.9309408068656921
abnormalities I-Disease 1 0.9999992847442627
and O 0 1.5901346159807872e-06
associated O 0 6.483066385953862e-07
with O 0 2.360351203378741e-07
mutations O 0 9.025917279359419e-06
in O 0 5.1452236249360794e-08
either O 0 7.606976026863776e-08
the O 0 1.181827400387192e-07
COL4A3 O 0 0.00012907553173135966
or O 0 4.9878732255592695e-08
the O 0 2.924690001293584e-08
COL4A4 O 0 1.820098259486258e-05
gene O 0 1.4631065425874112e-07
, O 0 1.4504578871310514e-08
which O 0 5.4370703495010275e-09
encode O 0 4.262059505322213e-08
the O 0 3.3891879525072e-08
alpha3 O 0 1.2892953236587346e-05
and O 0 2.088396939825543e-07
alpha4 O 0 8.826770681480411e-06
type O 0 1.0316948646504898e-06
IV O 0 9.302201942773536e-05
collagen O 0 9.846401553659234e-06
chains O 0 5.360653085517697e-05
, O 0 1.501455670904761e-07
respectively O 0 8.286045840577572e-07
. O 0 1.0201633813267108e-06

To O 0 1.150532511928759e-06
date O 0 6.268580250434752e-07
, O 0 3.68031116693146e-08
mutation O 0 1.7901308524415072e-07
screening O 0 4.606293657616334e-08
in O 0 6.6354894912024065e-09
the O 0 8.100499826468877e-09
two O 0 1.1895652818338931e-07
genes O 0 8.914547038330056e-07
has O 0 1.0871980521187652e-05
been O 0 4.119106961297803e-06
hampered O 0 0.0004309966752771288
by O 0 3.6046831297653625e-08
the O 0 7.060494056077005e-08
lack O 0 5.1932790512410065e-08
of O 0 8.12640532643627e-09
genomic O 0 1.4124755125521915e-06
structure O 0 4.0290041170010227e-07
information O 0 1.514034408955922e-07
. O 0 6.507118541776435e-07

We O 0 2.4904165911721066e-05
report O 0 6.099322149566433e-07
here O 0 4.783570162203432e-08
the O 0 1.5820189602777646e-08
complete O 0 9.64631823308082e-08
characterization O 0 5.624330583486881e-07
of O 0 6.276773767410759e-09
the O 0 5.3298872870755076e-08
48 O 0 1.5300562949960295e-07
exons O 0 2.9752592922704935e-07
of O 0 4.328077007897946e-09
the O 0 2.969795431795319e-08
COL4A4 O 0 8.6226464190986e-06
gene O 0 5.463154195695097e-08
, O 0 2.6749680248627783e-09
a O 0 5.079228593274365e-09
comprehensive O 0 1.982522057630831e-08
gene O 0 1.3301031742685154e-07
screen O 0 1.5081077435752377e-05
, O 0 1.1882216455205707e-07
and O 0 2.3249848268847018e-08
the O 0 6.9809900082873355e-09
subsequent O 0 1.992841625053643e-08
detection O 0 6.171853783598635e-08
of O 0 3.4000702253678128e-09
10 O 0 3.073560961297517e-08
novel O 0 3.439990905462764e-07
mutations O 0 7.041812750685494e-07
in O 0 6.520331652382083e-08
eight O 0 4.147746949456632e-05
patients O 0 9.520196908852085e-05
diagnosed O 0 0.31502577662467957
with O 0 0.00013833925186190754
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.5994537281803787e-05

Furthermore O 0 0.00012452695227693766
, O 0 1.417852445229073e-06
we O 0 3.787047120340503e-08
identified O 0 3.878828991332739e-08
a O 0 1.3463142600755873e-08
glycine O 0 5.704125101146929e-07
to O 0 1.1512735653695927e-08
alanine O 0 5.329185910341039e-07
substitution O 0 4.740644143907957e-08
in O 0 1.9298012077229032e-08
the O 0 1.7232501647868048e-08
collagenous O 0 3.5203929655835964e-06
domain O 0 4.1278109819131714e-08
that O 0 2.0395052757749e-08
is O 0 4.036283485220338e-08
apparently O 0 1.224479774464271e-06
silent O 0 2.6219484539069526e-07
in O 0 4.553338595059131e-09
the O 0 2.5149725857431804e-08
heterozygous O 0 4.3255005266473745e-07
carriers O 0 4.5196991038665146e-08
, O 0 7.485025044218219e-09
in O 0 4.554348365104488e-08
11 O 0 6.821007900725817e-07
. O 0 5.734549404223799e-07

5 O 0 5.0563932745717466e-05
% O 0 5.341499331734667e-07
of O 0 1.0466822963905997e-08
all O 0 7.540695179386603e-09
control O 0 7.863009159336798e-07
individuals O 0 1.8759152453640127e-08
, O 0 1.221100554005261e-08
and O 0 7.61956613359871e-08
in O 0 3.54429268156764e-08
one O 0 1.2885263345197018e-07
control O 0 1.5935047485982068e-06
individual O 0 4.191742775105922e-08
homozygous O 0 7.292750865417474e-07
for O 0 4.509174811317962e-09
this O 0 2.1112251502586332e-08
glycine O 0 2.841760760929901e-06
substitution O 0 1.7565145071785082e-06
. O 0 1.5465413980564335e-06

There O 0 2.797180786728859e-05
has O 0 1.0734755733210477e-06
been O 0 2.2267069255121896e-07
no O 0 2.6768017136191702e-08
previous O 0 5.873441821790948e-08
finding O 0 2.272109966838798e-08
of O 0 1.3992851322086608e-09
a O 0 1.4407688375683847e-08
glycine O 0 2.1625083945764345e-07
substitution O 0 3.6940392078577133e-08
that O 0 3.0349035284871206e-08
is O 0 2.872303994649883e-08
not O 0 5.6036939533044006e-09
associated O 0 1.0792877702670012e-08
with O 0 8.18508194555534e-09
any O 0 6.221969073294531e-08
obvious O 0 3.8971529647824354e-06
phenotype O 0 7.235852535814047e-05
in O 0 2.2353302142619214e-07
homozygous O 0 5.8608191466191784e-05
individuals O 0 1.8128049816823477e-07
. O 0 4.3716369191315607e-07

Founder O 0 0.0010340046137571335
BRCA1 O 0 0.010847036726772785
and O 0 3.254459807067178e-05
BRCA2 O 0 0.005507863126695156
mutations O 0 4.706670006271452e-05
in O 0 3.1636537300983036e-07
French O 0 0.0001673194346949458
Canadian O 0 0.0011195429833605886
breast B-Disease 1 0.9999781847000122
and I-Disease 1 0.9992703795433044
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.6973424862953834e-05
. O 0 1.926870027091354e-06

We O 0 1.0932000805041753e-05
have O 0 1.6577034500642185e-07
identified O 0 5.074656428405433e-07
four O 0 2.1356396473493078e-07
mutations O 0 1.3979647519590799e-06
in O 0 1.2323219777954364e-08
each O 0 1.0759209523314439e-08
of O 0 1.2620414935327062e-08
the O 0 3.1871029477770207e-06
breast B-Disease 1 0.9983025789260864
cancer I-Disease 0 0.007182293105870485
- O 0 0.00028551791911013424
susceptibility O 0 6.182627839734778e-05
genes O 0 1.335053525508556e-06
, O 0 1.269166745032635e-07
BRCA1 O 0 2.2474583602161147e-05
and O 0 1.462925524720049e-06
BRCA2 O 0 2.8887487133033574e-05
, O 0 3.2142516204203275e-08
in O 0 4.1605506595487896e-08
French O 0 2.1349716917029582e-05
Canadian O 0 7.558067591162398e-05
breast B-Disease 1 0.8974274396896362
cancer I-Disease 0 0.002619441831484437
and O 0 7.097898196661845e-05
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.2604682473902358e-06
from O 0 2.6079356985064805e-07
Quebec O 0 5.914438224863261e-05
. O 0 1.9765789147641044e-06

To O 0 7.363064469245728e-06
identify O 0 4.1724620132299606e-06
founder O 0 3.422778490858036e-06
effects O 0 2.0122292880841997e-06
, O 0 1.044825665985627e-07
we O 0 2.3794484604877653e-08
examined O 0 2.440130799641338e-07
independently O 0 3.630330240866897e-07
ascertained O 0 2.132701638402068e-06
French O 0 9.425344615010545e-06
Canadian O 0 2.3627440896234475e-05
cancer B-Disease 0 8.69113500812091e-06
families O 0 3.871231157859256e-08
for O 0 2.096529172490591e-09
the O 0 4.4921604214209765e-09
distribution O 0 1.3862453407398334e-08
of O 0 2.50040699256715e-09
these O 0 9.971028447353092e-09
eight O 0 6.52685798741004e-07
mutations O 0 1.1942741366510745e-05
. O 0 7.126885179786768e-07

Mutations O 0 0.06038125231862068
were O 0 4.000158241979079e-06
found O 0 1.805338030180792e-07
in O 0 6.540347641248445e-08
41 O 0 6.45550130684569e-07
of O 0 1.9669851525350168e-08
97 O 0 2.1388264030974824e-06
families O 0 5.996651566420041e-07
. O 0 8.967343205767975e-07

Six O 0 5.90216177442926e-06
of O 0 1.0571579167617529e-07
eight O 0 7.770661341055529e-07
mutations O 0 6.771607331756968e-06
were O 0 3.930822458642069e-07
observed O 0 5.48461969174241e-07
at O 0 1.4723573826813663e-07
least O 0 1.4284124461028114e-07
twice O 0 1.9582332697609672e-06
. O 0 5.712644792765786e-07

The O 0 7.599342552566668e-06
BRCA1 O 0 0.0009705422562547028
C4446T O 0 0.00013744033640250564
mutation O 0 9.133787534665316e-05
was O 0 4.349067694420228e-06
the O 0 2.519860764493842e-08
most O 0 1.391527515437474e-08
common O 0 1.3236268614491564e-07
mutation O 0 1.5091533214217634e-06
found O 0 1.281329531366282e-07
, O 0 2.4527242459271292e-08
followed O 0 8.564212805595162e-08
by O 0 9.795344091401148e-09
the O 0 2.789192308227939e-07
BRCA2 O 0 0.0004460472264327109
8765delAG O 0 4.1135004721581936e-05
mutation O 0 1.1286223525530659e-05
. O 0 9.089571904041804e-07

Together O 0 1.7266116628888994e-05
, O 0 3.455355113146652e-07
these O 0 3.2657219151133177e-08
mutations O 0 1.341850634162256e-06
were O 0 1.9072207635417726e-07
found O 0 3.650639968100222e-08
in O 0 2.9830456327317734e-08
28 O 0 5.451142328638525e-07
of O 0 6.121042783746589e-09
41 O 0 1.105757178265776e-06
families O 0 4.213160309518571e-08
identified O 0 1.9156114205998165e-07
to O 0 2.0712315418336402e-08
have O 0 1.3096703810333565e-07
a O 0 7.582074204037781e-07
mutation O 0 1.2181262718513608e-05
. O 0 5.634552167066431e-07

The O 0 4.4942935346625745e-06
odds O 0 4.558760338113643e-06
of O 0 3.04435374687273e-08
detection O 0 3.150009604269144e-07
of O 0 4.964654465311469e-09
any O 0 4.158922095598427e-09
of O 0 4.152548971347869e-09
the O 0 7.290304182561158e-08
four O 0 7.043302957754349e-06
BRCA1 O 0 0.03183675929903984
mutations O 0 3.630591163528152e-05
was O 0 2.5456276489421725e-05
18 O 0 1.5493195633098367e-06
. O 0 7.81462745180761e-07

7x O 0 0.002234862418845296
greater O 0 9.982799383578822e-06
if O 0 4.0923151800598134e-07
one O 0 3.888339961122256e-08
or O 0 1.7376668992596933e-08
more O 0 5.10815123533348e-09
cases O 0 1.2175716790352453e-07
of O 0 1.4141308383841533e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.0006582853966392577
also O 0 2.3089487513061613e-06
present O 0 3.562537997936488e-08
in O 0 3.7565655475191306e-08
the O 0 1.1877276762106703e-07
family O 0 4.146135779592441e-06
. O 0 1.2986549791094149e-06

The O 0 3.1399729323311476e-06
odds O 0 8.792174412519671e-06
of O 0 2.2416079659137722e-08
detection O 0 3.4129502068935835e-07
of O 0 6.927377338428187e-09
any O 0 4.469836500931024e-09
of O 0 6.957329379275734e-09
the O 0 1.3775490970147075e-07
four O 0 5.631572548736585e-06
BRCA2 O 0 0.01789284311234951
mutations O 0 3.0939736461732537e-05
was O 0 1.1451913451310247e-05
5 O 0 9.137548886428704e-07
. O 0 1.3601962791653932e-06

3x O 0 0.0008429703302681446
greater O 0 6.572093298018444e-06
if O 0 2.046377574060898e-07
there O 0 2.8764157278260427e-08
were O 0 1.2103787128125987e-07
at O 0 2.0004849332622143e-08
least O 0 6.43922914989048e-09
five O 0 9.402122636004151e-09
cases O 0 2.080683003669037e-08
of O 0 1.7475625213592139e-07
breast B-Disease 1 0.9996449947357178
cancer I-Disease 0 0.00134936417452991
in O 0 1.5805582620487257e-07
the O 0 4.468620034003834e-07
family O 0 4.819442438019905e-06
. O 0 2.2260387595451903e-06

Interestingly O 0 0.00036300456849858165
, O 0 5.191506602386653e-07
the O 0 2.1276781225765262e-08
presence O 0 3.47209550000116e-08
of O 0 1.1074752670481303e-08
a O 0 5.0432904572517145e-06
breast B-Disease 1 0.9623187780380249
cancer I-Disease 0 1.708404852251988e-05
case O 0 1.1790906739861384e-07
< O 0 3.876237428812601e-07
36 O 0 9.721919269622958e-08
years O 0 7.585138739329977e-09
of O 0 3.0855420440900616e-09
age O 0 8.780042293210499e-08
was O 0 6.504382668026665e-07
strongly O 0 1.8280402969139686e-08
predictive O 0 5.008054415611696e-08
of O 0 2.3413735394939295e-09
the O 0 7.826648662501157e-09
presence O 0 1.1082085471514347e-08
of O 0 7.479769026375038e-10
any O 0 1.2520642300728468e-09
of O 0 1.7346227787484736e-09
the O 0 2.303457513619378e-08
eight O 0 1.0848601732504903e-06
mutations O 0 1.2073254765709862e-05
screened O 0 9.365232472191565e-06
. O 0 9.443973567613284e-07

Carriers O 0 3.094652493018657e-05
of O 0 7.797506640372376e-08
the O 0 2.8038787291961853e-08
same O 0 8.533866946436319e-08
mutation O 0 1.2431127061063307e-06
, O 0 8.119201311274082e-09
from O 0 2.010099420246547e-09
different O 0 3.379380997259318e-09
families O 0 2.5972079598091113e-08
, O 0 6.073431091380144e-09
shared O 0 1.18408669536052e-08
similar O 0 4.3396848781185327e-08
haplotypes O 0 5.276145657262532e-06
, O 0 1.0459143595653586e-07
indicating O 0 2.821863347435283e-07
that O 0 3.0190940858432214e-09
the O 0 6.427780530060545e-09
mutant O 0 1.328845769421605e-06
alleles O 0 2.172714061998704e-07
were O 0 6.869368007755838e-07
likely O 0 1.6119609824727377e-07
to O 0 3.54448204120672e-08
be O 0 3.324915454072652e-08
identical O 0 3.577733878046274e-07
by O 0 1.6157835958097166e-08
descent O 0 1.608482875781192e-06
for O 0 4.83178252963512e-09
a O 0 5.135409537615487e-07
mutation O 0 1.5389744021376828e-06
in O 0 2.4696003464441674e-08
the O 0 8.967551679006647e-08
founder O 0 4.251020527590299e-06
population O 0 2.3296286144613987e-07
. O 0 4.3726959120249376e-07

The O 0 1.7349632344121346e-06
identification O 0 5.928535529164947e-07
of O 0 6.660724949369978e-08
common O 0 1.4689635463582817e-06
BRCA1 O 0 0.0030978452414274216
and O 0 3.434190512052737e-05
BRCA2 O 0 0.005340175237506628
mutations O 0 7.91920319898054e-06
will O 0 1.5086863314195398e-08
facilitate O 0 5.5547886290696624e-08
carrier O 0 3.312929663934483e-07
detection O 0 3.1608547601535975e-07
in O 0 1.1968228363912203e-07
French O 0 9.838907863013446e-05
Canadian O 0 0.00023174297530204058
breast B-Disease 1 0.9978265166282654
cancer I-Disease 0 0.11477283388376236
and O 0 0.0020198363345116377
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0620548891893122e-05
. O 0 1.6139497347467113e-06

Are O 0 7.686853678023908e-06
Dp71 O 0 0.00027530748047865927
and O 0 3.941493559977971e-06
Dp140 O 0 0.00041314217378385365
brain O 0 0.00041359022725373507
dystrophin O 0 5.69300536881201e-05
isoforms O 0 5.325656729837647e-06
related O 0 6.672067343060917e-07
to O 0 8.485789066980942e-07
cognitive B-Disease 0 0.004075034521520138
impairment I-Disease 0 0.019117996096611023
in O 0 0.00010450550325913355
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 0.9999972581863403
dystrophy I-Disease 1 0.9999938011169434
? O 0 0.00020485877757892013

Molecular O 0 4.510864528128877e-05
study O 0 8.154432293849823e-07
and O 0 1.5612283732480137e-07
neuropsychological O 0 2.151262151528499e-06
analysis O 0 7.354941544690519e-08
were O 0 4.043265562359011e-07
performed O 0 3.090730160693056e-07
concurrently O 0 9.104253706482268e-08
on O 0 2.2442213776230346e-06
49 O 0 1.2097101716790348e-05
patients O 0 1.5104851627256721e-06
with O 0 1.2664292626141105e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999995231628418
( O 0 3.289469168521464e-05
DMD B-Disease 1 1.0
) O 0 3.689962113639922e-07
in O 0 4.2119950194319244e-08
order O 0 2.5691829108609454e-08
to O 0 8.045867083694702e-09
find O 0 1.615219602513207e-08
a O 0 1.944758842853389e-08
molecular O 0 7.633254028860392e-08
explanation O 0 1.2317909359182977e-08
for O 0 2.4452866398405604e-09
the O 0 8.768595449737404e-08
cognitive B-Disease 0 3.183271110174246e-05
impairment I-Disease 0 6.9076540967216715e-06
observed O 0 6.350013563860557e-07
in O 0 2.452135561270552e-07
most O 0 4.625677320291288e-06
DMD B-Disease 1 1.0
patients O 0 0.00013276514073368162
. O 0 1.7958110447580111e-06

Complete O 0 8.746161256567575e-06
analysis O 0 4.208951907003211e-07
of O 0 2.5613447363070918e-08
the O 0 4.936782360687175e-08
dystrophin O 0 9.072226021089591e-06
gene O 0 2.2349026949086692e-06
was O 0 0.00516622606664896
performed O 0 1.5354809193013352e-06
to O 0 1.3152698485896508e-08
define O 0 1.5227212202262308e-07
the O 0 2.5227123501281312e-08
localization O 0 1.4038926110515604e-07
of O 0 5.863029617358961e-09
deletions O 0 8.512807653460186e-06
and O 0 6.418410407604824e-07
duplications O 0 2.24172072194051e-06
in O 0 3.185365926583472e-08
relation O 0 4.9338076735239156e-08
to O 0 2.8559590248278255e-08
the O 0 1.2452765929538145e-07
different O 0 1.547520923850243e-06
DMD B-Disease 1 0.9999997615814209
promoters O 0 9.278069774154574e-05
. O 0 2.855389766409644e-06

Qualitative O 0 1.577467810420785e-05
analysis O 0 7.773344918859948e-07
of O 0 3.0954407037597775e-08
the O 0 5.001009739658002e-08
Dp71 O 0 1.770215021679178e-05
transcript O 0 1.5785150026204064e-05
and O 0 2.4125995423673885e-07
testing O 0 1.7637455940189284e-08
for O 0 7.840450511054087e-10
the O 0 2.222347417202286e-09
specific O 0 2.425008194251177e-09
first O 0 1.1014273937348662e-08
exon O 0 2.1696970975426666e-07
of O 0 1.1986226233773323e-08
Dp140 O 0 5.009195319871651e-06
were O 0 1.755464609232149e-06
also O 0 4.556451074222423e-07
carried O 0 8.267836051345512e-07
out O 0 2.929092772774311e-07
. O 0 6.222859383342438e-07

Neuropsychological O 0 0.0009589242399670184
analysis O 0 9.687399142421782e-06
assessed O 0 1.3326161024451721e-05
verbal O 0 1.194317519548349e-05
and O 0 1.5306299019357539e-06
visuospatial O 0 4.594244092004374e-05
intelligence O 0 1.3125340956321452e-06
, O 0 1.308045227688126e-07
verbal O 0 1.718265139061259e-06
memory O 0 5.004965350963175e-05
, O 0 3.063874487452267e-07
and O 0 3.4532766335360066e-07
reading O 0 1.3064734503132058e-06
skills O 0 1.8467037534719566e-06
. O 0 1.3297737950779265e-06

Comparison O 0 1.0294971616531257e-05
of O 0 1.0847509912537134e-07
molecular O 0 1.6481553757330403e-06
and O 0 1.7773152194422437e-07
psychometric O 0 4.326401722209994e-06
findings O 0 8.073947128650616e-07
demonstrated O 0 3.4471236176614184e-07
that O 0 1.0843492326273463e-08
deletions O 0 2.541626599850133e-06
and O 0 3.0548238783012494e-07
duplications O 0 4.584089765558019e-06
that O 0 1.5092223293322604e-07
were O 0 2.8319570333223965e-07
localized O 0 2.9437796911224723e-06
in O 0 1.945410446069218e-07
the O 0 1.1797611421116017e-07
distal O 0 1.1495309991005342e-05
part O 0 3.8052789363973716e-08
of O 0 3.5643372697791165e-09
the O 0 2.4689596145321957e-08
gene O 0 2.5225781996596197e-07
seemed O 0 4.5445861474036064e-07
to O 0 1.6653006085221023e-08
be O 0 2.6660403662503995e-08
preferentially O 0 4.036769780668692e-07
associated O 0 1.820188231249631e-07
with O 0 2.72747939789042e-07
cognitive B-Disease 0 0.00016695543308742344
impairment I-Disease 0 0.0001253717055078596
. O 0 1.8570244719740003e-06

Two O 0 6.399533049261663e-06
altered O 0 2.097985452564899e-05
Dp71 O 0 4.916180841973983e-05
transcripts O 0 3.96343875763705e-06
and O 0 8.260870032472667e-08
two O 0 2.9576419535715104e-08
deleted O 0 2.4511959964002017e-06
Dp140 O 0 2.1582404770015273e-06
DNA O 0 4.680720167016261e-07
sequences O 0 2.602842243959458e-07
were O 0 2.362080664397581e-07
found O 0 2.8339552926581746e-08
in O 0 4.672812181638619e-08
four O 0 8.379091127608262e-07
patients O 0 1.8468622329237405e-06
with O 0 1.6530684661120176e-06
severe O 1 0.9543544054031372
cerebral B-Disease 1 0.998164713382721
dysfunction I-Disease 1 0.7840709686279297
. O 0 9.451125151827e-06

These O 0 1.4959160807848093e-06
findings O 0 6.92319190420676e-07
suggest O 0 2.3080981748080376e-07
that O 0 6.5059686527035865e-09
some O 0 1.7391049711434903e-09
sequences O 0 8.939186812995104e-08
located O 0 1.2542811589355551e-07
in O 0 3.679412685642092e-08
the O 0 1.6278141856673756e-07
distal O 0 1.5701374650234357e-05
part O 0 6.642240890641915e-08
of O 0 4.959505695012467e-09
the O 0 1.8645929245053594e-08
gene O 0 1.99203654460689e-07
and O 0 3.5298796774441143e-07
, O 0 2.071259253000335e-08
in O 0 8.962332209705437e-09
particular O 0 2.2457591342117666e-08
, O 0 1.473928801232205e-08
some O 0 1.683780581629435e-08
DMD B-Disease 1 0.9998446702957153
isoforms O 0 6.648730277447612e-07
expressed O 0 3.777344304012331e-08
in O 0 4.319321078583016e-08
the O 0 5.151921413926175e-07
brain O 0 0.005494313780218363
may O 0 2.8530025701911654e-06
be O 0 1.1350928197373378e-08
related O 0 1.1385404619090878e-08
to O 0 1.2802736648609425e-08
the O 0 2.4017640498641413e-07
cognitive B-Disease 0 0.00010457448661327362
impairment I-Disease 0 3.0734478059457615e-05
associated O 0 1.8773955616779858e-06
with O 0 1.5189621990430169e-05
DMD B-Disease 1 1.0
. O 0 4.929184342472581e-06
. O 0 2.544134076742921e-06

I1307K O 0 0.0016080852365121245
APC O 0 0.00019473345309961587
and O 0 2.039849277934991e-06
hMLH1 O 0 3.899088915204629e-05
mutations O 0 1.0345281225454528e-05
in O 0 2.3618456523877285e-08
a O 0 1.3268015663925325e-07
non O 0 3.4903928280982655e-07
- O 0 1.0156883945455775e-05
Jewish O 0 1.3644082628161414e-06
family O 0 6.234180887076946e-07
with O 0 4.3581579234341916e-07
hereditary B-Disease 1 0.9551171064376831
non I-Disease 0 0.004724419675767422
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5399949916172773e-05

We O 0 8.072452146734577e-06
describe O 0 1.9465680907160277e-06
a O 0 6.637060323555488e-07
French O 0 7.548344001406804e-05
Canadian O 0 8.259878086391836e-05
hereditary B-Disease 1 0.9768046736717224
non I-Disease 0 0.006705365609377623
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.042625657049939e-05
HNPCC B-Disease 0 0.22481900453567505
) O 0 1.1566968396437005e-06
kindred O 0 3.503788684611209e-05
which O 0 3.3287395240222395e-07
carries O 0 5.278624257698539e-07
a O 0 1.917759107072925e-07
novel O 0 2.340788796573179e-06
truncating O 0 1.8168502720072865e-05
mutation O 0 8.277040251414292e-06
in O 0 1.7593886525446578e-07
hMLH1 O 0 4.024987720185891e-05
. O 0 3.431181312407716e-06

Interestingly O 0 0.00016240325930994004
, O 0 5.440288077807054e-07
the O 0 1.0271704553588279e-07
I1307K O 0 8.793615961621981e-06
APC O 0 6.959826805541525e-06
polymorphism O 0 1.8359134628553875e-05
, O 0 3.1877849693273674e-08
associated O 0 1.5265053221469316e-08
with O 0 3.4512690483268216e-09
an O 0 3.886983179768322e-08
increased O 0 3.961806214647368e-06
risk O 0 7.475805887224851e-06
of O 0 0.001952759688720107
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.0406029004079755e-06
is O 0 1.548089159086885e-07
also O 0 6.08730488238507e-07
present O 0 2.41405810896822e-08
in O 0 2.3647755753586353e-08
this O 0 5.35257456135696e-08
family O 0 2.07870539270516e-06
. O 0 9.885162626233068e-07

The O 0 2.761615178314969e-06
I1307K O 0 1.8378352251602337e-05
polymorphism O 0 5.020382013753988e-05
has O 0 7.88098134307802e-07
previously O 0 2.5127917524514487e-07
only O 0 2.027094936352114e-08
been O 0 1.6643042499708827e-07
identified O 0 3.128299113086541e-07
in O 0 9.889923546779755e-09
individuals O 0 2.011426580850184e-09
of O 0 6.02353633638586e-09
self O 0 5.712792699341662e-06
- O 0 0.0017911471659317613
reported O 0 2.2940956114325672e-05
Ashkenazi O 0 9.448934179090429e-06
Jewish O 0 7.368849423983193e-07
origins O 0 2.4640539777465165e-06
. O 0 8.526397436980915e-07

In O 0 1.7951673498828313e-06
addition O 0 1.9565237607821473e-07
, O 0 1.8623502739956166e-08
in O 0 8.944162743773632e-09
this O 0 1.5899383143391788e-08
family O 0 1.629606600772604e-07
, O 0 2.9478986363074e-08
there O 0 1.0137790162900728e-08
appears O 0 4.192670530756004e-07
to O 0 2.9219243913303217e-08
be O 0 2.7163892468706763e-08
no O 0 9.492688413104133e-09
relationship O 0 1.9362717651461026e-08
between O 0 1.4155669525450776e-08
the O 0 3.505225976141446e-08
I1307K O 0 2.909706154241576e-06
polymorphism O 0 4.440185421117349e-06
and O 0 2.5270706416335997e-08
the O 0 5.9151483711161745e-09
presence O 0 3.201463982804853e-08
or O 0 4.1681122553427485e-08
absence O 0 7.453329686768484e-08
of O 0 6.739522717680302e-08
cancer B-Disease 0 2.8504699002951384e-05
. O 0 1.5800684138866927e-07
. O 0 7.943899049678294e-07

Identification O 0 6.52374183118809e-06
of O 0 8.855709410227064e-08
a O 0 3.8686778225383023e-07
novel O 0 4.5280144149728585e-06
mutation O 0 2.818218490574509e-06
of O 0 1.560917972653897e-08
the O 0 1.485979908011359e-07
CPO O 0 3.308051236672327e-05
gene O 0 1.4602015596665296e-07
in O 0 2.7229669186112915e-08
a O 0 4.7157044491541455e-07
Japanese O 0 5.825600055686664e-06
hereditary B-Disease 0 0.007079921197146177
coproporphyria I-Disease 0 0.00011453054321464151
family O 0 3.881126303895144e-06
. O 0 1.5427407333845622e-06

Hereditary B-Disease 1 0.9999649524688721
coproporphyria I-Disease 1 0.6238806247711182
( O 0 1.657015673117712e-05
HCP B-Disease 0 0.0015417381655424833
) O 0 2.665636600340804e-07
is O 0 6.204418667721256e-08
an O 0 1.244723648596846e-06
autosomal B-Disease 1 0.9999562501907349
dominant I-Disease 1 0.9995582699775696
disease I-Disease 1 0.8590399026870728
characterized O 0 3.9246471715159714e-05
by O 0 4.4320060510472103e-07
a O 0 0.0001536337222205475
deficiency B-Disease 0 0.011990844272077084
of I-Disease 0 2.143184119063335e-08
coproporphyrinogen I-Disease 0 0.00012580043403431773
oxidase I-Disease 0 3.9670808291703e-06
( O 0 1.4155945393667935e-07
CPO O 0 4.1073071770370007e-05
) O 0 3.674734827541215e-08
caused O 0 6.143302755390323e-08
by O 0 2.9764968267897984e-09
a O 0 1.8746352736798144e-07
mutation O 0 1.0699882295739371e-06
in O 0 2.116159869558487e-08
the O 0 2.1419789675292122e-07
CPO O 0 7.966427801875398e-05
gene O 0 4.06412846132298e-06
. O 0 1.3666416407431825e-06

Only O 0 1.0069215932162479e-05
11 O 0 4.021064796688734e-06
mutations O 0 1.4000555665916181e-06
of O 0 8.155036645973723e-09
the O 0 3.024340244905943e-08
gene O 0 4.5071735144119884e-07
have O 0 7.305071676455555e-07
been O 0 1.99340024664707e-06
reported O 0 1.0090632713399827e-05
in O 0 8.571776675125875e-07
HCP B-Disease 0 0.12199567258358002
patients O 0 9.312331712862942e-06
. O 0 1.0833351780092926e-06

We O 0 1.2637471627385821e-05
report O 0 8.202102321774873e-07
another O 0 2.765964381978847e-07
mutation O 0 1.1277059002168244e-06
in O 0 3.48207009892576e-08
a O 0 5.089268029223604e-07
Japanese O 0 2.91219885184546e-06
family O 0 1.954127128556138e-06
. O 0 1.165159915217373e-06

Polymerase O 0 0.0002910457842517644
chain O 0 0.00017536226368974894
reaction O 0 5.550759851757903e-06
- O 0 7.542879757238552e-06
single O 0 1.0790303122121259e-06
strand O 0 2.0637391571654007e-05
conformational O 0 5.662267312800395e-07
polymorphism O 0 3.092141469096532e-06
and O 0 1.2323501330513409e-08
direct O 0 1.4785296542640936e-08
sequence O 0 1.1700309698881028e-07
analyses O 0 1.52264291841675e-07
demonstrated O 0 5.4313929354066204e-08
a O 0 3.790421843063996e-08
C O 0 9.494661981079844e-07
to O 0 1.8547357427678435e-08
T O 0 1.148766273217916e-06
substitution O 0 1.2033024354707322e-08
in O 0 4.3927053106074254e-09
exon O 0 2.374851675313039e-07
1 O 0 4.302818013002252e-08
of O 0 3.4237777057910534e-09
the O 0 2.771175466875775e-08
CPO O 0 3.47664968103345e-06
gene O 0 6.036212596427504e-08
at O 0 3.7525410334637854e-08
nucleotide O 0 1.702919405488501e-07
position O 0 2.6961919274981483e-07
85 O 0 1.4445942042584647e-07
, O 0 4.8342371883336455e-08
which O 0 1.523479511433834e-07
lies O 0 1.5169047173912986e-07
in O 0 4.319657076479189e-09
the O 0 1.918087910723898e-08
putative O 0 9.6818166639423e-07
presequence O 0 9.77720219452749e-07
for O 0 7.592491968466675e-09
targeting O 0 3.1084928764357755e-07
to O 0 1.2699197782239935e-07
mitochondria O 0 6.192168712004786e-06
. O 0 1.5407675846290658e-06

This O 0 1.3959744364910875e-06
mutation O 0 3.3250792057515355e-06
changes O 0 4.366711436887272e-08
the O 0 7.550308822601437e-09
codon O 0 2.9086137942613277e-07
for O 0 6.367864902045994e-09
glutamine O 0 2.305779247535611e-07
to O 0 1.4096932510199167e-08
a O 0 8.101384452174898e-08
termination O 0 1.1782627780121402e-06
codon O 0 1.595402409293456e-06
at O 0 1.5772410222325561e-07
amino O 0 2.204037343744858e-07
acid O 0 6.85046757098462e-07
position O 0 6.338342473100056e-07
29 O 0 2.6790753508976195e-06
. O 0 7.02986937994865e-07

MaeI O 0 0.00034392729867249727
restriction O 0 5.1020324463024735e-06
analysis O 0 5.960856128695013e-07
showed O 0 1.5467700222870917e-06
two O 0 9.265753497800233e-09
other O 0 8.621851677048653e-09
carriers O 0 6.069404179243065e-08
in O 0 1.26368906450125e-08
the O 0 8.579434052080614e-08
family O 0 1.9230608359066537e-06
. O 0 5.939400580246001e-07

The O 0 8.929589967010543e-06
C O 0 0.00017558143008500338
- O 0 0.05647283419966698
T O 0 0.021576562896370888
mutation O 0 1.1779234228015412e-06
is O 0 9.147748336602035e-09
located O 0 2.786896935447203e-08
within O 0 6.953322362335257e-09
a O 0 4.734960157293244e-08
recently O 0 1.1512207720443257e-06
proposed O 0 9.375980170034381e-08
putative O 0 8.27765006761183e-07
alternative O 0 5.6792973879282727e-08
translation O 0 9.338304352013438e-08
initiation O 0 1.1928210597034195e-07
codon O 0 1.6745905213610968e-06
( O 0 5.3182294124098917e-08
TIC O 0 1.0225166988675483e-06
- O 0 8.597540954724536e-07
1 O 0 3.987722863030285e-08
) O 0 6.668896546102587e-09
, O 0 3.910546997332176e-09
supporting O 0 1.4800645153911773e-08
that O 0 1.4979026019545927e-08
TIC O 0 3.7917991448921384e-06
- O 0 3.1852493975748075e-06
1 O 0 5.406792880080502e-08
is O 0 4.712487733371518e-09
the O 0 8.552749619639144e-09
real O 0 1.654628363212396e-07
TIC O 0 1.5567605942123919e-06
rather O 0 2.6205553282920846e-08
than O 0 1.8767885023862618e-08
TIC O 0 1.6933303186306148e-06
- O 0 1.311017854277452e-06
2 O 0 1.8467902407337533e-07
. O 0 4.3760415735505376e-08
. O 0 3.8937102431191306e-07

Human B-Disease 0 3.423589441808872e-05
complement I-Disease 0 4.932108640787192e-05
factor I-Disease 0 0.001654033549129963
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999033212661743
associated O 0 0.00018157991871703416
with O 0 0.05230287089943886
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.979875302524306e-05

This O 0 6.784029551454296e-07
study O 0 2.1393087479282258e-07
reports O 0 1.9139879725571518e-07
on O 0 3.511075021833676e-07
six O 0 8.097388786154625e-07
cases O 0 3.383921125532652e-07
of O 0 1.0161794534724322e-06
deficiency B-Disease 0 0.01499252114444971
in I-Disease 0 1.8174400651105316e-08
the I-Disease 0 1.9344446045010955e-08
human I-Disease 0 2.130406961953213e-08
complement I-Disease 0 8.085931568757587e-08
regulatory I-Disease 0 1.8762523268378573e-07
protein I-Disease 0 5.624662549053028e-07
Factor I-Disease 0 1.3216493925938266e-06
H I-Disease 1 0.9999998807907104
( O 0 2.7022693416256516e-07
FH O 0 5.305094236973673e-05
) O 0 1.2909550761719402e-08
in O 0 3.855305408251297e-09
the O 0 6.9530838864295674e-09
context O 0 3.231544098980521e-08
of O 0 2.2728816162498333e-08
an O 0 1.6551504813833162e-05
acute B-Disease 1 0.999998927116394
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.4354948689287994e-05

Five O 0 4.373406682134373e-06
of O 0 4.483705851043851e-08
the O 0 4.069399750505909e-08
cases O 0 7.497988008253742e-08
were O 0 2.3712169650025317e-07
observed O 0 2.7936619062529644e-07
in O 0 2.0327089345073546e-08
children O 0 3.867394298140425e-07
presenting O 0 1.4588475778509746e-06
with O 0 0.00021126281353645027
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00025489655672572553
HUS B-Disease 1 0.9999880790710449
) O 0 6.733099326083902e-06
. O 0 5.3824610404262785e-06

Two O 0 1.7987472347158473e-06
of O 0 2.9130655221365487e-08
the O 0 4.388169116964491e-08
children O 0 1.4487845874100458e-06
exhibited O 0 1.3772638340014964e-05
a O 0 2.4389575628447346e-05
homozygous O 1 0.9998623132705688
deficiency O 0 0.21029910445213318
characterized O 0 2.9941154480184196e-06
by O 0 3.188374719798048e-08
the O 0 3.9941703278145724e-08
absence O 0 5.080064369167303e-08
of O 0 2.134766363681706e-09
the O 0 8.615917757026637e-09
150 O 0 3.671519266390533e-08
- O 0 3.0024824582142173e-07
kD O 0 4.680322831518424e-07
form O 0 7.129901558045049e-09
of O 0 5.3122350962553355e-09
Factor O 0 4.96932784699311e-07
H O 1 0.9999998807907104
and O 0 1.744282371873851e-07
the O 0 8.966281939137843e-09
presence O 0 2.8484842928833132e-08
, O 0 1.1707337321809064e-08
upon O 0 4.165090050634035e-09
immunoblotting O 0 7.348854751398903e-07
, O 0 2.70357447540448e-09
of O 0 8.326161982097346e-10
the O 0 1.0529978666795614e-08
42 O 0 1.9881078117123252e-07
- O 0 4.5307382379178307e-07
kD O 0 2.165287241950864e-06
Factor O 0 3.6925706581314444e-07
H O 1 0.9920257925987244
- O 0 8.808883080746455e-07
like O 0 5.481378195781872e-08
protein O 0 9.459344596507435e-08
1 O 0 3.361369849130824e-08
( O 0 3.274722715218559e-08
FHL O 0 2.114261178576271e-06
- O 0 2.352037654418382e-06
1 O 0 1.2471198829189234e-07
) O 0 7.894445985812126e-09
and O 0 6.323252588202877e-09
other O 0 1.0827496232934664e-08
FH O 0 2.015460813709069e-05
- O 0 2.4206160560424905e-06
related O 0 1.3049626090833044e-07
protein O 0 8.292710731439001e-07
( O 0 8.372671089773576e-08
FHR O 0 1.4395182915905025e-05
) O 0 1.0265809180509677e-07
bands O 0 1.8281417624166352e-06
. O 0 1.3703717058888287e-06

Southern O 0 6.076041245250963e-05
blot O 0 0.00019874298595823348
and O 0 6.791869395783579e-07
PCR O 0 2.6400746264698682e-06
analysis O 0 5.2776677250676585e-08
of O 0 3.298731066081473e-09
DNA O 0 1.4864886566101632e-07
of O 0 5.119661139474374e-09
one O 0 8.89802009851337e-08
patient O 0 1.0835386774488143e-06
with O 0 3.176682639605133e-06
homozygous O 1 0.9994496703147888
deficiency O 0 0.005802056286484003
ruled O 0 8.799394777270209e-07
out O 0 6.444429345719982e-08
the O 0 4.344925308430447e-09
presence O 0 7.85966491889667e-09
of O 0 6.548342978973665e-10
a O 0 6.119688755745756e-09
large O 0 8.604782664178856e-09
deletion O 0 3.138632962418342e-07
of O 0 3.5654661445505553e-09
the O 0 5.6009934468193023e-08
FH O 0 2.8343414669507183e-05
gene O 0 1.5260052066423668e-07
as O 0 5.937226532637396e-08
the O 0 1.487050269588508e-07
underlying O 0 2.1389454559539445e-05
defect O 0 1.1724804608093109e-05
for O 0 9.46535507750923e-08
the O 0 1.027497182803927e-05
deficiency O 0 0.024689586833119392
. O 0 1.1394146213206113e-06

The O 0 9.936723017744953e-07
other O 0 4.6094399408502795e-08
four O 0 6.887827908030886e-08
children O 0 2.3102209922853945e-07
presented O 0 2.785494928048138e-07
with O 0 2.3696668449701974e-06
heterozygous O 1 0.9274534583091736
deficiency O 0 0.005655053071677685
and O 0 3.4164023077210004e-07
exhibited O 0 1.5802628468009061e-06
a O 0 7.154534387154854e-08
normal O 0 5.632703619085078e-07
immunoblotting O 0 8.182232704712078e-06
pattern O 0 3.0383146167878294e-06
of O 0 7.695393655637872e-09
proteins O 0 3.026215367185614e-08
of O 0 1.1831024160358083e-08
the O 0 2.3358354894753575e-07
FH O 0 0.00038925171247683465
family O 0 3.362539018780808e-06
. O 0 1.2347992424110998e-06

Factor B-Disease 1 0.8668616414070129
H I-Disease 1 1.0
deficiency I-Disease 1 0.9972649812698364
is O 0 5.0629819270398e-07
the O 0 3.102823882272787e-07
only O 0 8.480453288939316e-06
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
associated O 0 6.112463324825512e-06
with O 0 3.6092694699618733e-06
HUS B-Disease 1 0.9999768733978271
. O 0 1.6496871467097662e-05

These O 0 2.130672783096088e-06
observations O 0 1.6479510804856545e-06
suggest O 0 1.431090339565344e-07
a O 0 2.450446956459018e-08
role O 0 4.571772294070797e-08
for O 0 7.091333031894465e-08
FH O 0 0.00024086827761493623
and O 0 1.0271562587149674e-06
/ O 0 3.068551450269297e-05
or O 0 3.5829577882395824e-07
FH O 0 7.451322744600475e-05
receptors O 0 4.2994383875338826e-07
in O 0 3.030611139820394e-08
the O 0 8.495864278756926e-08
pathogenesis O 0 9.440395842830185e-06
of O 0 5.83140888466005e-07
idiopathic O 1 0.957000732421875
HUS B-Disease 1 0.9999963045120239
. O 0 6.42530903860461e-06
. O 0 3.4759004847728647e-06

Further O 0 4.294744030630682e-06
evidence O 0 1.678120895576285e-07
for O 0 5.497132971044039e-09
a O 0 7.127797374550937e-08
major O 0 1.9035428522329312e-07
ancient O 0 2.9996942885190947e-06
mutation O 0 0.0168912373483181
underlying O 0 0.4099200367927551
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.651564722735202e-06
linkage O 0 0.00038493171450681984
disequilibrium O 0 0.0011696707224473357
studies O 0 5.554030622079154e-07
in O 0 8.186178490632301e-08
the O 0 9.989096838580735e-08
Japanese O 0 1.0646137980074855e-06
population O 0 5.159213287697639e-07
. O 0 5.020123694521317e-07

The O 0 0.002056399593129754
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.1070326715707779
DM B-Disease 1 1.0
) O 0 9.29968518903479e-06
mutation O 0 1.5488776625716127e-05
is O 0 4.4682021638209335e-08
an O 0 4.370744477455446e-08
unstable O 0 0.0020886033307760954
( O 0 4.768166661506257e-07
CTG O 0 8.45772501634201e-06
) O 0 2.2324257997752284e-08
n O 0 5.521461616808665e-07
repeat O 0 5.848244768458244e-07
, O 0 1.6559916105052253e-08
present O 0 7.911856059195088e-09
at O 0 9.192402394830879e-09
a O 0 1.4100911549519424e-08
copy O 0 1.5816031861959345e-07
number O 0 6.399436536241865e-09
of O 0 3.435270734541973e-09
5 O 0 5.332175234684655e-08
- O 0 9.266133815799549e-07
37 O 0 2.7171438432560535e-07
repeats O 0 1.8307275695406133e-07
on O 0 8.437662302185345e-08
normal O 0 4.9285031167300986e-08
chromosomes O 0 2.6510065254115034e-07
but O 0 1.4329800457346664e-08
amplified O 0 1.9388187411095714e-07
to O 0 7.65212870845744e-09
50 O 0 4.417308474558013e-08
- O 0 3.1629085128770384e-07
3000 O 0 2.2572170621515397e-07
copies O 0 1.9885365531990828e-07
on O 0 1.1154014828207437e-05
DM B-Disease 1 0.9999995231628418
chromosomes O 0 0.00014871874009259045
. O 0 3.1356366889667697e-06

Previous O 0 5.121421054354869e-05
findings O 0 6.036240392859327e-06
in O 0 2.7907807975680043e-07
Caucasian O 0 2.55383929470554e-05
populations O 0 2.499636480024492e-07
of O 0 1.46257574940023e-08
a O 0 7.4552654041326605e-06
DM B-Disease 1 1.0
founder O 0 7.787519280100241e-05
chromosome O 0 0.000170040424563922
raise O 0 2.420241287381941e-07
a O 0 2.9898128417471526e-08
question O 0 2.1393327997998313e-08
about O 0 3.508870083379634e-09
the O 0 3.961732719659494e-09
molecular O 0 8.50929211537732e-08
events O 0 4.4678440502821104e-08
involved O 0 1.2017656203511251e-08
in O 0 1.3207728244424288e-08
the O 0 1.1237258235041736e-07
expansion O 0 1.9768879155890318e-06
mutation O 0 1.9665367290144786e-05
. O 0 1.2939115094923181e-06

To O 0 1.1125745231765904e-06
investigate O 0 5.962760383226851e-07
whether O 0 6.046801814818537e-08
a O 0 1.1014824252697508e-07
founder O 0 1.3043545550317504e-06
chromosome O 0 1.0093039236380719e-05
for O 0 2.6114692630585523e-08
the O 0 4.102939328731736e-06
DM B-Disease 1 1.0
mutation O 0 2.9985307264723815e-05
exists O 0 2.359684536656914e-08
in O 0 5.603971953149767e-09
the O 0 6.513641626071376e-09
Japanese O 0 1.0246911585909402e-07
population O 0 1.2904552981751749e-08
, O 0 9.948972312656679e-09
we O 0 1.1799744292773084e-08
genotyped O 0 7.303518145818089e-07
families O 0 1.4076135812501889e-08
using O 0 2.1058880861346552e-08
polymorphic O 0 1.4854487062621047e-06
markers O 0 1.1460282621555962e-05
near O 0 4.89121202917886e-06
the O 0 1.7438466670682828e-07
( O 0 1.3513417229660263e-07
CTG O 0 8.574274033890106e-06
) O 0 6.287176290697971e-08
n O 0 1.787021119525889e-06
repeat O 0 2.550413682911312e-06
region O 0 1.2608115866896696e-06
and O 0 8.269428235507803e-07
constructed O 0 5.280211553326808e-05
haplotypes O 0 0.0002024108252953738
. O 0 3.613268063418218e-06

Six O 0 8.926252121455036e-06
different O 0 2.4774064399935014e-07
haplotypes O 0 5.414764382294379e-05
were O 0 3.314112746011233e-06
found O 0 7.923002272036683e-07
and O 0 7.010560238995822e-06
DM B-Disease 1 1.0
alleles O 0 1.5999159586499445e-05
were O 0 1.6000680034267134e-06
always O 0 7.661316203666502e-07
haplotype O 0 2.433458575978875e-05
A O 0 8.331860044563655e-06
. O 0 2.8714005111396546e-06

To O 0 2.7546025194169488e-06
find O 0 3.4900864420706057e-07
an O 0 1.4669788939158934e-08
origin O 0 2.2931036625095658e-08
of O 0 7.89464138506446e-09
the O 0 6.496174620451711e-08
( O 0 5.609193465261342e-08
CTG O 0 5.20362846145872e-06
) O 0 1.4342981025095014e-08
n O 0 7.271388540175394e-07
repeat O 0 2.9031534722889774e-06
mutation O 0 1.0827402547874954e-06
and O 0 1.9554114771835884e-08
to O 0 4.143458909311448e-09
investigate O 0 1.5251286455963964e-08
the O 0 4.262350028483297e-09
mechanism O 0 1.4574685458512704e-08
of O 0 1.0151580687178807e-09
the O 0 4.219133487026738e-09
expansion O 0 5.774942835046204e-08
mutation O 0 2.0239990305981337e-07
in O 0 4.63496929725693e-09
the O 0 1.267237070834426e-08
Japanese O 0 1.385409262866233e-07
population O 0 1.1607282246473005e-08
we O 0 3.722328223432214e-09
have O 0 4.0498848719039415e-09
studied O 0 1.83972996836701e-08
90 O 0 4.311164758519226e-08
Japanese O 0 3.8850342320984055e-07
DM B-Disease 1 0.999997615814209
families O 0 1.4424273331314907e-07
comprising O 0 2.7905937116656787e-08
190 O 0 6.451045209132644e-08
affected O 0 5.5035457080521155e-08
and O 0 5.137535552535155e-08
130 O 0 4.2673269717852236e-07
unaffected O 0 2.7414596388553036e-06
members O 0 2.996206944771984e-07
. O 0 9.030024443745788e-07

The O 0 2.922821749962168e-06
results O 0 1.0535482033446897e-06
suggest O 0 1.2346880851055175e-07
that O 0 7.976464821979334e-09
a O 0 5.4901466484125194e-08
few O 0 8.964285314050358e-08
common O 0 5.421208726374971e-08
ancestral O 0 1.4081822428124724e-06
mutations O 0 4.097823875781614e-06
in O 0 2.326302173116801e-08
both O 0 1.0075241618778819e-07
Caucasian O 0 1.611011612112634e-05
and O 0 2.616852157188987e-07
Japanese O 0 2.9449029881334354e-08
populations O 0 2.3628640377637566e-08
have O 0 1.0495229574303266e-08
originated O 0 1.7212068215144427e-08
by O 0 6.392198992344333e-10
expansion O 0 4.337738168658234e-09
of O 0 5.337898456581058e-10
an O 0 4.171896161864197e-09
ancestral O 0 3.7585050449706614e-07
n O 0 7.140537945815595e-06
= O 0 1.2928569503856124e-06
5 O 0 6.093484472557975e-08
repeat O 0 2.093130575531177e-07
to O 0 2.738885029884841e-08
n O 0 2.3466111542802537e-06
= O 0 3.4215581763419323e-06
19 O 0 6.25591326297581e-07
- O 0 1.9000220845555305e-06
37 O 0 5.428544227470411e-07
copies O 0 4.317822401844751e-07
. O 0 7.790206382196629e-07

These O 0 9.651487289374927e-07
data O 0 4.6563042133129784e-07
support O 0 3.5248497454176686e-08
multistep O 0 8.406672691307904e-07
models O 0 4.4347837047098437e-07
of O 0 1.2770129842465394e-08
triplet O 0 6.669006688753143e-05
repeat O 0 1.6683198964528856e-06
expansion O 0 2.588912195733428e-07
that O 0 3.737789810998038e-08
have O 0 3.5968813705267166e-08
been O 0 2.368034479616199e-08
proposed O 0 1.0835656816254868e-08
for O 0 1.3590388370232631e-08
both O 0 7.67426683978556e-07
DM B-Disease 1 1.0
and O 0 2.2399244699045084e-05
Friedreichs B-Disease 0 0.0025808203499764204
ataxia I-Disease 0 0.3329859972000122
. O 0 4.837862093154399e-07
. O 0 1.2747688060699147e-06

The O 0 2.0956681510142516e-06
molecular O 0 4.0567128962720744e-06
basis O 0 2.382065076744766e-06
of O 0 0.00044116334174759686
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.886167630502314e-07
the O 0 1.104107454352743e-07
western O 0 7.661082577214984e-07
Cape O 0 7.429155175486812e-06
, O 0 6.09706489740347e-08
South O 0 1.247934733328293e-07
Africa O 0 3.38025671453579e-07
. O 0 5.992764613438339e-07

Deficiency B-Disease 1 0.9999240636825562
of I-Disease 0 6.632897111558123e-07
the I-Disease 0 2.0114836729590024e-07
sixth I-Disease 0 4.7125354285526555e-06
component I-Disease 0 1.8524293921018398e-07
of I-Disease 0 5.510380596263076e-09
human I-Disease 0 3.072552701155473e-08
complement I-Disease 0 4.5971304984959716e-07
( O 0 1.479952373983906e-07
C6 O 0 0.0001642338465899229
) O 0 3.3168966240282316e-08
has O 0 2.903367715134664e-07
been O 0 5.397735094447853e-07
reported O 0 6.083573111936857e-07
in O 0 5.066514763285568e-09
a O 0 2.0793500254967512e-08
number O 0 1.0767196023664383e-08
of O 0 5.819722481703593e-09
families O 0 5.3685962342342464e-08
from O 0 2.8965534415448246e-09
the O 0 1.3455337288803548e-08
western O 0 1.4318345620267792e-07
Cape O 0 2.280999979120679e-06
, O 0 2.3921307601426633e-08
South O 0 5.369385291942308e-08
Africa O 0 2.0948799317466182e-07
. O 0 2.6562349830783205e-07

Meningococcal B-Disease 1 0.9999923706054688
disease I-Disease 1 0.9940896034240723
is O 0 1.7744779370332253e-06
endemic O 0 6.094711579862633e-07
in O 0 1.1863149040891585e-07
the O 0 2.803350014346506e-07
Cape O 0 1.596397123648785e-05
and O 0 4.807759523828281e-07
almost O 0 3.061829190187382e-08
all O 0 4.1701855302278545e-09
pedigrees O 0 1.2084715308446903e-06
of O 0 1.707064143374737e-07
total O 0 0.015745967626571655
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.195001738731662e-07
C6Q0 O 0 5.164087997400202e-05
) O 0 4.225239536026493e-08
have O 0 9.183905547160975e-08
been O 0 6.374854706336919e-07
ascertained O 0 2.572900939412648e-06
because O 0 3.9948485408558554e-08
of O 0 1.5271379538717156e-07
recurrent O 1 0.9791685938835144
disease O 0 0.037607014179229736
. O 0 3.4581580621306784e-06

We O 0 1.088705630536424e-05
have O 0 2.3335108778610447e-07
sequenced O 0 6.975541850806621e-07
the O 0 4.644369866468878e-08
expressed O 0 3.005209592288338e-08
exons O 0 7.37133746042673e-07
of O 0 1.4307159901250088e-08
the O 0 1.2712078500953794e-07
C6 O 0 0.0001059702190104872
gene O 0 2.4795622266537976e-07
from O 0 1.2108355207374188e-08
selected O 0 1.465798593613954e-08
cases O 0 2.4390228503534672e-08
and O 0 1.118557264589981e-07
have O 0 9.882780460657159e-08
found O 0 7.076740615730159e-08
three O 0 1.0285467055837216e-07
molecular O 0 1.791874092305079e-05
defects O 1 0.7455935478210449
leading O 0 4.282435668301332e-07
to O 0 1.2103198798740777e-07
total O 0 2.4478251816617558e-06
deficiency O 0 8.263991185231134e-05
879delG O 0 2.480269813531777e-06
, O 0 3.7962607279951044e-08
which O 0 1.036178787217068e-07
is O 0 1.296363638658704e-08
the O 0 1.4428533923194209e-08
common O 0 3.620272934767854e-07
defect O 0 3.984469003626145e-06
in O 0 5.1972921966125796e-08
the O 0 1.3987580871344107e-07
Cape O 0 8.609121323388536e-06
and O 0 1.1145683487256974e-07
hitherto O 0 3.6376428624862456e-07
unreported O 0 6.09181114441526e-08
, O 0 1.5714750389861365e-08
and O 0 1.7183792166974854e-08
1195delC O 0 8.449046617897693e-07
and O 0 5.149917114977143e-08
1936delG O 0 7.183577395153407e-07
, O 0 1.9635479020507773e-08
which O 0 4.234275152725786e-08
have O 0 2.4251434638244973e-08
been O 0 1.3081749727916758e-07
previously O 0 6.110792014624167e-07
reported O 0 8.065927659117733e-07
in O 0 3.708546358893727e-08
African O 0 1.0322631993631148e-07
- O 0 6.138154276413843e-06
Americans O 0 8.437370979663683e-07
. O 0 4.2704698444140377e-07

We O 0 2.5396311684744433e-05
also O 0 7.73079875671101e-07
show O 0 6.617770509365073e-07
that O 0 1.313915820588818e-08
the O 0 2.5563762662272893e-08
879delG O 0 1.3914253941038623e-05
and O 0 1.6519021528438316e-06
1195delC O 0 0.002063339576125145
defects O 1 0.5265350341796875
are O 0 1.6151242121509313e-08
associated O 0 8.408679974536426e-08
with O 0 2.029627665933731e-07
characteristic O 0 0.009471611119806767
C6 O 1 0.9925442934036255
/ O 0 0.0003830293717328459
C7 O 0 0.00021006245515309274
region O 0 1.293696755055862e-06
DNA O 0 3.360365553817246e-06
marker O 0 1.7344276784569956e-05
haplotypes O 0 2.687569212866947e-05
, O 0 1.0265534200470938e-07
although O 0 1.631403456769931e-08
small O 0 4.164361655512039e-08
variations O 0 2.8126712550147204e-06
were O 0 9.071144404515508e-07
observed O 0 3.515220214467263e-06
. O 0 9.776978231457178e-07

The O 0 7.178603937063599e-06
1936delG O 0 0.00021419080439954996
defect O 0 0.00033803112455643713
was O 0 8.275240361399483e-06
observed O 0 6.496267701550096e-07
only O 0 1.4240975509949294e-08
once O 0 8.773815096674298e-08
in O 0 2.2310297609351437e-08
the O 0 7.940008117657271e-08
Cape O 0 3.934778305847431e-06
, O 0 1.1474722505511181e-08
but O 0 5.573921324497633e-09
its O 0 1.9756932090331247e-08
associated O 0 2.3485920053190057e-07
haplotype O 0 1.7011165255098604e-05
could O 0 9.920096317728166e-07
be O 0 1.0936612682144187e-07
deduced O 0 3.7426736980705755e-06
. O 0 1.056090241036145e-06

The O 0 1.3097594546707114e-06
data O 0 5.027440010962891e-07
from O 0 1.799754123510411e-08
the O 0 2.5915468881976267e-08
haplotypes O 0 1.7880911400425248e-05
indicate O 0 7.970018032210646e-07
that O 0 1.070080113407812e-08
these O 0 4.712352730251723e-09
three O 0 7.756580799878066e-08
molecular O 0 0.00012935363338328898
defects O 1 0.821846067905426
account O 0 4.907257178388136e-08
for O 0 1.4688631644332872e-08
the O 0 1.4527913663187064e-06
defects O 1 0.5335943102836609
in O 0 2.2788936959727835e-08
all O 0 3.261556136280319e-09
the O 0 8.900579828718946e-09
38 O 0 2.0004398493256303e-07
unrelated O 0 1.7455803913435375e-07
C6Q0 O 0 2.6166799216298386e-05
individuals O 0 1.3808039156515406e-08
we O 0 7.189908224347619e-09
have O 0 5.4818150019286804e-09
studied O 0 1.1701332347513471e-08
from O 0 4.644349793636593e-09
the O 0 7.542151791994911e-08
Cape O 0 8.915209946280811e-06
. O 0 6.794622322559007e-07

We O 0 3.296801878605038e-05
have O 0 5.209673759054567e-07
also O 0 1.1276011235850092e-07
observed O 0 1.4730639463778061e-07
the O 0 3.791679858977659e-08
879delG O 0 1.1692713087541051e-05
defect O 0 3.0786854949838016e-06
in O 0 6.356665949169837e-08
two O 0 5.530881480808603e-06
Dutch O 1 0.9985740184783936
C6 B-Disease 1 1.0
- I-Disease 1 0.999996542930603
deficient I-Disease 1 0.9999998807907104
kindreds O 0 0.00013742157898377627
, O 0 6.044957245876503e-08
but O 0 1.0803422156868692e-08
the O 0 2.14979198887022e-08
879delG O 0 4.738845291285543e-06
defect O 0 1.766393779689679e-06
in O 0 2.4391811237478578e-08
the O 0 1.402133023020724e-07
Cape O 0 8.696790246176533e-06
probably O 0 1.647162321205542e-06
did O 0 8.869570677916272e-08
not O 0 8.552276220541444e-09
come O 0 4.070368042619066e-09
from O 0 2.1109141101760542e-09
The O 0 1.1667923516256451e-08
Netherlands O 0 4.5970827500241285e-07
. O 0 5.868391639296533e-08
. O 0 3.8050396256039676e-07

Complement B-Disease 1 0.999930739402771
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.355304334538232e-06
seven O 0 2.7620103537628893e-07
further O 0 2.953513558168197e-07
molecular O 0 0.00025018438464030623
defects O 1 0.9995619654655457
and O 0 1.1344227459630929e-06
their O 0 1.4598535358345544e-07
associated O 0 1.710841615931713e-06
marker O 0 9.19024387258105e-05
haplotypes O 0 0.00016144277469720691
. O 0 2.0467768990783952e-06

Seven O 0 1.3500137356459163e-05
further O 0 8.898188070816104e-07
molecular O 0 1.5988325685611926e-06
bases O 0 8.859053195919842e-06
of O 0 0.0001049469065037556
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.042012389822048e-07
described O 0 1.7253572877962142e-05
. O 0 2.2386057025869377e-06

All O 0 6.378418220265303e-07
these O 0 2.679396615690166e-08
new O 0 8.11977827197552e-08
molecular O 0 8.62966408021748e-06
defects O 0 0.006897139362990856
involve O 0 7.95588022128868e-08
single O 0 1.090869204745104e-06
- O 0 8.401476407016162e-06
nucleotide O 0 1.0482414154466824e-06
events O 0 6.241354810754274e-08
, O 0 2.7166743521434e-08
deletions O 0 1.4031872979103355e-06
and O 0 3.529849266215024e-07
substitutions O 0 8.606704113844899e-07
, O 0 2.872490156846652e-08
some O 0 1.1744233363586432e-09
of O 0 2.7986890582809565e-09
which O 0 4.981978207752036e-08
alter O 0 1.4872603060211986e-06
splice O 0 1.9129136489937082e-05
sites O 0 7.641847901140864e-07
, O 0 8.218061253728592e-08
and O 0 1.2610288990799745e-07
others O 0 3.406219377666275e-07
codons O 0 6.806239071011078e-06
. O 0 6.353635626510368e-07

They O 0 9.96466951619368e-06
are O 0 3.7927502916090816e-08
distributed O 0 2.694021894456e-08
along O 0 4.442030032691946e-08
the O 0 5.493802390788005e-08
C7 O 0 4.0172111766878515e-05
gene O 0 4.6132089437378454e-07
, O 0 2.5453125829244527e-08
but O 0 7.364512111251997e-09
predominantly O 0 1.2821186778921856e-08
towards O 0 1.272633731730366e-08
the O 0 1.4113880730803885e-08
3 O 0 2.3154176176376495e-07
end O 0 1.7660299818089698e-06
. O 0 8.03737066235044e-07

All O 0 2.388867414993001e-06
were O 0 3.318162953291903e-07
found O 0 3.7175404088429786e-08
in O 0 4.205396919587656e-08
compound O 0 1.0374131306889467e-05
heterozygous O 0 2.0564699298120104e-05
individuals O 0 3.2131981697602896e-07
. O 0 7.501191703340737e-07

The O 0 5.639953087666072e-05
C6 O 1 0.7767075896263123
/ O 0 0.008676641620695591
C7 O 0 0.0025299270637333393
marker O 0 0.00022543847444467247
haplotypes O 0 0.0006715693161822855
associated O 0 8.075687219388783e-06
with O 0 1.0370047220931156e-06
most O 0 1.1343016012688167e-05
C7 B-Disease 1 0.9999833106994629
defects I-Disease 1 0.9999265670776367
are O 0 5.222891559242271e-07
tabulated O 0 2.704419421206694e-05
. O 0 3.750162420601555e-07
. O 0 1.2891067626696895e-06

A O 0 3.0254648663685657e-05
genome O 0 6.861353995191166e-06
- O 0 2.472716687407228e-06
wide O 0 4.019137804789352e-07
search O 0 1.7946862840290123e-07
for O 0 3.8833444904184944e-08
chromosomal O 0 0.018598143011331558
loci O 0 1.939408502948936e-05
linked O 0 2.429375126666855e-05
to O 0 3.185749051226594e-07
mental O 0 0.00021518235735129565
health O 0 1.2246035794305499e-06
wellness O 0 5.247743047220865e-06
in O 0 8.135636875294949e-08
relatives O 0 2.4167238166228344e-07
at O 0 1.5300155098429968e-07
high O 0 1.4945969724067254e-06
risk O 0 2.520698217267636e-06
for O 0 4.894081939710304e-07
bipolar B-Disease 1 0.9999983310699463
affective I-Disease 1 0.99994957447052
disorder I-Disease 1 0.8918291330337524
among O 0 7.621775210964188e-08
the O 0 2.7642599320643058e-08
Old O 0 3.997580279246904e-06
Order O 0 2.585272795840865e-07
Amish O 0 4.084503962076269e-05
. O 0 1.5090193983269273e-06

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999991655349731
disorder I-Disease 1 0.9999997615814209
( O 0 0.0009737302316352725
BPAD B-Disease 1 1.0
; O 0 0.010366752743721008
manic B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
depressive I-Disease 1 1.0
illness I-Disease 1 0.9788835048675537
) O 0 1.742152875294778e-07
is O 0 1.6921189782692636e-08
characterized O 0 4.5293603534446447e-07
by O 0 1.7598173585042787e-08
episodes O 0 3.0538151349901455e-06
of O 0 5.5863555559199085e-08
mania B-Disease 0 0.0012132289120927453
and O 0 1.3691385447600624e-06
/ O 0 7.57032903493382e-05
or O 0 6.896167974446143e-07
hypomania B-Disease 0 0.003459163475781679
interspersed O 0 2.9941789762233384e-05
with O 0 9.591644811735023e-08
periods O 0 9.61928890319541e-07
of O 0 1.183642339697144e-07
depression B-Disease 0 8.802212687442079e-05
. O 0 1.4522968285746174e-06

Compelling O 0 1.8646500393515453e-05
evidence O 0 4.94676896778401e-07
supports O 0 2.5888402888085693e-07
a O 0 9.200351058780143e-08
significant O 0 5.32435997513403e-08
genetic O 0 7.922352551759104e-07
component O 0 3.11363464788883e-07
in O 0 4.083566196300126e-08
the O 0 1.1361968432765934e-07
susceptibility O 0 1.639996116864495e-05
to O 0 3.5056581282333354e-07
develop O 0 7.681137503823265e-06
BPAD B-Disease 1 0.9999996423721313
. O 0 7.001407084317179e-06

To O 0 2.537940190450172e-06
date O 0 3.1410002065968e-06
, O 0 7.242198307721992e-08
however O 0 2.6041526268727466e-08
, O 0 1.3100747153771408e-08
linkage O 0 1.0847567182281637e-06
studies O 0 4.631984751313212e-08
have O 0 2.79257434954161e-08
attempted O 0 1.6088908978417749e-06
only O 0 6.652051354194555e-09
to O 0 6.92647850186745e-09
identify O 0 3.240695036765828e-07
chromosomal O 0 0.0009802263230085373
loci O 0 1.528514872006781e-06
that O 0 1.328827607949279e-07
cause O 0 4.69427902771713e-07
or O 0 1.007549101927907e-07
increase O 0 1.050362499199764e-07
the O 0 3.3632492346669096e-08
risk O 0 2.6580465828374145e-07
of O 0 4.095883099353159e-08
developing O 0 2.4895023216231493e-06
BPAD B-Disease 1 0.9999964237213135
. O 0 4.512047325988533e-06

To O 0 1.3867233974451665e-06
determine O 0 4.967461109117721e-07
whether O 0 8.206157531276403e-08
there O 0 5.8863950158638545e-08
could O 0 2.0874092854228365e-07
be O 0 1.7492258308493547e-08
protective O 0 8.917795071283763e-07
alleles O 0 2.1760983770491293e-07
that O 0 2.458461878518392e-08
prevent O 0 2.3509606705829356e-07
or O 0 8.072586155094541e-08
reduce O 0 1.5783621165610384e-07
the O 0 2.0895678076726654e-08
risk O 0 4.588178015296762e-08
of O 0 2.5215949328583065e-09
developing O 0 1.2570869500905246e-07
BPAD B-Disease 1 0.9999996423721313
, O 0 1.9951958307729e-08
similar O 0 3.0991194055474125e-09
to O 0 6.651861284012739e-09
what O 0 4.94975305187495e-09
is O 0 5.400524027976417e-09
observed O 0 4.892462612815507e-08
in O 0 2.4516157992593435e-08
other O 0 1.085510007214907e-06
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.1556610246543642e-07
we O 0 3.900492373531961e-08
used O 0 5.210802100918954e-07
mental O 0 4.8874742788029835e-05
health O 0 6.450910063904303e-07
wellness O 0 1.4450931303144898e-05
( O 0 2.813677113522317e-08
absence O 0 2.909356311420197e-08
of O 0 9.467770567539446e-09
any O 0 8.902058539206337e-07
psychiatric B-Disease 1 0.9400425553321838
disorder I-Disease 0 0.42200061678886414
) O 0 3.25800755263117e-08
as O 0 2.9176808524766784e-08
the O 0 1.6046693929183675e-07
phenotype O 0 1.5240376342262607e-05
in O 0 1.512414549154073e-08
our O 0 2.7086340281812227e-08
genome O 0 2.276552635294138e-07
- O 0 1.1619928272921243e-06
wide O 0 3.056919410937553e-07
linkage O 0 2.4400035272265086e-06
scan O 0 7.156634183047572e-06
of O 0 5.5541606869269344e-09
several O 0 1.3508722140898044e-08
large O 0 2.8995728484915162e-08
multigeneration O 0 2.5322610781586263e-06
Old O 0 6.988892096160271e-07
Order O 0 4.624692806487474e-08
Amish O 0 1.2034183782816399e-05
pedigrees O 0 5.643200893246103e-06
exhibiting O 0 1.4102934642323817e-07
an O 0 1.6588145967944e-08
extremely O 0 3.591007100567367e-07
high O 0 3.709449174493784e-06
incidence O 0 0.0051816790364682674
of O 0 8.78745311183593e-07
BPAD B-Disease 1 0.9999998807907104
. O 0 6.6470961428422015e-06

We O 0 1.4921168258297257e-05
have O 0 4.37969049471576e-07
found O 0 6.386476769648652e-08
strong O 0 3.653063984643268e-08
evidence O 0 9.625087393771992e-09
for O 0 3.2790588022635347e-09
a O 0 1.3253055897166632e-07
locus O 0 5.815774784423411e-06
on O 0 9.563186722516548e-06
chromosome O 0 0.008739247918128967
4p O 0 0.00014016180648468435
at O 0 2.722567842283752e-07
D4S2949 O 0 1.1340192713760189e-06
( O 0 1.7844305588710085e-08
maximum O 0 5.078233300537249e-08
GENEHUNTER O 0 3.3978981264226604e-06
- O 0 1.4047712966203107e-06
PLUS O 0 2.7130502644467924e-07
nonparametric O 0 7.93387471276219e-07
linkage O 0 2.3402776605507825e-06
score O 0 1.3269436749396846e-06
= O 0 7.782527973176911e-07
4 O 0 7.551191316679251e-08
. O 0 8.087501335296565e-09
05 O 0 2.460493533362751e-07
, O 0 2.5503274159177636e-08
P O 0 1.0199532880506013e-05
= O 0 3.26874811662492e-07
5 O 0 3.3963448942131436e-08
. O 0 7.924739087172838e-09
22 O 0 6.853768041992225e-08
x O 0 3.3126655125670368e-06
10 O 0 9.529009048492298e-08
( O 0 1.3557352573911885e-08
- O 0 7.189019015640952e-07
4 O 0 1.7754754821908136e-07
) O 0 9.606655915206375e-09
; O 0 1.5055704238875478e-08
SIBPAL O 0 9.547444506097236e-07
Pempirical O 0 2.680404520560842e-07
value O 0 4.772786610374169e-09
< O 0 4.156870048177552e-08
3 O 0 2.4819012622856462e-08
x O 0 3.2922102946031373e-06
10 O 0 1.0888802393083097e-07
( O 0 1.0169279640592777e-08
- O 0 1.619540626052185e-06
5 O 0 2.6783447992784204e-07
) O 0 7.403665236438428e-09
) O 0 2.917629027265889e-09
and O 0 2.3657998227122334e-08
suggestive O 0 3.3378132684447337e-06
evidence O 0 1.5294604693849578e-08
for O 0 2.0744210793566253e-09
a O 0 7.391365386411053e-08
locus O 0 1.0985761946358252e-05
on O 0 3.37948658852838e-05
chromosome O 1 0.7229453325271606
4q O 0 0.12752455472946167
at O 0 2.4363268380511727e-07
D4S397 O 0 1.368436301163456e-06
( O 0 4.062489722400642e-08
maximum O 0 1.2842140506563737e-07
GENEHUNTER O 0 8.826416888041422e-06
- O 0 3.570569788280409e-06
PLUS O 0 7.531153869422269e-07
nonparametric O 0 1.3992585081723519e-06
linkage O 0 4.008735231764149e-06
score O 0 8.437805831817968e-07
= O 0 7.652261615476164e-07
3 O 0 7.232907961451929e-08
. O 0 1.3464836357002241e-08
29 O 0 2.9181214244999865e-07
, O 0 2.5505757506039117e-08
P O 0 3.041895070055034e-06
= O 0 3.095399563335377e-07
2 O 0 2.464584092365385e-08
. O 0 7.387217948462421e-09
57 O 0 1.2195089027500217e-07
x O 0 7.452194950019475e-06
10 O 0 2.6320321921957657e-07
( O 0 1.3043998770001508e-08
- O 0 1.207683453685604e-06
3 O 0 1.6529375557183812e-07
) O 0 1.2637324076081313e-08
; O 0 1.4570627371313094e-08
SIBPAL O 0 8.724034046281304e-07
Pempirical O 0 2.7689466719493794e-07
value O 0 4.837333644758246e-09
< O 0 4.947641585317797e-08
1 O 0 1.3670200971205304e-08
x O 0 2.848147460099426e-06
10 O 0 1.4688960447983845e-07
( O 0 1.2321669018433568e-08
- O 0 1.8030477804131806e-06
3 O 0 3.7344125303206965e-07
) O 0 1.0047296328252742e-08
) O 0 2.797173603852343e-09
that O 0 5.490635945903932e-09
are O 0 1.4675498150040767e-08
linked O 0 5.170209533389425e-06
to O 0 6.590701104869368e-07
mental O 0 0.0010574159678071737
health O 0 7.372535947069991e-06
wellness O 0 8.385630644625053e-05
. O 0 2.2426186205848353e-06

These O 0 1.911366325657582e-06
findings O 0 1.6346541542588966e-06
are O 0 3.149018112935664e-08
consistent O 0 2.3518578018411063e-07
with O 0 2.0941083533898563e-08
the O 0 6.572236088686623e-08
hypothesis O 0 6.586855079149245e-07
that O 0 1.3866631398684603e-08
certain O 0 8.180009558600432e-09
alleles O 0 1.873975747912482e-07
could O 0 5.512522420758614e-07
prevent O 0 1.8510449706354848e-07
or O 0 2.8020769704539816e-08
modify O 0 2.3423848460879526e-07
the O 0 7.322034178969261e-08
clinical O 0 4.616734656792687e-07
manifestations O 0 6.036806325937505e-07
of O 0 1.0315625331713818e-07
BPAD B-Disease 1 1.0
and O 0 2.9783436730212998e-06
perhaps O 0 1.1651982134708305e-07
other O 0 4.3989455633663965e-08
related O 0 8.225537385442294e-06
affective B-Disease 1 0.9992565512657166
disorders I-Disease 1 0.9718708395957947
. O 0 3.2820469186845003e-06

Segregation O 0 0.011260784231126308
distortion O 1 0.8569290637969971
in O 0 0.0005901139229536057
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00016772102389950305

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9874891638755798
DM B-Disease 1 1.0
) O 0 6.935093551874161e-06
is O 0 1.2842203034324484e-07
an O 0 4.907172979073948e-07
autosomal B-Disease 1 0.995400607585907
dominant I-Disease 1 0.9880934357643127
disease I-Disease 1 0.5897131562232971
which O 0 2.6095431167050265e-06
, O 0 5.344596942791213e-08
in O 0 2.7140330871588958e-08
the O 0 1.2839875296322134e-07
typical O 0 2.284705260535702e-06
pedigree O 0 4.879415882896865e-06
, O 0 1.9740095780207412e-08
shows O 0 4.378312112862659e-08
a O 0 2.2676333699678253e-08
three O 0 6.396473395398061e-08
generation O 0 5.717745921174355e-07
anticipation O 0 8.59269619013503e-07
cascade O 0 1.4340689631353598e-05
. O 0 1.2560016102725058e-06

This O 0 3.6843400721409125e-06
results O 0 3.6632586670748424e-06
in O 0 2.6878915377892554e-06
infertility B-Disease 1 0.99998939037323
and O 1 0.9997274279594421
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00012934325786773115
CDM B-Disease 0 0.00019004149362444878
) O 0 1.0517336335169603e-07
with O 0 9.852250570929755e-09
the O 0 7.567179949319325e-08
disappearance O 0 8.242373041866813e-06
of O 0 8.33538308597781e-07
DM B-Disease 1 1.0
in O 0 2.158553343178937e-06
that O 0 5.79485856633255e-07
pedigree O 0 2.528078584873583e-05
. O 0 1.284011204916169e-06

The O 0 1.0218177521892358e-06
concept O 0 4.3783123260254797e-07
of O 0 4.544369502923473e-08
segregation O 0 7.537860710726818e-06
distortion O 0 0.0034951281268149614
, O 0 9.72006546362536e-08
where O 0 2.0087245644617724e-08
there O 0 5.020695859059288e-09
is O 0 4.584816526431723e-09
preferential O 0 3.798107428565345e-08
transmission O 0 1.7727423937685671e-06
of O 0 1.2738959886959833e-09
the O 0 3.8315031147817535e-09
larger O 0 1.565354423860299e-08
allele O 0 1.9440842891071952e-07
at O 0 4.760660488045687e-08
the O 0 2.507032661469566e-07
DM B-Disease 1 1.0
locus O 0 2.1048794224043377e-05
, O 0 1.2426961859546282e-07
has O 0 1.0336916034248134e-07
been O 0 1.064632684233402e-07
put O 0 1.0758393642618103e-07
forward O 0 4.7842089401228804e-08
to O 0 1.1657668608222593e-08
explain O 0 1.2771035073910753e-07
partially O 0 1.389822841701971e-06
the O 0 2.7394753132625738e-08
maintenance O 0 1.0224787274637492e-06
of O 0 1.3079528571324772e-07
DM B-Disease 1 1.0
in O 0 4.5726883968200127e-07
the O 0 1.8808744073339767e-07
population O 0 2.3404778914937197e-07
. O 0 4.880491246694874e-07

In O 0 1.9789797534031095e-06
a O 0 9.417091746399819e-07
survey O 0 2.100584424624685e-06
of O 0 8.24289614342888e-08
DM B-Disease 1 1.0
in O 0 8.283035981548892e-07
Northern O 0 2.6295435873180395e-06
Ireland O 0 9.577347555023152e-07
, O 0 9.712282178497844e-08
59 O 0 1.0236377647743211e-06
pedigrees O 0 4.9713553380570374e-06
were O 0 7.320246595554636e-07
ascertained O 0 9.268155736208428e-06
. O 0 1.207046807394363e-06

Sibships O 0 0.002906020265072584
where O 0 3.9913256841828115e-06
the O 0 3.768557377270554e-08
status O 0 2.652862107765941e-08
of O 0 6.448336531406085e-09
all O 0 4.988517154913552e-09
the O 0 9.83325154635395e-09
members O 0 1.57759547647629e-08
had O 0 4.849530796491308e-06
been O 0 6.682485036435537e-07
identified O 0 6.505071041829069e-07
were O 0 1.0453479148964107e-07
examined O 0 9.434928927021247e-08
to O 0 1.1501629870735997e-08
determine O 0 3.3212838701501823e-08
the O 0 3.27127693822149e-08
transmission O 0 3.496776798783685e-06
of O 0 2.58831489574618e-09
the O 0 1.0394687421921844e-07
DM B-Disease 1 0.9999984502792358
expansion O 0 3.489018070013117e-07
from O 0 1.85587172296664e-08
affected O 0 6.93666137863147e-08
parents O 0 2.5791205615632862e-08
to O 0 7.565574833279243e-09
their O 0 9.660367794595004e-08
offspring O 0 6.296576430031564e-06
. O 0 3.517825177823397e-07

Where O 0 7.674328116991092e-06
the O 0 8.482172120238829e-07
transmitting O 0 4.60787232441362e-05
parent O 0 9.091651918424759e-06
was O 0 4.351680672698421e-06
male O 0 2.250340003229212e-06
, O 0 1.2219094003285136e-07
58 O 0 1.6572355434618657e-06
. O 0 4.752898519200244e-07

3 O 0 5.94365774304606e-05
% O 0 4.960402861797775e-07
of O 0 9.976145243228984e-09
the O 0 1.0425761587384841e-07
offspring O 0 2.0865087208221667e-05
were O 0 2.7771657187258825e-06
affected O 0 9.418441493380669e-08
, O 0 4.5261174363986356e-08
and O 0 6.297977961366996e-08
in O 0 1.8816416869071872e-08
the O 0 1.2750342115452895e-08
case O 0 4.588405744243573e-08
of O 0 3.4555636130306766e-09
a O 0 1.6368743160910526e-07
female O 0 9.862339538813103e-06
transmitting O 0 1.770093513187021e-05
parent O 0 5.244698400019843e-07
, O 0 5.95485083465519e-08
68 O 0 1.842061919887783e-06
. O 0 6.066186983844091e-07

7 O 0 0.0016457629390060902
% O 0 2.1464549718075432e-05
were O 0 1.9371659618627746e-06
affected O 0 3.577539928301121e-06
. O 0 3.1553906865156023e-06

Studies O 0 1.1481385627121199e-05
on O 0 1.8979683318320895e-06
meiotic O 0 4.407156666275114e-05
drive O 0 2.0366542230476625e-05
in O 0 2.0603881694114534e-06
DM B-Disease 1 1.0
have O 0 1.480427454225719e-05
shown O 0 4.988681894246838e-07
increased O 0 1.8120046263447875e-07
transmission O 0 1.9638830508483807e-06
of O 0 1.5063882363719472e-09
the O 0 4.732357172798629e-09
larger O 0 3.659612346496033e-08
allele O 0 4.373505078092421e-07
at O 0 1.0273311090713833e-07
the O 0 5.298607561599056e-07
DM B-Disease 1 0.9999998807907104
locus O 0 1.5355366485891864e-05
in O 0 3.6513404211291345e-07
non O 0 2.1267892407195177e-06
- O 0 0.15325169265270233
DM O 1 0.9999996423721313
heterozygotes O 0 3.394551094970666e-05
for O 0 2.2145066225220944e-07
CTGn O 0 8.710804104339331e-05
. O 0 2.2697768145008013e-06

This O 0 7.380728561656724e-07
study O 0 1.513787424300972e-07
provides O 0 4.018539101480201e-08
further O 0 2.3403655902143328e-08
evidence O 0 2.5176651874403433e-08
that O 0 1.7585323419666565e-08
the O 0 1.4271965653733787e-07
DM B-Disease 1 0.9999996423721313
expansion O 0 1.0070349389934563e-06
tends O 0 3.102927621512208e-07
to O 0 1.897633339353888e-08
be O 0 5.29791002179536e-08
transmitted O 0 3.888358151016291e-06
preferentially O 0 2.0314396351750474e-06
. O 0 8.200178172046435e-07

Diagnosis O 1 0.9971823692321777
of O 0 5.902566772419959e-05
hemochromatosis B-Disease 1 1.0
. O 0 8.48642666824162e-05

If O 0 0.0001107064526877366
untreated O 0 0.010938023217022419
, O 0 1.1916927178390324e-05
hemochromatosis B-Disease 1 1.0
can O 0 7.293838280020282e-05
cause O 0 0.00014793632726650685
serious O 0 0.0001791392860468477
illness O 0 0.0024171429686248302
and O 0 2.212964091086178e-06
early B-Disease 0 4.984177849109983e-06
death I-Disease 0 0.00024746989947743714
, O 0 1.8195026996181696e-07
but O 0 8.841244891755196e-08
the O 0 5.199607358008507e-07
disease O 0 8.564572453906294e-06
is O 0 5.202965880357624e-08
still O 0 2.517903681109601e-07
substantially O 0 3.20242816087557e-06
under O 0 1.029852569445211e-06
- O 1 0.7827296853065491
diagnosed O 0 0.1880488395690918
. O 0 2.0393981685629115e-06

The O 0 1.8518231854613987e-06
cornerstone O 0 2.100041683661402e-06
of O 0 2.9230951881231704e-08
screening O 0 2.3469642940199265e-07
and O 0 1.0551253382118375e-07
case O 0 5.873755171137418e-08
detection O 0 2.6900278271568823e-07
is O 0 1.503819646586635e-08
the O 0 1.189287957004126e-08
measurement O 0 1.448610532861494e-06
of O 0 3.450744401334305e-08
serum O 0 4.331955096859019e-06
transferrin O 0 1.3074106846033828e-06
saturation O 0 1.1437683724579983e-06
and O 0 6.004084696087375e-08
the O 0 6.99498770018181e-08
serum O 0 9.303969818574842e-06
ferritin O 0 3.636277688201517e-05
level O 0 1.4993323702583439e-06
. O 0 1.234834712704469e-06

Once O 0 4.469548002816737e-05
the O 0 5.246689624982537e-07
diagnosis O 0 5.8498637372395024e-05
is O 0 1.402179776732737e-07
suspected O 0 5.215393230173504e-06
, O 0 1.3147587196726818e-07
physicians O 0 1.661018842469275e-07
must O 0 2.183304737002345e-08
use O 0 3.213228083609465e-08
serum O 0 4.376030574348988e-06
ferritin O 0 2.048300302703865e-05
levels O 0 3.758225091132772e-07
and O 0 1.9548097895949468e-07
hepatic O 0 5.799484279123135e-05
iron O 0 0.000579513143748045
stores O 0 1.4711781659570988e-05
on O 0 1.2547349115266115e-06
liver O 0 1.249780962098157e-05
biopsy O 0 2.530068377382122e-05
specimens O 0 6.128229301793908e-08
to O 0 1.0781437076445854e-08
assess O 0 3.661023413314979e-07
patients O 0 1.2750797395710833e-07
for O 0 2.553110167724526e-09
the O 0 8.711611876321967e-09
presence O 0 1.2686597017363965e-07
of O 0 7.49026938251518e-08
iron B-Disease 0 0.4232855439186096
overload I-Disease 0 0.00043446107883937657
. O 0 1.2322242355367052e-06

Liver O 1 0.9990733861923218
biopsy O 1 0.8907439708709717
is O 0 1.584959704814537e-06
also O 0 2.1233104519069457e-07
used O 0 3.719094010534718e-08
to O 0 7.694792358847735e-09
establish O 0 4.398878417077867e-08
the O 0 2.6390841512125007e-08
presence O 0 7.203239249520266e-08
or O 0 3.230970690992763e-08
absence O 0 8.315408450698669e-08
of O 0 8.651920069269181e-08
cirrhosis B-Disease 0 9.822839638218284e-05
, O 0 1.7535727181439142e-07
which O 0 4.217438061004941e-07
can O 0 1.9447426780061505e-07
affect O 0 1.8691171135287732e-06
prognosis O 0 0.003707675728946924
and O 0 1.3086507806292502e-06
management O 0 1.5386501672765007e-06
. O 0 9.878556284093065e-07

A O 0 1.19106562124216e-05
DNA O 0 1.0061267857963685e-05
- O 0 9.725081326905638e-06
based O 0 8.492671810245156e-08
test O 0 1.4631393874253718e-08
for O 0 2.3819719530138173e-09
the O 0 1.977306851586036e-08
HFE O 0 4.872122372034937e-05
gene O 0 2.5987520757553284e-07
is O 0 1.4833938521974233e-08
commercially O 0 2.2459133219854266e-08
available O 0 1.1200063099181534e-08
, O 0 1.1178018510804577e-08
but O 0 1.7295482823698194e-09
its O 0 2.7366799937311725e-09
place O 0 9.714190696286096e-08
in O 0 2.1122925630834288e-08
the O 0 1.1438955027642805e-07
diagnosis O 0 0.00015576208534184843
of O 0 1.3372656439969433e-06
hemochromatosis B-Disease 1 1.0
is O 0 4.025051111966604e-06
still O 0 8.457858484689496e-07
being O 0 4.2402643884997815e-07
evaluated O 0 1.5647952977815294e-06
. O 0 1.0771179859148106e-06

Currently O 0 2.190935811086092e-05
, O 0 1.5001175768247776e-07
the O 0 9.703020609208579e-09
most O 0 3.7527039253859584e-09
useful O 0 2.5268138692524644e-09
role O 0 1.0475949885346836e-08
for O 0 5.489054988316866e-09
this O 0 1.0267645400574565e-08
test O 0 2.8817863650942854e-08
is O 0 7.705968307902822e-09
in O 0 1.475593425226407e-09
the O 0 6.379997419259098e-09
detection O 0 6.443457891691651e-07
of O 0 1.8494516496048163e-07
hemochromatosis B-Disease 1 1.0
in O 0 6.332608677439566e-07
the O 0 1.3917151875375566e-07
family O 0 2.3096218626506015e-07
members O 0 4.929327612757106e-09
of O 0 6.630441085064831e-09
patients O 0 4.937808739668981e-08
with O 0 7.04498148706989e-09
a O 0 5.845724331265956e-07
proven O 0 8.477060760014865e-07
case O 0 7.131781387670344e-08
of O 0 1.8127215284380327e-08
the O 0 2.531010295570013e-06
disease O 0 0.0001279524149140343
. O 0 1.0646544978953898e-06

It O 0 1.6796448107925244e-06
is O 0 7.489155251505508e-08
crucial O 0 4.231292507483886e-07
to O 0 4.9016066441254225e-06
diagnose O 1 0.9999972581863403
hemochromatosis B-Disease 1 1.0
before O 0 0.01176823303103447
hepatic B-Disease 1 0.9999396800994873
cirrhosis I-Disease 1 0.947335422039032
develops O 0 4.392484333948232e-05
because O 0 3.565251063264441e-07
phlebotomy O 0 0.00017071446927729994
therapy O 0 2.2318601622828282e-05
can O 0 1.2287729305171524e-06
avert O 0 0.120725616812706
serious O 0 0.22633564472198486
chronic O 1 0.9999866485595703
disease O 0 0.025333445519208908
and O 0 1.6476792552566621e-06
can O 0 3.27769782870746e-07
even O 0 2.8985175504203653e-07
lead O 0 1.1391853149689268e-06
to O 0 8.119467764799992e-08
normal O 0 8.432456297668978e-07
life O 0 2.749636962562363e-07
expectancy O 0 2.7212799977860413e-06
. O 0 3.6768099676010024e-08
. O 0 2.9408261070784647e-07

Prevalence O 0 0.004599709063768387
of O 0 6.653182822446979e-07
the O 0 2.722217402606475e-07
I1307K O 0 9.330537068308331e-06
APC B-Disease 0 3.401730509722256e-06
gene O 0 6.865150226076366e-07
variant O 0 2.849856628017733e-06
in O 0 8.685086783088991e-08
Israeli O 0 9.096395842789207e-06
Jews O 0 3.493666156373365e-07
of O 0 1.9823735986079782e-09
differing O 0 5.62402000525708e-08
ethnic O 0 1.6136237945829635e-07
origin O 0 9.641885156952412e-08
and O 0 6.510427397188323e-07
risk O 0 9.624807717045769e-06
for O 0 9.206663526128978e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5207535398076288e-05

BACKGROUND O 0 0.0005194682744331658
& O 0 7.621046825079247e-05
AIMS O 0 4.493222604651237e-06
Israeli O 0 6.7455866883392446e-06
Jews O 0 1.7164212806619616e-07
of O 0 4.991029811662884e-09
European O 0 6.992986811837909e-08
birth O 0 8.714549039723352e-06
, O 0 1.8833891601843789e-07
i O 0 1.0857839072286879e-07
. O 0 4.246194507118162e-09
e O 0 4.043742762860347e-08
. O 0 4.5491548306131335e-09
, O 0 7.732618101385924e-09
Ashkenazim O 0 6.654496473856852e-07
, O 0 1.5474094894329937e-08
have O 0 2.2767345342344925e-08
the O 0 1.0726588470788556e-06
highest O 1 0.9594448804855347
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.01218711119145155
of O 0 1.4768329670289404e-08
any O 0 2.2369695429347303e-08
Israeli O 0 1.2311082173255272e-05
ethnic O 0 2.325261220903485e-06
group O 0 7.378064765362069e-06
. O 0 1.1454908417363185e-06

The O 0 8.711947884876281e-06
I1307K O 0 6.120529724285007e-05
APC B-Disease 0 1.661924943618942e-05
gene O 0 3.9891187952889595e-06
variant O 0 5.640200834022835e-05
was O 0 0.0001124403061112389
found O 0 1.0024059520219453e-06
in O 0 3.3880479577419464e-07
6 O 0 5.208444235904608e-06
. O 0 1.7492495771875838e-06

1 O 0 2.9990340408403426e-05
% O 0 8.615409115009243e-07
of O 0 1.4641890366817734e-08
American O 0 1.4959331906538864e-07
Jews O 0 7.115041853467119e-07
, O 0 6.210125036432146e-08
28 O 0 2.875697759918694e-07
% O 0 8.819665886505845e-09
of O 0 7.712821492589228e-09
their O 0 2.6571151465759613e-05
familial O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.7160374429513467e-06
, O 0 8.419929997671716e-08
but O 0 2.1646826553478604e-08
not O 0 7.341679708616766e-09
in O 0 2.362350315365802e-08
non O 0 2.701264634197287e-07
- O 0 2.1431738787214272e-05
Jews O 0 4.082560735696461e-06
. O 0 5.954714197287103e-07

We O 0 9.621779099688865e-06
assessed O 0 9.754579650689266e-07
the O 0 7.231086840420176e-08
I1307K O 0 4.749858362629311e-06
prevalence O 0 1.2325462193985004e-05
in O 0 2.6836980637767738e-08
Israeli O 0 5.43711576028727e-06
Jews O 0 1.2702879814696644e-07
of O 0 2.8841051769035175e-09
differing O 0 6.06188379492778e-08
ethnic O 0 1.3577192703451146e-07
origin O 0 1.0950556372790743e-07
and O 0 1.2573066214827122e-06
risk O 0 1.465824152546702e-05
for O 0 6.667238631052896e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0928352821792942e-05

METHODS O 0 2.130929715349339e-05
DNA O 0 1.0072865734400693e-05
samples O 0 4.911883024760755e-07
from O 0 2.0746279361105735e-08
500 O 0 3.019740546506e-08
unrelated O 0 4.783825602316938e-08
Jews O 0 5.501163258259112e-08
of O 0 2.3523178960260793e-09
European O 0 1.741894450901782e-08
or O 0 3.535865999992893e-08
non O 0 1.7416553532711987e-08
- O 0 7.189923962869216e-07
European O 0 2.553130862281705e-08
origin O 0 1.2665991810933974e-08
, O 0 6.941343499988761e-09
with O 0 3.99888699931239e-09
or O 0 3.0961668784357244e-08
without O 0 4.676421028193545e-09
a O 0 1.828720286312091e-08
personal O 0 6.769371907466848e-07
and O 0 1.2868871408500127e-06
/ O 0 1.9718214389286004e-05
or O 0 1.0941099048977776e-07
family O 0 4.009397969184647e-08
history O 0 7.032603388523739e-09
of O 0 4.954589183370217e-09
neoplasia B-Disease 0 2.0864748876192607e-05
, O 0 4.0997054640001807e-08
were O 0 1.656148498341281e-07
examined O 0 1.284542321400295e-07
for O 0 5.461588958866059e-09
the O 0 3.457108022075772e-08
I1307K O 0 1.1422051784393261e-06
variant O 0 5.994261869091133e-07
by O 0 7.242098476467618e-09
the O 0 1.910194491472339e-08
allele O 0 4.819911509912345e-07
- O 0 5.2408483952604e-07
specific O 0 6.636263805148701e-08
oligonucleotide O 0 3.448084680712782e-05
( O 0 4.4507314100883377e-07
ASO O 0 1.0307576303603128e-05
) O 0 5.604765718203453e-08
method O 0 5.627206292047049e-07
. O 0 9.067286441677425e-07

RESULTS O 0 4.3849046051036566e-05
In O 0 2.7556484383239876e-07
persons O 0 8.190519906747795e-08
at O 0 9.653570742784723e-08
average O 0 2.6833197352971183e-06
risk O 0 5.482499091158388e-06
for O 0 4.3553736759349704e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.004784035620105e-07
I1307K O 0 9.096499525185209e-06
was O 0 6.183358891576063e-06
found O 0 6.633125337884849e-08
in O 0 7.435595250626648e-08
5 O 0 9.89939849205257e-07
. O 0 5.917035537095217e-07

0 O 0 9.827524627326056e-05
% O 0 2.3446873456123285e-06
of O 0 3.4150723138282046e-08
120 O 0 1.1054539328370083e-07
European O 0 1.2879402788712468e-07
and O 0 4.650082701118663e-07
1 O 0 2.5793870008783415e-06
. O 0 1.915954499054351e-06

6 O 0 0.00012338116357568651
% O 0 8.171621743713331e-07
of O 0 1.810724015172127e-08
188 O 0 3.279383236076683e-07
non O 0 1.8961578973630822e-07
- O 0 3.6721535252581816e-06
European O 0 1.3795934705740365e-07
Jews O 0 2.1061136123989854e-07
( O 0 5.42547056170406e-08
P O 0 7.16452814231161e-06
= O 0 9.249306458514184e-07
0 O 0 1.365337283232293e-07
. O 0 2.494439677036553e-08
08 O 0 5.16137333761435e-07
) O 0 1.3682152655292157e-07
. O 0 6.314950269370456e-07

It O 0 1.2133727068430744e-05
occurred O 0 7.465831004083157e-06
in O 0 2.6154376087106357e-07
15 O 0 1.9972421796410345e-06
. O 0 1.776015210452897e-06

4 O 0 7.744492177153006e-05
% O 0 1.3398685041465797e-06
of O 0 3.535765102924415e-08
52 O 0 2.9172915674280375e-06
Ashkenazi O 0 2.290349038958084e-05
Israelis O 0 2.6191914002993144e-05
with O 0 9.488244359090459e-07
familial O 1 0.7605003118515015
cancer B-Disease 0 0.02624688856303692
( O 0 2.204165525654389e-07
P O 0 4.142078978475183e-05
= O 0 2.2889885258337017e-06
0 O 0 1.8160719150728255e-07
. O 0 1.7766431881227618e-08
02 O 0 3.9181944089250464e-07
) O 0 9.315104243512451e-09
and O 0 1.2800971660453797e-07
was O 0 5.5370146583300084e-05
not O 0 3.293816419613904e-08
detected O 0 1.1574268654612752e-07
in O 0 1.616122702330358e-08
51 O 0 3.391419340914581e-07
non O 0 1.8313905059130775e-08
- O 0 4.636775656763348e-07
European O 0 1.914308711548074e-08
Jews O 0 5.406297631793677e-08
at O 0 5.067841613026758e-08
increased O 0 1.597316099832824e-06
cancer B-Disease 0 2.457219125062693e-05
risk O 0 1.300831627304433e-06
. O 0 5.997801508783596e-07

Colorectal B-Disease 1 0.9999760389328003
neoplasia I-Disease 1 0.975567102432251
occurred O 0 0.001995789585635066
personally O 0 2.985682112921495e-05
or O 0 4.0342024476558436e-07
in O 0 4.416718724087332e-08
the O 0 4.448838808457367e-08
families O 0 7.031774629240317e-08
of O 0 3.840765927520806e-09
13 O 0 7.464583262617452e-08
of O 0 3.6446827778036095e-09
20 O 0 1.0644581038832257e-07
Ashkenazi O 0 1.1638305750238942e-06
I1307K O 0 2.858886603007704e-07
carriers O 0 3.070566734209024e-08
, O 0 5.371318501090627e-09
8 O 0 1.9923513505659685e-08
of O 0 1.988546216580289e-09
whom O 0 1.3008117321078316e-06
also O 0 2.096203843393596e-06
had O 0 9.510199561191257e-06
a O 0 3.235423662317771e-07
personal O 0 1.4086308510741219e-06
or O 0 4.207888082419231e-07
family O 0 1.686712778337096e-07
history O 0 4.7297792349354495e-08
of O 0 7.842716343020584e-08
noncolonic O 0 0.0001915161992656067
neoplasia B-Disease 0 0.0005970675265416503
. O 0 1.9817844076897018e-06

CONCLUSIONS O 0 3.187560650985688e-05
The O 0 9.547135277898633e-07
I1307K O 0 6.001146903145127e-05
APC O 0 2.305553061887622e-05
variant O 0 4.390750837046653e-05
may O 0 1.1421278713896754e-06
represent O 0 2.380329000573056e-08
a O 0 9.470013395684873e-08
susceptibility O 0 1.7215970729012042e-05
gene O 0 2.1314531295502093e-06
for O 0 2.2201513729669387e-06
colorectal B-Disease 1 1.0
, I-Disease 0 2.0325635432527633e-06
or I-Disease 0 1.425715083769319e-07
other I-Disease 0 2.7839750060820734e-08
, I-Disease 0 5.008918719795474e-07
cancers I-Disease 0 0.0003979855391662568
in O 0 7.127321310917978e-08
Ashkenazi O 0 4.696806354331784e-05
Jews O 0 2.1865944290766492e-06
, O 0 7.35659710926484e-08
and O 0 1.3617936645005102e-07
partially O 0 3.0006929137016414e-06
explains O 0 1.658630282008744e-07
the O 0 8.372826876268391e-09
higher O 0 2.105226144522021e-07
incidence O 0 0.06918706744909286
of O 0 0.006406112108379602
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.762410069110047e-07
European O 0 8.925094903133868e-07
Israelis O 0 6.776495138183236e-05
. O 0 2.2942294890526682e-06

Systematic O 0 3.515485877869651e-05
analysis O 0 3.2801601719256723e-06
of O 0 3.309721421373979e-07
coproporphyrinogen O 0 0.0003211170551367104
oxidase O 0 0.0001215797892655246
gene O 0 0.00032718913280405104
defects O 1 0.998978853225708
in O 0 8.219178198487498e-06
hereditary B-Disease 1 0.9848953485488892
coproporphyria I-Disease 0 0.005592135712504387
and O 0 4.624243501893943e-06
mutation O 0 1.6643260096316226e-05
update O 0 2.361327460675966e-05
. O 0 4.077941866853507e-06

Hereditary B-Disease 1 0.9998239874839783
coproporphyria I-Disease 0 0.25326278805732727
( O 0 1.3866591871192213e-05
HC B-Disease 0 0.0005779372295364738
) O 0 8.913730766835215e-07
is O 0 3.1671581268710725e-07
an O 0 2.1796840883325785e-06
acute O 1 0.9998675584793091
hepatic B-Disease 1 0.9999990463256836
porphyria I-Disease 1 0.9999997615814209
with O 0 0.0020823285449296236
autosomal O 1 0.9999898672103882
dominant O 1 0.7122800946235657
inheritance O 0 0.10442548990249634
caused O 0 0.0005363543168641627
by O 0 2.543478672123456e-07
deficient B-Disease 0 6.188503175508231e-05
activity I-Disease 0 3.7390631746347935e-07
of I-Disease 0 4.859169067117364e-08
coproporphyrinogen I-Disease 0 0.0003001438162755221
III I-Disease 0 0.001160824322141707
oxidase I-Disease 0 3.834320523310453e-05
( O 0 7.20609023119323e-07
CPO O 0 2.7016509193344973e-05
) O 0 4.173756735781353e-07
. O 0 1.0595817911962513e-06

Clinical O 0 0.00025441969046369195
manifestations O 0 3.79555749532301e-05
of O 0 2.6466540248293313e-07
the O 0 7.213953722384758e-06
disease O 0 0.005229975562542677
are O 0 7.066220319984495e-08
characterized O 0 8.577291737310588e-06
by O 0 4.0672702539268357e-07
acute O 0 0.0002259557950310409
attacks O 0 0.0016741522122174501
of O 0 1.2929437616548967e-05
neurological B-Disease 1 0.9999798536300659
dysfunction I-Disease 1 0.9066205024719238
often O 0 7.020797056611627e-06
precipitated O 0 5.656267148879124e-06
by O 0 1.6432707639069122e-08
drugs O 0 4.699860411960799e-08
, O 0 2.471579563234627e-08
fasting O 0 2.8801382541132625e-06
, O 0 2.6413301768002384e-08
cyclical O 0 4.131046807742678e-06
hormonal O 0 2.0450093870749697e-05
changes O 0 2.1410946260402852e-07
, O 0 1.7238984639789123e-07
or O 0 1.749871898937272e-06
infectious B-Disease 0 0.00022579253709409386
diseases I-Disease 0 0.0001220132180606015
. O 0 2.4109076548484154e-06

Skin O 1 0.9999994039535522
photosensitivity O 1 0.9999274015426636
may O 0 0.006360637955367565
also O 0 3.2001630643208046e-06
be O 0 1.396574731415967e-07
present O 0 4.202145760245912e-07
. O 0 2.6168449949182104e-06

The O 0 2.538337184887496e-06
seven O 0 6.15347062193905e-07
exons O 0 5.789599981653737e-06
, O 0 5.3761279872333034e-08
the O 0 2.8784574723772494e-08
exon O 0 5.483215772983385e-06
/ O 0 7.3392984631937e-06
intron O 0 4.7533550969092175e-05
boundaries O 0 5.73466559217195e-06
and O 0 3.8069634911153116e-07
part O 0 2.6211152359678636e-08
of O 0 6.867832524903861e-09
3 O 0 1.8966534298670013e-07
noncoding O 0 8.22491188046115e-07
sequence O 0 4.6420851163020416e-08
of O 0 2.243270680324372e-09
the O 0 4.509693241061541e-08
CPO O 0 1.5608826288371347e-05
gene O 0 2.1168546027183766e-07
were O 0 1.4933731051769428e-07
systematically O 0 5.18796298365487e-07
analyzed O 0 6.669140617532321e-08
by O 0 1.2981073993501013e-09
an O 0 2.047205294175569e-09
exon O 0 4.938534061693645e-07
- O 0 1.7436300367990043e-06
by O 0 4.060359870550201e-08
- O 0 4.1841176425805315e-06
exon O 0 1.895874629553873e-05
denaturing O 0 0.00016049346595536917
gradient O 0 0.0001837782619986683
gel O 0 0.0004461079661268741
electrophoresis O 0 0.00022875780996400863
( O 0 3.7979268086019147e-07
DGGE O 0 1.543969483464025e-05
) O 0 1.5810837084018203e-08
strategy O 0 4.7172921568972015e-08
followed O 0 3.0029461584035744e-08
by O 0 1.5185301904807602e-09
direct O 0 4.65827820761433e-09
sequencing O 0 4.5912067037079396e-08
in O 0 1.1072999406280815e-08
seven O 0 1.0534020589147985e-07
unrelated O 0 2.4892792680475395e-06
heterozygous O 0 1.1766303941840306e-05
HC B-Disease 0 9.826127643464133e-05
patients O 0 3.183318312949268e-06
from O 0 9.286776503358851e-08
France O 0 4.866802555625327e-06
, O 0 8.241890014915043e-08
Holland O 0 4.681221071223263e-06
, O 0 4.0503969955807406e-08
and O 0 7.0219904557689e-08
Czech O 0 4.620125935161923e-07
Republic O 0 4.377677953470993e-07
. O 0 9.358021770822234e-07

Seven O 0 2.457071423123125e-05
novel O 0 1.0291104445059318e-05
mutations O 0 2.0427212803042494e-05
and O 0 4.5824844363551165e-08
two O 0 8.906323500923463e-08
new O 0 2.096883690683171e-06
polymorphisms O 0 0.025756150484085083
were O 0 7.817780897312332e-06
detected O 0 1.2521825738076586e-05
. O 0 1.4510412711388199e-06

Among O 0 5.380094989959616e-06
these O 0 1.4622347066506336e-07
mutations O 0 3.1177251003100537e-06
two O 0 1.0109158665727591e-07
are O 0 8.052010969095136e-08
missense O 0 6.975745782256126e-05
( O 0 6.493957016573404e-08
G197W O 0 1.6891351606318494e-06
, O 0 4.517165663742162e-08
W427R O 0 1.5228054053295637e-06
) O 0 8.888314084742888e-09
, O 0 5.612978970503946e-09
two O 0 1.8956763270239207e-08
are O 0 2.2960007228789436e-08
nonsense O 0 1.638903199818742e-06
( O 0 2.0528682753706562e-08
Q306X O 0 5.023068752052495e-07
, O 0 1.9219625002619978e-08
Q385X O 0 5.16024613261834e-07
) O 0 5.383143264481305e-09
, O 0 1.4712457918619748e-09
two O 0 3.0271145590177184e-09
are O 0 4.048294144354259e-09
small O 0 1.7619232295373877e-08
deletions O 0 4.864928087044973e-06
( O 0 5.5696837364394014e-08
662de14bp O 0 5.557246822718298e-07
; O 0 2.273445254274975e-08
1168del3bp O 0 2.621475800879125e-07
removing O 0 3.7780360173655936e-08
a O 0 4.5793481007194714e-08
glycine O 0 1.5505287365158438e-06
at O 0 1.3988366731609858e-07
position O 0 2.44510204083781e-07
390 O 0 1.9735206535642646e-07
) O 0 2.054168746212781e-08
, O 0 1.4309861740002816e-08
and O 0 5.649468093338328e-08
one O 0 3.1284120183272535e-08
is O 0 6.461337687113655e-09
a O 0 3.766516698533451e-08
splicing O 0 7.433655355271185e-06
mutation O 0 2.799459934976767e-06
( O 0 5.994873220060981e-08
IVS1 O 0 3.1224112717609387e-06
- O 0 2.385727839282481e-06
15c O 0 1.77563583747542e-06
- O 0 1.3727482155445614e-06
- O 0 6.4635923990863375e-06
> O 0 1.2247191989445128e-06
g O 0 6.577178282896057e-06
) O 0 1.6547948789025213e-08
which O 0 1.6253624224304986e-08
creates O 0 6.671240271316492e-08
a O 0 1.8158496928322165e-08
new O 0 5.9266586305284363e-08
acceptor O 0 2.9862198402952345e-07
splice O 0 3.856907642330043e-05
site O 0 8.85535337147303e-06
. O 0 1.7629823787501664e-06

The O 0 4.7627540880057495e-06
pathological O 0 1.0279921298206318e-05
significance O 0 5.907478453082149e-07
of O 0 2.700570966851501e-08
the O 0 9.357167840562397e-08
point O 0 8.095767043414526e-06
mutations O 0 1.0383385415480006e-05
G197W O 0 2.455597041262081e-06
, O 0 4.030867728488374e-08
W427R O 0 6.329203756649804e-07
, O 0 1.6042065453802934e-08
and O 0 1.0814905415656995e-08
the O 0 3.706260853775234e-09
in O 0 1.120724313352639e-08
- O 0 1.32191917145974e-06
frame O 0 3.337383895996027e-05
deletion O 0 4.930006980430335e-06
390delGly O 0 3.4907329791167285e-06
were O 0 6.499682285721065e-07
assessed O 0 5.2103246162005235e-08
by O 0 3.4818026239946676e-09
their O 0 1.262359283771275e-08
respective O 0 6.075832459373487e-08
expression O 0 9.280508095343976e-08
in O 0 6.030031141079917e-09
a O 0 2.707069057805711e-08
prokaryotic O 0 4.3085094603156904e-08
system O 0 2.246860120180827e-08
using O 0 2.8170493493462345e-08
site O 0 1.5005625755293295e-06
- O 0 1.576132490299642e-05
directed O 0 2.1544731225731084e-06
mutagenesis O 0 1.658799192227889e-05
. O 0 6.987586402829038e-07

These O 0 6.461478278652066e-06
mutations O 0 4.0254872146761045e-05
resulted O 0 8.064258167905791e-07
in O 0 6.447256595265571e-08
the O 0 2.967350383187295e-07
absence O 0 1.2763210861521657e-06
or O 0 1.57871880901439e-07
a O 0 4.671627209518192e-07
dramatic O 0 1.0666733942343853e-05
decrease O 0 5.349305865820497e-06
of O 0 3.645567758780999e-08
CPO O 0 8.126923785312101e-05
activity O 0 1.5788950804562774e-06
. O 0 3.1871684313955484e-07

The O 0 2.6940017505694414e-06
two O 0 7.940603836686932e-07
polymorphisms O 0 0.0011452804319560528
were O 0 1.8114067188435001e-06
localized O 0 3.956369255320169e-06
in O 0 1.6718047390895663e-07
noncoding O 0 3.4563481676741503e-06
part O 0 2.9449481075971562e-08
of O 0 2.5802953107501025e-09
the O 0 6.054140300193467e-09
gene O 0 5.8681564496509964e-08
1 O 0 2.1499969804494867e-08
) O 0 3.2796341198348955e-09
a O 0 7.167797377860552e-08
C O 0 2.98946542898193e-05
/ O 0 3.137665044050664e-05
G O 0 0.0013095969334244728
polymorphism O 0 2.232523229395156e-06
in O 0 2.1747139200556376e-08
the O 0 7.620539577146701e-08
promotor O 0 1.5176531633187551e-05
region O 0 5.943627456872491e-07
, O 0 3.240883117427984e-08
142 O 0 2.4250539354397915e-07
bp O 0 2.5316983283119043e-06
upstream O 0 1.2351779332675505e-07
from O 0 3.621247746110612e-09
the O 0 2.1235335712077585e-09
transcriptional O 0 6.172678013172117e-08
initiation O 0 5.1605365314344454e-08
site O 0 1.0521128501750354e-07
( O 0 1.552894168810326e-08
- O 0 6.134919772193825e-07
142C O 0 2.246551048301626e-06
/ O 0 2.6313571197533747e-06
G O 0 2.9208295018179342e-05
) O 0 1.1300229196820055e-08
, O 0 5.972569994128207e-09
and O 0 1.906009217123028e-08
2 O 0 7.311972183288162e-08
) O 0 4.799680652922689e-09
a O 0 2.5232898437366202e-08
6 O 0 8.104264566100028e-07
bp O 0 1.0950239811791107e-05
deletion O 0 4.312054898036877e-06
polymorphism O 0 2.6933698791253846e-06
in O 0 2.6202053859947227e-08
the O 0 6.670553176491012e-08
3 O 0 2.7731746854442463e-07
noncoding O 0 6.183395839798322e-07
part O 0 1.983221586954187e-08
of O 0 2.6116522278130105e-09
the O 0 3.9798052853257104e-08
CPO O 0 7.17161765351193e-06
gene O 0 1.1560335622107232e-07
, O 0 3.757869748710618e-08
574 O 0 2.7832138016492536e-07
bp O 0 1.3910213283452322e-06
downstream O 0 6.881603553665627e-08
of O 0 1.9642472093295282e-09
the O 0 1.1457511384094232e-08
last O 0 2.6210361170342367e-07
base O 0 5.743558872950416e-08
of O 0 2.2070392180495446e-09
the O 0 1.0582226650512894e-08
normal O 0 1.954140600446408e-07
termination O 0 7.688310006415122e-07
codon O 0 2.5315148377558216e-06
( O 0 1.4281768301316333e-07
+ O 0 1.6557220305912779e-06
574 O 0 4.149204869463574e-06
delATTCTT O 0 7.112910225259839e-06
) O 0 2.7078959874415887e-07
. O 0 7.5319007919461e-07

Five O 0 1.419446289219195e-05
intragenic O 0 3.8032096199458465e-05
dimorphisms O 0 3.5706845665117726e-05
are O 0 1.0635833547212314e-07
now O 0 4.397637098918494e-08
well O 0 4.130252051481875e-08
characterized O 0 1.9358085410203785e-06
and O 0 1.9660367911455978e-07
the O 0 3.1815527989920156e-08
high O 0 2.3528897941105242e-07
degree O 0 3.546537641341274e-08
of O 0 7.686210778956593e-09
allelic O 0 2.6391430765215773e-06
heterogeneity O 0 6.028428288118448e-06
in O 0 1.5281270293598936e-07
HC B-Disease 0 0.0001311973319388926
is O 0 5.404569947131677e-07
demonstrated O 0 2.999494768118893e-07
with O 0 5.894256194238778e-09
seven O 0 1.9513949567340205e-08
new O 0 1.0412779971602504e-08
different O 0 1.4180502994065591e-08
mutations O 0 1.470213533139031e-07
making O 0 6.7131429304367884e-09
a O 0 2.1437195130147302e-08
total O 0 8.949965213389532e-09
of O 0 9.85525705488044e-09
nineteen O 0 8.149277164193336e-06
CPO O 0 0.00048618356231600046
gene B-Disease 0 2.1052246665931307e-05
defects I-Disease 1 0.6160516738891602
reported O 0 1.0202052180829924e-05
so O 0 4.294135891313999e-08
far O 0 6.6247174856926e-08
. O 0 7.409997238028154e-08
. O 0 5.689314548362745e-07

Coincidence O 0 7.009253749856725e-05
of O 0 3.996167663444794e-07
two O 0 1.772720992221366e-07
novel O 0 1.1866492286571884e-06
arylsulfatase O 0 2.7065814720117487e-05
A O 0 9.558312967783422e-07
alleles O 0 2.9139380330889253e-06
and O 0 5.214585030444141e-07
mutation O 0 9.212129043589812e-06
459 O 0 1.326886717833986e-06
+ O 0 8.875067578628659e-07
1G O 0 3.0142047762637958e-05
> O 0 4.975075285074126e-07
A O 0 5.644879408350789e-08
within O 0 1.159672624595487e-08
a O 0 6.400281193919e-08
family O 0 8.907637720767525e-07
with O 0 7.496738362533506e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999988079071045
: O 0 3.836924022948551e-08
molecular O 0 9.663039435281462e-08
basis O 0 5.0221441227904506e-08
of O 0 6.756163628551803e-08
phenotypic O 0 2.9308268494787626e-05
heterogeneity O 0 0.00019638608500827104
. O 0 4.725811322714435e-06

In O 0 2.49032859755971e-06
a O 0 5.624276582238963e-07
family O 0 2.600509958483599e-07
with O 0 9.027168346165126e-08
three O 0 1.0341052529838635e-06
siblings O 0 2.9939765227027237e-05
, O 0 2.483326611013581e-08
one O 0 1.3443178126237854e-08
developed O 0 1.4207013521172485e-07
classical O 0 7.148790928113158e-07
late O 0 4.5728000259259716e-05
infantile O 1 0.9996271133422852
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.626864650461357e-05
MLD B-Disease 1 0.9999935626983643
) O 0 2.1471022648711369e-07
, O 0 4.862840441433036e-08
fatal O 0 6.484973710030317e-06
at O 0 4.2063956584570406e-07
age O 0 2.4165370859918767e-07
5 O 0 1.5387367113817163e-07
years O 0 5.694005622558507e-08
, O 0 2.1869348998393434e-08
with O 0 1.020240816274054e-07
deficient O 0 0.00011966189049417153
arylsulfatase O 0 2.06965360121103e-05
A O 0 2.4592272893642075e-06
( O 0 2.00874239908444e-07
ARSA O 0 2.915694858529605e-05
) O 0 1.590296250242318e-08
activity O 0 5.749181397618486e-08
and O 0 5.037023242948635e-08
increased O 0 1.3522948165700654e-06
galactosylsulfatide O 0 0.0011517417151480913
( O 0 2.043373569904361e-06
GS O 1 0.999997615814209
) O 0 4.98488702760369e-07
excretion O 0 4.060099399794126e-06
. O 0 1.5635587260476314e-06

The O 0 1.5542683513558586e-06
two O 0 1.9409091578381776e-07
other O 0 2.819387567853937e-08
siblings O 0 5.696791959053371e-06
, O 0 5.162564420402305e-08
apparently O 0 9.768310746949282e-07
healthy O 0 1.2417011419074697e-07
at O 0 1.8828336223464248e-08
12 O 0 2.1050729159810544e-08
( O 0 5.1423563185437615e-09
1 O 0 1.5087497473587064e-08
/ O 0 5.847280135640176e-07
2 O 0 8.525456252073127e-08
) O 0 5.676966008394402e-09
and O 0 2.8710168464840535e-08
15 O 0 6.85171599457135e-08
years O 0 1.6562916371754e-08
, O 0 1.2927932502293515e-08
respectively O 0 7.150864433924653e-08
, O 0 1.507921076893126e-08
and O 0 4.9111147149005774e-08
their O 0 1.906838242859976e-08
father O 0 8.112499472190393e-07
, O 0 3.970206918779695e-08
apparently O 0 9.116075716519845e-07
healthy O 0 2.7488392007057882e-08
as O 0 7.253074585378272e-09
well O 0 1.170965990837658e-08
, O 0 1.2684510330984722e-08
presented O 0 1.1133785449146671e-07
ARSA O 0 0.0002845464332494885
and O 0 4.486409579840256e-06
GS O 1 0.9999988079071045
values O 0 1.7454554779305909e-07
within O 0 8.526884087700637e-09
the O 0 1.6446440653794525e-08
range O 0 3.387472418125981e-07
of O 0 4.3512309844118136e-07
MLD B-Disease 1 0.9999998807907104
patients O 0 2.721422424656339e-05
. O 0 1.4651076298832777e-06

Mutation O 0 0.0003434271493460983
screening O 0 6.299434971879236e-06
and O 0 2.251944977160747e-07
sequence O 0 2.8973875032534124e-07
analysis O 0 9.964587377453427e-08
disclosed O 0 3.992982726686023e-07
the O 0 6.569676358481047e-09
involvement O 0 3.388289471217831e-08
of O 0 4.0055967431840145e-09
three O 0 4.335812775480008e-08
different O 0 2.543971220347885e-07
ARSA O 1 0.5179588794708252
mutations O 0 1.1158121196785942e-05
being O 0 3.395321357402281e-08
the O 0 6.8282037801736806e-09
molecular O 0 8.03400155291456e-08
basis O 0 4.493448102493858e-08
of O 0 3.1565349445372703e-08
intrafamilial O 0 4.923335291096009e-05
phenotypic O 0 2.8116708563175052e-05
heterogeneity O 0 0.00013314030366018414
. O 0 8.808422535366844e-06

The O 0 7.188084964582231e-06
late O 0 3.813895091298036e-05
infantile O 0 0.27395907044410706
patient O 0 0.000658780918456614
inherited O 0 0.0011217320570722222
from O 0 4.379581923785736e-07
his O 0 2.392346459600958e-06
mother O 0 1.008152321446687e-05
the O 0 2.2206707583904972e-08
frequent O 0 4.424319968165946e-07
0 O 0 5.440998620542814e-07
- O 0 1.0460580597282387e-05
type O 0 2.4484672849212075e-06
mutation O 0 1.9934479951189132e-06
459 O 0 7.369214358732279e-07
+ O 0 6.044312499398075e-07
1G O 0 6.8867302616126835e-06
> O 0 2.7678930791807943e-07
A O 0 2.494875559477805e-07
, O 0 6.174055755536756e-08
and O 0 6.303999100509827e-08
from O 0 1.7624072867761242e-08
his O 0 6.752299555046193e-07
father O 0 7.976633469297667e-07
a O 0 2.999654569180166e-08
novel O 0 1.9216879820760369e-07
, O 0 1.4763625877378672e-08
single O 0 9.620759300332793e-08
basepair O 0 3.056478362850612e-06
microdeletion O 0 7.406400754916831e-07
of O 0 4.234345762910152e-09
guanine O 0 1.8258002398852113e-07
at O 0 2.8322531875346613e-08
nucleotide O 0 2.786905497487169e-07
7 O 0 9.351530394496876e-08
in O 0 2.5391591051970863e-08
exon O 0 4.621144398697652e-06
1 O 0 1.9905621684301877e-06
( O 0 1.5486148186028004e-07
7delG O 0 5.676249656971777e-06
) O 0 2.6457098556420533e-07
. O 0 7.595216970912588e-07

The O 0 3.5668972486746497e-06
two O 0 2.308990588062443e-06
clinically O 0 0.010633541271090508
unaffected O 0 7.728041236987337e-05
siblings O 0 4.7186425945255905e-05
carried O 0 2.3750967557134572e-06
the O 0 9.374388554306279e-08
maternal O 0 3.092977203777991e-05
mutation O 0 3.884837042278377e-06
459 O 0 7.510017212553066e-07
+ O 0 7.037314730951039e-07
1G O 0 1.959755718417e-05
> O 0 6.064532840355241e-07
A O 0 6.571232802343729e-07
and O 0 3.4270536275471386e-07
, O 0 2.781161967391199e-08
on O 0 1.2903043966616679e-07
their O 0 6.176894373766117e-08
paternal O 0 7.892227586125955e-06
allele O 0 8.524120289621351e-07
, O 0 5.3135829070072305e-09
a O 0 1.5836372213584582e-08
novel O 0 2.3723163167232997e-07
cytosine O 0 6.942034360690741e-07
to O 0 1.7770704019426375e-08
thymidine O 0 7.891902669143747e-07
transition O 0 2.1270376748816489e-07
at O 0 5.207681752494864e-08
nucleotide O 0 4.6244193185884797e-07
2435 O 0 2.0459845018194756e-06
in O 0 2.9697048375965096e-08
exon O 0 2.185210178140551e-06
8 O 0 1.3605400681626634e-06
, O 0 1.4181774865562602e-08
resulting O 0 2.8921824934968754e-08
in O 0 5.032248395764327e-09
substitution O 0 2.5372370870968552e-08
of O 0 1.1807016697673589e-08
alanine O 0 2.6663090466172434e-05
464 O 0 5.917581802350469e-06
by O 0 2.2283276734924584e-07
valine O 0 0.0004966548294760287
( O 0 3.300470439171477e-07
A464V O 0 6.983894763834542e-06
) O 0 3.758200080028473e-07
. O 0 6.069873279557214e-07

The O 0 2.0503171981545165e-05
fathers O 0 9.55935029196553e-05
genotype O 0 0.00014650265802629292
thus O 0 2.0153636342001846e-06
was O 0 4.506160621531308e-06
7delG O 0 8.680985774844885e-05
/ O 0 5.614019028143957e-05
A464V O 0 8.967420581029728e-05
. O 0 5.146066541783512e-06

Mutation O 0 0.003502256702631712
A464V O 0 0.0002131566870957613
was O 0 2.7343465262674727e-05
not O 0 2.6346233639173988e-08
found O 0 4.5702904571953695e-08
in O 0 5.653046386555616e-08
18 O 0 2.9355826427490683e-06
unrelated O 0 9.560024773236364e-05
MLD B-Disease 1 1.0
patients O 0 8.124156738631427e-05
and O 0 1.0012776101575582e-06
50 O 0 3.2425003837488475e-07
controls O 0 4.191673724562861e-06
. O 0 1.562504849061952e-06

A464V O 0 0.0011066755978390574
, O 0 3.96804534830153e-06
although O 0 4.700375768607046e-07
clearly O 0 7.024990509307827e-07
modifying O 0 2.690697328944225e-06
ARSA O 0 0.10807490348815918
and O 0 9.283060353482142e-05
GS O 1 1.0
levels O 0 6.1933737924846355e-06
, O 0 1.4775338286199258e-07
apparently O 0 2.8319695957179647e-06
bears O 0 1.1074056374127395e-06
little O 0 9.75172724793083e-08
significance O 0 4.402294706551402e-08
for O 0 9.917862087149842e-09
clinical O 0 4.613120836438611e-07
manifestation O 0 1.901120413094759e-06
of O 0 3.568101476503216e-07
MLD B-Disease 1 1.0
, O 0 3.5492655570124043e-07
mimicking O 0 5.204939043323975e-06
the O 0 2.668683976025932e-07
frequent O 0 1.0574725820333697e-05
ARSA O 0 0.004871927667409182
pseudodeficiency O 0 0.00025082490174099803
allele O 0 5.91573552810587e-05
. O 0 1.9570438780647237e-06

Our O 0 2.279851833009161e-05
results O 0 3.2976245165627915e-06
demonstrate O 0 5.092452965982375e-07
that O 0 1.2789996617357247e-08
in O 0 2.0170979553313373e-08
certain O 0 2.960124945161624e-08
genetic O 0 1.1750325029424857e-05
conditions O 0 0.0003690940502565354
MLD B-Disease 1 0.9999998807907104
- O 0 0.00028965395176783204
like O 0 2.64709569819388e-06
ARSA O 0 0.00575579097494483
and O 0 8.838748726702761e-06
GS O 1 0.9999997615814209
values O 0 6.516881398965779e-07
need O 0 2.1753693957293763e-08
not O 0 4.296271782777694e-09
be O 0 5.481751941260882e-09
paralleled O 0 1.2476377833081642e-06
by O 0 9.665970424066472e-08
clinical O 0 7.854489012970589e-06
disease O 0 6.048283921700204e-06
, O 0 1.082706191368743e-08
a O 0 3.6417034721125674e-08
finding O 0 1.174126538217024e-07
with O 0 1.550747583678458e-07
serious O 0 2.9860455015295884e-06
diagnostic O 0 2.0956977095920593e-05
and O 0 3.802300852839835e-06
prognostic O 0 0.00032185937743633986
implications O 0 5.712972324545262e-06
. O 0 3.0378510018636007e-06

Moreover O 0 8.256964065367356e-05
, O 0 6.020621299285267e-07
further O 0 7.926221883280959e-07
ARSA O 0 0.0015725356061011553
alleles O 0 9.036572009790689e-06
functionally O 0 3.162020448144176e-06
similar O 0 1.0053894783368378e-07
to O 0 1.4729472752605943e-07
A464V O 0 1.7284832210862078e-05
might O 0 9.543683745505405e-07
exist O 0 6.60309567024342e-08
which O 0 4.4090842976629574e-08
, O 0 4.099859562955999e-09
together O 0 1.0107226167122008e-08
with O 0 1.0780101256102625e-08
0 O 0 5.800464464300603e-07
- O 0 1.9100425561191514e-05
type O 0 7.719329005340114e-06
mutations O 0 9.753745871421415e-06
, O 0 1.2606645327650767e-07
may O 0 1.456181507819565e-06
cause O 0 6.428899155253021e-07
pathological O 0 8.855286068865098e-06
ARSA O 1 0.6268136501312256
and O 0 0.0009264249238185585
GS O 1 1.0
levels O 0 1.016255055219517e-06
, O 0 1.3075234228665522e-08
but O 0 5.399257041460714e-09
not O 0 9.027871783473529e-09
clinical O 0 1.2793965709079202e-07
outbreak O 0 3.873558398481691e-07
of O 0 1.1517942155592209e-08
the O 0 1.543319058328052e-06
disease O 0 3.7179470382397994e-05
. O 0 1.9273629447980056e-07
. O 0 5.848813771081041e-07

Human O 0 0.004411409143358469
MLH1 O 1 0.999901533126831
deficiency O 1 0.9991243481636047
predisposes O 0 0.002501722890883684
to O 0 2.3774222427164204e-05
hematological B-Disease 1 0.9965248703956604
malignancy I-Disease 1 0.995587944984436
and O 0 4.222558345645666e-05
neurofibromatosis B-Disease 0 0.12024828791618347
type I-Disease 0 1.1865296073665377e-05
1 I-Disease 0 5.244471140031237e-06
. O 0 3.045305447813007e-06

Heterozygous O 0 0.002491817343980074
germ O 0 0.003349786624312401
- O 0 0.18097683787345886
line O 0 0.0034266519360244274
mutations O 0 5.771738415205618e-06
in O 0 1.8273953017455824e-08
the O 0 4.717661283848429e-08
DNA O 0 1.5537199942627922e-05
mismatch O 0 0.003633909160271287
repair O 0 0.00040297742816619575
genes O 0 6.692155238852138e-06
lead O 0 1.4322225979412906e-05
to O 0 1.0979436410707422e-05
hereditary B-Disease 1 0.9999970197677612
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.7243422917090356e-05

The O 0 3.5418615880189463e-05
disease O 0 0.0002906304143834859
susceptibility O 0 3.908231883542612e-05
of O 0 9.010912549456407e-08
individuals O 0 2.7117312129121274e-07
who O 0 6.7322775976208504e-06
constitutionally O 0 1.787032488209661e-05
lack O 0 1.5758352844841284e-07
both O 0 3.2946331884886604e-08
wild O 0 8.01359078650421e-07
- O 0 6.948306690901518e-05
type O 0 1.924627667904133e-06
alleles O 0 1.0226523272649501e-06
is O 0 1.8432569959259126e-07
unknown O 0 2.2284689293883275e-06
. O 0 1.3307378594618058e-06

We O 0 1.2946685274073388e-05
have O 0 3.5492180927576555e-07
identified O 0 5.318366333995073e-07
three O 0 8.903656834036155e-08
offspring O 0 1.5123561070140568e-06
in O 0 1.0741436540229188e-07
a O 0 2.0015739210066386e-05
hereditary B-Disease 1 0.9999996423721313
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.3662188393936958e-05
who O 0 2.403827238595113e-06
developed O 0 3.7976765270286705e-06
hematological B-Disease 0 0.00045515247620642185
malignancy I-Disease 0 0.00018589913088362664
at O 0 6.54636309604939e-08
a O 0 5.502842626015081e-08
very O 0 3.161331108003651e-08
early O 0 1.9593544209328684e-07
age O 0 6.004061958719831e-08
, O 0 6.272369290627466e-09
and O 0 4.088085958642296e-08
at O 0 2.2263918708631536e-08
least O 0 3.8069614127778095e-09
two O 0 2.905118368090598e-09
of O 0 4.076093684801663e-09
them O 0 2.3201605969802586e-08
displayed O 0 2.448420445944066e-06
signs O 0 7.369123409262102e-07
of O 0 3.239436807689344e-08
neurofibromatosis B-Disease 0 0.0007292822701856494
type I-Disease 0 1.4722718333359808e-06
1 I-Disease 0 1.2642188949030242e-06
( O 0 3.778436337142921e-07
NF1 B-Disease 0 6.491001840913668e-05
) O 0 3.475077505754598e-07
. O 0 1.0813749895532965e-06

DNA O 0 3.819376797764562e-05
sequence O 0 1.7978553614739212e-06
analysis O 0 2.6142930664718733e-07
and O 0 9.890870700246523e-08
allele O 0 9.307200912189728e-07
- O 0 9.047212756740919e-07
specific O 0 3.643461354840838e-08
amplification O 0 1.7603716742087272e-06
in O 0 3.871312159731133e-08
two O 0 3.490592348498467e-07
siblings O 0 3.034711699001491e-05
revealed O 0 6.259706424316391e-06
a O 0 1.8617625983097241e-06
homozygous O 0 0.0006609344272874296
MLH1 O 0 0.0017845695838332176
mutation O 0 6.193693025124958e-06
( O 0 1.025782339070247e-07
C676T O 0 4.7653938963776454e-06
- O 0 2.4840361220412888e-05
- O 0 5.483099084813148e-05
> O 0 4.558064574666787e-06
Arg226Stop O 0 1.717418672342319e-05
) O 0 4.1906599790308974e-07
. O 0 9.11441532025492e-07

Thus O 0 2.7360572858015075e-05
, O 0 6.254404070205055e-07
a O 0 4.7318184215328074e-07
homozygous O 0 5.175911064725369e-05
germ O 0 0.0002291402342962101
- O 0 0.005097196437418461
line O 0 0.010880490764975548
MLH1 O 0 0.003626530757173896
mutation O 0 2.543970367696602e-05
and O 0 5.922466357333178e-07
consequent O 0 0.000624994863756001
mismatch O 1 0.999992847442627
repair O 1 0.9999997615814209
deficiency O 1 0.9965527057647705
results O 0 8.291176527563948e-07
in O 0 8.297632803078159e-08
a O 0 5.144864189787768e-06
mutator O 1 0.9579470157623291
phenotype O 0 0.1472153663635254
characterized O 0 1.674839404586237e-05
by O 0 6.902668587827065e-07
leukemia B-Disease 1 0.636572539806366
and O 0 3.567958265193738e-05
/ O 1 0.569711446762085
or O 0 0.09734058380126953
lymphoma B-Disease 1 1.0
associated O 0 1.5211699064821005e-05
with O 0 1.2409095688781235e-06
neurofibromatosis B-Disease 0 0.10764112323522568
type I-Disease 0 3.5460213894111803e-06
1 I-Disease 0 1.163236902357312e-06
. O 0 2.6382295459370653e-07
. O 0 1.5145066072363988e-06

Missense O 1 0.9984880685806274
mutations O 0 0.3096870183944702
in O 0 8.360708534382866e-07
the O 0 6.863317736360841e-08
most O 0 6.9050307693885316e-09
ancient O 0 1.3692459610581409e-08
residues O 0 6.966906340721835e-08
of O 0 9.036588366484466e-09
the O 0 1.9896822323062224e-07
PAX6 O 0 9.395988308824599e-05
paired O 0 5.370089183998061e-06
domain O 0 5.720151534660545e-07
underlie O 0 1.799642973310256e-06
a O 0 3.282136447069206e-07
spectrum O 0 3.89254364563385e-06
of O 0 3.963057793043845e-07
human O 0 0.0005508714239113033
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999860525131226
malformations I-Disease 1 0.9999552965164185
. O 0 1.4293256754172035e-05

Mutations O 0 0.002195569686591625
of O 0 3.357039304319187e-07
the O 0 2.385096991019964e-07
human O 0 1.2828655826524482e-06
PAX6 O 0 0.001359325717203319
gene O 0 0.000508418888784945
underlie O 1 0.8228874206542969
aniridia B-Disease 1 1.0
( O 0 0.04724576696753502
congenital B-Disease 1 0.9999998807907104
absence I-Disease 0 6.452697107306449e-06
of I-Disease 0 4.525633912066951e-08
the I-Disease 0 7.38817902856681e-07
iris I-Disease 0 0.12963071465492249
) O 0 1.8924977496226347e-07
, O 0 2.5002078629654534e-08
a O 0 3.7583077983072144e-07
rare O 0 7.002194706728915e-06
dominant O 0 0.06816792488098145
malformation B-Disease 1 0.9501270651817322
of I-Disease 0 7.99512704929839e-08
the I-Disease 0 2.774560925900005e-06
eye I-Disease 0 0.26368948817253113
. O 0 4.3480554268171545e-06

The O 0 3.149768190269242e-06
spectrum O 0 5.936659363214858e-06
of O 0 1.4115232715994352e-07
PAX6 O 0 0.00045001754187978804
mutations O 0 0.00012720389349851757
in O 0 4.564089522318682e-06
aniridia B-Disease 1 1.0
patients O 0 4.490224819164723e-05
is O 0 6.470367708288904e-08
highly O 0 3.186100983043616e-08
biased O 0 1.0617931138767744e-06
, O 0 5.47668612682628e-08
with O 0 2.1623222323796654e-08
92 O 0 6.336257456496242e-07
% O 0 9.973367909310582e-09
of O 0 1.381488146101617e-09
all O 0 2.789970920957785e-08
reported O 0 2.8583555831573904e-05
mutations O 0 2.668309889486409e-06
leading O 0 2.78823222288338e-07
to O 0 4.7452580531626154e-08
premature O 0 7.494712690458982e-07
truncation O 0 1.4508405001834035e-06
of O 0 2.1856253695773376e-08
the O 0 8.80887682797038e-08
protein O 0 1.0973624284815742e-06
( O 0 2.8492449288819444e-08
nonsense O 0 2.224639388259675e-07
, O 0 3.7195106994403204e-09
splicing O 0 2.0871524952781328e-07
, O 0 1.51077692578383e-08
insertions O 0 7.573164566565538e-07
and O 0 8.490032143981807e-08
deletions O 0 1.1054556807721383e-06
) O 0 2.455556114000501e-08
and O 0 6.569278099277653e-08
just O 0 1.407286589483192e-07
2 O 0 1.343692872524116e-07
% O 0 1.822894191150226e-08
leading O 0 1.01645873940015e-08
to O 0 8.091508574281647e-10
substitution O 0 8.06450373147527e-09
of O 0 2.4296842315862932e-09
one O 0 7.018749670351099e-08
amino O 0 1.5878298142979475e-07
acid O 0 2.064389406086775e-07
by O 0 5.913986189653997e-09
another O 0 1.1084288331630887e-07
( O 0 1.6019323823002196e-07
missense O 0 2.188496910093818e-05
) O 0 2.4186007863136183e-07
. O 0 5.935912668064702e-07

The O 0 2.2920119135960704e-06
extraordinary O 0 8.42102053866256e-07
conservation O 0 1.2167882346147962e-07
of O 0 9.455264127211649e-09
the O 0 3.8360528975545094e-08
PAX6 O 0 1.5207477190415375e-05
protein O 0 8.903620027922443e-07
at O 0 9.585372851006468e-08
the O 0 4.073694270800843e-08
amino O 0 4.5478205379367864e-07
acid O 0 8.810017106952728e-07
level O 0 5.796837498905916e-08
amongst O 0 5.8912696943025367e-08
vertebrates O 0 7.395384216124512e-08
predicts O 0 3.9931961737238453e-07
that O 0 8.02125832422007e-09
pathological O 0 3.974908395321108e-06
missense O 0 0.0009196649771183729
mutations O 0 2.5610142984078266e-05
should O 0 8.267206652590176e-08
in O 0 2.045286251473044e-08
fact O 0 2.0218125840187895e-08
be O 0 4.912866558015594e-08
common O 0 6.807309205214551e-08
even O 0 5.5943846888339976e-08
though O 0 3.79117359727843e-08
they O 0 2.0274583789614553e-08
are O 0 7.2314838561737815e-09
hardly O 0 1.8961939929340588e-07
ever O 0 9.340281792447058e-08
seen O 0 9.672863825471723e-07
in O 0 3.85630471555487e-07
aniridia B-Disease 1 0.9999997615814209
patients O 0 1.271380915568443e-05
. O 0 1.1839024409709964e-06

This O 0 1.9119243006571196e-06
indicates O 0 1.3998165968587273e-06
that O 0 2.5116408508552013e-08
there O 0 7.273175395283715e-09
is O 0 7.529312284759726e-09
a O 0 6.180040657000063e-08
heavy O 0 6.219172064447775e-05
ascertainment O 0 0.0001613669010112062
bias O 0 0.00011937275849049911
in O 0 1.2681438121830979e-08
the O 0 5.26400256717352e-09
selection O 0 9.520321420097844e-09
of O 0 2.0152521429395165e-08
patients O 0 2.7575859462558583e-07
for O 0 3.395742709244587e-08
PAX6 O 0 0.00010074166493723169
mutation O 0 1.2530726962722838e-06
analysis O 0 2.423622191827235e-08
and O 0 6.663343299351254e-08
that O 0 1.8115670741281065e-08
the O 0 1.0523034887910399e-07
missing O 0 1.312191307079047e-05
PAX6 O 0 0.0012636790052056313
missense O 0 0.005214048083871603
mutations O 0 9.871752990875393e-05
frequently O 0 1.3123114513291512e-05
may O 0 1.1558318874449469e-05
underlie O 0 0.00011017536598956212
phenotypes O 0 9.749620949150994e-05
distinct O 0 1.116644625653862e-06
from O 0 5.310885171638802e-07
textbook O 0 0.00015486420306842774
aniridia B-Disease 1 0.9999991655349731
. O 0 9.806050911720376e-06

Here O 0 1.7868655049824156e-05
we O 0 3.426543457862863e-07
present O 0 1.092249988232652e-07
four O 0 1.142722325653267e-07
novel O 0 6.986213065829361e-06
PAX6 O 0 0.0011843397514894605
missense O 0 0.021134233102202415
mutations O 0 3.4784494346240535e-05
, O 0 4.20306349724342e-08
two O 0 3.67130184031339e-08
in O 0 1.617730021052921e-07
association O 0 7.763626541645863e-08
with O 0 7.454140416029986e-08
atypical O 0 0.00039346207631751895
phenotypes O 0 0.0005438337684608996
ectopia B-Disease 0 0.00032845427631400526
pupillae I-Disease 0 0.0003143753274343908
( O 0 2.1275691608479974e-07
displaced B-Disease 0 1.3342872762223124e-06
pupils I-Disease 0 2.039734454228892e-06
) O 0 4.1468692302260024e-07
and O 0 0.00020592489454429597
congenital B-Disease 1 0.9999998807907104
nystagmus I-Disease 0 0.032565295696258545
( O 0 1.415383792391367e-07
searching B-Disease 0 2.9407223678390437e-07
gaze I-Disease 0 5.322379001881927e-05
) O 0 4.1377269610620715e-08
, O 0 1.3054252789856946e-08
and O 0 4.387014485018881e-08
two O 0 5.098605271314227e-08
in O 0 1.1199171012776787e-07
association O 0 1.6627298649041222e-08
with O 0 9.574807613432768e-09
more O 0 9.225497166198693e-08
recognizable O 0 9.242314990842715e-05
aniridia B-Disease 1 0.9999974966049194
phenotypes O 0 0.0005789692513644695
. O 0 2.354780235691578e-06

Strikingly O 0 0.004550545942038298
, O 0 1.3287304909681552e-06
all O 0 3.145416371808096e-08
four O 0 1.7929328066657035e-07
mutations O 0 2.4498358470737003e-06
are O 0 5.759166032959229e-09
located O 0 6.511334049719153e-08
within O 0 1.134090865662074e-08
the O 0 5.810563763475329e-08
PAX6 O 0 1.2535983842099085e-05
paired O 0 1.202297312374867e-06
domain O 0 1.573281167566165e-07
and O 0 1.134970872840313e-07
affect O 0 1.0110836967669456e-07
amino O 0 1.895611774216377e-07
acids O 0 1.6220586473991716e-07
which O 0 1.9574788012732824e-08
are O 0 2.472285265398e-09
highly O 0 8.9019032145643e-09
conserved O 0 2.938204168856373e-08
in O 0 1.3236478579869981e-08
all O 0 4.612533910375305e-09
known O 0 8.919941052454305e-08
paired O 0 6.101178087192238e-07
domain O 0 4.749985009766533e-07
proteins O 0 8.815252954263997e-07
. O 0 9.852439006863278e-07

Our O 0 2.060008773696609e-05
results O 0 1.907720616145525e-06
support O 0 7.570226756570264e-08
the O 0 3.670321646609409e-08
hypothesis O 0 1.5876057091190887e-07
that O 0 5.094160204777154e-09
the O 0 4.642596085346895e-09
under O 0 1.638310287432887e-08
- O 0 4.391363290778827e-07
representation O 0 3.2141780792471764e-08
of O 0 3.5067174053438066e-08
missense O 0 0.0012480856385082006
mutations O 0 4.50984516646713e-05
is O 0 1.1034906322038296e-07
caused O 0 8.566554470235133e-07
by O 0 7.386573486201087e-08
ascertainment O 0 0.00013294987729750574
bias O 0 0.01508269738405943
and O 0 1.5156076642597327e-06
suggest O 0 1.7197079671404936e-07
that O 0 6.1411093987828735e-09
a O 0 4.102607320533025e-08
substantial O 0 6.600413371415925e-08
burden O 0 2.1646006587161537e-07
of O 0 2.3553315742219638e-08
PAX6 B-Disease 0 0.000368444190826267
- I-Disease 0 0.032455187290906906
related I-Disease 0 1.0291427315678447e-05
disease I-Disease 0 5.381684604799375e-05
remains O 0 3.5102078754789545e-07
to O 0 2.6848193002138032e-08
be O 0 7.781579824950313e-08
uncovered O 0 8.033875928958878e-06
. O 0 1.5108814466202602e-07
. O 0 4.845388730245759e-07

The O 0 1.8752626829154906e-06
chromosomal O 0 0.0003955450374633074
order O 0 3.1539474321107264e-07
of O 0 2.266863852184997e-08
genes O 0 1.129352654061222e-06
controlling O 0 1.6072085600171704e-06
the O 0 3.976072449063395e-08
major O 0 1.9593488786995295e-07
histocompatibility O 0 1.2416766139722313e-06
complex O 0 7.959994263728731e-08
, O 0 1.6304298355862556e-08
properdin O 0 5.783815595350461e-07
factor O 0 9.352832108788789e-08
B O 0 1.3558162663684925e-06
, O 0 1.4469272002770595e-07
and O 0 8.162250196619425e-06
deficiency B-Disease 0 1.430229804100236e-05
of I-Disease 0 1.944616911941921e-09
the I-Disease 0 2.2421939860350903e-08
second I-Disease 0 1.3216960041972925e-06
component I-Disease 0 3.4506564361436176e-07
of I-Disease 0 2.3667883652933597e-08
complement I-Disease 0 1.2829757451982005e-06
. O 0 1.1383957598809502e-06

The O 0 1.0220702506558155e-06
relationship O 0 2.6131641561732977e-07
of O 0 1.209404487667598e-08
the O 0 1.4751861066031324e-08
genes O 0 1.1069519700868113e-07
coding O 0 1.8910882317868527e-06
for O 0 7.00361155736573e-08
HLA O 0 1.4418168575502932e-05
to O 0 1.2640699154076174e-08
those O 0 4.4626635720135255e-09
coding O 0 2.973605432998738e-07
for O 0 1.1641514419125087e-08
properdin O 0 1.0571392294878024e-06
Factor O 0 6.701529287056474e-08
B O 0 1.9230813563808624e-07
allotypes O 0 2.036306113950559e-06
and O 0 3.003227107001294e-07
for O 0 1.19617368454783e-07
deficiency B-Disease 0 8.505820915161166e-06
of I-Disease 0 1.8669585877262307e-09
the I-Disease 0 1.3857800240657525e-08
second I-Disease 0 4.0890228092393954e-07
component I-Disease 0 7.552170444569128e-08
of I-Disease 0 2.9080786667634584e-09
complement I-Disease 0 1.4201647502432024e-07
( O 0 8.202042067750881e-08
C2 O 0 3.749132883967832e-05
) O 0 4.529934827246507e-08
was O 0 8.106111977213004e-07
studied O 0 2.671384891073103e-08
in O 0 1.1305898439673001e-08
families O 0 3.807536685940249e-08
of O 0 1.6791462442711236e-08
patients O 0 9.581549420545343e-07
with O 0 2.0233499071764527e-06
connective O 1 0.9998807907104492
tissue O 1 0.99986732006073
disorders O 1 0.9746055006980896
. O 0 4.0162512959796e-06

Patients O 0 0.10610289126634598
were O 0 5.252469236438628e-06
selected O 0 1.7030995991262898e-07
because O 0 3.719654273481865e-08
they O 0 2.948275223957353e-08
were O 0 3.228494733775733e-07
heterozygous O 0 3.0581838927901117e-06
or O 0 5.061813794782211e-07
homozygous O 0 0.0005385761614888906
for O 0 5.6832312111509964e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 7.472662673535524e-06

12 O 0 8.339625492226332e-05
families O 0 1.1193056934644119e-06
with O 0 1.3592233472081716e-07
15 O 0 4.456040301192843e-07
matings O 0 1.6140182196977548e-05
informative O 0 1.9913211872335523e-05
for O 0 0.0012482819147408009
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.1672191249090247e-05
found O 0 1.4499815961244167e-06
. O 0 1.1645888662314974e-06

Of O 0 2.0538961962301983e-06
57 O 0 6.190261956362519e-06
informative O 0 1.51173321683018e-06
meioses O 0 2.055309414572548e-05
, O 0 4.391007379922485e-08
two O 0 2.2285076894945632e-08
crossovers O 0 5.210640210862039e-06
were O 0 8.995257303467952e-07
noted O 0 1.184150306698939e-07
between O 0 8.006547886907356e-07
the O 0 0.004215585999190807
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
gene O 0 2.918937127560639e-07
and O 0 3.4508893520524e-08
the O 0 4.3552823569825705e-08
HLA O 0 3.0186922231223434e-05
- O 0 1.2542417607619427e-05
B O 0 8.787897058937233e-07
gene O 0 6.511842798317957e-08
, O 0 4.436177203359648e-09
with O 0 1.756379375272843e-09
a O 0 3.026129036243219e-08
recombinant O 0 9.780600151998442e-08
fraction O 0 1.0606783007460763e-07
of O 0 2.4973198620159565e-08
0 O 0 8.944231808527547e-07
. O 0 7.261770065269957e-07

035 O 0 0.12262462824583054
. O 0 0.0005871975445188582

A O 0 5.7140219723805785e-05
lod O 0 0.000888256763573736
score O 0 5.11218286192161e-06
of O 0 5.004893566251667e-08
13 O 0 7.99888482561073e-07
was O 0 1.2580815109686228e-06
calculated O 0 2.100675544625119e-07
for O 0 1.466808186023627e-08
linkage O 0 0.0010294497478753328
between O 0 0.24012599885463715
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 2.9366950116127555e-07
HLA O 0 1.29699810713646e-05
- O 0 5.973311999696307e-06
B O 0 5.625258268082689e-07
at O 0 8.013611996204872e-09
a O 0 1.3686062061424309e-08
maximum O 0 2.177781333045914e-08
likelihood O 0 2.2036415359139028e-08
value O 0 3.132566206431875e-09
of O 0 9.00784558055534e-10
the O 0 5.027873228868884e-09
recombinant O 0 3.719306818084078e-08
fraction O 0 4.825752952797302e-08
of O 0 2.3556191663942627e-08
0 O 0 6.638048262175289e-07
. O 0 7.84822077548597e-07

04 O 0 0.0097385598346591
. O 0 0.0001004828154691495

18 O 0 0.0002009165909839794
families O 0 1.3881709719498758e-06
with O 0 1.6644200684368116e-07
21 O 0 5.188348382034746e-07
informative O 0 3.388018683381233e-07
matings O 0 6.680715159745887e-06
for O 0 3.1803331523860834e-08
both O 0 4.834375744167119e-08
properdin O 0 4.885678208665922e-06
Factor O 0 1.619225713511696e-07
B O 0 5.184564884075371e-07
allotype O 0 1.624301489755453e-06
and O 0 2.1506578207208804e-07
HLA O 0 2.261361623823177e-05
- O 0 2.47062198468484e-05
B O 0 2.9191614885348827e-06
were O 0 1.8373074794908462e-07
found O 0 2.3333060994445987e-07
. O 0 3.5682103316503344e-07

Of O 0 2.7668268103298033e-06
72 O 0 4.926872406940674e-06
informative O 0 8.613346835772973e-07
meioses O 0 1.1097103197243996e-05
, O 0 4.852519452924753e-08
three O 0 5.027021998671444e-08
recombinants O 0 2.298387698829174e-05
were O 0 7.172117761911068e-07
found O 0 8.212764868176237e-08
, O 0 6.295309162851481e-09
giving O 0 4.212691973037863e-09
a O 0 1.147546679902689e-08
recombinant O 0 6.926349271907384e-08
fraction O 0 5.374005596081588e-08
of O 0 2.0247570731157793e-08
0 O 0 1.2963582776137628e-06
. O 0 6.350643388941535e-07

042 O 0 0.010444559156894684
. O 0 0.00016803923062980175

A O 0 8.719821198610589e-05
lod O 0 0.0014651037054136395
score O 0 6.037438197381562e-06
of O 0 3.121462199828784e-08
16 O 0 1.7152561326838622e-07
between O 0 4.5429828787746374e-08
HLA O 0 3.355609442223795e-05
- O 0 1.132211309595732e-05
B O 0 5.95792926105787e-07
and O 0 1.7817063380221043e-08
Factor O 0 4.353189453354389e-08
B O 0 2.0951895862708625e-07
allotypes O 0 1.0404700105937081e-06
was O 0 1.1165636806254042e-06
calculated O 0 6.336801305906192e-08
at O 0 4.0988585858769966e-09
a O 0 7.195368301182725e-09
maximum O 0 2.68498325795008e-08
likelihood O 0 4.173219281256024e-08
value O 0 2.0344301798758124e-09
of O 0 1.5301775402321027e-09
the O 0 4.017449040105703e-09
recombinant O 0 7.048532779663219e-08
fraction O 0 8.020420949605978e-08
of O 0 3.0611403190050623e-08
0 O 0 1.0560460168562713e-06
. O 0 7.45704028304317e-07

04 O 0 0.015269492752850056
. O 0 0.00011565921158762649

A O 0 1.0997008757840376e-05
crossover O 0 2.524122828617692e-05
was O 0 6.468207720899954e-05
shown O 0 3.2811038863655995e-07
to O 0 1.489267908993952e-08
have O 0 8.76724044474031e-08
occurred O 0 2.4747498628130415e-07
between O 0 1.018778128525355e-08
genes O 0 2.6686146625820584e-08
for O 0 6.976916377965381e-09
Factor O 0 1.1976837299698673e-07
B O 0 4.755288216529152e-07
and O 0 1.0243081760563655e-07
HLA O 0 1.7789270714274608e-05
- O 0 2.471526931913104e-05
D O 0 3.368295801919885e-05
, O 0 1.1825902923590093e-08
in O 0 7.932149159728397e-09
which O 0 9.750331741997798e-08
HLA O 0 1.0683632353902794e-05
- O 0 4.114556304557482e-06
D O 0 1.314058590651257e-05
segregared O 0 1.1111652611361933e-06
with O 0 3.7352315018779336e-08
HLA O 0 1.6011937987059355e-05
- O 0 3.1786339604877867e-06
A O 0 1.4701043937748182e-06
and O 0 1.1880862302859896e-06
B O 0 5.203112323215464e-06
. O 0 1.247442696694634e-06

These O 0 9.805346508073853e-07
studies O 0 1.8634860055044555e-07
suggest O 0 7.455789585719685e-08
that O 0 3.876460485940925e-09
the O 0 4.6329629022068275e-09
genes O 0 4.2533866206895254e-08
for O 0 6.6544245669319935e-09
Factor O 0 5.626669690173003e-07
B O 0 0.00024921828298829496
and O 0 0.36607593297958374
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.468583281180827e-09
located O 0 8.013536501039198e-09
outside O 0 9.318853244622005e-09
those O 0 1.7170350696815717e-09
for O 0 5.231193256349798e-09
HLA O 0 1.5219665328913834e-05
, O 0 2.40450912514234e-08
that O 0 2.0396908606556963e-09
the O 0 2.4125608177882896e-09
order O 0 6.944893105043093e-09
of O 0 2.2771373675567474e-09
genese O 0 1.944475343407248e-06
is O 0 3.713600449373189e-08
HLA O 0 1.4161091712594498e-06
- O 0 2.491449606623064e-07
A O 0 2.9462637485266896e-07
, O 0 2.1797220028929587e-08
- O 0 9.779478205018677e-07
B O 0 3.615208186147356e-07
, O 0 1.153381390395225e-08
- O 0 7.106165185177815e-07
D O 0 1.4859942893963307e-06
, O 0 8.156453290553145e-09
Factor O 0 5.3466870042484516e-08
B O 0 7.295164436982304e-07
allotype O 0 8.013247133931145e-05
, O 0 0.00022966323012951761
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.7311235112060785e-08
that O 0 2.1295405439047954e-09
the O 0 4.209848913916403e-09
genes O 0 2.6509027861720824e-07
coding O 0 7.479898340534419e-05
for O 0 0.0029143113642930984
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.4279602567057736e-07
Factor O 0 1.0862623867069487e-07
B O 0 2.364138111943248e-07
allotypes O 0 3.4272562743353774e-07
are O 0 1.9442127907609574e-09
approximately O 0 2.9335269768893113e-09
3 O 0 2.9643908661114438e-08
- O 0 1.0082264907396166e-06
- O 0 3.566148961908766e-06
5 O 0 9.767344977262837e-08
centimorgans O 0 3.840746387595573e-07
from O 0 5.547797332638993e-09
the O 0 1.3996007908190222e-08
HLA O 0 2.266975343445665e-06
- O 0 3.376883057626401e-07
A O 0 1.6797909552224155e-07
and O 0 2.024746237339059e-07
HLA O 0 1.6194931959034875e-05
- O 0 7.553288924100343e-06
B O 0 5.085668135507149e-07
loci O 0 1.3349958294384123e-07
, O 0 8.11423195301586e-09
and O 0 2.0013320778389243e-08
that O 0 6.460844304001512e-09
the O 0 3.8018402648276606e-08
apparent O 0 3.026902504643658e-06
lack O 0 3.8973983151890934e-08
of O 0 3.520977731596986e-09
recombinants O 0 1.1833799362648278e-06
between O 0 1.1584059933511526e-08
the O 0 8.20364931541917e-09
Factor O 0 1.1998329796369944e-07
B O 0 2.0924649106746074e-06
gene O 0 9.185820090351626e-06
and O 0 0.17626257240772247
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 4.893433356301102e-07
suggests O 0 1.138234750897027e-07
that O 0 3.183760588498785e-09
these O 0 1.6598519225752284e-09
two O 0 2.2776641017685506e-08
genes O 0 5.623911647489876e-07
lie O 0 1.8158672219215077e-06
in O 0 2.605419524570607e-08
close O 0 2.3425813822086639e-07
proximity O 0 1.187042641959124e-07
to O 0 1.1052178194859152e-07
one O 0 1.3619040828416473e-07
another O 0 5.89061187383777e-07
. O 0 1.6455090872113942e-06

Distribution O 0 1.1888006156368647e-05
of O 0 2.8281729669288325e-07
emerin O 0 5.406848868005909e-05
and O 0 1.328672169620404e-06
lamins O 0 3.338605893077329e-05
in O 0 1.9934923045639152e-07
the O 0 4.1784207382988825e-07
heart O 0 3.656742046587169e-05
and O 0 1.9770604353652743e-07
implications O 0 2.2136261179639405e-07
for O 0 1.3545958665872604e-07
Emery B-Disease 1 0.9145051836967468
- I-Disease 1 0.9994839429855347
Dreifuss I-Disease 1 0.9999608993530273
muscular I-Disease 1 0.9973433613777161
dystrophy I-Disease 1 0.9865744709968567
. O 0 9.355084330309182e-06

Emerin O 0 0.002626561326906085
is O 0 1.3168056511858595e-06
a O 0 1.8473502905180794e-07
nuclear O 0 2.706308066535712e-07
membrane O 0 3.8950730640863185e-07
protein O 0 4.359500849204778e-07
which O 0 1.3632542561481387e-07
is O 0 3.561097727811102e-08
missing O 0 6.146011060081946e-07
or O 0 2.038805746451544e-07
defective O 0 1.3540417057811283e-05
in O 0 1.5411731055792188e-06
Emery B-Disease 1 0.9797002673149109
- I-Disease 1 0.999967098236084
Dreifuss I-Disease 1 0.9999973773956299
muscular I-Disease 1 0.9999949932098389
dystrophy I-Disease 1 0.9999872446060181
( O 0 2.848448093573097e-05
EDMD B-Disease 1 0.9999994039535522
) O 0 2.9941154480184196e-06
. O 0 2.579682131909067e-06

It O 0 7.381787327176426e-06
is O 0 1.8937760160042671e-07
one O 0 2.10202362183054e-08
member O 0 1.3831050971191416e-08
of O 0 2.443342417279837e-09
a O 0 1.443453925276117e-07
family O 0 2.451010914228391e-07
of O 0 1.6155093263137132e-08
lamina O 0 1.3183663213567343e-05
- O 0 3.378426481503993e-05
associated O 0 3.6597143093786144e-07
proteins O 0 2.684307354172688e-08
which O 0 3.812682081161256e-08
includes O 0 3.8060555596075574e-08
LAP1 O 0 3.1075585866346955e-05
, O 0 7.337146712416143e-08
LAP2 O 0 7.178987289080396e-06
and O 0 3.5058153002864856e-07
lamin O 0 0.00011354793241480365
B O 0 1.9258324755355716e-05
receptor O 0 1.0114727956533898e-05
( O 0 8.662419759275508e-07
LBR O 0 8.147455082507804e-05
) O 0 9.54313804868434e-07
. O 0 1.7121146811405197e-06

A O 0 1.4618565728596877e-05
panel O 0 3.10495738631289e-06
of O 0 1.0444252040997526e-07
16 O 0 5.889853582630167e-07
monoclonal O 0 1.0599036613712087e-05
antibodies O 0 2.642759909576853e-06
( O 0 5.2489262714061624e-08
mAbs O 0 1.4160308410282596e-06
) O 0 2.1217006818119444e-08
has O 0 9.144856960574543e-08
been O 0 7.827249248748558e-08
mapped O 0 2.4527369077986805e-06
to O 0 6.997493695592993e-09
six O 0 9.512444165693523e-09
specific O 0 3.708410467595513e-09
sites O 0 1.349481504320238e-08
throughout O 0 6.890715997798225e-09
the O 0 7.199458806894654e-09
emerin O 0 1.9031381270906422e-07
molecule O 0 2.2503385821437405e-08
using O 0 2.1151508988737078e-08
phage O 0 1.563627307632487e-07
- O 0 2.152915072883843e-07
displayed O 0 1.830062501539942e-07
peptide O 0 3.041619933696893e-08
libraries O 0 5.974688743748402e-09
and O 0 6.253495499208839e-09
has O 0 1.2733525345254293e-08
been O 0 9.584491422742758e-09
used O 0 9.543866141825674e-09
to O 0 8.945356455569708e-09
localize O 0 3.1634288006898714e-06
emerin O 0 1.2436519682523794e-05
in O 0 8.787078797922732e-08
human O 0 1.9241032589434326e-07
and O 0 2.257665983051993e-06
rabbit O 0 0.006664983928203583
heart O 0 0.0001469292037654668
. O 0 1.9381564015930053e-06

Several O 0 1.0473598194948863e-05
mAbs O 0 6.758102972526103e-05
against O 0 4.329833984684228e-07
different O 0 1.0011527962205946e-07
emerin O 0 2.8959782866877504e-05
epitopes O 0 5.2379789849510416e-05
did O 0 2.241928086732514e-06
not O 0 1.802007254525506e-08
recognize O 0 2.504044971374242e-08
intercalated O 0 2.607326621273387e-07
discs O 0 9.412061444891151e-06
in O 0 3.4338449950155336e-07
the O 0 3.8088992937446164e-07
heart O 0 6.056892380001955e-05
, O 0 1.237565783185346e-07
though O 0 1.6380727885234592e-08
they O 0 7.466260498745214e-09
recognized O 0 1.1187082371577617e-08
cardiomyocyte O 0 6.968008392504998e-07
nuclei O 0 2.8656970130214177e-07
strongly O 0 8.164379039499181e-08
, O 0 9.039070825167528e-09
both O 0 7.59991003462801e-09
at O 0 6.006386854551238e-08
the O 0 2.353598205218077e-08
rim O 0 1.6981543922156561e-06
and O 0 1.9339729817602347e-07
in O 0 4.759697702638732e-08
intranuclear O 0 1.1500375876494218e-05
spots O 0 7.901211574790068e-06
or O 0 4.0809274537423335e-07
channels O 0 4.580641416396247e-06
. O 0 1.3689649449588615e-06

A O 0 7.86797099863179e-05
polyclonal O 0 0.0005406690179370344
rabbit O 0 0.00012244237586855888
antiserum O 0 4.363534753792919e-05
against O 0 1.441683593839116e-06
emerin O 0 0.0001726304617477581
did O 0 2.8057086183252977e-06
recognize O 0 1.2993396580895933e-07
both O 0 2.99865341446548e-08
nuclear O 0 2.749353598119342e-07
membrane O 0 3.1725605253996036e-07
and O 0 8.595830536251015e-08
intercalated O 0 2.2572773161755322e-07
discs O 0 1.0062381079478655e-05
but O 0 5.0467455992020405e-08
, O 0 5.811957581869365e-09
after O 0 4.295886757432754e-09
affinity O 0 9.052131488829218e-09
purification O 0 3.80434244107164e-08
against O 0 1.1670638677685474e-08
a O 0 3.8311391392653604e-08
pure O 0 1.249902510380707e-07
- O 0 1.179999435407808e-05
emerin O 0 8.810463441477623e-06
band O 0 1.3285821296449285e-06
on O 0 4.1822076468633895e-08
a O 0 3.5712801604859123e-08
western O 0 1.6431586402632092e-07
blot O 0 0.0001889146660687402
, O 0 3.719076744346239e-07
it O 0 8.012148811076258e-08
stained O 0 0.0004768084909301251
only O 0 1.841755903342346e-08
the O 0 2.3869761278660917e-08
nuclear O 0 6.837283308414044e-07
membrane O 0 2.017399992837454e-06
. O 0 6.645338430644188e-07

These O 0 2.0895015495625557e-06
results O 0 6.721690510858025e-07
would O 0 1.04862699856767e-07
not O 0 1.301055352342928e-08
be O 0 8.272329488079322e-09
expected O 0 3.7014164178117426e-08
if O 0 9.4694501129311e-09
immunostaining O 0 1.7613976979191648e-06
at O 0 5.006889125525049e-08
intercalated O 0 1.0805919714584888e-07
discs O 0 1.5784638890181668e-05
were O 0 2.387177573837107e-06
due O 0 2.8936337770346654e-08
to O 0 7.902414722593676e-09
a O 0 1.8210176477850837e-08
product O 0 1.7288467546450192e-08
of O 0 6.851945122399172e-10
the O 0 1.0672713379733523e-08
emerin O 0 2.3562315618619323e-06
gene O 0 1.896302563864083e-07
and O 0 2.404918006959633e-07
, O 0 2.3870262211289628e-08
therefore O 0 1.0762104096784242e-08
, O 0 7.667000367916899e-09
cast O 0 9.257578170718261e-08
some O 0 3.991251773527438e-09
doubt O 0 1.3964997158666392e-08
upon O 0 2.0012393964208286e-09
the O 0 6.83273793100625e-09
hypothesis O 0 4.557120689696603e-07
that O 0 2.573440838204988e-07
cardiac B-Disease 1 0.5933592915534973
defects I-Disease 1 0.9986075758934021
in O 0 7.951441148179583e-06
EDMD B-Disease 1 1.0
are O 0 5.829935503243178e-07
caused O 0 1.5760113001306308e-06
by O 0 2.6664372043683215e-08
absence O 0 2.2507897767809482e-07
of O 0 3.2707337283000015e-08
emerin O 0 6.521969044115394e-05
from O 0 5.7329426539354245e-08
intercalated O 0 4.723477559309686e-06
discs O 0 6.428753840737045e-05
. O 0 1.7248914900847012e-06

Although O 0 2.288554242113605e-05
emerin O 0 0.00023025015252642334
was O 0 7.576980351586826e-06
abundant O 0 9.812757895133473e-08
in O 0 2.3004149696248533e-08
the O 0 1.7492657988782412e-08
membranes O 0 2.423081753022416e-07
of O 0 1.2119653725051194e-08
cardiomyocyte O 0 5.648472324537579e-06
nuclei O 0 1.2248185612406814e-06
, O 0 8.077391555616487e-08
it O 0 6.344601644059367e-08
was O 0 2.9382907086983323e-05
absent O 0 1.5862890734297252e-07
from O 0 4.858935032103773e-09
many O 0 2.2449484493591854e-09
non O 0 4.933318109578977e-08
- O 0 9.905244951369241e-06
myocyte O 0 6.365432636812329e-05
cells O 0 4.829136059925077e-07
in O 0 3.721520869248707e-08
the O 0 2.8030933663103497e-07
heart O 0 3.352858766447753e-05
. O 0 2.401068741164636e-06

This O 0 4.0998386907631357e-07
distribution O 0 1.3317887237462855e-07
of O 0 1.6012414505439665e-08
emerin O 0 4.676185199059546e-05
was O 0 9.523078915663064e-06
similar O 0 3.312426954948933e-08
to O 0 1.3472724269547598e-08
that O 0 1.2214825595435741e-08
of O 0 7.551490099899638e-09
lamin O 0 8.730694389669225e-06
A O 0 9.16371106995939e-07
, O 0 1.864031062837057e-08
a O 0 3.311845730991081e-08
candidate O 0 1.8918046862381743e-07
gene O 0 1.0474435185869879e-07
for O 0 1.1400462796018473e-08
an O 0 1.7310780719981267e-07
autosomal O 0 0.00010475972521817312
form O 0 9.322533855993242e-07
of O 0 4.679734502133215e-06
EDMD B-Disease 1 1.0
. O 0 2.345225220778957e-05

In O 0 6.951229806873016e-06
contrast O 0 7.453793841705192e-06
, O 0 5.393829383137927e-07
lamin O 0 0.000825013848952949
B1 O 0 0.32494494318962097
was O 0 3.13052732963115e-05
absent O 0 1.2239941042935243e-06
from O 0 3.0369299963695084e-08
cardiomyocyte O 0 4.93725292471936e-06
nuclei O 0 9.86236614153313e-07
, O 0 2.7723384476985302e-08
showing O 0 6.549866498062329e-07
that O 0 5.050905826919916e-08
lamin O 0 0.00012034881365252659
B1 O 0 0.0003474358527455479
is O 0 5.8237674238625914e-08
not O 0 2.4871364967538057e-09
essential O 0 2.5388335878062662e-09
for O 0 1.1669720745288714e-09
localization O 0 1.1852372239218312e-07
of O 0 6.61590116024513e-09
emerin O 0 3.759429318961338e-06
to O 0 2.8338309476794166e-08
the O 0 1.0183879339820123e-07
nuclear O 0 2.0589247924363008e-06
lamina O 0 3.3295546018052846e-05
. O 0 1.0448171678945073e-06

Lamin O 0 0.40658867359161377
B1 O 1 0.8347185850143433
is O 0 6.863029284431832e-06
also O 0 2.6242926196573535e-06
almost O 0 3.8672246205351257e-07
completely O 0 7.208941042335937e-06
absent O 0 3.592080020098365e-06
from O 0 2.2072346439472312e-07
skeletal O 0 0.0033103295136243105
muscle O 0 0.0001126785937231034
nuclei O 0 3.1039635359775275e-05
. O 0 1.9785420590778813e-06

In O 0 0.00018269431893713772
EDMD B-Disease 1 0.9999994039535522
, O 0 2.1195494070980203e-07
the O 0 1.789324777234924e-08
additional O 0 3.876920828815855e-08
absence O 0 1.361285910661536e-07
of O 0 6.082174763832882e-08
lamin O 0 0.015193185769021511
B1 O 0 0.01929670199751854
from O 0 3.169415379034035e-07
heart O 0 2.3938297090353444e-05
and O 0 1.890861085485085e-06
skeletal O 0 0.019376792013645172
muscle O 0 4.8049321776488796e-05
nuclei O 0 3.169244791934034e-06
which O 0 3.3652773367975897e-07
already O 0 2.4587788516328146e-07
lack O 0 9.625568253568417e-08
emerin O 0 2.3890588636277243e-05
may O 0 4.0366384723711235e-07
offer O 0 1.034718888348607e-08
an O 0 4.335422243428866e-09
alternative O 0 2.8161576182128556e-08
explanation O 0 1.9319003286000225e-08
of O 0 3.776520873799427e-09
why O 0 3.248680968681583e-08
these O 0 1.0517673842969089e-08
tissues O 0 3.7061570878904604e-07
are O 0 1.4775261014676744e-08
particularly O 0 6.690685694366039e-08
affected O 0 1.1529694887713049e-07
. O 0 3.3887417316691426e-08
. O 0 3.7431053101499856e-07

Genetic O 0 0.00032644325983710587
mapping O 0 1.7611037037568167e-05
of O 0 2.5085083166231925e-07
the O 0 8.159192930179415e-07
copper B-Disease 0 0.0006926670321263373
toxicosis I-Disease 0 0.0011167306220158935
locus O 0 9.541550753056072e-06
in O 0 3.0380601856450085e-07
Bedlington O 0 8.470466855214909e-05
terriers O 0 7.66747398301959e-05
to O 0 1.4157808436721098e-07
dog O 0 3.9516751712653786e-05
chromosome O 0 0.00016202201368287206
10 O 0 2.07578835897948e-07
, O 0 1.1615166606304683e-08
in O 0 7.3590498139708416e-09
a O 0 1.249529333335886e-07
region O 0 7.616731068083027e-07
syntenic O 0 5.567469997913577e-06
to O 0 2.3736463461432322e-08
human O 0 1.7792416429074365e-07
chromosome O 0 0.00016181202954612672
region O 0 1.3682105191037408e-06
2p13 O 0 2.3183762095868587e-05
- O 0 6.099855454522185e-05
p16 O 0 3.702527465065941e-05
. O 0 1.071714109457389e-06

Abnormal O 1 0.999900221824646
hepatic B-Disease 1 0.9998761415481567
copper I-Disease 0 0.029232850298285484
accumulation I-Disease 0 1.66820809681667e-05
is O 0 9.968122327563833e-08
recognized O 0 2.7976286176567555e-08
as O 0 2.2966256096879079e-07
an O 0 0.00014523015124723315
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.091423311867402e-06
man O 0 0.0004527655546553433
, O 0 1.1697308366365178e-07
mouse O 0 4.265385359758511e-05
, O 0 2.690818234896142e-07
rat O 0 8.872799662640318e-05
and O 0 1.5808265061423299e-06
dog O 0 8.732102287467569e-05
. O 0 1.5854253661018447e-06

The O 0 2.1274970549711725e-06
major O 0 1.503924977441784e-06
cause O 0 3.549797384039266e-06
of O 0 2.9362331588345114e-07
hepatic B-Disease 0 0.36319708824157715
copper I-Disease 0 0.0779109001159668
accumulation I-Disease 0 7.88501256465679e-06
in O 0 2.3708506091679737e-07
man O 0 9.60265697358409e-06
is O 0 2.571408863616398e-08
a O 0 1.1139711375562911e-07
dysfunctional O 0 1.6428291928605177e-05
ATP7B O 0 6.520588794955984e-05
gene O 0 2.4069699975370895e-06
, O 0 4.0865512573873275e-07
causing O 0 2.1961028323858045e-05
Wilson B-Disease 0 0.0024490640498697758
disease I-Disease 0 0.0006712289177812636
( O 0 4.5091255174156686e-07
WD B-Disease 0 0.0007270900532603264
) O 0 1.1936328974115895e-06
. O 0 1.3322082850208972e-06

Mutations O 0 0.00241013802587986
in O 0 5.029055500926916e-07
the O 0 9.359220598526008e-08
ATP7B O 0 7.510869909310713e-05
genes O 0 1.4643576378148282e-06
have O 0 4.5446384433489584e-07
also O 0 1.2873205150754075e-06
been O 0 1.1308766261208802e-06
demonstrated O 0 6.780381340831809e-07
in O 0 8.345597990455644e-08
mouse O 0 0.00010584862320683897
and O 0 3.828776698355796e-06
rat O 0 0.0004979408113285899
. O 0 2.0837646843574475e-06

The O 0 4.409716893860605e-06
ATP7B O 0 0.00016269016487058252
gene O 0 9.982751180359628e-06
has O 0 1.973412508959882e-06
been O 0 1.4635865852596908e-07
excluded O 0 1.1198700633485714e-07
in O 0 2.6455099444433472e-08
the O 0 3.831314643321093e-08
much O 0 8.35002467169943e-08
rarer O 0 3.6037529298482696e-06
human O 0 8.340567774212104e-07
copper B-Disease 0 0.006126743275672197
overload I-Disease 0 0.07281883805990219
disease O 0 1.4454915799433365e-05
non B-Disease 0 1.1150149248351227e-07
- I-Disease 0 1.1234080375288613e-05
Indian I-Disease 0 4.234021275806299e-07
childhood I-Disease 0 1.8462194930179976e-05
cirrhosis I-Disease 0 0.00016420987958554178
, O 0 1.6835019778227434e-07
indicating O 0 4.114305738767143e-06
genetic O 0 1.4696425751026254e-05
heterogeneity O 0 0.00022478577739093453
. O 0 6.387436314980732e-06

By O 0 3.4422625958541175e-06
investigating O 0 3.274634536865051e-06
the O 0 7.001287372077059e-07
common O 0 2.7848414902109653e-05
autosomal O 1 0.9986145496368408
recessive O 1 0.9999520778656006
copper B-Disease 1 0.9865100979804993
toxicosis I-Disease 1 0.951131284236908
( O 0 2.1004341306252172e-06
CT B-Disease 0 0.00040689975139684975
) O 0 1.3564704204327427e-07
in O 0 1.24119665656508e-07
Bedlington O 0 0.00027352446340955794
terriers O 0 0.0015858428087085485
, O 0 2.724510750340414e-07
we O 0 1.2841646856998068e-08
have O 0 8.934188500120399e-09
identified O 0 3.2273369754420855e-08
a O 0 1.4936031078605083e-08
new O 0 5.7410947107428e-08
locus O 0 4.197193447907921e-06
involved O 0 4.89955993998592e-07
in O 0 6.90461138219689e-06
progressive O 1 0.9971209168434143
liver B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 6.650748218817171e-06

We O 0 1.6083529772004113e-05
examined O 0 4.723148776974995e-06
whether O 0 2.455858805205935e-07
the O 0 1.0792716409468994e-07
WD B-Disease 0 0.00024686282267794013
gene O 0 5.921025149291381e-06
ATP7B O 0 0.0002842769317794591
was O 0 1.817195152398199e-05
also O 0 1.4621413413351547e-07
causative O 0 4.840151177631924e-07
for O 0 1.5507838568851184e-08
CT B-Disease 0 6.492722604889423e-05
by O 0 2.017524991515529e-08
investigating O 0 6.13312920449971e-08
the O 0 3.572786155814356e-08
chromosomal O 0 0.0005778716877102852
co O 0 1.6380206943722442e-05
- O 0 8.686561159265693e-06
localization O 0 9.622518746255082e-07
of O 0 2.3204659527209515e-08
ATP7B O 0 4.4972144678467885e-05
and O 0 2.1048164455805818e-07
C04107 O 0 6.383791628650215e-07
, O 0 5.178340423128702e-09
using O 0 1.7502870264252124e-08
fluorescence O 0 2.034815906881704e-07
in O 0 5.1720164151447534e-08
situ O 0 1.6505100575159304e-06
hybridization O 0 1.0442623761264258e-06
( O 0 9.053861305119426e-08
FISH O 0 6.317890210993937e-07
) O 0 2.561875476203568e-07
. O 0 7.169957143560168e-07

C04107 O 0 0.0009613282745704055
is O 0 1.4462142416959978e-06
an O 0 2.62629271219339e-07
anonymous O 0 2.583554760349216e-06
microsatellite O 0 0.00017575394304003567
marker O 0 0.0001599990064278245
closely O 0 5.652136678691022e-06
linked O 0 1.591872569406405e-05
to O 0 9.344947784484248e-07
CT B-Disease 0 0.021545175462961197
. O 0 5.756511654908536e-06

However O 0 3.192778240190819e-05
, O 0 1.5105658803804545e-06
BAC O 0 4.9839425628306344e-05
clones O 0 8.264955795311835e-06
containing O 0 3.4363185363872617e-07
ATP7B O 0 4.83298790641129e-05
and O 0 2.2270806709911994e-07
C04107 O 0 1.9458998394839e-06
mapped O 0 3.616450158006046e-06
to O 0 1.6768161970048823e-08
the O 0 3.9856395517290366e-08
canine O 0 0.00010635998478392139
chromosome O 0 9.21156388358213e-05
regions O 0 2.634330087403214e-07
CFA22q11 O 0 5.709829565603286e-06
and O 0 3.322437578390236e-07
CFA10q26 O 0 9.691770173958503e-06
, O 0 4.192614255771332e-08
respectively O 0 9.622502972206348e-08
, O 0 9.381092347382491e-09
demonstrating O 0 4.0485584662519614e-08
that O 0 2.2000591570758843e-08
WD B-Disease 0 6.588468386325985e-05
cannot O 0 1.6060762675351725e-07
be O 0 9.410913826002343e-09
homologous O 0 1.7969590260236146e-07
to O 0 2.789870734432043e-07
CT B-Disease 0 0.0011271697003394365
. O 0 3.0007474833837477e-06

The O 0 3.7325719404179836e-06
copper O 0 1.4626989468524698e-05
transport O 0 6.820539510954404e-07
genes O 0 6.869649382679199e-07
CTR1 O 0 5.209037408349104e-05
and O 0 6.593165267076984e-07
CTR2 O 0 0.0014865458942949772
were O 0 3.60213471140014e-06
also O 0 2.2734610638508457e-07
excluded O 0 6.219928394557428e-08
as O 0 1.917634229187115e-08
candidate O 0 9.173261616979289e-08
genes O 0 3.6186811769312044e-08
for O 0 6.527782758780631e-09
CT B-Disease 0 0.0005352188600227237
since O 0 8.201664627449645e-07
they O 0 1.3123555575589307e-08
both O 0 8.152455599486075e-09
mapped O 0 5.245070951787056e-06
to O 0 9.989192051307327e-08
canine O 0 0.0002902007254306227
chromosome O 0 0.0014084517024457455
region O 0 7.379570433840854e-06
CFA11q22 O 0 5.7490247854730114e-05
. O 0 2.0029722236358793e-06

2 O 0 0.00019423980847932398
- O 0 0.0006495632114820182
22 O 0 1.2318164408497978e-05
. O 0 1.9270262328063836e-06

5 O 0 0.00024037272669374943
. O 0 3.151125565636903e-05

A O 0 1.0176914656767622e-05
transcribed O 0 2.522902468626853e-05
sequence O 0 3.0534858979081037e-06
identified O 0 9.519940817881434e-07
from O 0 1.2992450670878952e-08
the O 0 1.704284890990948e-08
C04107 O 0 1.8516890349928872e-06
- O 0 2.939431396953296e-06
containing O 0 5.125643838255201e-07
BAC O 0 3.134916187264025e-05
was O 0 3.133923883069656e-06
found O 0 3.624919031608442e-08
to O 0 5.45776712712609e-09
be O 0 4.8788364459539935e-09
homologous O 0 2.7688191295283104e-08
to O 0 8.43846326148423e-09
a O 0 7.623708597748191e-08
gene O 0 2.478800809058157e-07
expressed O 0 1.0940823358396301e-08
from O 0 6.696594390120936e-09
human O 0 2.81674843449764e-08
chromosome O 0 3.2615433156024665e-05
2p13 O 0 3.827966338576516e-06
- O 0 5.654713731928496e-06
p16 O 0 7.530535981459252e-07
, O 0 9.063585437729671e-09
a O 0 2.214964389679608e-08
region O 0 1.711607353627187e-07
devoid O 0 2.6616586978889245e-07
of O 0 3.82250986419308e-09
any O 0 1.0463010013950225e-08
positional O 0 1.7245216440642253e-05
candidate O 0 6.903972462168895e-06
genes O 0 7.386815923382528e-06
. O 0 2.059376356555731e-06

Molecular O 0 2.9187827749410644e-05
analysis O 0 7.033470410533482e-07
of O 0 2.3559067585665616e-08
the O 0 4.106490436583954e-08
APC B-Disease 0 1.232838940268266e-06
gene O 0 1.2951407768468925e-07
in O 0 3.483770782963802e-08
205 O 0 2.659748190581013e-07
families O 0 7.82172691060623e-08
: O 0 2.1910013359160985e-08
extended O 0 1.6415528989455197e-06
genotype O 0 0.00017877174832392484
- O 0 0.0026982284616678953
phenotype O 0 9.321630204794928e-05
correlations O 0 2.5470762921031564e-06
in O 0 1.2236657198627654e-07
FAP B-Disease 0 2.5805236418818822e-06
and O 0 9.43559541610739e-08
evidence O 0 8.930678419005744e-09
for O 0 1.5476301351569077e-09
the O 0 7.419696856914015e-09
role O 0 4.065939407382757e-08
of O 0 1.2655125836147363e-08
APC B-Disease 0 2.040799017777317e-06
amino O 0 1.1773916952506625e-07
acid O 0 3.0269836770457914e-07
changes O 0 4.570682676785509e-07
in O 0 0.0006904829060658813
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.017776427790522575
. O 0 3.603849108912982e-06

BACKGROUND O 0 0.00023818286717869341
/ O 0 0.00013202574336901307
AIMS O 0 2.910655211962876e-06
The O 0 3.7948268527543405e-08
development O 0 1.258726882724659e-07
of O 0 0.0004343078762758523
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.978647656476824e-07
a O 0 1.1192891946620875e-07
variable O 0 3.245742732360668e-07
range O 0 1.8407186530566833e-07
of O 0 4.066443537453779e-08
extracolonic O 0 6.251137529034168e-05
manifestations O 0 1.8985161659657024e-05
in O 0 1.3956688235339243e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 7.384616765193641e-05
FAP B-Disease 0 4.845632429351099e-05
) O 0 2.065933557560129e-07
is O 0 3.368018752780699e-08
the O 0 1.730905552221884e-08
result O 0 5.9153766329700375e-08
of O 0 7.44725880963415e-09
the O 0 1.9960091890425247e-07
dominant O 0 3.6474848457146436e-05
inheritance O 0 3.504008782329038e-05
of O 0 9.809267794480547e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 1.0
( O 0 4.143914338783361e-06
APC B-Disease 0 1.798418816179037e-05
) O 0 5.175870114726422e-07
gene O 0 9.71595090959454e-06
mutations O 0 5.534534284379333e-05
. O 0 2.60229376181087e-06

In O 0 3.235638132537133e-06
this O 0 5.717141959848959e-08
study O 0 3.020143779508544e-08
, O 0 8.811544383036107e-09
direct O 0 1.4854691698928946e-08
mutation O 0 1.8501026488593197e-07
analysis O 0 5.143023340536956e-09
of O 0 1.6314182227361584e-09
the O 0 1.6735986818616766e-08
APC B-Disease 0 9.553218660585117e-07
gene O 0 2.8187753287056694e-07
was O 0 3.083114279434085e-05
performed O 0 2.6855551027438196e-07
to O 0 2.705984947226625e-08
determine O 0 7.108300792424416e-07
genotype O 0 8.871615136740729e-05
- O 0 0.00027440726989880204
phenotype O 0 2.131880864908453e-05
correlations O 0 1.6519935570613598e-06
for O 0 5.895496002494838e-08
nine O 0 1.1980189356108895e-06
extracolonic O 0 3.307559745735489e-05
manifestations O 0 1.3157085732018459e-06
and O 0 5.7058777258589544e-08
to O 0 6.2042855297761434e-09
investigate O 0 3.4551963068452096e-08
the O 0 5.236167410771486e-08
incidence O 0 2.6413301384309307e-05
of O 0 4.764075711705118e-08
APC B-Disease 0 1.2506787243182771e-05
mutations O 0 2.7422152015788015e-06
in O 0 1.9251125138453062e-07
non O 0 2.3881157176219858e-05
- O 1 0.9989022016525269
FAP O 1 0.9997453093528748
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9006103684660047e-05

METHODS O 0 1.4818696399743203e-05
The O 0 8.370146247216326e-07
APC B-Disease 0 1.2878096640633885e-05
gene O 0 1.8862735942093423e-06
was O 0 2.5590311452106107e-06
analysed O 0 9.213818543685193e-07
in O 0 6.614995129439194e-08
190 O 0 2.8337780122456024e-07
unrelated O 0 9.644218152971007e-07
FAP B-Disease 0 5.711800895369379e-06
and O 0 3.271670436788554e-07
15 O 0 1.6015642358979676e-06
non O 0 4.16680359194288e-06
- O 1 0.9988079071044922
FAP O 1 0.9998430013656616
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.482619599206373e-06
using O 0 3.2822649131958315e-07
denaturing O 0 0.00020682753529399633
gradient O 0 0.0001520279620308429
gel O 0 8.442501712124795e-05
electrophoresis O 0 2.4326651328010485e-05
, O 0 5.204126907187856e-08
the O 0 1.20617018595226e-08
protein O 0 1.5272165398982906e-07
truncation O 0 2.0033389773743693e-06
test O 0 1.5222842364437383e-07
, O 0 1.3809619225924052e-08
and O 0 1.1983072312204968e-08
direct O 0 4.583061397056554e-08
sequencing O 0 1.7085557146856445e-06
. O 0 6.410238597709395e-07

RESULTS O 0 0.0001147597940871492
Chain O 0 5.67872375540901e-05
terminating O 0 9.328145097242668e-06
signals O 0 9.964650416804943e-06
were O 0 4.1712547727001947e-07
only O 0 1.1801251531551316e-08
identified O 0 3.728242177203356e-07
in O 0 1.834073941608949e-07
patients O 0 3.267180659349833e-07
belonging O 0 6.675835351188653e-08
to O 0 4.8137646757595576e-08
the O 0 1.1868321081465183e-07
FAP B-Disease 0 9.151134690910112e-06
group O 0 5.896440598007757e-07
( O 0 7.018749670351099e-08
105 O 0 1.2678024177148473e-06
patients O 0 1.219946739183797e-06
) O 0 1.1766329066631442e-07
. O 0 5.338687856237812e-07

Amino O 0 5.3482759540202096e-05
acid O 0 8.06212756288005e-06
changes O 0 2.0652163357226527e-07
were O 0 1.5840305422898382e-07
identified O 0 1.5488866722535022e-07
in O 0 4.303901590674286e-08
four O 0 6.476788030340686e-07
patients O 0 3.9705332710582297e-07
, O 0 2.6357140470167906e-08
three O 0 2.111406338656252e-08
of O 0 2.6197657376769712e-08
whom O 0 2.8555725748447003e-06
belonged O 0 4.710553298536979e-07
to O 0 9.615069629376194e-09
the O 0 3.533748937911696e-08
non O 0 1.9805874273970403e-07
- O 0 1.590904503245838e-05
FAP O 0 8.056639671849553e-06
group O 0 1.7212813645528513e-06
of O 0 1.80656152224401e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00014859938528388739
. O 0 2.3195580070023425e-06

Genotype O 1 0.9958155751228333
- O 1 0.9827933311462402
phenotype O 0 0.054859813302755356
correlations O 0 0.000191766899661161
identified O 0 1.0814536835823674e-05
significant O 0 2.417991709080525e-07
differences O 0 1.5582608057229663e-06
in O 0 2.0786092136404477e-07
the O 0 4.9546770242159255e-08
nature O 0 4.166291844853731e-08
of O 0 4.607003223355832e-09
certain O 0 2.8306706312264396e-08
extracolonic O 0 2.2218197045731358e-05
manifestations O 0 1.3492906418832717e-06
in O 0 2.0196819150442025e-07
FAP B-Disease 0 2.0407391275512055e-05
patients O 0 5.474241788760992e-07
belonging O 0 6.866237356462079e-08
to O 0 2.8623068359934223e-08
three O 0 5.668463813890412e-07
mutation O 0 2.0457233404158615e-05
subgroups O 0 1.809382411011029e-05
. O 0 2.114244807671639e-06

CONCLUSIONS O 0 8.065722795436159e-05
Extended O 0 4.014201113022864e-05
genotype O 0 0.0018555112183094025
- O 0 0.054679375141859055
phenotype O 0 0.0004099031793884933
correlations O 0 1.6274292647722177e-05
made O 0 1.7035544885857234e-07
in O 0 3.145716220842587e-08
this O 0 1.5891863824890606e-08
study O 0 2.7416550807402018e-08
may O 0 6.195313630996679e-07
have O 0 1.4025538064288412e-08
the O 0 6.294036403176051e-09
potential O 0 9.893678765138247e-09
to O 0 8.77143513378087e-09
determine O 0 1.348231215558826e-08
the O 0 5.212150711031427e-09
most O 0 4.476491177740627e-09
appropriate O 0 4.5982946339506725e-09
surveillance O 0 2.2791030573898752e-07
and O 0 2.4319897207192298e-08
prophylactic O 0 7.164194926190248e-07
treatment O 0 2.6956416832035757e-07
regimens O 0 8.047786650422495e-07
for O 0 1.7922793915658985e-08
those O 0 4.57873667869535e-08
patients O 0 8.0496775467509e-08
with O 0 9.248718413346069e-08
mutations O 0 2.109992055920884e-05
associated O 0 1.6303962979691278e-07
with O 0 1.332791157437896e-07
life O 0 3.880341864714865e-06
threatening O 0 8.479680400341749e-05
conditions O 0 6.891851808177307e-05
. O 0 2.742246806519688e-06

This O 0 2.612172465887852e-06
study O 0 2.22520597503717e-07
also O 0 1.412583117144095e-07
provided O 0 3.80688298662335e-08
evidence O 0 2.112671282361589e-08
for O 0 5.9801843477202965e-09
the O 0 4.889589177992093e-08
pathological O 0 2.242836899313261e-06
nature O 0 4.716167723017861e-08
of O 0 8.580330224106092e-09
amino O 0 2.0502393738297542e-07
acid O 0 1.5191371005585097e-07
changes O 0 4.3039097619157474e-08
in O 0 3.7685936149500776e-08
APC O 0 1.0519879651837982e-06
associated O 0 6.80628389204685e-08
with O 0 1.3055198699873927e-08
both O 0 1.2433861229510512e-07
FAP B-Disease 0 4.684052328229882e-06
and O 0 6.193287163114292e-07
non O 0 7.89524619904114e-06
- O 1 0.9991542100906372
FAP O 1 0.9998670816421509
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00010278446279698983
. O 0 3.1688080071035074e-07
. O 0 1.1589593214011984e-06

Inherited B-Disease 1 0.9999970197677612
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999984502792358
and O 0 0.16893431544303894
cancer B-Disease 1 0.5481890439987183
risk O 0 1.492836190664093e-06
of O 0 1.924544790199434e-08
the O 0 3.2700265251150995e-07
APC O 0 5.361067087505944e-05
I1307K O 0 4.991438254364766e-05
polymorphism O 0 8.930649346439168e-05
. O 0 2.6520633582549635e-06

Germ O 0 0.00867997296154499
- O 0 0.013087415136396885
line O 0 0.00015223945956677198
and O 0 2.621270880354132e-07
somatic O 0 4.797331257577753e-06
truncating O 0 1.5029047972348053e-05
mutations O 0 4.8785641411086544e-06
of O 0 1.0373787162620829e-08
the O 0 6.979208677648785e-08
APC B-Disease 0 1.953281298483489e-06
gene O 0 1.485391862843244e-07
are O 0 1.2051995845752117e-08
thought O 0 4.613037418721433e-08
to O 0 5.2266379668708396e-08
initiate O 0 7.615750655531883e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.29802194237709045
formation O 0 2.4804428903735243e-05
in O 0 6.914589903317392e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.001080246758647263
sporadic O 1 0.9999288320541382
colorectal O 1 1.0
carcinogenesis O 1 0.9987273812294006
, O 0 1.0186615327256732e-05
respectively O 0 9.934212357620709e-06
. O 0 2.0308641524025006e-06

Recently O 0 0.00014700207975693047
, O 0 4.2914831510643126e-07
an O 0 6.36199146697436e-08
isoleucine O 0 0.00038424230297096074
- O 0 8.382416126551107e-05
- O 0 0.00011826389527413994
> O 0 3.7921320199529873e-06
lysine O 0 8.716111551620997e-06
polymorphism O 0 4.519204594544135e-06
at O 0 1.2714684771708562e-07
codon O 0 1.987604946407373e-06
1307 O 0 7.691346581850667e-06
( O 0 7.162753945522127e-08
I1307K O 0 7.082856541273941e-07
) O 0 5.99901106568268e-09
of O 0 9.463505534768046e-10
the O 0 2.7294927207321962e-08
APC B-Disease 0 5.485514407155279e-07
gene O 0 1.33296410353978e-07
has O 0 3.5835898870573146e-07
been O 0 6.907483651730217e-08
identified O 0 8.254097849658137e-08
in O 0 4.918958573796317e-09
6 O 0 8.481162439011314e-08
% O 0 1.2311613950544142e-08
- O 0 1.927323864947539e-06
7 O 0 1.8473801901564002e-06
% O 0 1.3215439409464125e-08
of O 0 1.7615393588243933e-09
the O 0 5.957224757935364e-08
Ashkenazi O 0 1.6530508219148032e-05
Jewish O 0 6.950513693482208e-07
population O 0 1.8993938510902808e-07
. O 0 4.0873581497180567e-07

To O 0 3.011836952282465e-06
assess O 0 1.7063948689610697e-06
the O 0 1.0776918202282104e-07
risk O 0 2.3345391753082367e-07
of O 0 4.15589296309804e-09
this O 0 1.4079733823280094e-08
common O 0 3.0089205438343924e-07
APC B-Disease 0 5.943933047092287e-06
allelic O 0 8.206239726860076e-06
variant O 0 0.0001398276654072106
in O 0 5.2224568207748234e-05
colorectal O 1 1.0
carcinogenesis O 0 0.19544975459575653
, O 0 8.876202173269121e-07
we O 0 3.645261870133254e-08
have O 0 1.3133720777602775e-08
analyzed O 0 4.527153407707374e-08
a O 0 2.000927601386593e-08
large O 0 4.870192071848578e-08
cohort O 0 5.938811682426604e-07
of O 0 8.55942428046319e-09
unselected O 0 1.3580273844127078e-05
Ashkenazi O 0 1.203578995045973e-05
Jewish O 0 3.218466986254498e-07
subjects O 0 1.0482769852160345e-07
with O 0 1.3405340837380209e-07
adenomatous B-Disease 0 0.0002794213069137186
polyps I-Disease 0 0.001536828582175076
and O 0 2.06588561013632e-06
. O 0 1.355297854388482e-06
or O 1 0.546832799911499
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.8923822153738001e-07
for O 0 8.077850388588104e-09
the O 0 1.8003296986535133e-07
APC O 0 1.8437351172906347e-05
I1307K O 0 3.1774114177096635e-05
polymorphism O 0 3.5122488043271005e-05
. O 0 1.305494492953585e-06

The O 0 9.035114999278449e-06
APC O 0 4.66942074126564e-05
I1307K O 0 3.084293712163344e-05
allele O 0 1.4597670997318346e-05
was O 0 2.2127089778223308e-06
identified O 0 4.255780652329122e-07
in O 0 3.85355036769397e-08
48 O 0 3.987396439697477e-07
( O 0 1.1443556324763904e-08
10 O 0 1.588725950796288e-08
. O 0 4.6722044011460184e-09
1 O 0 6.636200566845218e-08
% O 0 2.551626820945785e-08
) O 0 5.682101011927898e-09
of O 0 1.8480653452002116e-08
476 O 0 7.415606432914501e-06
patients O 0 3.480308805592358e-06
. O 0 5.420112074716599e-07

Compared O 0 0.00012846221216022968
with O 0 1.2580187558342004e-07
the O 0 2.9923572952839095e-08
frequency O 0 1.388460873386066e-06
in O 0 2.0063543715309606e-08
two O 0 2.6525484031481028e-08
separate O 0 1.0973575825801163e-07
population O 0 3.656019487152662e-08
control O 0 1.613334461580962e-07
groups O 0 8.516367167032968e-09
, O 0 2.7083537634808863e-09
the O 0 9.188737770671196e-09
APC O 0 1.5496948435611557e-06
I1307K O 0 1.989749762287829e-06
allele O 0 6.031851285115408e-07
is O 0 1.2616803601872562e-08
associated O 0 1.0502137826051694e-08
with O 0 2.6297168886912914e-09
an O 0 1.8245847499542833e-08
estimated O 0 1.6620677456558042e-07
relative O 0 3.0930863204048364e-07
risk O 0 1.808707139616672e-07
of O 0 1.2604994381604229e-08
1 O 0 8.930765602599422e-07
. O 0 1.0668092045307276e-06

5 O 0 0.00017965726146940142
- O 0 0.00021327620197553188
1 O 0 9.618035619496368e-06
. O 0 5.074233285995433e-06

7 O 0 0.0008829230209812522
for O 0 3.311418913654052e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.957547128200531
( O 0 3.3035516935342457e-06
both O 0 9.656320116846473e-07
P O 0 0.047115497291088104
= O 0 6.500325253000483e-05
. O 0 3.111046282811003e-07
01 O 0 1.0646347618603613e-05
) O 0 3.2238949643215165e-07
. O 0 7.004012445577246e-07

Furthermore O 0 6.172224675538018e-05
, O 0 3.7832538168913743e-07
compared O 0 2.84302473119169e-07
with O 0 4.597253422389258e-08
noncarriers O 0 3.117273445241153e-05
, O 0 5.9327213364213094e-08
APC O 0 4.337719872182788e-07
I1307K O 0 8.088428558039595e-07
carriers O 0 1.36841364906104e-07
had O 0 4.123625103602535e-07
increased O 0 3.743804555256247e-08
numbers O 0 2.2385915343647866e-08
of O 0 1.6142555736564645e-08
adenomas B-Disease 0 0.0006938655278645456
and O 0 0.0037911119870841503
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9960463643074036
per O 0 2.8662132081080927e-06
patient O 0 8.804105164017528e-06
( O 0 2.3019387640488276e-07
P O 0 8.718317258171737e-05
= O 0 4.421710400492884e-06
. O 0 4.289060839823833e-08
03 O 0 1.900033339552465e-07
) O 0 1.256675297156562e-08
, O 0 6.706922572874419e-09
as O 0 1.1913813047215172e-08
well O 0 1.1260897991860475e-08
as O 0 7.0194432488790426e-09
a O 0 8.613324808948164e-08
younger O 0 1.0573388635748415e-06
age O 0 1.2384701619794214e-07
at O 0 1.9934314821057342e-07
diagnosis O 0 4.3940424802713096e-05
. O 0 1.0817896054504672e-06

We O 0 2.076211058010813e-05
conclude O 0 1.444805207029276e-06
that O 0 2.3207977761785514e-08
the O 0 6.812284425450343e-08
APC O 0 2.6116144908883143e-06
I1307K O 0 2.323589797015302e-06
variant O 0 3.7203185456746724e-06
leads O 0 8.556568786843854e-07
to O 0 1.3842047508205724e-07
increased O 0 2.928273352154065e-05
adenoma B-Disease 1 0.9999997615814209
formation O 0 1.6202480992433266e-06
and O 0 4.493491445600739e-08
directly O 0 1.7194709656109808e-08
contributes O 0 4.3825817641618414e-08
to O 0 8.176858301567336e-09
3 O 0 2.2974887770033092e-07
% O 0 3.107822621473133e-08
- O 0 9.501093813923944e-07
4 O 0 5.458779241962475e-07
% O 0 1.3899890127788694e-08
of O 0 3.452164776263089e-09
all O 0 8.329028133857719e-08
Ashkenazi O 0 0.027200650423765182
Jewish O 1 0.8285220265388489
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.735616923630005e-06

The O 0 3.6847334285994293e-06
estimated O 0 1.2760933714162093e-06
relative O 0 6.743160838595941e-07
risk O 0 2.065716699917175e-07
for O 0 1.9822989472118024e-08
carriers O 0 2.6003115749517747e-07
may O 0 7.008181768242139e-08
justify O 0 2.5952669346906987e-08
specific O 0 6.01500582675385e-09
clinical O 0 3.8814192748759524e-08
screening O 0 2.2699701673900563e-08
for O 0 2.0373773779169824e-09
the O 0 3.550136407071136e-09
360 O 0 1.1222842744018635e-07
, O 0 6.8412924214555915e-09
000 O 0 1.1772609553872826e-08
Americans O 0 6.741345703886736e-09
expected O 0 1.5243726281255476e-08
to O 0 1.1950501033197725e-08
harbor O 0 1.3929621900388156e-06
this O 0 5.640754086044808e-09
allele O 0 1.6128544189086824e-07
, O 0 1.2079244271490097e-08
and O 0 3.5010899068765866e-08
genetic O 0 2.508838576886774e-07
testing O 0 2.0373512654714432e-08
in O 0 1.7379510053316949e-09
the O 0 3.994998998280153e-09
setting O 0 9.050166482893474e-08
of O 0 1.538747795848394e-08
long O 0 7.454096930814558e-07
- O 0 3.712832722158055e-06
term O 0 2.149550510921472e-07
- O 0 8.850303743201948e-07
outcome O 0 3.880812471379613e-08
studies O 0 1.2040921149036876e-08
may O 0 3.599557629740957e-08
impact O 0 5.3109410202978324e-08
significantly O 0 4.638699465431273e-05
on O 1 0.9987945556640625
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 7.620519227202749e-06
in O 0 5.708914585511593e-08
this O 0 4.299323563827784e-08
population O 0 5.395573339228577e-07
. O 0 9.232095976585697e-07

Localization O 0 0.00010274456872139126
of O 0 4.5754103439321625e-07
human O 0 4.4491446260508383e-07
BRCA1 O 0 7.31053005438298e-05
and O 0 9.291441642744758e-07
its O 0 2.3476447097436903e-07
loss O 0 2.785005563055165e-06
in O 0 1.6674785285886173e-07
high O 0 1.0586349162622355e-05
- O 0 0.006400457117706537
grade O 0 5.612528184428811e-06
, O 0 8.904675752319235e-08
non B-Disease 0 1.3054982446192298e-06
- I-Disease 0 0.10049106925725937
inherited I-Disease 1 0.5301157832145691
breast I-Disease 1 0.9997573494911194
carcinomas I-Disease 1 1.0
. O 0 1.2740839338221122e-05

Although O 0 1.2823755241697654e-05
the O 0 1.1559983192910295e-07
link O 0 1.2341117781033972e-06
between O 0 3.4955661476487876e-07
the O 0 2.3262680315383477e-06
BRCA1 O 1 0.7546358108520508
tumour B-Disease 1 1.0
- O 0 0.0003518004377838224
suppressor O 0 0.0009763549896888435
gene O 0 2.0022458556923084e-05
and O 0 3.258894503233023e-05
hereditary B-Disease 1 0.9999301433563232
breast I-Disease 1 0.9999995231628418
and I-Disease 1 0.999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 6.540909112118243e-07
established O 0 6.336801305906192e-08
, O 0 1.0478947487513324e-08
the O 0 4.9908970289891386e-09
role O 0 4.129921293838379e-08
, O 0 3.183822983032769e-08
if O 0 2.8744728819418697e-09
any O 0 1.7409105268484382e-09
, O 0 5.021471238819686e-09
of O 0 3.150506300286793e-09
BRCA1 O 0 6.723179467371665e-06
in O 0 1.3197131920605898e-07
non B-Disease 0 1.0805430292748497e-06
- I-Disease 0 0.06014368683099747
familial I-Disease 1 0.6415531039237976
cancers I-Disease 1 0.9537939429283142
is O 0 4.0227575937024085e-07
unclear O 0 1.8778788444251404e-06
. O 0 1.2515382650235551e-06

BRCA1 O 1 0.9912238121032715
mutations O 0 0.013149783946573734
are O 0 2.537058776397316e-07
rare O 0 2.574385860043549e-07
in O 0 1.7887280989725696e-07
sporadic B-Disease 1 0.8228728771209717
cancers I-Disease 1 0.9998894929885864
, O 0 2.448499799356796e-06
but O 0 2.915873551501136e-07
loss O 0 3.4799529657902895e-07
of O 0 2.8664205231621054e-08
BRCA1 O 0 0.00010233224020339549
resulting O 0 1.520680825706222e-06
from O 0 9.122400967953581e-08
reduced O 0 8.911648023968155e-07
expression O 0 2.0813030232602614e-07
or O 0 2.8373680294180303e-08
incorrect O 0 8.305405003738997e-07
subcellular O 0 1.366641117783729e-05
localization O 0 8.291086487588473e-06
is O 0 6.299948296373259e-08
postulated O 0 2.7960047077613126e-07
to O 0 4.440590117837928e-08
be O 0 9.596088368368783e-09
important O 0 4.025978661559293e-09
in O 0 1.3484807048769198e-08
non B-Disease 0 3.403313542094111e-07
- I-Disease 0 0.01289194542914629
familial I-Disease 0 0.48770540952682495
breast I-Disease 1 0.9999961853027344
and I-Disease 1 0.9997523427009583
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.5491597878281027e-05

Epigenetic O 0 0.004106275271624327
loss O 0 0.0035494177136570215
, O 0 1.2892592167190742e-06
however O 0 2.4397772335760237e-07
, O 0 7.201988694305328e-08
has O 0 3.551337783846975e-07
not O 0 1.381625924778973e-08
received O 0 1.1384079456888685e-08
general O 0 7.853789618650353e-09
acceptance O 0 1.034952248346599e-07
due O 0 4.004819587066777e-08
to O 0 1.155863404989077e-08
controversy O 0 7.398643475653444e-08
regarding O 0 1.083689671332877e-08
the O 0 1.2375934943520406e-08
subcellular O 0 2.574032578195329e-06
localization O 0 6.559274083883793e-07
of O 0 1.913366887151824e-08
BRCA1 O 0 1.0103824024554342e-05
proteins O 0 4.298577138683868e-08
, O 0 1.6118004708687295e-08
reports O 0 1.6585298467930443e-08
of O 0 3.543277005135792e-09
which O 0 1.780565810349799e-07
have O 0 8.052748512454855e-08
ranged O 0 6.341020934996777e-07
from O 0 3.708431561832981e-09
exclusively O 0 6.4582326153583836e-09
nuclear O 0 4.096101946515773e-08
, O 0 1.9201988887829202e-09
to O 0 2.2782451480907184e-09
conditionally O 0 2.6430419097778213e-07
nuclear O 0 3.5684749377651315e-08
, O 0 2.72746181195771e-09
to O 0 3.300285600360553e-09
the O 0 2.936226550787069e-08
ER O 0 0.00011511346383485943
/ O 0 4.136041297897464e-06
golgi O 0 4.128974978812039e-06
, O 0 2.7576877670298927e-08
to O 0 7.256866219051972e-09
cytoplasmic O 0 3.4159657502641494e-07
invaginations O 0 2.008086539717624e-06
into O 0 3.785219959695496e-08
the O 0 7.625585141113334e-08
nucleus O 0 2.289554004164529e-06
. O 0 6.742357641087438e-07

In O 0 1.8302943090020563e-06
an O 0 8.024322539768036e-08
attempt O 0 3.988631306128809e-06
to O 0 2.1377709913394938e-07
resolve O 0 1.8274497506354237e-06
this O 0 1.4132683467948937e-08
issue O 0 1.7773253091490915e-07
, O 0 1.1362792662339416e-07
we O 0 2.35156996097885e-08
have O 0 3.6893354149469815e-08
comprehensively O 0 3.949674010073068e-06
characterized O 0 2.504165422578808e-06
19 O 0 1.0257672329316847e-06
anti O 0 2.3079537641024217e-06
- O 0 0.0001345581404166296
BRCA1 O 0 0.0003750390314962715
antibodies O 0 7.989417099452112e-06
. O 0 7.976116194186034e-07

These O 0 1.4973219322200748e-06
reagents O 0 2.9299105790414615e-06
detect O 0 1.3370578244575881e-06
a O 0 1.4450461094384082e-07
220 O 0 4.171942862285505e-07
- O 0 1.9929022982978495e-06
kD O 0 3.6297112728789216e-06
protein O 0 2.979614919240703e-07
localized O 0 6.582723699466442e-07
in O 0 3.249349944667301e-08
discrete O 0 6.089778707973892e-07
nuclear O 0 5.322775677996106e-07
foci O 0 7.1579988798475824e-06
in O 0 2.7572564675892863e-08
all O 0 1.152945916516046e-08
epithelial O 0 1.8526762914916617e-06
cell O 0 0.00012661756773013622
lines O 0 0.0004998520598746836
, O 0 1.2758516021449395e-08
including O 0 6.376493999482591e-09
those O 0 1.0865996991071825e-08
derived O 0 9.773084741482307e-08
from O 0 2.0884149876110314e-07
breast B-Disease 0 0.007580117788165808
malignancies I-Disease 0 0.0005470741889439523
. O 0 2.6593345410219627e-06

Immunohistochemical O 0 0.00360679579898715
staining O 0 0.00044672866351902485
of O 0 1.047882619786833e-06
human O 0 2.5993049348471686e-06
breast O 0 0.09987206012010574
specimens O 0 9.929731277225073e-07
also O 0 5.324390031091752e-07
revealed O 0 1.582477671036031e-05
BRCA1 O 0 0.00016493108705617487
nuclear O 0 1.795617549760209e-06
foci O 0 2.69788179139141e-05
in O 0 7.156417609621712e-07
benign O 0 0.29377344250679016
breast O 1 0.847366988658905
, O 0 1.2938917279825546e-06
invasive B-Disease 0 0.00028305500745773315
lobular I-Disease 1 0.9997995495796204
cancers I-Disease 1 0.997763991355896
and O 0 5.803889962407993e-06
low B-Disease 0 0.001166361733339727
- I-Disease 1 0.7085681557655334
grade I-Disease 0 0.0010990697192028165
ductal I-Disease 1 0.9970663189888
carcinomas I-Disease 1 1.0
. O 0 4.9107686209026724e-05

Conversely O 0 0.00027360059903003275
, O 0 2.189538918173639e-06
BRCA1 O 0 7.66015873523429e-05
expression O 0 2.1195119188632816e-06
was O 0 6.045066129445331e-06
reduced O 0 3.3661729048617417e-07
or O 0 1.1198978455695396e-07
undetectable O 0 5.11506698330777e-07
in O 0 2.0007863810178605e-08
the O 0 2.1323216969904024e-08
majority O 0 1.0692069452034048e-08
of O 0 6.299585741942337e-09
high O 0 3.948604444303783e-06
- O 0 0.0013993704924359918
grade O 0 4.301753506297246e-06
, O 0 4.7358363985949836e-07
ductal B-Disease 0 0.0046198866330087185
carcinomas I-Disease 1 1.0
, O 0 1.2133598374930443e-06
suggesting O 0 4.551838799216057e-07
that O 0 1.0483545587192111e-08
absence O 0 3.795992853383723e-08
of O 0 3.4436041573826515e-08
BRCA1 O 0 0.0002461457916069776
may O 0 2.551559646235546e-06
contribute O 0 1.1443642478070615e-08
to O 0 5.686209725297431e-09
the O 0 1.6696930060788873e-08
pathogenesis O 0 2.0843778258949897e-07
of O 0 3.809489168560276e-09
a O 0 6.267336516430078e-08
significant O 0 8.38292990579248e-08
percentage O 0 1.5783183471285156e-06
of O 0 5.3888992823658555e-08
sporadic B-Disease 1 0.9661936163902283
breast I-Disease 1 0.9999967813491821
cancers I-Disease 1 0.9939171671867371
. O 0 5.295182745612692e-07
. O 0 1.5215483699648757e-06

